FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Njoku, C Self, SE Ruiz, P Hofbauer, AF Gilkeson, GS Oates, JC AF Njoku, Chinedu Self, Sally E. Ruiz, Philip Hofbauer, Ann F. Gilkeson, Gary S. Oates, Jim C. TI Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE lupus nephritis; nitric oxide; animal models; nitric oxide synthase; enzyme inhibitors ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MRL-LPR/LPR MICE; GLOMERULAR PODOCYTOPATHY; AUTOIMMUNE-DISEASE; RENAL-DISEASE; ARGININE; ANTIOXIDANT; GLOMERULONEPHRITIS; NEPHROPATHY; MODULATION AB Several studies have demonstrated the effectiveness of arginine analog nitric oxide synthase (NOS) inhibitor therapy in preventing and treating murine lupus nephritis. However, MRL/MpJ-FAS(lpr) (MRL/lpr) mice lacking a functional NOS2 (inducible NOS [iNOS]) gene (NOS2(-/-)) develop proliferative glomerulonephritis in a fashion similar to their wild-type (wt) littermates. This finding suggests that the effect of arginine analog NOS inhibitors is through a non-iNOS-mediated mechanism. This study was designed to address this hypothesis. NOS2(-/-) mice were given either vehicle or a NOS inhibitor (SD-3651) to determine if pharmacological NOS inhibition prevented glomerulonephritis, using wt rnice as positive controls. Urine was collected fortnightly to measure albumin. At the time of full disease expression in wt rnice, all mice were killed, and renal tissue was examined for light, immunofluorescence, and electron microscopic evidence of disease. Scrum was analyzed for anti-double-stranded DNA antibody production. NOS2(-/-) mice had higher serum anti-double-stranded DNA antibody antibody levels than those of wt mice. SD-3651 therapy reduced proteinuria, glomerular immunoglobulin G deposition, and electron microscopic evidence of podocytopathy and endothelial cell swelling without affecting proliferative lesions by light microscopy. These studies confirm that genetic iNOS deficiency alone is insufficient to prevent proliferative glomerulonephritis and suggest that iNOS activity may inhibit autoantibody production. These results also suggest that SD-3651 therapy acts via a non-iNOS-mediated mechanism to prevent endothelial cell and podocyte pathology. Studies that elucidate this mechanism could provide a useful drug target for the treatment of nephritis. C1 [Njoku, Chinedu; Gilkeson, Gary S.; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Self, Sally E.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Surg, Miami, FL USA. [Ruiz, Philip] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, Miami, FL USA. [Hofbauer, Ann F.; Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA. RP Oates, JC (reprint author), 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU National Institutes of Health, Bethesda, MD [K08AR002193, R01AR045476]; Career Development, Research Enhancement Award Program; Medical Research Service; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC FX The work of Drs Oates and Gilkeson was supported by grants K08AR002193 and R01AR045476 from the National Institutes of Health, Bethesda, MD, and Career Development, Research Enhancement Award Program, and Merit Review grants from the Medical Research Service, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC. NR 29 TC 11 Z9 11 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD OCT PY 2008 VL 56 IS 7 BP 911 EP 919 PG 9 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 358YV UT WOS:000259954300008 PM 18797415 ER PT J AU Sundararaj, KP Samuvel, DJ Li, YC Nareika, A Slate, EH Sanders, JJ Lopes-Virella, MF Huang, Y AF Sundararaj, Kamala P. Samuvel, Devadoss J. Li, Yanchun Nareika, Alena Slate, Elizabeth H. Sanders, John J. Lopes-Virella, Maria F. Huang, Yan TI Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article; Proceedings Paper CT Pennington Scientific Symposium on Neuro-Immune Signaling and Inflammation CY DEC 02-05, 2007 CL Baton Rouge, LA DE matrix metalloproteinases; statin; lipopolysaccharide; mitogen-activated protein kinase; gene expression ID KAPPA-B ACTIVATION; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; LIPOPOLYSACCHARIDE; STATINS; COLLAGENASE; INDUCTION; MONOCYTES; PERIODONTITIS; MACROPHAGES AB Matrix metalloproteinase (MMP) plays a crucial role in periodontal disease and is up-regulated by oral Gram-negative, pathogen-derived LPS. In this study, we reported that simvastatin, a 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitor, effectively inhibited LPS-stimulated MMP-1 as well as MMP-8 and MMP-9 expression by U937 mononuclear cells. Our studies showed that the geranylgeranyl transferase inhibitor inhibited LPS-stimulated MMP-1 expression, and addition of isoprenoid intermediate geranylgeranyl pyrophosphate (GGPP) reduced the inhibitory effect of simvastatin on LPS-stimulated MMP-1 expression. We also demonstrated that simvastatin inhibited the activation of Ras and Rac, and the inhibition was abolished by addition of GGPP. The above results indicate that protein isoprenylation is involved in the regulation of MMP-1 expression by LPS and simvastatin. Moreover, we showed that simvastatin inhibited LPS-stimulated nuclear AP-1, but not NF-kappa B activity, and the inhibition was reversed by addition of GGPP. Simvastatin also inhibited LPS-stimulated ERK but not p38 MAPK and JNK. Finally, we showed that the inhibition of LPS-stimulated ERK activation by simvastatin was reversed by GGPP. Taken together, this study showed that simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by targeting protein isoprenylation-mediated ERK activation. C1 [Huang, Yan] Med Univ S Carolina, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Sundararaj, Kamala P.; Samuvel, Devadoss J.; Nareika, Alena; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29403 USA. [Slate, Elizabeth H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA. [Sanders, John J.] Med Univ S Carolina, Dept Stomatol, Div Periodont, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU NIDCR NIH HHS [DE16353, R01 DE016353] NR 28 TC 27 Z9 28 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD OCT 1 PY 2008 VL 84 IS 4 BP 1120 EP 1129 DI 10.1189/jlb.0108064 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 354KW UT WOS:000259639500029 PM 18625914 ER PT J AU Kerwin, WS Liu, F Yarnykh, V Underhill, H Oikawa, M Yu, W Hatsukami, TS Yuan, C AF Kerwin, William S. Liu, Fei Yarnykh, Vasily Underhill, Hunter Oikawa, Minako Yu, Wei Hatsukami, Thomas S. Yuan, Chun TI Signal features of the atherosclerotic plaque at 3.0 Tesla versus 1.5 Tesla: Impact on automatic classification SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE carotid artery; MRI; atherosclerosis; segmentation; field strength ID MAGNETIC-FIELD STRENGTHS; IN-VIVO ACCURACY; BLACK-BLOOD MRI; CAROTID PLAQUE; HIGH-RESOLUTION; INTRAPLAQUE HEMORRHAGE; INVERSION-RECOVERY; CEREBRAL-ISCHEMIA; FIBROUS-CAP; ASSOCIATION AB Purpose: To investigate the impact of different field strengths on determining plaque composition with an automatic classifier. Materials and Methods: We applied a previously developed automatic classifier-the morphology enhanced probabilistic plaque segmentation (MEPPS) algorithm-to images from 20 subjects scanned at both 1.5 Tesla (T) and 3T. Average areas per slice of lipid-rich core, intraplaque hemorrhage, calcification, and fibrous tissue were recorded for each subject and field strenght. Results: All measurements showed close agreement at the two field strengths, with correlation coefficients of 0.91, 0.93, 0.95, and 0.93, respectively. None of these measurements showed a statistically significant difference between field strengths in the average area per slice by a paired t-test, although calcification tended to be measured larger at 3T (P = 0.09). Conclusion: Automated classification results using an identical algorithm at 1.5T and 3T produced highly similar results, suggesting that with this acquisition protocol, 3T signal characteristics of the atherosclerotic plaque are sufficiently similar to 1.5T characteristics for MEPPS to provide equivalent performance. C1 [Kerwin, William S.; Liu, Fei; Yarnykh, Vasily; Underhill, Hunter; Oikawa, Minako; Yu, Wei; Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98109 USA. [Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98109 USA. [Hatsukami, Thomas S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kerwin, WS (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA. EM bkerwin@u.washington.edu RI Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014 OI Yarnykh, Vasily/0000-0002-1583-8979; FU NIH [R01-HL056874, R44-HL070576, P01-HL072262, R01-HL073401]; Pfizer FX Contract grant sponsor: NIH; Contract grant number: R01-HL056874; Contract grant number: R44-HL070576; Contract grant number: P01-HL072262; Contract grant number: R01-HL073401; Contract grant sponsor: Pfizer. NR 28 TC 24 Z9 24 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD OCT PY 2008 VL 28 IS 4 BP 987 EP 995 DI 10.1002/jmri.21529 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 356PY UT WOS:000259791300021 PM 18821634 ER PT J AU Chen, LJ Na, R Gu, MJ Richardson, A Ran, Q AF Chen, Liuji Na, Ren Gu, Mingjun Richardson, Arlan Ran, Qitao TI Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE beta-amyloid; beta-site amyloid precursor protein cleavage enzyme 1; Alzheimer's disease; amyloid precursor protein transgenic mice; glutathione peroxidase 4; lipid peroxidation ID MILD COGNITIVE IMPAIRMENT; BETA-SECRETASE ACTIVITY; AMYLOID PRECURSOR PROTEIN; OXIDATIVE STRESS; TRANSGENIC MICE; A-BETA; BRAIN; MOUSE; GENERATION; PRODUCT AB Increased lipid peroxidation is shown to be an early event of Alzheimer's disease (AD). However, it is not clear whether and how increased lipid peroxidation might lead to amyloidogenesis, a hallmark of AD. Glutathione peroxidase 4 (Gpx4) is an essential antioxidant defense enzyme that protects an organism against lipid peroxidation. Gpx4+/- mice show increased lipid peroxidation in brain, as evidenced by their elevated levels of 4-hydroxy-2-nonenal. To understand the role of lipid peroxidation in amyloidogenesis, we studied secretase activities in Gpx4+/- mice as a function of age. Both young (6 months) and middle-aged (17-20 months) Gpx4+/- mice had higher levels of beta-secretase activity than their age-matched wildtype controls, and the increased beta-secretase activity in Gpx4+/- mice was a result of up-regulation of beta-site amyloid precursor protein cleavage enzyme 1 (BACE1) expression at the protein level. The high level of BACE1 protein led to increased endogenous beta-amyloid (A beta)(1-40) in middle-aged Gpx4+/- mice. We further studied amyloidogenesis in APPGpx4+/- mice. Our data indicate that APPGpx4+/- mice had significantly increased amyloid plaque burdens and increased A beta(1-40) and A beta(1-42) levels compared with APPGpx4+/+ mice. Therefore, our results indicate that increased lipid peroxidation leads to increased amyloidogenesis through up-regulation of BACE1 expression in vivo, a mechanism that may be important in pathogenesis of AD at early stages. C1 [Chen, Liuji; Na, Ren; Gu, Mingjun; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Chen, Liuji; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Richardson, Arlan; Ran, Qitao] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ran, Q (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM ran@uthscsa.edu FU Department of Veteran Affairs; NIH/NIA [K01AG022014] FX The study was supported by a Merit Award (QR) from the Department of Veteran Affairs and a K01AG022014 Award (QR) from NIH/NIA. NR 48 TC 45 Z9 47 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD OCT PY 2008 VL 107 IS 1 BP 197 EP 207 DI 10.1111/j.1471-4159.2008.05603.x PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 349HA UT WOS:000259270700017 PM 18680556 ER PT J AU Zhang, F Chen, J AF Zhang, Feng Chen, Jun TI Leptin protects hippocampal CA1 neurons against ischemic injury SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Akt; extracellular signal-related kinase 1/2; global ischemia; leptin antagonist; neuroprotection ID TRANSIENT FOREBRAIN ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; SIGNALING MECHANISMS; LONG FORM; ACTIVATION; APOPTOSIS; RECEPTOR; KINASE; DEATH; RAT AB Leptin is an adipose hormone with well characterized roles in regulating food intake and energy balance. A novel neuroprotective role for leptin has recently been discovered; however, the underlying mechanisms are not clearly defined. The purpose of this study was to determine whether leptin protects against delayed neuronal cell death in hippocampal CA1 following transient global cerebral ischemia in rats and to study the signaling mechanism responsible for the neuroprotective effects of leptin. Leptin receptor antagonist, protein kinase inhibitors and western blots were used to assess the molecular signaling events that were altered by leptin after ischemia. The results revealed that intracerebral ventricle infusion of leptin markedly increased the numbers of survival CA1 neurons in a dose-dependent manner. Infusion of a specific leptin antagonist 10 min prior to transient global ischemia abolished the pro-survival effects of leptin, indicating the essential role of leptin receptors in mediating this neuroprotection. Both the Akt and extracellular signal-related kinase 1/2 (ERK1/2) signaling pathways appear to play a critical role in leptin neuroprotection, as leptin infusion increased the phosphorylation of Akt and ERK1/2 in CA1. Furthermore, pharmacological inhibition of either pathway compromised the neuroprotective effects of leptin. Taken together, the results suggest that leptin protects against delayed ischemic neuronal death in the hippocampal CA1 by maintaining the pro-survival states of Akt and ERK1/2 MAPK signaling pathways. C1 [Zhang, Feng; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Zhang, Feng; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Zhang, Feng; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomedical Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS43802, NS45048, NS36736, NS 56118] FX This project was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke grants NS43802, NS45048, NS36736, NS 56118 and a VA Merit Review grant. We thank Carol Culver and Aalap C. Shan for editorial assistance and Pat Strickler for secretarial support. NR 40 TC 43 Z9 48 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD OCT PY 2008 VL 107 IS 2 BP 578 EP 587 DI 10.1111/j.1471-4159.2008.05645.x PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 358XD UT WOS:000259949900024 PM 18752642 ER PT J AU Lu, HF Wei, GW Wang, DM Yung, P Ying, WH AF Lu, Huafei Wei, Gangwei Wang, Dongmin Yung, Patrick Ying, Weihai TI Posttreatment with the Ca(2+)-Mg(2+)-dependent endonuclease inhibitor aurintricarboxylic acid abolishes genotoxic agent-induced nuclear condensation and DNA fragmentation and decreases death of astrocytes SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE DNA fragmentation; nuclear condensation; cell death; Ca(2+)-Mg(2+) -endonucleases; astrocyte ID PROGRAMMED CELL-DEATH; NEURONAL DEATH; POLY(ADP-RIBOSE) POLYMERASE-1; APOPTOSIS; DAMAGE; ACTIVATION; ISCHEMIA; NECROSIS; NAD(+); DIFFERENTIATION AB DNA fragmentation and nuclear condensation are important nuclear changes in apoptosis. In this study we determined whether DNA fragmentation and nuclear condensation occur in astrocytes treated with 100-200 mu M of the genotoxic agent M-nitroso-N-nitroguanidine (MNNG). Our study also investigated the roles of Ca(2+) -Mg(2+) -dependent endonuclease (CME) in the MNNG-induced nuclear changes. We found that MNNG induced profound ATP depletion as well as marked nuclear condensation and DNA fragmentation in the cells. Both the nuclear condensation and the DNA fragmentation were abolished by posttreatment of the cells with the CME inhibitor aurintricarboxylic acid (ATA). The ATA posttreatment also significantly, but only partially, decreased MNNG-induced cell death. In contrast, pretreatment plus cotreatment with ATA did not affect either MNNG-induced nuclear condensation or cell death. Our study further suggests that ATA does not decrease the cytotoxicity of MNNG by directly inhibiting poly(ADPribose) polymerases. Collectively, our observations suggest that MNNG can induce both DNA fragmentation and nuclear condensation in astrocytes by a CME-dependent mechanism, which partially contributes to the genotoxic agent-induced cell death. Published 2008 Wiley-Liss, Inc. C1 Univ Calif San Francisco, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. RP Ying, WH (reprint author), Vet Adm Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM weihai.ying@ucsf.edu FU VA MREP Award; Department of Defense; American Heart Association FX Contract grant sponsor: VA MREP Award; Contract grant sponsor: Department of Defense; Contract grant sponsor: American Heart Association (to W.Y.). NR 38 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD OCT PY 2008 VL 86 IS 13 BP 2925 EP 2931 DI 10.1002/jnr.21733 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 356PU UT WOS:000259790900013 PM 18506851 ER PT J AU Compton, PA Wu, SM Schieffer, B Pham, Q Naliboff, BD AF Compton, Peggy A. Wu, Stephen M. Schieffer, Beatrix Pham, Quvnh Naliboff, Bruce D. TI Introduction of a self-report version of the prescription drug use questionnaire and relationship to medication agreement noncompliance SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE chronic nonmalignant pain; opioid medications; substance use disorder; problematic opioid use and/or misuse; medication agreements ID CHRONIC PAIN PATIENTS; NONMALIGNANT PAIN; OPIOID THERAPY; NEUROPATHIC PAIN; SUBSTANCE-ABUSE; ADDICTION; MANAGEMENT; EFFICACY; VALIDATION; MISUSE AB The Prescription, Drug Use Questionnaire (PDUQ) is one of several published tools developed to help clinicians better identify the presence of opioid abuse or dependence in patients with chronic pain. This paper introduces a patient version of the PDUQ (PDUQp), a 31-item questionnaire derived from the items of the original tool designed for self-administration, and describes evidence for its validity and reliability in a sample of patients with chronic nonmalignant pain and on opioid therapy. Further, this study examines instances of discontinuation from opioid medication treatment related to violation of the medication agreement in this population, and the relationship of these with problematic opioid misuse behaviors, PDUQ and PDUQp scores. A sample of 135 consecutive patients with chronic nonmalignant pain was recruited from a multidisciplinary Veterans Affairs chronic pain clinic, and prospectively followed over one year of opioid therapy. Using the PDUQ as a criterion measure, moderate to good concurrent and predictive validity data for the PDUQp are presented, as well as item-by-item comparison of the two formats. Reliability data indicate moderate test stability over time. Of those patients whose opioid treatment was discontinued due to medication agreement violation-related discontinuation (MAVRD) (n = 38 or 28% of sample), 40% of these (n = 11) were due to specific problematic opioid misuse behaviors. Based upon specificity and sensitivity analyses, a suggested cutoff PDUQp score for predicting MAVRD is provided. This study supports the PDUQp as a useful tool for assessing and predicting problematic opioid medication use in a chronic pain patient sample. C1 [Compton, Peggy A.] Univ Calif Los Angeles, Sch Nursing, Acute Care Sect, Los Angeles, CA 90095 USA. [Wu, Stephen M.; Schieffer, Beatrix; Pham, Quvnh; Naliboff, Bruce D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Wu, Stephen M.; Schieffer, Beatrix; Naliboff, Bruce D.] Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90024 USA. [Pham, Quvnh] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Naliboff, Bruce D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Compton, PA (reprint author), Univ Calif Los Angeles, Sch Nursing, Acute Care Sect, Factor Bldg 4-246,Box 956918, Los Angeles, CA 90095 USA. EM pcompton@sonnet.ucla.edu FU VA Health Services Research and Development FX This work was supported by VA Health Services Research and Development. NR 44 TC 34 Z9 34 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2008 VL 36 IS 4 BP 383 EP 395 DI 10.1016/j.jpainsymman.2007.11.006 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 360SP UT WOS:000260078300006 PM 18508231 ER PT J AU Goldsmith, B Dietrich, J Du, QL Morrison, RS AF Goldsmith, Benjamin Dietrich, Jessica Du, Qingling Morrison, R. Sean TI Variability in Access to Hospital Palliative Care in the United States SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE; END; HOME AB Background: Hospital palliative care programs provide high-quality, comprehensive care for seriously ill patients and their families. Objective: To examine geographic variation in patient and medical trainee access to hospital palliative care and to examine predictors of these programs. Methods: Primary and secondary analyses of national survey and census data. Hospital data including hospital palliative care programs were obtained from the American Hospital Association (AHA) Annual Survey Database (TM) for fiscal year 2006 supplemented by mailed surveys. Medical school-affiliated hospitals were obtained from the American Association of Medical Colleges, Web-site review, and telephone survey. Health care utilization data were obtained from the Dartmouth Atlas of Health Care 2008. Multivariate logistic regression was used to identify characteristics significantly associated with the presence of hospital palliative care. Results: A total of 52.8% of hospitals with 50 or more total facility beds reported hospital palliative care with considerable variation by state; 40.9% (144/352) of public hospitals, 20.3% (84/413) of for-profit hospitals, and 28.8% (160/554) of Medicare sole community providers reported hospital palliative care. A total of 84.5% of medical schools were associated with at least one hospital palliative care program. Factors significantly associated (p < 0.05) with hospital palliative care included geographic location, owning a hospice program, having an American College of Surgery approved cancer program, percent of persons in the county with a university education, and medical school affiliation. For-profit and public hospitals were significantly less likely to have hospital palliative care when compared with nonprofit institutions. States with higher hospital palliative care penetration rates were observed to have fewer Medicare hospital deaths, fewer intensive care unit/cardiac care unit (ICU/CCU) days and admissions during the last 6 months of life, fewer ICU/CCU admission during terminal hospitalizations, and lower overall Medicare spending/enrollee. Discussion: This study represents the most recent estimate to date of the prevalence of hospital palliative care in the United States. There is wide geographic variation in access to palliative care services although factors predicting hospital palliative care have not changed since 2005. Overall, medical students have high rates of access to hospital palliative care although complete penetration into academic settings has not occurred. The association between hospital palliative care penetration and lower Medicare costs is intriguing and deserving of further study. C1 [Morrison, R. Sean] Mt Sinai Sch Med, Dept Geriatr & Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Goldsmith, Benjamin; Morrison, R. Sean] Natl Palliat Care Res Ctr, New York, NY USA. [Dietrich, Jessica] Ctr Adv Palliat Care, New York, NY USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Morrison, RS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU National Palliative Care Research Center; Center to Advance Palliative Care; National Institute on Aging [K24 AG022345]; Olive Branch Foundations FX This study was supported by the National Palliative Care Research Center and the Center to Advance Palliative Care. Dr. Morrison is the recipient of a mid-career investigator award in patient oriented research from the National Institute on Aging (K24 AG022345). Mr. Goldsmith is a Doris Duke Clinical Research Fellow.; The Center to Advance Palliative Care and the National Palliative Care Research Center are supported by the Aetna, Brookdale, John A. Hartford, Jeht, Robert Wood Johnson, Emily Davie and Joseph S. Kornfeld, and Olive Branch Foundations. NR 13 TC 92 Z9 93 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD OCT PY 2008 VL 11 IS 8 BP 1094 EP 1102 DI 10.1089/jpm.2008.0053 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 372QZ UT WOS:000260917800011 PM 18831653 ER PT J AU Blanco, CL Falck, A Green, BK Cornell, JE Gong, AK AF Blanco, Cynthia Lidmilla Falck, Alison Green, Belinda Kay Cornell, John E. Gong, Alice Kim TI Metabolic Responses to Early and High Protein Supplementation in a Randomized Trial Evaluating the Prevention of Hyperkalemia in Extremely Low Birth Weight Infants SO JOURNAL OF PEDIATRICS LA English DT Article ID INTRAVENOUS AMINO-ACIDS; PRETERM INFANTS; INSULIN; LIFE AB Objective To determine whether early and higher intravenous amino acid (EHAA) supplementation decreases hyperkalemia in extremely low birth weight (ELBW) infants (<1000 g). Study design infants were enrolled at birth in a randomized, double-masked, prospective fashion and treated for 7 days. The standard group (SAA) infants received intravenous aminoacid (AA) starting at 0.5 g.kg(-1).d(-1) laid increased by 0.5 g.kg(-1).d(-1) every day to a maximum of 3 g.kg(-1).d(-1). EHAA group infants received 2 g.kg(-1).d(-1) of AA soon after birth and advanced by 1 g.kg(-1).d(-1) every day to 4 g.kg(-1).d(-1). Data analysis was by SPSS 11.5, with statistical significance at alpha = 0.05 and 90% power to determine a difference in mean K+ level of 2. Results Sixty-two patients, mean gestational age of 26.0 +/- 2.0 weeks and birth weight of 775 +/- 136 g, were enrolled. Hyperkalemia (K+ >= 6.5 mEq/L) occurred in 13% of the studied population; no difference in incidence of hyperkalemia was found between the SAA and EHAA groups (16% vs 10%. respectively, P = .70). Serum blood urea nitrogen was higher in the EHAA group. AA infusion was stopped early in 6 patients for high blood urea nitrogen or elevated ammonia level. Conclusions During the study period, hyperkalemia decreased significantly and was not affected by EHAA supplementation in the first week of life. C1 [Blanco, Cynthia Lidmilla; Gong, Alice Kim] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA. [Green, Belinda Kay] Univ Hlth Syst, Dept Pharm, San Antonio, TX USA. [Cornell, John E.] S Texas Vet Hlth Care Syst, Dept Epidemiol & Biostat, San Antonio, TX USA. [Falck, Alison] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA. RP Blanco, CL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, 7703 Floyd Curl Dr,MSC 7812, San Antonio, TX 78229 USA. EM blanco@uthscsa.edu NR 23 TC 28 Z9 33 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR JI J. Pediatr. PD OCT PY 2008 VL 153 IS 4 BP 535 EP 540 DI 10.1016/j.jpeds.2008.04.059 PG 6 WC Pediatrics SC Pediatrics GA 361BD UT WOS:000260101600021 PM 18589451 ER PT J AU Yehuda, R Bell, A Bierer, LM Schmeidler, J AF Yehuda, Rachel Bell, Amanda Bierer, Linda M. Schmeidler, James TI Maternal, not paternal, PTSD is related to increased risk for PTSD in offspring of Holocaust survivors SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE parental PTSD; maternal PTSD; intergenerational transmission of trauma; Holocaust survivors; depressive disorder; prevalence ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; FAMILIAL PSYCHIATRIC-ILLNESS; AUSTRALIAN VIETNAM VETERANS; MAJOR DEPRESSIVE DISORDER; PITUITARY-ADRENAL AXIS; WORLD-WAR-II; SURVEY REPLICATION; PARENTAL PTSD; SECONDARY TRAUMATIZATION AB Background: A significant association between parental PTSID and the occurrence of PTSD in offspring has been noted, consistent with the idea that risk for the development of PTSD is transmitted from parent to child. Two recent reports linking maternal PTSD and low offspring cortisol prompted us to examine the relative contributions of maternal vs. paternal PTSD in the prediction of PTSD and other psychiatric diagnoses in offspring. Methods: One hundred seventeen men and 167 women, recruited from the community, were evaluated using a comprehensive psychiatric battery designed to identify traumatic life experiences and lifetime psychiatric diagnoses. 211 of these subjects were the adult offspring of Holocaust survivors and 73 were demographically comparable Jewish controls. Participants were further subdivided based on whether their mother, father, neither, or both parents met diagnostic criteria for lifetime PTSD. Results: A higher prevalence of lifetime PTSD, mood, anxiety disorders, and to a lesser extent, substance abuse disorders, was observed in offspring of Holocaust survivors than controls. The presence of maternal PTSD was specifically associated with PTSD in adult offspring of Holocaust Survivors. However, other psychiatric diagnoses did not show specific effects associated with maternal PTSD. Conclusion: The tendency for maternal PTSD to make a greater contribution than paternal PTSD to PTSD risk suggests that classic genetic mechanisms are not the sole model of transmission, and paves way for the speculation that epigenetic factors may be involved. In contrast, PTSD in any parent contributes to risk for depression, and parental traumatization is associated with increased anxiety disorders in offspring. Published by Elsevier Ltd. C1 Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY 10468 USA. James J Peters Vet Affairs Med Ctr, OOMH, Bronx, NY 10468 USA. RP Yehuda, R (reprint author), Bronx Vet Affairs Med Ctr, Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Ritchel.Yehuda@va.gov FU NCRR NIH HHS [5 M01 RR00071]; NIMH NIH HHS [R01 MH064675-03, R01 MH064675, R01 MH064675-01, R01 MH064675-02, R01 MH064675-04, R01 MH064675-05, R01 MH64675-01] NR 49 TC 100 Z9 103 U1 8 U2 28 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD OCT PY 2008 VL 42 IS 13 BP 1104 EP 1111 DI 10.1016/j.jpsychires.2008.01.002 PG 8 WC Psychiatry SC Psychiatry GA 351JL UT WOS:000259420500007 PM 18281061 ER PT J AU Hula, SNA Robin, DA Maas, E Ballard, KJ Schmidt, RA AF Hula, Shannon N. Austermann Robin, Donald A. Maas, Edwin Ballard, Kirrie J. Schmidt, Richard A. TI Effects of Feedback Frequency and Timing on Acquisition, Retention, and Transfer of Speech Skills in Acquired Apraxia of Speech SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE apraxia of speech; apraxia treatment; feedback; principles of motor learning ID GENERALIZED MOTOR PROGRAM; LEARNING CONCEPTS; SCHEMA THEORY; KNOWLEDGE; APHASIA; DELAY; SCHEDULES; STROKE; ADULTS AB Purpose: Two studies examined speech skill learning in persons with apraxia of speech (AOS). Motor-learning research shows that delaying or reducing the frequency of feedback promotes retention and transfer of skills. By contrast, immediate or frequent feedback promotes temporary performance enhancement but interferes with retention and transfer. These principles were tested in the context of a common treatment for AOS. Method: Two studies (N = 4, N = 2) employed single-subject treatment designs to examine acquisition and retention of speech skills in adults with AOS under different feedback conditions. Results: Reduced-frequency or delayed feedback enhanced learning in 3 participants with AOS. Feedback manipulation was not an influential variable in 3 other cases in which stimulus-complexity effects may have masked treatment effects. Conclusions: These findings demonstrate that individuals with AOS can benefit from structured intervention. They provide qualified support for reduction and delay of feedback, although interaction with other factors such as stimulus complexity or task difficulty needs further exploration. This study adds to the growing body of literature investigating the use of principles of motor learning in treating AOS and provides impetus for consideration of pre-treatment variables that affect outcome in treatment studies. C1 [Hula, Shannon N. Austermann; Robin, Donald A.; Maas, Edwin] San Diego State Univ, San Diego, CA 92182 USA. [Hula, Shannon N. Austermann; Robin, Donald A.; Maas, Edwin] Univ Calif San Diego, La Jolla, CA 92093 USA. [Ballard, Kirrie J.] Univ Iowa, Iowa City, IA USA. [Schmidt, Richard A.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Hula, SNA (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. EM shannon.hula@va.gov RI Robin, Donald/F-2109-2010; Ballard, Kirrie/F-9558-2011 OI Ballard, Kirrie/0000-0002-9917-5390 NR 62 TC 26 Z9 26 U1 1 U2 21 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD OCT 1 PY 2008 VL 51 IS 5 BP 1088 EP 1113 DI 10.1044/1092-4388(2008/06-0042) PG 26 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 357SD UT WOS:000259865700003 ER PT J AU Sano, Y Gomez, FE Hermsen, JL Kang, W Lan, JG Maeshima, Y Kudsk, KA AF Sano, Yoshifumi Gomez, F. Enrique Hermsen, Joshua L. Kang, Woodae Lan, Jinggang Maeshima, Yoshinori Kudsk, Kenneth A. TI Parenteral nutrition induces organ specific alterations in polymeric immunoglobulin receptor levels SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE immunoglobulin A; polymeric immunoglobulin receptor; mucosal immunity; parenteral nutrition ID UPPER RESPIRATORY-TRACT; MUCOSAL IMMUNITY; ABDOMINAL-TRAUMA; LYMPHOID-TISSUE; SECRETORY IGA; FED MICE; ROUTE; MOUSE; EXPRESSION; INTESTINE AB Background. Secretory immunoglobulin A (IgA) prevents pathogen adherence at mucosal surfaces to prevent infection. Polymeric immunoglobulin receptor (pIgR), located on the basolateral. surface of mucosal cells, binds dimeric IgA produced by B cells with the cooperation of T cells in the lamina propria. This IgA-pIgR complex is transported apically, where it is exocytosed as secretory IgA to the mucosal surface. Our prior work shows that parenteral nutrition (PN) impairs both airway and small intestine mucosal immunity by reducing T and B cells and IgA levels. This work examines intestinal and respiratory tissue-specific pIgR responses to PN. Methods. Cannulated male Institute of Cancer Research mice were randomized to Chow (n = 10) or PN (n = 10). After 5 days, animals were sacrificed and lavages obtained from the small intestine, lung (BAL = bronchoalveolar lavage), and nasal airways (NAL). Small intestine, lung, and nasal passage tissues were also collected. Lavage and tissue homogenate IgA levels were quantified by enzyme-linked immunosorbent assay and pIgR by Western blot. Results. PN group SIL and NAL IgA levels dropped significantly compared with Chow. PN significantly reduced pIgR levels in the SI while no pIgR change was noted in nasal passages and lung pIgR actually increased with PN. Tissue homogenate IgA levels did not change with PN in the SI while levels in the nasal passage and lung decreased. Conclusions. PN impairs airway mucosal immunity by reduction in IgA available for transport rather than via a reduction in pIgR levels. In the small intestine, diminished pIgR is implicated in the deterioration of antibody-mediated mucosal immunity. (c) 2008 Elsevier Inc. All rights reserved. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Sano, Yoshifumi; Gomez, F. Enrique; Hermsen, Joshua L.; Kang, Woodae; Lan, Jinggang; Maeshima, Yoshinori; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Sano, Yoshifumi] Jikei Univ, Dept Surg, Sch Med, Tokyo, Japan. RP Kudsk, KA (reprint author), Univ Wisconsin Hosp & Clin, H4-736 CSC,600 Highland Ave, Madison, WI 53792 USA. EM KUDSK@surgery.wisc.edu FU NIH [R01 GM53439] FX The authors acknowledge support by NIH grant R01 GM53439; also based upon work supported in part by the Office of Research and Development, Biomedical Laboratory R and D Service, Department of Veterans Affairs. The authors thank the Yakult Central Institute for Microbiological Research for providing the SC antibody. NR 37 TC 14 Z9 15 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2008 VL 149 IS 2 BP 236 EP 242 DI 10.1016/j.jss.2007.12.790 PG 7 WC Surgery SC Surgery GA 350DG UT WOS:000259332200011 PM 18599079 ER PT J AU Farrow, B Albo, D Berger, DH AF Farrow, Buckminster Albo, Daniel Berger, David H. TI The role of the tumor microenvironment in the progression of pancreatic cancer SO JOURNAL OF SURGICAL RESEARCH LA English DT Review DE pancreatic cancer; tumor microenvironment; review; pancreatic stellate cells; perineural invasion; tumor stroma ID GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX PROTEINS; HUMAN PROSTATE-CANCER; PLASMINOGEN-ACTIVATOR SYSTEM; CELL INVASION; STELLATE-CELLS; TGF-BETA; PERINEURAL INVASION; DUCTAL CARCINOMA; GENE-EXPRESSION AB Pancreatic cancer is the most lethal abdominal malignancy due to its aggressive growth and rapid development of distant metastases, thus making treatment extremely difficult. Additionally, pancreatic adenocarcinoma is locally invasive, surrounded by a dense desmoplastic reaction which can involve adjacent vital structures, limiting the number of patients who are candidates for surgical resection at the time of diagnosis. Recently the tumor microenvironment in other adenocarcinomas has been determined to be an important mediator of cancer cell behavior; however, few studies have elucidated the tumor-stroma interactions in pancreatic cancer. This review summarizes the role of pancreatic stellate cells, perineural. invasion, angiogenesis, and inflammatory cells in fostering pancreatic cancer cell growth and invasion. The importance of extracellular matrix proteins, growth factors, and cytokines is also presented. Finally we suggest ideas for new avenues of research into the pancreatic tumor microenvironment which may permit the development of novel, more effective treatments for pancreatic cancer. (c) 2008 Elsevier Inc. All rights reserved. C1 [Farrow, Buckminster; Albo, Daniel; Berger, David H.] Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Farrow, B (reprint author), Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM bfarrow@bcm.edu NR 110 TC 88 Z9 93 U1 4 U2 22 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2008 VL 149 IS 2 BP 319 EP 328 DI 10.1016/j.jss.2007.12.7157 PG 10 WC Surgery SC Surgery GA 350DG UT WOS:000259332200021 PM 18639248 ER PT J AU Kidd, G Richards, VM Mason, CR Gallun, FJ Huang, R AF Kidd, Gerald, Jr. Richards, Virginia M. Mason, Christine R. Gallun, Frederick J. Huang, Rong TI Informational masking increases the costs of monitoring multiple channels SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID UNCERTAIN FREQUENCY; SIGNAL-DETECTION; MASKERS AB This study examined the costs of simultaneously monitoring two frequency regions. Listeners detected low- and high-frequency tones in a 2I4AFC procedure. On every trial, each signal was presented in either the first or second interval independently. Comparison of thresholds in single- and dual-signal conditions provided an estimate of the costs. Thresholds were obtained in quiet, in notched-filtered noise, and in randomized multitone maskers. No cost was found in quiet, whereas large costs were found for the masked conditions, especially for the multitone masker. These results suggest that costs of dividing attention in frequency depend on both signal and non-signal channels. (C) 2008 Acoustical Society of America C1 [Kidd, Gerald, Jr.; Mason, Christine R.] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA. [Kidd, Gerald, Jr.; Mason, Christine R.] Boston Univ, Ctr Hearing Sci, Boston, MA 02215 USA. [Richards, Virginia M.; Huang, Rong] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Gallun, Frederick J.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. RP Kidd, G (reprint author), Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA. EM gkidd@bu.edu; richards@psych.uppen.edu; cmason@bu.edu; frederick.gallun@va.gov; rongh@sas.upenn.edu RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU AFOSR [FA9550-05-1-2005]; NIH/NIDCD [DC004545, DC02012]; NIDCD [F32 DC006526] FX This work was supported by AFOSR Award No. FA9550-05-1-2005 and by Grant No. DC004545 and DC02012 from NIH/NIDCD. EG. was supported by F32 DC006526 from NIDCD. NR 14 TC 5 Z9 6 U1 0 U2 2 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD OCT PY 2008 VL 124 IS 4 BP EL223 EP EL229 DI 10.1121/1.2968302 PN 1 PG 7 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 363WQ UT WOS:000260298600058 PM 19062790 ER PT J AU Bilimoria, KY Talamonti, MS Sener, SF Bilimoria, MM Stewart, AK Winchester, DP Ko, CY Bentrem, DJ AF Bilimoria, Karl Y. Talamonti, Mark S. Sener, Stephen F. Bilimoria, Malcolm M. Stewart, Andrew K. Winchester, David P. Ko, Clifford Y. Bentrem, David J. TI Effect of Hospital Volume on Margin Status after Pancreaticoduodenectomy for Cancer SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID LONG-TERM SURVIVAL; MINIMAL POSTOPERATIVE COMPLICATIONS; PANCREATIC-CANCER; PROGNOSTIC-FACTORS; RESECTABLE ADENOCARCINOMA; SURGEONS CONTRIBUTION; RESECTION MARGINS; DATA-BASE; OUTCOMES; HEAD AB BACKGROUND: The volume-outcome relationship has been repeatedly demonstrated for pancreatectomy, but identifying underlying reasons for this association has been challenging. Some have Suggested that differences in surgical technique may affect longterm survival, but it is unknown whether margin-positive resection rates vary by hospital Volume. Our objective was to evaluate the effect of hospital pancreatectomy Volume on margin status. STUDY DESIGN: Patients who underwent pancreaticoduodenectomy for localized pancreatic adenocarcinoma were identified from the National Cancer Data Base (1998 to 2004). Regression modeling adjusting for patient, tumor, and hospital factors was used to assess predictors of margin involvement and to evaluate the effect of margin status on survival. Volume quintiles were based on average annual hospital pancreatectomy Volume. RESULTS: Of 12,101 patients, 24.4% had positive resection margins (14.6% microscopic/R1; 9.8% macroscopic/R2). From 1998 to 2004, there was nor a significant change in margin-positive resection rates (p = 0.43). Oil multivariable analysis, patients were more likely to have a margin-positive resection if they had a higher T classification or nodal involvement, were uninsured or living in lower-incline areas, or underwent resection at lowest-volume hospitals compared with highest-volume hospitals (25.9% versus 22.6%, p < 0.0001; odds ratio, 1.21; 95% confidence interval, 1.01 to 1.43). On multivariable analysis, margin involvement was associated with a higher risk of longterm mortality compared with margin-negative resections (p < 0.0001). CONCLUSIONS: Involved resection margins are a poor prognostic factor after a pancreaticoduodenectomy. Patients undergoing pancreaticoduodenectomy at low-volume centers are more likely to have margin-positive resections. Standardization of pathologic evaluation for pancreatectomy specimens is needed. (J Am Coll Surg 2008;207:510-519. (C) 2008 by the American College of Surgeons) C1 [Bilimoria, Karl Y.; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.] Amer Coll Surg, Canc Program, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Talamonti, Mark S.; Sener, Stephen F.; Bilimoria, Malcolm M.; Winchester, David P.; Bentrem, David J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Evanston, IL 60208 USA. [Talamonti, Mark S.; Sener, Stephen F.; Bilimoria, Malcolm M.; Winchester, David P.] Evanston NW Healthcare, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Program, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. NR 55 TC 70 Z9 75 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2008 VL 207 IS 4 BP 510 EP 519 DI 10.1016/j.jamcollsurg.2008.04.033 PG 10 WC Surgery SC Surgery GA 363NM UT WOS:000260274000007 PM 18926452 ER PT J AU Hazzard, WR AF Hazzard, William R. TI Defining geriatrics to forge coalitions and gain leverage SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material C1 [Hazzard, William R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Hazzard, William R.] VA Puget Sound Hlth Care Syst, Dept Geriatr & Extended Care, Seattle, WA USA. RP Hazzard, WR (reprint author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. EM william.ha-zzard@med.va.gov NR 9 TC 3 Z9 3 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2008 VL 56 IS 10 BP 1812 EP 1815 DI 10.1111/j.1532-5415.2008.02003.x PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 358EO UT WOS:000259900100005 PM 19054200 ER PT J AU Crnich, CJ Drinka, P AF Crnich, Christopher J. Drinka, Paul TI Treatment of Bacteriuria in Older Adults: Still Room for Improvement SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material ID NURSING-HOME RESIDENTS; TERM-CARE FACILITIES; ASYMPTOMATIC BACTERIURIA; ANTIBIOTIC USE; EDUCATIONAL INTERVENTION; ANTIMICROBIAL USE; TRACT-INFECTIONS; PROCALCITONIN; TRIAL; PYELONEPHRITIS C1 [Crnich, Christopher J.] Univ Wisconsin, Dept Med, Infect Dis Sect, Sch Med & Publ Hlth, Madison, WI USA. [Crnich, Christopher J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Drinka, Paul] Univ Wisconsin, Sch Med & Publ Hlth, Sect Geriatr, Madison, WI USA. [Drinka, Paul] Bethany Home, Waupaca, WI USA. RP Crnich, CJ (reprint author), 600 Highland Ave,CSC H4-557, Madison, WI 53792 USA. EM cjc@medicine.wisc.edu OI Crnich, Christopher/0000-0002-9320-9262 NR 31 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2008 VL 9 IS 8 BP 542 EP 544 DI 10.1016/j.jamda.2008.07.004 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 362YN UT WOS:000260233200003 PM 19083286 ER PT J AU Buchanan, RJ Rosenthal, M Graber, DR Wang, SJ Kim, MS AF Buchanan, Robert J. Rosenthal, Mark Graber, David R. Wang, Suojin Kim, Myung Suk TI Racial and Ethnic Comparisons of Nursing Home Residents at Admission SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Nursing facilities; race; ethnicity; minorities; Minimum Data Set ID MINIMUM DATA SET; OLDER-ADULTS; CARE; HEALTH; DISPARITIES; POPULATION; PREDICTORS; DISEASE; HIV; MANAGEMENT AB Objective: To present racial/ethnic comparisons of comprehensive profiles of nursing home residents at admission, including whites, African Americans, Hispanics, Asians/Pacific Islanders, and American Indians/Alaska Natives. Methods: More than 885,000 admission assessments recorded in the national Minimum Data Set (MDS) were analyzed. Racial and ethnic analyses of the MDS admission assessments were conducted using the software package SAS. Results: There were significant racial/ethnic differences in gender and age, with minority residents more likely to be male and younger. African American, Hispanic, and Asian/Pacific Islanders were significantly more likely than white residents to exhibit total dependence in the self-performance of the ADLs and to have greater cognitive impairments, with Asian/Pacific Islanders the most physically dependent and cognitively impaired. Discussion: The results illustrate significant and substantive differences among the racial/ethnic groups for many demographic characteristics, as well as health-related indicators and conditions. This analysis suggests that the general perspective that economically disadvantaged minorities enter nursing homes in worse condition than whites is too simplistic. More research, particularly qualitative studies of specific minority groups, will advance our understanding of why members of some racial/ethnic groups require nursing home placement sooner than other groups. C1 [Buchanan, Robert J.] Mississippi State Univ, Dept Polit Sci & Publ Adm, Mississippi State, MS 39762 USA. [Rosenthal, Mark] Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA USA. [Rosenthal, Mark] W Los Angeles Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90073 USA. [Graber, David R.] Med Univ S Carolina, Dept Hlth Adm & Policy, Charleston, SC 29425 USA. [Wang, Suojin] Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA. [Kim, Myung Suk] Sogang Univ, Coll Business Adm, Seoul, South Korea. RP Buchanan, RJ (reprint author), Mississippi State Univ, Dept Polit Sci & Publ Adm, Mississippi State, MS 39762 USA. EM rjb161@ps.msstate.edu FU National Institute of Environmental Health Sciences [P30 ES09106] FX S.W.'s research was supported in part by the Texas A&M University Center for Environmental and Rural Health via a grant from the National Institute of Environmental Health Sciences (P30 ES09106) to do statistical methodology research and its applications to the health sciences. NR 53 TC 6 Z9 6 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2008 VL 9 IS 8 BP 568 EP 579 DI 10.1016/j.jamda.2008.04.012 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 362YN UT WOS:000260233200008 PM 19083291 ER PT J AU Imam, SN Wright, K Bhoopalam, N Choudhury, A AF Imam, Syed Nasrat Wright, Khadijah Bhoopalam, Nimiala Choudhury, Abdul TI Hemolytic Anemia From Ceftriaxone in an Elderly Patient: A Case Report SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Ceftriaxone; hemolytic anemia; elderly ID IMMUNE HEMOLYSIS AB Hemolytic anemia is uncommon in the general population; however, drug-induced hemolysis is not rare in hospitalized patients. We report a case of unrecognized subacute hemolytic anemia due to ceftriaxone in a geriatric patient requiring multiple blood transfusions before a correct diagnosis could be established. This is a US government work. There are no restrictions on its use. C1 [Imam, Syed Nasrat; Wright, Khadijah] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Imam, Syed Nasrat; Wright, Khadijah; Bhoopalam, Nimiala; Choudhury, Abdul] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Imam, SN (reprint author), Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. EM syed.imam@va.gov NR 3 TC 5 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT PY 2008 VL 9 IS 8 BP 610 EP 611 DI 10.1016/j.jamda.2008.05.001 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 362YN UT WOS:000260233200014 PM 19083297 ER PT J AU Sawhney, R Allen, D Nanavati, S AF Sawhney, Rajiv Allen, Derrick Nanavati, Sujal TI Kissing balloon-expandable iliac stents complicated by stent fracture SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter ID SIROLIMUS-ELUTING STENT; LIMITATIONS; ARTERIES C1 [Sawhney, Rajiv; Allen, Derrick; Nanavati, Sujal] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Radiol, San Francisco, CA 94121 USA. RP Sawhney, R (reprint author), Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD OCT PY 2008 VL 19 IS 10 BP 1519 EP 1520 DI 10.1016/j.jvir.2008.06.022 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 356XW UT WOS:000259811900020 PM 18755601 ER PT J AU Schauer, I Bergman, B Snell-Bergeon, J Maahs, DM Eckel, RH Rewers, M AF Schauer, Irene Bergman, Bryan Snell-Bergeon, Janet Maahs, David M. Eckel, Robert H. Rewers, Marian TI Insulin Resistance in Type 1 Diabetes Correlates With Coronary Artery Calcification SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Schauer, Irene; Bergman, Bryan; Eckel, Robert H.] Univ Colorado, Dept Med, Div Endocrinol, Denver, CO USA. [Schauer, Irene] Denver VA Med Ctr, Dept Med, Div Endocrinol, Denver, CO USA. [Snell-Bergeon, Janet; Maahs, David M.; Rewers, Marian] Univ Colorado, Dept Pediat, Barbara Davis Ctr Childhood Diabet, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2008 VL 17 IS 8 BP 1242 EP 1242 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 378OE UT WOS:000261331200047 ER PT J AU Larauche, MH Yuan, PQ Wang, L Mulugeta, M Tache, Y AF Larauche, Muriel H. Yuan, Pu-Qing Wang, Lixin Mulugeta, Million Tache, Yvette. TI Sex-Related Differences of Colonic Response to Stress: Role of Colonic Corticotropin Releasing Factor SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Larauche, Muriel H.] Univ Calif Los Angeles, Dept Med, Specialized Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90024 USA. Div Digest Dis, Los Angeles, CA USA. VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2008 VL 17 IS 8 BP 1252 EP 1253 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 378OE UT WOS:000261331200076 ER PT J AU Hutt, E Radcliff, TA Liebrecht, D Fish, R McNulty, M Kramer, AM AF Hutt, Evelyn Radcliff, Tiffany A. Liebrecht, Debra Fish, Ron McNulty, Monica Kramer, Andrew M. TI Associations Among Nurse and Certified Nursing Assistant Hours per Resident per Day and Adherence to Guidelines for Treating Nursing Home-Acquired Pneumonia SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Nursing homes; Pneumonia; Nurse staffing ID MINIMUM DATA SET; HOSPITALIZATION; OUTCOMES; QUALITY; CARE AB Background. Nursing home (NH)-acquired pneumonia (NHAP) causes excessive mortality, hospitalization, and functional decline, partly because many NH residents do not receive appropriate care. Care structures like nurse/resident staffing ratios can impede or abet quality care. This study examines the relationship between nurse/resident staffing ratios, turnover, and adherence to evidence-based guidelines for treating NHAP. Methods. A prospective, chart-review study was conducted among residents of 16 NHs in three states with >= 2 signs and symptoms of NHAP during the 2004-2005 influenza season. NH medical records were reviewed concurrently for functional status, comorbidity, NHAP severity, and guideline adherence. Ratio of licensed nurse and Certified Nursing Assistant (CNA) hours per resident per day (hrpd) and ratio of newly hired nursing staff/year to current nursing staff were provided by Directors of Nursing. Associations among guideline adherence, nurse and CNA hrpd, and turnover were assessed using multiple regression to adjust for case mix, facility characteristics, and clustering of residents in facilities. Results. Mid (1.7-2.0) and high (> 2.0) CNA hrpd were significantly associated with better pneumococcal and influenza vaccination rates. More than 1.2 licensed nurse hrpd was significantly associated with appropriate hospitalization (odds ratio [OR] 12.4: 95% confidence interval [CI], 3.5-43.8) and guideline-recommended antibiotics (OR 3.8: 95% CI, 1.7-8.7). A > 70% turnover was inversely related to timely physician notification (OR 0.4: 95% CI. 0.2-0.7) and appropriate hospitalization (OR 0.09: 95% CI, 0.05-0.26). Conclusions. NHAP treatment guideline adherence is associated with rtursc and CNA hr-Ixl and stability. An NI-I's ability to implement evidence-based care may depend on adeqtnnc staffing ratios and stability. C1 [Hutt, Evelyn] Denver VA Med Ctr, Colorado REAP Improve Care Coordinat CRICC, Denver, CO 80220 USA. [Hutt, Evelyn; Radcliff, Tiffany A.; Liebrecht, Debra; Fish, Ron; McNulty, Monica; Kramer, Andrew M.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Hutt, E (reprint author), Denver VA Med Ctr, Colorado REAP Improve Care Coordinat CRICC, 151,1055 Clermont St, Denver, CO 80220 USA. EM erelyn.hutt@uchsc.edu FU National Institutes of Health to the University of Colorado Health Sciences Center [AHRQ 5 R01-HS013618-04] FX This work was supported by AHRQ 5 R01-HS013618-04 from the National Institutes of Health to the University of Colorado Health Sciences Center (Principal Investigator Evelyn Hutt). NR 28 TC 10 Z9 10 U1 0 U2 2 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2008 VL 63 IS 10 BP 1105 EP 1111 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 366LS UT WOS:000260483600012 PM 18948562 ER PT J AU Rafikova, O Salah, EM Tofovic, SP AF Rafikova, Olga Salah, Eman M. Tofovic, Stevan P. TI Renal and metabolic effects of tempol in obese ZSF(1) rats-distinct role for superoxide and hydrogen peroxide in diabetic renal injury SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID IMPROVES INSULIN SENSITIVITY; PERMEABLE RADICAL SCAVENGER; OXIDATIVE STRESS; GLOMERULAR INJURY; ANTIOXIDANT ENZYMES; OXYGEN RADICALS; ORGAN INJURY; NITRIC-OXIDE; DISMUTASE; HYPERTENSION AB Oxidative stress, that is, overproduction of reactive oxygen species and reduced antioxidant system activity, is implicated in the pathogenesis of diabetic complications; and therefore, Superoxide dismutase (SOD) mimetic tempol should be protective in diabetic kidney. However, the effects of tempol in metabolic syndrome-associated renal injury have not been thoroughly examined. In this study, we examined the effects of 9 weeks of treatment with tempol on metabolic status, renal oxidative stress, and kidney function and structure in obese, diabetic, hypertensive ZSF(1) rats and their nondiabetic, hypertensive, lean littermates. The obese rats had significantly reduced total SOD and catalase activity, increased peroxidase activity and lipid peroxidation, and higher level of protein oxidation in renal cortical tissue compared with their lean littermates. These changes were accompanied by renal injury (proteinuria; reduced excretory function; and markedly increased glomerular and interstitial inflammation, proliferation, and collagen IV synthesis). Tempol treatment slightly increased total SOD activity. significantly reduced lipid peroxidation and peroxidase activity, but had no effect on catalase and protein oxidation. Tempol had no effects on blood pressure, renal hemodynamics and excretory function, and proteinuria in obese rats, yet improved insulin sensitivity and reduced renal inflammatory, proliferative, and fibrotic changes. Because tempol possesses no catalase activity and, in diabetes, not only SOD but also catalase is inhibited, it is possible that the toxicity of hydrogen peroxide (H2O2) remains unaltered under tempol treatment. This Study Suggests that superoxide and H2O2 may have distinct roles in the pathogenesis of diabetic renal injury, with superoxide mainly being involved in inflammatory, proliferative, and fibrotic changes, and H2O2 in glomerular hemodynamics and proteinuria. (C) 2008 Elsevier Inc. All rights reserved. C1 [Tofovic, Stevan P.] Univ Pittsburgh, Sch Med, Dept Med, Ctr Clin Pharmacol, Pittsburgh, PA 15219 USA. [Salah, Eman M.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15219 USA. [Salah, Eman M.] VA Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. RP Tofovic, SP (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Ctr Clin Pharmacol, Pittsburgh, PA 15219 USA. EM tofovic@dom.pitt.edu NR 51 TC 17 Z9 17 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD OCT PY 2008 VL 57 IS 10 BP 1434 EP 1444 DI 10.1016/j.metabol.2008.05.014 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 363BI UT WOS:000260240500019 PM 18803950 ER PT J AU Ilvesaro, JM Merrell, MA Li, L Wakchoure, S Graves, D Brooks, S Rahko, E Jukkola-Vuorinen, A Vuopala, KS Harris, KW Selander, KS AF Ilvesaro, Joanna M. Merrell, Melinda A. Li, Li Wakchoure, Savita Graves, David Brooks, Sonja Rahko, Eeva Jukkola-Vuorinen, Arja Vuopala, Katri S. Harris, Kevin W. Selander, Katri S. TI Toll-Like Receptor 9 Mediates CpG Oligonucleotide-Induced Cellular Invasion SO MOLECULAR CANCER RESEARCH LA English DT Article ID BREAST-CANCER CELLS; BACTERIAL-DNA; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; IN-VITRO; EXPRESSION; ACTIVATION; TLR9; PATHWAYS AB Toll-like receptor 9 (TLR9) belongs to the innate immune system and recognizes microbial and vertebrate DNA. We showed previously that treatment with the TLR9-agonistic ODN M362 (a CpG sequence containing oligonucleotide) induces matrix metalloproteinase-13-mediated invasion in TLR9-expressing human cancer cell lines. Here, we further characterized the role of the TLR9 pathway in this process. We show that CpG oligonucleotides induce invasion in macrophages from wild-type C57/B6 and MyD88 knockout mice and in human MDA-MB-231 breast cancer cells lacking MyD88 expression. This effect was significantly inhibited in macrophages from TLR9 knockout mice and in human MDA-MB-231 breast cancer cells stably expressing TLR9 small interfering RNA or dominant-negative tumor necrosis factor receptor-associated factor 6 (TRAF6). Sequence modifications to the CpG oligonucleotides that targeted the stem loop and other secondary structures were shown to influence the invasion-inducing effect in MDA-MB-231 cells. In contrast, methylation of the cytosine residues of the parent CpG oligonucleotide did not affect the TLR9-mediated invasion compared with the unmethylated parent CpG oligonucleotide. Finally, expression of TLR9 was studied in clinical breast cancer samples and normal breast epithelium with immunohistochemistry. TLR9 staining localized in epithelial cells in both cancer and normal samples. The mean TLR9 staining intensity was significantly increased in the breast cancer cells compared with normal breast epithelial cells. In conclusion, our results suggest that TLR9 expression is increased in breast cancer and CpG oligonucleotide-induced cellular invasion is mediated via TLR9 and TRAF6, independent of MyD88. Further, our findings suggest that the structure and/or stability of DNA may influence the induction of TLR9-mediated invasion in breast cancer. (Mol Cancer Res 2008;6(10):1534-43) C1 [Ilvesaro, Joanna M.; Merrell, Melinda A.; Li, Li; Wakchoure, Savita; Harris, Kevin W.; Selander, Katri S.] Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Graves, David; Brooks, Sonja] Univ Alabama, Dept Chem, Birmingham, AL 35294 USA. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Rahko, Eeva; Jukkola-Vuorinen, Arja] Univ Hosp Oulu, Dept Oncol, Oulu, Finland. [Vuopala, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. RP Selander, KS (reprint author), Univ Alabama, Dept Med, Div Hematol Oncol, WT1 T558,1824 6th Ave S, Birmingham, AL 35294 USA. EM Katri.Selander@ccc.uab.edu FU Academy of Finland; Paavo Nurmi Foundation; Finnish Cultural Foundation; Northern Finland Duodecim Foundation FX Academy of Finland, Paavo Nurmi Foundation, Finnish Cultural Foundation (J.M. Ilvesaro), Finnish Cancer Foundation (K.S. Selander), Northern Finland Duodecim Foundation (A. Jukkola-Vuorinen, E. Rahko. and K.S. Selander), and Barry M. Goldwater Scholarship (S. Brooks).; The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with IS U.S.C. Section 1734 solely to indicate this fact. NR 49 TC 52 Z9 56 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 J9 MOL CANCER RES JI Mol. Cancer Res. PD OCT PY 2008 VL 6 IS 10 BP 1534 EP 1543 DI 10.1158/1541-7786.MCR-07-2005 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 363CS UT WOS:000260244100002 PM 18922969 ER PT J AU Basak, S Pookot, D Noonan, EJ Dahiya, R AF Basak, Shashwati Pookot, Deepa Noonan, Emily J. Dahiya, Rajvir TI Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID PROSTATE-CANCER CELLS; HISTONE DEACETYLASE INHIBITORS; TUMOR-SUPPRESSOR GENES; NF-KAPPA-B; BREAST-CANCER; UP-REGULATION; IN-VIVO; EXPRESSION; APOPTOSIS; HEAT-SHOCK-PROTEIN-90 AB Androgen receptor (AR) is a ligand-activated transcription factor belonging to the steroid hormone receptor family and is very important for the development and progression of prostate cancer. The soy isoflavone genistein has been shown previously to down-regulate AR in androgen-dependent prostate cancer cell lines such as LNCaP. However, the mechanism(s) by which AR is down-regulated by genistein is still not known fully. We show a new mechanism by which genistein inhibits AR protein levels. We show that genistein-treated LNCaP cells exhibit increased ubiquitination of AR, suggesting that AR protein is down-regulated via a proteasome-mediated pathway. AR is normally stabilized by the chaperone activity of the heat shock protein Hsp90. The increased ubiquitination of AR after genistein treatment is attributed to decreased Hsp90 chaperone activity as assessed by its increased functionally inactive acetylated form. Consistent with this result, we find that HDAC6, which is a Hsp90 deacetylase, is inhibited by the antiestrogenic activity of genistein. Hence, in this study, we elucidate a novel mechanism of AR down-regulation by genistein through inhibition of HDAC6-Hsp90 cochaperone function required to stabilize AR protein. Our results suggest that genistein could be used as a potential chemopreventive agent for prostate cancers along with known inhibitors of HDAC6 and Hsp90. [Mol Cancer Ther 2008;7(10):3195-202] C1 [Dahiya, Rajvir] San Francisco VA Med Ctr, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA. [Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Urol Res Ctr 112F, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA. EM Rdahiya@urology.ucsf.edu FU NIH [NIHNCI R01CA 111470, T32DK007790]; VA Merit Review and Research Enhancement Award FX Grant support: NIH grants NIHNCI R01CA 111470 and T32DK007790; VA Merit Review and Research Enhancement Award Program (Principal Investigator: R. Dahiya). NR 46 TC 62 Z9 64 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD OCT PY 2008 VL 7 IS 10 BP 3195 EP 3202 DI 10.1158/1535-7163.MCT-08-0617 PG 8 WC Oncology SC Oncology GA 362MO UT WOS:000260202000009 PM 18852123 ER PT J AU Lu, Y Nie, DB Witt, WT Chen, QY Shen, M Xie, HY Lai, LX Dai, YF Zhang, J AF Lu, Yi Nie, Daibang Witt, William T. Chen, Qiuyan Shen, Miaoda Xie, Haiyang Lai, Liangxue Dai, Yifan Zhang, Jian TI Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-30 phosphorylation SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID ESSENTIAL FATTY-ACIDS; BETA-CATENIN; TRANSGENIC MICE; CELLS; OMEGA-3-FATTY-ACIDS; ACCUMULATION; MODULATION; MECHANISMS; RATIOS; RISK AB Epidemiologic studies inclusively indicate that "unhealthy" dietary fat intake is one of the potential risk factors for cancer. In dietary fat, there are two types of polyunsaturated fatty acids (PUFA), omega-3 (n-3) and omega-6 (n-6). Numerous studies support that the ratio of n-6/n-3 affects tumorigenesis. It was reported that adenoviral transfer of the fat-1 gene, which converts n-6 to n-3, into breast and lung cancer cells had an antitumor effect in vitro. However, the effects of the fat-1 gene expression on tumor growth in vivo have not been studied and the mechanisms remain unclear. Accordingly, prostate cancer DU145 and PC3 cells were transfected with either the fat-1 gene or a control vector. The cells that expressed the fat-1 gene had a lower n-6/n-3 PUFA ratio compared with the cells that expressed the control vector. The fat-1 gene expression significantly inhibited prostate cancer cell proliferation and invasion in vitro. The fat-1 and control vector-transfected prostate cancer cells were s.c. implanted into severe combined immunodeficient mice for 6 weeks. The fat-1 gene expression significantly diminished tumor growth in vivo, but the control vector had no effect. Finally, we evaluated signaling pathways that may be important for fat-1 gene function. Administration of n-3 PUFA induced caspase-3-mediated prostate cancer cell apoptosis in vitro. The fat-1 gene expression inhibited prostate cancer cell proliferation via reduction of GSK-3 beta phosphorylation and subsequent down-regulation of both beta-catenin and cyclin D1. These results suggest that fat-1 gene transfer directly into tumor cells could be used as a novel therapeutic approach. [Mol Cancer Ther 2008;7(10):3203-11] C1 [Zhang, Jian] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA 15240 USA. [Witt, William T.; Shen, Miaoda; Xie, Haiyang; Dai, Yifan] Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA USA. [Nie, Daibang; Lai, Liangxue] Jilin Univ, Coll Anim Sci & Vet Technol, Changchun 130023, Peoples R China. RP Zhang, J (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Med, Room 2E146,Univ Dr, Pittsburgh, PA 15240 USA. EM daiy@upmc.edu; zhangj2@upmc.edu FU Department of Defense [PC061231]; University of Pittsburgh Cancer Institute CCSG FX Grant support: Department of Defense PC061231 and University of Pittsburgh Cancer Institute CCSG (J. Zhang). NR 28 TC 29 Z9 29 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD OCT PY 2008 VL 7 IS 10 BP 3203 EP 3211 DI 10.1158/1535-7163.MCT-08-0494 PG 9 WC Oncology SC Oncology GA 362MO UT WOS:000260202000010 PM 18852124 ER PT J AU Wetmore, JB Lovett, DH Hung, AM Cook-Wiens, G Mahnken, JD Sen, S Johansen, KL AF Wetmore, James B. Lovett, David H. Hung, Adriana M. Cook-Wiens, Galen Mahnken, Jonathan D. Sen, Saunak Johansen, Kirsten L. TI Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients SO NEPHROLOGY LA English DT Article DE albumin; CRP; dialysis; IL-6; mortality; serum amyloid A ID CHRONIC-RENAL-FAILURE; APPARENTLY HEALTHY-MEN; CARDIOVASCULAR MORTALITY; DIALYSIS PATIENTS; ALBUMIN CONCENTRATION; GENE-EXPRESSION; BLOOD-PRESSURE; ALL-CAUSE; FETUIN-A; INFLAMMATION AB Background: Individuals with end-stage renal disease (ESRD) manifest a chronic inflammatory state. Serum albumin, C-reactive protein (CRIP), interleukin-6 (IL-6) and serum amyloid A (SAA) have been associated with mortality in ESRD, although reports vary as to whether they are true independent markers of mortality. We undertook a prospective study to determine whether these markers could predict mortality in ESRD. Methods: A cohort of individuals on haemodialysis was followed prospectively for a mean of 2.1 years. Albumin, CRR IL-6 and SAA were drawn at enrolment. Association between mortality and serum markers was assessed using Cox proportional hazards regression. A trend analysis was undertaken to establish the functional form of the association between serum markers and outcome. Results: After multivariable adjustment, IL-6 was most strongly associated with mortality, followed Closely by albumin (P = 0.0002 and P = 0.0005, respectively). CRP was marginally associated with mortality (P = 0.046), and SAA was not independently associated with mortality. In the final model adjusting for the effects of both IL-6 and albumin simultaneously, both markers remained associated with mortality (P = 0.003 and P = 0.011). Conclusion: IL-6 had the strongest independent association with mortality, followed closely by albumin. CRP and SAA were not associated with mortality when measured at single time points. Increasing levels of IL-6 and decreasing levels of albumin were associated with increased mortality. IL-6 and albumin may be capturing different aspects of the inflammatory burden observed in haemodialysis patients. C1 [Wetmore, James B.; Lovett, David H.; Hung, Adriana M.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco VAMC, San Francisco, CA USA. [Cook-Wiens, Galen; Mahnken, Jonathan D.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Mahnken, Jonathan D.] Univ Kansas, Sch Med, Ctr Biostat & Adv Informat, Kansas City, KS USA. [Sen, Saunak] Univ Kansas, Sch Med, Dept Biostat, Kansas City, KS USA. RP Wetmore, JB (reprint author), MS 3002,3901 Rainbow Blvd, Kansas City, KS 66160 USA. EM jwetmore@kumc.edu FU NIH [DK 39776, DK 56182, DK 07219]; UCSF Foundation Greenberg Awards [80357, 60519]; Amgen [20010180]; National Kidney Foundation FX This Study was supported by NIH grants DK 39776 (DHL), DK 56182 (KLJ), DK 07219 (JBW), UCSF Foundation Greenberg Awards #80357 and #60519 (DHL, KLJ), Amgen Grant. #20010180 (AMH, DHL, KLJ) mid National Kidney Foundation Fellow Grants (AMH, JBW). We thank Satellite Dialysis for assistance in patient recruitment. NR 55 TC 16 Z9 16 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1320-5358 J9 NEPHROLOGY JI Nephrology PD OCT PY 2008 VL 13 IS 7 BP 593 EP 600 DI 10.1111/j.1440-1797.2008.01021.x PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 361PJ UT WOS:000260139300007 PM 18826487 ER PT J AU Voss, AC Maki, KC Garvey, WT Hustead, DS Alish, C Fix, B Mustad, VA AF Voss, Anne Coble Maki, Kevin C. Garvey, W. Timothy Hustead, Deborah S. Alish, Carolyn Fix, Brenda Mustad, Vikkie A. TI Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes SO NUTRITION LA English DT Article DE type 2 diabetes; tube-feeding; slowly digested carbohydrate; monounsaturated fatty acids; glucose; insulin; glucagon-like peptide-1; fructo-oligosaccharides; omega-3 fatty acids; enteral formulas ID GLUCAGON-LIKE PEPTIDE-1; MONOUNSATURATED FATTY-ACIDS; GLYCEMIC INDEX; INSULIN-SECRETION; ENTERAL FORMULA; PLASMA-GLUCOSE; BLOOD-PRESSURE; MELLITUS; METAANALYSIS; HUMANS AB Objectives: This study evaluated the glycemic, insulinemic, and glucagon-like peptide-1 (GLP-1) responses of subjects with type 2 diabetes mellitus to consumption of two diabetes-specific tube-feeding formulas (slowly digested carbohydrate formula [SDC] and diabetes-specific formula [DSF]) and-one formula intended for individuals without diabetes (standard formula [STND]). Methods: Forty-eight subjects controlled with diet and/or oral anti hyperglycemic medications received the SDC, DSF, and STND. Postprandial glucose, insulin, and GLP-1 were measured on three occasions after an overnight fast in a double-blinded, randomized, three-treatment, crossover design. Results: The positive area under the curve for glucose and insulin with the STND was higher (P < 0.001) compared with the SDC and DSF. The adjusted GLP-1 concentration at 60 min was higher for the SDC compared with the DSF and STND (P < 0.05). Conclusion: Both lower-carbohydrate diabetes-specific formulas resulted in a lower postprandial blood glucose response compared with the STND. The formula also rich in slowly digested carbohydrate and monounsaturated and omega-3 fatty acids (SDC) produced significantly lower blood glucose and insulin responses and higher levels of GLP-1 in the presence of significantly lower insulin concentrations. These results support the view that the quantity and quality of carbohydrate and fat may play important roles in the management of patients with type 2 diabetes mellitus and could result in improved beta-cell function over the long term. (C) 2008 Elsevier Inc. All rights reserved. C1 [Voss, Anne Coble; Hustead, Deborah S.; Alish, Carolyn; Fix, Brenda; Mustad, Vikkie A.] Abbott Labs, Columbus, OH 43125 USA. [Maki, Kevin C.] Provident Clin Res, Glen Ellyn, IL USA. [Garvey, W. Timothy] Univ Alabama, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Voss, AC (reprint author), Abbott Labs, Columbus, OH 43125 USA. EM anne.voss@abbott.com NR 51 TC 14 Z9 16 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-9007 J9 NUTRITION JI Nutrition PD OCT PY 2008 VL 24 IS 10 BP 990 EP 997 DI 10.1016/j.nut.2008.06.009 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 352ZF UT WOS:000259535200010 PM 18718737 ER PT J AU Ausk, KJ Ioannou, GN AF Ausk, Karlee J. Ioannou, George N. TI Is obesity associated with anemia of chronic disease? A population-based study SO OBESITY LA English DT Article ID C-REACTIVE PROTEIN; ADIPOSE-TISSUE; INSULIN-RESISTANCE; IRON-DEFICIENCY; SIGNALING ROLE; UNITED-STATES; INFLAMMATION; HEPCIDIN; PREVALENCE; ADULTS AB Obesity is characterized by chronic, low-grade, systemic inflammation, which, in turn, has been associated with anemia of chronic disease. We hypothesized that obesity may be associated with the features of anemia of chronic disease, including low hemoglobin concentration, low serum iron and transferrin saturation (TS), and elevated serum ferritin. We compared normal-weight to overweight and obese adult participants of the third National Health and Nutrition Examination Survey with respect to hemoglobin concentration and levels of serum iron, TS, and ferritin. Measured BMI was used to categorize participants into normal weight (BMI < 25 kg/m(2), n = 6,059), overweight (BMI 25 to < 30 kg/m(2), n = 5,108), mildly obese (BMI 30 to < 35 kg/m(2), n = 2,366), moderately obese (BMI 35 to < 40 kg/m(2), n = 850), and severely obese (BMI >= 40 kg/m(2), n = 465). After adjustment for age, gender, menstruation, race/ethnicity, education, alcohol consumption, smoking, blood donation, and dietary iron intake, serum ferritin was progressively higher with increasing BMI category, whereas serum iron and TS were progressively lower. However, compared to normal-weight persons, those in all other higher BMI categories did not have a significant change in hemoglobin concentration after adjustment for the above-mentioned confounders. Overweight and obesity were associated with changes in serum iron, TS, and ferritin that would be expected to occur in the setting of chronic, systemic inflammation. However, overweight and obese persons were not more likely to be anemic compared with normal-weight persons. C1 [Ausk, Karlee J.; Ioannou, George N.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA. RP Ioannou, GN (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM georgie@medicine.washington.edu FU American Liver Foundation and American Association for the Study of Liver Diseases Jan Albrecht Award; Research Enhancement Award Program, Veterans Affairs Puget Sound Health Care System FX This work was supported by the American Liver Foundation and American Association for the Study of Liver Diseases Jan Albrecht Award (G.N.I.), Research Enhancement Award Program, Veterans Affairs Puget Sound Health Care System (G.N.I.). NR 27 TC 64 Z9 67 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD OCT PY 2008 VL 16 IS 10 BP 2356 EP 2361 DI 10.1038/oby.2008.353 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 354OR UT WOS:000259649400025 PM 18719644 ER PT J AU Shea, JA Guerra, CE Weiner, J Aguirre, AC Ravenell, KL Asch, DA AF Shea, Judy A. Guerra, Carmen E. Weiner, Janet Aguirre, Abigail C. Ravenell, Karima L. Asch, David A. TI Adapting a patient satisfaction instrument for low literate and Spanish-speaking populations: Comparison of three formats SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE health literacy; patient satisfaction; survey formats ID FUNCTIONAL HEALTH LITERACY; CAHPS(R) HOSPITAL SURVEY; DATA QUALITY; CORE SURVEY; CARE; TELEPHONE; MAIL; INSTRUCTIONS; ILLUSTRATIONS; EQUIVALENCE AB Objective: To compare responses to print versions of the Consumer Assessment of Healthcare Providers and Systems 2.0 survey (CAHPS) to those for an illustration enhanced format and a telephone based interactive voice response format. Methods: First, 2015 adult patients awaiting primary care visits completed: demographic information. Test of Functional Health Literacy (S-TOFHLA). CAHPS in one of three formats: print, illustrated, or interactive voice. A second sample of 4800 active patients was randomized to receive alternative formats. Results: Response rates for the illustrated (31.3%) and print (30.4%) formats were significantly higher than for the interactive voice format (18.1%). The results of the illustrated format were comparable to the traditional text version, but required about 2 min more to complete by both low and high literacy groups. There were almost no invalid responses for the interactive voice format, but the format was associated with lower CAHPS satisfaction scores. Conclusion: Despite extensive efforts to produce formats tailored to individuals with limited literacy, surprisingly we found no consistent advantages to either alternative format. In fact. the interactive voice format yielded lower satisfaction scores and lower response rates. Practice implications: Practitioners need to ensure the health instruments they use are aligned with literacy skills and delivery preferences of their consumers. The lack of benefit of the illustrated form does not Support investment Of resources in these formats to measure satisfaction. The interactive voice response deserves more study-do lower scores register limited access to Or use of telephones. irritation or true signal? (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Shea, Judy A.; Guerra, Carmen E.; Weiner, Janet; Aguirre, Abigail C.; Ravenell, Karima L.; Asch, David A.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Shea, Judy A.; Ravenell, Karima L.; Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Shea, Judy A.; Weiner, Janet; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Shea, JA (reprint author), Univ Penn, Dept Med, Div Gen Internal Med, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM sheaja@mail.upenn.edu OI Weiner, Janet/0000-0001-5810-5807; Asch, David/0000-0002-7970-286X FU Agency for Healthcare Research and Quality [R01 HS10299, HS10299-S] FX This study was supported by R01 HS10299 and HS10299-S from the Agency for Healthcare Research and Quality. We are indebted to our collaborators at Health Partners, particularly Michael Schaffer, Pharm. D, MBA. NR 37 TC 18 Z9 18 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD OCT PY 2008 VL 73 IS 1 BP 132 EP 140 DI 10.1016/j.pec.2008.03.026 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 356JI UT WOS:000259774100020 PM 18486414 ER PT J AU Sanches, M Keshavan, MS Brambilla, P Soares, JC AF Sanches, Marsal Keshavan, Matcheri S. Brambilla, Paolo Soares, Jair C. TI Neurodevelopmental basis of bipolar disorder: A critical appraisal SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE bipolar disorder; development; magnetic resonance imaging; mood disorders; neuroimaging ID MINOR PHYSICAL ANOMALIES; MAGNETIC-RESONANCE SPECTROSCOPY; MAJOR DEPRESSIVE DISORDER; DEFICIT HYPERACTIVITY DISORDER; STRUCTURAL BRAIN ABNORMALITIES; MONOZYGOTIC TWINS DISCORDANT; SUBGENUAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; CAVUM-SEPTUM-PELLUCIDUM; PERINATAL RISK-FACTORS AB Neurodevelopmental factors have been implicated in the pathophysiology of mental disorders. However, the evidence regarding their role in bipolar disorder is controversial. We reviewed the pertinent literature searching for evidence regarding a neurodevelopmental origin of bipolar disorder. Findings from clinical, epidemiological, neuroimaging, and post-mortem studies are discussed, as well as the implications of the available data for a better understanding of the mechanisms involved in the genesis of bipolar disorder. While some evidence exists for developmental risk factors in bipolar disorder, further research is needed to determine the precise extent of their contribution to pathogenesis. The timing and course of such developmentally mediated neurobiological alterations also need to be determined. Of particular importance for further study is the possibility that bipolar disorder may be mediated by an abnormal maturation of brain structures involved in affect regulation. (c) 2008 Published by Elsevier Inc. C1 [Brambilla, Paolo; Soares, Jair C.] Univ N Carolina, Dept Psychiat, CERT BD, Chapel Hill, NC 27515 USA. [Sanches, Marsal] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX 78229 USA. [Sanches, Marsal] Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanches, Marsal] Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil. [Keshavan, Matcheri S.] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Brambilla, Paolo] Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. [Brambilla, Paolo] IRCCS E Medea, Inst Sci, Udine, Italy. RP Soares, JC (reprint author), Univ N Carolina, Dept Psychiat, CERT BD, Chapel Hill, NC 27515 USA. EM jair_Soares@med.unc.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU UTHSCSA GCRC [M01-RR-01346]; NARSAD; Krus Endowed Chair in Psychiatry (UTHSCSA); Veterans Administration (VA Merit Review); CAPES Foundation (Brazil); [MH 01736]; [MH 068662]; [MH 068766]; [MH 69774]; [MH 64023]; [RR020571] FX This work was partly supported by MH 01736, MH 068662, MH 068766, MH 69774, MH 64023 and RR020571, UTHSCSA GCRC (M01-RR-01346), NARSAD, the Krus Endowed Chair in Psychiatry (UTHSCSA), Veterans Administration (VA Merit Review), NARSAD and CAPES Foundation (Brazil). NR 160 TC 46 Z9 47 U1 6 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD OCT 1 PY 2008 VL 32 IS 7 BP 1617 EP 1627 DI 10.1016/j.pnpbp.2008.04.017 PG 11 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 357KA UT WOS:000259843500001 PM 18538910 ER PT J AU Pekary, AE Sattin, A Blood, J Furst, S AF Pekary, Albert Eugene Sattin, Albert Blood, James Furst, Stephanie TI TRH and TRH-like peptide expression in rat following episodic or continuous corticosterone SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Chronic corticosterone; Thyrotropin-releasing; hormone; Limbic system; Depression ID THYROTROPIN-RELEASING-HORMONE; CENTRAL-NERVOUS-SYSTEM; PITUITARY-ADRENAL FUNCTION; GLUCOCORTICOIDS STIMULATE; PROLONGED TREATMENT; RAPID MODULATION; MOOD DISORDERS; IN-VITRO; BRAIN; DEPRESSION AB Sustained abnormalities of glucocorticoid Levels have been associated with neuropsychiatric illnesses such as major depression, posttraumatic stress disorder (PTSD), panic disorder, and obsessive compulsive disorder. The pathophysiological effects of glucocorticoids may depend not only on the amount of glucocorticoid exposure but also on its temporal pattern, since it is well established that hormone receptors are down-regulated by continuously elevated cognate hormones. We have previously reported that TRH (pGLu-His-Pro-NH2) and TRH-like peptides (pGlu-X-Pro-NH2) have endogenous antidepressant-like properties and mediate or modulate the acute effects of a single i.p. injection of high dose corticosterone (CORT) in rats. For these reasons, two accepted methods for inducing chronic hyperglucocorticoidemia have been compared for their effects on brain and peripheral tissue Levels of TRH and TRH-like peptides in mate, 250 g, Sprague-Dawley rats: (1) the dosing effect of CORT hemisuccinate in drinking water, and (2) s.c. slow-release pellets. Overall, there were 93% more significant changes in TRH and TRH-Like peptide Levels in brain and 111% more in peripheral tissues of those rats ingesting various doses of CORT in drinking water compared to those with 1-3 s.c. pellets. We conclude that providing rats with CORT in drinking water is a convenient model for the pathophysiological effects of hyperglucocorticoidemia in rodents. Published by Elsevier Ltd. C1 [Pekary, Albert Eugene; Sattin, Albert; Blood, James; Furst, Stephanie] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. [Pekary, Albert Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Res Inst, Los Angeles, CA 90073 USA. [Pekary, Albert Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Room 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov FU Department of Veterans Affairs FX This work was supported by the Department of Veterans Affairs (A.E.P. and A.S.). The authors thank Fredericka Martin, Ph.D., for suggesting Experiment 4. NR 59 TC 8 Z9 8 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD OCT PY 2008 VL 33 IS 9 BP 1183 EP 1197 DI 10.1016/j.psyneuen.2008.06.001 PG 15 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 361XA UT WOS:000260159800002 PM 18657370 ER PT J AU Naliboff, BD Waters, AM Labus, JS Kilpatrick, L Craske, MG Chang, L Negoro, H Ibrahimovic, H Mayer, EA Ornitz, E AF Naliboff, Bruce D. Waters, Allison M. Labus, Jennifer S. Kilpatrick, Lisa Craske, Michelle G. Chang, Lin Negoro, Hideki Ibrahimovic, Hana Mayer, Emeran A. Ornitz, Edward TI Increased Acoustic Startle Responses in IBS Patients During Abdominal and Nonabdominal Threat SO PSYCHOSOMATIC MEDICINE LA English DT Article DE irritable bowel syndrome; functional bowel disorders; acoustic startle response; fear-potentiated startle ID IRRITABLE-BOWEL-SYNDROME; FEAR-POTENTIATED STARTLE; VISCERAL STIMULI; ANXIETY; PAIN; PERCEPTION; DISORDERS; SEX; SENSITIVITY; INHIBITION AB Background and Aims: Visceral hypersensitivity and symptom severity in Irritable Bowel Syndrome (IBS) are both exacerbated by stress. The eye-blink startle response represents a noninvasive measure of central defensive responding. Evidence for central hyperexcitability was studied in IBS patients by examining potentiation of the startle reflex to a nociceptive threat. Methods: Acoustic startle responses were examined in fernale IBS patients (n = 42) and healthy controls (n = 22) during cued periods in which an aversive abdominal or biceps stimulation was impossible (safe), possible (imminent threat) or anticipated (period just before the imminent threat), and during a threatening context (muscle stimulation pads attached but no cues for stimulation). Results: Both groups showed potentiation of startle responses during the imminent threat condition compared with both the anticipation and safe conditions. Compared With controls, IBS subjects showed significantly larger startle responses during anticipation and imminent threat conditions after receiving an initial aversive stimulation. There were no group differences during the context threat manipulation. Moreover, in IBS patients but not controls, higher neuroticism was associated with larger startle responses during safe and anticipation conditions but not imminent threat, whereas anxiety symptoms were negatively associated with startle magnitude during imminent threat. Conclusions: Female IBS patients show increased startle responses to threat of aversive stimulation at both abdominal and nonabdominal sites compared with controls. The data represent the first demonstration of altered threat potentiated startle in a functional pain condition and provide support for the use of these paradigms in further evaluation of affective mechanisms in these disorders. C1 [Naliboff, Bruce D.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Chang, Lin; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Naliboff, Bruce D.; Labus, Jennifer S.; Kilpatrick, Lisa; Craske, Michelle G.; Mayer, Emeran A.; Ornitz, Edward] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Naliboff, Bruce D.; Ibrahimovic, Hana] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Waters, Allison M.] Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia. [Negoro, Hideki] Nara Med Univ, Dept Psychiat, Nara, Japan. [Mayer, Emeran A.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Naliboff, BD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu RI Kilpatrick, Lisa/E-6995-2015 OI Waters, Allison/0000-0003-2453-793X FU NIH [NR007768, P50 DK64539, R24 AT002681]; VA Medical Research; Virginia Friedhofer Charitable Trust FX Supported in part by NIH Grants NR007768 (to B.N.), P50 DK64539 (to E.A.M.), R24 AT002681 (to E.A.M.), VA Medical Research (to B.N.), and a gift from the Virginia Friedhofer Charitable Trust (to E.O.). NR 37 TC 27 Z9 27 U1 9 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD OCT PY 2008 VL 70 IS 8 BP 920 EP 927 DI 10.1097/PSY.0b013e318186d858 PG 8 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 365JF UT WOS:000260401100012 PM 18842745 ER PT J AU Ogrinc, G Mooney, SE Estrada, C Foster, T Goldmann, D Hall, LW Huizinga, MM Liu, SK Mills, P Neily, J Nelson, W Pronovost, PJ Provost, L Rubenstein, LV Speroff, T Splaine, M Thomson, R Tomolo, AM Watts, B AF Ogrinc, G. Mooney, S. E. Estrada, C. Foster, T. Goldmann, D. Hall, L. W. Huizinga, M. M. Liu, S. K. Mills, P. Neily, J. Nelson, W. Pronovost, P. J. Provost, L. Rubenstein, L. V. Speroff, T. Splaine, M. Thomson, R. Tomolo, A. M. Watts, B. TI The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID INTENSIVE-CARE-UNIT; RANDOMIZED CONTROLLED-TRIALS; BLOOD-STREAM INFECTIONS; RAPID RESPONSE TEAM; DECREASES CARDIAC-ARREST; CONSORT STATEMENT; OUTCOMES; IMPLEMENTATION; PROGRAM; PROJECT AB As the science of quality improvement in health care advances, the importance of sharing its accomplishments through the published literature increases. Current reporting of improvement work in health care varies widely in both content and quality. It is against this backdrop that a group of stakeholders from a variety of disciplines has created the Standards for QUality Improvement Reporting Excellence, which we refer to as the SQUIRE publication guidelines or SQUIRE statement. The SQUIRE statement consists of a checklist of 19 items that authors need to consider when writing articles that describe formal studies of quality improvement. Most of the items in the checklist are common to all scientific reporting, but virtually all of them have been modified to reflect the unique nature of medical improvement work. This "Explanation and Elaboration'' document (E & E) is a companion to the SQUIRE statement. For each item in the SQUIRE guidelines the E & E document provides one or two examples from the published improvement literature, followed by an analysis of the ways in which the example expresses the intent of the guideline item. As with the E & E documents created to accompany other biomedical publication guidelines, the purpose of the SQUIRE E & E document is to assist authors along the path from completion of a quality improvement project to its publication. The SQUIRE statement itself, this E & E document, and additional information about reporting improvement work can be found at http://www.squire-statement.org. C1 [Ogrinc, G.] Dartmouth Inst Hlth Policy & Clin Practice, Qual Literature Program, Hanover, NH USA. [Ogrinc, G.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Off Res & Innovat Med Educ, Hanover, NH 03756 USA. [Ogrinc, G.] White River Junct VA Hosp, White River Jct, VT USA. [Mooney, S. E.] Alice Peck Day Mem Hosp, Lebanon, NH USA. [Estrada, C.] Univ Alabama, VA Natl Qual Scholars Program, Birmingham VA Med Ctr, Birmingham, AL USA. [Foster, T.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Goldmann, D.] Harvard Univ, Sch Med, IHI, Boston, MA USA. [Hall, L. W.] Univ Missouri, Sch Med, Univ Missouri Hlth Care, Columbia, MO USA. [Huizinga, M. M.] Vanderbilt Univ, Med Ctr, Nashville, TN 37212 USA. [Liu, S. K.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. [Liu, S. K.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA. [Mills, P.] VA Natl Ctr Patient Safety Field Off, White River Jct, VT USA. [Mills, P.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Neily, J.] Field Off VHAs Natl Ctr Patient Safety, White River Jct, VT USA. [Nelson, W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Inst Hlth Policy & Clin Practice, Rural Eth Initiat,Dartmouth Med Sch, Hanover, NH 03756 USA. [Pronovost, P. J.] Johns Hopkins Univ, Sch Med, Ctr Innovat Qual Patient Care, Dept Anesthesiol & Crit Car,Qual & Safety Res Grp, Baltimore, MD USA. [Pronovost, P. J.] Johns Hopkins Univ, Sch Med, Ctr Innovat Qual Patient Care, Qual & Safety Res Grp,Dep Surg, Baltimore, MD USA. [Pronovost, P. J.] Johns Hopkins Univ, Qual & Safety Res Grp, Ctr Innovat Qual Patient Care, Dep Hlth Policy & Management,Sch Med, Baltimore, MD USA. [Provost, L.] Associates Proc Improvement, Austin, TX USA. [Rubenstein, L. V.] VA Greater Angeles, North Hills, CA USA. [Rubenstein, L. V.] Univ Calif Los Angeles, VA HSRD Ctr Excellence Study Healthcare Provider, RAND Corp, VA Greater Los Angeles Sepulveda, North Hills, CA USA. [Speroff, T.] Vanderbilt Univ, Sch Med, VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. [Splaine, M.] Dartmouth Coll, Dartmouth Inst Hlth Policy & Clin Practice, VA Natl Qual Scholars Fellowship Program, Hitchcock Med Ctr,Dartmouth Med Sch, Hanover, NH 03756 USA. [Thomson, R.] Newcastle Univ, Sch Med, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Tomolo, A. M.] Case Western Reserve Univ, SOM, Emergency Dept, Louis Stokes Cleveland DVAMC, Cleveland, OH 44106 USA. [Watts, B.] Louis Stokes Cleveland VA Med Ctr, Dept Med, Cleveland, OH USA. RP Ogrinc, G (reprint author), Dartmouth Med Sch, 215 N Main St, White River Jct, VT 05009 USA. EM greg.ogrinc@med.va.gov NR 46 TC 154 Z9 154 U1 1 U2 8 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD OCT PY 2008 VL 17 SU 1 BP 13 EP 32 DI 10.1136/qshc.2008.029058 PG 20 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 356WM UT WOS:000259808300004 ER PT J AU Carvounis, PE Kopel, AC Kuhl, DP Heffez, J Pepple, K Holz, ER AF Carvounis, Petros E. Kopel, Andrew C. Kuhl, Derek P. Heffez, Jordan Pepple, Kathryn Holz, Eric R. TI 25-GAUGE VITRECTOMY USING SULFUR HEXAFLUORIDE AND NO PRONE POSITIONING FOR REPAIR OF MACULAR HOLES SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE macular hole; 25-gauge vitrectomy ID AUTOLOGOUS PLATELET CONCENTRATE; LIMITING MEMBRANE REMOVAL; PARS-PLANA VITRECTOMY; INTRAOCULAR TAMPONADE; SURGICAL-MANAGEMENT; VITREOUS SURGERY; RANDOMIZED-TRIAL; DURATION; FACE; PATHOGENESIS AB Purpose: To report on the outcomes of 25-gauge pars plana vitrectomy using sulfur hexafluoride and no prone positioning for repair of macular holes. Methods: Retrospective case series of 44 consecutive patients who underwent pars plana vitrectomy with internal limiting membrane peeling for repair of stages 2 to 4 idiopathic macular holes using 20% to 30% sulfur hexafluoride. No postoperative prone positioning or gas augmentation was used. Results: The macular hole closure rate was 88.6%. There were no differences in the macular hole closure rates between phakic and pseudophakic patients (21 of 23 vs. 17 of 21, respectively) or among stages 2, 3, and 4 macular holes (12 of 13, 20 of 23, and 7 of 8, respectively). In eyes successfully operated on, visual acuity improved from 0.61 logarithm of the minimal angle of resolution (logMAR) (20 of 82) preoperatively to 0.483 logMAR (20 of 61) at 1 month and 0.396 logMAR (20 of 50) at a mean final follow-up of 10.8 months. Adverse effects were elevation of intraocular pressure to >30 mmHg in 7 (13.6%) of 44 patients on the first postoperative day, postoperative retinal detachments in 2 (4.5%) of 44 patients, and progression of cataract requiring cataract surgery in 7 (30.4%) of 23 phakic patients during follow-up. Conclusions: Macular hole closure rates similar to those achieved using pars plana vitrectomy with perfluoropropane and prone positioning can be achieved using sutureless 25-gauge vitrectomy with sulfur hexafluoride tamponade and no prone positioning for both phakic and pseudophakic patients. RETINA 28:1188-1192, 2008 C1 [Holz, Eric R.] Baylor Coll Med, Cullen Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA. [Carvounis, Petros E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kuhl, Derek P.] Retina Ctr, Bryan, TX USA. RP Holz, ER (reprint author), Baylor Coll Med, Cullen Eye Inst, Dept Ophthalmol, 6565 Fannin,NC 205, Houston, TX 77030 USA. EM eholz@bcm.tmc.edu RI Pepple, Kathryn /J-6229-2016 OI Carvounis, Petros/0000-0002-3879-3486 NR 33 TC 20 Z9 21 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD OCT PY 2008 VL 28 IS 9 BP 1188 EP 1192 DI 10.1097/IAE.0b013e318177f9a8 PG 5 WC Ophthalmology SC Ophthalmology GA 366IM UT WOS:000260474200002 PM 19430387 ER PT J AU Kelley, ME Haas, GL van Kammen, DP AF Kelley, Mary E. Haas, Gretchen L. van Kammen, Daniel P. TI Longitudinal progression of negative symptoms in schizophrenia: A new look at an old problem SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Negative symptoms; Longitudinal data; Ordinal data; Symptomatology ID NEUROLEPTIC TREATMENT; CONSENSUS STATEMENT; DEFICIT; REPLICATION; HALOPERIDOL; DISTINCTION; DEFINITION; VALIDATION; REGRESSION; DICHOTOMY AB Objective: Longitudinal analysis is crucial in determining the ability of new interventions to successfully reduce negative symptoms in schizophrenia. However, there are still conflicting reports as to whether there are significant treatment effects on these symptoms and the extent of these effects. We examine the possible effects of analysis method on these questions. Methods: We use generalized linear mixed models (GLMM) to assess the change in specific negative symptom items following treatment changes in two separate cohorts of schizophrenia patients, one chronic and one first episode. Results: Both data sets indicate that examining the change in prevalence of moderate to severe symptoms provides a useful estimate of the effect size associated with changes in treatment that often differs from that given using analysis of means. Conclusions: The use of categorical longitudinal methods may be critical to determining the responsiveness of negative symptoms to treatment as well as determining the stability of these symptoms over time. (c) 2008 Elsevier B.V. All rights reserved. C1 [Kelley, Mary E.] Emory Univ, Dept Biostat, RSPH, Atlanta, GA 30322 USA. [Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [van Kammen, Daniel P.] CHDI Inc, New York, NY USA. RP Kelley, ME (reprint author), Emory Univ, Dept Biostat, RSPH, Rm 352,1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM mekelle@emory.edu FU NIMH [R01MH44-841, P50MH45156-14]; NIH/NCRR/GCRC [M01 RR00056]; VISN 4 Mental Illness Research and Clinical Center (MIRECC); VA Merit Review Board FX This publication was supported, in part, by funds received from NIMH R01MH44-841 (PI - DvK), P50MH45156-14 (P.I. - David A. Lewis), the NIH/NCRR/GCRC grant #M01 RR00056, and pilot funding from the VISN 4 Mental Illness Research and Clinical Center (MIRECC), as well as the VA Merit Review Board (PI - DvK). The funding sources had no further role in study design or implementation, or the writing and decision to submit the manuscript. NR 55 TC 8 Z9 8 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2008 VL 105 IS 1-3 BP 188 EP 196 DI 10.1016/j.schres.2008.06.003 PG 9 WC Psychiatry SC Psychiatry GA 367ZU UT WOS:000260591900020 PM 18619815 ER PT J AU Batki, SL Leontieva, L Dimmock, JA Ploutz-Snyder, R AF Batki, Steven L. Leontieva, Luba Dimmock, Jacqueline A. Ploutz-Snyder, Robert TI Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Alcohol; PANSS; Negative symptom; Positive symptom; Naltrexone; Craving ID COMORBID SUBSTANCE-USE; DUAL DIAGNOSIS; SCALE; ABUSE; DISORDERS AB Background: Alcohol use disorders (AUDs) frequently co-occur with and exacerbate schizophrenia, yet the specific relationships between schizophrenia symptoms and alcohol use remain unclear. Methods: PANSS scores were correlated with measures of alcohol and other substance use in patients with schizophrenia-spectrum disorders and AUDs entering a trial of monitored naltrexone treatment. Data were analyzed from the first 80 participants; 55% had schizophrenia and 45% had schizoaffective disorder. All had AUDs; 95% had alcohol dependence and 5% alcohol abuse; 34% also had cannabis abuse/dependence and 31% cocaine abuse/dependence. Results: PANSS Negative scores were inversely correlated with Addiction Severity Index alcohol composite scores, alcohol craving, quality of alcohol "high" (euphoria), and with frequency of cannabis use. An exploratory analysis indicated that the negative symptoms that may most strongly con-elate with less alcohol use, craving and/or euphoria were passive/apathetic social withdrawal, blunted affect, difficulty in abstract thinking, and stereotyped thinking. Higher PANSS Composite scores, indicating the predominance of positive over negative PANSS symptoms, correlated with more alcohol craving and cannabis use. Higher PANSS General scores were associated with more alcohol craving. Conclusions: These findings extend previous reports of the association of negative schizophrenia symptoms with less alcohol and substance use to patients with AUDs and indicate that this relationship also includes less alcohol craving and less alcohol euphoria. The findings may also provide some initial evidence that specific negative symptoms may be keys to these relationships. (c) Published by Elsevier B.V. C1 [Batki, Steven L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA. [Batki, Steven L.; Leontieva, Luba; Dimmock, Jacqueline A.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Ploutz-Snyder, Robert] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA. RP Batki, SL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr 1169, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu; dimmockj@upstate.edu FU NIAAA [5RO1 AA013655] FX NIAAA grant 5RO1 AA013655. The NIAAA had no further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of report; and in the decision to submit the paper for publication. NR 22 TC 7 Z9 8 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2008 VL 105 IS 1-3 BP 201 EP 207 DI 10.1016/j.schres.2008.06.020 PG 7 WC Psychiatry SC Psychiatry GA 367ZU UT WOS:000260591900022 PM 18701256 ER PT J AU Kim, JH Studer, RK Sowa, GA Vo, NV Kang, JD AF Kim, Joo Han Studer, Rebecca K. Sowa, Gwendolyn A. Vo, Nam Viet Kang, James D. TI Activated macrophage-like THP-1 cells modulate anulus fibrosus cell production of inflammatory mediators in response to cytokines SO SPINE LA English DT Article DE low back pain; intervertebral disc; anulus fiborsus; macrophages; coculture; cytokines ID NECROSIS-FACTOR-ALPHA; INTERVERTEBRAL-DISC DEGENERATION; LOW-BACK-PAIN; NITRIC-OXIDE; HERNIATED DISC; MATRIX METALLOPROTEINASES; INTERLEUKIN-6; EXPRESSION; PATHOGENESIS; INDUCTION AB Study Design. Anulus fibrosus (AF) cells obtained from patients undergoing surgery were cocultured with macrophage-like cells and production of inflammatory mediators was analyzed by quantitative assay. Objective. To investigate the role of macrophages in AF cell production of inflammatory mediators by cytokines stimulation. Summary of Background Data. Discogenic pain caused by anular disruption is an important cause of low back pain and recent studies show the presence of macrophages in symptomatic discs but not in normal and aging discs. We hypothesize that macrophages play a major role in development of symptomatic disc. Methods. Human AF cells were cocultured with phorbol myristate acetate stimulated macrophage-like THP-1 cells. The conditioned medium from cells cultured alone or in coculture was assayed for cytokines by Enzyme-linked immunosorbent assay and nitric oxide (NO) by the Greiss method. Using the same outcome measures, comparisons of cell response to cytokines were made among macrophage-like cells, naive AF cells, and macrophage exposed AF cells. Results. Tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, IL-6, and NO (TNF-alpha: 1.45 +/- 0.29 ng/mL, IL-8: 97.02 +/- 7.94 ng/mL, IL-6: 33.40 +/- 3.55 ng/mL, NO: 8.42 +/- 0.78 mu mol/L) were secreted in much greater amounts by cells maintained in coculture compared to macrophages (TNF-alpha: 0.78 +/- 0.12 ng/mL, IL-8: 58.04 +/- 4.44 ng/mL, IL-6: 0.14 +/- 0.03 ng/mL, NO: 0.30 +/- 0.08 mu mol/L) or AF cells cultured alone. In addition, IL-6 secretion from AF cells in response to TNF-alpha was up-regulated by coculture, however, IL-6 secretion in response to IL-1 beta was down-regulated in a dose-dependent manner. Coculture with macrophages also up-regulated AF cell secretion of IL-8 dose-dependently and downregulated NO to TNF-alpha or IL-1 beta stimulation. Conclusion. We conclude that exposure to macrophages, as can be expected after anular injury, can result in enhanced response to local inflammation. Although changes were observed in all inflammatory mediators after macrophage exposure, the most significant change was observed in IL-6 and IL-8, implicating these mediators in development of symptomatic disc. C1 [Kim, Joo Han; Sowa, Gwendolyn A.; Vo, Nam Viet; Kang, James D.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15261 USA. [Kim, Joo Han] Korea Univ, Coll Med, Dept Neurosurg, Seoul 136705, South Korea. [Studer, Rebecca K.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA. RP Kang, JD (reprint author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Ferguson Lab Orthopaed Res, 200 Lothrop St,E1641 BST, Pittsburgh, PA 15261 USA. EM kangjd@upmc.edu RI Kim, Joo Han/B-8129-2014 OI Kim, Joo Han/0000-0002-4747-9763 FU Pittsburgh Foundation at Department of Orthopedic Surgery, University of Pittsburgh FX Foundation funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.; Supported by the Pittsburgh Foundation at Department of Orthopedic Surgery, University of Pittsburgh. NR 42 TC 23 Z9 26 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD OCT 1 PY 2008 VL 33 IS 21 BP 2253 EP 2259 PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 354KF UT WOS:000259637800001 PM 18784630 ER PT J AU Yenari, M Kitagawa, K Lyden, P Perez-Pinzon, M AF Yenari, Midori Kitagawa, Kazuo Lyden, Patrick Perez-Pinzon, Miguel TI Metabolic downregulation - A key to successful neuroprotection? SO STROKE LA English DT Review DE cerebral ischemia; ischemic tolerance; hypothermia ID TRANSIENT ISCHEMIC ATTACKS; ASPHYXIAL CARDIAC-ARREST; PRESERVES MITOCHONDRIAL-FUNCTION; POSTISCHEMIC MILD HYPOTHERMIA; GLOBAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; MODERATE HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; EXPERIMENTAL STROKE AB Background and Purpose - The search for effective neuroprotectants remains frustrating, particularly with regard to specific pharmaceuticals. However, laboratory studies have consistently shown remarkable neuroprotection with 2 nonpharmacological strategies - therapeutic hypothermia and ischemic preconditioning. Recent studies have shown that the mechanism of protection underlying both of these treatments is correlated to downregulation of cellular and tissue metabolism. Thus, understanding the mechanisms underlying such robust protective effects could lead to appropriate translation at the clinical level. In fact, hypothermia is already being used at many centers to improve neurological outcome from cardiac arrest. Methods - A systematic review of both topics is presented in terms of underlying pathophysiological mechanisms and application at the clinical level. Results - Although the mechanisms of protection for both therapeutic strategies are multifold, both share features of downregulating metabolism. Both therapeutic strategies are robust neuroprotectants, but translating them to the clinical arena is challenging, though not impossible, and clinical studies have shown or suggest benefits of both treatments. Conclusions - The strategy of metabolic downregulation should be further explored to identify effective neuroprotectants that can be easily applied clinically. C1 [Yenari, Midori] Univ Calif San Francisco, Dept Neurol, Neurol VAMC 127, San Francisco, CA 94121 USA. [Yenari, Midori] San Francisco VA Med Ctr, San Francisco, CA USA. [Kitagawa, Kazuo] Osaka Univ, Grad Sch Med, Dept Neurol, Osaka, Japan. [Lyden, Patrick] San Diego Vet Adm, Med Ctr, Neurol & Res Serv, San Diego, CA USA. [Lyden, Patrick] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Perez-Pinzon, Miguel] Univ Miami, Dept Neurol, Coral Gables, FL 33124 USA. RP Yenari, M (reprint author), Univ Calif San Francisco, Dept Neurol, Neurol VAMC 127, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS [R01 NS40516, P50 NS014543, P01 NS37520, P50 NS044148]; American Heart Association Established Investigator Award FX The work was funded, in part, by grants NINDS R01 NS40516 (to M. A. Y.), P50 NS014543 (to M. A. Y.), P01 NS37520 (to M. A. Y.), P50 NS044148 (to P. D. L.), and the American Heart Association Established Investigator Award (to M. A. Y.). NR 102 TC 67 Z9 71 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD OCT PY 2008 VL 39 IS 10 BP 2910 EP 2917 DI 10.1161/STROKEAHA.108.514471 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 354OK UT WOS:000259648700038 PM 18658035 ER PT J AU Spinale, FG Koval, CN Deschamps, AM Stroud, RE Ikonomidis, JS AF Spinale, Francis G. Koval, Christine N. Deschamps, Anne M. Stroud, Robert E. Ikonomidis, John S. TI Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion SO CIRCULATION LA English DT Article DE microdialysis; cardiac surgery; fluorogenic substrates; extracellular matrix ID PREVENTS CARDIAC RUPTURE; METALLOPROTEINASE ACTIVITY; CARDIOPULMONARY BYPASS; FLUOROGENIC SUBSTRATE; HUMAN HEART; INFARCTION; ISCHEMIA; INHIBITION; MATRIX-METALLOPROTEINASE-9; ACTIVATION AB Background-Past studies have clearly established that matrix metalloproteinases (MMPs) contribute to adverse myocardial remodeling with ischemia and reperfusion. However, these studies measured MMP levels in extracted samples, and therefore whether and to what degree actual changes in interstitial MMP activity occur within the human myocardium in the context of ischemia/reperfusion remained unknown. Methods and Results-The present study directly quantified MMP interstitial activity within the myocardium of patients (n=14) undergoing elective cardiac surgery during steady-state conditions, as well as during and following an obligatory period of myocardial arrest and reperfusion achieved by cardiopulmonary bypass. Interstitial MMP activity was continuously monitored using a validated MMP fluorogenic substrate, a microdialysis system placed within the myocardium, and in-line fluorescent detection system. MMP activity, as measured by fluorescent emission, reached a stable steady state level by 10 minutes after deployment of the microdialysis system. During initiation of cardiopulmonary bypass, MMP activity increased by 20% from baseline values ( P<0.05), and then rapidly fell with cardiac arrest and longer periods of cardiopulmonary bypass. However, with restoration of myocardial blood flow and separation from cardiopulmonary bypass, MMP interstitial activity increased by over 30% from baseline ( P<0.05). Conclusions-The present study directly demonstrated that MMP proteolytic activity exists within the human myocardial interstitium and is a dynamic process under conditions such as myocardial arrest and reperfusion. C1 [Spinale, Francis G.; Koval, Christine N.; Deschamps, Anne M.; Stroud, Robert E.] Med Univ S Carolina, Strom Thurmond Res Ctr, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Spinale, Francis G.; Ikonomidis, John S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Strom Thurmond Res Ctr, Div Cardiothorac Surg, 114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM wilburnm@musc.edu OI Deschamps, Anne/0000-0001-7415-1408 FU NIH [HL59165, PO1 HL48788-08]; Veterans' Affairs Health Administration FX This study was supported by NIH grants HL59165, PO1 HL48788-08 and a Merit Award from the Veterans' Affairs Health Administration. NR 32 TC 22 Z9 22 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD SEP 30 PY 2008 VL 118 IS 14 SU 1 BP S16 EP S23 DI 10.1161/CIRCULATIONAHA.108.786640 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 354OJ UT WOS:000259648600003 PM 18824748 ER PT J AU Jin, JF Hou, Q Mullen, TD Zeidan, YH Bielawski, J Kraveka, JM Bielawska, A Obeid, LM Hannun, YA Hsu, YT AF Jin, Junfei Hou, Qi Mullen, Thomas D. Zeidan, Youssef H. Bielawski, Jacek Kraveka, Jacqueline M. Bielawska, Alicja Obeid, Lina M. Hannun, Yusuf A. Hsu, Yi-Te TI Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced bax redistribution to mitochondria in NT-2 cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PERMEABILITY TRANSITION PORE; DELTA-MEDIATED PHOSPHORYLATION; CYTOCHROME-C RELEASE; ACID SPHINGOMYELINASE; CONFORMATIONAL-CHANGE; TNF-ALPHA; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; SIGNALS APOPTOSIS; HL-60 CELLS AB Ceramide functions as an important second messenger in apoptosis signaling pathways. In this report, we show that treatment of NT-2 neuronal precursor cells with hypoxia/reoxygenation (H/R) resulted in ceramide up-regulation. This elevation in ceramide was primarily due to the actions of acid sphingomyelinase and ceramide synthase LASS 5, demonstrating the action of the salvage pathway. Hypoxia/reoxygenation treatment led to Bax translocation from the cytoplasm to mitochondria and cytochrome c release from mitochondria. Down-regulation of either acid sphingomyelinase or LASS 5-attenuated ceramide accumulation and H/R-induced Bax translocation to mitochondria. Overall, we have demonstrated that ceramide upregulation following H/R is pertinent to Bax activation to promote cell death. C1 [Jin, Junfei; Hou, Qi; Zeidan, Youssef H.; Bielawski, Jacek; Bielawska, Alicja; Hannun, Yusuf A.; Hsu, Yi-Te] Med Univ S Carolina, Dept Biochem & Mol Biol, Div Hematol Oncol, Charleston, SC 29425 USA. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA. [Kraveka, Jacqueline M.] Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA. [Hou, Qi] Peking Union Med Coll, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China. [Hou, Qi] Chinese Acad Med Sci, Beijing 100050, Peoples R China. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hsu, YT (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Div Hematol Oncol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA. EM hsuy@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [NS40932, CA97132] FX This work was supported, in whole or in part, by National Institutes of Health Grants NS40932 (to Y.-T. H.) and CA97132 ( to Y. A. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 71 TC 45 Z9 45 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 26 PY 2008 VL 283 IS 39 BP 26509 EP 26517 DI 10.1074/jbc.M801597200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 350GV UT WOS:000259341600027 PM 18676372 ER PT J AU Brent, GA AF Brent, Gregory A. TI Graves' disease - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID RADIOIODINE TREATMENT; CANCER INCIDENCE; HYPERTHYROIDISM C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 25 PY 2008 VL 359 IS 13 BP 1409 EP 1409 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 351QZ UT WOS:000259440900023 ER PT J AU Lieberman, DA Holub, JL Moravec, MD Eisen, GM Peters, D Morris, CD AF Lieberman, David A. Holub, Jennifer L. Moravec, Matthew D. Eisen, Glenn M. Peters, Dawn Morris, Cynthia D. TI Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID COLORECTAL-CANCER; AFRICAN-AMERICANS; ANATOMICAL DISTRIBUTION; MEDICARE POPULATION; ADENOMATOUS POLYPS; UNITED-STATES; SURVEILLANCE; LOCATION; PATTERNS; GENDER AB Context Compared with white individuals, black men and women have a higher incidence and mortality from colorectal cancer and may develop cancer at a younger age. Colorectal cancer screening might be less effective in black individuals, if there are racial differences in the age- adjusted prevalence and location of cancer precursor lesions. Objectives To determine and compare the prevalence rates and location of polyps sized more than 9 mm in diameter in asymptomatic black and white individuals who received colonoscopy screening. Design, Setting, and Patients Colonoscopy data were prospectively collected from 67 adult gastrointestinal practice sites in the United States using a computerized endoscopic report generator between January 1, 2004, and December 31, 2005. Data were transmitted to a central data repository, where all asymptomatic white ( n = 80 061) and black ( n= 5464) patients who had received screening colonoscopy were identified. Main Outcome Measures Prevalence and location of polyps sized more than 9 mm, adjusted for age, sex, and family history of colorectal cancer in a multivariate analysis. Results Both black men and women had a higher prevalence of polyps sized more than 9 mm in diameter compared with white men and women ( 422 [ 7.7%] vs 4964 [ 6.2%]; P <. 001). Compared with white patients, the adjusted odds ratio ( OR) for black men was 1.16 ( 95% confidence interval [ CI], 1.01- 1.34) and the adjusted OR for black women was 1.62 ( 95% CI, 1.39- 1.89). Black and white patients had a similar risk of proximal polyps sized more than 9 mm( OR, 1.13; 95% CI, 0.93- 1.38). However, in a subanalysis of patients older than 60 years, proximal polyps sized more than 9 mm were more likely prevalent in black men ( P=. 03) and women ( P <. 001) compared with white men and women. Conclusion Compared with white individuals, black men and women undergoing screening colonoscopy have a higher risk of polyps sized more than 9 mm, and black individuals older than 60 years are more likely to have proximal polyps sized more than 9 mm. C1 [Lieberman, David A.] Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97239 USA. [Lieberman, David A.; Holub, Jennifer L.; Moravec, Matthew D.; Eisen, Glenn M.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. [Peters, Dawn] Oregon Hlth & Sci Univ, Div Biostat, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Morris, Cynthia D.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. RP Lieberman, DA (reprint author), Portland VA Med Ctr, Div Gastroenterol, 1037 SW Vet Hosp Rd,P3-GI, Portland, OR 97239 USA. EM lieberma@ohsu.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [UO1 DK57132, R33-DK61778-01]; AstraZeneca FX This work was supported by grants UO1 DK57132 and R33-DK61778-01 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) since 1999, and funding from AstraZeneca. NR 24 TC 112 Z9 114 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 24 PY 2008 VL 300 IS 12 BP 1417 EP 1422 DI 10.1001/jama.300.12.1417 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 351FR UT WOS:000259410400019 PM 18812532 ER PT J AU Chen, G Kozell, LB Hitzemann, R Buck, KJ AF Chen, Gang Kozell, Laura B. Hitzemann, Robert Buck, Kari J. TI Involvement of the limbic basal ganglia in ethanol withdrawal convulsivity in mice is influenced by a chromosome 4 locus SO JOURNAL OF NEUROSCIENCE LA English DT Article DE seizure; c-Fos; substantia nigra; lesion; Mpdz; MUPP1 ID NIGRA PARS RETICULATA; RAT SUBSTANTIA-NIGRA; C-FOS EXPRESSION; ACUTE ALCOHOL-WITHDRAWAL; GAMMA-AMINOBUTYRIC-ACID; SUBTHALAMIC NUCLEUS; VENTRAL PALLIDUM; GLOBUS-PALLIDUS; DEVELOPMENTAL REGULATION; INFERIOR COLLICULUS AB Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force that sustains ethanol (alcohol) use/abuse and may contribute to relapse in alcoholics. Although no animal model duplicates alcoholism, models for specific factors, like the withdrawal syndrome, are useful for identifying potential genetic and neural determinants of liability in humans. We generated congenic mice that confirm a quantitative trait locus (QTL) on chromosome 4 with a large effect on predisposition to alcohol withdrawal. Using c-Fos expression as a high-resolution marker of neuronal activation, congenic mice demonstrated significantly less neuronal activity associated with ethanol withdrawal than background strain mice in the substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), rostromedial lateral globus pallidus, and ventral pallidum. Notably, neuronal activation in subregions of the basal ganglia associated with limbic function was more intense than in subregions associated with sensorimotor function. Bilateral lesions of caudolateral SNr attenuated withdrawal severity after acute and repeated ethanol exposures, whereas rostrolateral SNr and STN lesions did not reduce ethanol withdrawal severity. Caudolateral SNr lesions did not affect pentylenetetrazol-enhanced convulsions. Our results suggest that this QTL impacts ethanol withdrawal via basal ganglia circuitry associated with limbic function and that the caudolateral SNr plays a critical role. These are the first analyses to elucidate circuitry by which a confirmed addiction-relevant QTL influences behavior. This mouse QTL is syntenic with human chromosome 9p. Given the growing body of evidence that a gene(s) on chromosome 9p influences alcoholism, our results can facilitate human research on alcohol dependence and withdrawal. C1 [Chen, Gang] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Res Serv R&D40, Dept Behav Neurosci, Portland, OR 97239 USA. [Kozell, Laura B.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Chen, Gang; Kozell, Laura B.; Hitzemann, Robert; Buck, Kari J.] Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Hitzemann, Robert; Buck, Kari J.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Chen, G (reprint author), Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Res Serv R&D40, Dept Behav Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM chenga@ohsu.edu OI Kozell, Laura/0000-0003-3059-2046 FU Public Health Service [AA011114, AA10760, DA05228, AA11034, AA13484]; Veterans Affairs FX This work was supported by Public Health Service Grants AA011114, AA10760, DA05228, AA11034, and AA13484 and a Veterans Affairs Merit grant. We are grateful to Drs. Charles Meshul, John Belknap, John Crabbe, and Pam Metten for many helpful discussions of these experiments and their comments on a draft of this manuscript. NR 78 TC 13 Z9 13 U1 2 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD SEP 24 PY 2008 VL 28 IS 39 BP 9840 EP 9849 DI 10.1523/JNEUROSCI.1713-08.2008 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 352MG UT WOS:000259500700023 PM 18815268 ER PT J AU Ho, PM Magid, DJ AF Ho, P. Michael Magid, David J. TI Medication nonadherence for blood pressure control is primarily a physician-related factor - Reply SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID HYPERTENSION MANAGEMENT C1 [Ho, P. Michael] Univ Colorado, Dept Med, Denver VA Med Ctr, Denver, CO 80220 USA. RP Ho, PM (reprint author), Univ Colorado, Dept Med, Denver VA Med Ctr, 1055 Clermont St,Mail Code 111B, Denver, CO 80220 USA. EM michael.ho@uchsc.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 22 PY 2008 VL 168 IS 17 BP 1929 EP 1929 DI 10.1001/archinte.168.17.1929 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 350ZP UT WOS:000259393000017 ER PT J AU Houser, CR Huang, CS Peng, Z AF Houser, C. R. Huang, C. S. Peng, Z. TI Dynamic seizure-related changes in extracellular signal-regulated kinase activation in a mouse model of temporal lobe epilepsy SO NEUROSCIENCE LA English DT Article DE dentate gyrus; ERK; hippocampus; immunohistochemistry; pilocarpine; spontaneous seizures ID LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE; MAP-KINASE; RAT-BRAIN; SYNAPTIC PLASTICITY; STATUS EPILEPTICUS; NMDA RECEPTOR; MESSENGER-RNA; DENTATE GYRUS AB Extracellular signal-regulated kinase (ERK) is highly sensitive to regulation by neuronal activity and is critically involved in several forms of synaptic plasticity. These features suggested that alterations in ERK signaling might occur in epilepsy. Previous studies have described increased ERK phosphorylation immediately after the induction of severe seizures, but patterns of ERK activation in epileptic animals during the chronic period have not been determined. Thus, the localization and abundance of phosphorylated extracellular signal-regulated kinase (pERK) were examined in a pilocarpine model of recurrent seizures in C57BL/6 mice during the seizure-free period and at short intervals after spontaneous seizures. Immunolabeling of pERK in control animals revealed an abundance of distinctly-labeled neurons within the hippocampal formation. However, in pilocarpine-treated mice during the seizure-free period, the numbers of pERK-labeled neurons were substantially decreased throughout much of the hippocampal formation. Double labeling with a general neuronal marker suggested that the decrease in pERK-labeled neurons was not due primarily to cell loss. The decreased ERK phosphorylation in seizure-prone animals was interpreted as a compensatory response to increased neuronal excitability within the network. Nevertheless, striking increases in pERK labeling occurred at the time of spontaneous seizures and were evident in large populations of neurons at very short intervals (as early as 2 min) after detection of a behavioral seizure. These findings suggest that increased pERK labeling could be one of the earliest immunohistochemical indicators of neurons that are activated at the time of a spontaneous seizure. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Houser, C. R.; Huang, C. S.; Peng, Z.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Houser, C. R.; Huang, C. S.] Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, CHS 73-235,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM houser@mednet.ucla.edu FU Veterans Affairs Medical Research Funds; National Institutes of Health [NS046524] FX This work was supported by Veterans Affairs Medical Research Funds (C.R.H.) and National Institutes of Health grant NS046524 (C.R.H.). We thank Christine Farrar for conducting the Western blot analyses, Yliana Cetina for expert assistance with the seizure monitoring, and Drs. Tom O'Dell and Istvan Mody for helpful discussions. NR 66 TC 31 Z9 38 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD SEP 22 PY 2008 VL 156 IS 1 BP 222 EP 237 DI 10.1016/j.neuroscience.2008.07.010 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 352BE UT WOS:000259469300022 PM 18675888 ER PT J AU Bilimoria, KY Bentrem, DJ Stewart, AK Talamonti, MS Winchester, DP Russell, TR Ko, CY AF Bilimoria, Karl Y. Bentrem, David J. Stewart, Andrew K. Talamonti, Mark S. Winchester, David P. Russell, Thomas R. Ko, Clifford Y. TI Lymph node evaluation as a colon cancer quality measure: A national hospital report card SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID COLORECTAL-CANCER; MINIMUM NUMBER; SURVIVAL; RESECTION; SURGERY; SPECIMENS; OUTCOMES; RECOMMENDATIONS; PROGNOSIS; VOLUME AB Background Examination of 12 or more regional lymph nodes for colon cancer is associated with improved staging and survival, and the National Quality Forum recently endorsed lymph node examination for colon cancer as a quality surveillance measure. However, information regarding the extent of hospital compliance with the 12-node measure in the United States is lacking. Methods From the National Cancer Data Base, 1296 hospitals that performed 156 789 colectomies in 1996-1997 and 2004-2005 were identified, and rates of hospital-level compliance (defined as examination of >= 12 nodes in >= 75% of patients) in these two time periods were compared. Multivariable models were developed to determine if hospital type, volume, or differences in case mix were associated with 12-node measure compliance. All statistical tests were two-sided. Reults In 1996-1997, 15% of hospitals were compliant with the 12-node measure; in 2004-2005 the percentage of compliant hospitals had increased to 38%. From 1996-1997 to 2004-2005, 12-node measure compliance increased at 980 hospitals, remained unchanged at 6 hospitals, and decreased at 310 hospitals. In 2004-2005, National Cancer Institute-designated Comprehensive Cancer Centers were more frequently compliant with the 12-node measure than other academic hospitals, Veterans' Administration hospitals, or community hospitals (78.1% versus 52.4%, 53.1%, and 33.7%, respectively, all P < .001), even after adjustment for differences in characteristics of the colon cancer patients at these hospitals. Conclusions This study provides a national report card of nearly 1300 hospitals showing that more than 60% of institutions failed to achieve a compliance benchmark for the 12-node measure. Considerable improvement is needed in colon cancer nodal evaluation in the United States. C1 [Bilimoria, Karl Y.; Stewart, Andrew K.; Winchester, David P.; Russell, Thomas R.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, David J.; Talamonti, Mark S.; Winchester, David P.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL USA. [Talamonti, Mark S.; Winchester, David P.] Evanston NW Healthcare, Dept Surg, Evanston, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org FU American College of Surgeons; Clinical Scholars in Residence program; American Cancer Society [ACS IRG 93-037-12]; National Cancer Institute [NCI-60058-NE] FX American College of Surgeons, Clinical Scholars in Residence program (to K. Y. B.); American Cancer Society (ACS IRG 93-037-12 to D. J. B.); National Cancer Institute (NCI-60058-NE to C. Y. K.). NR 42 TC 107 Z9 109 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD SEP 17 PY 2008 VL 100 IS 18 BP 1310 EP 1317 DI 10.1093/jnci/djn293 PG 8 WC Oncology SC Oncology GA 350BR UT WOS:000259328000010 PM 18780863 ER PT J AU Lee, TA Pickard, AS Au, DH Bartle, B Weiss, KB AF Lee, Todd A. Pickard, A. Simon Au, David H. Bartle, Brian Weiss, Kevin B. TI Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID INHALED CORTICOSTEROIDS; BIASED SELECTION; MORTALITY; COPD; HEALTH; HOSPITALIZATIONS; EXACERBATIONS; METAANALYSIS; FLUTICASONE; IPRATROPIUM AB Background: Concerns exist regarding increased risk for mortality associated with some chronic obstructive pulmonary disease (COPD) medications. Objective: To examine the association between various respiratory medications and risk for death in veterans with newly diagnosed COPD. Design: Nested case - control study in a cohort identified between 1 October 1999 and 30 September 2003 and followed through 30 September 2004 by using National Veterans Affairs inpatient, outpatient, pharmacy, and mortality databases; Centers for Medicare & Medicaid Services databases; and National Death Index Plus data. Cause of death was ascertained for a random sample of 40% of those who died during follow-up. Case patients were categorized on the basis of all-cause, respiratory, or cardiovascular death. Mortality risk associated with medications was assessed by using conditional logistic regression adjusted for comorbid conditions, health care use, and markers of COPD severity. Setting: U. S. Veterans Health Administration health care system. Participants: 32 130 case patients and 320 501 control participants in the all-cause mortality analysis. Of 11 897 patients with cause-of-death data, 2405 case patients had respiratory deaths and 3159 case patients had cardiovascular deaths. Measurements: All-cause mortality; respiratory and cardiovascular deaths; and exposure to COPD medications, inhaled corticosteroids, ipratropium, long-acting beta-agonists, and theophylline in the 6 months preceding death. Results: Adjusted odds ratios (ORs) for all-cause mortality were 0.80 (95% CI, 0.78 to 0.83) for inhaled corticosteroids, 1.11 ( CI, 1.08 to 1.15) for ipratropium, 0.92 (CI, 0.88 to 0.96) for long-acting beta-agonists, and 1.05 (CI, 0.99 to 1.10) for theophylline. Ipratropium was associated with increased cardiovascular deaths (OR, 1.34 [CI, 1.22 to 1.47]), whereas inhaled corticosteroids were associated with reduced risk for cardiovascular death ( OR, 0.80 [ CI, 0.72 to 0.88]). Results were consistent across sensitivity analyses. Limitations: Current smoking status and lung function were not measured. Misclassification of cause-specific mortality is unknown. Conclusion: The possible association between ipratropium and elevated risk for all-cause and cardiovascular death needs further study. C1 [Lee, Todd A.] Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NW Univ Feinberg, Sch Med, Chicago, IL USA. Univ Illinois, Chicago, IL USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Amer Board Med Specialties, Evanston, IL USA. RP Lee, TA (reprint author), Vet Affairs Edward Hines Jr Hosp, 5000 S 5th Ave,151-H, Hines, IL 60141 USA. EM todd.lee@va.gov FU the U. S. Department of Veterans Affairs Health Services Research and Development [IIR 03-307] FX By the U. S. Department of Veterans Affairs Health Services Research and Development (IIR 03-307). NR 38 TC 124 Z9 127 U1 0 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 16 PY 2008 VL 149 IS 6 BP 380 EP W73 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 348SM UT WOS:000259230200002 PM 18794557 ER PT J AU Qaseem, A Snow, V Shekelle, P Hopkins, R Forciea, MA Owens, DK AF Qaseem, Amir Snow, Vincenza Shekelle, Paul Hopkins, Robert, Jr. Forciea, Mary Ann Owens, Douglas K. CA Clinical Efficacy Assessment Subco TI Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; CORTICOSTEROID-INDUCED OSTEOPOROSIS; CYCLICAL ETIDRONATE THERAPY; VITAMIN-D SUPPLEMENTATION; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; HEALTHY POSTMENOPAUSAL WOMEN; HORMONE REPLACEMENT THERAPY; PRIMARY BILIARY-CIRRHOSIS; ESTROGEN PLUS PROGESTIN AB Description: The American College of Physicians (ACP) developed this guideline to present the available evidence on various pharmacologic treatments to prevent fractures in men and women with low bone density or osteoporosis. Methods: Published literature on this topic was identified by using MEDLINE (1966 to December 2006), the ACP Journal Club database, the Cochrane Central Register of Controlled Trials (no date limits), the Cochrane Database of Systematic Reviews (no date limits), Web sites of the United Kingdom National Institute of Health and Clinical Excellence (no date limits), and the United Kingdom Health Technology Assessment Program (January 1998 to December 2006). Searches were limited to English-language publications and human studies. Keywords for search included terms for osteoporosis, osteopenia, low bone density, and the drugs listed in the key questions. This guideline grades the evidence and recommendations according to the ACP's clinical practice guidelines grading system. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. RAND, Santa Monica, CA USA. Univ Arkansas, Little Rock, AR 72204 USA. Stanford Univ, Stanford, CA 94305 USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU the American College of Physicians' operating budget FX Financial support for the development of this guideline comes exclusively from the American College of Physicians' operating budget. NR 151 TC 95 Z9 96 U1 1 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 16 PY 2008 VL 149 IS 6 BP 404 EP W77 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 348SM UT WOS:000259230200005 PM 18794560 ER PT J AU Cavazos, JM Naik, AD Woofter, A Abraham, NS AF Cavazos, J. M. Naik, A. D. Woofter, A. Abraham, N. S. TI Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; HEART-FAILURE; MANAGEMENT; OSTEOARTHRITIS; PATIENT; HYPERTENSION; PRESCRIPTION; HEURISTICS; KNOWLEDGE; ATTITUDES AB Background Despite wide availability of physician guidelines for safer use of nonsteroidal anti-inflammatory drugs (NSAIDs) and widespread use of these drugs in the US, NSAID prescribing guidelines have been only modestly effective. Aim To identify and describe comprehensively barriers to provider adherence to NSAID prescribing guidelines. Methods We conducted interviews with 25 physicians, seeking to identify the major influences explaining physician non-adherence to guidelines. Interviews were standardized and structured probes were used for clarification and detail. All interviews were audio-taped and transcribed. Three independent investigators analysed the transcripts, using the constant-comparative method of qualitative analysis. Results Our analysis identified six dominant physician barriers explaining non-adherence to established NSAID prescribing guidelines. These included (i) lack of familiarity with guidelines, (ii) perceived limited validity of guidelines, (iii) limited applicability of guidelines among specific patients, (iv) clinical inertia, (v) influences of prior anecdotal experiences and (vi) medical heuristics. Conclusions A heterogeneous set of influences are barriers to physician adherence to NSAID prescribing guidelines. Suggested measures for improving guideline-concordant prescribing should focus on measures to improve physician education and confidence in guidelines, implementation of physician/pharmacist co-management strategies and expansion of guideline scope. C1 [Woofter, A.; Abraham, N. S.] Michael E DeBakey Vet Affairs Med ctr, Houston, TX 77030 USA. [Woofter, A.; Abraham, N. S.] Baylor Coll Med, Houston, TX 77030 USA. [Cavazos, J. M.; Naik, A. D.; Abraham, N. S.] Gastrointestinal Outcomes Geriat GO GERI Unit, Houston, TX USA. [Cavazos, J. M.; Abraham, N. S.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM nabraham@bcm.tmc.edu FU American Gastroenterological Association Foundation-Sucampo-ASP; Department of Veterans Affairs (VA) [IIR 115-05]; NIA K23 [5K23AG027144]; Houston VA HSR&D Center of Excellence [HFP90-020] FX Declaration of personal interests: Dr Abraham guarantees the intellectual content of this paper. Each author's contribution to the paper: Dr Abraham conceived, designed and conducted the study, acquired necessary funding, interpreted the data, assisted in preparation of the manuscript and had final approval of this research. Dr Woofter conducted interviews and participated in data analysis. Dr Cavazos participated in analysis of data and preparation of the manuscript. Dr Naik participated in data analysis, interpretation and in preparation of the manuscript. Declaration of funding interests: Dr Abraham is supported by an American Gastroenterological Association Foundation-Sucampo-ASP Designated Research Award in Geriatric Gastroenterology and a Merit Review Award from the Department of Veterans Affairs (VA) (IIR 115-05). Dr Naik is supported by an NIA K23 grant (5K23AG027144). None of the funding agencies played a role in the design and conduct of the study, analysis and interpretation of the data, or the preparation and approval of the manuscript. This material is the result of work supported with resources and the use of facilities at Houston VA HSR&D Center of Excellence (HFP90-020). The views expressed herein are those of the authors and do not necessarily reflect those of the Department of Veterans Affairs (Baylor College of Medicine). NR 39 TC 22 Z9 22 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD SEP 15 PY 2008 VL 28 IS 6 BP 789 EP 798 DI 10.1111/j.1365-2036.2008.03791.x PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 339SD UT WOS:000258596700014 PM 19145734 ER PT J AU Gordin, FM Roediger, MP Girard, PM Lundgren, JD Miro, JM Palfreeman, A Rodriguez-Barradas, MC Wolff, MJ Easterbrook, PJ Clezy, K Slater, LN AF Gordin, Fred M. Roediger, Mollie P. Girard, Pierre-Marie Lundgren, Jens D. Miro, Jose M. Palfreeman, Adrian Rodriguez-Barradas, Maria C. Wolff, Marcelo J. Easterbrook, Philippa J. Clezy, Kate Slater, Leonard N. TI Pneumonia in HIV-infected persons - Increased risk with cigarette smoking and treatment interruption SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE pneumonia; smoking; HIV; bacterial infections ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; BACTERIAL PNEUMONIA; PULMONARY COMPLICATIONS; POLYSACCHARIDE VACCINE; DRUG-USERS; COHORT; ADULTS AB Rationale: Bacterial pneumonia is a major cause of morbidity for HIV-infected persons and contributes to excess mortality in this population. Objectives: To evaluate the frequency and risk factors for occurrence of bacterial pneumonia in the present era of potent antiretroviral therapy. Methods: We evaluated data from a randomized trial of episodic antiretroviral therapy. The study, Strategies for Management of Antiretroviral Therapy, enrolled 5,472 participants at 318 sites in 33 countries. Study patients had more than 350 CD4 cells at baseline. Diagnosis of bacterial pneumonia was confirmed by a blinded clinical-events committee. Measurements and Main Results: During a mean follow-up of 16 months, 116 participants (2.2%) developed at least one episode of bacterial pneumonia. Patients randomized to receive episodic antiretroviral therapy were significantly more likely to develop pneumonia than patients randomized to receive continuous antiretroviral therapy (hazard ratio, 1.55; 95% confidence interval, 1.07-2.25; P = 0.02). Cigarette smoking was a major risk factor: Current-smokers had more than an 80% higher risk of pneumonia compared with never-smokers (hazard ratio, 1.82; 95% confidence interval, 1.09-3.04; P = 0.02). Participants who were on continuous HIV treatment and were current smokers were three times more likely to develop bacterial pneumonia than nonsmokers. Current smoking status was significant, but a past history of smoking was not. Conclusions: Bacterial pneumonia is a major source of morbidity, even for persons on potent antiretroviral therapy, including those with high CD4 cells. Efforts to reduce this illness should stress the importance of uninterrupted antiretroviral therapy and attainment and/or maintenance of nonsmoking status. C1 [Gordin, Fred M.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Gordin, Fred M.] George Washington Univ, Washington, DC USA. [Roediger, Mollie P.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA. [Girard, Pierre-Marie] Univ Paris 06, Hop St Antoine, Serv Malad Infect & Trop, Paris, France. [Girard, Pierre-Marie] Inst Med & Epidemiol Appl, Paris, France. [Lundgren, Jens D.] Univ Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark. [Miro, Jose M.] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer, Barcelona, Spain. [Palfreeman, Adrian] Univ Hosp, Leicester, Leics, England. [Palfreeman, Adrian] MRC, London, England. [Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Wolff, Marcelo J.] Univ Chile, Sch Med, Santiago, Chile. [Wolff, Marcelo J.] Arriaran Fdn, Santiago, Chile. [Easterbrook, Philippa J.] Kings Coll London, Dept HIV & Genitourinary Med, London WC2R 2LS, England. [Clezy, Kate] Univ New S Wales, Sydney, NSW, Australia. [Slater, Leonard N.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA. [Slater, Leonard N.] Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA. RP Gordin, FM (reprint author), Vet Affairs Med Ctr, 151B,50 Irving St NW, Washington, DC 20422 USA. EM fred.gordin@med.va.gov OI Lundgren, Jens/0000-0001-8901-7850 FU Medical Research Council [MC_U122886352, G0200585]; NIAID NIH HHS [U01AI042170, U01AI46362] NR 28 TC 52 Z9 55 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2008 VL 178 IS 6 BP 630 EP 636 DI 10.1164/rccm.200804-617OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 347RL UT WOS:000259158600013 PM 18617640 ER PT J AU Slatore, CG Au, DH White, E AF Slatore, Christopher G. Au, David H. White, Emily TI Can moderate doses of vitamin E protect against lung cancer? Reply SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter C1 [Slatore, Christopher G.; Au, David H.; White, Emily] Univ Washington, Seattle, WA 98195 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Slatore, CG (reprint author), Univ Washington, Seattle, WA 98195 USA. OI Slatore, Christopher/0000-0003-0958-8122 NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2008 VL 178 IS 6 BP 653 EP 654 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 347RL UT WOS:000259158600020 ER PT J AU Contreras, MA Haq, E Uto, T Singh, I Singh, AK AF Contreras, Miguel Agustin Haq, Ehtishamul Uto, Takuhiro Singh, Inderjit Singh, Avtar Kaur TI Psychosine-induced alterations in peroxisomes of twitcher mouse liver SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE TNF-alpha; IL-6; neuroinflammation; Krabbe disease; twitcher mouse; peroxisomes; psychosine; sphingolipid; catalase; liver ID GLOBOID-CELL LEUKODYSTROPHY; TANDEM MASS-SPECTROMETRY; BETA-OXIDATION ENZYMES; NECROSIS-FACTOR-ALPHA; C6 GLIAL-CELLS; RAT-LIVER; TNF-ALPHA; BRAIN; EXPRESSION; DISEASE AB Krabbe disease is a neuroinflammatory disorder in which galactosylsphingosine (psychosine) accumulates in nervous tissue. To gain insight into whether the psychosine-induced effects in nervous tissue extend to peripheral organs, we investigated the expression of cytokines and their effects on peroxisomal structure/functions in twitcher mouse liver (animal model of Krabbe disease). Immunofluorescence analysis demonstrated TNF-alpha and IL-6 expression, which was confirmed by mRNAs quantitation. Despite the presence of TNF-alpha, lipidomic analysis did not indicate a significant decrease in sphingomyelin or an increase in ceramide fractions. Ultrastructural analysis of catalase-dependent staining of liver sections showed reduced reactivity without significant changes in peroxisomal contents. This observation was confirmed by assaying catalase activity and quantitation of its mRNA, both of which were found significantly decreased in twitcher mouse liver. Western blot analysis demonstrated a generalized reduction of peroxisomal matrix and membrane proteins. These observations indicate that twitcher mouse pathobiology extends to the liver, where psychosine-incluced TNF-alpha and IL-6 compromise peroxisomal structure and functions. (C) 2008 Published by Elsevier Inc. C1 [Singh, Avtar Kaur] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar Kaur] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. [Contreras, Miguel Agustin; Haq, Ehtishamul; Uto, Takuhiro; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Contreras, Miguel Agustin; Haq, Ehtishamul; Uto, Takuhiro; Singh, Inderjit] Med Univ S Carolina, Charles Darby Childrens Res Inst, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. EM avtar.singh@med.va.gov OI Haq, Ehtishamul/0000-0002-4195-0606 FU National Center for Research Resources [C06 RR018823, C06 RR015455]; National Institutes of Health [NS-22576, NS-34741, NS-37766, NS-40810, AG-25307] FX The authors would like to thank Ms. Joyce Bryan, Mrs. Rifat Yasmeen, Mrs. Carol Moskos, Mrs. Carrie Barnes (R.H. Johnson Veteran's Administration Medical Center), and Dr. Jacek Bielawsky and Mr. Jason Pierce (Lipidomics Core Facility) for excellent technical assistance; and Drs. Ernest Barbosa, Ravinder Pannu and Mushfiquddin Khan for helpful discussions and scientific advice. This work was supported by Grants from the Extramural Research Facilities Program of the National Center for Research Resources (C06 RR018823 and C06 RR015455) and from the National Institutes of Health (NS-22576, NS-34741, NS-37766, NS-40810 and AG-25307). NR 57 TC 11 Z9 11 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 EI 1096-0384 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD SEP 15 PY 2008 VL 477 IS 2 BP 211 EP 218 DI 10.1016/j.abb.2008.06.012 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 347VR UT WOS:000259170000004 PM 18602885 ER PT J AU Law, RJ Munson, K Sachs, G Lightstone, FC AF Law, Richard J. Munson, Keith Sachs, George Lightstone, Felice C. TI An ion gating mechanism of gastric H,K-ATPase based on molecular dynamics simulations SO BIOPHYSICAL JOURNAL LA English DT Article ID SARCOPLASMIC-RETICULUM; BINDING-SITES; CALCIUM-PUMP; TRANSMEMBRANE SEGMENT; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; K+; NA,K-ATPASE; WATER AB Gastric H, K-ATPase is an electroneutral transmembrane pump that moves protons from the cytoplasm of the parietal cell into the gastric lumen in exchange for potassium ions. The mechanism of transport against the established electrochemical gradients includes intermediate conformations in which the transferred ions are trapped (occluded) within the membrane domain of the pump. The pump cycle involves switching between the E1 and E2P states. Molecular dynamics simulations on homology models of the E2P and E1 states were performed to investigate the mechanism of K+ movement in this enzyme. We performed separate E2P simulations with one K+ in the luminal channel, one K+ ion in the occlusion site, two K+ ions in the occlusion site, and targeted molecular dynamics from E2P to E1 with two K+ ions in the occlusion site. The models were inserted into a lipid bilayer system and were stable over the time course of the simulations, and K+ ions in the channel moved to a consistent location near the center of the membrane domain, thus de. ning the occlusion site. The backbone carbonyl oxygen from residues 337 through 342 on the nonhelical turn of M4, as well as side-chain oxygen from E343, E795, and E820, participated in the ion occlusion. A single water molecule was stably bound between the two K+ ions in the occlusion site, providing an additional ligand and partial shielding the positive charges from one another. Targeted molecular dynamics was used to transform the protein from the E2P to the E1 state (two K+ ions to the cytoplasm). This simulation identified the separation of the water column in the entry channel as the likely gating mechanism on the luminal side. A hydrated exit channel also formed on the cytoplasmic side of the occlusion site during this simulation. Hence, water molecules became available to hydrate the ions. The movement of the M1M2 transmembrane segments, and the displacement of residues Q159, E160, Q110, and T152 during the conformational change, as well as the motions of E343 and L346, acted as the cytoplasmic-side gate. C1 [Law, Richard J.; Lightstone, Felice C.] Lawrence Livermore Natl Lab, Chem Mat Earth & Life Sci Directorate, Livermore, CA 94550 USA. [Munson, Keith; Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Lab Membrane Biol, Los Angeles, CA 90024 USA. [Munson, Keith; Sachs, George] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Lightstone, FC (reprint author), Lawrence Livermore Natl Lab, Chem Mat Earth & Life Sci Directorate, L-372,700 E Ave, Livermore, CA 94550 USA. EM felice@llnl.gov FU National Institutes of Health [DK058333]; U. S. Department of Energy by the Lawrence Livermore National Laboratory [DE-AC52-07NA27344]; Laboratory Directed Research and Development Program at the Lawrence Livermore National Laboratory [UCRL-JRNL-2333318] FX The work of K. M and G. S. is supported by the National Institutes of Health grant DK058333. This work was performed under the auspices of the U. S. Department of Energy by the Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344. The project 06-SI-003 was funded by the Laboratory Directed Research and Development Program at the Lawrence Livermore National Laboratory, UCRL-JRNL-2333318. NR 37 TC 10 Z9 10 U1 0 U2 2 PU BIOPHYSICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD SEP 15 PY 2008 VL 95 IS 6 BP 2739 EP 2749 DI 10.1529/biophysj.107.128025 PG 11 WC Biophysics SC Biophysics GA 343BI UT WOS:000258826900014 PM 18567633 ER PT J AU Saha, S Guiton, G Wimmers, PF Wilkerson, L AF Saha, Somnath Guiton, Gretchen Wimmers, Paul F. Wilkerson, LuAnn TI Student body racial and ethnic composition and diversity-related outcomes in US medical schools SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CULTURAL COMPETENCE; HIGHER-EDUCATION; CARE; PERSPECTIVES; PHYSICIANS; WORKFORCE; IMPACT; POLICY AB Context Many medical schools assert that a racially and ethnically diverse student body is an important element in educating physicians to meet the needs of a diverse society. However, there is limited evidence addressing the educational effects of student body racial diversity. Objective To determine whether student body racial and ethnic diversity is associated with diversity- related outcomes among US medical students. Design, Setting, and Participants A Web- based survey ( Graduation Questionnaire) administered by the Association of American Medical Colleges of 20 112 graduating medical students ( 64% of all graduating students in 2003 and 2004) from 118 allopathic medical schools in the United States. Historically black and Puerto Rican medical schools were excluded. Main Outcome Measures Students' self- rated preparedness to care for patients from other racial and ethnic backgrounds, attitudes about equity and access to care, and intent to practice in an underserved area. Results White students within the highest quintile for student body racial and ethnic diversity, measured by the proportion of underrepresented minority ( URM) students, were more likely to rate themselves as highly prepared to care for minority populations than those in the lowest diversity quintile ( 61.1% vs 53.9%, respectively; P <. 001; adjusted odds ratio [ OR], 1.33; 95% confidence interval [ CI], 1.13- 1.57). This association was strongest in schools in which students perceived a positive climate for interracial interaction. White students in the highest URM quintile were also more likely to have strong attitudes endorsing equitable access to care ( 54.8% vs 44.2%, respectively; P <. 001; adjusted OR, 1.42; 95% CI, 1.15- 1.74). For nonwhite students, after adjustment there were no significant associations between student body URM proportions and diversity- related outcomes. Student body URM proportions were not associated with white or nonwhite students' plans to practice in underserved communities, although URM students were substantially more likely than white or nonwhite/ non- URM students to plan to serve the underserved ( 48.7% vs 18.8% vs 16.2%, respectively; P <. 001). Conclusion Student body racial and ethnic diversity within US medical schools is associated with outcomes consistent with the goal of preparing students to meet the needs of a diverse population. C1 [Saha, Somnath] Oregon Hlth & Sci Univ, Gen Internal Med Sect, Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. [Guiton, Gretchen] Univ Colorado, Sch Med, Educ Dev & Res Off, Denver, CO USA. [Wimmers, Paul F.; Wilkerson, LuAnn] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Saha, S (reprint author), Oregon Hlth & Sci Univ, Gen Internal Med Sect, Portland VA Med Ctr, Dept Med, P3HSRD,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sahas@ohsu.edu FU Advanced Research Career Development award; US Department of Veterans Affairs Health Services Research and Development Service FX Dr Saha was supported by an Advanced Research Career Development award from the US Department of Veterans Affairs Health Services Research and Development Service when this study was conducted. The Association of American Medical Colleges (AAMC) collected and manages the Graduation Questionnaire data analyzed for this study. Dr Saha has served on Advisory Committees for AAMC initiatives related to medical school diversity. NR 31 TC 85 Z9 85 U1 2 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 10 PY 2008 VL 300 IS 10 BP 1135 EP 1145 DI 10.1001/jama.300.10.1135 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 345ZR UT WOS:000259038700006 PM 18780842 ER PT J AU Volpp, KG Landrigan, CP AF Volpp, Kevin G. Landrigan, Christopher P. TI Building physician work hour regulations from first principles and best evidence SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID MEDICAL ERRORS; INTERNS; MORTALITY; PERFORMANCE; DURATION; SHIFTS; REFORM; RISK; CARE C1 [Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Landrigan, Christopher P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Landrigan, Christopher P.] Harvard Univ, Sch Med, Boston, MA USA. RP Volpp, KG (reprint author), Univ Penn, Sch Med, Dept Med, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu FU AHRQ HHS [U18 HS15906]; NHLBI NIH HHS [R01 HL082637] NR 15 TC 19 Z9 19 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 10 PY 2008 VL 300 IS 10 BP 1197 EP 1199 DI 10.1001/jama.300.10.1197 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 345ZR UT WOS:000259038700012 PM 18780848 ER PT J AU Goldstein, NE Back, AL Morrison, S AF Goldstein, Nathan E. Back, Anthony L. Morrison, Sean TI Titrating guidance - A model to guide physicians in assisting patients and family members who are facing complex decisions SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID BREAST-CANCER; OF-LIFE; CARE; PREFERENCES; INFORMATION; DEPRESSION; HEALTH; END AB Over the last century, developments in new medical treatments have led to an exponential increase in longevity, but, as a consequence, patients may be left with chronic illness associated with long-term severe functional and cognitive disability. Patients and their families are often forced to make a difficult and complex choice between death and long-term debility, neither of which is an acceptable outcome. Traditional models of medical decision making, however, do not fully address how clinicians should best assist with these decisions. Herein, we present a new paradigm that demonstrates how the role of the physician changes over time in response to the curved relationship between the predictability of a patient's outcome and the chance of returning to an acceptable quality of life. To translate this model into clinical practice, we propose a 5-step model for physicians with which they can (1) determine at which point the patient is on our model; (2) identify the cognitive factors and preferences for outcomes that affect the decision-making process of the patient and his or her family; (3) reflect on their own reaction to the decision at hand; (4) acknowledge how these factors can be addressed in conversation; and (5) guide the patient and his or her family in creating a plan of care. This model can help improve patient-physician communication and decision making so that complex and difficult decisions can be turned into ones that yield to medical expertise, good communication, and personal caring. C1 [Goldstein, Nathan E.; Morrison, Sean] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Hertzberg Palliat Care Inst Brookdale, New York, NY 10029 USA. [Goldstein, Nathan E.; Morrison, Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. RP Goldstein, NE (reprint author), Mt Sinai Sch Med, Dept Geriatr, 1 Gustave Levy Pl,Box 1070, New York, NY 10029 USA. EM Nathan.Goldstein@mssm.edu FU National Institute of Aging [K23AG025933]; National Cancer Institute [R2592055]; National Palliative Care Research Center; National Institute on Aging [K24AG22345] FX Dr Goldstein is supported by a Mentored Patient-Oriented Research Career Development Award (K23AG025933) from the National Institute of Aging. Dr Back is supported by grant R2592055 from the National Cancer Institute. Dr Morrison is supported by the National Palliative Care Research Center and a Mid-Career Investigator Award in Patient-Oriented Research Award (K24AG22345) from the National Institute on Aging. NR 28 TC 26 Z9 26 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 8 PY 2008 VL 168 IS 16 BP 1733 EP 1739 DI 10.1001/archinte.168.16.1733 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 345XI UT WOS:000259030600002 PM 18779459 ER PT J AU Morrison, RS Penrod, JD Cassel, JB Caust-Ellenbogen, M Litke, A Spragens, L Meier, DE AF Morrison, R. Sean Penrod, Joan D. Cassel, J. Brian Caust-Ellenbogen, Melissa Litke, Ann Spragens, Lynn Meier, Diane E. CA Palliative Care Leadership Ctr Out TI Cost savings associated with US hospital palliative care consultation programs SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CLUSTER RANDOMIZED-TRIAL; OF-LIFE CARE; PROPENSITY SCORES; IMPROVE CARE; END; OUTCOMES; IMPACT; FAMILIES; SERVICE; MODELS AB Background: Hospital palliative care consultation teams have been shown to improve care for adults with serious illness. This study examined the effect of palliative care teams on hospital costs. Methods: We analyzed administrative data from 8 hospitals with established palliative care programs for the years 2002 through 2004. Patients receiving palliative care were matched by propensity score to patients receiving usual care. Generalized linear models were estimated for costs per admission and per hospital day. Results: Of the 2966 palliative care patients who were discharged alive, 2630 palliative care patients (89%) were matched to 18 427 usual care patients, and of the 2388 palliative care patients who died, 2278 (95%) were matched to 2124 usual care patients. The palliative care patients who were discharged alive had an adjusted net savings of $1696 in direct costs per admission (P = .004) and $279 in direct costs per day (P < .001) including significant reductions in laboratory and intensive care unit costs compared with usual care patients. The palliative care patients who died had an adjusted net savings of $4908 in direct costs per admission (P = .003) and $374 in direct costs per day (P < .001) including significant reductions in pharmacy, laboratory, and intensive care unit costs compared with usual care patients. Two confirmatory analyses were performed. Including mean costs per day before palliative care and before a comparable reference day for usual care patients in the propensity score models resulted in similar results. Estimating costs for palliative care patients assuming that they did not receive palliative care resulted in projected costs that were not significantly different from usual care costs. Conclusion: Hospital palliative care consultation teams are associated with significant hospital cost savings. C1 [Morrison, R. Sean; Penrod, Joan D.; Litke, Ann; Meier, Diane E.] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr, New York, NY 10029 USA. [Morrison, R. Sean; Meier, Diane E.] Natl Palliat Care Res Ctr, New York, NY USA. [Morrison, R. Sean; Cassel, J. Brian; Caust-Ellenbogen, Melissa; Spragens, Lynn; Meier, Diane E.] Ctr Adv Palliat Care, New York, NY USA. [Morrison, R. Sean; Penrod, Joan D.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Caust-Ellenbogen, Melissa] Mt Carmel Hlth Syst, Columbus, OH USA. RP Morrison, RS (reprint author), Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU Center to Advance Palliative Care; National Palliative Care Research Center; National Institute on Aging [K24 AG022345]; Aetna, Brookdale, John A. Hartford, Jeht, Robert Wood Johnson, Emily Davie and Joseph S. Kornfeld, and Olive Branch Foundations FX This project was supported by the Center to Advance Palliative Care, the National Palliative Care Research Center, and by a Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345) from the National Institute on Aging (Dr Morrison). The Center to Advance Palliative Care and the National Palliative Care Research Center are supported by the Aetna, Brookdale, John A. Hartford, Jeht, Robert Wood Johnson, Emily Davie and Joseph S. Kornfeld, and Olive Branch Foundations. NR 39 TC 304 Z9 306 U1 5 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD SEP 8 PY 2008 VL 168 IS 16 BP 1783 EP 1790 DI 10.1001/archinte.168.16.1783 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 345XI UT WOS:000259030600010 PM 18779466 ER PT J AU Kulkarni, H Agan, BK Marconi, VC O'Connell, RJ Camargo, JF He, WJ Delmar, J Phelps, KR Crawford, G Clark, RA Dolan, MJ Ahuja, SK AF Kulkarni, Hemant Agan, Brian K. Marconi, Vincent C. O'Connell, Robert J. Camargo, Jose F. He, Weijing Delmar, Judith Phelps, Kenneth R. Crawford, George Clark, Robert A. Dolan, Matthew J. Ahuja, Sunil K. TI CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected Individuals SO PLOS ONE LA English DT Article AB Background: Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is unclear. For example, when to initiate highly active antiretroviral therapy ( HAART) during HIV-1 infection remains a clinical dilemma. This decision relies heavily on assessing AIDS risk based on the CD4(+) T cell count and plasma viral load. However, the trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk. Methods and Findings: In a prospective, single-site, ethnically-mixed cohort of 1,132 HIV-positive subjects, we determined the AIDS risk conveyed by the laboratory and genetic markers separately and in combination. Subjects were assigned to a low, moderate or high genetic risk group (GRG) based on variations in CCL3L1 and CCR5. The predictive value of the CCL3L1-CCR5 GRGs, as estimated by likelihood ratios, was equivalent to that of the laboratory markers. GRG status also predicted AIDS development when the laboratory markers conveyed a contrary risk. Additionally, in two separate and large groups of HIV(+) subjects from a natural history cohort, the results from additive risk-scoring systems and classification and regression tree (CART) analysis revealed that the laboratory and CCL3L1-CCR5 genetic markers together provided more prognostic information than either marker alone. Furthermore, GRGs independently predicted the time interval from seroconversion to CD4(+) cell count thresholds used to guide HAART initiation. Conclusions: The combination of the laboratory and genetic markers captures a broader spectrum of AIDS risk than either marker alone. By tracking a unique aspect of AIDS risk distinct from that captured by the laboratory parameters, CCL3L1-CCR5 genotypes may have utility in HIV clinical management. These findings illustrate how genomic information might be applied to achieve practical benefits of personalized medicine. C1 [Kulkarni, Hemant; Camargo, Jose F.; He, Weijing; Crawford, George; Clark, Robert A.; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Kulkarni, Hemant; Camargo, Jose F.; He, Weijing; Ahuja, Sunil K.] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX USA. [Agan, Brian K.; Marconi, Vincent C.; O'Connell, Robert J.; Delmar, Judith; Dolan, Matthew J.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD USA. [Agan, Brian K.; Marconi, Vincent C.; O'Connell, Robert J.; Delmar, Judith; Dolan, Matthew J.] Wilford Hall United States Air Force Med Ctr, Infect Dis Serv, Lackland AFB, TX USA. [Agan, Brian K.; Dolan, Matthew J.] Wilford Hall United States Air Force Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX USA. [Agan, Brian K.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. [Phelps, Kenneth R.] Stratton Veterans Affairs Med Ctr, Albany, NY USA. [Phelps, Kenneth R.] Albany Med Coll, Albany, NY USA. [Ahuja, Sunil K.] Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol & Biochem, San Antonio, TX USA. RP Kulkarni, H (reprint author), S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. EM mdolan@idcrp.org; ahujas@uthscsa.edu RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669 FU Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System; MERIT [R37046326]; NIH [AI043279, MH069270]; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award in Translational Research; Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS); HHS/NIH/NIAID/DCR [HU0001-05-2-0011] FX This work was supported by the Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. Support for the Wilford Hall Medical Center cohort was provided by the Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS), of which the Tri-Service AIDS Clinical Consortium (TACC) is a component. The IDCRP is a Department of Defense tri-service program executed through USUHS and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), in collaboration with HHS/NIH/NIAID/DCR through Interagency Agreement HU0001-05-2-0011. The authors have no commercial or other association that might pose a conflict of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 92 TC 16 Z9 16 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 8 PY 2008 VL 3 IS 9 AR e3165 DI 10.1371/journal.pone.0003165 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 422JQ UT WOS:000264424300009 PM 18776933 ER PT J AU Sugimoto, M Furuta, T Nakamura, A Shirai, N Ikuma, M Misaka, S Uchida, S Watanabe, H Ohashi, K Ishizaki, T Hishida, A AF Sugimoto, Mitsushige Furuta, Takahisa Nakamura, Akiko Shirai, Naohito Ikuma, Mutsuhiro Misaka, Shingen Uchida, Shinya Watanabe, Hiroshi Ohashi, Kyoichi Ishizaki, Takashi Hishida, Akira TI Maintenance time of sedative effects after an intravenous infusion of diazepam: A guide for endoscopy using diazepam SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE diazepam; sedation; cytochrome P450 (CYP) 2C19; endoscopy; complication; critical flicker fusion test; eye movement analysis; postural sway test; visual analog scale ID N-DESMETHYLDIAZEPAM; CYP2C19 GENOTYPE; PLASMA-LEVELS; IN-VIVO; METABOLISM; OMEPRAZOLE; PHARMACOKINETICS; SCHIZOPHRENIA; DISPOSITION; POLYMORPHISM AB AIM: To examine whether the sedative effects assessed by psychomotor tests would depend on the cytochrome P450 (CYP) 2C19 genotypes after an infusion regimen of diazepam commonly used for gastrointestinal endoscopy in Japan. METHODS: Fifteen healthy Japanese volunteers consisting of three different CYP2C19 genotype groups underwent a critical flicker fusion test, an eye movement analysis and a postural sway test as a test for physical sedative effects, and a visual analog scale (VAS) symptom assessment method as a test for mental sedative effects during the 336 h period after the intravenous infusion of diazepam (5 mg). RESULTS: The physical sedative effects assessed by the critical flicker test continued for 1 h (t values of 5 min, 30 min and 60 min later: 4.35, 5.00 and 3.19, respectively) and those by the moving radial area of a postural sway test continued for 3 h (t values of 5 h, 30 h, 60 min and 3 h later: -4.05, -3.42, -2.17 and -2.58, respectively), which changed significantly compared with the baseline level before infusion (P < 0.05). On the other hand, the mental sedative effects by the VAS method improved within 1 h. The CYP2C19 genotype-dependent differences in the postinfusion sedative effects were not observed in any of the four psychomotor function tests. CONCLUSION: With the psychomotor tests, the objective sedative effects of diazepam continued for 1 h to 3 h irrespective of CYP2C19 genotype status and the subjective sedative symptoms improved within I h. Up to 3 h of clinical care appears to be required after the infusion of diazepam, although patients feel subjectively improved. (c) 2008 The WJG Press. All rights reserved. C1 [Sugimoto, Mitsushige; Nakamura, Akiko; Ikuma, Mutsuhiro; Hishida, Akira] Hamamatsu Univ Sch Med, Dept Med 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. [Furuta, Takahisa] Hamamatsu Univ Sch Med, Clin Res Ctr, Hamamatsu, Shizuoka 4313192, Japan. [Shirai, Naohito] Enshu Gen Hosp, Dept Gastroenterol, Naka Ku, Hamamatsu, Shizuoka 4300929, Japan. [Misaka, Shingen; Uchida, Shinya] Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharmacokinet & Pharmacodynam, Suruga Ku, Shizuoka 4228526, Japan. [Watanabe, Hiroshi; Ishizaki, Takashi] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. [Ohashi, Kyoichi] Oita Univ, Dept Clin Pharmacol & Therapeut, Hazama, Yufu 8795593, Japan. RP Sugimoto, M (reprint author), Hamamatsu Univ Sch Med, Dept Med 1, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM sugimoto@bcm.edu NR 38 TC 1 Z9 1 U1 2 U2 3 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD SEP 7 PY 2008 VL 14 IS 33 BP 5197 EP 5203 DI 10.3748/wjg.14.5197 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 346TB UT WOS:000259091000013 PM 18777597 ER PT J AU Mexal, S Berger, R Pearce, L Barton, A Logel, J Adams, CE Ross, RG Freedman, R Leonard, S AF Mexal, Sharon Berger, Ralph Pearce, Lucy Barton, Amanda Logel, Judy Adams, Catherine E. Ross, Randal G. Freedman, Robert Leonard, Sherry TI Regulation of a novel alpha N-catenin splice variant in schizophrenic smokers SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE schizophrenia; nicotine addiction; CTNNA2; evolution; primate ID CELL-ADHESION; NICOTINE DEPENDENCE; CIGARETTE-SMOKING; BIPOLAR DISORDER; GENE-EXPRESSION; GENOME; EVOLUTION; CADHERIN; ORGANIZATION; METAANALYSIS AB The alpha N-catenin (CTNNA2) gene represents a promising candidate gene for schizophrenia based upon previous genetic linkage, expression, and mouse knockout studies. CTNNA2 is differentially regulated by smoking in schizophrenic patients. In this report, the genomic structure of a primate-specific alpha N-catenin splice variant (alpha N-catenin III) is described. A comparison of alpha N-catenin III mRNA expression across postmortem hippocampi from schizophrenic and non-mentally ill smokers and non-smokers revealed a significant decrease in expression among patient non-smokers compared to all other groups. The recent evolutionary divergence of this gene, as well as the differences in gene expression in postmortem brain of schizophrenic non-smokers, supports the role of alpha N-catenin III as a novel disease susceptibility gene. (c) 2007 Wiley-Liss, Inc. C1 [Berger, Ralph; Pearce, Lucy; Barton, Amanda; Logel, Judy; Adams, Catherine E.; Ross, Randal G.; Freedman, Robert; Leonard, Sherry] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Berger, Ralph; Pearce, Lucy; Barton, Amanda; Logel, Judy; Adams, Catherine E.; Ross, Randal G.; Freedman, Robert; Leonard, Sherry] Hlth Sci Ctr, Aurora, CO USA. [Mexal, Sharon] Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA. [Adams, Catherine E.; Freedman, Robert; Leonard, Sherry] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Leonard, S (reprint author), Univ Colorado Denver, Dept Psychiat, Mailstop 8344,POB 6511, Aurora, CO 80045 USA. EM sherry.leonard@uchsc.edu RI Barton, Anne/N-2053-2014 OI Barton, Anne/0000-0003-3316-2527 FU Veterans Affairs Medical Research Service; NIH [DA09457, MH81177] FX Grant sponsor: Veterans Affairs Medical Research Service; Grant sponsor: NIH; Grant numbers: DA09457, MH81177. NR 39 TC 15 Z9 16 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD SEP 5 PY 2008 VL 147B IS 6 BP 759 EP 768 DI 10.1002/ajmg.b.30679 PG 10 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 346EB UT WOS:000259050100014 PM 18163523 ER PT J AU Novgorodov, SA Gudz, TI Obeid, LM AF Novgorodov, Sergei A. Gudz, Tatyana I. Obeid, Lina M. TI Long-chain ceramide is a potent inhibitor of the mitochondrial permeability transition pore SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Review ID NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; RAT-LIVER MITOCHONDRIA; APOPTOTIC CELL-DEATH; ADENINE-NUCLEOTIDE TRANSLOCASE; DEPENDENT ANION CHANNEL; 2 SEPARATE SITES; CYCLOPHILIN-D; PROTEIN PHOSPHATASE; CYCLOSPORINE-A AB The sphingolipid ceramide has been implicated in mediating cell death that is accompanied by mitochondrial functional alterations. Moreover, ceramide has been shown to accumulate in mitochondria upon induction of apoptotic processes. In this study, we sought to evaluate the effects of natural, highly hydrophobic long-chain ceramides on mitochondrial function in vitro. Ceramide in a dodecane/ethanol delivery system inhibited the opening of the mitochondrial permeability transition pore (PTP) induced by either oxidative stress, SH group cross-linking, or high Ca(2+) load, suggesting that the inhibitory point is at a level at which major PTP regulatory pathways converge. Moreover, ceramide had no effect on well known mitochondrial components that modulate PTP activity, such as cyclophilin D, voltage-dependent anion channel, adenine nucleotide transporter, and ATP synthase. The inhibitory effect of ceramide on PTP was not stereospecific, nor was there a preference for ceramide over dihydroceramide. However, the effect of ceramide on PTP was significantly influenced by the fatty acid moiety chain length. These studies are the first to show that long-chain ceramide can influence PTP at physiologically relevant concentrations, suggesting that it is the only known potent natural inhibitor of PTP. These results suggest a novel mechanism of ceramide regulation of mitochondrial function. C1 [Novgorodov, Sergei A.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Novgorodov, Sergei A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Gudz, Tatyana I.; Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [AG16583, P20 RR 17677-04, CO6 RR018823]; Veterans Affairs Merit Awards FX This work was supported, in whole or in part, by National Institutes of Health Grant AG16583 (to L. M. O.), National Institutes of Health Grant P20 RR 17677-04 (to T. I. G.), and National Institutes of Health Grant CO6 RR018823. This work was also supported by Veterans Affairs Merit Awards (to T. I. G. and L. M. O.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 115 TC 24 Z9 25 U1 1 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 5 PY 2008 VL 283 IS 36 BP 24707 EP 24717 DI 10.1074/jbc.M801810200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 342YR UT WOS:000258820000040 PM 18596045 ER PT J AU Chandrasekar, B Boylston, WH Venkatachalam, K Webster, NJG Prabhu, SD Valente, AJ AF Chandrasekar, Bysani Boylston, William H. Venkatachalam, Kaliyamurthi Webster, Nicholas J. G. Prabhu, Sumanth D. Valente, Anthony J. TI Adiponectin Blocks Interleukin-18-mediated Endothelial Cell Death via APPL1-dependent AMP-activated Protein Kinase (AMPK) Activation and IKK/NF-kappa B/PTEN Suppression SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HUMAN ATHEROSCLEROTIC PLAQUES; CORONARY-ARTERY-DISEASE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; B ACTIVATION; STIMULATES ANGIOGENESIS; INSULIN-RESISTANCE; SIGNALING PATHWAY; FUNCTIONAL IL-18; HIGH-GLUCOSE AB The adipocyte-derived cytokine adiponectin is known to exert anti-inflammatory and anti-apoptotic effects. In patients with atherosclerotic cardiovascular disease, circulating levels of adiponectin correlate inversely with those of the proinflammatory, proapoptotic cytokine interleukin (IL)-18. The opposing actions of IL-18 and adiponectin on both cell survival and inflammation led us to investigate whether adiponectin signaling antagonizes IL-18-mediated endothelial cell death and to identify the underlying molecular mechanisms. Treatment with IL-18 suppressed Akt phosphorylation and its associated kinase activity, induced I kappa B kinase (IKK)-NF-kappa B-dependent PTEN activation, and promoted endothelial cell death. Pretreatment with adiponectin stimulated APPL1-dependent AMPK activation, reversed Akt inhibition in a phosphatidylinositol 3-kinase-dependent manner, blocked IKK-NF-kappa B-PTEN signaling, reduced caspase-3 activity, blocked Bax translocation, and inhibited endothelial cell death. The cytoprotective effect of adiponectin signaling was recapitulated by treatment with the pharmacological AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-riboside. Collectively, these results demonstrated that adiponectin reverses IL-18-mediated endothelial cell death through an AMPK-associated mechanism, which may thus have therapeutic potential for diminishing IL-18-dependent vascular injury and inflammation. C1 [Chandrasekar, Bysani; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chandrasekar, Bysani; Venkatachalam, Kaliyamurthi] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Boylston, William H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Webster, Nicholas J. G.] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA. [Prabhu, Sumanth D.] Univ Louisville, Dept Med, Inst Mol Cardiol, Louisville, KY 40292 USA. [Prabhu, Sumanth D.] Louisville Vet Affairs Med Ctr, Med Serv, Louisville, KY 40292 USA. RP Chandrasekar, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Prabhu, Sumanth/D-5223-2009 FU Research Service of the Department of Veterans Affairs FX This work was supported in part by the Research Service of the Department of Veterans Affairs. NR 49 TC 77 Z9 90 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 5 PY 2008 VL 283 IS 36 BP 24889 EP 24898 DI 10.1074/jbc.M804236200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 517MA UT WOS:000271617300007 PM 18632660 ER PT J AU Poole, JE Johnson, GW Hellkamp, AS Anderson, J Callans, DJ Raitt, MH Reddy, RK Marchlinski, FE Yee, R Guarnieri, T Talajic, M Wilber, DJ Fishbein, DP Packer, DL Mark, DB Lee, KL Bardy, GH AF Poole, Jeanne E. Johnson, George W. Hellkamp, Anne S. Anderson, Jill Callans, David J. Raitt, Merritt H. Reddy, Ramakota K. Marchlinski, Francis E. Yee, Raymond Guarnieri, Thomas Talajic, Mario Wilber, David J. Fishbein, Daniel P. Packer, Douglas L. Mark, Daniel B. Lee, Kerry L. Bardy, Gust H. TI Prognostic importance of defibrillator shocks in patients with heart failure SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; PROPHYLACTIC IMPLANTATION; MYOCARDIAL DYSFUNCTION; ATRIAL-FIBRILLATION; TRIAL; TACHYARRHYTHMIA; THERAPY AB Background: Patients with heart failure who receive an implantable cardioverter-defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) may later receive therapeutic shocks from the ICD. Information about long-term prognosis after ICD therapy in such patients is limited. Methods: Of 829 patients with heart failure who were randomly assigned to ICD therapy, we implanted the ICD in 811. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate. All other ICD shocks were considered to be inappropriate. Results: Over a median follow-up period of 45.5 months, 269 patients (33.2%) received at least one ICD shock, with 128 patients receiving only appropriate shocks, 87 receiving only inappropriate shocks, and 54 receiving both types of shock. In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes (hazard ratio, 5.68; 95% confidence interval [CI], 3.97 to 8.12; P<0.001). An inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death (hazard ratio, 1.98; 95% CI, 1.29 to 3.05; P=0.002). For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated (hazard ratio, 2.99; 95% CI, 2.04 to 4.37; P<0.001). The most common cause of death among patients who received any ICD shock was progressive heart failure. Conclusions: Among patients with heart failure in whom an ICD is implanted for primary prevention, those who receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks. C1 [Poole, Jeanne E.; Fishbein, Daniel P.; Bardy, Gust H.] Univ Washington, Sch Med, Div Cardiol, Seattle, WA 98195 USA. [Johnson, George W.; Anderson, Jill; Bardy, Gust H.] Seattle Inst Cardiac Res, Seattle, WA USA. [Hellkamp, Anne S.; Mark, Daniel B.; Lee, Kerry L.] Duke Clin Res Inst, Durham, NC USA. [Callans, David J.; Marchlinski, Francis E.] Univ Penn, Philadelphia, PA 19104 USA. [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA. [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Reddy, Ramakota K.] Oregon Cardiol Assoc, Eugene, OR USA. [Yee, Raymond] Univ Western Ontario, Univ Hosp, London, ON N6A 5A5, Canada. [Guarnieri, Thomas] Johns Hopkins Univ, Baltimore, MD USA. [Talajic, Mario] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada. [Wilber, David J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Packer, Douglas L.] Mayo Clin, Rochester, MN USA. RP Poole, JE (reprint author), Univ Washington, Sch Med, Div Cardiol, 1959 NE Pacific St,Box 356422, Seattle, WA 98195 USA. EM jpoole@u.washington.edu OI Mark, Daniel/0000-0001-6340-8087; Marchlinski, Francis/0000-0001-7962-9423 FU National Heart, Lung, and Blood Institute [UO1 HL55766, UO1 HL55297, UO1 HL55496]; Medtronic; Wyeth Pharmaceuticals; Boston Scientific/Guidant; Biotronik; Biosense Webster; Siemens Acuson; Boston Scientific; St. Jude Medical FX Supported by grants from the National Heart, Lung, and Blood Institute (UO1 HL55766, UO1 HL55297, and UO1 HL55496) and by Medtronic and Wyeth Pharmaceuticals. Dr. Poole reports receiving lecture fees from Medtronic and Boston Scientific/Guidant, grant support from Biotronik, and consulting fees from Philips; Ms. Anderson, receiving lecture fees from Boston Scientific/Guidant; Dr. Callans, receiving lecture fees from Biosense Webster, Siemens Acuson, Boston Scientific, and Medtronic and consulting fees from St. Jude Medical; Dr. Reddy, receiving consulting fees and lecture fees from Boston Scientific/Guidant, Medtronic, and St. Jude and holding stock options in Cambridge Heart; Dr. Marchlinski, receiving consulting fees, lecture fees, and grant support from Biosense Webster, lecture fees and grant support from Boston Scientific and St. Jude Medical, lecture fees from Medtronic, and consulting fees from GE Healthcare; Dr. Yee, receiving consulting fees from Medtronic; Dr. Talajic, receiving consulting fees and lecture fees from Medtronic and lecture fees from St. Jude Medical; Dr. Wilber, receiving consulting fees and lecture fees from Medtronic and lecture fees from Boston Scientific and St. Jude Medical; Dr. Fishbein, receiving lecture fees from Medtronic; Dr. Packer, receiving consulting fees from Medtronic and Boston Scientific/ Guidant, royalties from St. Jude Medical, and grant support from Boston Scientific; Dr. Mark, receiving consulting fees, lecture fees, and research grants from Medtronic and fees as editor of the American Heart Journal from Mosby; Dr. Lee, receiving grant support and consulting fees from Medtronic; and Dr. Bardy, receiving grant support from and having intellectual property rights with Medtronic, receiving consulting fees and grant support from Philips, receiving grant support from Laerdal and being a founder of and board member of and having equity and intellectual property rights with Cameron Health. No other potential conflict of interest relevant to this article was reported. We thank R. Conklin for help in the preparation of the manuscript. NR 21 TC 577 Z9 587 U1 1 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 4 PY 2008 VL 359 IS 10 BP 1009 EP 1017 DI 10.1056/NEJMoa071098 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 343KN UT WOS:000258852500005 PM 18768944 ER PT J AU Penrod, J Morrison, RS Meier, DE AF Penrod, Joan Morrison, R. Sean Meier, Diane E. TI Studying the effectiveness of palliative care SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Penrod, Joan] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Morrison, R. Sean] Natl Palliat Care Res Ctr, New York, NY USA. [Meier, Diane E.] Ctr Adv Palliat Care, New York, NY USA. RP Penrod, J (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. EM sean.morrison@mssm.edu NR 5 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 3 PY 2008 VL 300 IS 9 BP 1022 EP 1023 DI 10.1001/jama.300.9.1022-b PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 342YN UT WOS:000258819600014 PM 18768410 ER PT J AU Beach, TG White, CL Hamilton, RL Duda, JE Iwatsubo, T Dickson, DW Leverenz, JB Roncaroli, F Buttini, M Hladik, CL Sue, LI Noorigian, JV Adler, CH AF Beach, Thomas G. White, Charles L. Hamilton, Ronald L. Duda, John E. Iwatsubo, Takeshi Dickson, Dennis W. Leverenz, James B. Roncaroli, Federico Buttini, Manuel Hladik, Christa L. Sue, Lucia I. Noorigian, Joseph V. Adler, Charles H. TI Evaluation of alpha-synuclein immunohistochemical methods used by invited experts SO ACTA NEUROPATHOLOGICA LA English DT Article ID LEWY-BODY-DISEASE; MULTIPLE SYSTEM ATROPHY; FORMIC-ACID PRETREATMENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HUMAN-BRAIN; NACP/ALPHA-SYNUCLEIN; NEURODEGENERATIVE SYNUCLEINOPATHIES; PATHOLOGY; BODIES AB The use of alpha-synuclein immunohistochemistry has altered our concepts of the cellular pathology, anatomical distribution and prevalence of Lewy body disorders. However, the diversity of methodology between laboratories has led to some inconsistencies in the literature. Adoption of uniformly sensitive methods may resolve some of these differences. Eight different immunohistochemical methods for demonstrating alpha-synuclein pathology, developed in eight separate expert laboratories, were evaluated for their sensitivity for neuronal elements affected by human Lewy body disorders. Identical test sets of formalin-fixed, paraffin-embedded sections from subjects diagnosed neuropathologically with or without Lewy body disorders were stained with the eight methods and graded by three observers for specific and nonspecific staining. The methods did not differ significantly in terms of Lewy body counts, but varied considerably in their ability to reveal neuropil elements such as fibers and dots. One method was clearly superior for revealing these neuropil elements and the critical factor contributing to its high sensitivity was considered to be its use of proteinase K as an epitope retrieval method. Some methods, however, achieved relatively high sensitivities with optimized formic acid protocols combined with a hydrolytic step. One method was developed that allows high sensitivity with commercially available reagents. C1 [Beach, Thomas G.; Sue, Lucia I.] Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ 85351 USA. [White, Charles L.; Hladik, Christa L.] Univ Texas Dallas, SW Med Ctr, Neuropathol Lab, Dallas, TX 75230 USA. [White, Charles L.; Hladik, Christa L.] Univ Texas Dallas, SW Med Ctr, Pathol Immunohistochem Lab, Dallas, TX 75230 USA. [Hamilton, Ronald L.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Duda, John E.; Noorigian, Joseph V.] Philadelphia Vet AVairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Iwatsubo, Takeshi] Univ Tokyo, Dept Life Pharmaceut, Tokyo, Japan. [Dickson, Dennis W.] Mayo Clin, Dept Lab Med & Pathol, Jacksonville, FL USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Roncaroli, Federico] Univ London Imperial Coll Sci Technol & Med, Dept Clin Neurosci, London, England. [Buttini, Manuel] Elan Pharmaceut, San Francisco, CA USA. [Adler, Charles H.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. RP Beach, TG (reprint author), Sun Hlth Res Inst, Civin Lab Neuropathol, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA. EM thomas.beach@sunhealth.org OI Dickson, Dennis W/0000-0001-7189-7917 FU NIA NIH HHS [P30 AG019610, P30 AG019610-069002, P30 AG019610-079002, P30 AG019610-089002, P30 AG19610, P50 AG005133-25, P50 AG005136, P50 AG005136-25] NR 50 TC 78 Z9 78 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD SEP PY 2008 VL 116 IS 3 BP 277 EP 288 DI 10.1007/s00401-008-0409-8 PG 12 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 334QB UT WOS:000258235200006 PM 18626651 ER PT J AU Cornelius, JR Kirisci, L Reynolds, M Homish, GG Clark, DB AF Cornelius, Jack R. Kirisci, Levent Reynolds, Maureen Homish, Gregory G. Clark, Duncan B. TI Husbands' SUD is associated with higher levels of co-occurring but not non-co-occurring psychiatric disorders among their wives SO ADDICTIVE BEHAVIORS LA English DT Article DE substance use disorders; psychiatric disorders; psychiatric symptoms ID SUBSTANCE USE DISORDERS; MARIJUANA USE AB Objective: Substance use among husbands has been shown to be associated with higher rates of substance use and of psychiatric symptoms among their wives. However, substance use disorders (SUD) and psychiatric disorders (as opposed to substance use or psychiatric symptoms) are rarely rigorously assessed among large samples of couples, so it is unclear whether SUD among husbands are associated with SUD among their wives, and whether the wives also display a higher prevalence of co-occurring or non-co-occurring psychiatric disorders. We compared the level of SUD, of co-occurring (with SUD) psychiatric disorders, and of non-co-occurring psychiatric diagnoses among the wives of males with SUDs vs among the wives of males without SUDs. We hypothesized that the presence of SUDs among males would be associated with a higher level of SUDs, of co-occurring psychiatric disorders, and of non-co-occurring psychiatric disorders in their wives. Method: The subjects in this study were the spouses of adult men with a lifetime history of an SUD (SUD+ husbands, N=342) vs those with no lifetime history of an SUD (SUD- husbands, N=350). These subjects were recruited for participation in a longitudinal project designed to elucidate the etiology of substance use disorders. Results: Co-occurring SUDs were five times more common among the spouses of SUD+ usbands than among the spouses of SUD- husbands (10.2% vs 2.0%, chi-square = 19.7, p=0.000). SUD/depressive disorder and SUD/anxiety disorder were both seven times more common among the spouses of SUD+ husbands than among the spouses of SUD- husbands (19.4% vs 4.7%, chi-square =45.8, p=0.000; 14.3% vs 2.0%, chi-square =34.5, p=0.000). In contrast, non-co-occurring depressive disorders and non-co-occurring anxiety disorders were not more common among the wives of the SUD+ husbands than among the SUD- husbands. Conclusions: These findings demonstrate that SUD and co-occurring psychiatric disorders (with SUD) are more common among the spouses of SUD+ husbands than among the spouses of SUD- husbands, but non-co-occurring ("pure") psychiatric disorders are not more common among the spouses of the SUD+ husbands. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Cornelius, Jack R.; Kirisci, Levent; Reynolds, Maureen; Clark, Duncan B.] Univ Pittsburgh, CEDAR, Pittsburgh, PA 15213 USA. [Cornelius, Jack R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Homish, Gregory G.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Hlth Behav, Buffalo, NY 14214 USA. [Homish, Gregory G.] SUNY Buffalo, Res Inst Addict, Buffalo, NY 14203 USA. RP Cornelius, JR (reprint author), 3811 OHara St, Pittsburgh, PA 15213 USA. EM corneliusjr@upmc.edu FU NIAAA NIH HHS [K24 AA15320, R01 AA015173-04, K24 AA015320, K02 AA00291, R01 AA013370, K02 AA000291, K24 AA015320-04, R01 AA013370-05, R01 AA015173]; NIDA NIH HHS [P50 DA005605, P50 DA005605-189002, R01 DA14635, R01 DA014635, R01 DA019142, P50 DA05605, R01 DA019142-04] NR 11 TC 4 Z9 4 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD SEP PY 2008 VL 33 IS 9 BP 1231 EP 1234 DI 10.1016/j.addbeh.2008.04.013 PG 4 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 331XT UT WOS:000258046600019 PM 18544467 ER PT J AU Clark, A Mayben, JK Hartman, C Kallen, MA Giordano, TP AF Clark, April Mayben, Jennifer K. Hartman, Christine Kallen, Michael A. Giordano, Thomas P. TI Conspiracy beliefs about HIV infection are common but not associated with delayed diagnosis or adherence to care SO AIDS PATIENT CARE AND STDS LA English DT Article ID AFRICAN-AMERICANS; TRUST; HIV/AIDS; PROVIDERS; POPULATION; QUALITY; BARRIER AB We Sought to determine the prevalence of HIV conspiracy beliefs in patients with HIV and how those beliefs correlate with access and adherence to HIV care and health outcomes. From March to December 2005,113 patients at four public facilities in Houston, Texas, diagnosed with HIV for 3 years or less, participated in a cross-sectional Survey. Conspiracy beliefs were assessed with five items that dealt with HIV origin, cure, and vaccine. Medical records were reviewed for CD4 cell counts, HAART use, and appointment dates. Statistical analyses (including analysis of variance [ANOVA], chi(2) testing, and regression) determined the predictors of conspiracy beliefs and correlated them with outcomes. Sixty-three percent of the participants endorsed 1 or more conspiracy beliefs. African American patients more often held HIV conspiracy beliefs than white and other/mixed race patients (73%, 52'%, 47%; p = 0.045). Persons holding I or more conspiracy beliefs had higher CD4 cell counts at diagnosis (254 cells/mm(3) versus 92, p = 0.03); and similar rates of highly active antiretroviral therapy (HAART) use (73%, versus 71%), 100% adherence to HAART by self-report (53% versus 45%,), mean adherence by pharmacy refill (83% versuss 87%), and gaps in care greater than 120 days (49%, versus 53%), compared to subjects who did not hold any conspiracy beliefs (all p > 0.40). Since recruitment focused on patients in care, patients with extreme conspiracy beliefs may be underrepresented. Despite this, more than 50%, of the study population endorsed 1 or more conspiracy belief. However, these beliefs did not negatively impact access or adherence to HIV care. Efforts to improve adherence to HIV care may not need to focus on eliminating conspiracy beliefs. C1 [Clark, April; Mayben, Jennifer K.; Hartman, Christine; Kallen, Michael A.; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Clark, April; Hartman, Christine; Kallen, Michael A.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Mayben, Jennifer K.] Baylor Coll Med, Dept Community & Family Med, Houston, TX 77030 USA. RP Giordano, TP (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tpg@bcm.tmc.edu FU National Institutes of Mental Health; National Institutes of Health [MH067505]; Agency for Healthcare Quality and Research [HP10031] FX The authors would like to thank Sallye M. Stapleton and Erick Villareal for their help in conducting the interviews. This work was suupported by the National Institutes of Mental Health, National Institutes of Health (Grant MH067505), the Agency for Healthcare Quality and Research (Grant HP10031), and the facilities and resources of the Michael E. DeBakey Veterans Affairs Medical Center and the Harris County Hospital District, Houston, Texas. NR 14 TC 17 Z9 17 U1 2 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD SEP PY 2008 VL 22 IS 9 BP 753 EP 759 DI 10.1089/apc.2007.0249 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 354LR UT WOS:000259641600009 PM 18754706 ER PT J AU Durazzo, TC Rothlind, JC Gazdzinski, S Meyerhoff, DJ AF Durazzo, Timothy C. Rothlind, Johannes C. Gazdzinski, Stefan Meyerhoff, Dieter J. TI The relationships of sociodemographic factors, medical, psychiatric, and substance-misuse co-morbidities to neurocognition in short-term abstinent alcohol-dependent individuals SO ALCOHOL LA English DT Review DE alcohol use disorders; alcohol dependence; cigarette smoking; age effects; co-morbidities ID CHRONIC CIGARETTE-SMOKING; ANTISOCIAL PERSONALITY-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; CHRONIC HEPATITIS-C; DSM-IV ALCOHOL; MAJOR DEPRESSION; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE EFFICIENCY; PROCESSING-SPEED; RESONANCE-SPECTROSCOPY AB Co-morbidities that commonly accompany those afflicted with an alcohol use disorder (AUD) may promote variability in the pattern and magnitude of neurocognitive abnormalities demonstrated. The goal of this study was to investigate the influence of several common co-morbid medical conditions (primarily hypertension and hepatitis Q, psychiatric (primarily unipolar mood and anxiety disorders), and substance use (primarily psychostimulant and cannabis) disorders, and chronic cigarette smoking on the neurocognitive functioning in short-term abstinent, treatment-seeking individuals with AUD. Seventy-five alcohol -dependent participants (ALC; 51 +/- 9 years of age; three females) completed comprehensive neurocognitive testing after approximately I month of abstinence. Multivariate multiple linear regression evaluated the relationships among neurocognitive variables and medical conditions, psychiatric, and substance-use disorders, controlling for sociodemographic factors. Sixty-four percent of ALC had at least one medical, psychiatric, or substance-abuse co-morbidity (excluding smoking). Smoking status (smoker or nonsmoker) and age were significant independent predictors of cognitive efficiency, general intelligence, postural stability, processing speed, and visuospatial memory after age-normed adjustment and control for estimated premorbid verbal intelligence, education, alcohol consumption, and medical, psychiatric, and substance-misuse co-morbidities. Results indicated that chronic smoking accounted for a significant portion of the variance in the neurocognitive performance of this middle-aged AUD cohort. The age-related findings for ALC suggest that alcohol dependence, per se, was associated with diminished neurocognitive functioning with increasing age. The study of participants who demonstrate common co-morbidities observed in AUD is necessary to fully understand how AUD, as a clinical syndrome, affects neurocognition, brain neurobiology, and their changes with extended abstinence. (C) 2008 Elsevier Inc. All rights reserved. C1 [Durazzo, Timothy C.; Rothlind, Johannes C.; Gazdzinski, Stefan; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Rothlind, Johannes C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 114M 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU NIH [AA10788] FX This project was supported by NIH AA10788 (DJ-M). We thank the San Francisco VA Medical Center Research Service for logistical support; Mary Rebecca Young and Bill Clift of the VA Substance Abuse Day Hospital; and Drs. David Pating, Peter Washburn, and Karen Moise and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 118 TC 16 Z9 16 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD SEP PY 2008 VL 42 IS 6 BP 439 EP 449 DI 10.1016/j.alcohol.2008.06.001 PG 11 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 352NE UT WOS:000259503100001 PM 18760713 ER PT J AU Braithwaite, RS Conigliaro, J McGinnis, KA Maisto, SA Bryant, K Justice, AC AF Braithwaite, R. Scott Conigliaro, Joseph McGinnis, Kathleen A. Maisto, Stephen A. Bryant, Kendall Justice, Amy C. TI Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE human immunodeficiency virus; alcohol; nonadherence ID OLDER-ADULTS; PRIMARY-CARE; ADHERENCE; DRINKING; DRINKERS; VETERANS; RELIABILITY; TOXICITY; OUTCOMES; FRAILTY AB Background: Screening for hazardous drinking may fail to detect a substantial proportion of individuals harmed by alcohol. We investigated whether considering an individual's usual drinking quantity or threshold for alcohol-induced cognitive impairment improves the prediction of nonadherence with prescribed medications. Method: Cross-sectional analysis of participants in a large, multi-site cohort study. We used the timeline followback to reconstruct 30-day retrospective drinking histories and the timeline followback modified for adherence to reconstruct 30-day medication adherence histories among 3,152 individuals in the Veterans Aging Cohort Study, 1,529 HIV infected and 1,623 uninfected controls. We categorized daily alcohol consumption by using quantity alone, quantity after adjustment for the individual's mean daily alcohol consumption, and self-reported level of impairment corresponding to each quantity. A standard drink was defined as 14 g of ethanol. Nonadherence was defined as the proportion of days with >= 1 medication doses missed or taken >= 2 hours late, and clinically significant nonadherence was defined as >= 5% absolute increase in the proportion of days with nonadherence. Results: The mean adjusted- and impairment-based methods showed greater discrimination of nonadherence risk compared to the measure based on quantity alone (quantity-based categorization, 3.2-fold increase; quantity adjusted for mean daily consumption, 4.6-fold increase, impairment-based categorization, 3.6-fold increase). The individualized methods also detected greater numbers of days with clinically significant nonadherence associated with alcohol. Alcohol was associated with clinically significant nonadherence at a lower threshold for HIV infected versus uninfected patients (2 standard drinks vs. 4 standard drinks) using quantity-based categorization, but this difference was no longer apparent when individualized methods were used. Conclusions: Tailoring screening questions to an individual's usual level of alcohol consumption or threshold for impairment improves the ability to predict alcohol-associated medication nonadherence. C1 [Braithwaite, R. Scott; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, West Haven, CT 06516 USA. [Braithwaite, R. Scott; Justice, Amy C.] Connecticut Vet Adm Med Ctr, West Haven, CT USA. [Conigliaro, Joseph] Univ Kentucky, Dept Med, Gen Internal Med Sect, Lexington, KY 40506 USA. [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Bryant, Kendall] NIAAA, NIH, Bethesda, MD USA. RP Braithwaite, RS (reprint author), Yale Univ, Sch Med, Dept Gen Internal Med, VA Connecticut Healthcare Syst, 11ACSLG,950 Campbell Ave, West Haven, CT 06516 USA. EM ronald.braithwaite@med.va.gov FU National Institute of Alcohol Abuse and Alcoholism [K23 AA14483-01, R21 AA015894-01] FX This work was funded by Grants K23 AA14483-01 and R21 AA015894-01 from the National Institute of Alcohol Abuse and Alcoholism. This study was approved by the Yale University and West Haven VA Institutional Review Boards. NR 25 TC 25 Z9 26 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD SEP PY 2008 VL 32 IS 9 BP 1645 EP 1651 DI 10.1111/j.1530-0277.2008.00732.x PG 7 WC Substance Abuse SC Substance Abuse GA 341PN UT WOS:000258726700015 PM 18616666 ER PT J AU Sheinkopf, LE Rafi, AW Do, LT Katz, RM Klaustermeyer, WB AF Sheinkopf, Lee E. Rafi, Asif W. Do, LanAnh T. Katz, Roger M. Klaustermeyer, William B. TI Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article DE Anti-IgE; asthma; atopic dermatitis; biologic therapeutic; IgE; investigator global assessment; omalizumab; prospective; treatment ID ANTIIMMUNOGLOBULIN-E THERAPY; ANTI-IGE THERAPY; TACROLIMUS OINTMENT 0.03-PERCENT; EPIDERMAL LANGERHANS CELLS; LONG-TERM MANAGEMENT; FC-EPSILON-RI; ALLERGIC-ASTHMA; IMMUNOLOGICAL MECHANISMS; PIMECROLIMUS CREAM; SCORAD INDEX AB Omalizumab is a unique biologic therapeutic drug approved for treating atopic patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. This study was performed to examine the efficacy of omalizumab for the treatment of atopic dermatitis (AD), a disease with siginificant morbidity. A prospective analysis was performed to assess the efficacy of omalizumab in 21 patients with moderate to severe persistent allergic asthma and AD. Patients were stratified into the following groups: very high IgE (> 700 IU/mL), high IgE (186-700 IU/mL), and normal IgE (0-185 IU/mL). AD severity was assessed at 0, 1, 3, 6, and 9 months via 0)7 Investigator Global Assessment index. Twenty-one patients (14-64 years old) were evaluated. Pretreatment IgE levels ranged from 18.2 to 8396 IU/mL, (mean IgE level was 1521. IU/mL). All 21 patients showed clinical and statistically significant improvement of their atopic dermatitis (p < 0.00052). In conclusion, this study indicates that omnalizumab is effective in treating AD in patients with moderate to severe persistent allergic asthma. C1 [Sheinkopf, Lee E.; Klaustermeyer, William B.] Univ Calif Los Angeles, Dept Allergy & Immunol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Rafi, Asif W.; Do, LanAnh T.; Katz, Roger M.] Allergy Asthma Care Ctr Inc, Los Angeles, CA USA. RP Sheinkopf, LE (reprint author), Univ Calif Los Angeles, Dept Allergy & Immunol, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111R, Los Angeles, CA 90073 USA. NR 46 TC 76 Z9 80 U1 1 U2 2 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD SEP-OCT PY 2008 VL 29 IS 5 BP 530 EP 537 DI 10.2500/aap.2008.29.3160 PG 8 WC Allergy SC Allergy GA 358JA UT WOS:000259911800016 PM 18926061 ER PT J AU Stein, R Gupta, B Agarwal, S Golub, J Bhutan, D Rosman, A Eng, C AF Stein, Russell Gupta, Bhanu Agarwal, Sanjay Golub, Jason Bhutan, Divaya Rosman, Alan Eng, Calvin TI Prognostic implications of normal (< 0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID I LEVELS; MYOCARDIAL-INFARCTION; RISK-FACTOR; MORTALITY; PREDICT; SCORE AB Borderline increase of troponin I (cTnI) is associated with higher rates of cardiovascular events compared with normal levels in the setting of acute coronary syndrome (ACS), but the significance of borderline cTnI levels in patients without chest pain may differ. The aim of this study was to determine the prognostic implications of intermediate serum cTnI levels in patients without ACS in the intensive care unit (ICU). This was a 12-month retrospective study of 240 patients without ACS in the ICU with normal (<0.1 ng/ml) or intermediate (0.1 to 1.49 ng/ml) cTnI levels. End points included in-hospital mortality, lengths of ICU and hospital stays, and rates of postdischarge readmission and mortality. Overall in-hospital mortality was 13%, with 5% in the normal cTnI group and 28% in the intermediate cTnI group. By multivariate analysis, intermediate cTnI was independently associated with in-hospital mortality (p = 0.004) and length of ICU stay (p = 0.028). The only other independent risk factor for inpatient mortality was a standardized ICU prognostic measurement (Simplified Acute Physiology Score 11 score). Intermediate cTnI had no prognostic implications regarding length of hospital stay, readmission rate, or postdischarge mortality at 6 months. In conclusion, an intermediate level of cTnI in patients without ACS in the ICU is an independent prognostic marker predicting in-hospital mortality and length of ICU stay. Patients with intermediate cTnI levels who survive to discharge have equivalent out-of-hospital courses for up to 6 months compared with patients with normal cTnI levels. (C) 2008 Elsevier Inc. All rights reserved. C1 [Stein, Russell] Mt Sinai Med Ctr, Zena & Michael A Wietner Cardiovasc Inst, New York, NY 10029 USA. [Stein, Russell] Mt Sinai Med Ctr, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA. [Gupta, Bhanu; Agarwal, Sanjay; Bhutan, Divaya; Rosman, Alan; Eng, Calvin] Bronx Vet Affairs Med Ctr, Cardiol Sect, Bronx, NY USA. [Gupta, Bhanu; Agarwal, Sanjay; Bhutan, Divaya; Rosman, Alan; Eng, Calvin] Bronx Vet Affairs Med Ctr, Med Serv, Bronx, NY USA. [Golub, Jason] Jacobi Med Ctr, Dept Med, Bronx, NY USA. RP Stein, R (reprint author), Mt Sinai Med Ctr, Zena & Michael A Wietner Cardiovasc Inst, New York, NY 10029 USA. EM Russell.Stein@mssm.edu NR 13 TC 27 Z9 27 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD SEP 1 PY 2008 VL 102 IS 5 BP 509 EP 512 DI 10.1016/j.amjcard.2008.04.026 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 342LB UT WOS:000258784500001 PM 18721503 ER PT J AU Sobhani, K Bankson, DD AF Sobhani, Kimia Bankson, Daniel D. TI Can reflexive testosterone testing improve service and decrease costs? SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the Academy-of-Clinical-Laboratory-Physicians-and-Scientists CY JUN 05-07, 2008 CL Philadelphia, PA SP Acad Clin Lab Phys & Sci C1 [Sobhani, Kimia; Bankson, Daniel D.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Bankson, Daniel D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2008 VL 130 IS 3 BP 477 EP 478 PG 2 WC Pathology SC Pathology GA 338WA UT WOS:000258538900042 ER PT J AU Ford, A Chey, W Talley, N Malhotra, A Spiegel, B Moayyedi, P AF Ford, Alexander Chey, William Talley, Nicholas Malhotra, Ashish Spiegel, Brennan Moayyedi, Paul TI Utility of diagnostic tests for Celiac disease in irritable bowel syndrome: Systematic review and meta-analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 73rd Annual Meeting of the American-College-of-Gastroenterology CY OCT 03-08, 2008 CL Orlando, FL SP Amer Coll Gastroenterol C1 McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON, Canada. Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA. Mayo Clin Florida, Dept Med, Jacksonville, FL USA. Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. Univ Calif Los Angeles, Sch Publ Hlth, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,VA Ctr Ou, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2008 VL 103 SU S MA 1185 BP S463 EP S463 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 347MH UT WOS:000259145201174 ER PT J AU Ford, A Talley, N Spiegel, B Foxx-Orenstein, A Schiller, L Quigley, E Moayyedi, P AF Ford, Alexander Talley, Nicholas Spiegel, Brennan Foxx-Orenstein, Amy Schiller, Lawrence Quigley, Eamonn Moayyedi, Paul TI Efficacy of antispasmodics and peppermint oil in irritable bowel syndrome: Systematic review and meta-analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 73rd Annual Meeting of the American-College-of-Gastroenterology CY OCT 03-08, 2008 CL Orlando, FL SP Amer Coll Gastroenterol C1 McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON, Canada. Mayo Clin Florida, Dept Med, Jacksonville, FL USA. Univ Calif Los Angeles, Sch Publ Hlth, David Geffen Sch Med, VA Greater Angeles Healthcare Syst,VA Ctr Outcome, Los Angeles, CA 90024 USA. Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. Cork Univ Hosp, Dept Med, Cork, Ireland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2008 VL 103 SU S MA 1177 BP S459 EP S459 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 347MH UT WOS:000259145201166 ER PT J AU Ford, A Talley, N Spiegel, B Foxx-Orenstein, A Schiller, L Quigley, E Moayyedi, P AF Ford, Alexander Talley, Nicholas Spiegel, Brennan Foxx-Orenstein, Amy Schiller, Lawrence Quigley, Eamonn Moayyedi, Paul TI Efficacy of fiber in irritable bowel syndrome: Systematic review and meta-analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 73rd Annual Meeting of the American-College-of-Gastroenterology CY OCT 03-08, 2008 CL Orlando, FL SP Amer Coll Gastroenterol C1 McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON, Canada. Mayo Clin, Dept Med, Jacksonville, FL 32224 USA. Univ Calif Los Angeles, Sch Publ Hlth, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,VA Ctr Out, Los Angeles, CA 90024 USA. Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. Cork Univ Hosp, Dept Med, Cork, Ireland. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2008 VL 103 SU S MA 1176 BP S459 EP S459 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 347MH UT WOS:000259145201165 ER PT J AU West, R Beeri, MS Schmeidler, J Hannigan, CM Angelo, G Grossman, HT Rosendorff, C Silverman, JM AF West, Rebecca Beeri, Michal Schnaider Schmeidler, James Hannigan, Christine M. Angelo, Gary Grossman, Hillel T. Rosendorff, Clive Silverman, Jeremy M. TI Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE dementia; cognitive performance; apolipoprotein E; cholesterol ID ALZHEIMER-DISEASE; OLDEST-OLD; DEMENTIA; RISK; DECLINE AB Objective: To examine the association of cholesterol with cognitive functioning in oldest old community dwelling individuals with and without the apolipoprotein e4 (APOE4) allele. Method: One hundred eighty-five nondemented, community dwelling individuals (>= 85) were assessed with a broad neuropsychological battery. Bloods were drawn to assess total, low-density lipoprotein (LDL), and high-density lipoprotein cholesterol, as well as for APOE genotyping. Results: In contrast to our expectations, high total cholesterol and high LDL cholesterol were associated with higher memory scores for noncarriers of the APOE4 allele. No significant associations between cognitive performance and lipid profile were found for carriers of the APOE4 allele. Conclusions: In oldest old nondemented noncarriers of the APOE4 allele, high cholesterol is associated with better memory function. Further examination of the role of APOE genotype on the association between cholesterol and cognitive performance, especially in the oldest old is warranted. C1 [West, Rebecca; Beeri, Michal Schnaider; Schmeidler, James; Hannigan, Christine M.; Angelo, Gary; Grossman, Hillel T.; Rosendorff, Clive; Silverman, Jeremy M.] Mt Sinai Sch Med, New York, NY USA. [Grossman, Hillel T.; Rosendorff, Clive; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP West, R (reprint author), 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM rebecca.west@mssm.edu FU National Institutes of Health [AG002219, AG023515]; United States Department of Veterans Affairs; Berkman Charitable Trust FX This work was supported by National Institutes of Health AG002219 ( to JMS), AG023515 ( to MSB), United States Department of Veterans Affairs, Berkman Charitable Trust. NR 18 TC 36 Z9 36 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SEP PY 2008 VL 16 IS 9 BP 781 EP 785 DI 10.1097/JGP.0b013e3181812790 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 343KL UT WOS:000258852200011 PM 18757771 ER PT J AU Rahman, M Baimbridge, C Davis, BR Barzilay, J Basile, JN Henriquez, MA Huml, A Kopyt, N Louis, GT Pressel, SL Rosendorff, C Sastrasinh, S Stanford, C AF Rahman, Mahboob Baimbridge, Charles Davis, Barry R. Barzilay, Joshua Basile, Jan N. Henriquez, Mario A. Huml, Anne Kopyt, Nelson Louis, Gail T. Pressel, Sara L. Rosendorff, Clive Sastrasinh, Sithiporn Stanford, Carol CA ALLHAT Collaborative Res Grp TI Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE hyperlipidemia; glomerular filtration rate; pravastatin ID RENAL-FUNCTION; SIMVASTATIN TREATMENT; NEPHROTIC SYNDROME; DIABETIC-NEPHROPATHY; ALBUMIN EXCRETION; CLINICAL-TRIAL; STATINS; PROTEINURIA; DYSLIPIDEMIA; METAANALYSIS AB Background: Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear. Study Design: Prospective randomized clinical trial, post hoc analyses. Setting & Participants: 10,060 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) stratified by baseline estimated glomerular filtration rate (eGFR): less than 60, 60 to 89, and 90 or greater mL/min/1.73 m(2). Mean follow-up was 4.8 years. Intervention: Randomized; pravastatin, 40 mg/d, or usual care. Outcomes & Measurements: Total, high-density lipoprotein, and low-density lipoprotein cholesterol; end-stage renal disease (ESRD), eGFR. Results: Through year 6, total cholesterol levels decreased in the pravastatin (-20.7%) and usual-care groups (-11.2%). No significant differences were seen between groups for rates of ESRD (1.36 v 1.45/100 patient-years; P = 0.9), composite end points of ESRD and 50% or 25% decrease in eGFR, or rate of change in eGFR. Findings were consistent across eGFR strata. In patients with eGFR of 90 mL/min/1.73 m(2) or greater, the pravastatin arm tended to have a higher eGFR. Limitations: Proteinuria data unavailable, post hoc analyses, unconfirmed validity of the Modification of Diet in Renal Disease Study equation in normal eGFR range, statin drop-in rate in usual-care group with small cholesterol differential between groups. Conclusions: In hypertensive patients with moderate dyslipidemia and decreased eGFR, pravastatin was not superior to usual care in preventing clinical renal outcomes. This was consistent across the strata of baseline eGFR. However, benefit from statin therapy may depend on the degree of the cholesterol level decrease achieved. C1 [Rahman, Mahboob; Huml, Anne] Case Western Reserve Univ, Univ Hosp Cleveland Case Med Ctr, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH 44106 USA. [Baimbridge, Charles; Davis, Barry R.; Pressel, Sara L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Barzilay, Joshua] Kaiser Permanente Georgia, Tucker, GA USA. [Basile, Jan N.] VAMC Charleston, Charleston, SC USA. [Henriquez, Mario A.] Bronx Nephrol Hypertens, Bronx, NY USA. [Kopyt, Nelson] Lehigh Valley Hosp, Allentown, PA USA. [Louis, Gail T.] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Rosendorff, Clive] Mt Sinai Sch Med, New York, NY USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. [Sastrasinh, Sithiporn] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Stanford, Carol] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. RP Pressel, SL (reprint author), 1200 Herman Pressler St,Ste E801, Houston, TX 77030 USA. EM sara.l.pressel@uth.tmc.edu FU NHLBI NIH HHS [N01 HC035130, N01-HC-35130, N01HC35130] NR 37 TC 47 Z9 53 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD SEP PY 2008 VL 52 IS 3 BP 412 EP 424 DI 10.1053/j.ajkd.2008.05.027 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 343ML UT WOS:000258857900008 PM 18676075 ER PT J AU Wu, SV Harikumar, KG Burgess, RJ Reeve, JR Miller, LJ AF Wu, S. Vincent Harikumar, Kaleeckal G. Burgess, Rebecca J. Reeve, Joseph R. Miller, Laurence J. TI Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE bioluminescence resonance energy transfer ID DIFFERENT CONFORMATIONS; FOOD-INTAKE; CCK-58; RATS; OLIGOMERIZATION; PEPTIDES; BLOOD; FORM; LOOP AB Cholecystokinin, like many peptide hormones, is present as multiple molecular forms. CCK-58 has been identified as the dominant form in the circulation, whereas most of the studies of CCK-receptor interactions have been performed with CCK-8. Despite both sharing the pharmacophoric region of CCK, representing its carboxy terminal heptapeptide amide, studies in vivo have demonstrated biological diversity of action of the two peptides, with CCK-58, but not CCK-8, stimulating pancreatic fluid secretion and lengthening the interval between meals. Here, we have directly studied the ability of these two CCK peptides to bind to the type 1 CCK receptor and to stimulate it to elicit an intracellular calcium response. The calcium response relative to receptor occupation was identical for CCK-58 and CCK-8, with the longer peptide binding with approximately fivefold lower affinity. We also examined the ability of the two peptides to elicit receptor internalization using morphological techniques and to disrupt the constitutive oligomerization of the CCK receptor using receptor bioluminescence resonance energy transfer. Here, both full agonist peptides had similar effects on these regulatory processes. These data suggest that both molecular forms of CCK act at the CCK1 receptor quite similarly and elicit similar regulatory processes for that receptor, suggesting that the differences in biological activity observed in vivo most likely reflect differences in the clearance and/or metabolism of these long and short forms of CCK peptides. C1 [Harikumar, Kaleeckal G.; Burgess, Rebecca J.; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA. [Wu, S. Vincent; Reeve, Joseph R.] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst &, Digest Dis Res Ctr,CURE, Los Angeles, CA USA. RP Miller, LJ (reprint author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA. EM miller@mayo.edu FU National Institutes of Health [DK- 32878, DK- 33850, DK-41301]; Peptidomic, Radioimmunoassay, and Proteomic Core of the CURE Digestive Diseases [P50-AA011999]; Research Center for Alcoholic Liver and Pancreatic Diseases; Veterans Affairs Research Administration at Veterans Affairs Greater Los Angeles Healthcare System; Fiterman Foundation; Mayo Clinic FX This work was supported by grants from the National Institutes of Health, DK-32878 (L. J. Miller), DK-33850 (J. R. Reeve), DK-41301 (Peptidomic, Radioimmunoassay, and Proteomic Core of the CURE Digestive Diseases Center, J. R. Reeve), and P50-AA011999 (a pilot study supported by the Research Center for Alcoholic Liver and Pancreatic Diseases, S. V. Wu), as well as by the Veterans Affairs Research Administration at Veterans Affairs Greater Los Angeles Healthcare System (J. R. Reeve), the Fiterman Foundation (L. J. Miller), and the Mayo Clinic (L. J. Miller). NR 28 TC 10 Z9 10 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP PY 2008 VL 295 IS 3 BP G641 EP G647 DI 10.1152/ajpgi.90390.2008 PG 7 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 345HD UT WOS:000258986100025 PM 18776046 ER PT J AU Seal, KH Maguen, S Bertenthal, D Gima, K Marmar, CR AF Seal, Karen H. Maguen, Shira Bertenthal, Daniel Gima, Kristian Marmar, Charles R. TI The case for postdeployment mental health screening was not made - Seal et al. respond SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID CARE C1 [Seal, Karen H.; Maguen, Shira; Bertenthal, Daniel; Gima, Kristian; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Seal, KH (reprint author), San Francisco VA Med Ctr, 1450 Clement St,Box 111A-1, San Francisco, CA 94121 USA. EM karen.seal@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2008 VL 98 IS 9 BP 1542 EP 1543 DI 10.2105/AJPH.2008.141333 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 338AF UT WOS:000258476400002 ER PT J AU Wise, SK Ahn, CN Lathers, DMR Mulligan, RM Schlosser, RJ AF Wise, Sarah K. Ahn, Chadwick N. Lathers, Deanne M. R. Mulligan, Ryan M. Schlosser, Rodney J. TI Antigen-specific IgE in sinus mucosa of allergic fungal rhinosinusitis patients SO AMERICAN JOURNAL OF RHINOLOGY LA English DT Article; Proceedings Paper CT Spring Meeting of the American-Rhinologic-Society CY MAY 01, 2008 CL Orlando, FL SP Amer Rhinol Soc DE Allergic fungal sinusitis; allergic rhinitis; allergy; chronic rhinosinusitis; immunoglobulin E; local production; nasal polyps; specific IgE ID STAPHYLOCOCCUS-AUREUS ENTEROTOXINS; NASAL POLYP TISSUE; IMMUNOGLOBULIN-E; SOCIOECONOMIC-FACTORS; LOCAL PRODUCTION; BONE EROSION; IMMUNOTHERAPY; INFLAMMATION; ANTIBODIES; DIAGNOSIS AB Background: Local tissue production of antigen-specific immunoglobulin E (IgE) has been shown in patients With allergic rhinitis and in patients with chronic rhinosinusitis (CRS) With nasal polyps. In allergic fungal rhinosinusitis (AFRS), specific IgE has been established in nasal lavage fluid and eosinophilic mucin. In this stud, local production of antigen-specific IgE within sinus mucosa of AFRS patients was evaluated. Methods: Sinus mucosa homogenates front 11 AFRS patients, 8 patients with CRS without nasal polyps (CRSsNP), and 9 nonrhinosinusitis control patients were assessed for IgE localization by immunohistochemistry. AFRS and control tissue homogenates were also evaluated for antigen-specific IgE to 14 common antigens by ImmunoCAP testing (Phadia AB, Portage, MI). Results: There was a significant increase in IgE staining in AFRS sinus epithelium and subepithelium compared with controls and with patients with CRSsNP (p <= 0.012 for all group differences). AFRS patients showed increased IgE staining in the subepithelium when compared with epithelium (p < 0.001). AFRS sinus tissue had significantly more IgE measured by ImmunoCAP when compared with control shuts tissue for 7 of 14 specific antigens (p < 0.05) and for total IgE (p = 0.004). Antigens with a significant difference on ImmunoCAP included Cladosporium, Aspergillus, Timothy grass, red maple, cockroach, ragweed, and cocklebur. Conclusion: AFRS patients showed significantly more IgE in sinus mucosa tissue specimens, with increased IgE in subepithelial sites when compared with epithelium. The increased expression of antigen-specific IgE is not limited to fungal antigens. These findings support the role of type I hypersensitivity and local manifestations of allergy in AFRS patients. C1 [Wise, Sarah K.; Ahn, Chadwick N.; Lathers, Deanne M. R.; Mulligan, Ryan M.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Wise, Sarah K.] Emory Univ, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA. [Lathers, Deanne M. R.] Res Serv, Ralph H Johnson VAMC, Charleston, SC USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Suite 1130,POB 250550, Charleston, SC 29425 USA. EM schlossr@musc.edu NR 27 TC 26 Z9 27 U1 0 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1050-6586 J9 AM J RHINOL JI Am. J. Rhinol. PD SEP-OCT PY 2008 VL 22 IS 5 BP 451 EP 456 DI 10.2500/ajr.2008.22.3227 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 364UQ UT WOS:000260361300001 PM 18954501 ER PT J AU Yang, M Barner, JC Lawson, KA Rascati, KL Wilson, JP Crismon, ML Worchel, J Mascarenas, CA AF Yang, Min Barner, Jamie C. Lawson, Kenneth A. Rascati, Karen L. Wilson, James P. Crismon, M. Lynn Worchel, Jason Mascarenas, Cynthia A. TI Antipsychotic medication utilization trends among Texas veterans: 1997-2002 SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE antipsychotic; medication utilization; trends ID ATYPICAL ANTIPSYCHOTICS; CHRONIC-SCHIZOPHRENIA; PSYCHIATRIC-PATIENTS; UNITED-STATES; RISPERIDONE; DISORDER; OLANZAPINE; CLOZAPINE; AGENTS; DRUGS AB BACKGROUND: An antipsychotic utilization pattern has evolved substantially over the past 20 years or so due to the introduction of the second-generation antipsychotics (SGAs) and the increasing understanding of their adverse effect profile. OBJECTIVE: To understand antipsychotic utilization trends (including monotherapy, antipsychotic switching, and combination therapy) and to investigate factors associated with antipsychotic index medication selection (SGAs vs first-generation antipsychotics [FGAs]) among Texas veterans. METHODS: Data were taken from the Veterans Administration North Texas Health Care System (VANTHCS) and South Texas Veterans Health Care System (STVHCS) from January 1996 to December 2003. Adults with continuous enrollment (1 y before and after the index date) who had newly initiated antipsychotic therapy were included. Prescriptions were followed for up to 12 months. Descriptive analyses examined utilization trends; logistic regression evaluated factors associated with antipsychotic index medication selection. RESULTS: A total of 8096 patients were included in the study (VANTHCS n = 4477; STVHCS n = 3619), with the majority being male (93.6%) and white (62.6%) and nearly half aged 55 years or older (44.1%). Between 1997 and 2002, antipsychotic prescriptions changed from primarily FGAs (1997: 71.7%; 1999: 25.2%; 2002: 5.7%) to SGAs. Over the 6-year time frame, risperidone (31.0%) and olanzapine (30.7%) were most commonly prescribed. The overall combination therapy slightly increased over time (4.3%), switching to another antipsychotic remained stable (14.2%), and antipsychotic monotherapy remained dominant (81.5%). Hispanic and black patients were less likely than white patients to be initiated on SGAs. Patients who were older, had hypertension, and were in STVHCS were less likely to start on SGAs. Patients with dyslipidemia, bipolar disorder, and treatment in recent years were more likely to start on SGAs. CONCLUSIONS: SGAs have replaced FGAs as first-line medications for patients with mental disorders. Race, age, physical comorbidities (ie, dyslipidemia, hyperlension), and treatment initiation year were important factors in index medication selection. C1 [Yang, Min] QualityMetr Hlth Outcomes Solut, Outcomes Insight Consulting, Lincoln, RI 02865 USA. [Barner, Jamie C.; Lawson, Kenneth A.; Rascati, Karen L.; Wilson, James P.; Crismon, M. Lynn] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Worchel, Jason] Cent Texas Vet Hlth Care Syst, US Dept Vet Affairs, Temple, TX USA. [Mascarenas, Cynthia A.] S Texas Vet Hlth Care Syst, US Dept Vet Affairs, San Antonio, TX USA. RP Yang, M (reprint author), QualityMetr Hlth Outcomes Solut, Outcomes Insight Consulting, 640 George Washington Hwy,Ste 201, Lincoln, RI 02865 USA. EM myang@QualityMetric.com NR 55 TC 19 Z9 19 U1 2 U2 4 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD SEP PY 2008 VL 42 IS 9 BP 1229 EP 1238 DI 10.1345/aph.1L155 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 346WE UT WOS:000259099500007 PM 18682544 ER PT J AU Kelz, RR Hosokawa, P Spitz, F Freeman, KM Moskowitz, M Henderson, W Itani, K AF Kelz, Rachel R. Hosokawa, Patrick Spitz, Francis Freeman, Kathryn M. Moskowitz, Miriam Henderson, William Itani, Kamal TI Time of day is associated with postoperative morbidity: An analysis of the National Surgical Quality Improvement Program data - Reply SO ANNALS OF SURGERY LA English DT Letter ID SURGERY C1 [Kelz, Rachel R.; Spitz, Francis; Moskowitz, Miriam] Philadelphia VA Med Ctr, Dept Surg, Philadelphia, PA 19104 USA. [Kelz, Rachel R.; Spitz, Francis; Freeman, Kathryn M.] Hosp Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Hosokawa, Patrick] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Aurora, CO USA. [Henderson, William] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Itani, Kamal] Boston Univ, Boston Med Ctr, Boston, MA 02215 USA. [Itani, Kamal] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. [Itani, Kamal] Boston VAHCS, Boston, MA USA. RP Kelz, RR (reprint author), Philadelphia VA Med Ctr, Dept Surg, Philadelphia, PA 19104 USA. EM Rachel.kelz@uphs.upenn.edu NR 5 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD SEP PY 2008 VL 248 IS 3 BP 501 EP 501 DI 10.1097/SLA.0b013e3181860b1f PG 1 WC Surgery SC Surgery GA 352DK UT WOS:000259475200040 ER PT J AU Gilbert, TW Gilbert, S Madden, M Reynolds, SD Badylak, SF AF Gilbert, Thomas W. Gilbert, Sebastien Madden, Matthew Reynolds, Susan D. Badylak, Stephen F. TI Morphologic assessment of extracellular matrix scaffolds for patch tracheoplasty in a canine model SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 28-30, 2008 CL Ft Lauderdale, FL SP Soc Thorac Surg ID TRACHEAL BIOARTIFICIAL ORGAN; INTESTINAL SUBMUCOSA; RABBIT MODEL; TISSUE; RECONSTRUCTION; CELLS; EPITHELIUM; DETERGENT; STENOSIS; STENTS AB Background. The optimal management of benign tracheal stricture remains surgical resection. Resection is not always an option because of the challenges posed by anastomotic tension and a tenuous blood supply. Regenerative medicine approaches, such as extracellular matrix (ECM) scaffold technology, may alleviate some of the limitations to tracheal replacement. ECM scaffolds facilitate site-specific tissue remodeling when used to reconstruct a variety of soft-tissue structures. Methods. A 1-cm wide x 2-cm-long defect was created in the ventral trachea of 15 dogs and repaired with one of three acellular biologic scaffolds: urinary bladder matrix (UBM), UBM crosslinked with carbodiimide (UBMC), and decellularized tracheal matrix (DTM). The grafts were evaluated periodically using bronchoscopy and by macroscopic and microscopic morphologic examination at either 2 months or 6 months. Results. The UBM, UBMC, and DTM groups showed no evidence of stenosis or tracheomalacia. The UBM, UBMC, and DTM groups all showed deposition of organized collagenous tissue at the site of scaffold placement and an intact epithelial layer. Scattered areas of mucociliary differentiation were present at the edges of the graft site. There was no evidence cartilage observed within the remodeled tissue at 6 months. Conclusions. ECM scaffolds promote healing of significantly sized tracheal defects without stricture and with some, but not all, of the necessary structures required for tracheal reconstruction, including complete coverage with ciliated epithelium and dense organized collagenous tissue. C1 [Badylak, Stephen F.] Univ Pittsburgh, McGowan Inst Regenerat Med, Dept Surg, Heart Lung & Esophageal Inst,Med Ctr, Pittsburgh, PA 15219 USA. Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA. RP Badylak, SF (reprint author), Univ Pittsburgh, McGowan Inst Regenerat Med, Dept Surg, Heart Lung & Esophageal Inst,Med Ctr, 100 Technol Dr,Ste 200, Pittsburgh, PA 15219 USA. EM badylaks@upmc.edu OI Gilbert, Sebastien/0000-0003-4357-9553; Badylak, Stephen/0000-0003-3555-0689 NR 25 TC 49 Z9 52 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2008 VL 86 IS 3 BP 967 EP 974 DI 10.1016/j.athoracsur.2008.04.071 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 340AT UT WOS:000258619100038 PM 18721593 ER PT J AU Holodniy, M Penzak, SR Straight, TM Davey, RT Lee, KK Goetz, MB Raisch, DW Cunningham, F Lin, ET Olivo, N Deyton, LR AF Holodniy, Mark Penzak, Scott R. Straight, Timothy M. Davey, Richard T. Lee, Kelvin K. Goetz, Matthew Bidwell Raisch, Dennis W. Cunningham, Francesca Lin, Emil T. Olivo, Noemi Deyton, Lawrence R. TI Pharmacokinetics and tolerability of oseltamivir combined with probenecid SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID INFLUENZA-A H5N1; NEURAMINIDASE; VIRUS; TRANSMISSION; INHIBITOR; ELIMINATION; VOLUNTEERS; PHOSPHATE; BINDING; H9N2 AB Oseltamivir is an inhibitor of influenza virus neuraminidase, which is approved for use for the treatment and prophylaxis of influenza A and B virus infections. In the event of an influenza pandemic, oseltamivir supplies may be limited; thus, alternative dosing strategies for oseltamivir prophylaxis should be explored. Healthy volunteers were randomized to a three-arm, open-label study and given 75 mg oral oseltamivir every 24 h (group 1), 75 mg oseltamivir every 48 h (q48h) combined with 500 mg probenecid four times a day (group 2), or 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3) for 15 days. Pharmacokinetic data, obtained by noncompartmental methods, and safety data are reported. Forty-eight subjects completed the pharmacokinetic analysis. The study drugs were generally well tolerated, except for one case of reversible grade 4 thrombocytopenia in a subject in group 2. The calculated 90% confidence intervals (CIs) for the geometric mean ratios between groups 2 and 3 and group 1 were outside the bioequivalence criteria boundary (0.80 to 1.25) at 0.63 to 0.89 for group 2 versus group 1 and 0.57 to 0.90 for group 3 versus group 1. The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance). The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012). Alternate-day dosing of oseltamivir plus dosing with probenecid four times daily achieved trough oseltamivir carboxylate concentrations adequate for neuraminidase inhibition in vitro, and this combination should be studied further. C1 [Holodniy, Mark] VA Palo Alto Hlth Care Syst, Publ Hlth Res Ctr, Palo Alto, CA 94304 USA. [Holodniy, Mark; Deyton, Lawrence R.] US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC USA. [Holodniy, Mark] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. [Penzak, Scott R.] NIH, Clin Pharmacokinet Res Lab, Bethesda, MD 20892 USA. [Straight, Timothy M.] Brooke Army Med Ctr, Dept Clin Invest, Ft Sam Houston, TX 78234 USA. [Davey, Richard T.] CRS LIR NIAID, NIH, Bethesda, MD USA. [Lee, Kelvin K.] VA Cooperat Studies Program, Palo Alto, CA USA. [Goetz, Matthew Bidwell] Greater Angeles Hlth Care Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Infect Dis Sect, Los Angeles, CA 90095 USA. [Raisch, Dennis W.] Clin Res Pharm Coordinating Ctr, VA Cooperat Studies Program, Albuquerque, NM USA. [Cunningham, Francesca] US Dept Vet Affairs, Pharm Benefits Management Grp, Hines, IL USA. [Lin, Emil T.] UCSF, Dept Biopharmaceut Sci, San Francisco, CA USA. [Deyton, Lawrence R.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. RP Holodniy, M (reprint author), VA Palo Alto Hlth Care Syst, Publ Hlth Res Ctr, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA. EM Holodniy@stanford.edu OI Goetz, Matthew/0000-0003-4542-992X FU U.S. Department of Veterans Affairs Merit; U.S. Departments of Defense; Health and Human Services FX This work was supported by a U.S. Department of Veterans Affairs Merit review grant to Mark Holodniy and additional financial support from the U.S. Departments of Defense (T. M. Straight) and Health and Human Services (R. T. Davey and S. R. Penzak).; None of the authors have any significant conflict of interest related to this study.; We thank the study participants, Cooperative Studies Program staff (Nigel Gladhart, Lauren Uyeda, Sachiko Kutsuna) for data management, and the data safety monitoring committee members (Thomas C. Merigan, Rex Jamison, and Larry Mole). NR 37 TC 33 Z9 35 U1 2 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2008 VL 52 IS 9 BP 3013 EP 3021 DI 10.1128/AAC.00047-08 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 340TG UT WOS:000258667300003 PM 18559644 ER PT J AU Clark, FL Sahay, A Bertenthal, D Maddock, L Lindquist, K Grekin, R Chren, MM AF Clark, F. Landon Sahay, Anju Bertenthal, Daniel Maddock, Leah Lindquist, Karla Grekin, Roy Chren, Mary-Margaret TI Variation in care for recurrent nonmelanoma skin cancer in a university-based practice and a veterans affairs clinic SO ARCHIVES OF DERMATOLOGY LA English DT Article ID BASAL-CELL CARCINOMA; MOHS MICROGRAPHIC SURGERY; FACE AB Objective: To learn if treatment of recurrent nonmelanoma skin cancer (NMSC) varied in different practice settings. Design: Prospective cohort study of consecutive patients with recurrent NMSC. Setting: A university-based dermatology practice and the dermatology clinic at the affiliated Veterans Affairs Medical Center (VAMC). Conventional therapies for NMSC were available at both sites. Patients: All 191 patients diagnosed as having recurrent NMSC in 1999 and 2000 were included in the study. Data were collected from medical record review and surveys mailed to patients. Main Outcome Measure: Performance of Mohs micrographic surgery (Mohs). Results: Patients at the VAMC were older, less educated, poorer, and had more comorbid illnesses, but their tumors were similar to those of patients at the university-based practice. Treatment choices differed at the 2 sites: the proportions of tumors treated in the VAMC and university sites were 60% and 14%, respectively, for excisional surgery; and 24% and 61%, respectively, for Mohs(P<.001). In multivariate analyses adjusting for patient, tumor, and physician features that may have affected treatment choice, tumors treated at the university-based site remained significantly more likely to be treated with Mohs (odds ratio, 8.68 [95% confidence interval, 3.66-20.55]; P<.001). Conclusions: Substantial variation existed in the treatment of recurrent NMSC in different practice settings. This variation was not explained by measured clinical characteristics of the patients or the tumors. C1 [Bertenthal, Daniel; Maddock, Leah; Lindquist, Karla; Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA. [Clark, F. Landon] Stanford Univ, Med Ctr, Dept Dermatol, Stanford, CA 94305 USA. [Sahay, Anju] Palo Alto Vet Affairs Hlth Care Syst, Res Serv, Palo Alto, CA USA. [Bertenthal, Daniel; Maddock, Leah; Lindquist, Karla; Chren, Mary-Margaret] Hlth Serv Res & Dev Ser, Res Enhancement Award Program, Dept Vet Affairs, San Francisco, CA USA. [Grekin, Roy; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. RP Chren, MM (reprint author), San Francisco VA Med Ctr, 151R,4150 Clement St, San Francisco, CA USA. EM chrenm@derm.ucsf.edu FU Health Services Research and Development Service of the Department of Veterans Affairs [97010-2, 04-043-3]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K02 AR 02203, K24-AR052667]; National Institutes of Health FX This work was supported by Investigator-Initiated Research (IIR) grants 97010-2 and 04-043-3 from the Health Services Research and Development Service of the Department of Veterans Affairs, and by an Independent Scientist Award (K02 AR 02203) and Midcareer Investigator Award (K24-AR052667) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health. NR 11 TC 4 Z9 4 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD SEP PY 2008 VL 144 IS 9 BP 1148 EP 1152 DI 10.1001/archderm.144.9.1148 PG 5 WC Dermatology SC Dermatology GA 348RQ UT WOS:000259228000006 PM 18794460 ER PT J AU Haroutunian, V Schnaider-Beeri, M Schmeidler, J Wysocki, M Purohit, DP Perl, DP Libow, LS Lesser, GT Maroukian, M Grossman, HT AF Haroutunian, Vahram Schnaider-Beeri, Michal Schmeidler, James Wysocki, Michael Purohit, Dushyant P. Perl, Daniel P. Libow, Leslie S. Lesser, Gerson T. Maroukian, Maria Grossman, Hillel T. TI Role of the neuropathology of Alzheimer disease in dementia in the oldest-old SO ARCHIVES OF NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLES; REGIONAL-DISTRIBUTION; STEREOLOGIC ANALYSIS; NEURITIC PLAQUES; ELDERLY SUBJECTS; CEREBRAL-CORTEX; RATING-SCALE; NONAGENARIANS; CENTENARIANS AB Background: Neuritic plaques (NPs) and neurofibrillary tangles (NFTs) in the brain, especially in the hippocampus, entorhinal cortex, and isocortex, are hallmark lesions of Alzheimer disease and dementia in the elderly. However, this association has not been extensively studied in the rapidly growing population of the very old. Objective: To assess the relationship between estimates of cognitive function and NP and NFT pathologic conditions in 317 autopsied persons aged 60 to 107 years. Design: We studied the relationship between severity of dementia and the density of these characteristic lesions of Alzheimer disease in young-old, middle-old, and oldest-old persons. The relationship of the severity of dementia as measured by the Clinical Dementia Rating scale to the density of NPs and NFTs was then assessed in each age group. Participants: Three hundred seventeen brains of persons aged 60 years and older were selected to have either no remarkable neuropathological lesions or only NP and NFT lesions. Brains with any other neuropathological conditions, either alone or in addition to Alzheimer disease findings, were excluded. The study cohort was then stratified into the youngest quartile (aged 60-80 years), middle 2 quartiles (aged 81-89 years), and oldest quartile (aged 90-107 years). Results: While the density of NPs and NFTs rose significantly by more than 10-fold as a function of the severity of dementia in the youngest-old group, significant increases in the densities of NPs and NFTs were absent in the brains of the oldest-old. This lack of difference in the densities of NPs and NFTs was due to reduced lesion densities in the brains of oldest-old persons with dementia rather than to increased density of these lesions in the brains of nondemented oldest-old persons. Conclusions: These findings suggest that the neuropathological features of dementia in the oldest-old are not the same as those of cognitively impaired younger-old persons and compel a vigorous search for neuropathological indices of dementia in this most rapidly growing segment of the elderly population. C1 [Haroutunian, Vahram; Schnaider-Beeri, Michal; Schmeidler, James; Wysocki, Michael; Maroukian, Maria; Grossman, Hillel T.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Purohit, Dushyant P.; Perl, Daniel P.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. [Libow, Leslie S.; Lesser, Gerson T.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Haroutunian, Vahram; Grossman, Hillel T.] Bronx VA Med Ctr, Dept Psychiat, Bronx, NY USA. [Haroutunian, Vahram; Libow, Leslie S.] Jewish Home & Hosp, New York, NY USA. RP Haroutunian, V (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu FU NCRR NIH HHS [M01 RR000071, M01RR00071, M01 RR000071-36]; NIA NIH HHS [P01 AG002219, P01 AG002219-23, AG02219] NR 44 TC 84 Z9 87 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD SEP PY 2008 VL 65 IS 9 BP 1211 EP 1217 DI 10.1001/archneur.65.9.1211 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 345XJ UT WOS:000259030700011 PM 18779425 ER PT J AU Walsh, NE Brooks, P Hazes, JM Walsh, RM Dreinhoefer, K Woolf, AA Akesson, K Lidgren, L AF Walsh, Nicolas E. Brooks, Peter Hazes, J. Mieke Walsh, Rorey M. Dreinhoefer, Karsten Woolf, Anthony A. Akesson, Kristina Lidgren, Lars CA Bone TI Standards of care for acute and chronic musculoskeletal pain: The bone and joint decade (2000-2010) SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE musculoskeletal system; pain; rehabilitation; treatment outcome ID POPULATION; MANAGEMENT; SIGNS AB Musculoskeletal conditions often manifest with the onset of pain and the resulting physical limitations. Musculoskeletal pain is almost inevitable in in individual's lifetime. It is one of the most common reasons for self-medication and entry into the health care system. Musculoskeletal pain affects in 4 adults and is the Most commons Source of serious long-term pain and physical disability. The Monumental impact Of musculoskeletal conditions is now recognized by the United Nations, the World Health Organization, World Bank, and numerous governments throughout the World through Support of the Bone and Joint Decade 2000 to 2010 initiative. Individuals With musculoskeletal pain concerns are regularly ignored. their complaints often Misunderstood by health care providers, and accordingly they do not receive timely or effective treatment. The standards of care in this document are designed to provide generic guidelines for appropriate care of people with acute or chronic musculoskeletal pain, This document was developed over a 4-year period using Multiple international meetings and a Task Force of the Bone and Joint Decade for developing international standards for the care of acute and chronic musculoskeletal pain. The final document is a product of the World Health Organization Collaborating Centre for Evidence-Based Health Care ill Musculoskeletal Disorders. C1 [Walsh, Nicolas E.; Walsh, Rorey M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA. [Walsh, Nicolas E.] S Texas Vet Adm Hlth Care Syst, Pain Med Serv, San Antonio, TX USA. [Brooks, Peter] Univ Queensland, Brisbane, Qld, Australia. [Hazes, J. Mieke] Erasmus Med Coll, Dept Rheumatol, Rotterdam, Netherlands. [Dreinhoefer, Karsten] Univ Ulm, Dept Orthoped, Ulm, Germany. [Woolf, Anthony A.] Royal Cornwall Hosp, Duke Cornwall Rheumatol Unit, Truro, England. [Akesson, Kristina] Malmo Univ Hosp, Dept Orthopaed Surg, Malmo, Sweden. [Lidgren, Lars] Univ Lund Hosp, Dept Orthoped, World Hlth Org Collaborat Ctr Evidenced Based Hea, Lund, Sweden. RP Walsh, NE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walshn@uthscsa.edu OI Dreinhoefer, Karsten/0000-0001-6021-2804 NR 36 TC 24 Z9 26 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2008 VL 89 IS 9 BP 1830 EP 1845 DI 10.1016/j.apmr.2008.04.009 PG 16 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 346GR UT WOS:000259057300029 PM 18760171 ER PT J AU Bilimoria, KY Bentrem, D Nelson, H Stryker, S Stewart, AK Soper, NJ Russell, TR Ko, CY AF Bilimoria, Karl Y. Bentrem, Davidj. Nelson, Heidi Stryker, Steven J. Stewart, Andrew K. Soper, Nathaniel J. Russell, Thomas R. Ko, Clifford Y. TI Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States SO ARCHIVES OF SURGERY LA English DT Article; Proceedings Paper CT 79th Annual Meeting of the Pacific-Coast-Surgical-Association CY FEB 16-17, 2008 CL San Diego, CA SP Pacific Coast Surg Assoc ID MRC CLASICC TRIAL; COST STUDY-GROUP; COLON-CANCER; COLORECTAL-CANCER; RANDOMIZED-TRIAL; PROCEDURE VOLUME; HOSPITAL VOLUME; RESECTION; SURGERY; IMPACT AB Background: Laparoscopic-assisted colectomy (LAC) has gained acceptance for the treatment of colon cancer. However, long-term outcomes of LAC have not been examined at the national level outside of experienced centers. Objective: To compare use and outcomes of LAC and open colectomy (OC). Design: Retrospective cohort study. Setting: National Cancer Data Base. Patients: Patients who underwent LAC (n = 11038) and OC (n = 23138 1) for nonmetastatic colon cancer (19982002). Main Outcome Measures: Regression methods were used to assess use and outcomes of LAC compared with OC. Results: Laparoscopic-assisted colectomy use increased from 3.8% in 1998 to 5.2% in 2002 (P < .001). Patients were significantly more likely to undergo LAC if they were younger than 75 years, had private insurance, lived in higher-income areas, had stage I cancer, had descending and/or sigmoid cancers, or were treated at National Cancer Institute-designated hospitals. Compared with those undergoing OC, patents undergoing LAC had 12 or more nodes examined less frequently (P < .001), similar perioperative mortality and recurrence rates, and higher 5-year survival rates (64.1% vs 58.5%, P < .001). After adjusting for patient, tumor, treatment, and hospital factors, 5-year survival was significantly better after LAC compared with OC for stage I and 11 but not for stage III cancer. Highest-volume centers had comparable short- and long-term LAC outcomes compared with lowest-volume hospitals, except highest-volume centers had significantly higher lymph node counts (median, 12 vs 8 nodes; P < .001). Conclusions: Laparoscopic-assisted colectomy and OC outcomes are generally comparable in the population. However, survival was better after an LAC than after an OC in select patients. C1 [Bilimoria, Karl Y.; Stewart, Andrew K.; Russell, Thomas R.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, Davidj.; Stryker, Steven J.; Soper, Nathaniel J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL USA. [Nelson, Heidi] Mayo Clin, Dept Surg, Rochester, MN USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. EM kbilimoria@facs.org NR 35 TC 65 Z9 70 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD SEP PY 2008 VL 143 IS 9 BP 832 EP 839 DI 10.1001/archsurg.143.9.832 PG 8 WC Surgery SC Surgery GA 346SJ UT WOS:000259089200002 PM 18794419 ER PT J AU Bartels, CM Bell, CL Shinki, K Bridges, AJ AF Bartels, Christie M. Bell, Carolyn L. Shinki, Kazuhiko Bridges, Alan J. TI Declines in rheumatoid arthritis and rheumatoid vasculitis among US veterans SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Bartels, Christie M.; Bell, Carolyn L.; Shinki, Kazuhiko] Univ Wisconsin, Madison, WI USA. [Bridges, Alan J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S MA 790 BP S460 EP S460 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244201053 ER PT J AU Jeffries, M Hamadeh, F Aberle, T Glenn, S Kamen, DL Kelly, JA Reichlin, M Harley, JB Sawalha, AH AF Jeffries, Matlock Hamadeh, Fahed Aberle, Teresa Glenn, Stuart Kamen, Diane L. Kelly, Jennifer A. Reichlin, Morris Harley, John B. Sawalha, Amr H. TI Hemolytic anemia in a multi-ethnic cohort of lupus patients: A clinical and serological perspective SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Jeffries, Matlock; Reichlin, Morris] Univ Oklahoma, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Hamadeh, Fahed] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Kamen, Diane L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Harley, John B.; Sawalha, Amr H.] Univ Oklahoma, US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S337 EP S337 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200481 ER PT J AU Luk, AJ Moore, EE Levin, GP Zhou, XH Choi, HK Kestenbamn, BR AF Luk, Andrew J. Moore, Elya E. Levin, Gregory P. Zhou, Xiao-Hua Choi, Hyon K. Kestenbamn, Bryan R. TI Allopurinol treatment and mortality in hyperuricemic veterans SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Luk, Andrew J.; Zhou, Xiao-Hua] VA Puget Sound, Seattle, WA USA. [Moore, Elya E.; Levin, Gregory P.; Kestenbamn, Bryan R.] Univ Washington, Seattle, WA 98195 USA. [Choi, Hyon K.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S179 EP S179 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200051 ER PT J AU Mikuls, TR Michaud, KD Thiele, GM O'Dell, JR Cannella, AC Reimold, AM Hooker, RS Caplan, L Johnson, DS Richards, JS Kerr, GS Cannon, GW AF Mikuls, Ted R. Michaud, Kaleb D. Thiele, Geoffrey M. O'Dell, James R. Cannella, Amy C. Reimold, Andreas M. Hooker, Roderick S. Caplan, Liron Johnson, Dannette S. Richards, John S. Kerr, Gail S. Cannon, Grant W. TI Autoantibody status in USveterans with rheumatoid arthritis (RA): Implications of discordance between anti-CCP antibody and rheumatoid factor SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Mikuls, Ted R.; Michaud, Kaleb D.; Thiele, Geoffrey M.; O'Dell, James R.; Cannella, Amy C.] Omaha VAMC, Omaha, NE USA. [Reimold, Andreas M.; Hooker, Roderick S.] Dallas VAMC, Dallas, TX USA. [Caplan, Liron] Denver VAMC, Aurora, CO USA. [Johnson, Dannette S.] Jackson VAMC, Jackson, MS USA. [Richards, John S.; Kerr, Gail S.] Washington DC VAMC, Washington, DC USA. [Cannon, Grant W.] Salt Lake City VAMC, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S763 EP S763 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244202108 ER PT J AU Mikuls, TR Michaud, KD Thiele, GM O'Dell, JR Cannella, AC Reimold, AM Hooker, RS Caplan, L Johnson, DS Cannon, GW Kerr, GS Richards, JS AF Mikuls, Ted R. Michaud, Kaleb D. Thiele, Geoffirey M. O'Dell, James R. Cannella, Amy C. Reimold, Andreas M. Hooker, Roderick S. Caplan, Liron Johnson, Dannette S. Cannon, Grant W. Kerr, Gail S. Richards, John S. TI The association of cigarette smoking with disease expression in US veterans with rheumatoid arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Mikuls, Ted R.; Michaud, Kaleb D.; Thiele, Geoffirey M.; O'Dell, James R.; Cannella, Amy C.] Omaha VAMC, Omaha, NE USA. [Reimold, Andreas M.; Hooker, Roderick S.] Dallas VAMC, Dallas, TX USA. [Caplan, Liron] Denver VAMC, Denver, CO USA. [Johnson, Dannette S.] Jackson VAMC, Jackson, MS USA. [Cannon, Grant W.] Salt Lake City VAMC, Salt Lake City, UT USA. [Kerr, Gail S.; Richards, John S.] Washington DC VAMC, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S273 EP S274 PG 2 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200312 ER PT J AU Moghadam-Kia, S Chilek, K Gaines, E Costner, M Rose, M Okawa, J Werth, VP AF Moghadam-Kia, Siamak Chilek, Katherine Gaines, Elizabeth Costner, Melissa Rose, Mathew Okawa, Joyce Werth, Victoria P. TI Skin manifestations of lupus erythematosus: A cohort of 119 prospectively enrolled patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Moghadam-Kia, Siamak; Chilek, Katherine; Gaines, Elizabeth; Rose, Mathew; Okawa, Joyce] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Costner, Melissa] Univ Texas SW, Dallas, TX USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S810 EP S810 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244202236 ER PT J AU Niewold, TB Kelly, JA Kariuki, SN Thomas, K Walker, D Merrill, JT Alarcon-Riquelme, ME James, JA Vyse, TJ Kimberly, RP Edberg, JC Gaffney, PM Moser, KL Crow, MK Harley, JB AF Niewold, T. B. Kelly, J. A. Kariuki, S. N. Thomas, K. Walker, D. Merrill, J. T. Alarcon-Riquelme, M. E. James, J. A. Vyse, T. J. Kimberly, R. P. Edberg, J. C. Gaffney, P. M. Moser, K. L. Crow, M. K. Harley, J. B. TI Association of IRF5 with systemic lupus erythematosus is driven by particular patient subgroups defined by autoantibodies and serum interferon SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Niewold, T. B.; Kariuki, S. N.] Univ Chicago, Chicago, IL 60637 USA. [Merrill, J. T.; James, J. A.; Harley, J. B.] Univ Oklahoma, Oklahoma Med Res Fdn, Dept Med, Oklahoma City, OK USA. [Alarcon-Riquelme, M. E.] Uppsala Univ, Uppsala, Sweden. [Alarcon-Riquelme, M. E.] Oklahoma Med Res Fdn, Uppsala, Sweden. [Vyse, T. J.] Univ London Imperial Coll Sci Technol & Med, London, England. [Kimberly, R. P.; Edberg, J. C.] Univ Alabama, Birmingham, AL USA. [Crow, M. K.] Hosp Special Surg, Mary Kirkland Ctr Lupus Res, New York, NY 10021 USA. [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RI Vyse, Tim/G-3887-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S341 EP S341 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200491 ER PT J AU Ogdie, AR Schumacher, HR Chen, L Dai, L Frank, P AF Ogdie, Alexis R. Schumacher, H. Ralph Chen, Lan Dai, L. Frank, Pessler TI Histopathologic features of synovial biopsies in arthritis associated with hepatitis C virus infection SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ogdie, Alexis R.; Chen, Lan] Univ Penn, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schumacher, H. Ralph] Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510275, Guangdong, Peoples R China. [Frank, Pessler] Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S700 EP S700 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244201688 ER PT J AU Pan, YJ Fei, YP Sawalha, AH AF Pan, Yujun Fei, Yiping Sawalha, Anir H. TI CD40L overexpression in human T cells results in autologous B cell activation and plasma cell differentiation in vitro in the absence of antigen presentation SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Fei, Yiping] Univ Oklahoma, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Sawalha, Anir H.] Univ Oklahoma, Oklahoma Med Res Fdn, US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Pan, Yujun] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S845 EP S845 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244202335 ER PT J AU Petri, M Naqibuddin, M Wallace, DJ Weisman, MH Holliday, SL Sampedro, MM Carson, KA Padilla, P Brey, RL AF Petri, Michelle Naqibuddin, Mohammad Wallace, Daniel J. Weisman, Michael H. Holliday, Stephen L. Sampedro, Margaret M. Carson, Kathryn A. Padilla, Patricia Brey, Robin L. TI Cognitive function over time in SLE: The brain CONECTIONS inception cohort SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Petri, Michelle; Naqibuddin, Mohammad; Sampedro, Margaret M.; Carson, Kathryn A.] Johns Hopkins Univ, Baltimore, MD USA. [Weisman, Michael H.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA. [Holliday, Stephen L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Padilla, Patricia; Brey, Robin L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S635 EP S636 PG 2 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244201510 ER PT J AU Sawalha, AH Jeftries, M Webb, R Lu, Q Gorelik, G Ray, D Osban, J Knowlton, N Johnson, K Richardson, B AF Sawalha, Amr H. Jeftries, Matlock Webb, Ryan Lu, Qianjin Gorelik, Gabriela Ray, Donna Osban, Jeanette Knowlton, Nicholas Johnson, Kent Richardson, Bruce TI Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation sensitive genes similar to lupus patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sawalha, Amr H.] Univ Oklahoma, Oklahoma Med Res Fdn, US Dept Vet Affairs, Oklahoma City, OK USA. [Lu, Qianjin] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China. [Richardson, Bruce] Univ Michigan, US Dept Vet Affairs, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S318 EP S318 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200426 ER PT J AU Sawalha, AH Webb, R Han, S Kelly, JA Kaufman, KM Kimberl, RP Alarcon-Riquelme, ME James, JA Vyse, TJ Gilkeson, GS Choi, CB Scofield, RH Bae, SC Nath, SK Harley, JB AF Sawalha, Amr H. Webb, Ryan Han, Shizhon Kelly, Jennifer A. Kaufman, Kenneth M. Kimberl, Robert P. Alarcon-Riquelme, Marta E. James, Judith A. Vyse, Timothy J. Gilkeson, Gary S. Choi, Chan-Burn Scofield, R. Hal Bae, Sang-Cheol Nath, Swapan K. Harley, John B. TI Genetic association of the X-chromosome gene MECP2 with systemic lupus erythematosus SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sawalha, Amr H.; Scofield, R. Hal; Harley, John B.] Univ Oklahoma, US Dept Vet Affairs, Med Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK USA. [Kimberl, Robert P.] Univ Alabama, Birmingham, AL USA. [Alarcon-Riquelme, Marta E.] Uppsala Univ, Uppsala, Sweden. [Vyse, Timothy J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England. [Gilkeson, Gary S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Choi, Chan-Burn; Bae, Sang-Cheol] Hanyang Univ, Seoul 133791, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD SEP PY 2008 VL 58 IS 9 SU S BP S219 EP S219 PG 1 WC Rheumatology SC Rheumatology GA 348XU UT WOS:000259244200163 ER PT J AU Mao, CG Obeid, LM AF Mao, Cungui Obeid, Lina M. TI Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS LA English DT Review DE apoptosis; bioactive lipid; cell adhesion; differentiation; growth arrest; proliferation ID HUMAN ACID CERAMIDASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; NORMAL HUMAN KERATINOCYTES; STRESS-INDUCED APOPTOSIS; LOW-DENSITY-LIPOPROTEIN; RENAL MESANGIAL CELLS; FULL-LENGTH CDNA; NEUTRAL CERAMIDASE; FARBER-DISEASE AB Ceramidases catalyze hydrolysis of ceramides to generate sphingosine (SPH). which is phosphorylated to form sphingosine-1-phosphate (S1P). Ceramide, SPH, and S1P are bioactive lipids that mediate cell proliferation. differentiation, apoptosis, adhesion, and migration. Presently, 5 human ceramidases encoded by 5 distinct genes have been cloned: acid ceramidase (AC), neutral ceramidase (NC) alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 (ACER2), and alkaline ceramidase 3 (ACER3). Each human ceramidase has a mouse counterpart. AC, NC, and ACERI-3 have maximal activities in acidic, neutral, and alkaline environments, respectively. ACERI-3 have similar protein sequences but 110 homology to AC and NC. AC and NC also have distinct protein sequences. The human AC (hAC was implicated in Farber disease, and hAC may be important for cell Survival. The mouse AC (mAC) is needed for early embryo Survival. NC is protective against inflammatory cytokines, and the mouse NC(mNC) is required for the catabolism of ceramides in the digestive tract. ACER 1 is critical in mediating cell differentiation by controlling the generation of SPH and S1P and that ACER2's role in cell proliferation and survival depends on its expression or the cell type in which it is found. Here, we discuss the role of each ceramidase in regulating cellular responses mediated by ceramides, SPH. and S1P. Published by Elsevier B.V C1 [Mao, Cungui; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Mao, Cungui; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA. RP Mao, CG (reprint author), Med Univ S Carolina, Dept Med, Room 646,STB,114 Doughty St, Charleston, SC 29425 USA. EM maoc@musc.edu; obeidi@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIH [R01 CA104834 (CM)]; VA merit award (LMO) FX Studies oil the role of the acid and alkaline ceramidases in our laboratories are supported by the NIH grant R01 CA104834 (CM) and a VA merit award (LMO). NR 140 TC 150 Z9 157 U1 1 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-1981 J9 BBA-MOL CELL BIOL L JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids PD SEP PY 2008 VL 1781 IS 9 BP 424 EP 434 DI 10.1016/j.bbalip.2008.06.002 PG 11 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 355MC UT WOS:000259712000002 PM 18619555 ER PT J AU Uriel, S Huang, JJ Moya, ML Francis, ME Wang, R Chang, SY Cheng, MH Brey, EM AF Uriel, Shiri Huang, Jung-Ju Moya, Monica L. Francis, Megan E. Wang, Rui Chang, Shu-ying Cheng, Ming-Huei Brey, Eric M. TI The role of adipose protein derived hydrogels in adipogenesis SO BIOMATERIALS LA English DT Article DE preadipocytes; extracellular matrix; basement membrane; adipogenesis; angiogenesis; differentiation ID FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; TISSUE FORMATION; STEM-CELLS; IN-VIVO; LAMININ; DIFFERENTIATION; ANGIOGENESIS; LOCALIZATION AB Biomaterials that induce adipogenesis may ultimately serve as alternatives to traditional tissue reconstruction and regeneration techniques. In addition, these materials can provide environments for studying factors that regulate adipogenesis. The present study investigates the potential of adipose-derived matrices to induce adipogenesis in vitro and in vivo. Solutions containing basement membrane proteins and growth factors were extracted from subcutaneous adipose tissue. These extracts could be induced to form gels by either incubating the solutions at 37 degrees C or adjusting the pH to 4.0. The adipose extracts Promoted rapid preadipocyte aggregation and formation of lipid-loaded colonies in vitro. Differentiation on adipose-derived gels was greater than tissue culture dishes and the tumor-derived product Matrigel (TM) (p < 0.05). Significant adipose formation was observed when adipose-derived gels were implanted around a rat epigastric pedicle bundle. Adipose levels in these gels were significantly greater than Matrigel (TM) (p < 0.05). The duration of adipose formation depended on the mechanism for gelling the solutions, with acid gelled matrices having greater adipose levels at 6 weeks than temperature gelled matrices. These adipose-derived hydrogels promote rapid adipogenesis in vitro and in vivo. They may lead to new materials for adipose tissue engineering, and provide an environment for studying cell-matrix interactions in adipogenesis. Published by Elsevier Ltd. C1 [Cheng, Ming-Huei] Chang Gung Univ, Chang Gung Med Coll, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg,Div Reconstruct Mic, Tao Yuan 333, Kweishan, Taiwan. [Uriel, Shiri; Moya, Monica L.; Francis, Megan E.; Wang, Rui; Brey, Eric M.] IIT, Dept Biomed Engn, Pritzker Inst Biomed Sci & Engn, Chicago, IL 60616 USA. [Francis, Megan E.; Brey, Eric M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Res, Hines, IL 60141 USA. RP Cheng, MH (reprint author), Chang Gung Univ, Chang Gung Med Coll, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg,Div Reconstruct Mic, 5 Fu Hsing St, Tao Yuan 333, Kweishan, Taiwan. EM minghueicheng@gmail.com NR 36 TC 45 Z9 45 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 J9 BIOMATERIALS JI Biomaterials PD SEP PY 2008 VL 29 IS 27 BP 3712 EP 3719 DI 10.1016/j.biomaterials.2008.05.028 PG 8 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 337MD UT WOS:000258439300011 PM 18571717 ER PT J AU Altshuler, L Bookheimer, S Townsend, J Proenza, MA Sabb, F Mintz, J Cohen, MS AF Altshuler, Lori Bookheimer, Susan Townsend, Jennifer Proenza, Manuel A. Sabb, Fred Mintz, Jim Cohen, Mark S. TI Regional brain changes in bipolar I depression: a functional magnetic resonance imaging study SO BIPOLAR DISORDERS LA English DT Article DE amygdala; bipolar depression; bipolar disorder; functional magnetic resonance imaging; orbitofrontal cortex ID POSITRON-EMISSION-TOMOGRAPHY; ORBITAL PREFRONTAL CORTEX; SPATIAL WORKING-MEMORY; CEREBRAL-BLOOD-FLOW; GLUCOSE-METABOLISM; HUMAN AMYGDALA; FACIAL EXPRESSIONS; SYMPTOMATIC STATUS; INTERFERENCE TASK; MAJOR DEPRESSION AB Objective: To investigate neural activity in prefrontal cortex and amygdala during bipolar depression. Methods: Eleven bipolar I depressed and 17 normal subjects underwent functional magnetic resonance imaging (fMRI) while performing a task known to activate prefrontal cortex and amygdala. Whole brain activation patterns were determined using statistical parametric mapping (SPM) when subjects matched faces displaying neutral or negative affect (match condition) or matched a geometric form (control condition). Contrasts for each group for the match versus control conditions were used in a second-level random effects analysis. Results: Random effects between-group analysis revealed significant attenuation in right and left orbitofrontal cortex (BA47) and right dorsolateral prefrontal cortex (DLPFC) (BA9) in bipolar depressed subjects. Additionally, random effects analysis showed a significantly increased activation in left lateral orbitofrontal cortex (BA10) in the bipolar depressed versus control subjects. Within-group contrasts demonstrated significant amygdala activation in the controls and no significant amygdala activation in the bipolar depressed subjects. The amygdala between-group difference, however, was not significant. Conclusions: Bipolar depression is associated with attenuated bilateral orbitofrontal (BA47) activation, attenuated right DLPFC (BA9) activation and heightened left orbitofrontal (BA10) activation. BA47 attenuation has also been reported in mania and may thus represent a trait feature of the disorder. Increased left prefrontal (BA10) activation may be a state marker to bipolar depression. Our findings suggest dissociation between mood-dependent and disease-dependent functional brain abnormalities in bipolar disorder. C1 [Altshuler, Lori; Mintz, Jim] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA 90095 USA. [Altshuler, Lori; Bookheimer, Susan; Proenza, Manuel A.; Mintz, Jim; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Bookheimer, Susan; Townsend, Jennifer; Sabb, Fred; Cohen, Mark S.] Univ Calif Los Angeles, Sch Med, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA USA. RP Altshuler, L (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu RI Cohen, Mark/C-6610-2011 OI Cohen, Mark/0000-0001-6731-4053 FU Stanley Medical Research Institute; National Alliance for Research on Schizophrenia and Depression; National Institute of Mental Health [K24 MH01848]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund; National Institute of Drug Abuse [DA13054]; National Center for Research Resources [RR12169, RR13642, RR08655] FX The authors gratefully acknowledge the Stanley Medical Research Institute, the National Alliance for Research on Schizophrenia and Depression, and the National Institute of Mental Health (K24 MH01848) for their financial support of this study. For generous support, the authors also wish to thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, the Ahmanson Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, Northstar Fund, the National Institute of Drug Abuse grant DA13054 and the National Center for Research Resources grants RR12169, RR13642, and RR08655. NR 81 TC 80 Z9 81 U1 3 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD SEP PY 2008 VL 10 IS 6 BP 708 EP 717 DI 10.1111/j.1399-5618.2008.00617.x PG 10 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 337XU UT WOS:000258469600007 PM 18837865 ER PT J AU Wiren, KM Sernirale, AA Zhang, XW Woo, A Tornmasini, SM Price, C Schaffler, MB Jepsen, KJ AF Wiren, Kristine M. Sernirale, Anthony A. Zhang, Xiao-Wei Woo, Adrian Tornmasini, Steven M. Price, Christopher Schaffler, Mitchell B. Jepsen, Karl J. TI Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis - A model for compartment-specific androgen action in the skeleton SO BONE LA English DT Article DE androgen receptor; osteocyte; bone histomorphometry; biomechanics; dual energy X-ray absorptiometry ID MINERAL DENSITY; ELDERLY-MEN; MALE-MICE; DIFFERENTIATED OSTEOBLASTS; OSTEOSARCOMA CELLS; GENDER DIFFERENCES; TESTOSTERONE GEL; PROSTATE-CANCER; SEX-DIFFERENCES; I COLLAGEN AB Androgens are anabolic hormones that affect many tissues, including bone. However, an anabolic effect of androgen treatment oil bone in eugonadal subjects has not been observed and clinical trials have been disappointing. The androgen receptor(AR) mediates biological responses to androgens. In bone tissue, both AR and the estrogen receptor (ER) are expressed. Since androgens can be converted into estrogen, the specific role of the AR in maintenance of skeletal homoeostasis remains controversial. The goal of this study was to use skeletally targeted overexpression of AR in differentiated osteoblasts as a means of elucidating the specific role(s) for AR transactivation in the mature bone compartment. Transgenic mice overexpressing AR under the control of the 2.3-kb alpha 1(1)-collagen promoter fragment showed no difference in body composition, testosterone, or 17 beta-estradiol levels. However, transgenic males have reduced serum osteocalcin, CTx and TRAPC5b levels, and a bone phenotype was observed. In cortical bone, high-resolution micro-computed tomography revealed no difference in periosteal perimeter but a significant reduction in cortical bone area due loan enlarged marrow cavity. Endocortical bone formation rate was also significantly inhibited. Biomechanical analyses showed decreased whole bone strength and quality, with significant reductions in all parameters tested. Trabecular morphology was altered, with increased bone volume comprised of more trabeculae that were closer together but not thicker. Expression of genes involved in bone formation and bone resorption was significantly reduced. The consequences of androgen action are compartment-specific; anabolic effects are exhibited exclusively at periosteal Surfaces, but in mature osteoblasts androgens inhibited osteogenesis with detrimental effects oil matrix quality, bone fragility and whole bone strength. Thus, the present data demonstrate that enhanced androgen signaling targeted to bone results in low bone turnover and inhibition of bone formation by differentiated osteoblasts. These results indicate that direct androgen action in mature osteoblasts is not anabolic, and raise concerns regarding anabolic steroid abuse in the developing skeleton or high-close treatment in eugonadal adults. Published by Elsevier Inc. C1 [Wiren, Kristine M.; Sernirale, Anthony A.; Zhang, Xiao-Wei] Portland VA Med Ctr, Bone & Mineral Res Unit, Portland, OR 97239 USA. [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Wiren, Kristine M.; Sernirale, Anthony A.; Zhang, Xiao-Wei] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Woo, Adrian; Tornmasini, Steven M.; Price, Christopher; Schaffler, Mitchell B.; Jepsen, Karl J.] Mt Sinai Sch Med, Dept Orthopaed, New York, NY USA. RP Wiren, KM (reprint author), Portland VA Med Ctr, Bone & Mineral Res Unit, P3-R&D39,3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU United States Army Research Acquisition Activity [W81XWH-05-1-0086 (KMW)]; National Institute of Diabetes, Digestive and Kidney Disease [R01 DK067541 (KMW)] FX The authors would like to thank Dr. David Rowe (University of Connecticut Health Center) for providing the plasmids containing the rat col alpha 1 promoter sequences, Dr. Shutsung Liao (University of Chicago) for the rat AR cDNA, Dr. Robert Klein (Oregon Health and Science University) for the use of equipment for DXA analysis, Drs. Russell Turner and Urszula Iwaniec (Oregon State University) for the careful reading of the manuscript, and Joel Hashimoto for the excellent technical assistance. This material is based upon work Supported by grants from the United States Army Research Acquisition Activity Award No. W81XWH-05-1-0086 (KMW) and the National Institute of Diabetes, Digestive and Kidney Disease R01 DK067541 (KMW). The information contained in this publication does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. All work was performed in facilities provided by the Department of Veterans Affairs. NR 69 TC 36 Z9 37 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 EI 1873-2763 J9 BONE JI Bone PD SEP PY 2008 VL 43 IS 3 BP 440 EP 451 DI 10.1016/j.bone.2008.04.026 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 344UW UT WOS:000258953800005 PM 18595795 ER PT J AU Aqel, RA Hage, FG AF Aqel, Raed A. Hage, Fadi G. TI Time is muscle; But should it be D2B or D2T? SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; ANGIOPLASTY C1 [Aqel, Raed A.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Aqel, Raed A.; Hage, Fadi G.] Univ Alabama, Div Cardiovasc Dis, Dept Internal Med, Birmingham, AL 35294 USA. RP Aqel, RA (reprint author), BDB 383,1530 3rd Ave S, Birmingham, AL 35294 USA. EM raed.aqel@med.va.gov OI Hage, Fadi/0000-0002-1397-4942 NR 8 TC 2 Z9 2 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD SEP 1 PY 2008 VL 72 IS 3 BP 424 EP 425 DI 10.1002/ccd.21613 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 344CI UT WOS:000258902800024 PM 18727124 ER PT J AU Liu, S Heitz, RP Sampson, AR Zhang, W Bradberry, CW AF Liu, S. Heitz, R. P. Sampson, A. R. Zhang, W. Bradberry, C. W. TI Evidence of temporal cortical dysfunction in rhesus monkeys following chronic cocaine self-administration SO CEREBRAL CORTEX LA English DT Article DE addiction; cognition; prefrontal; primate; psychostimulant ID PREFRONTAL CORTEX; DECISION-MAKING; WORKING-MEMORY; EXTRACELLULAR DOPAMINE; LESIONS; PERFORMANCE; DEPENDENCE; DEFICITS; ABUSERS; SENSITIZATION AB Cocaine abusers show impaired performance on cognitive tasks that engage prefrontal cortex. These deficits may contribute to impaired control and relapse in abusers. Understanding the neuronal substrates that lead to these deficits requires animal models that are relevant to the human condition. However, to date, models have mostly focused on behaviors mediated by subcortical systems. Here we evaluated the impact of long-term self-administration of cocaine in the rhesus monkey on cognitive performance. Tests included stimulus discrimination (SD)/reversal and delayed alternation tasks. The chronic cocaine animals showed marked deficits in ability to organize their behavior for maximal reward. This was demonstrated by an increased time needed to acquire SDs. Deficits were also indicated by an increased time to initially learn the delayed alternation task, and to adapt strategies for bypassing a reliance on working memory to respond accurately. Working memory per se (delay dependent performance) was not affected by chronic self-administration. This pattern of cognitive deficits suggests dysfunction that extends beyond localized prefrontal cortical areas. In particular, it appears that temporal cortical function is also compromised. This agrees with other recent clinical and preclinical findings, and suggests further study into addiction related dysfunction across more widespread cortical networks is warranted. C1 [Liu, S.; Bradberry, C. W.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA. [Heitz, R. P.] Vanderbilt Univ, Ctr Integrat & Cognit Neurosci, Nashville, TN 37203 USA. [Sampson, A. R.; Zhang, W.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15261 USA. [Bradberry, C. W.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15261 USA. [Bradberry, C. W.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. RP Bradberry, CW (reprint author), Univ Pittsburgh, Dept Psychiat, Rm 4078,3501 5th Ave, Pittsburgh, PA 15261 USA. EM bradberrycw@upmc.edu RI bradberry, charles/M-2082-2015 OI bradberry, charles/0000-0003-2630-4144 FU National Institutes of Health [DA 10331, MH 78789]; Veteran's Administration Biomedical Laboratory Research and Development Service FX National Institutes of Health (DA 10331, MH 78789); and the Veteran's Administration Biomedical Laboratory Research and Development Service. NR 52 TC 14 Z9 14 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 J9 CEREB CORTEX JI Cereb. Cortex PD SEP PY 2008 VL 18 IS 9 BP 2109 EP 2116 DI 10.1093/cercor/bhm236 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 347MD UT WOS:000259144800014 PM 18096561 ER PT J AU Weintraub, WS Boden, WE Zhang, ZG Kolm, P Zhang, ZF Spertus, JA Hartigan, P Veledar, E Jurkovitz, C Bowen, J Maron, DJ O'Rourke, R Dada, M Teo, KK Goeree, R Barnett, PG AF Weintraub, William S. Boden, William E. Zhang, Zugui Kolm, Paul Zhang, Zefeng Spertus, John A. Hartigan, Pamela Veledar, Emir Jurkovitz, Claudine Bowen, Jim Maron, David J. O'Rourke, Robert Dada, Marcin Teo, Koon K. Goeree, Ron Barnett, Paul G. CA Cooperative Studies Program 424 CO TI Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE coronary disease; angina; epidemiology; cost-benefit analysis; stents AB Background-The COURAGE ( Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluations) trial compared the effect of percutaneous coronary intervention (PCI) plus optimal medical therapy with optimal medical therapy alone on cardiovascular events in 2287 patients with stable coronary disease. After 4.6 years, there was no difference in the primary end point of death or myocardial infarction, although PCI improved quality of life. The present study evaluated the relative cost and cost-effectiveness of PCI in the COURAGE trial. Methods and Results-Resource use was assessed by diagnosis-related group for hospitalizations and by current procedural terminology code for outpatient visits and tests and then converted to costs by use of 2004 Medicare payments. Medication costs were assessed with the Red Book average wholesale price. Life expectancy beyond the trial was estimated from Framingham survival data. Utilities were assessed by the standard gamble method. The incremental cost-effectiveness ratio was expressed as cost per life-year and cost per quality- adjusted life-year gained. The added cost of PCI was approximately $10 000, without significant gain in life-years or quality-adjusted life-years. The incremental cost-effectiveness ratio varied from just over $168 000 to just under $300 000 per life-year or quality- adjusted life-year gained with PCI. A large minority of the distributions found that medical therapy alone offered better outcome at lower cost. The costs per patient for a significant improvement in angina frequency, physical limitation, and quality of life were $154 580, $112 876, and $124 233, respectively. Conclusions-The COURAGE trial did not find the addition of PCI to optimal medical therapy to be a cost-effective initial management strategy for symptomatic, chronic coronary artery disease. (Circ Cardiovasc Qual Outcomes. 2008; 1: 12-20.) C1 [Weintraub, William S.] Christiana Care Hlth Syst, Cardiol Sect, Newark, DE 19718 USA. [Boden, William E.] Western New York Vet Affairs Healthcare Network, Buffalo, NY USA. [Boden, William E.] Kaleida Hlth Syst, Buffalo, NY USA. [Zhang, Zefeng] Emory Univ, Atlanta, GA 30322 USA. [Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Hartigan, Pamela] VA Connecticut Healthcare Syst, Coordinating Ctr, Cooperat Studies Program, West Haven, CT USA. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [O'Rourke, Robert] San Antonio Vet Affairs Med Ctr, San Antonio, TX USA. [Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA. [Teo, Koon K.; Goeree, Ron] McMaster Univ, Hamilton, ON, Canada. [Barnett, Paul G.] Vet Affairs Hlth Econ Resource Ctr, Palo Alto, CA USA. RP Weintraub, WS (reprint author), Christiana Care Hlth Syst, Cardiol Sect, 4755 Ogletown Stanton Rd, Newark, DE 19718 USA. EM wweintraub@christianacare.org RI Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 FU Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; Canadian Institutes for Health Research; Merck Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Fujisawa; Kos Pharmaceuticals; Data Scope; AstraZeneca; Key Pharmaceutical Co, Ltd; Sanofi-Aventis, Inc; First Horizon; Nycomed Amersham; Department of Veterans Affairs FX This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development, in collaboration with the Canadian Institutes for Health Research; unrestricted research grants were obtained from Merck & Co, Pfizer Pharmaceuticals, Bristol-Myers Squibb Medical Imaging, Fujisawa, Kos Pharmaceuticals, Data Scope, AstraZeneca, Key Pharmaceutical Co, Ltd, Sanofi-Aventis, Inc, First Horizon, and Nycomed Amersham. All industrial funding in support of the trial was directed through the Department of Veterans Affairs. NR 29 TC 59 Z9 59 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD SEP PY 2008 VL 1 IS 1 BP 12 EP U33 DI 10.1161/CIRCOUTCOMES.108.798462 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V11AK UT WOS:000207504300005 PM 20031783 ER PT J AU Keenan, PS Normand, SLT Lin, ZQ Drye, EE Bhat, KR Ross, JS Schuur, JD Stauffer, BD Bernheim, SM Epstein, AJ Wang, YF Herrin, J Chen, J Federer, JJ Mattera, JA Wang, Y Krumholz, HM AF Keenan, Patricia S. Normand, Sharon-Lise T. Lin, Zhenqiu Drye, Elizabeth E. Bhat, Kanchana R. Ross, Joseph S. Schuur, Jeremiah D. Stauffer, Brett D. Bernheim, Susannah M. Epstein, Andrew J. Wang, Yongfei Herrin, Jeph Chen, Jersey Federer, Jessica J. Mattera, Jennifer A. Wang, Yun Krumholz, Harlan M. TI An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE health policy; heart failure; quality of health care AB Background-Readmission soon after hospital discharge is an expensive and often preventable event for patients with heart failure. We present a model approved by the National Quality Forum for the purpose of public reporting of hospital-level readmission rates by the Centers for Medicare & Medicaid Services. Methods and Results-We developed a hierarchical logistic regression model to calculate hospital risk-standardized 30-day all-cause readmission rates for patients hospitalized with heart failure. The model was derived with the use of Medicare claims data for a 2004 cohort and validated with the use of claims and medical record data. The unadjusted readmission rate was 23.6%. The final model included 37 variables, had discrimination ranging from 15% observed 30-day readmission rate in the lowest predictive decile to 37% in the upper decile, and had a c statistic of 0.60. The 25th and 75th percentiles of the risk-standardized readmission rates across 4669 hospitals were 23.1% and 24.0%, with 5th and 95th percentiles of 22.2% and 25.1%, respectively. The odds of all-cause readmission for a hospital 1 standard deviation above average was 1.30 times that of a hospital 1 standard deviation below average. State-level adjusted readmission rates developed with the use of the claims model are similar to rates produced for the same cohort with the use of a medical record model (correlation, 0.97; median difference, 0.06 percentage points). Conclusions-This claims-based model of hospital risk-standardized readmission rates for heart failure patients produces estimates that may serve as surrogates for those derived from a medical record model. ( Circ Cardiovasc Qual Outcomes. 2008;1:29-37.) C1 [Keenan, Patricia S.; Epstein, Andrew J.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lin, Zhenqiu; Drye, Elizabeth E.; Bhat, Kanchana R.; Mattera, Jennifer A.; Wang, Yun; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Ross, Joseph S.] HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Schuur, Jeremiah D.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Schuur, Jeremiah D.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Stauffer, Brett D.] Baylor Univ, Med Hosp Syst, Dallas, TX USA. [Bernheim, Susannah M.] Yale New Haven Hlth Syst, Performance Management, New Haven, CT USA. [Wang, Yongfei; Herrin, Jeph; Chen, Jersey; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Federer, Jessica J.] Bayer Healthcare Pharmaceut, Wayne, NJ USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, Room I-456 SHM,333 Cedar St,POB 208088, New Haven, CT 06520 USA. EM harlan.krumholz@yale.edu FU Department of Veterans Affairs; CMS; US Department of Health and Human Services; [HHSM-500-2005-CO001C] FX The authors thank Dima Turkmani, Maureen O'Brien, and Debra Chromik at the Colorado Foundation for Medical Care; Geoffrey Schreiner from the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital; Angela Merrill and Eric Schone from Mathematica Policy Research; and Lein Han and Michael Rapp at CMS for their contributions to this work. CMS reviewed and approved the use of its data for this work and approved submission of the manuscript.; Drs Stauffer and Schuur were funded by the Department of Veterans Affairs during the time the work was conducted. The analyses on which this publication is based were performed under contract No. HHSM-500-2005-CO001C, entitled "Utilization and Quality Control Quality Improvement Organization for the State (Commonwealth) of Colorado," funded by the CMS, an agency of the US Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. The authors assume full responsibility for the accuracy and completeness of the ideas presented. NR 29 TC 226 Z9 228 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD SEP PY 2008 VL 1 IS 1 BP 29 EP U56 DI 10.1161/CIRCOUTCOMES.108.802686 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V11AK UT WOS:000207504300007 PM 20031785 ER PT J AU Chen, SM Cheng, DS Williams, BJ Sherrill, TP Han, W Chont, M Saint-Jean, L Christman, JW Sadikot, RT Yull, FE Blackwell, TS AF Chen, S. M. Cheng, D. -S. Williams, B. J. Sherrill, T. P. Han, W. Chont, M. Saint-Jean, L. Christman, J. W. Sadikot, R. T. Yull, F. E. Blackwell, T. S. TI The nuclear factor kappa-B pathway in airway epithelium regulates neutrophil recruitment and host defence following Pseudomonas aeruginosa infection SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Article DE chemokines; immune regulation; infections; lung immunology; transgenics ID VENTILATOR-ASSOCIATED PNEUMONIA; MACROPHAGE INFLAMMATORY PROTEIN-2; MYELOID DIFFERENTIATION FACTOR-88; INNATE IMMUNE-RESPONSE; ALVEOLAR MACROPHAGES; LUNG INFLAMMATION; RESPIRATORY EPITHELIUM; CELLS; EXPRESSION; ACTIVATION AB Pseudomonas aeruginosa pneumonia usually results from a deficit of the innate immune system. To investigate whether inflammatory signalling by airway epithelial cells provides a pivotal line of defence against P. aeruginosa infection, we utilized two separate lines of inducible transgenic mice that express a constitutive activator of the nuclear factor kappa-B (NF-kappa B) pathway (IKTA) or a dominant inhibitor of NF-kappa B (DNTA) in airway epithelial cells. Compared with control mice, IKTA mice showed an enhanced host response to P. aeruginosa infection with greater neutrophil influx into the lungs, increased expression of Glu-Leu-Arg-positive (ELR+) CXC chemokines macrophage inflammatory protein-2 and keratinocyte chemoattractant (KC), superior bacterial clearance and improved survival at 24 h after infection. Neutrophil depletion abrogated the improvement in host defence identified in IKTA mice. In contrast, DNTA mice showed impaired responses to P. aeruginosa infection with higher bacterial colony counts in the lungs, decreased neutrophilic lung inflammation and lower levels of KC in lung lavage fluid. DNTA mice given recombinant KC at the time of P. aeruginosa infection demonstrated improved neutrophil recruitment to the lungs and enhanced bacterial clearance. Our data indicate that the NF-kappa B pathway in airway epithelial cells plays an essential role in defence against P. aeruginosa through generation of CXC chemokines and recruitment of neutrophils. C1 [Blackwell, T. S.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA. [Chont, M.; Saint-Jean, L.; Yull, F. E.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA. [Chen, S. M.; Cheng, D. -S.; Williams, B. J.; Sherrill, T. P.; Han, W.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. [Christman, J. W.; Sadikot, R. T.; Blackwell, T. S.] Univ Illinois, US Dept Vet Affairs, Chicago, IL USA. [Christman, J. W.; Sadikot, R. T.] Univ Illinois, Sect Pulm Crit Care & Sleep Med, Chicago, IL USA. RP Blackwell, TS (reprint author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Cell & Dev Biol, T-1218 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM timothy.blackwell@vanderbilt.edu FU NHLBI NIH HHS [HL07123, HL61419, HL66196, P01 HL066196, R01 HL061419, T32 HL007123] NR 38 TC 18 Z9 18 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9104 EI 1365-2249 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD SEP PY 2008 VL 153 IS 3 BP 420 EP 428 DI 10.1111/j.1365-2249.2008.03707.x PG 9 WC Immunology SC Immunology GA 336PD UT WOS:000258376200014 PM 18647324 ER PT J AU Weisbord, SD Mor, MK Resnick, AL Hartwig, KC Palevsky, PM Fine, MJ AF Weisbord, Steven D. Mor, Maria K. Resnick, Abby L. Hartwig, Kathryn C. Palevsky, Paul M. Fine, Michael J. TI Incidence and outcomes of contrast-induced AKI following computed tomography SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HIGH-RISK PATIENTS; RANDOMIZED CONTROLLED-TRIAL; INDUCED NEPHROPATHY; RENAL-FUNCTION; CORONARY-ANGIOGRAPHY; CARDIAC ANGIOGRAPHY; N-ACETYLCYSTEINE; MEDIA; PREVENTION; IODIXANOL AB Background and objectives: Most studies of contrast-induced acute kidney injury (CIAKI) have focused on patients undergoing angiographic procedures. The incidence and outcomes of CIAKI in patients undergoing nonemergent, contrast-enhanced computed tomography in the inpatient and outpatient setting were assessed. Design, setting, participants, & measurements: Patients with estimated glomerular filtration rates (GFRs) <60 ml/min per 1.73 m(2) undergoing nonemergent computed tomography with intravenous iodinated radiocontrast at an academic VA Medical Center were prospectively identified. Serum creatinine was assessed 48 to 96 h postprocedure to quantify the incidence of CIAKI, and the need for postprocedure dialysis, hospital admission, and 30-d mortality was tracked to examine the associations of CIAKI with these medical outcomes. Results: A total of 421 patients with a median estimated GFR of 53 ml/min per 1.73 m(2) were enrolled. Overall, 6.5% of patients developed an increase in serum creatinine >= 25%, and 3.5% demonstrated a rise in serum creatinine >= 0.5 mg/dl. Although only 6% of outpatients received preprocedure and postprocedure intravenous fluid, <1% of outpatients with estimated GFRs >45 ml/min per 1.73 m(2) manifested an increase in serum creatinine >= 0.5 mg/dl. None of the study participants required postprocedure dialysis. Forty-six patients (10.9%) were hospitalized and 10 (2.4%) died by 30-d follow-up; however, CIAKI was not associated with these outcomes. Conclusions: Clinically significant CIAKI following nonemergent computed tomography is uncommon among outpatients with mild baseline kidney disease. These findings have important implications for providers ordering and performing computed tomography and for future clinical trials of CIAKI. C1 [Weisbord, Steven D.; Mor, Maria K.; Resnick, Abby L.; Hartwig, Kathryn C.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Hartwig, Kathryn C.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU VA Health Services Research and Development Career Development Award [RCD 03176]; VA Stars and Stripes Competitive Pilot Project; National Institute of Allergy and Infectious Diseases [K24 AI001769] FX This work was supported by a VA Health Services Research and Development Career Development Award of Dr. Weisbord (RCD 03176) and a VA Stars and Stripes Competitive Pilot Project Fund Award. Dr. Fine was supported in part by a mid-career development award (K24 AI001769) from the National Institute of Allergy and Infectious Diseases. NR 30 TC 101 Z9 104 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP PY 2008 VL 3 IS 5 BP 1274 EP 1281 DI 10.2215/CJN.01260308 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 342AR UT WOS:000258757500012 PM 18463172 ER PT J AU Winthrop, KL Nyendak, M Calvet, H Oh, P Lo, M Swarbrick, G Johnson, C Lewinsohn, DA Lewinsohn, DM Mazurek, GH AF Winthrop, Kevin L. Nyendak, Melissa Calvet, Helene Oh, Peter Lo, Melanie Swarbrick, Gwendolyn Johnson, Carol Lewinsohn, Deborah A. Lewinsohn, David M. Mazurek, Gerald H. TI Interferon-gamma release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SKIN-TEST; HEMODIALYSIS-PATIENTS; HIGH PREVALENCE; VACCINATION; ANERGY; CELLS AB Background and objectives: End-stage renal disease (ESRD) patients are at high risk for tuberculosis (TB). IFN-gamma release assays that assess immune responses to specific TB antigens offer potential advantages over tuberculin skin testing (TST) in screening such patients for Mycobacterium tuberculosis infection. This study sought to determine whether IFN-gamma release assay results are more closely associated with recent TB exposure than TST results. Design, setting, participants, and measures: Prospective cohort investigation of patients at a hemodialysis center with a smear-positive case of TB. Patients without a history of TB underwent initial and repeat testing with TST, and with the IFN-gamma assays QuantiFERON-TB Gold(R) (QFT-G) and ELISPOT test. Outcome measures included the prevalence of positive test results, identification of factors associated with positive results, and test result discordance. Results: A total of 100 (47% foreign born; median age, 55 yr, age range, 18 to 83 yr) of 124 eligible patients were enrolled. Twenty-six persons had positive TST results, 21 had positive QFT-G results, and 27 had positive ELISPOT results. Patients with TB case contact were likely to have a positive QFT-G result (P = 0.02) and ELISPOT results (P = 0.04), whereas TB case contact was not associated with positive TST results (P = 0.7). Positive TST results were associated with foreign birth (P = 0.04) and having had a TST in the previous year (P = 0.04). Conclusions: Positive IFN-gamma assay results were more closely associated with recent TB exposure than were positive TST results. QFT-G and ELISPOT might offer a better method for detecting TB infection in ESRD patients. C1 [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA. [Winthrop, Kevin L.; Mazurek, Gerald H.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Johnson, Carol; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA. [Calvet, Helene] Long Beach Dept Hlth & Human Serv, Long Beach, CA USA. [Winthrop, Kevin L.; Oh, Peter; Lo, Melanie] Calif Dept Hlth Serv, Div Communicable Dis Control, Richmond, CA USA. RP Winthrop, KL (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM Winthrop@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 22 TC 47 Z9 48 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP PY 2008 VL 3 IS 5 BP 1357 EP 1363 DI 10.2215/CJN.01010208 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 342AR UT WOS:000258757500023 PM 18550653 ER PT J AU Kramer, H Palmas, W Kestenbaum, B Cushman, M Allison, M Astor, B Shlipak, M AF Kramer, Holly Palmas, Walter Kestenbaum, Bryan Cushman, Mary Allison, Matt Astor, Brad Shlipak, Michael TI Chronic kidney disease prevalence estimates among racial/ethnic groups: The Multi-Ethnic Study of Atherosclerosis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; CHINESE PATIENTS; RENAL-FUNCTION; CREATININE; MARKER; EQUATION AB Background and objectives: Muscle mass is not a major determinant of serum cystatin C levels, and its use to estimate GFR may lead to more congruent estimates of chronic kidney disease (CKD) across gender and racial/ethnic groups. Design, setting, participants, & measurements: The Multi-Ethnic Study of Atherosclerosis is a population-based study of 6814 men and women who are aged 45 to 85 yr and do not have clinical cardiovascular disease. Estimated CKD prevalence, defined as an estimated GFR <60 ml/min per 1.73 m(2) body surface area, was compared using three different GFR prediction equations: The abbreviated Modification of Diet in Renal Disease (MDRD) equation and two equations based on serum cystatin C. Results: Among women, CKD prevalence estimates across the four racial/ethnic groups using the MDRD- or the cystatin C-based GFR equations, which include gender and race coefficients, varied by approximately two-fold (P < 0.0001) but were more congruent with use of a serum cystatin C-based equation without the use of coefficients (P = 0.3). CKD prevalence estimates did not differ significantly across racial/ethnic groups among men with the MDRD (P = 0.07) or cystatin C formula without coefficients (P = 0.05) but did differ significantly with the cystatin C formula, which incorporates gender and race coefficients (P = 0.006). Conclusions: CKD prevalence estimates vary across racial/ethnic groups, and the degree of variability depends on the method used to estimate GFR, especially among women. Further research is needed to determine the accuracy and precision of GFR prediction equations in racially diverse populations. C1 [Kramer, Holly] Loyola Univ, Med Ctr, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA. [Kramer, Holly] Loyola Univ, Med Ctr, Div Nephrol, Maywood, IL 60153 USA. [Palmas, Walter] Columbia Univ, Dept Med, Div Gen Med, Mailman Sch Publ Hlth,Med Ctr, New York, NY USA. [Kestenbaum, Bryan] Univ Washington, Harborview Med Ctr, Div Nephrol, Seattle, WA 98104 USA. [Cushman, Mary] Univ Vermont, Dept Med, Colchester, VT USA. [Allison, Matt] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Astor, Brad] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Shlipak, Michael] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kramer, H (reprint author), Loyola Med Ctr, Dept Epidemiol & Prevent Med, 2160 1st Ave, Maywood, IL 60153 USA. EM hkramer@lumc.edu OI Allison, Matthew/0000-0003-0777-8272 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95166]; American Heart Association Established Investigator Award [R01 DK066488-01] FX This research was supported by contracts N01-HC-95159 through N01-HC-95166 from the National Heart, Lung, and Blood Institute. M.S. is supported by R01 DK066488-01 and the American Heart Association Established Investigator Award. NR 22 TC 30 Z9 31 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD SEP PY 2008 VL 3 IS 5 BP 1391 EP 1397 DI 10.2215/CJN.04160907 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 342AR UT WOS:000258757500028 PM 18550650 ER PT J AU Swartz, BE McDonald, CR Patel, A Torgersen, D AF Swartz, Barbara E. McDonald, Carrie R. Patel, Ashok Torgersen, Denise TI The Effects of Guanfacine on Working Memory Performance in Patients With Localization-Related Epilepsy and Healthy Controls SO CLINICAL NEUROPHARMACOLOGY LA English DT Review DE alpha(2) agonists; guanfacine; working memory; frontal lobe epilepsy ID DEFICIT HYPERACTIVITY DISORDER; DORSOLATERAL PREFRONTAL CORTEX; CORTICAL COGNITIVE FUNCTION; FRONTAL-LOBE EPILEPSY; TO-SAMPLE PERFORMANCE; AGED RHESUS-MONKEYS; ALPHA-2-ADRENERGIC AGONIST; ALPHA(2)-ADRENERGIC ANTAGONIST; KORSAKOFFS PSYCHOSIS; SELECTIVE ATTENTION AB Objectives: Previous research has demonstrated that alpha(2) agonists improve working memory performances in healthy individuals and in primates with prefrontal lesions. We conducted this study to determine whether the a2 agonist, guanfacine, could improve working memory performances in patients with frontal lobe epilepsy (FLE) and/or in those with focal epilepsy outside the frontal lobes (ie, temporal lobe epilepsy [TLE]). Methods: Fourteen patients with FLE, 13 patients with TLE, and 10 healthy controls completed immediate and delayed match-to-sample tasks before and after ingestion of 2 to 3 mg of guanfacine. Results: All 3 groups showed an increase in accuracy on the delayed match-to-sample task, but not the immediate match-to-sample task, following administration of guanfacine. Inspection of the group means revealed somewhat greater benefits for the control and FLE groups relative to the TLE group. Increased accuracy was not associated with slower performances in any group, suggesting that the cognitive benefits of guanfacine did not occur at the expense of increased sedation. Conclusions: These data suggest that guanfacine improves working memory in patients with FLE and may be a viable treatment for attenuating such deficits in this patient population. C1 [Swartz, Barbara E.] Hoag Mem Hosp, Epilepsy Ctr, Newport Beach, CA USA. [Torgersen, Denise] VA Greater Angeles Hlth Care Syst, Div Res, Los Angeles, CA USA. [McDonald, Carrie R.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Patel, Ashok] Univ S Carolina, Dept Neurosci, Columbia, SC 29208 USA. RP Swartz, BE (reprint author), 351 Hosp Rd St 420, Newport Beach, CA 92663 USA. EM epidoc@cox.net NR 52 TC 14 Z9 14 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-5664 J9 CLIN NEUROPHARMACOL JI Clin. Neuropharmacol. PD SEP-OCT PY 2008 VL 31 IS 5 BP 251 EP 260 DI 10.1097/WNF.0B013E3181633461 PG 10 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 360VX UT WOS:000260087400001 PM 18836342 ER PT J AU Goudreau, KA Smolenski, M AF Goudreau, Kelly A. Smolenski, Mary TI Credentialing and certification - Issues for clinical nurse specialists SO CLINICAL NURSE SPECIALIST LA English DT Article DE advanced practice registered nurses; advanced practice regulation certification; credentialing AB This article will provide a brief overview of the concepts of credentialing and certification and will identify some of the issues around certification and credentialing for clinical nurse specialists (CNSs). The article will also describe some of the misconceptions about certification and licensure that cause problems to CNSs, identify the current questions on the debated regulation of CNSs, and outline some of the proactive steps that can be taken to stay ahead of the current wave of change anticipated with the suggested changes in the forthcoming regulation of CNSs. Information provided is pertinent for new graduates and seasoned CNSs and provides an opportunity for both to gain a better understanding of certification and credentialing. C1 [Goudreau, Kelly A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Smolenski, Mary] Amer Nurses Credentialing Ctr, Silver Spring, MD USA. RP Goudreau, KA (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM kagoudreau@hotmail.com NR 9 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD SEP-OCT PY 2008 VL 22 IS 5 BP 240 EP 244 DI 10.1097/01.NUR.0000325369.61668.7c PG 5 WC Nursing SC Nursing GA 345CX UT WOS:000258974700017 PM 18753882 ER PT J AU Schelleman, H Chen, J Chen, Z Christie, J Newcomb, CW Brensinger, CM Price, M Whitehead, AS Kealey, C Thorn, CF Samaha, FF Kimmel, SE AF Schelleman, H. Chen, J. Chen, Z. Christie, J. Newcomb, C. W. Brensinger, C. M. Price, M. Whitehead, A. S. Kealey, C. Thorn, C. F. Samaha, F. F. Kimmel, S. E. TI Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID GAMMA-GLUTAMYL-CARBOXYLASE; FACTOR-VII; LINKAGE-DISEQUILIBRIUM; ORAL ANTICOAGULATION; CLINICAL-PRACTICE; CYP2C9 GENOTYPE; GENE VARIANTS; VKORC1 GENE; FACTOR-II; POLYMORPHISMS AB The objective of this study was to determine whether warfarin dosing algorithms developed for Caucasians and African Americans on the basis of clinical, environmental, and genetic factors will perform better than an empirical starting dose of 5 mg/day. From April 2002 through December 2005, 259 subjects (Caucasians and African Americans) who started using warfarin were prospectively followed until they reached maintenance dose. The Caucasian algorithm included 11 variables (R-2 = 0.43). This model (which predicted 51% of the doses to within 1 mg of the observed dose) performed better than 5 mg/day (which predicted 29% of the doses to within 5 +/- 1 mg). The African-American algorithm included 10 variables (R-2 = 0.28). This model predicted 37% of the doses to within 1 mg of the observed dose, representing a small improvement compared with 5 mg/day (which predicted 34% of the doses to within 1 mg of 5 mg/day). These results were similar to the results we obtained from testing other published algorithms. The dosing algorithms explained < 45% of the observed variability in Caucasians, and the algorithms performed only marginally better for African Americans when compared with giving 5 mg empirically. C1 [Schelleman, H.; Chen, J.; Chen, Z.; Christie, J.; Newcomb, C. W.; Brensinger, C. M.; Price, M.; Kimmel, S. E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Whitehead, A. S.; Kealey, C.; Thorn, C. F.] Univ Penn, Sch Med, Dept Pharmacol, Ctr Pharmacogenet, Philadelphia, PA 19104 USA. [Samaha, F. F.] Univ Penn, Sch Med, Dept Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Schelleman, H (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. EM hschelle@mail.med.upenn.edu FU National Institutes of Health (NIH) [R01HL066176, P20RR020741, K24HL070936] FX This study was funded by National Institutes of Health (NIH) grant R01HL066176. S.E.K. was supported by NIH grants P20RR020741 and K24HL070936, and A.S.W. was supported by NIH grant P20RR020741. The funding agencies had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. We thank Joseph A. Gascho and Francis Herrmann at Penn State Milton S. Hershey Medical Center; Mitchell Laskin at Hospital of the University of Pennsylvania; and Mabel Chin at the Philadelphia Veterans Affairs Medical Center for their dedication to our fieldwork. S. E. K. and H. S. had full access to all data in the study, and they take responsibility for the integrity of the data and the accuracy of the data analysis. The factor 2 and factor 7 data will be deposited in PharmGKB (http://www.pharmgkb.org). NR 36 TC 81 Z9 84 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD SEP PY 2008 VL 84 IS 3 BP 332 EP 339 DI 10.1038/clpt.2008.101 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 339MW UT WOS:000258582700012 PM 18596683 ER PT J AU Pessler, F Chen, LX Dai, L Gomez-Vaquero, C Diaz-Torne, C Paessler, ME Scanzello, C Cakir, N Einhorn, E Schumacher, HR AF Pessler, F. Chen, L. X. Dai, L. Gomez-Vaquero, C. Diaz-Torne, C. Paessler, M. E. Scanzello, C. Cakir, N. Einhorn, E. Schumacher, H. R. TI A histomorphometric analysis of synovial biopsies from individuals with Gulf War Veterans' Illness and joint pain compared to normal and osteoarthritis synovium SO CLINICAL RHEUMATOLOGY LA English DT Article DE arthralgia; chronic fatigue syndrome; fibromyalgia; Gulf War Veterans' Illnesses; synovium ID HISTOPATHOLOGICAL GRADING SYSTEM; ANGIOGENESIS; SCORE AB We compared histologic, immunohistochemical, and vascular findings in synovial biopsies from individuals with Gulf War Veterans Illness and joint pain (GWVI) to findings in normal and osteoarthritis (OA) synovium. The following parameters were assessed in synovial biopsies from ten individuals with GWVI: lining thickness, histologic synovitis score, and vascular density in hematoxylin & eosin-stained sections; and CD68+ lining surface cells and CD15+, CD3+, CD8+, CD20+, CD38+, CD68+, and Ki-67+ subintimal cells and von Willebrand Factor+ vessels immunohistochemically. Comparisons were made to synovial specimens from healthy volunteers (n = 10) and patients with OA or RA (n = 25 each). Histologic appearance and quantitative assessments were nearly identical in the GWVI and normal specimens. Vascular density was between 25% (H & E stains; p = 0.003) and 31% (vWF immunostains; p = 0.02) lower in GWVI and normal specimens than in OA. CD68+ macrophages were the most common inflammatory cells in GWVI (45.3 +/- Ce10.1 SEM cells/mm(2)) and normal synovium (45.6 +/- Ce7.4) followed by CD3+ T cells (GWVI, 15.1 +/- Ce6.3; normal, 27.1 +/- Ce9.2), whereas there were practically no CD20+, CD38+, and CD15+ cells. All parameters except lining thickness and CD15 and CD20 expression were significantly higher in OA. Five (20%) OA specimens contained significant fractions of humoral immune cells in mononuclear infiltrates, although the overall differences in the relative composition of the OA mononuclear infiltrates did not reach statistical significance compared to GWVI and normal synovium. In summary, the GWVI and normal synovia were indistinguishable from each other and contained similar low-grade inflammatory cell populations consisting almost entirely of macrophages and T cells. C1 [Pessler, F.] Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA. [Dai, L.] Sun Yat sen Univ, Affiliated Hosp 2, Dept Rheumatol, Guangzhou, Peoples R China. [Chen, L. X.; Diaz-Torne, C.; Cakir, N.; Schumacher, H. R.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Chen, L. X.; Schumacher, H. R.] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Gomez-Vaquero, C.] Hosp Univ Belvitge, Dept Rheumatol, Barcelona, Spain. [Diaz-Torne, C.] Hosp Santa Creu & Sant Pau, Rheumatol Unit, Barcelona, Spain. [Paessler, M. E.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Scanzello, C.] Hosp Special Surg, Dept Rheumatol, New York, NY 10021 USA. [Einhorn, E.] Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA USA. RP Pessler, F (reprint author), Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany. EM frank.pessler@uniklinikum-dresden.de OI Cesar, Diaz-Torne/0000-0001-6275-7699 FU NCI NIH HHS [T32-CA 09140]; NIAMS NIH HHS [T32-AR 007442] NR 19 TC 18 Z9 19 U1 0 U2 2 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD SEP PY 2008 VL 27 IS 9 BP 1127 EP 1134 DI 10.1007/s10067-008-0878-0 PG 8 WC Rheumatology SC Rheumatology GA 330DH UT WOS:000257919200008 PM 18414968 ER PT J AU Tobin, MJ Jubran, A AF Tobin, Martin J. Jubran, Amal TI Four questions for Dr. MacIntyre on his editorial SO CRITICAL CARE MEDICINE LA English DT Letter C1 [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. Loyola Univ, Chicago Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 5 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD SEP PY 2008 VL 36 IS 9 BP 2709 EP 2709 DI 10.1097/CCM.0b013e31817c44fa PG 1 WC Critical Care Medicine SC General & Internal Medicine GA 345TV UT WOS:000259020800046 PM 18728497 ER PT J AU Zeber, JE Copeland, LA Hosek, BJ Karnad, AB Lawrence, VA Sanchez-Reilly, SE AF Zeber, John E. Copeland, Laurel A. Hosek, Brandon J. Karnad, Arland B. Lawrence, Valerie A. Sanchez-Reilly, Sandra E. TI Cancer rates, medical comorbidities, and treatment modalities in the oldest patients SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE neoplasms; aged, 80 and over; radiation oncology; medical oncology; epidemiology; veterans ID GERIATRIC-ONCOLOGY; BREAST-CANCER; DEMENTIA; CHEMOTHERAPY; VETERANS; UNDERTREATMENT; POPULATION; PREVALENCE; MORTALITY; SERVICES AB Cancer disproportionately afflicts older patients, with 56% of incident diagnoses and 71% of deaths occurring in this population. Yet little is known about the "oldest of the old", oncology patients underrepresented in clinical trials. We examined elderly veterans diagnosed with lung, colorectal, prostate or head-neck cancer in 2005 (n = 194,797), analyses comparing treatment receipt by age group, 70-84 versus 85-115. Treatment was more common among younger elders, including surgery (1.3% versus 0.6%), chemotherapy (2.1% versus 0.8%) and radiation (1.7% versus 0.7%). Differences were sharper for certain cancers, e.g., chemotherapy for lung (9.0% versus 2.9%), or colorectal surgery (5.8% versus 3.4%). Cancer prevalence is high among elders yet treatment rates appear extremely low, despite evidence of well-tolerated treatment. Toxicity concerns and comorbidities may inhibit pursuit of definitive treatment. As we reconcile definitions of 'elderly' with appropriate treatment options, compassionate care requires identifying geriatric oncology guidelines that improve survival and quality of life. Published by Elsevier Ireland Ltd. C1 [Zeber, John E.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Karnad, Arland B.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Med Oncol, San Antonio, TX USA. [Karnad, Arland B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol Oncol, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra E.] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Sanchez-Reilly, Sandra E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr, San Antonio, TX 78229 USA. [Zeber, John E.; Copeland, Laurel A.; Hosek, Brandon J.; Lawrence, Valerie A.] S Texas Vet Hlth Care Syst Verdict, HSR&D, Dept Vet Affairs, San Antonio, TX USA. RP Zeber, JE (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd,Verdict 11C6, San Antonio, TX 78229 USA. EM zeber@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs, including the VERDICT Research Program at the South Texas Veterans Health Care System, San Antonio, Texas; HRSA's Geriatric Academic Career Award; VISN; VA Health Services Research and Development Career Development Award [MRP-05-145] FX This research was supported by the Department of Veterans Affairs, including the VERDICT Research Program at the South Texas Veterans Health Care System, San Antonio, Texas. Dr. Sanchez-Reilly is supported in part by a grant from HRSA's Geriatric Academic Career Award and a VISN Grant from the Department of Veteran Affairs. Dr. Copeland is funded by VA Health Services Research and Development Career Development Award #MRP-05-145. We wish to sincerely thank Mary Jo Pugh, Ph.D., for her contributions to this study and insightful comments on this manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 33 TC 21 Z9 21 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD SEP PY 2008 VL 67 IS 3 BP 237 EP 242 DI 10.1016/j.critrevonc.2008.02.002 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 351LE UT WOS:000259425000006 PM 18356072 ER PT J AU Devin, JK Young, PP AF Devin, Jessica K. Young, Pampee P. TI The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells SO CURRENT OPINION IN INVESTIGATIONAL DRUGS LA English DT Review DE aging; cardiovascular; endothelial progenitor cell; growth hormone; growth hormone secretagogue; nitric oxide ID ACUTE MYOCARDIAL-INFARCTION; FACTOR-BINDING PROTEIN-3; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MESENCHYMAL STEM-CELLS; SEVERE GH DEFICIENCY; SMOOTH-MUSCLE-CELLS; RISK-FACTORS; NITRIC-OXIDE; THERAPEUTIC NEOVASCULARIZATION AB Aging is a major risk factor for the development of cardiovascular disease. Aging is also associated with a decline in the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis. This axis impacts endothelial and vascular smooth muscle cell biology, as well as cardiac function. The number of endothelial progenitor cells (EPCs) also decreases with age and is emerging as a surrogate measurement of vascular senescence. Studies suggest that EPCs impact vascular health by modulating vascular repair and function. Current evidence demonstrates that EPC number and function is restored with a GH-mediated increase in serum IGF-1. Modulation of the GH and IGF-1 system may therefore provide a useful therapy in the prevention of age-associated changes in the cardiovascular system and in future regenerative cell-based therapies. C1 [Young, Pampee P.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA. [Devin, Jessica K.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA. [Young, Pampee P.] US Dept Vet Affairs, Nashville, TN 37203 USA. RP Young, PP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol, C-3321A Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM Pampee.Young@Vanderbilt.edu NR 91 TC 14 Z9 14 U1 0 U2 3 PU THOMSON REUTERS (SCIENTIFIC) LTD PI LONDON PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND SN 1472-4472 EI 2040-3429 J9 CURR OPIN INVEST DR JI Curr. Opin. Investig. Drugs PD SEP PY 2008 VL 9 IS 9 BP 983 EP 992 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 341EE UT WOS:000258696200006 PM 18729005 ER PT J AU Beard, S Pott, GB Morris, K Palmer, B Shapiro, L AF Beard, Scott Pott, Gregory B. Morris, Kristin Palmer, Brent Shapiro, Leland TI Alpha-1-antitrypsin is an inhibitor of intracellular pro-inflammatory cytokine production in monocytes and T-cells SO CYTOKINE LA English DT Meeting Abstract CT 7th Joint Conference of the International-Cytokine-Society/International-Society-for-Interferon-and- Cytoklin-Research CY OCT 12-16, 2008 CL Montreal, CANADA SP Int Cytokine Soc, Int Soc Interferon & Cytokin Res C1 [Beard, Scott; Pott, Gregory B.; Morris, Kristin; Shapiro, Leland] Denver Vet Affairs Med Ctr, Denver, CO USA. [Beard, Scott; Pott, Gregory B.; Morris, Kristin; Palmer, Brent; Shapiro, Leland] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD SEP PY 2008 VL 43 IS 3 BP 310 EP 310 DI 10.1016/j.cyto.2008.07.365 PG 1 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 362QT UT WOS:000260212900331 ER PT J AU Pott, GB Chan, ED Dinarello, CA Shapiro, L AF Pott, Gregory B. Chan, Edward D. Dinarello, Charles A. Shapiro, Leland TI Alpha-1-antitrypsin is an endogenous and specific inhibitor of pro-inflammatory cytokine production in whole blood SO CYTOKINE LA English DT Meeting Abstract CT 7th Joint Conference of the International-Cytokine-Society/International-Society-for-Interferon-and- Cytoklin-Research CY OCT 12-16, 2008 CL Montreal, CANADA SP Int Cytokine Soc, Int Soc Interferon & Cytokin Res C1 [Pott, Gregory B.; Chan, Edward D.; Shapiro, Leland] Denver Vet Affairs Med Ctr, Denver, CO USA. [Pott, Gregory B.; Chan, Edward D.; Shapiro, Leland] Natl Jewish Med & Res Ctr, Denver, CO USA. [Chan, Edward D.; Dinarello, Charles A.] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD SEP PY 2008 VL 43 IS 3 BP 310 EP 310 DI 10.1016/j.cyto.2008.07.364 PG 1 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 362QT UT WOS:000260212900330 ER PT J AU De Gasperi, R Sosa, MAG Wen, PH Li, JJ Perez, GM Curran, T Elder, GA AF De Gasperi, Rita Sosa, Miguel A. Gama Wen, Paul H. Li, Jingjun Perez, Gissel M. Curran, Tom Elder, Gregory A. TI Cortical development in the presenilin-1 null mutant mouse fails after splitting of the preplate and is not due to a failure of reelin-dependent signaling SO DEVELOPMENTAL DYNAMICS LA English DT Article DE presenilin-1; reelin; gamma-secretase; cortical lamination ID CENTRAL-NERVOUS-SYSTEM; CAJAL-RETZIUS CELLS; NEURAL PROGENITOR CELLS; APOE RECEPTOR 2; INTRACELLULAR DOMAIN; WILD-TYPE; NEOCORTICAL DEVELOPMENT; LIPOPROTEIN RECEPTORS; EXTRACELLULAR-MATRIX; DEVELOPING BRAIN AB Cortical development is disrupted in presenilin-1 null mutant, (Psen1-/-) mice. Prior studies have commented on similarities between Psen1-/- and reeler mice. Reelin induces phosphorylation of Dab1 and activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Psen1 is known to modulate PI3K/Akt signaling and both known reelin receptors (apoER2 and VLDLR) are substrates for Psen1 associated gamma-secretase activity. The purpose of this study was to determine whether reelin signaling is disrupted in Psen1-/- mice. We show that, while Dab1 is hypophosphorylated late in cortical development in Psen1-/- mice, it is normally phosphorylated at earlier ages and reelin signaling is intact in Psen1-/- primary neuronal cultures. gamma-secretase activity was also not required for reelin-induced phosphorylation of Dab1. Unlike reeler mice the preplate splits in Psen1-/- brain. Thus cortical development in Psen1-/- mice fails only after splitting of the preplate and is not due to an intrinsic failure of reelin signaling. C1 [De Gasperi, Rita; Sosa, Miguel A. Gama; Wen, Paul H.; Perez, Gissel M.; Elder, Gregory A.] Res & Dev James J Peters Dept Vet Affairs Med Ctr, Bronx, NY USA. [De Gasperi, Rita; Sosa, Miguel A. Gama; Wen, Paul H.; Li, Jingjun; Perez, Gissel M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Curran, Tom; Elder, Gregory A.] Childrens Hosp Philadelphia, Abramson Res Ctr, Philadelphia, PA 19104 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY USA. RP Elder, GA (reprint author), James J Peters VA Med Ctr, Res & Dev 3F22, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu RI Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011 OI Curran, Tom/0000-0003-1444-7551; FU National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) FX R.D.G. received a Young Investigator Award from the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 58 TC 3 Z9 3 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1058-8388 J9 DEV DYNAM JI Dev. Dyn. PD SEP PY 2008 VL 237 IS 9 BP 2405 EP 2414 DI 10.1002/dvdy.21661 PG 10 WC Anatomy & Morphology; Developmental Biology SC Anatomy & Morphology; Developmental Biology GA 349OI UT WOS:000259289800012 PM 18729224 ER PT J AU Kahn, SE Herman, WH Holman, RR Haffner, SM Zinman, B Aftring, RP Kravitz, BG Paul, G Jones, NP Lachin, JM Viberti, GF AF Kahn, S. E. Herman, W. H. Holman, R. R. Haffner, S. M. Zinman, B. Aftring, R. P. Kravitz, B. G. Paul, G. Jones, N. P. Lachin, J. M. Viberti, G. F. CA Adopt Study Grp TI Changes in bone metabolism biomarkers in the ADOPT study SO DIABETOLOGIA LA English DT Meeting Abstract C1 [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Herman, W. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Holman, R. R.] Churchill Hosp, OCDEM, Diabet Trial Unit, Oxford OX3 7LJ, England. [Haffner, S. M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Zinman, B.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Paul, G.] GlaxoSmithKline Inc, Biomed Data Serv, King Of Prussia, PA USA. [Aftring, R. P.; Kravitz, B. G.] GlaxoSmithKline Inc, Metabol Med Dev Ctr, King Of Prussia, PA USA. [Jones, N. P.] GlaxoSmithKline Inc, Harlow, Essex, England. [Lachin, J. M.] George Washington Univ, Rockville, MD USA. [Viberti, G. F.] Kings Coll London, Sch Med, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2008 VL 51 SU 1 MA 24 BP S16 EP S16 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 340QN UT WOS:000258660200024 ER PT J AU Pratley, R Reusch, J Fleck, P Wilson, C Mekki, Q AF Pratley, R. Reusch, J. Fleck, P. Wilson, C. Mekki, Q. TI Alogliptin added to pioglitazone therapy improves glycaemic control in patients with type 2 diabetes without increasing weight gain or hypoglycaemia SO DIABETOLOGIA LA English DT Meeting Abstract C1 [Pratley, R.] Univ Vermont, Burlington, VT 05405 USA. [Reusch, J.] Univ Colorado, Denver, CO 80202 USA. [Reusch, J.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Reusch, J.] Denver VAMC, Denver, CO USA. [Fleck, P.; Wilson, C.; Mekki, Q.] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2008 VL 51 SU 1 MA 860 BP S343 EP S343 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 340QN UT WOS:000258660201150 ER PT J AU El-Serag, H AF El-Serag, Hashem TI The association between obesity and GERD: A review of the epidemiological evidence SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE gastroesophageal reflux disease; obesity; body mass index; epidemiology ID GASTROESOPHAGEAL-REFLUX DISEASE; BODY-MASS INDEX; BARRETTS-ESOPHAGUS; RISK-FACTORS; GASTRIC CARDIA; ABDOMINAL OBESITY; UNITED-STATES; EROSIVE ESOPHAGITIS; HIATAL-HERNIA; US CHILDREN AB The current epidemics of obesity and gastroesophageal reflux disease (GERD)-related disorders have generated much interest in studying the association between them. Results of multiple studies indicate that obesity satisfies several criteria for a causal association with GERD and some of its complications, including a generally consistent association with GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma. An increase in GERD symptoms has been shown to occur in individuals who gain weight but continue to have a body mass index (BMI) in the normal range, contributing to the epidemiological evidence for a possible dose-response relationship between BMI and increasing GERD. Data are less clear on the relationship between Barrett's esophagus (BE) and obesity. However, when considered separately, abdominal obesity seems to explain a considerable part of the association with GERD, including BE. Overall, epidemiological data show that maintaining a normal BMI may reduce the likelihood of developing GERD and its potential complications. C1 [El-Serag, Hashem] Houston Vet Affairs Med Ctr 152, Houston, TX 77030 USA. [El-Serag, Hashem] Vet Affairs Med Ctr, Houston Dept, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, Hashem] Vet Affairs Med Ctr, Houston Dept, Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem] Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, H (reprint author), Houston Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU TAP Pharmaceuticals; AstraZeneca; Eisai; Novartis FX Dr. El-Serag has served as a consultant for TAP Pharmaceuticals, AstraZeneca, Eisai, and Novartis. NR 51 TC 89 Z9 91 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2008 VL 53 IS 9 BP 2307 EP 2312 DI 10.1007/s10620-008-0413-9 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 339UC UT WOS:000258601800004 PM 18651221 ER PT J AU Ito, K Yamaoka, Y Yoffe, B Graham, DY AF Ito, Kyoko Yamaoka, Yoshio Yoffe, Boris Graham, David Y. TI Disturbance of apoptosis and DNA synthesis by Helicobacter pylori infection of hepatocytes SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Helicobacter; apoptosis; cell proliferations; hepatocytes; internalizations ID GASTRIC EPITHELIAL-CELLS; HEPATOCELLULAR-CARCINOMA; IN-VITRO; PROLIFERATION; LIVER; HEPATITIS; PATHOGENESIS; ADHERENCE; SURVIVAL; CIRRHOSIS AB We evaluated the effects of infection of hepatocytes with the well-characterized Helicobacter species, H. pylori. Cell number doubled during each 24 h period in mock cultures or following infection with H. pylori 401C (CagA-, VacA-, BabA-, OipA-) (P < 0.05). In contrast, infection with the more virulent H. pylori NCTC11637 (CagA+, VacA+, BabA+, OipA+) resulted in cell arrest (P < 0.05). Furthermore, NCTC11637 activated caspase-3 and increased DNA fragmentation 6.1 +/- 1.2 fold (P < 0.01) and the number of apoptotic bodies 9.4 +/- 3.5 fold (P < 0.01) compared to controls. The effect was greater than with the less virulent strain 401C (3.8 +/- 0.6 fold and 3.9 +/- 1.7, respectively, P < 0.05). Strain NCTC11637 at low concentrations increased cellular DNA synthesis 139 +/- 6% (P < 0.05) but decreased it to 16 +/- 7% (P < 0.01) at high concentrations. In contrast, strain 401C increased DNA synthesis 155 +/- 14% of controls (P < 0.05) at high concentrations. The presence of intracellular NCTC11637 within hepatocytes increased DNA fragmentation 3.0 +/- 0.4 fold (P < 0.01) greater than in controls. H. pylori infection resulted in strain-species-dependent effects on hepatocytes, and virulent strain caused cell arrest and apoptosis of infected hepatocytes. C1 [Ito, Kyoko; Yamaoka, Yoshio; Yoffe, Boris; Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, GI Sect, Dept Med, Houston, TX 77030 USA. [Ito, Kyoko] Jikei Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Tokyo, Japan. RP Graham, DY (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, GI Sect, Dept Med, 2002 Holcombe Blvd 3A-320, Houston, TX 77030 USA. EM dgraham@bcm.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Texas Gulf Coast Digestive Diseases Center [DK56338]; NIH [DK 62813]; American College of Gastroenterology FX We are grateful to Dr. Andre Dubois and Dr. Cristina Semino- Mora for insightful discussions as assistance. We also thank Mr. Giovanni Suarez for performing the quantitative apoptosis ELISA assays and Dr. Reyes for his excellent advice. This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338 which funds the Texas Gulf Coast Digestive Diseases Center. Dr. Yoshio Yamaoka is supported in part by NIH grant DK 62813. Dr. Kyoko Ito was supported in part by an International GI Training Grant from the American College of Gastroenterology. NR 38 TC 9 Z9 10 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2008 VL 53 IS 9 BP 2532 EP 2540 DI 10.1007/s10620-007-0163-0 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 339UC UT WOS:000258601800033 PM 18253829 ER PT J AU Rosengren, DB Hartzler, B Baer, JS Wells, EA Dunn, CW AF Rosengren, David B. Hartzler, Bryan Baer, John S. Wells, Elizabeth A. Dunn, Christopher W. TI The video assessment of simulated encounters-revised (VASE-R): Reliability and validity of a revised measure of motivational interviewing skills SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE motivational interviewing; training evaluation; skill assessment; evaluation instruments ID CLINICAL-SIGNIFICANCE; VALIDATION AB The video assessment of simulated encounters-revised (VASE-R) is a video-based method. administered in individual or group settings, for assessing motivational interviewing (MI) skills. The 18-item instrument includes three video-based vignettes. in which actors portray substance abusers, with each vignette followed by questions that prompt examinees to write responses that are then scored against MI standards. The VASE-R was administered to two independent samples: (1) substance abuse practitioners participating in a study of MI training methods, and (2) MI training facilitators with a high level of MI skill and expertise. This multi-study report describes basic VASE-R psychometric properties - including scoring reliability, internal consistency, concurrent validity, and sensitivity to the effects of training - and then presents proficiency standards based oil administration to a sample of MI training facilitators (MI Experts). The findings indicate excellent inter-rater reliability using intra-class correlations for the full-scale score (.85) and acceptable levels for subscales (.44 to .73). The instrument displayed strong concurrent validity with the Helpful Responses Questionnaire (HRQ) and a behavioral sample of clinician behavior with a standardized patient scored using the MI Treatment Integrity (MITI) system. as well as good sensitivity to improvement in MI skill as a result of training. The findings provide an empirical basis for suggesting VASE-R benchmarks for beginning proficiency and expert MI practice. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Rosengren, David B.; Hartzler, Bryan; Baer, John S.; Wells, Elizabeth A.; Dunn, Christopher W.] Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98108 USA. [Baer, John S.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Wells, Elizabeth A.] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. [Dunn, Christopher W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Rosengren, DB (reprint author), Univ Washington, Inst Alcohol & Drug Abuse, 1107 NE 45th St,Suit 120, Seattle, WA 98195 USA. EM dhr@u.washington.edu FU NIDA NIH HHS [L30 DA020240-01, L30 DA020240, R01 DA 016360, R01 DA016360, R01 DA016360-03] NR 19 TC 20 Z9 20 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 1 PY 2008 VL 97 IS 1-2 BP 130 EP 138 DI 10.1016/j.drugalcdep.2008.03.018 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 335RQ UT WOS:000258308100013 PM 18499356 ER PT J AU Artifon, ELA da Silveira, EB Lopes, RI Kumar, A Bhutani, MS Mesquita, JL Souza, T Dall'oglio, M Lucon, AM Couto, D Sakai, P Srougi, M AF Artifon, E. L. A. da Silveira, E. B. Lopes, R. I. Kumar, A. Bhutani, M. S. Mesquita, J. L. Souza, T. Dall'oglio, M. Lucon, A. M. Couto, D. Sakai, P. Srougi, M. TI Endoscopic ultrasound-guided ureterosigmoidostomy in malignant ureteral obstruction: description of a new method SO ENDOSCOPY LA English DT Editorial Material ID DIVERSION; QUALITY; STENTS; LIFE C1 [da Silveira, E. B.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Gastroenterol, Div Gastroenterol, Portland, OR 97239 USA. [Artifon, E. L. A.; Kumar, A.; Souza, T.; Couto, D.; Sakai, P.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil. [Lopes, R. I.; Mesquita, J. L.; Dall'oglio, M.; Lucon, A. M.; Srougi, M.] Univ Sao Paulo, Sch Med, Dept Urol, Sao Paulo, Brazil. [Bhutani, M. S.] Univ Texas MD Anderson Canc Ctr, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. RP da Silveira, EB (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Gastroenterol, Div Gastroenterol, 3710 SW US Vet Hosp,Blvd MC,P3GI, Portland, OR 97239 USA. EM eda_silveira@hotmail.com OI Dall'Oglio, Marcos Francisco/0000-0002-9611-6846; Lopes, Roberto/0000-0002-6636-7679 NR 6 TC 0 Z9 0 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD SEP PY 2008 VL 40 IS 9 BP 769 EP 772 DI 10.1055/s-2008-1077447 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 351EX UT WOS:000259408400012 PM 18668473 ER PT J AU Dorian, P Singh, BN AF Dorian, Paul Singh, Brarnah N. TI Upstream therapies to prevent atrial fibrillation SO EUROPEAN HEART JOURNAL SUPPLEMENTS LA English DT Review DE atrial fibrillation; upstream therapy; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; statins; steroids; N-3 polyunsaturated fatty acids; fish oil ID C-REACTIVE PROTEIN; CONVERTING ENZYME-INHIBITORS; N-3 FATTY-ACIDS; LEFT-VENTRICULAR DYSFUNCTION; II RECEPTOR BLOCKERS; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; CARDIAC-SURGERY; RANDOMIZED-TRIAL; ELECTRICAL CARDIOVERSION AB Atrial fibrillation (AF) is the most common sustained arrhythmia in the western world. It is associated with increased morbidity and mortality and decreased quality of life. The absence of a clear benefit of a rhythm-control strategy over a rate-control strategy observed in recent trials may be due to the fact that none of the available membrane-acting antiarrhythmics is entirely satisfactory. In addition, ablative therapy is available only for a small number of patients. Besides research efforts to improve the efficacy and safety of conventional antiarrhythmic agents, therapies directed 'upstream' of the electrical aspects of AF, towards the underlying anatomical substrate (atrial. remodelling), have emerged as potential new pharmacological therapies. Potential upstream therapies for AF comprise a variety of agents such as those targeting the renin-angiotensin system [angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB)], statins, steroids, and N-3 polyunsaturated fatty acids. On the basis of suggestive experimental data, early phase clinical studies have been conducted and have provided exciting information on the potential of upstream therapy for the prevention of AF across a broad spectrum of cardiovascular patient groups. In some of these groups, such as patients with hypertension or heart failure, data may be considered to be sufficient to support the use of ACEI or ARB, at least in combination with membrane-acting antiarrhythmics. However, in most clinical settings examined, the evidence appears to be insufficient to drive changes in therapy management, and additional data from large-scale, randomized, double-blind, placebo-controlled trials with adequately defined endpoints are still needed. Numerous such trials are ongoing, reflecting the intense scientific interest in this field. The data derived from these trials may add to our understanding of the complex mechanisms that lead to AF and its maintenance, and may provide the necessary substantive evidence clarifying the benefit-to-risk ratio of these new therapeutic approaches. C1 [Singh, Brarnah N.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dorian, Paul] Univ Toronto, Div Cardiol, Toronto, ON, Canada. [Dorian, Paul] Univ Toronto, Div Clin Pharmacol, Toronto, ON, Canada. [Singh, Brarnah N.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Singh, BN (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. EM Bramah.Singh@va.gov FU sanofiaventis FX Funding for editorial support was provided by sanofiaventis. NR 104 TC 17 Z9 17 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1520-765X J9 EUR HEART J SUPPL JI Eur. Heart J. Suppl. PD SEP PY 2008 VL 10 IS H BP H11 EP H31 DI 10.1093/eurheartj/sun033 PG 21 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 356LX UT WOS:000259780800003 ER PT J AU Singh, BN AF Singh, Bramah N. TI Recent advances in the management of atrial fibrillation SO EUROPEAN HEART JOURNAL SUPPLEMENTS LA English DT Editorial Material C1 [Singh, Bramah N.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Singh, Bramah N.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Singh, BN (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM bramah.singh@va.gov NR 0 TC 1 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1520-765X J9 EUR HEART J SUPPL JI Eur. Heart J. Suppl. PD SEP PY 2008 VL 10 IS H BP H2 EP H3 DI 10.1093/eurheartj/sun032 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 356LX UT WOS:000259780800001 ER PT J AU Leung, FW Schnelle, JF AF Leung, Felix W. Schnelle, John F. TI Urinary and fecal incontinence in nursing home residents SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article DE fecal incontinence; constipation; urinary incontinence ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; RISK-FACTORS; ELDERLY-PATIENTS; INTERVENTION; MANAGEMENT; CONSTIPATION; QUALITY; CONTINENCE; EXERCISE AB Urinary and fecal incontinence are comorbid conditions affecting over 50% of nursing home residents. Management should focus on identifying and treating underlying causes. Despite appropriate management, residents may remain incontinent because of dementia and health- or restraint-related immobility. This article reviews the results of studies that have documented how prompted voiding programs can significantly reduce urinary and fecal incontinence, particularly if the intervention includes dietary and exercise components. Documentation of noninvasive and efficacious interventions by randomized, controlled trials and the labor costs of implementing these measures can lead to changes in how nursing home care is provided and funded. C1 [Schnelle, John F.] Vanderbilt Univ, Med Ctr, Dept Med, Ctr Qual Aging, Nashville, TN 37232 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA. RP Schnelle, JF (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Ctr Qual Aging, 1161 21st Ave S,S-1121 Med Ctr N, Nashville, TN 37232 USA. EM john.schnelle@vanderbilt.edu FU VA Clinical Merit Research Funds (FWL) and National Institutes of Health [1R02 AG 23,555-01A1] FX Supported in part by VA Clinical Merit Research Funds (FWL) and National Institutes of Health grant 1R02 AG 23,555-01A1 "Interventions to Improve Fecal Incontinence" (JFS). NR 59 TC 18 Z9 21 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 EI 1558-1942 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD SEP PY 2008 VL 37 IS 3 BP 697 EP + DI 10.1016/j.gtc.2008.06.005 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 357OH UT WOS:000259855500013 PM 18794004 ER PT J AU Singal, AK AF Singal, Ashwani K. TI Silent Cirrhosis in Hepatitis B Virus Related Hepatocellular Carcinoma SO HEPATO-GASTROENTEROLOGY LA English DT Article DE Hepatitis B; Helpatocellular carcinoma; Silent cirrhosis; Liver cirrhosis; Person-years follow up ID SAUDI-ARABIA; INFECTION; PROGRESS; RISK AB Background/Aims: Prevalence of hepatitis B virus (HBV) related cirrhosis and hepatocellular carcinoma (HCC) is high in Saudi Arabia. However, thee relationship between these two presentations is not well studied. Methodology: Medical charts of 170 Saudi HBV patients (70 with HCC and 100 with cirrhosis without HCC) were reviewed. Results: Patients with HCC at presentation were older compared to those with cirrhosis without H CC at presentation (60.9 y vs. 51.2 y; p < 0.05). Right tipper quadrant pain (p < 0.001) and hepatic bruit (p < 0.0001) independently predicted the presence of HCC. Cirrhosis, present, in 76% of HCC patients, remained silent and only 4% (3 of 73) of all HCC cases had clinical manifest cirrhosis. Cirrhotics without HCC at presentation developed HCC at the rate of 0.67% per 100 person years follow up. Conclusions: Liver cirrhosis and HCC are distinct presentations of HBV in Saudi Arabia. Majority of patients with HCC at, presentation have silent cirrhosis. Rate of development of HCC in patients with HBV related cirrhosis is low. C1 [Singal, Ashwani K.] King Fahd Cent Hosp, Dept Med, Div Gastroenterol, Gizan, Saudi Arabia. RP Singal, AK (reprint author), James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ashwanisingal.com@gmail.com NR 25 TC 1 Z9 2 U1 0 U2 1 PU H G E UPDATE MEDICAL PUBLISHING S A PI ATHENS PA PO BOX 17257, ATHENS GR-10024, GREECE SN 0172-6390 J9 HEPATO-GASTROENTEROL JI Hepato-Gastroenterol. PD SEP-OCT PY 2008 VL 55 IS 86-87 BP 1734 EP 1737 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 371YK UT WOS:000260868400051 PM 19102380 ER PT J AU Kiefer, SM Robbins, L Barina, A Zhang, ZH Rauchman, M AF Kiefer, Susan M. Robbins, Lynn Barina, Andrew Zhang, Zhihong Rauchman, Michael TI SALL1 truncated protein expression in Townes-Brocks syndrome leads to ectopic expression of downstream genes SO HUMAN MUTATION LA English DT Article DE Sall1; spalt; Townes-Brocks; Shox2; Nppa; derepression ID MESSENGER-RNA DECAY; NONSENSE-MEDIATED DECAY; TRANSCRIPTIONAL REPRESSOR; KIDNEY DEVELOPMENT; MURINE HOMOLOG; MOUSE LIMB; COMPLEX; MUTATIONS; HAPLOINSUFFICIENCY; PROLIFERATION AB Mutations in SALL1 lead to the dominant multiorgan congenital anomalies that define Townes-Brocks syndrome (TBS). The majority of these mutations result in premature termination codons that would be predicted to trigger nonsense-mediated decay (NMD) of mutant mRNA and cause haploinsufficiency. Our previous studies using a gene targeted mouse model (Sall1-Delta Zn) suggested that TBS phenotypes are due to expression of a truncated mutant protein, not haploinsufficiency. In this report, we strengthen this hypothesis by showing that expression of the mutant protein alone in transgenic mice is sufficient to cause limb phenotypes that are characteristic of TBS patients. We prove that the same pathogenetic mechanism elucidated in mice is occur-ring in humans by demonstrating that truncated SALL1 protein is expressed in cells derived from a TBS patient. TBS mutant protein is capable of dominant negative activity that results in ectopic activation of two downstream genes, Nppa and Shox2, in the developing heart and limb. We propose a model for the pathogenesis of TBS in which truncated Sall1 protein causes derepression of Sall-responsive target genes. C1 [Kiefer, Susan M.; Robbins, Lynn; Rauchman, Michael] US Dept Vet Affairs, Res & Educ Serv Line, St Louis VA Med Ctr, St Louis, MO 63106 USA. [Kiefer, Susan M.; Robbins, Lynn; Barina, Andrew; Zhang, Zhihong; Rauchman, Michael] St Louis Univ, Hlth Sci Ctr, Dept Internal Med, St Louis, MO 63103 USA. RP Rauchman, M (reprint author), US Dept Vet Affairs, Res & Educ Serv Line, St Louis VA Med Ctr, 915 N Grand Blvd,657-111B JC, St Louis, MO 63106 USA. EM Rauchman@slu.edu FU Veterans Administration Merit Award; VISN (Veterns Integrated Service Network); American Society of Nephrology Gottschalk Award; NIH FX We thank Juergen Kohlhase and Dan Hoft for the generous gifts of TBS and normal patient B-cell lines. Yiping Chen kindly provided the Hoxb6 promoter. Heart phenotypes were analyzed with the invaluable help of Jun Takeuchi (Tokyo). James Kiefer, Shannon Lauberth, and Sandy McLeskey gave valuable constructive comments on the data and manuscript and Amy Bilyeu and Emily Royse provided excellent technical assistance with genotyping. We thank BMJ Publishing group and Elsevier Limited for permission to reprint TBS patient figures. This work funded by a Veterans Administration Merit Award (to M.R.), a VISN (Veterns Integrated Service Network) 15 VA Award (to S.K.), an American Society of Nephrology Gottschalk Award (to S.K.), and an NIH grant (to M.R). NR 34 TC 15 Z9 16 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PD SEP PY 2008 VL 29 IS 9 BP 1133 EP 1140 DI 10.1002/humu.20759 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 349KZ UT WOS:000259281000008 PM 18470945 ER PT J AU Cornia, PB Lipsky, BA AF Cornia, Paul B. Lipsky, Benjamin A. TI Indwelling urinary catheters in hospitalized patients: When in doubt, pull it out SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID TRACT-INFECTION; UNITED-STATES; CARE; PHYSICIANS; BACTERIURIA; DURATION C1 [Cornia, Paul B.; Lipsky, Benjamin A.] Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Serv, Seattle, WA 98108 USA. [Cornia, Paul B.; Lipsky, Benjamin A.] Univ Washington, Sch Med, Seattle, WA USA. RP Cornia, PB (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 28 TC 3 Z9 3 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2008 VL 29 IS 9 BP 820 EP 822 DI 10.1086/590535 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 348MG UT WOS:000259214000003 PM 18700832 ER PT J AU Aslam, S Trautner, BW Ramanathan, V Darouiche, RO AF Aslam, Saima Trautner, Barbara W. Ramanathan, Venkat Darouiche, Rabih O. TI Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT, 2007 CL San Diego, CA SP Infect Dis Soc Amer ID ANTIBIOTIC LOCK; INFECTIONS AB We evaluated a catheter-lock solution consisting of N-acetylcysteine, tigecycline, and heparin for catheter salvage in patients with hemodialysis catheter-associated bacteremia. Eighteen case patients received the catheter-lock solution for 14 days plus systemic antibiotic therapy. Treatment was successful for 15 (83%) of the 18 case patients within 90 days of follow-up, with a median catheter retention interval of 64.5 days. C1 [Aslam, Saima] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Aslam, Saima; Trautner, Barbara W.; Darouiche, Rabih O.] Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA. [Ramanathan, Venkat] Baylor Coll Med, Nephrol Sect, Dept Med, Houston, TX 77030 USA. [Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. RP Aslam, S (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd,Room 4B-370, Houston, TX 77030 USA. EM saslam@bcm.tmc.edu FU NICHD NIH HHS [HD43943-01A1, HD024014]; NIDDK NIH HHS [DK077313] NR 10 TC 16 Z9 16 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2008 VL 29 IS 9 BP 894 EP 897 DI 10.1086/590192 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 348MG UT WOS:000259214000017 PM 18643743 ER PT J AU Hsiao, AF Wong, MD Miller, MF Ambs, AH Goldstein, MS Smith, A Ballard-Barbash, R Becerra, LS Cheng, EM Wenger, NS AF Hsiao, An-Fu Wong, Mitchell D. Miller, Melissa F. Ambs, Anita H. Goldstein, Michael S. Smith, Ashley Ballard-Barbash, Rachel Becerra, Lida S. Cheng, Eric M. Wenger, Neil S. TI Role of religiosity and spirituality in complementary and alternative medicine use among cancer survivors in California SO INTEGRATIVE CANCER THERAPIES LA English DT Article DE CAM; integrative medicine; spirituality; religiosity; survivors ID HEALTH-CARE; ETHNIC-DIFFERENCES; ONCOLOGY; PREVALENCE; ADULTS AB Objectives. Cancer survivors often turn to religion, spirituality, and complementary and alternative medicine (CAM) because they perceive these areas as being more holistic and patient-centered than conventional medicine. Because increased religiosity and spirituality have been found to be associated with higher CAM use in the general population, it was hypothesized that these factors would be important predictors of CAM use in cancer survivors. Design and Subjects. The study included a subsample of 1844 people with cancer or a history of cancer from the 2003 California Health Interview Survey of CAM, a cross-sectional survey of a population-based sample of adults in California. Prevalence and predictors of religious/spiritual forms of CAM (R/S CAM) and nonreligious/nonspiritual forms of CAM (non-R/S CAM) were compared. Multivariate logistic regression was used to identify the predictors of R/S CAM and non-R/S CAM. Results. Nearly two thirds of participants reported using at least 1 type of R/S CAM, and 85% reported ever using non-R/S CAM. The majority of cancer survivors reported that they were very/moderately religious or spiritual. Both religiosity and spirituality were strongly related to non-R/S CAM use, but in opposite directions. Very or moderately religious cancer survivors were less likely (odds ratio = 0.30; 95% confidence interval, 0.12-0.40) than nonreligious cancer survivors to use non-R/S CAM. In contrast, very or moderately spiritual cancer survivors were more likely (odds ratio = 2.42; 95% confidence interval, 1.16-6.02) than nonspiritual cancer survivors to use non-R/S CAM. Conclusions. The use of R/S CAM and non-R/S CAM is very high in cancer survivors. It may be helpful for clinicians to ascertain their patients' use of these types of CAM to integrate all forms of care used to managing their cancer. C1 [Hsiao, An-Fu] VA Long Beach Healthcare Syst, Long Beach, CA 90822 USA. [Hsiao, An-Fu] Univ Calif Irvine, Ctr Hlth Policy Res, Irvine, CA USA. [Wong, Mitchell D.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA USA. [Wong, Mitchell D.; Wenger, Neil S.] Univ Calif Los Angeles, Hlth Serv Res, Los Angeles, CA USA. [Miller, Melissa F.; Ambs, Anita H.; Smith, Ashley; Ballard-Barbash, Rachel] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Goldstein, Michael S.] Univ Calif Los Angeles, Dept Community Hlth Sci, Los Angeles, CA USA. [Becerra, Lida S.] Univ Calif Los Angeles, Ctr Hlth Policy & Res, Los Angeles, CA USA. [Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. [Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Hsiao, AF (reprint author), VA Long Beach Healthcare Syst, 5901 E 7th St,Mail Code 11-111, Long Beach, CA 90822 USA. EM anfu.hsiao@va.gov OI Wong, Mitchell/0000-0002-4800-8410 FU National Institutes of Health (NIH); National Center of Complementary and Alternative Medicine [R21 AT002248-01]; NCCAM [R21-AT002248-01]; National Cancer institute (NCI) [NO2-PC-95057] FX We thank Victor Gonzalez for his technical assistance. We thank UCLA Center for Health Policy Research for their assistance in carrying out the research. FUNDING/GRANT INFORMATION: Dr. Hsiao was supported by National Institutes of Health (NIH), National Center of Complementary and Alternative Medicine (R21 AT002248-01). This publication was made possible by Grant No. R21-AT002248-01 from NCCAM. The collection of data used in this study was supported by the National Cancer institute (NCI) under contract NO2-PC-95057 awarded to the UCLA Center for Health Policy Research. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, NCI, or the NIH. NR 36 TC 20 Z9 21 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-7354 J9 INTEGR CANCER THER JI Integr. Cancer Ther. PD SEP PY 2008 VL 7 IS 3 BP 139 EP 146 DI 10.1177/1534735408322847 PG 8 WC Oncology; Integrative & Complementary Medicine SC Oncology; Integrative & Complementary Medicine GA 351PQ UT WOS:000259436800004 PM 18815145 ER PT J AU Darouiche, RO AF Darouiche, R. O. TI Prevention of infections associated with vascular catheters SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS LA English DT Article DE Prevention; Catheter infection; Catheter colonization; Anti-infective approach ID CENTRAL VENOUS CATHETERS; BLOOD-STREAM INFECTION; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; DOUBLE-BLIND TRIAL; PROSPECTIVE RANDOMIZED-TRIAL; SILVER-SULFADIAZINE; ANTIMICROBIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; CLINICAL-TRIAL AB The expanding use of vascular catheters has increased the need to prevent hazardous infectious complications. Since bloodstream infection is the most common serious complication of indwelling vascular catheters, the proof that a potentially preventive approach is truly protective against clinical infection requires a significant reduction in the incidence of this infectious complication. Although catheter colonization is a prelude to infection, most colonized catheters do not result in catheter-related infection and, therefore, a mere reduction in catheter colonization does not, in and by itself, confirm protection against clinical infection. Adherence to optimal infection control guidelines is the primary measure for preventing infection, but in most instances the level of adherence to guidelines drops subsequent to the initial surge that follows the institutional adoption of educational programs. This explains the need to assess the potential clinical protection afforded by anti-infective technologies. In addition to improving patient care, a clinically protective anti-infective approach can also bring tremendous cost savings, (Int J Artif Organs 2008; 31: 810-19) C1 [Darouiche, R. O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. [Darouiche, R. O.] Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 68 TC 4 Z9 5 U1 1 U2 1 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0391-3988 J9 INT J ARTIF ORGANS JI Int. J. Artif. Organs PD SEP PY 2008 VL 31 IS 9 BP 810 EP 819 PG 10 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 405SQ UT WOS:000263244900009 PM 18924093 ER PT J AU Arabi, Y Al-Shirawi, N Memish, Z Anzueto, A AF Arabi, Yaseen Al-Shirawi, Nehad Memish, Ziad Anzueto, Antonio TI Ventilator-associated pneumonia in adults in developing countries: a systematic review SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE ventilator-associated pneumonia; developing countries; intensive care; mechanical ventilation; complication; nosocomial infection; prevention ID INTENSIVE-CARE UNITS; INFECTION-CONTROL CONSORTIUM; NOSOCOMIAL INFECTIONS; RISK-FACTORS; MECHANICAL VENTILATION; RATES; MORTALITY; SURVEILLANCE; HOSPITALS; MICROBIOLOGY AB Background: Ventilator-associated pneumonia (VAP) is a leading cause of death in hospitalized patients, but there has been no systematic analysis of the incidence, microbiology, and outcome of VAP in developing countries or of the interventions most applicable in that setting. Methods: We reviewed MEDLINE (January 1966-April 2007) and bibliographies of the retrieved articles for all observational or interventional studies that examined the incidence, microbiology, outcome, and prevention of VAP in ventilated adults in developing countries. We evaluated the rates of VAP using the National Healthcare Safety Network (NHSN) definitions and the impact of VAP on the intensive care unit (ICU) length of stay (LOS) and mortality, and the impact of interventions used to reduce VAP rates. Results: The rates of VAP varied from 10 to 41.7 per 1000 ventilator-days and were generally higher than NHSN benchmark rates. Gram-negative bacilli were the most common pathogens (41-92%), followed-by Gram-positive cocci (6-58%). VAP was associated with a crude mortality that ranged from 16% to 94% and with increased ICU LOS. Only a small number of VAP intervention studies were performed; these found that staff education programs, implementation of hand hygiene, and VAP prevention practice guidelines, and/or implementation of sedation protocol were associated with a significant reduction in VAP rates. Only one interventional study was a randomized controlled trial comparing two technologies, the rest were sequential observational. This study compared a heat and moisture exchanger (HME) to a heated humidifying system (HHS) and found no difference in VAP rates. Conclusions: Based on the existing literature, the rate of VAP in developing countries is higher than NHSN benchmark rates and is associated with a significant impact on patient outcome. Only a few studies reported successful interventions to reduce VAP There is a clear need for additional epidemiologic studies to better understand the scope of the problem. Additionally, more work needs to be done on strategies to prevent VAP, probably with emphasis on practical, Low-cost, low technology, easily implemented measures. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. C1 [Arabi, Yaseen; Al-Shirawi, Nehad] King Abdul Aziz Med City, Dept Intens Care, Riyadh 11426, Saudi Arabia. [Memish, Ziad] King Abdul Aziz Med City, Infect Prevent & Control Program, Riyadh 11426, Saudi Arabia. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis Crit Care Med, Dept Med, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. RP Arabi, Y (reprint author), King Abdul Aziz Med City, Dept Intens Care, ICU 1425,POB 22490, Riyadh 11426, Saudi Arabia. EM arabi@ngha.med.sa NR 58 TC 49 Z9 63 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD SEP PY 2008 VL 12 IS 5 BP 505 EP 512 DI 10.1016/j.ijid.2008.02.010 PG 8 WC Infectious Diseases SC Infectious Diseases GA 357LE UT WOS:000259846500013 PM 18502674 ER PT J AU Eisenstein, EM Eisenstein, DL Sarma, JSM AF Eisenstein, E. M. Eisenstein, D. L. Sarma, J. S. M. TI Does the behavioral homeostasis theory of habituation and sensitization apply to Pavlovian conditioning? SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 14th World Congress of Psychophysiology the Olympics of the Brain CY SEP 08-13, 2008 CL St Petersburg, RUSSIA SP Int Org Psychophysiol C1 [Eisenstein, E. M.; Eisenstein, D. L.; Sarma, J. S. M.] VA Greater Los Angeles Healthcare Syst, Res & Dev 691 151, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD SEP PY 2008 VL 69 IS 3 BP 166 EP 167 DI 10.1016/j.ijpsycho.2008.05.429 PG 2 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 336VU UT WOS:000258393700101 ER PT J AU Mathalon, DH Calhoun, VD Kiehl, KA Pearlson, GD Mcglashan, TH Woods, SW AF Mathalon, D. H. Calhoun, V. D. Kiehl, K. A. Pearlson, G. D. Mcglashan, T. H. Woods, S. W. TI Abnormal sensory registration, deviance detection, and attention allocation in the schizophrenia prodrome SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 14th World Congress of Psychophysiology the Olympics of the Brain CY SEP 08-13, 2008 CL St Petersburg, RUSSIA SP Int Org Psychophysiol C1 [Mathalon, D. H.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Calhoun, V. D.; Kiehl, K. A.] Univ New Mexico, Albuquerque, NM 87131 USA. [Pearlson, G. D.] Yale Univ, Hartford Hosp, Inst Living, New Haven, CT 06520 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD SEP PY 2008 VL 69 IS 3 BP 186 EP 187 DI 10.1016/j.ijpsycho.2008.05.497 PG 2 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 336VU UT WOS:000258393700169 ER PT J AU Knapp, H Anaya, HD Feld, JE AF Knapp, Herschel Anaya, Henry D. Feld, Jamie E. TI Expanding HIV rapid testing via point-of-care paraprofessionals SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; screening; health personnel; education; community outreach AB HIV counselling and testing has traditionally been performed by highly trained professionals in clinical settings. With HIV rapid testing, a reliable and easy to use diagnostic tool, paraprofessionals can be trained to administer on-site HIV testing in a variety of non-traditional settings, broadening the HIV detection rates. Our objective was to create a robust and sustainable paraprofessional training module to facilitate off-site HIV rapid testing in non-clinical settings. Trainees attended a series of training sessions involving HIV education, rapid test instructions and communication techniques. After these sessions, trainees competently carried out HIV rapid testing in homeless shelters throughout the Los Angeles county. Agencies motivated to expand HIV screening programmes may use trained paraprofessionals to administer a full range of services (recruitment, pretest counselling, test administration, interpretation of results, post-test counselling and documentation) through this training model and enabling more highly trained healthcare providers to focus efforts on patients identified as HIV-positive. C1 Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev HRS&D, Ctr Study Healthcare Provider Behav, Ctr Excellence, Los Angeles, CA USA. RP Knapp, H (reprint author), 11301 Wilshire Blvd,111G,Bldg 500,Off 4681, Los Angeles, CA 90073 USA. EM Herschel.Knapp@va.gov FU US Department of Veteran's Affairs [RRP: 06-129] FX The authors wish to thank Rini Rajan and Mark Frank for their assistance with the project from which this work derived. This project was funded through a US Department of Veteran's Affairs grant (Implementing an HIV Rapid Testing Pilot Project among Homeless Veterans: RRP: 06-129) awarded to the second author. The OraQuick (R) Advance (TM) Rapid Tests used in this project were donated by OraSure Technologies, Inc. All views are expressly those of the authors and do not necessarily reflect those of the US government or of OraSure Technologies. NR 12 TC 4 Z9 4 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD SEP PY 2008 VL 19 IS 9 BP 629 EP 632 DI 10.1258/ijsa.2008.008027 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 350SZ UT WOS:000259374700012 PM 18725556 ER PT J AU Oh, JW Feldman, MD Kim, J Sanghi, P Do, D Mancuso, JJ Kemp, N Cilingiroglu, M Milner, TE AF Oh, Junghwan Feldman, Marc D. Kim, Jihoon Sanghi, Pramod Do, Dat Mancuso, J. Jacob Kemp, Nate Cilingiroglu, Mehmet Milner, Thomas E. TI Detection of macrophages in atherosclerotic tissue using magnetic nanoparticles and differential phase optical coherence tomography SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE differential phase optical coherence tomography; macrophages; iron oxide nanoparticles; atherosclerosis; inflammation; vulnerable plaque; MIONs ID IN-VIVO; INTRAVASCULAR ULTRASOUND; VULNERABLE PLAQUE; IRON-OXIDE; MICROSCOPY; CONTRAST; REFLECTOMETRY; DISEASE AB We demonstrate the detection of iron oxide nanoparticles taken up by macrophages in atherosclerotic plaque with differential phase optical coherence tomography (DP-OCT). Magneto mechanical detection of nanoparticles is demonstrated in hyperlipidemic Watanabe and balloon-injured fat-fed New Zealand white rabbits injected with monocrystalline iron oxide nanoparticles (MIONs) of <40 nm diam. MIONs taken up by macrophages was excited by an oscillating magnetic flux density and resulting nanometer tissue surface displacement was detected by DP-OCT. Frequency response of tissue surface displacement in response to an externally applied magnetic flux density was twice the stimulus frequency as expected from the equations of motion for the nanoparticle cluster. (C) 2008 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.2985762] C1 [Oh, Junghwan; Feldman, Marc D.; Kim, Jihoon; Kemp, Nate; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Oh, Junghwan] Pukyong Natl Univ, Dept Mech Engn, Pusan 608739, South Korea. [Feldman, Marc D.; Sanghi, Pramod; Do, Dat; Mancuso, J. Jacob; Cilingiroglu, Mehmet] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Feldman, MD (reprint author), Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. EM feldmanm@uthscsa.edu FU Veterans Administration FX This work was supported by a Veterans Administration Merit Grant to Dr. Marc D. Feldman. NR 36 TC 13 Z9 13 U1 0 U2 5 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD SEP-OCT PY 2008 VL 13 IS 5 AR 054006 DI 10.1117/1.2985762 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 384SQ UT WOS:000261764900015 PM 19021386 ER PT J AU Bischoff, DS Makhijani, NS Yamaguchi, DT AF Bischoff, D. S. Makhijani, N. S. Yamaguchi, D. T. TI Transient Expression of CXC Receptor 2 in Human Mesenchymal Stem Cells Stimulates Chemotaxis Toward CXC Ligand 8 and increased Mineralization in the Presence of Osteogenic Medium SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Bischoff, D. S.; Makhijani, N. S.; Yamaguchi, D. T.] VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S167 EP S167 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000598 ER PT J AU Cackowski, FC Choksi, RJ Windle, JJ Roodman, D AF Cackowski, F. C. Choksi, R. J. Windle, J. J. Roodman, D. TI Angiogenic Potential of Osteoclasts SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Cackowski, F. C.; Choksi, R. J.; Roodman, D.] Univ Pittsburgh, Pittsburgh, PA USA. [Windle, J. J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S261 EP S261 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411001342 ER PT J AU Grbic, J Black, D Lyles, K Reid, D Bucci-Rechtweg, C Mesenbrink, P Orwoll, E Eriksen, E AF Grbic, J. Black, D. Lyles, K. Reid, D. Bucci-Rechtweg, C. Mesenbrink, P. Orwoll, E. Eriksen, E. TI Osteonecrosis of the Jaw: Zoledronic Acid 5 mg Experience in a Variety of Osteoporosis Indications SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Grbic, J.] Columbia Univ, Coll Dent Med, New York, NY USA. [Black, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lyles, K.] VA Med Ctr, Durham, NC USA. [Reid, D.] Univ Aberdeen, Aberdeen, Scotland. [Bucci-Rechtweg, C.; Mesenbrink, P.] Novartis Pharmaceut, New Jersey, NJ USA. [Orwoll, E.] Portland VA Med Ctr, Portland, OR USA. [Eriksen, E.] Novartis Pharma AG, Basel, Switzerland. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S69 EP S69 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000247 ER PT J AU Hiruma, Y Kurihara, N Zhou, H Subler, MA Dempster, DW Windle, JJ Roodman, GD AF Hiruma, Y. Kurihara, N. Zhou, H. Subler, M. A. Dempster, D. W. Windle, J. J. Roodman, G. D. TI Co-Expression of p62(P392L) and MVNP in Osteoclasts (OCL) precursors Increases the Formation of OCL that Express a Pagetic phenotype SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Hiruma, Y.; Kurihara, N.; Roodman, G. D.] Univ Pittsburgh, Pittsburgh, PA USA. [Zhou, H.; Dempster, D. W.] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA. [Subler, M. A.; Windle, J. J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, G. D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S127 EP S127 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000456 ER PT J AU Hiruma, Y Kurihara, N Zhou, H Subler, MA Dempster, DW Windle, JJ Roodman, GD AF Hiruma, Y. Kurihara, N. Zhou, H. Subler, M. A. Dempster, D. W. Windle, J. J. Roodman, G. D. TI High Levels of IL-6 and Hyper-responsivity to 1,25-(OH)(2) D-3 Are Both Required for Development of Pagetic Osteoclasts (PD-OCL) SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Hiruma, Y.; Kurihara, N.; Roodman, G. D.] Univ Pittsburgh, Pittsburgh, PA USA. [Zhou, H.; Dempster, D. W.] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA. [Subler, M. A.; Windle, J. J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, G. D.] VA Pittsburgh Healthcare System, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S128 EP S128 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000457 ER PT J AU Hiruma, Y Ishizuka, S Roodman, GD Kurihara, N AF Hiruma, Y. Ishizuka, S. Roodman, G. D. Kurihara, N. TI The Rapid-Nontransriptional Action of 1,25-(OH)(2)D-3 Induces IL-6 Production in Osteoclast Precursors Expressin Measles Virus Nucleocapsid Protein (MVNP) SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Hiruma, Y.; Roodman, G. D.; Kurihara, N.] Univ Pittsburgh, Pittsburgh, PA USA. [Roodman, G. D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ishizuka, S.] Teijin Inst Biomed Res, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S53 EP S53 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000187 ER PT J AU Huang, W Jarrahy, R Rudkin, GH Yamaguchi, DT Miller, TA AF Huang, W. Jarrahy, R. Rudkin, G. H. Yamaguchi, D. T. Miller, T. A. TI Synergistic Activation of Osteogenesis in Multi-Lineage Progenitor Cells by Oxysterols SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Huang, W.; Jarrahy, R.; Rudkin, G. H.; Yamaguchi, D. T.; Miller, T. A.] VA Greater LA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S252 EP S252 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411001305 ER PT J AU Kurihara, N Hiruma, Y Lorenzo, JA Roodman, GD AF Kurihara, N. Hiruma, Y. Lorenzo, J. A. Roodman, G. D. TI 1,25-dihydroxyvitamin D-3 Can Directly Induce Osteoclast Formation in Osteoclast Precursors in the Absence of RANKL SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Kurihara, N.; Hiruma, Y.; Roodman, G. D.] Univ Pittsburgh, Pittsburgh, PA USA. [Lorenzo, J. A.] Univ Connecticut, Farmington, CT USA. [Roodman, G. D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S259 EP S259 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411001337 ER PT J AU Lu, G Hiruma, Y Cackowski, F Boykin, C Patrene, K Anderson, JL Del Prete, D Windle, JJ Roodman, GD AF Lu, G. Hiruma, Y. Cackowski, F. Boykin, C. Patrene, K. Anderson, J. L. Del Prete, D. Windle, J. J. Roodman, G. D. TI High Dose of RANKL Rescues Integrin alpha(-/-)(9) Osteoclast Phenotype SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Lu, G.; Hiruma, Y.; Cackowski, F.; Patrene, K.; Anderson, J. L.; Del Prete, D.; Roodman, G. D.] Univ Pittsburgh, Pittsburgh, PA USA. [Boykin, C.; Windle, J. J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, G. D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S92 EP S92 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000328 ER PT J AU Mandal, CC Ghosh-Choudhury, N AF Mandal, C. C. Ghosh-Choudhury, N. TI Simvastatin Induces Wnt Signaling and Reduces CSF-1 Secretion and RANKL/OPG Ratio to Block Osteoclast Differentiation. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Mandal, C. C.; Ghosh-Choudhury, N.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ghosh-Choudhury, N.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S266 EP S266 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411001363 ER PT J AU Mandal, CC Choudhury, GG Ghosh-Choudhury, N AF Mandal, C. C. Choudhury, G. G. Ghosh-Choudhury, N. TI BMP-2 Stimulates a Feedback Activation loop for Expression of NFATc1 in Osteoblasts SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Mandal, C. C.; Choudhury, G. G.; Ghosh-Choudhury, N.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Choudhury, G. G.; Ghosh-Choudhury, N.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S86 EP S86 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000302 ER PT J AU McDonough, AK Teng, GG Abott, J Nair, R Amling, C Colli, J Fiveash, JB Lopez, R Urban, D Curtis, JR Saag, K AF McDonough, A. K. Teng, G. G. Abott, J. Nair, R. Amling, C. Colli, J. Fiveash, J. B. Lopez, R. Urban, D. Curtis, J. R. Saag, K. TI Effects of Androgen Deprivation Therapy on Bone Health in Prostate Cancer SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [McDonough, A. K.; Abott, J.; Nair, R.; Curtis, J. R.; Saag, K.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Teng, G. G.] Natl Univ Singapore Hosp, Div Rheumatol, Singapore 117548, Singapore. [Amling, C.; Urban, D.] Univ Alabama Birmingham, Div Urol, Birmingham, AL USA. [Colli, J.] Birmingham VA Med Ctr, Birmingham, AL USA. [Fiveash, J. B.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA. [Lopez, R.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 SU S BP S187 EP S187 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411001070 ER PT J AU Schafer, AL Silva, R Yafai, M Shoback, D AF Schafer, A. L. Silva, R. Yafai, M. Shoback, D. TI Diffuse Sclerosing Osteomyelitis of the Mandible: Case Report and Literature Review. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S508 EP S508 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411002644 ER PT J AU Schafer, AL Silva, R Yafai, M Shoback, D AF Schafer, A. L. Silva, R. Yafai, M. Shoback, D. TI Diffuse Sclerosing Osteomyelitis of the Mandible: Case Report and Literature Review. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S489 EP S489 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411002586 ER PT J AU Wang, Y Long, RK Elalieh, HZ Bikle, DD AF Wang, Y. Long, R. K. Elalieh, H. Z. Bikle, D. D. TI Ablation of IGF-1 Signaling in Osteoprogenitors; Decreases Bone Formation and Blunts the Skeletal Response to PTH SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 30th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-16, 2008 CL Montreal, CANADA SP Amer Soc Bone & Mineral Res C1 [Wang, Y.; Long, R. K.; Elalieh, H. Z.; Bikle, D. D.] Univ Calif San Francisco, San Francisco VA Med Ctr, Endocrine Unit, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2008 VL 23 BP S55 EP S55 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 351FX UT WOS:000259411000194 ER PT J AU Shuhaiber, JH Gunnar, W AF Shuhaiber, Jeffrey H. Gunnar, William TI Intra-cardiac thrombosis following aortic valve replacement SO JOURNAL OF CARDIAC SURGERY LA English DT Article C1 [Shuhaiber, Jeffrey H.; Gunnar, William] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Sect Thorac & Cardiovasc Surg, Hines, IL 60141 USA. RP Shuhaiber, JH (reprint author), 614 G Laflin, Chicago, IL 60607 USA. EM jeffrey01@mac.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0886-0440 J9 J CARDIAC SURG JI J. Card. Surg. PD SEP-OCT PY 2008 VL 23 IS 5 BP 552 EP 552 DI 10.1111/j.1540-8191.2008.00703.x PG 1 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA 339SG UT WOS:000258597000034 PM 18928493 ER PT J AU Karasawa, T Wang, Q Fu, Y Cohen, DM Steyger, PS AF Karasawa, Takatoshi Wang, Qi Fu, Yi Cohen, David M. Steyger, Peter S. TI TRPV4 enhances the cellular uptake of aminoglycoside antibiotics SO JOURNAL OF CELL SCIENCE LA English DT Article DE gentamicin; ototoxicity; aminoglycosides; cochlea; hair cells; stria vascularis; TRPV4; drug permeability ID CATION CHANNEL TRPV4; SENSORY HAIR-CELLS; STRIA VASCULARIS; EPITHELIAL-CELLS; INNER-EAR; IN-VITRO; GENTAMICIN; EXPRESSION; KIDNEY; ENDOCYTOSIS AB The cochlea and kidney are susceptible to aminoglycoside-induced toxicity. The non-selective cation channel TRPV4 is expressed in kidney distal tubule cells, and hair cells and the stria vascularis in the inner ear. To determine whether TRPV4 is involved in aminoglycoside trafficking, we generated a murine proximal-tubule cell line (KPT2) and a distal-tubule cell line (KDT3). TRPV4 expression was confirmed in KDT3 cells but not in KPT2 cells. Removal of extracellular Ca(2+) significantly enhanced gentamicin-Texas-Red (GTTR) uptake by KDT3, indicative of permeation through non-selective cation channels. To determine whether TRPV4 is permeable to GTTR, stable cell lines were generated that express TRPV4 in KPT2 (KPT2-TRPV4). KPT2-TRPV4 cells took up more GTTR than control cell lines (KPT2-pBabe) in the absence of extracellular Ca(2+). TRPV4-dependent GTTR uptake was abolished by a point mutation within the crucial pore region of the channel, suggesting that GTTR permeates the TRPV4 channel. In an endolymph-like extracellular environment, clearance of GTTR was attenuated from KPT2-TRPV4 cells in a TRPV4-dependent fashion. We propose that TRPV4 has a role in aminoglycoside uptake and retention in the cochlea. C1 [Karasawa, Takatoshi; Wang, Qi; Steyger, Peter S.] Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97239 USA. [Fu, Yi; Cohen, David M.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Fu, Yi; Cohen, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Steyger, PS (reprint author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA. EM steygerp@ohsu.edu OI Steyger, Peter/0000-0002-6103-5237 FU NIH NIDCD [DC04555, P30 DC05983, T32 DC005945, F32 DC008465]; Oregon Medical Research Foundation FX We thank Stefan Heller for anti-TRPV4 antibody and Wolfgang Liedtke for TRPV4 cDNA and TRPV4- knockout mice. This work was supported by NIH NIDCD grants DC04555 (P. S. S.), P30 DC05983, T32 DC005945 and F32 DC008465 (T. K.), and by the Oregon Medical Research Foundation. NR 50 TC 34 Z9 36 U1 0 U2 3 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD SEP 1 PY 2008 VL 121 IS 17 BP 2871 EP 2879 DI 10.1242/jcs.023705 PG 9 WC Cell Biology SC Cell Biology GA 339SC UT WOS:000258596600010 PM 18682499 ER PT J AU Yong, PL Russo, P Sullivan, KE AF Yong, Pierre L. Russo, Pierre Sullivan, Kathleen E. TI Use of sirolimus in IPEX and IPEX-like children SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE IPEX; enteropathy; regulatory T cells; sirolimus; rapamycin ID X-LINKED SYNDROME; BONE-MARROW-TRANSPLANTATION; REGULATORY T-CELLS; IMMUNE DYSREGULATION; AUTOIMMUNE ENTEROPATHY; PROTRACTED DIARRHEA; POLYENDOCRINOPATHY; INFANCY; IMMUNODYSREGULATION; AUTOANTIBODIES AB Introduction IPEX (immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome), a rare inflammatory disease caused by mutations of Foxp3, destroys the immunoregulatory environment of affected male infants. Data on optimal therapy are limited. Methods We reviewed the effect of sirolimus use in our cohort of IPEX and IPEX-like patients (n=7). Results and Discussion Our patients exhibited features of enteropathy and recurrent infections with bacterial and viral pathogens. Before initiating sirolimus, six patients were treated with corticosteroids. Several also received other immunosuppressive agents. After starting sirolimus, six patients had improvement in diarrhea, and two were able to decrease corticosteroid dosages. Several also had significantly decreased number of infections after treatment. Of the three patients with post-treatment duodenal biopsies, two showed improvement in villous architecture. No significant adverse events occurred. Our experience suggests that sirolimus is a clinically effective and safe therapeutic option in IPEX and IPEX-like patients. C1 [Yong, Pierre L.] Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Yong, Pierre L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Yong, Pierre L.] Hosp Univ Penn, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Russo, Pierre] Childrens Hosp Philadelphia, Div Pathol, Philadelphia, PA 19104 USA. [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA. RP Yong, PL (reprint author), Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,1303A Blockley Hall, Philadelphia, PA 19104 USA. EM pyong@mail.med.upenn.edu OI Sullivan, Kathleen/0000-0003-4018-1646 FU Philadelphia Veterans Affairs Medical Center; Robert Wood Johnson Clinical Scholars Program FX Dr. Pierre Yong is supported by a training grant from the Philadelphia Veterans Affairs Medical Center and the Robert Wood Johnson Clinical Scholars Program at the University of Pennsylvania. NR 24 TC 32 Z9 36 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD SEP PY 2008 VL 28 IS 5 BP 581 EP 587 DI 10.1007/s10875-008-9196-1 PG 7 WC Immunology SC Immunology GA 345OV UT WOS:000259007000020 PM 18481161 ER PT J AU Eap, S DeGarmo, DS Kawakami, A Hara, SN Hall, GCN Teten, AL AF Eap, Sopagna DeGarmo, David S. Kawakami, Ayaka Hara, Shelley N. Hall, Gordon C. N. Teten, Andra L. TI Culture and personality among European American and Asian American men SO JOURNAL OF CROSS-CULTURAL PSYCHOLOGY LA English DT Article DE Asian Americans; loss of face; acculturation; Big Five personality ID ACCULTURATION SCALE; CHINESE; TRAITS; BIG-5; VALIDATION; PSYCHOLOGY; INVENTORY; PROFILES AB Personality differences between Asian American (N = 320) and European American men (N = 242) and also among Asian American ethnic groups (Korean, Chinese, Japanese, Filipino, and mixed Asian) are examined on the Big Five personality dimension. Personality structures for Asian Americans and European Americans closely replicate established norms. However, congruence is greater for European American and highly acculturated Asian American men than for low acculturated Asian American men. Similar patterns are found for the construct loss of face (LOF). Asian American men with a high concern for LOF are less similar in their personality structure to European American men than Asian American men with low LOF concern. Mean differences are also found among Asian American and European American men, who differ significantly on Extraversion, Conscientiousness, Openness, and Neuroticism. Results indicate that acculturation and LOF are significantly associated with these four personality dimensions for both Asian American and European American men. C1 [Eap, Sopagna] Univ Oregon, Eugene, OR 97403 USA. [DeGarmo, David S.] Oregon Social Learning Ctr, Eugene, OR 97401 USA. [Hara, Shelley N.] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. [Teten, Andra L.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Eap, S (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. EM seap@uoregon.edu FU NICHD NIH HHS [R01 HD042115, R01 HD042115-04]; NIDA NIH HHS [P20 DA017592, P20 DA017592-057874]; NIMH NIH HHS [P50 MH073511, P50 MH073511-02, R01 MH058726, R01 MH058726-03] NR 40 TC 16 Z9 16 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0221 J9 J CROSS CULT PSYCHOL JI J. Cross-Cult. Psychol. PD SEP PY 2008 VL 39 IS 5 BP 630 EP 643 DI 10.1177/0022022108321310 PG 14 WC Psychology, Social SC Psychology GA 340QO UT WOS:000258660300006 PM 19169434 ER PT J AU Hermsen, JL Dobrescu, C Kudsk, KA AF Hermsen, Joshua L. Dobrescu, Cosmin Kudsk, Kenneth A. TI Clostridium difficile infection: A surgical disease in evolution SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Clostridium difficile; colitis; colectomy ID HOSPITALIZED-PATIENTS; DIARRHEA; COLITIS; CLINDAMYCIN; COLONIZATION; RESTRICTION; FACILITY; TOXIN AB Introduction Several recent publications suggest an increase in the incidence of Clostridium difficile colitis. However, such studies commonly lack denominators over which to index this rise. There is also concern in the literature that disease virulence is increasing. Methods Billing, admission, operative, and infection databases at a single tertiary care center identified patients admitted from 1990 to 2006 with a diagnosis of C. difficile infection. Grouped by era, case numbers were indexed against overall hospital, operative, and laboratory volumes. C. difficile colectomy cases were individually examined and analyzed. Results The number of hospitalized patients diagnosed with C. difficile colitis increased in a linear fashion during the study period (1990, 14 cases; 2006, 927 cases). The colectomy per C. difficile case ratio did not change over the study period (era 1, 0.17%; era 2, 0.20%; era 3, 0.16%). Thirteen patients underwent colectomy with 54% surviving. The increase in patients admitted with a diagnosis of C. difficile was significantly associated with hospital volume (p=0.04), operative volume (p<0.001), and lab testing volume (p=0.008). Conclusion The number of C. difficile patients admitted to our hospital is rising at an alarming rate. This reflects national trends and urgent action seems warranted to prevent a C. difficile epidemic. C1 [Hermsen, Joshua L.; Dobrescu, Cosmin; Kudsk, Kenneth A.] Univ Wisconsin, Coll Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Coll Med & Publ Hlth, Dept Surg, 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu NR 30 TC 25 Z9 25 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD SEP PY 2008 VL 12 IS 9 BP 1512 EP 1517 DI 10.1007/s11605-008-0569-9 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 339FP UT WOS:000258563800007 PM 18612709 ER PT J AU Ross, JT TenHave, T Eakin, AC Difilippo, S Oslin, DW AF Ross, Jennifer T. TenHave, Thomas Eakin, April C. Difilippo, Suzanne Oslin, David W. TI A randomized controlled trial of a close monitoring program for minor depression and distress SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE minor depression; close monitoring; telephone care management ID PRIMARY-CARE PATIENTS; GENERAL-POPULATION; SYMPTOMS; RELIABILITY; PREVALENCE; TELEPHONE; MANAGEMENT; DISORDERS; DYSTHYMIA; VALIDITY AB BACKGROUND: Minor depression is almost twice as common in primary care (PC) as major depression. Despite the high prevalence, few evidence-based algorithms exist for managing patients with minor depression or patients presenting solely with distress. OBJECTIVES: The aim of this study was to test the effectiveness of a telephone-based close monitoring program to manage PC patients with minor depression or distress. DESIGN: Subjects were randomly assigned to either the control arm (usual care; UC) or the intervention arm (close monitoring; CM). We hypothesized that those randomized to CM would exhibit less depression and be less likely to have symptoms progress to the point of meeting diagnostic criteria. SUBJECTS: Overall, 223 PC subjects with minor depression or distress consented to participation in this trial. MEASUREMENTS: At baseline, subjects completed a telephone-based evaluation comprised of validated diagnostic assessments of depression and other MH disorders. Outcomes were assessed at six months utilizing this same battery. Chart reviews were conducted to track care received, such as prescribed antidepressants and MH and primary care visits. RESULTS: Subjects in the CM arm exhibited fewer psychiatric diagnoses than those in the UC arm (chi(2) = 4.04, 1 df, p = 0.04). In addition, the intervention group showed improved overall physical health (SF-12 PCS scores) (M = 45.1, SD = 11.8 versus M = 41.5, SD = 12.4) (chi(2) = 5.90, 1 df, p = .02). CONCLUSIONS: Those randomized to CM exhibited less MH problems at the conclusion of the trial, indicating that the close monitoring program is effective, feasible and valuable. The findings of this study will allow us to enhance clinical care and support the integration of mental health services and primary care. C1 [Ross, Jennifer T.; Eakin, April C.; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Ross, Jennifer T.; Eakin, April C.; Oslin, David W.] VISN 4 Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Oslin, David W.] Philadelphia VA Ctr Excellence Subst Abuse Treatm, Philadelphia, PA USA. [Ross, Jennifer T.; Difilippo, Suzanne; Oslin, David W.] Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. [TenHave, Thomas] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. RP Oslin, DW (reprint author), Philadelphia Vet Affairs Med Ctr, Mail Stop 116,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM oslin@mail.med.upenn.edu FU Philadelphia Veterans Affairs Medical Center (PVAMC); Robert Wood Johnson foundation; Veterans Integrated Service Network 4 Mental Illness Research Education and Clinical Center; Behavioral Health Laboratory staff FX Supported by Robert Wood Johnson and VISN 4 the Mental Illness Research, Education, and Clinical Center (MIRECC) at the Philadelphia Veterans Affairs Medical Center (PVAMC).; This work was supported by a grant from the Robert Wood Johnson foundation and support from the Veterans Integrated Service Network 4 Mental Illness Research Education and Clinical Center. We acknowledge the support and dedication of the Primary Care Clinicians at the Philadelphia Veterans Affairs Medical Center and the Behavioral Health Laboratory staff. NR 27 TC 18 Z9 18 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2008 VL 23 IS 9 BP 1379 EP 1385 DI 10.1007/s11606-008-0663-4 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 339LJ UT WOS:000258578800014 PM 18498013 ER PT J AU Covinsky, KE Lin, F Bittner, V Hlatky, MA Knight, SJ Vittinghoff, E AF Covinsky, Kenneth E. Lin, Feng Bittner, Vera Hlatky, Mark A. Knight, Sara J. Vittinghoff, Eric TI Health-related quality of life following coronary artery bypass graft surgery in post-menopausal women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE coronary artery bypass graft; health related quality of life; physical function; post-menopausal women ID OPEN-HEART OPERATIONS; ESTROGEN/PROGESTIN REPLACEMENT; DEPRESSIVE SYMPTOMS; RANDOMIZED-TRIAL; OLDER-ADULTS; OUTCOMES; QUESTIONNAIRE; DISEASE; OCTOGENARIANS; ANGIOPLASTY AB OBJECTIVES: To describe the impact of coronary artery bypass graft (CABG) surgery on health related quality of life (HRQOL) in post-menopausal women. DESIGN: Prospective cohort study. SETTING: Women enrolled in the Heart and Estrogen/progestin Replacement Study (HERS). PARTICIPANTS: One hundred and thirty-seven women (mean age 66.6) who had CABG surgery while enrolled in HERS. MEASUREMENTS: Physical function was assessed using the 12-item Duke Activity Status Index (DASI), energy-fatigue with the four-item RAND scale, and mental health with the RAND mental health inventory each year. We defined baseline HRQOL from the interview that preceded the CABG (mean 4.6 months pre-CABG). To assess post-CABG HRQOL, we used the first interview that was obtained at least 6 months following the CABG (mean 11.5 months post-CABG). RESULTS: For all three measures of HRQOL, mean scores post-CABG were virtually identical to mean scores pre-CABG (mean pre and post scores were 20.8, 20.4 for physical function, 49.3, 49.2 for energy-fatigue, and 71.9 and 72.3 for mental health). After adjusting for demographic and clinical characteristics and the expected temporal change in HRQOL, differences between pre and post-operative HRQOL remained minimal. However, on an individual patient level, there was significant variability in HRQOL outcomes. For example, while mean physical function scores changed little, 32% of women were at least moderately better (scores improved by at least 0.5 standard deviations) following surgery, while 26% were at least moderately worse (scores declined by at least 0.5 standard deviations). CONCLUSION: Following CABG surgery in post-menopausal women, on average, HRQOL is virtually identical to the pre-operative baseline. However, there is significant variability, as substantial numbers of women are significantly better or significantly worse. C1 [Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Covinsky, Kenneth E.; Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lin, Feng; Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Bittner, Vera] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hlatky, Mark A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Hlatky, Mark A.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Covinsky, KE (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement, San Francisco, CA 94121 USA. EM covinsky@medicine.ucsf.edu OI Bittner, Vera/0000-0001-9456-850X FU National Institute on Aging [5 R01 AG023626-03, 1K24AG029812-01A1]; Wyeth Pharmaceuticals FX Supported in part by grants from the National Institute on Aging (5 R01 AG023626-03 and 1K24AG029812-01A1). The HERS study was funded by Wyeth Pharmaceuticals. Wyeth Pharmaceuticals was not involved in the plans to use the HERS database to conduct this study, and was not involved in the data analysis, preparation of the manuscript, or decision to publish this manuscript. NR 34 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2008 VL 23 IS 9 BP 1429 EP 1434 DI 10.1007/s11606-008-0691-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 339LJ UT WOS:000258578800021 PM 18574638 ER PT J AU Silberman, J Tentler, A Ramgopal, R Epstein, RM AF Silberman, Jordan Tentler, Aleksey Ramgopal, Rajeev Epstein, Ronald M. TI Recall-promoting physician behaviors in primary care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE communication skills; medical education-communication skills; patient education ID CONTROLLED-TRIAL; COMMUNICATION; PATIENT; INFORMATION; SATISFACTION; DOCTORS; ADVICE AB BACKGROUND: Effective treatments can be rendered useless by poor patient recall of treatment instructions. Studies suggest that patients forget a great deal of important information and that recall can be increased through recall-promoting behaviors (RPBs) like repetition or summarization. OBJECTIVE: To assess how frequently RPBs are used in primary care, and to reveal how they might be applied more effectively. DESIGN: Recordings of 49 unannounced standardized patient (SP) visits were obtained using hidden audiorecorders. All SPs presented with typical gastroesophageal reflux disease symptoms. Transcripts were coded for treatment recommendations and RPBs. PARTICIPANTS: Forty-nine primary care physicians. RESULTS: Of 1,140 RPBs, 53.7% were repetitions, 28.2% were communication of the rationale for a treatment, 11.7% were categorizations of treatments (i.e., stating that a treatment could be placed into a treatment category, such as medication-related or lifestyle-related categories), and 3.8% were emphasis of a recommendation's importance. Physicians varied substantially in their use of most RPBs, although no physicians summarized or asked patients to restate recommendations. The number of RPBs was positively correlated with visit length. CONCLUSIONS: Primary care physicians apply most RPBs inconsistently, do not utilize several RPBs that are particularly helpful, and may use RPBs inefficiently. Simple principles guiding RPB use may help physicians apply these communication tools more effectively. C1 [Silberman, Jordan; Tentler, Aleksey; Epstein, Ronald M.] Univ Rochester, Med Ctr, Rochester Ctr Improve Commun Hlth Care, Rochester, NY 14610 USA. [Ramgopal, Rajeev] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Silberman, J (reprint author), Univ Rochester, Med Ctr, Rochester Ctr Improve Commun Hlth Care, 1381 S Ave, Rochester, NY 14610 USA. EM jordan_silberman@urmc.rochester.edu RI Tentler, Aleksey/I-6404-2013 OI Tentler, Aleksey/0000-0001-7741-3776 FU AHRQ HHS [R01-HS1610-01A1] NR 20 TC 12 Z9 12 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2008 VL 23 IS 9 BP 1487 EP 1490 DI 10.1007/s11606-008-0597-x PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 339LJ UT WOS:000258578800031 PM 18548316 ER PT J AU Schillerstrom, JE Royall, DR Palmer, RF AF Schillerstrom, Jason E. Royall, Donald R. Palmer, Raymond F. TI Depression, disability and intermediate pathways: A review of longitudinal studies in elders SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE depression; disability; functional status; longitudinal study; cohort ID PREDICT FUNCTIONAL DECLINES; PHYSICAL-DISABILITY; OLDER-ADULTS; LATE-LIFE; EXECUTIVE DYSFUNCTION; GERIATRIC DEPRESSION; VASCULAR DEMENTIA; METHYLPHENIDATE TREATMENT; CARDIOVASCULAR HEALTH; DISABLEMENT PROCESS AB Cross-sectional studies demonstrate depression is associated with disability in elders. These studies also report that disability in depressed elders is associated with greater medical illness burden, cognitive impairment, and behavioral changes. Only longitudinal Studies, however, can determine the impact of depression and its comorbidities on functional decline. This review summarizes the findings of 20 longitudinal Studies examining the relationship between baseline or incident depression and functional decline. However, the mediational effects of potential risk factors identified by cross-sectional studies cannot be derived from the current literature. We propose a mediational effects model for future longitudinal studies, incorporating measures sensitive to both mood symptoms and the medical, cognitive, and behavioral comorbidities of depression to better understand the impact of each on functional decline and to focus future clinical interventions. C1 [Schillerstrom, Jason E.; Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Royall, Donald R.] Audie Murphy Div GRECC, S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Schillerstrom, JE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM schillerstr@uthscsa.edu NR 78 TC 40 Z9 42 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD SEP PY 2008 VL 21 IS 3 BP 183 EP 197 DI 10.1177/0891988708320971 PG 15 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 347TN UT WOS:000259164100004 PM 18838741 ER PT J AU Hauer, KE Landefeld, CS AF Hauer, Karen E. Landefeld, C. Seth TI CHAMP Trains Champions: Hospitalist-Educators Develop New Ways to Teach Care for Older Patients SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID GENERAL INTERNAL-MEDICINE; GERIATRICS; PHYSICIANS; OUTCOMES; IMPROVE; FACULTY C1 [Hauer, Karen E.] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA 94143 USA. [Landefeld, C. Seth] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, Div Hosp Med, 533 Parnassus Ave,U137,Box 0131, San Francisco, CA 94143 USA. EM khauer@medicine.ucsf.edu NR 15 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD SEP-OCT PY 2008 VL 3 IS 5 BP 357 EP 360 DI 10.1002/jhm.357 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 369JK UT WOS:000260690300001 PM 18951398 ER PT J AU Li, YM Chen, FQ Putt, M Koo, YK Madaio, M Cambier, JC Cohen, PL Eisenberg, RA AF Li, Yongmei Chen, Fangqi Putt, Mary Koo, Yumee K. Madaio, Michael Cambier, John C. Cohen, Philip L. Eisenberg, Robert A. TI B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MURINE LUPUS; IG-BETA; IN-VIVO; ACTIVATION; RECEPTOR; ALPHA/BETA; ROLES; CD79 AB MRL/lpr mice develop a spontaneous systemic lupus erythematosus-like autoimmune syndrome due to a dysfunctional Fas receptor, with contributions from other less well-defined genetic loci. The removal of B cells by genetic manipulation not only prevents autoantibody formation, but it also results in substantially reduced T cell activation and kidney inflammation. To determine whether B cell depletion by administration of Abs is effective in lupus mice with an intact immune system and established disease, we screened several B cell-specific mAbs and found that a combination of anti-CD79 alpha and anti-CD79 beta Abs was most effective at depleting B cells in vivo. Anti-CD79 therapy started at 4-5 mo of age in MRL/lpr mice significantly decreased B cells (B220(+)CD19(+)) in peripheral blood, bone marrow, and spleens. Treated mice also had a significant increase in the number of both double-negative T cells and naive CD4(+) T cells, and a decreased relative abundance of CD4(+) memory cells. Serum anti-chromatin IgG levels were significantly decreased compared with controls, whereas serum anti-dsDNA IgG, total IgG, or total IgM were unaffected. Overall, survival was improved with lower mean skin scores and significantly fewer focal inflammatory infiltrates in submandibular salivary glands and kidneys. Anti-CD79 mAbs show promise as a potential treatment for systemic lupus erythematosus and as a model for B cell depletion in vivo. C1 [Eisenberg, Robert A.] Univ Penn, Div Rheumatol, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Putt, Mary] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Koo, Yumee K.] Univ Sci Philadelphia, Dept Chem & Biochem, Philadelphia, PA 19104 USA. [Madaio, Michael] Temple Univ, Philadelphia, PA 19140 USA. [Cambier, John C.] Univ Colorado, Denver Sch Med, Denver, CO 80206 USA. [Cambier, John C.] Natl Jewish Med & Res Ctr, Denver, CO 80206 USA. [Cohen, Philip L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Eisenberg, RA (reprint author), Univ Penn, Div Rheumatol, Sch Med, Dept Med, Room 747,BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA. EM raemd@mail.med.upenn.edu OI Cambier, John/0000-0002-7803-242X FU Lupus Research Institute; Arthritis Foundation and the Alliance for Lupus Research; Lupus Foundation of South New Jersey; Department of Veterans Affairs; National Institutes of Health [R01-AR-34156, U19-AI-46358, R01-AI063626, R01-DE017590] FX Supported by the Lupus Research Institute, the Arthritis Foundation and the Alliance for Lupus Research, the Lupus Foundation of South New Jersey, the Department of Veterans Affairs, and the National Institutes of Health (Grants R01-AR-34156, U19-AI-46358, R01-AI063626, and R01-DE017590). NR 27 TC 36 Z9 38 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 1 PY 2008 VL 181 IS 5 BP 2961 EP 2972 PG 12 WC Immunology SC Immunology GA 352QJ UT WOS:000259511800004 PM 18713966 ER PT J AU Wegmann, KW Wagner, CR Whitham, RH Hinrichs, DJ AF Wegmann, Keith W. Wagner, Cynthia R. Whitham, Ruth H. Hinrichs, David J. TI Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis SO JOURNAL OF IMMUNOLOGY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REGULATORY T-CELLS; PROTEOLIPID PROTEIN; TOLERANCE INDUCTION; MULTIPLE-SCLEROSIS; IN-VIVO; ENCEPHALITOGENIC PEPTIDES; PERIPHERAL TOLERANCE; DELIVERY VEHICLES; TRANSGENIC MICE AB Multiple Ag peptides (MAPS) containing eight proteolipid protein (PLP)(139-151) peptides arranged around a dendrimeric branched lysine core were used to influence the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice. The PLP139-151 MAN were very efficient agents in preventing the development of clinical disease when administered after immunization with the PLP139-151 monomeric encephalitogenic peptide in CFA. The treatment effect with these MAPs was peptide specific; irrelevant multimeric peptides such as guinea pig myelin basic protein GPBP(72-84) MAP (a dendrimeric octamer composed of the 72-84 peptide) and PLP178-191 MAP (a dendrimeric octamer composed of the PLP178-191 peptide) bad no treatment effect on PLP139-151-induced EAE. PLP139-151 MAP treatment initiated after clinical signs of paralysis also altered the subsequent course of EAE; it limited developing signs of paralysis and effectively limited the severity and number of disease relapses in MAP-treated mice over a 60-day observation period. PLP139-151 MAP therapy initiated before disease onset acts to limit the numbers of Th17 and IFN-gamma-producing cells that enter into the CNS. However, Foxp3(+) cells entered the CNS in numbers equivalent for nontreated and PLP139-151 MAP-treated animals. The net effect of PLP139-151 MAP treatment dramatically increases the ratio of Foxp3(+) cells to Th17 and IFN-gamma-producing cells in the CNS of PLP139-151. MAP-treated animals. C1 [Wegmann, Keith W.; Wagner, Cynthia R.; Whitham, Ruth H.; Hinrichs, David J.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97239 USA. [Wegmann, Keith W.; Wagner, Cynthia R.; Hinrichs, David J.] Oregon Hlth & Sci Univ, Immunol Res Grp, Portland, OR 97239 USA. [Whitham, Ruth H.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Wagner, Cynthia R.] Oregon Hlth & Sci Univ, Dept Cardiol, Portland, OR 97239 USA. RP Hinrichs, DJ (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, R&D 21, Portland, OR 97201 USA. EM hinrichs@ohsu.edu FU Department of Veterans Affairs FX This work was supported by Merit Review funds from the Department of Veterans Affairs. NR 60 TC 22 Z9 22 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD SEP 1 PY 2008 VL 181 IS 5 BP 3301 EP 3309 PG 9 WC Immunology SC Immunology GA 352QJ UT WOS:000259511800040 PM 18714002 ER PT J AU Signore, AP Zhang, F Weng, ZF Gao, YQ Chen, J AF Signore, Armando P. Zhang, Feng Weng, Zhongfang Gao, YanQin Chen, Jun TI Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials SO JOURNAL OF NEUROCHEMISTRY LA English DT Review DE neurodegeneration; stroke; epilepsy; mitogen-activated protein kinase kinase/extracellular signal-regulated kinase; phosphatidylinositol 3-kinase ID BLOOD-BRAIN-BARRIER; HIPPOCAMPAL SYNAPTIC PLASTICITY; STREPTOZOTOCIN-DIABETIC RATS; DOPAMINERGIC CELL-DEATH; PITUITARY-ADRENAL AXIS; RECEPTOR MESSENGER-RNA; LONG-TERM POTENTIATION; NF-KAPPA-B; GENE-EXPRESSION; OB/OB MICE AB Leptin is well known as a hormone important in the central control of appetitive behaviors via receptor-mediated actions in the hypothalamus, where leptin adjusts food intake to maintain homeostasis with the body's energy stores. Recent evidence has shown that leptin and its receptors are widespread in the CNS and may provide neuronal survival signals. This review summarizes our current knowledge of how leptin functions in the brain and then focuses on the ability of leptin to mitigate neuronal damage in experimental models of human neurological disorders. Damage to the brain by acute events such as stroke, or long-term loss of neurons associated with neurodegenerative diseases, including Parkinson's and Alzheimer's disease, may be amenable to treatment using leptin to limit death of susceptible cells. Leptin-mediated pro-survival signaling is now known to prevent the death of neurons in these models. The signaling cascades that leptin generates are shared by other neuroprotective molecules including insulin and erythropoietin, and are thus a component of the neurotrophic effects mediated by endogenous hormones. Coupled with evidence that leptin dysregulation in human disease also results in enhanced neuronal susceptibility to damage, development of leptin as a therapeutic methodology is an attractive and viable possibility. C1 [Signore, Armando P.; Zhang, Feng; Weng, Zhongfang; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Gao, YanQin; Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NINDS NIH HHS [NS43802, NS44178, NS45048, NS56118, R01 NS036736, NS36736, R01 NS036736-10, R01 NS043802, R01 NS043802-05, R01 NS044178, R01 NS044178-05, R01 NS045048, R01 NS045048-05, R01 NS056118] NR 142 TC 74 Z9 83 U1 2 U2 14 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD SEP PY 2008 VL 106 IS 5 BP 1977 EP 1990 DI 10.1111/j.1471-4159.2008.05457.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 336JL UT WOS:000258360000001 PM 18466320 ER PT J AU Upenieks, VV Needleman, J Soban, L Pearson, ML Parkerton, P Yee, T AF Upenieks, Valda V. Needleman, Jack Soban, Lynn Pearson, Marjorie L. Parkerton, Pat Yee, Tracy TI The relationship between the volume and type of Transforming Care at the Bedside innovations and changes in nurse vitality SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID HOSPITALS; UNITS; MAGNET; WORK C1 [Upenieks, Valda V.] Univ Calif Los Angeles, Sch Nursing, Nursing Adm Grad Program, Los Angeles, CA 90095 USA. [Needleman, Jack; Parkerton, Pat; Yee, Tracy] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Soban, Lynn] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare, Los Angeles, CA USA. [Pearson, Marjorie L.] RAND Corp, Santa Monica, CA USA. RP Upenieks, VV (reprint author), Univ Calif Los Angeles, Sch Nursing, Nursing Adm Grad Program, 3-242 Factor Bldg,Box 956917, Los Angeles, CA 90095 USA. EM vupeniek@ucla.edu RI Needleman, Jack/I-5461-2013 OI Needleman, Jack/0000-0002-2875-0589 FU Robert Wood Johnson Foundation; Veterans Affairs Health Services Research and Development FX Funding for this work was provided by the Robert Wood Johnson Foundation. Dr Soban is currently funded by a Career Development Award from the Veterans Affairs Health Services Research and Development program. The conclusions are those of the authors and do not necessarily reflect the opinions of the Robert Wood Johnson Foundation or the Veterans Health Administration. NR 20 TC 13 Z9 13 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD SEP PY 2008 VL 38 IS 9 BP 386 EP 394 DI 10.1097/01.NNA.0000323959.52415.86 PG 9 WC Nursing SC Nursing GA 354UY UT WOS:000259665700005 PM 18791422 ER PT J AU Morone, NE Lynch, CS Greco, CM Tindle, HA Weiner, DK AF Morone, Natalia E. Lynch, Cheryl S. Greco, Carol M. Tindle, Hilary A. Weiner, Debra K. TI "I Felt Like a New Person." The effects of mindfulness meditation on older adults with chronic pain: Qualitative narrative analysis of diary entries SO JOURNAL OF PAIN LA English DT Article DE qualitative research; meditation; back pain; aging; mindfulness ID LOW-BACK-PAIN; STRESS REDUCTION MBSR; HEALTH-CARE; ATTENTION; BRAIN; STATE AB To identify the effects of mindfulness meditation on older adults with chronic low back pain (CLBP), we conducted a qualitative study based on grounded theory and used content analysis of diary entries from older adults who had participated in a clinical trial of an 8-week mindfulness meditation program. Participants were 27 adults >= 65 years of age with CLBP of at least moderate severity and of at least 3 months duration. We found several themes reflecting the beneficial effects of mindfulness meditation on pain, attention, sleep, and achieving well-being. Various methods of pain reduction were used, including distraction, increased body awareness leading to behavior change, better pain coping, and direct pain reduction through meditation. Participants described improved attention skills. A number of participants reported improved sleep latency as well as quality of sleep. Participants described achieving well-being during and after a meditation session that had immediate effects on mood elevation but also long-term global effects on improved quality of life. Several themes were identified related to pain reduction, improved attention, improved sleep, and achieving well-being resulting from mindfulness meditation that suggest it has promising potential as a nonpharmacologic treatment of chronic pain for older adults. Perspective: Community-dwelling older adults with chronic low back pain experience numerous benefits from mindfulness meditation including less pain, improved attention, better sleep, enhanced well-being, and improved quality of life. Additional research is needed to determine how mindfulness meditation works and how it might help with other chronic illnesses. (C) 2008 by the American Pain Society. C1 [Morone, Natalia E.; Lynch, Cheryl S.; Tindle, Hilary A.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Greco, Carol M.; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Lynch, Cheryl S.; Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Morone, NE (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu FU National Institutes of Health (NIH) [AG23641 K07]; National Center for Research Resources (NCRR) [1KL2RR024154-01]; National Institutes of Health [T32 AG 021885-05] FX Supported by grant AG23641 K07 to Dr. Stephanie Studenski from the National Institutes of Health (NIH). During the time of this work, Dr. Morone and Dr. Tindle were supported by the NIH Roadmap Multidisciplinary Clinical Research Career Development Award Grant (1KL2RR024154-01) from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Dr. Lynch was supported by grant T32 AG 021885-05 from the National Institutes of Health. NR 29 TC 54 Z9 56 U1 9 U2 62 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD SEP PY 2008 VL 9 IS 9 BP 841 EP 848 DI 10.1016/j.jpain.2008.04.003 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 347WN UT WOS:000259172200009 PM 18550444 ER PT J AU O'Neill, SM Ettner, SL Lorenz, KA AF O'Neill, Sean M. Ettner, Susan L. Lorenz, Karl A. TI Paying the Price at the End of Life: A Consideration of Factors that Affect the Profitability of Hospice SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID PALLIATIVE CARE; NURSING-HOMES; HOSPITALS AB Objective: To evaluate factors that affect the financial performance of hospice. Methods: Using the California Office of Statewide Health Planning and Development 2003 survey, we evaluated the organizational attributes, clinical care, and financial performance of 185 operational hospices. As outcomes, we evaluated revenues, costs, and profits per patient and per patient-day, the intensity and skill mix of care, and the provision of charitable and special palliative services. We evaluated regression-adjusted differences by profit status controlling for other organizational features and aggregate patient characteristics. Results: Hospices reported median revenue of $6865 per patient and $138 per patient-day (for-profit-not-for profit [FP-NFP] difference -$20, p = 0.045), median cost of $6737 per patient, and $135 per patient-day (FP-NFP difference -$55, p = 0.002), and median pretax profit of $334 per patient and $6 per patient-day (FP-NFP difference $34, p = 0.026). Patients received a median of 29.9 total visits by all providers per patient (FP-NFP difference 8.8 visits, p = 0.010), but there was no difference in total visits per patient-day. A median of 50.8% of all nursing visits were registered nurse (RN) visits (FP-NFP difference -14.1%, p < 0.001). Few hospices provided charity care, and only 4% of hospices reported expenditures on chemotherapy and only 9% on radiation therapy. Conclusions: Overall hospice profitability is low. Length of stay is strongly associated with financial performance, and greater FP profitability is related to lower costs. FP hospices also provide less RN care as a proportion of nursing care. Few hospices provide charitable care or special costly services. The relationship of service patterns to patient quality needs to be examined. C1 [O'Neill, Sean M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lorenz, Karl A.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. RP O'Neill, SM (reprint author), Pardee RAND Grad Sch, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM soneill@prgs.edu OI O'Neill, Sean/0000-0001-7759-8942 FU NIA/AFAR; Lillian R. Gleitsman Summer Training Institute at UCLA; VA HSR&D Advanced Career Development Awardee FX Mr. O'Neill's work was supported by the NIA/AFAR and Lillian R. Gleitsman Summer Training Institute at UCLA. Dr. Lorenz is a VA HSR&D Advanced Career Development Awardee. NR 26 TC 16 Z9 16 U1 1 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2008 VL 11 IS 7 BP 1002 EP 1008 DI 10.1089/jpm.2007.0252 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 364XQ UT WOS:000260369400014 PM 18788962 ER PT J AU Williams, BR Allman, RM AF Williams, Beverly R. Allman, Richard M. TI Marital status and health: Exploring pre-widowhood (vol 11, pg 6, 2008) SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Correction C1 [Williams, Beverly R.; Allman, Richard M.] Birmingham VA Med Ctr, GRECC, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Williams, Beverly R.; Allman, Richard M.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2008 VL 11 IS 7 BP 1060 EP 1060 DI 10.1089/jpm.2008.9822 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 364XQ UT WOS:000260369400023 ER PT J AU Petri, M Naqibuddin, M Carson, KA Sampedro, M Wallace, DJ Weisman, MH Holliday, SL Padilla, PA Brey, RL AF Petri, Michelle Naqibuddin, Mohammad Carson, Kathryn A. Sampedro, Margaret Wallace, Daniel J. Weisman, Michael H. Holliday, Stephen L. Padilla, Patricia A. Brey, Robin L. TI Cognitive function in a systemic lupus erythematosus inception cohort SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE systemic lupus erythematosus; cognitive function; automated neuropsychological assessment metrics ID OVERT NEUROPSYCHIATRIC MANIFESTATIONS; CA3 PYRAMIDAL NEURONS; NEUROCOGNITIVE DYSFUNCTION; REVISED CRITERIA; APICAL DENDRITES; INDUCED ATROPHY; IMPAIRMENT; PREVALENCE; CLASSIFICATION; DEFINITIONS AB Objective. Measurable cognitive impairment occurs in 30-75% of patients with systemic lupus erythematosus (SLE). We compared cognitive functioning in recently-diagnosed SLE patients and normal controls. Methods. The Automated Neuropsychological Assessment Metrics (ANAM), a repeatable computerized cognitive battery assessing cognitive processing speed and efficiency, was administered to I I I recently diagnosed SLE patients and 79 normal controls. Throughput scores on ANAM subtests were compared using linear regression. Results. After adjusting for age, gender, ethnicity, and education, SLE patients scored significantly lower than controls on throughput measures of 4 ANAM subtests: code substitution immediate recall (p = 0.02), continuous performance (1) = 0.02), matching to sample (p = 0.02), and Sternberg subtest (p = 0.0002). Conclusions. Recently diagnosed SLE patients performed significantly worse than normal controls on 4 of 9 ANAM subtests. ANAM subtests of cognitive efficiency requiring sustained attention/vigilance, visuospatial span of attention/working memory, and simple reaction time showed the greatest impairment. These cognitive deficits were particularly striking, because the SLE patients in this sample were not selected for the presence of neuropsychiatric manifestations, had mild SLE-related disease/damage, and were recently diagnosed with SLE. This suggests that deficits in cognitive efficiency and sustained attention are present early in the course of SLE and in the absence of other significant neuropsychiatric manifestations. C1 [Petri, Michelle; Carson, Kathryn A.] Johns Hopkins Univ, Dept Epidemiol, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Wallace, Daniel J.; Weisman, Michael H.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA. [Holliday, Stephen L.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Padilla, Patricia A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Neurol, San Antonio, TX 78229 USA. RP Petri, M (reprint author), 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA. EM mpetri@jhmi.edu FU NIH [RO1 AR049125]; Johns Hopkins University; General Clinical Research Center [M01 RR00052, MO1-RR-01346]; University of Texas Health Science Center at San Antonio FX The Brain CONECTIONS study is supported by NIH RO1 AR049125 and the Johns Hopkins University: General Clinical Research Center (Kathryn Carson is supported by M01 RR00052) and the University of Texas Health Science Center at San Antonio Frederic C. Bartter General Clinical Research Center (MO1-RR-01346). NR 37 TC 30 Z9 31 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD SEP PY 2008 VL 35 IS 9 BP 1776 EP 1781 PG 6 WC Rheumatology SC Rheumatology GA 344CY UT WOS:000258904500015 PM 18634154 ER PT J AU Hawkins, EJ Baer, JS Kivlahan, DR AF Hawkins, Eric J. Baer, John S. Kivlahan, Daniel R. TI Concurrent monitoring of psychological distress and satisfaction measures as predictors of addiction treatment retention SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE concurrent monitoring; feasibility; substance use disorders; retention ID INTERACTIVE VOICE RESPONSE; SUBSTANCE-ABUSE TREATMENT; THERAPEUTIC ALLIANCE; USE DISORDERS; ALCOHOL-CONSUMPTION; OUTCOME PREDICTORS; TREATMENT SERVICES; FOLLOW-UP; CORE-OM; COCAINE AB Dropout from addiction services is common, and strategies to improve retention represent potentially important opportunities for quality improvement and treatment effectiveness. Identification of pretreatment predictors of dropout has not led to advances in treatment delivery. Via telephone monitoring, we examined the feasibility and predictive validity of weekly assessment of psychological distress and treatment satisfaction as factors potentially associated with retention and engagement over the initial 8 weeks of treatment. Participants included 107 addiction treatment patients, of whom 78% met criteria for 4 weeks of engagement and 59%, were retained for 8 weeks. Of 8 weekly assessments, 63% of participants completed six or more calls. Baseline distress, baseline satisfaction, and change in distress over 4 weeks were not related reliably to treatment dropout or engagement. Decrease in satisfaction was significantly but modestly associated with low engagement. Implications for applications of weekly monitoring to improve retention are discussed. Published by Elsevier Inc. C1 [Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA 98108 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Ctr Excellence Substance Abuse Treatment & Educ, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eric.hawkings@va.gov NR 38 TC 21 Z9 21 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD SEP PY 2008 VL 35 IS 2 BP 207 EP 216 DI 10.1016/j.jsat.2007.10.001 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 342QR UT WOS:000258799100012 PM 18082998 ER PT J AU Blevins, J Overduin, J Fuller, J Cummings, D Matsumoto, K Moralejo, DH AF Blevins, J. Overduin, J. Fuller, J. Cummings, D. Matsumoto, K. Moralejo, D. H. TI Normal Feeding and Body Weight in Fischer 344 Rats Lacking the Cholecystokinin-1 Receptor Gene SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Meeting Abstract C1 [Fuller, J.; Moralejo, D. H.] Univ Washington, Seattle, WA 98195 USA. [Blevins, J.; Overduin, J.; Cummings, D.] VA Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. [Matsumoto, K.] Univ Tokushima, Div Anim Res Resources, Tokushima 770, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD SEP PY 2008 VL 47 IS 5 BP 84 EP 84 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 361MJ UT WOS:000260131500047 ER PT J AU Paster, E Colgin, L Wilk, J Maginnis, G AF Paster, E. Colgin, L. Wilk, J. Maginnis, G. TI Diabetic Ketoacidosis in a Pregnant Rhesus Macaque (Macaca mulatta) SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Meeting Abstract C1 [Paster, E.; Colgin, L.; Wilk, J.; Maginnis, G.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD SEP PY 2008 VL 47 IS 5 BP 88 EP 88 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 361MJ UT WOS:000260131500059 ER PT J AU Paster, E Hickman, D Baldwin, R AF Paster, E. Hickman, D. Baldwin, R. TI Dehydration and Excessive Salviation in B6.129-Slc6a4(tm1kpl)N10 Mice SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Meeting Abstract C1 [Paster, E.; Hickman, D.; Baldwin, R.] Portland VA Med Ctr, Portland, OR USA. RI Hickman, Debra/D-3289-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD SEP PY 2008 VL 47 IS 5 BP 105 EP 105 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 361MJ UT WOS:000260131500105 ER PT J AU Koszdin, K Frayo, S Cummings, D AF Koszdin, K. Frayo, S. Cummings, D. TI Method for Repeated Blood Sampling from the Medial Saphenous Vein of Conscious Rats in a Longterm Study SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Meeting Abstract C1 [Koszdin, K.] VA Puget Sound Hlth Care Syst, Anim Res Facil, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD SEP PY 2008 VL 47 IS 5 BP 113 EP 113 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 361MJ UT WOS:000260131500129 ER PT J AU Goode, PS FitzGerald, MP Richter, HE Whitehead, WE Nygaard, I Wren, PA Zyczynski, HM Cundiff, G Menefee, S Senka, JM Gao, X Weber, AM AF Goode, Patricia S. FitzGerald, Mary P. Richter, Holly E. Whitehead, William E. Nygaard, Ingrid Wren, Patricia A. Zyczynski, Halina M. Cundiff, Geoffrey Menefee, Shawn Senka, Judith M. Gao, Xin Weber, Anne M. CA Pelvic Floor Disorders Network TI Enhancing participation of older women in surgical trials SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PELVIC ORGAN PROLAPSE; RECRUITMENT STRATEGIES; CLINICAL-TRIAL; STRESS-INCONTINENCE; ADULTS; DYSFUNCTION; DEPRESSION; EXCLUSION; PEOPLE AB BACKGROUND: Older participants are often excluded from clinical trials, precluding a representative sample. STUDY DESIGN: Using qualitative and quantitative methods, we examined recruitment and retention of older women with pelvic organ prolapse in two surgical trials: the randomized Colpopexy And Urinary Reduction Efforts (CARE) study and the Longitudinal Pelvic Symptoms and Patient Satisfaction After Colpocleisis cohort study. Using focus groups, we developed a questionnaire addressing factors facilitating and impeding the recruitment and retention of older study participants and administered it to research staff. Enrollment-to-surgery ratios, missed visit rates, and dropout rates for older and younger participants were compared using Fisher's exact test, with cut-points of 70 and 80 years for the CARE and Colpocleisis studies, respectively. RESULTS: Questionnaires were completed by 23 physician investigators and I I nurses or coordinators (92% response rate). Respondents indicated it was more difficult to recruit older research participants (32%), obtain informed con sent (56%), and retain participants to study completion (50%). Challenges to recruitment included caregiver involvement in the decision to participate and participant comorbidities. Perceived barriers to retention were transportation, caregiver availability, and participant fatigue. Data quality was challenged by sensory and cognitive impairment, resulting in a change from telephone inter-views to in-person visits in the Colpocleisis study. Older participants did not have higher dropout rates than younger participants. There were no differences in missed in-person visits or telephone interview rates between age groups. CONCLUSIONS: Strategies, albeit unstudied, could assist investigators in planning surgical trials-that successfully enroll and retain older women. C1 [Goode, Patricia S.] Univ Alabama, Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35233 USA. [Richter, Holly E.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA. [Goode, Patricia S.] Vet Affairs Med Ctr, Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [FitzGerald, Mary P.] Loyola Univ, Med Ctr, Dept Obstet & Gynecol, Maywood, IL 60153 USA. [Whitehead, William E.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Nygaard, Ingrid] Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Salt Lake City, UT USA. [Wren, Patricia A.] Oakland Univ, Dept Hlth Behav Hlth Educ, Rochester, MI 48063 USA. [Zyczynski, Halina M.] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet & Gynecol, Pittsburgh, PA 15213 USA. [Cundiff, Geoffrey] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada. [Menefee, Shawn] Univ Calif San Diego, Dept Obstet & Gynecol, San Diego, CA 92103 USA. [Senka, Judith M.] Northwestern Univ, Evanston Hosp, Dept Obstet & Gynecol, Evanston, IL 60201 USA. [Gao, Xin] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Weber, Anne M.] NICHHD, NIH, Bethesda, MD 20892 USA. RP Goode, PS (reprint author), Univ Alabama, Birmingham VA Med Ctr, Dept Med, 11G,700 S 19th St, Birmingham, AL 35233 USA. FU National Institute of Child Health and Human Development [U01 HD41249, U10 HD41268, U10 HD41248, U10 HD41250, U10 HD41261, U10 HD41263, U10 HD41269, U10 HD41267] FX Supported by grants from the National Institute of Child Health and Human Development (U01 HD41249, U10 HD41268, U10 HD41248, U10 HD41250, U10 HD41261, U10 HD41263, U10 HD41269, and U10 HD41267). NR 26 TC 11 Z9 12 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD SEP PY 2008 VL 207 IS 3 BP 303 EP 311 DI 10.1016/j.jamcollsurg.2008.03.012 PG 9 WC Surgery SC Surgery GA 349FD UT WOS:000259265800001 PM 18722933 ER PT J AU Shega, JW Rudy, T Keefe, FJ Perri, LC Mengin, OT Weiner, DK AF Shega, Joseph W. Rudy, Thomas Keefe, Francis J. Perri, Lisa Caitlin Mengin, Olga Telgarska Weiner, Debra K. TI Validity of pain behaviors in persons with mild to moderate cognitive impairment SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognitive impairment; non-cancer pain; pain behaviors ID LOW-BACK-PAIN; NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE; NONMALIGNANT PAIN; SELF-ASSESSMENT; RATING-SCALE; DEMENTIA; INTENSITY; PATTERNS; PATIENT AB OBJECTIVES: To evaluate the validity of traditional pain behaviors (guarding, bracing, rubbing, grimacing, and sighing) in persons with and without cognitive impairment and chronic low back pain (CLBP). DESIGN: Prospective observational study. SETTING: Outpatient clinics. PARTICIPANTS: Thirty-seven cognitively intact and 40 cognitively impaired participants with and without CLBP. MEASUREMENTS: Frequency of traditional pain behaviors. RESULTS: Forty-six of the participants were pain free, and 31 had CLBP. The internal consistency reliability coefficient of the five pain behaviors was 0.32, suggesting that a unidimensional scale did not exist. Multivariate analysis of variance analysis according to the independent variables pain status (pain free vs CLBP) and cognitive status (intact vs impaired) with the dependent variable frequency of pain behaviors found significant differences according to pain status (F[5,61]=3.06, P=.02) and cognitive status (F[5,61]=5.41, P <.001) but without evidence of an interaction (F[5,61]=1.14, P=.35). Participants with CLBP exhibited significantly higher levels of grimacing (P <.001) and guarding (P=.02) than pain-free participants. Intact subjects exhibited fewer guarding (P=.02) and rubbing behaviors (P <.001) but a higher number of bracing behaviors (P=.03) than cognitively impaired participants. CONCLUSION: These results support the utility of facial grimacing in assessing pain in patients with mild to moderate cognitive impairment and call into question the validity of guarding and rubbing in assessing pain in persons with mild to moderate cognitive impairment. C1 [Shega, Joseph W.; Perri, Lisa Caitlin] Northwestern Univ, Div Hematol & Oncol, Dept Med, Chicago, IL 60611 USA. [Rudy, Thomas; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Rudy, Thomas; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Rudy, Thomas] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Keefe, Francis J.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Perri, Lisa Caitlin] Duke Univ, Dept Psychol Social & Hlth Sci, Durham, NC USA. [Mengin, Olga Telgarska] Univ Illinois, Coll Med, Chicago, IL USA. [Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Shega, JW (reprint author), Northwestern Univ, Div Hematol & Oncol, Dept Med, 676 N St Clair,Suite 850, Chicago, IL 60611 USA. EM j-shega@northwestern.edu RI Comba, Valentina/G-6210-2014 FU University of Pittsburgh; Alzheimer's Disease Research Center FX The authors would like to thank Dr. Natalia Morone for her thoughtful review of this manuscript.; Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. Debra K. Weiner and Francis J. Keefe received federal funding during the study period, but the authors report no known conflicts of interest. The University of Pittsburgh. Alzheimer's Disease Research Center provided funding. NR 32 TC 26 Z9 26 U1 2 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2008 VL 56 IS 9 BP 1631 EP 1637 DI 10.1111/j.1532-5415.2008.01831.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 347PC UT WOS:000259152500006 PM 18662203 ER PT J AU Barnes, DE Blackwell, T Stone, KL Goldman, SE Hillier, T Yaffe, K AF Barnes, Deborah E. Blackwell, Terri Stone, Katie L. Goldman, Suzanne E. Hillier, Teresa Yaffe, Kristine CA Study Osteoporotic Fractures TI Cognition in older women: The importance of daytime movement SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE movement; exercise; activity; cognition; risk factor ID ALZHEIMERS-DISEASE; LEISURE ACTIVITIES; PHYSICAL-ACTIVITY; OSTEOPOROTIC FRACTURES; RISK; DEMENTIA; ACTIGRAPHY; SLEEP; HEALTH; PARTICIPATION AB OBJECTIVES: To determine whether an objective measure of daytime movement is associated with better cognitive function in women in their 80s. DESIGN: Cross-sectional. SETTING: A study of health and aging. PARTICIPANTS: Two thousand seven hundred thirty-six older women without evidence of dementia. MEASUREMENTS: Daytime movement was assessed using actigraphy, which involved wearing a watch-like device that objectively quantified accelerometer motion over a mean of 3.0 +/- 0.8 days. Cognitive function was measured using the Trail-Making Test, Part B (Trails B) and the Mini-Mental State Examination (MMSE). Cognitive impairment was defined as performing 1.5 standard deviations (SDs) worse than the mean on a given test. RESULTS: Participants had a mean age of 83 +/- 4; 10% were African American. After adjustment for age, race, and education, women in the highest movement quartiles had better mean cognitive test scores (20 +/- 0.3 seconds faster on Trails B and 0.3 +/- 0.2 points higher on MMSE, both P <.001) than those in the lowest quartile and were less likely to be cognitively impaired (odds ratio (OR)=0.61, 95% confidence interval (CI)=0.41-0.92 for Trails B; OR=0.68, 95% CI=0.44-1.07 for MMSE). Associations were similar in different subgroups and were independent of self-reported walking, medical comorbidities, physical function, and other health-related behaviors. CONCLUSION: Daytime movement as measured objectively using actigraphy was associated with better cognitive function and lower odds of cognitive impairment in women in their 80s. Additional studies are needed to clarify the direction of the association and to explore potential mechanisms. C1 [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Blackwell, Terri; Stone, Katie L.; Yaffe, Kristine] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA. [Goldman, Suzanne E.] Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN USA. [Hillier, Teresa] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA. [Hillier, Teresa] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM Deborah.Barnes@ucsf.edu FU National Institutes of Health [AG05407, AR35582, AG05394, AR35584, AR35583, AG08415, K01 AG024069] FX Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. The Study of Osteoporotic Fractures was funded through grants from the National Institutes of Health (AG05407, AR35582, AG05394, AR35584, AR35583, AG08415). Dr. Barnes is supported by a Career Development Award from the National Institutes of Health (K01 AG024069). Dr. Yaffe was supported in part by an anonymous foundation for this work. This study was presented at the American Academy of Neurology meeting in Boston, Massachusetts, on May 2, 2007, and at the American Geriatrics Society meeting in San Francisco, California, on November 19, 2007. NR 40 TC 30 Z9 30 U1 0 U2 16 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2008 VL 56 IS 9 BP 1658 EP 1664 DI 10.1111/j.1532-5415.2008.01841.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 347PC UT WOS:000259152500010 PM 18662201 ER PT J AU Espinoza, SE Hazuda, HP AF Espinoza, Sara E. Hazuda, Helen P. TI Frailty in older Mexican-American and European-American adults: Is there an ethnic disparity? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE frailty; ethnic disparities; screening ID WOMENS HEALTH; ASSOCIATION; OBESITY AB Because conventional frailty screening criteria have been standardized in predominantly European-American (EA) cohorts, applying them to ethnically diverse populations may result in inaccurate estimation of frailty prevalence in ethnic minorities. The objective of this study was to determine whether use of ethnic-specific criteria (EC) to characterize frailty in a bi-ethnic cohort results in significant differences in frailty prevalence when compared with the prevalence obtained using conventional criteria (CC). Data were from a random sample of community-dwelling Mexican Americans (MAs) (n=394) and EAs (n=355) aged 65 to 80 who participated in the baseline examination of the San Antonio Longitudinal Study of Aging. Frailty was defined as three or more of five characteristics: slow walking speed, weak grip strength, low energy expenditure, self-reported exhaustion, and weight loss. For CC, walking speed was standardized to height and sex, grip strength was standardized to body mass index and sex, and energy expenditure was standardized to sex using the pooled sample. For EC, these criteria were applied within each ethnic group. Frailty prevalence in MAs and EAs was compared using chi-square statistic. Using CC, a higher proportion of MAs than EAs were frail (11.3% vs 7.0%, P=.045). Using EC, there was no difference in frailty prevalence between MAs and EAs (9.9% in both ethnic groups). The application of conventional frailty screening criteria in a bi-ethnic cohort results in a higher prevalence of frailty in MAs than in EAs. In determining whether there are ethnic disparities in frailty, future studies should carefully consider whether CC or EC should be applied. C1 [Espinoza, Sara E.; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Espinoza, Sara E.] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Espinoza, Sara E.] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Espinoza, SE (reprint author), 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA. EM espinozas2@uthscsa.edu FU National Institute on Aging [R01AG10444, R01-AG16518]; National Center for Research Resources [M01-RR01346] FX The authors would like to acknowledge Adrienne Boulton for her assistance with data management.; Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. This study was supported by National Institute on Aging Grants R01AG10444 and R01-AG16518 and National Center for Research Resources Grant M01-RR01346. NR 16 TC 29 Z9 31 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2008 VL 56 IS 9 BP 1744 EP 1749 DI 10.1111/j.1532-5415.2008.01845.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 347PC UT WOS:000259152500023 PM 18662198 ER PT J AU Pittman, J Rawl, SM Schmidt, CM Grant, M Ko, CY Wendel, C Krouse, RS AF Pittman, Joyce Rawl, Susan M. Schmidt, C. Max Grant, Marcia Ko, Clifford Y. Wendel, Christopher Krouse, Robert S. TI Demographic and clinical factors related to ostomy complications and quality of life in veterans with an ostomy SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article ID PERISTOMAL COMPLICATIONS; STOMA; COLOSTOMY; PATIENT; CARE AB PURPOSE: The purpose of this study is to describe demographic, clinical, and quality-of-life variables related to ostomy complications (skin irritation, leakage, and difficulty adjusting to an ostomy) in a veteran population in the United States. DESIGN: The original study employed a descriptive cross-sectional study using a mixed method design. This secondary analysis used the quantitative data collected. SAMPLE AND SETTING: Two hundred thirty-nine veterans with intestinal ostomies from 3 Veteran's Administration hospitals participated in the study. METHODS: Instruments used for this investigation included the City of Hope Quality of Life: Ostomy Instrument. Demographic and medical history data were collected from the survey, the Veteran's Administration health information system, and the Tumor Registry database. A self-administered survey questionnaire (mCOH-QOL-Ostomy) was mailed to each participant. RESULTS: The severity of skin irritation, problems with leakage, and difficulty adjusting were significantly related to demographic, clinical, and quality-of-life domains. Univariate analyses showed that age, income, employment, preoperative care (stoma site marking and education), having a partner, ostomy type, reason for ostomy, time since surgery, total quality-of-life scores and scores on all 4 domains of quality of life were related to the severity of these ostomy complications. Age was inversely related to severity of all 3 ostomy complications (skin irritation, leakage, and difficulty adjusting). Having an ileostomy, rather than a colostomy, was associated with higher severity of skin irritation. Having had the stoma site marked preoperatively was associated with less difficulty adjusting to an ostomy, and having had preoperative ostomy education was associated with less severe problems with skin irritation and leakage. Severity of each ostomy complication predicted total quality-of-life scores. Difficulty adjusting to the ostomy was related to all 4 quality-of-life domains (physical, psychological, social, and spiritual). CONCLUSIONS: This study found important relationships between demographic and clinical factors and ostomy complications. Skin problems, leakage, and difficulty adjusting predicted total quality of life scores and domains. Establishing relationships among ostomy complications and demographic, clinical factors, and quality of life can enhance identification of patients at risk for the development of complications and is an important first step in identifying the development of effective interventions to reduce the negative impact of complications for people with ostomies. Further study of predictors and outcomes of ostomy complications is needed to improve care. C1 [Pittman, Joyce; Rawl, Susan M.] Indiana Univ Purdue Univ, Sch Nursing, Indianapolis, IN 46202 USA. [Pittman, Joyce] Clarian Hlth Syst Methodist Hosp, Wound Ost Continence Team, Indianapolis, IN USA. [Schmidt, C. Max] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Schmidt, C. Max] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA. [Grant, Marcia] City Hope Natl Med Ctr & Beckman Res, Dept Nursing Res & Educ, Durante, CA USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Wendel, Christopher] So Arizona VA Healthcare Syst, Res Serv Line, Tucson, AZ USA. [Krouse, Robert S.] Univ Arizona, Tucson, AZ USA. RP Pittman, J (reprint author), Clarian Hlth Methodist, 1701 Senate Blvd,B250, Indianapolis, IN 46206 USA. EM jpittma3@clarian.org OI Rawl, Susan/0000-0003-2052-2853 FU Veterans Affairs Health Services Research and Development Service (HSRD) [IIR 02-221-2] FX This research was supported by a grant from the Veterans Affairs Health Services Research and Development Service (HSR&D) IIR 02-221-2: Health-Related Quality of Life in VA Patients with Intestinal Stomas. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 22 TC 75 Z9 80 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD SEP-OCT PY 2008 VL 35 IS 5 BP 493 EP 503 PG 11 WC Nursing SC Nursing GA 357FC UT WOS:000259830700006 PM 18794701 ER PT J AU Cadogan, MP Edelen, MO Lorenz, KA Jones, M Yosef, J Hascall, T Simon, B Harker, JO Ferrell, B Saliba, D AF Cadogan, Mary P. Edelen, Maria Orlando Lorenz, Karl A. Jones, Malia Yosef, Julia Hascall, Thomas Simon, Barbara Harker, Judith O. Ferrell, Bruce Saliba, Debra TI The Relationship of Reported Pain Severity to Perceived Effect on Function of Nursing Home Residents SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Pain; Nursing home; Activity limitation ID MINIMUM DATA SET; SYMPTOM ASSESSMENT SCALE; RECEIVING PRIMARY-CARE; QUALITY INDICATOR; NONMALIGNANT PAIN; OLDER-ADULTS; PREVALENCE; INTENSITY; RELIABILITY; PERSPECTIVE AB Background. We examined whether questions addressing the effect of pain on day-to-day function add unique information to the standardized verbal descriptor scale for pain severity in nursing homes (NHs). Methods. Interviews were conducted with 123 residents in two Veterans Affairs NHs. All participants were asked about pain presence. Residents reporting pain were asked about severity of worst pain (mild, moderate, severe, very severe/horrible), degree of bother (not at all, a little, a moderate amount, a great deal), and the effect of pain on daily function (whether pain made it hard to "sleep," "get out of bed," or "spend time with other people" and whether activities were limited because of pain). Results. Fifty-one percent of participants reported pain. The correlation between pain severity report and overall count of activity interference was significant (Spearman's rho = .449, p = .001). In general, for each activity, the proportion reporting interference increased as severity increased. Fischer's exact test showed significant association only for "hard to get out of bed" (p = .0175) and "hard to sleep" (p = .0211). As expected, residents reporting "mild" pain reported less activity interference than those reporting "very severe" pain. The association between pain and activity interference was more variable and less predictable among residents with "moderate" or "severe" pain. Conclusion. Questions addressing the effect of pain on day-to-day functions are an important addition to standardized pain assessments, particularly for persons who report intermediate levels of pain severity because the perceived effect on daily function may vary most among individuals at these levels. C1 [Cadogan, Mary P.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Lorenz, Karl A.; Ferrell, Bruce] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. [Edelen, Maria Orlando; Lorenz, Karl A.; Jones, Malia; Saliba, Debra] RAND Corp, Santa Monica, CA USA. [Cadogan, Mary P.; Lorenz, Karl A.; Yosef, Julia; Hascall, Thomas; Simon, Barbara; Harker, Judith O.; Saliba, Debra] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA 90095 USA. RP Cadogan, MP (reprint author), Univ Calif Los Angeles, Sch Nursing, Factor 5-952,Box 956919, Los Angeles, CA 90095 USA. EM mcadogan@sonnet.ucla.edu FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [SDR 03-217] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service SDR 03-217.; The views expressed in this research are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 31 TC 20 Z9 20 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD SEP PY 2008 VL 63 IS 9 BP 969 EP 973 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 360RI UT WOS:000260074800010 PM 18840802 ER PT J AU Fried, LF AF Fried, Linda F. TI Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease SO KIDNEY INTERNATIONAL LA English DT Review DE proteinuria; chronic kidney disease; statin; lipids; progression ID CHRONIC RENAL-INSUFFICIENCY; CORONARY-HEART-DISEASE; DIABETIC-NEPHROPATHY; MESANGIAL CELLS; DENSITY LIPOPROTEINS; NEPHROTIC PATIENTS; RAT MODEL; PROTEINURIA; SIMVASTATIN; INJURY AB Chronic kidney disease, especially in the setting of proteinuria, is characterized by hyperlipidemia. In animal models, hyperlipidemia causes glomerular foam cells and glomerulosclerosis. Treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) ameliorates kidney disease in these models. The data of the role of hyperlipidemia in progression of human kidney disease are less clear. Data from small studies in glomerular disease suggest that statins decrease proteinuria. Data mainly from cardiovascular studies suggest that statins decrease the loss of glomerular filtration. The benefit of statins may derive from their lipid lowering effects. More recently, data suggest that the benefit of statins is greater than lipid lowering alone. The pleiotropic effects of statins may derive from inhibition of other downstream targets (isoprenoids) of the mevalonic acid pathway that are separate from cholesterol synthesis. Statins inhibits isoprenylation of Ras and Rho GTPases. These effects may lead to decreased monocyte/macrophage infiltration in the glomerulus, decreased mesangial proliferation and decreased accumulation of extracellular matrix and fibrosis. In addition, inhibition of RhoA and Ras may decrease inflammation and increase eNOS activity. These effects could lead to improvement in the progression of kidney disease. C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. RP Fried, LF (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 60 TC 41 Z9 47 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD SEP PY 2008 VL 74 IS 5 BP 571 EP 576 DI 10.1038/ki.2008.231 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 338TM UT WOS:000258531800009 PM 18528321 ER PT J AU Hausmann, LRM Jeong, K Bost, JE Ibrahim, SA AF Hausmann, Leslie R. M. Jeong, Kwonho Bost, James E. Ibrahim, Said A. TI Perceived discrimination in health care and health status in a racially diverse sample SO MEDICAL CARE LA English DT Article DE discrimination; health inequality; health status; national surveys; race and ethnicity ID SELF-REPORTED DISCRIMINATION; AFRICAN-AMERICAN WOMEN; US BLACK-WOMEN; MENTAL-HEALTH; INTERVIEW SURVEY; BLOOD-PRESSURE; NEW-HAMPSHIRE; RACISM; PERCEPTIONS; EXPERIENCES AB Background: Despite the surge of recent research on the association between perceived discrimination and health-related outcomes, few studies have focused on race-based discrimination encountered in health care settings. This study examined the prevalence of such discrimination, and its association with health status, for the 3 largest race/ethnic groups in the United States. Methods: Data were drawn from the 2004 Behavioral Risk Factor Surveillance System survey. The primary variables were perceived racial discrimination in health care and self-reported health status. Multivariable logistic regression was used to compare the prevalence of perceived discrimination for whites, African Americans, and Hispanics, and to examine the association between perceived discrimination and health status, controlling for sex, age, income, education, health care coverage, affordability of medical care, racial salience, and state. Results: Perceived discrimination was reported by 2%, 5.2%, and 10.9% of whites, Hispanics, and African Americans, respectively. Only the difference between African Americans and whites remained significant in adjusted analyses [odds ratio (OR) = 3.22, 95% confidence interval (CI) = 2.46-4.21]. Racial/ethnic differences in perceived discrimination depended on income, education, health care coverage, and affordability of medical care. Perceived discrimination was associated with worse health status for the overall sample (OR = 1.71, 95% CI = 1.35-2.16). Stratified analyses revealed that this relationship was significant for whites (OR = 2.00, 95% CI = 1.45-2.77) and African Americans (OR = 1.95, 95% CI = 1.39-2.73), but not for Hispanics (OR = 0.55, 95% CI = 0.24-1.22). Conclusions: Perceived racial discrimination in health care is much more prevalent for African Americans than for whites or Hispanics. Furthermore, such discrimination is associated with worse health both for African Americans and for whites. C1 [Hausmann, Leslie R. M.; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Jeong, Kwonho; Bost, James E.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Bost, James E.] Univ Pittsburgh, Res Ctr, Hlth Care Data Ctr, Pittsburgh, PA USA. [Ibrahim, Said A.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@gmail.com FU VA Health Services Research and Development Career Development Award [RCD 06-287]; National Center for Research Resources (NCRR); National Institutes of Health (NIH); NIH Roadmap for Medical Research [ULI RR024153]; National Institutes of Musculoskeletal and Skin Disorders K24 Award [1K24AR055259-01]; VA Health Services Research and Development Award; Harold Amos Robert Wood Johnson Scholar Award FX Supported by VA Health Services Research and Development Career Development Award #RCD 06-287 (to L.R.M.H.). Supported by the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research grant #ULI RR024153. Supported by the National Institutes of Musculoskeletal and Skin Disorders K24 Award #1K24AR055259-01 (to S.A.I., also the recipient of a VA Health Services Research and Development Award and the Harold Amos Robert Wood Johnson Scholar Award). NR 52 TC 77 Z9 78 U1 5 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2008 VL 46 IS 9 BP 905 EP 914 DI 10.1097/MLR.0b013e3181792562 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 344RQ UT WOS:000258945400004 PM 18725844 ER PT J AU Sales, A Sharp, N Li, YF Lowy, E Greiner, G Liu, CF Alt-White, A Rick, C Sochalski, J Mitchell, PH Rosenthal, G Stetler, C Cournoyer, P Needleman, J AF Sales, Anne Sharp, Nancy Li, Yu-Fang Lowy, Elliott Greiner, Gwendolyn Liu, Chuan-Fen Alt-White, Anna Rick, Cathy Sochalski, Julie Mitchell, Pamela H. Rosenthal, Gary Stetler, Cheryl Cournoyer, Paulette Needleman, Jack TI The association between nursing factors and patient mortality in the Veterans Health Administration - The view from the nursing unit level SO MEDICAL CARE LA English DT Article ID COMORBIDITY INDEX; HOSPITALS; CARE; DATABASES; OUTCOMES; QUALITY; VALIDATION; ICD-9-CM; AFFAIRS AB Context: Nurse staffing is not the same across an entire hospital. Nursing care is delivered in geographically-based units, with wide variation in staffing levels. In particular, staffing in intensive care is much richer than in nonintensive care acute units. Objective: To evaluate the association of in-hospital patient mortality with registered nurse staffing and skill mix comparing hospital and unit level analysis using data from the Veterans Health Administration (VHA). Design, Settings, and Patients: A retrospective observational study using administrative data from 129,579 patients from 453 nursing units (171 ICU and 282 non-ICU) in 123 VHA hospitals. Methods: We used hierarchical multilevel regression models to adjust for patient, unit, and hospital characteristics, stratifying by whether or not patients had an ICU stay during admission. Main Outcome Measure: In-hospital mortality. Results: Of the 129,579 patients, mortality was 2.9% overall: 6.7% for patients with an ICU stay compared with 1.6% for those without. Whether the analysis was done at the hospital or unit level affected findings. RN staffing was not significantly associated with in-hospital mortality for patients with ail ICU stay (OR, 1.02; 95% Cl, 0.99-1.03). For non-ICU patients, increased RN staffing was significantly associated with decreased mortality risk (OR, 0.91; 95% CI, 0.86-0.96). RN education was not significantly associated with mortality. Conclusions: Our findings suggest that the association between RN staffing and skill mix and in-hospital patient mortality depends on whether the analysis is conducted at the hospital or unit level. Variable staffing on non-ICU units may significantly contribute to in-hospital mortality risk. C1 [Sales, Anne] Univ Alberta, Fac Nursing, Edmonton, AB T6G 2G3, Canada. [Sales, Anne; Sharp, Nancy; Li, Yu-Fang; Lowy, Elliott; Greiner, Gwendolyn; Liu, Chuan-Fen] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Sales, Anne; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Alt-White, Anna; Rick, Cathy] VA Cent Off, Off Nursing Serv, Washington, DC USA. [Sochalski, Julie] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Mitchell, Pamela H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Rosenthal, Gary] Univ Iowa, Iowa City, IA 52242 USA. [Rosenthal, Gary] Iowa City VA Med Ctr, Iowa City, IA USA. [Stetler, Cheryl; Cournoyer, Paulette; Needleman, Jack] Univ Calif Los Angeles, Los Angeles, CA USA. RP Sales, A (reprint author), Univ Alberta, Fac Nursing, 3-114 Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada. EM anne.sales@ualberta.ca RI Sales, Anne/D-9678-2012; Needleman, Jack/I-5461-2013 OI Needleman, Jack/0000-0002-2875-0589; Sales, Anne/0000-0001-9360-3334 FU Office of Research and Development; Health Services RD Service; Department of Veterans Affairs [IIR 01-160] FX Supported by the Office of Research and Development, Health Services R&D Service, Department of Veterans Affairs, project number IIR 01-160. NR 23 TC 50 Z9 53 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2008 VL 46 IS 9 BP 938 EP 945 DI 10.1097/MLR.0b013e3181791a0a PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 344RQ UT WOS:000258945400008 PM 18725848 ER PT J AU Ling, BS Trauth, JM Fine, MJ Mor, MK Resnick, A Braddock, CH Bereknyei, S Weissfeld, JL Schoen, RE Ricci, EM Whittle, J AF Ling, Bruce S. Trauth, Jeanette M. Fine, Michael J. Mor, Maria K. Resnick, Abby Braddock, Clarence H. Bereknyei, Sylvia Weissfeld, Joel L. Schoen, Robert E. Ricci, Edmund M. Whittle, Jeffrey TI Informed decision-making and colorectal cancer screening - Is it occurring in primary care? SO MEDICAL CARE LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med DE informed choice; decision-making; patient preference; colorectal cancer screening; communication ID RECOMMENDATIONS; PREFERENCES; GUIDELINES; RATIONALE; RISK AB Background: Current recommendations advise patients to participate in the decision-making for selecting a colorectal cancer (CRC) screening option. The degree to which providers communicate the information necessary to prepare patients for participation in this process is not known. Objective: To assess the level of informed decision-making occurring during actual patient-provider communications on CRC screening and test for the association between informed decision-making and screening behavior. Research Design: Observational study of audiotaped clinic visits between patients and their providers in the primary care clinic at a Veterans Administration Medical Center. Subjects: Male patients, age 50-74 years, presenting to a primary care visit at the study site. Measures: The Informed Decision-Making (IDM) Model was used to code the audiotapes for 9 elements of communication that should occur to prepare patients for participation in decision-making. The primary outcome is completion of CRC screening during the study period. Results: The analytic cohort consisted of 91 patients due for CRC screening who had a test ordered at the visit. Six of the 9 IDM elements occurred in <= 20% of the visits with none addressed in >= 50%. CRC screening occurred less frequently for those discussing "pros and cons" (12% vs. 46%, P = 0.01) and "patient preferences" (6% vs. 47%, P = 0.001) compared with those who did not. Conclusions: We found that a lack of informed decision-making occurred during CRC screening discussions and that particular elements of the process were negatively associated with screening. Further research is needed to better understand the effects of informed decision-making on screening behavior. C1 [Ling, Bruce S.; Fine, Michael J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Ling, Bruce S.; Fine, Michael J.; Mor, Maria K.; Resnick, Abby] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ling, Bruce S.; Fine, Michael J.; Weissfeld, Joel L.; Schoen, Robert E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Trauth, Jeanette M.; Ricci, Edmund M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Braddock, Clarence H.; Bereknyei, Sylvia] Stanford Univ, Div Gen Internal Med, Sch Med, Palo Alto, CA 94304 USA. [Whittle, Jeffrey] Med Coll Wisconsin, Milwaukee, WI 53226 USA. RP Ling, BS (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM lingbs@upmc.edu FU AHRQ HHS [5P01 HS10864]; NCI NIH HHS [5K07 CA090359] NR 23 TC 48 Z9 49 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2008 VL 46 IS 9 SU 1 BP S23 EP S29 DI 10.1097/MLR.0b013e31817dc496 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 344RR UT WOS:000258945500005 PM 18725829 ER PT J AU Solomon, VR Haq, W Smilkstein, M Srivastava, K Rajakumar, S Puri, SK Katti, SB AF Solomon, V. Raja Haq, W. Smilkstein, M. Srivastava, Kumkum Rajakumar, S. Puri, Sunil K. Katti, S. B. TI Synthesis and antimalarial activity of novel side chain modified antimalarial agents derived from 4-aminoquinoline SO MEDICINAL CHEMISTRY LA English DT Article DE 4-aminoquinoline; amino acid conjugates; antimalarial agents ID BETA-HEMATIN FORMATION; PLASMODIUM-FALCIPARUM; ANTIPLASMODIAL ACTIVITY; RETAIN ACTIVITY; CHLOROQUINE; INHIBITION; RESISTANCE; PROTEIN; POLYMERIZATION; MECHANISM AB Malaria is one of the foremost public health problems in developing countries affecting nearly 40% of the global population. Apart from this, the past two decade's emergence of drug resistance has severely limited the choice of available antimalarial drugs. Furthermore, the general trend emerging from the SAR-studies is that chloroquine resistance does not involve any change to the target of this class of drugs but involves compound specific efflux mechanism. Based on this premise a number of groups have developed short chain analogues of 4-aminoquinoline, which are active against CQ-resistant strains of P. falciparum in in vitro studies. However, these derivatives undergo biotransformation (de-alklyation) significantly affecting lipid solubility of the drug. In view of this background information, we thought that it would be interesting to study the effect of additional lipophilicity and cationic charge at the lateral side chain of 4-aminoquinoline. This prompted us to explore the cationic amino acid conjugates namely, lysine and ornithine of 4-aminoquinoline with a view to achieve improved antimalarial activity and to the best of our knowledge such amino acid conjugates have not been hitherto reported in the literature in the case of 4-aminoquinolines. In the present study, a new series of side-chain modified 4-aminoquinolines have been synthesized and found active against both susceptible and multidrug resistant strains of P. falciparum in vitro and P. yoelli in vivo. The seminal finding of the present study is that a new series of compounds having significantly more activity against CQ resistant parasites has been identified. C1 [Solomon, V. Raja; Haq, W.; Katti, S. B.] Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226001, Uttar Pradesh, India. [Smilkstein, M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Srivastava, Kumkum; Rajakumar, S.; Puri, Sunil K.] Cent Drug Res Inst, Div Parasitol, Lucknow 226001, Uttar Pradesh, India. RP Katti, SB (reprint author), Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226001, Uttar Pradesh, India. EM setu_katti@yahoo.com FU CDRI [7213]; CSIR, New Delhi FX The authors thank the Director, CDRI for the support and the SAIF for the spectral data. The authors are thankful to Michael Riscoe, Ph. D., for careful reading the manuscript. One of the authors (V. R. Solomon) thanks the CSIR, New Delhi for Senior Research Fellowship. CDRI communication no. 7213. NR 25 TC 6 Z9 6 U1 0 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1573-4064 J9 MED CHEM JI Med. Chem. PD SEP PY 2008 VL 4 IS 5 BP 446 EP 456 DI 10.2174/157340608785700207 PG 11 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 352OH UT WOS:000259506100004 PM 18782041 ER PT J AU Lu, TC Wang, ZH Feng, XB Chuang, P Fang, W Chen, YB Neves, S Maayan, A Xiong, HB Liu, YS Iyengar, R Klotman, PE He, JC AF Lu, Ting-Chi Wang, Zhaohui Feng, Xiaobei Chuang, Peter Fang, Wei Chen, Yibang Neves, Susana Maayan, Avi Xiong, Huabao Liu, Yusen Iyengar, Ravi Klotman, Paul E. He, John Cijiang TI Retinoic acid utilizes CREB and USF1 in a transcriptional feed-forward loop in order to stimulate MKP1 expression in human immunodeficiency virus-infected podocytes SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID PROTEIN-KINASE PHOSPHATASE-1; HIV-ASSOCIATED NEPHROPATHY; MAP KINASE; GENE-TRANSCRIPTION; NEPHROTIC SYNDROME; PROXIMAL PROMOTER; RENAL DEVELOPMENT; NPHS2 PROMOTER; MESSENGER-RNA; ACTIVATION AB Nef-induced podocyte proliferation and dedifferentiation via mitogen-activated protein kinase 1,2 (MAPK1,2) activation plays a role in human immunodeficiency virus (HIV) nephropathy pathogenesis. All-trans retinoic acid (atRA) reverses the HIV-induced podocyte phenotype by activating cyclic AMP (cAMP)/protein kinase A (PKA) and inhibiting MAPK1,2. Here we show that atRA, through cAMP and PKA, triggers a feed-forward loop involving CREB and USF1 to induce biphasic stimulation of MKP1. atRA stimulated CREB and USF1 binding to the MKP1 gene promoter, as shown by gel shifting and chromatin immunoprecipitation assays. CREB directly mediated the early phase of atRA-induced MKP1 stimulation; whereas the later phase was mediated by CREB indirectly through induction of USF1. These findings were confirmed by a reporter gene assay using the MKP1 promoter with mutation of CRE or Ebox binding sites. Consistent with these findings, the biological effects of atRA on podocytes were inhibited by silencing either MKP1, CREB, or USF1 with small interfering RNA. atRA also induced CREB phosphorylation and MKP1 expression and reduced MAPK1,2 phosphorylation in kidneys of HIV type 1-infected transgenic mice. We conclude that atRA induces sustained activation of MKP1 to suppress Nef-induced activation of the Src-MAPK1,2 pathway, thus returning the podocyte to a more differentiated state. The mechanism involves a feed-forward loop where activation of one transcription factor (TF) (CREB) leads to induction of a second TF (USF1). C1 [Lu, Ting-Chi; Chuang, Peter; Fang, Wei; Klotman, Paul E.; He, John Cijiang] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. [Chen, Yibang; Neves, Susana; Maayan, Avi; Iyengar, Ravi; He, John Cijiang] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Xiong, Huabao] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA. [He, John Cijiang] James J Peters VA Med Ctr, Bronx, NY USA. [Wang, Zhaohui; Feng, Xiaobei] Shanghai Jiao Tong Univ, Sch Med, Dept Nephrol, Rui Jin Hosp, Shanghai 200030, Peoples R China. [Liu, Yusen] Ohio State Univ, Childrens Res Inst, Columbus, OH 43210 USA. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Cijiang.he@mssm.edu RI Liu, Yusen/E-3527-2011 FU NIH [K08 DK079781, K08 DK065495, R01 DK078897, P01 DK056492, R01 DK38761] FX Ting-Chi Lu is a recipient of an NIH career development award (K08 DK079781). John Cijiang He is a recipient of an NIH career development award (K08 DK065495) and is supported by NIH R01 DK078897. This work was also supported by NIH grants P01 DK056492 to Paul E. Klotman and R01 DK38761 to Ravi Iyengar. NR 48 TC 25 Z9 28 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD SEP PY 2008 VL 28 IS 18 BP 5785 EP 5794 DI 10.1128/MCB.00245-08 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 344TU UT WOS:000258951000019 PM 18625721 ER PT J AU Rettig, MB Heber, D An, JB Seeram, NP Rao, JY Liu, HR Klatte, T Belldegrun, A Moro, A Henning, SM Mo, DQ Aronson, WJ Pantuck, A AF Rettig, Matthew B. Heber, David An, Jiabin Seeram, Navindra P. Rao, Jian Y. Liu, Huiren Klatte, Tobias Belldegrun, Arie Moro, Aune Henning, Susanne M. Mo, Deqiong Aronson, William J. Pantuck, Allan TI Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappa B-dependent mechanism SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; MOUSE MODEL; IN-VITRO; PROGRESSION; INFLAMMATION; CARCINOGENESIS; ANGIOGENESIS; METABOLITES AB Constitutive nuclear factor-kappa B (NF-kappa B) activation is ob served in androgen-independent prostate cancer and represents a predictor for biochemical recurrence after radical prostatectomy. Dietary agents such as pomegranate extract (PE) have received increasing attention as potential agents to prevent the onset or progression of many malignancies, including prostate cancer. Here, we show that PE inhibited NF-kappa B and cell viability of prostate cancer cell lines in a dose-dependent fashion in vitro. Importantly, maximal PE-induced apoptosis was dependent on PE-mediated NF-kappa B blockade. In the LAPC4 xenograft model, PE delayed the emergence of LAPC4 androgen-independent xenografts in castrated mice through an inhibition of proliferation and induction of apoptosis. Moreover, the observed increase in NF-kappa B activity during the transition from androgen dependence to androgen independence in the LAPC4 xenograft model was abrogated by PE. Our study represents the first description of PE as a promising dietary agent for the prevention of the emergence of androgen independence that is driven in part by heightened NF-kappa B activity. C1 [Rettig, Matthew B.; An, Jiabin; Mo, Deqiong] VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Med, Los Angeles, CA 90073 USA. [Rettig, Matthew B.; Liu, Huiren] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA. [Rettig, Matthew B.; Klatte, Tobias; Belldegrun, Arie; Aronson, William J.; Pantuck, Allan] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90024 USA. [Rao, Jian Y.] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA. [Seeram, Navindra P.; Moro, Aune; Henning, Susanne M.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA. [Aronson, William J.] VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Urol, Los Angeles, CA 90073 USA. RP Rettig, MB (reprint author), VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Med, Bldg 304,Room E1-113,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mrettig@mednet.ucla.edu FU Sence Foundation and POM Wonderful; University of California-Los Angeles Prostate Specialized Program of Research Excellence [P50 CA92131]; Department of Defense [W81XWH-04-1-0529]; Department of Veterans Affairs Merit Review Program FX Sence Foundation and POM Wonderful (A. Pantuck), University of California-Los Angeles Prostate Specialized Program of Research Excellence grant P50 CA92131, and Department of Defense award W81XWH-04-1-0529 and Department of Veterans Affairs Merit Review Program (M.B. Rettig). NR 36 TC 59 Z9 62 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD SEP PY 2008 VL 7 IS 9 BP 2662 EP 2671 DI 10.1158/1535-7163.MCT-08-0136 PG 10 WC Oncology SC Oncology GA 350XP UT WOS:000259387300008 PM 18790748 ER PT J AU Hawker, KS O'Connor, P Freedman, MS Calabresi, PA Antel, JP Simon, J Hauser, SL Waubant, E Vollmer, T Panitch, H Zhang, J Chin, P Smith, C AF Hawker, Kathleen S. O'Connor, Paul Freedman, Mark S. Calabresi, Peter A. Antel, Jack P. Simon, Jack Hauser, Stephen L. Waubant, Emmanuelle Vollmer, Timothy Panitch, Hillel Zhang, Jiameng Chin, Peter Smith, Craig TI Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial SO MULTIPLE SCLEROSIS LA English DT Meeting Abstract CT 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis CY SEP 17-20, 2008 CL Montreal, CANADA SP Amer Comm Treatment & Res Multiple Scleros, European Comm Treatment & Res Multiple Scleros, Latin Amer Comm Treatment & Res Multiple Scleros C1 [Hawker, Kathleen S.] Ohio State Univ, Columbus, OH 43210 USA. [O'Connor, Paul] Univ Toronto, Toronto, ON, Canada. [Freedman, Mark S.] Ottawa Hosp, Ottawa, ON, Canada. [Calabresi, Peter A.] Johns Hopkins Univ, Baltimore, MD USA. [Antel, Jack P.] McGill Univ, Montreal, PQ, Canada. [Simon, Jack] Portland VA Med Ctr, Portland, OR USA. [Hauser, Stephen L.; Waubant, Emmanuelle] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Vollmer, Timothy] Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Panitch, Hillel] Univ Vermont, Burlington, VT USA. [Zhang, Jiameng; Chin, Peter; Smith, Craig] Genentech Inc, San Francisco, CA 94080 USA. RI Hauser, Stephen/J-2978-2016 NR 0 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD SEP PY 2008 VL 14 BP S299 EP S299 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 354YL UT WOS:000259675700978 ER PT J AU Kinkel, RP O'Connor, P Simon, J Carulli, J Castrillo, MD Goelz, S Hyde, R Lanker, S Pace, A Sandrock, A Zhang, H AF Kinkel, R. P. O'Connor, Paul Simon, Jack Carulli, John Castrillo, Maria del Carmen Goelz, Susan Hyde, Robert Lanker, Stefan Pace, Amy Sandrock, Alfred Zhang, Hao TI Magnetic resonance imaging activity predicts multiple sclerosis patients' response to treatment with interferon beta-1a SO MULTIPLE SCLEROSIS LA English DT Meeting Abstract CT 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis CY SEP 17-20, 2008 CL Montreal, CANADA SP Amer Comm Treatment & Res Multiple Scleros, European Comm Treatment & Res Multiple Scleros, Latin Amer Comm Treatment & Res Multiple Scleros C1 [Kinkel, R. P.] Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Boston, MA 02215 USA. [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Simon, Jack] Portland VA Med Ctr, Portland, OR USA. [Carulli, John; Castrillo, Maria del Carmen; Goelz, Susan; Hyde, Robert; Lanker, Stefan; Pace, Amy; Sandrock, Alfred; Zhang, Hao] Biogen Idec Inc, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD SEP PY 2008 VL 14 BP S51 EP S51 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 354YL UT WOS:000259675700153 ER PT J AU Vandenbark, AA Burrows, GG Ravey, EP Offner, H AF Vandenbark, Arthur A. Burrows, Gregory G. Ravey, Edward P. Offner, Halina TI Phase I safety study of RTL1000, a recombinant T-cell receptor ligand specific for MOG peptide, in multiple sclerosis SO MULTIPLE SCLEROSIS LA English DT Meeting Abstract CT 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis CY SEP 17-20, 2008 CL Montreal, CANADA SP Amer Comm Treatment & Res Multiple Scleros, European Comm Treatment & Res Multiple Scleros, Latin Amer Comm Treatment & Res Multiple Scleros C1 [Vandenbark, Arthur A.] Portland VA Med Ctr, Portland, OR USA. [Burrows, Gregory G.; Ravey, Edward P.; Offner, Halina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD SEP PY 2008 VL 14 BP S247 EP S247 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 354YL UT WOS:000259675700811 ER PT J AU Muller, FL Liu, Y Jernigan, A Borchelt, D Richardson, A van Remmen, H AF Muller, Florian L. Liu, Yuhong Jernigan, Amanda Borchelt, David Richardson, Arlan van Remmen, Holly TI MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models SO MUSCLE & NERVE LA English DT Article DE ALS; MnSOD; oxidative stress; G93A; H46R/H48Q ID AMYOTROPHIC-LATERAL-SCLEROSIS; MANGANESE SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; MICE; MINOCYCLINE; DAMAGE; ONSET; INCLUSIONS AB Mitochondrial dysfunction and oxidative stress are thought to participate in the pathogenesis of amyotrophic lateral sclerosis (ALS). The purpose of this study was to determine the effect of reduced mitochondrial antioxidant defense on lifespan and disease progression in two mouse models of familial ALS (G93A and H46R/H48Q mutant lines) that represent pseudo-wildtype and metal-deficient AILS mutants, respectively. The metal-deficient H46R/H48Q mutant differs from the G93A mutant in that it cannot bind copper in the active site and thus lacks SOD activity. We crossed each of these mutant lines with mice deficient in the mitochondrial matrix antioxidant enzyme MnSOD (Sod2(+/-) mice). In both high (G93A(1) (Gur)) and low (G93A(DL)) copy G93A strains, MnSOD deficiency caused a decrease in lifespan that was associated with a reduced disease duration rather than earlier disease onset. In contrast, MnSOD deficiency had no effect on lifespan or disease parameters of H46R/H48Q mutant mice. MnSOD deficiency thus has a differential effect on disease progression in different mutant SOD1 ALS mouse models, suggesting that different ALS-causing mutations in SOD1 result in disease progression by at least proximally different mechanisms/pathways. C1 [Richardson, Arlan; van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Muller, Florian L.; Richardson, Arlan; van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Liu, Yuhong; Jernigan, Amanda; Richardson, Arlan; van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Borchelt, David] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA. RP van Remmen, H (reprint author), S Texas Vet Hlth Care Syst, San Antonio, TX USA. EM vanremmen@uthscsa.edu FU Department of Veteran Affairs (HVR); Muscular Dystrophy Association [MDA 3879]; NIA [5T3-AG021890-02] FX Supported by a VA Merit grant from the Department of Veteran Affairs (HVR), a grant from the Muscular Dystrophy Association (#MDA 3879), and NIA training grant #5T3-AG021890-02 (FLM). We thank Jay Cox and Marian Sabia for excellent animal care and husbandary and Morgen Hickey for assistance with the tables. NR 38 TC 13 Z9 14 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD SEP PY 2008 VL 38 IS 3 BP 1173 EP 1183 DI 10.1002/mus.21049 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 346ES UT WOS:000259052000011 PM 18720509 ER PT J AU Bogaert, YE Chonchol, M AF Bogaert, Yolanda E. Chonchol, Michel TI Assessing the benefits and harms of statin treatment in patients with chronic kidney disease SO NATURE CLINICAL PRACTICE NEPHROLOGY LA English DT Editorial Material DE cardiovascular risk; chronic kidney disease; meta-analysis; mortality; statins ID RENAL-FUNCTION; PEOPLE; ATORVASTATIN; METAANALYSIS; PRAVASTATIN AB This Practice Point commentary discusses a meta-analysis by Strippoli et al. that included 50 randomized and quasi-randomized trials of statins in patients with different stages of kidney disease (predialysis, dialysis and transplantation; n = 30,144). The authors found that statins safely reduced lipid concentrations and the risk of cardiovascular events and cardiovascular mortality, but that the agents had no effect on all-cause mortality overall and had uncertain renoprotective effects. The analysis was comprehensive and well executed. A decreased risk of all-cause mortality with statins was found in studies of predialysis patients but not in studies of renal transplant recipients or patients on chronic dialysis. Statin doses used in the trials were well tolerated and safe in all subgroups of patients with chronic kidney disease; therefore, we feel that statin use to maintain LDL cholesterol below 100 mg/dl (2.6 mmol/l) should be initiated to potentially decrease cardiovascular risk in such patients. The benefits of statin therapy on all-cause mortality and the clinically significant benefits of this treatment on progression of kidney disease are still unclear, and additional trial evidence in patients with chronic kidney disease is needed. C1 [Bogaert, Yolanda E.] Denver Vet Affairs Med Ctr, Div Renal Dis & Hypertens, Denver, CO 80262 USA. [Chonchol, Michel] Univ Colorado Hlth Sci, Div Renal Dis & Hypertens, Denver, CO USA. RP Bogaert, YE (reprint author), Denver Vet Affairs Med Ctr, Div Renal Dis & Hypertens, Denver, CO 80262 USA. EM yolanda.bogaert@uchsc.edu NR 7 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1745-8323 J9 NAT CLIN PRACT NEPHR JI Nat. Clin. Pract. Nephrol. PD SEP PY 2008 VL 4 IS 9 BP 470 EP 471 DI 10.1038/ncpneph0892 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 339JK UT WOS:000258573700002 PM 18628740 ER PT J AU Hertig, A Watnick, S Strevens, H Boulanger, H Berkane, N Rondeau, E AF Hertig, Alexandre Watnick, Suzanne Strevens, Helena Boulanger, Henri Berkane, Nadia Rondeau, Eric TI How should women with pre-eclampsia be followed up? New insights from mechanistic studies SO NATURE CLINICAL PRACTICE NEPHROLOGY LA English DT Review DE gestational hypertension; glomerular endotheliosis; pre-eclampsia; pregnancy; sFlt-1 ID URINARY ALBUMIN EXCRETION; GROWTH-FACTOR RECEPTOR-1; NORMAL-PREGNANCY; TYROSINE KINASE-1; ANTIANGIOGENIC FACTORS; RETROSPECTIVE COHORT; ANGIOGENIC FACTORS; REMOTE PROGNOSIS; SOLUBLE ENDOGLIN; BLOOD-PRESSURE AB Understanding of the maternal syndrome of pre-eclampsia has greatly improved over the past 5 years. Specifically, the notion has emerged that the placenta is a source of antiangiogenic factors, such as soluble fms-like tyrosine kinase 1, that can progressively impair the mother's vascular and glomerular function throughout pregnancy. This impairment can be harmless during normal pregnancy, but in cases of defective placentation, concentrations of antiangiogenic factors increase to a level that compromises vital vascular functions in the short term and jeopardizes long-term maternal and fetal outcomes. In both pre-eclamptic and healthy pregnancies, the transient imbalance between angiogenic and antiangiogenic factors elicited by pregnancy acts as a 'stress test' for the endothelium, particularly in the glomerular capillary bed. Women who do not pass this test (i.e. those who develop pre-eclampsia or gestational hypertension) should be screened for glomerular disease, and their cardiovascular risk should be carefully monitored throughout life. C1 [Hertig, Alexandre; Rondeau, Eric] Hop Tenon, Dept Nephrol & Renal Transplantat, F-75020 Paris, France. [Watnick, Suzanne] Portland VA Med Ctr, Portland, OR USA. [Strevens, Helena] Lund Univ, Dept Obstet & Gynecol, Lund, Sweden. [Boulanger, Henri] Clin Estree, Dept Nephrol & Dialysis, Stains, France. [Berkane, Nadia] Hop Tenon, Dept Obstet & Gynecol, F-75020 Paris, France. RP Hertig, A (reprint author), Hop Tenon, Dept Nephrol & Renal Transplantat, 4 Rue Chine, F-75020 Paris, France. EM alexandre.hertig@tnn.aphp.fr RI Strevens, Helena/B-4976-2009 OI Boulanger, Henri/0000-0001-8017-1640 NR 59 TC 9 Z9 11 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1745-8323 J9 NAT CLIN PRACT NEPHR JI Nat. Clin. Pract. Nephrol. PD SEP PY 2008 VL 4 IS 9 BP 503 EP 509 DI 10.1038/ncpneph0880 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 339JK UT WOS:000258573700013 PM 18628742 ER PT J AU Hazlett, EA Buchsbaum, MS Zhang, J Newmark, RE Glanton, CF Zelmanova, Y Haznedar, MM Chu, KW Nenadic, I Kemether, EM Tang, CY New, AS Siever, LJ AF Hazlett, Erin A. Buchsbaum, Monte S. Zhang, Jing Newmark, Randall E. Glanton, Cathryn F. Zelmanova, Yuliya Haznedar, M. Mehmet Chu, King-Wai Nenadic, Igor Kemether, Eileen M. Tang, Cheuk Y. New, Antonia S. Siever, Larry J. TI Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating SO NEUROIMAGE LA English DT Article DE dorsolateral prefrontal cortex; caudate nucleus; putamen; thalamus; mediodorsal nucleus; fMRI; schizophrenia; schizotypal personality disorder; startle; prepulse inhibition; attention; sensorimotor gating ID SCHIZOTYPAL PERSONALITY-DISORDER; DEFICIENT ATTENTIONAL MODULATION; STARTLE EYEBLINK MODIFICATION; POSITRON-EMISSION-TOMOGRAPHY; PREPULSE INHIBITION; ACOUSTIC STARTLE; CAUDATE-NUCLEUS; METABOLIC RATES; FUNCTIONAL MRI; BASAL GANGLIA AB Prepulse inhibition (PPI) refers to a reduction in the amplitude of the startle eyeblink reflex to a strong sensory stimulus, the pulse, when it is preceded shortly by a weak stimulus, the prepulse. PPI is a measure of sensorimotor gating which serves to prevent the interruption of early attentional processing and it is impaired in schizophrenia-spectrum patients. In healthy individuals, PPI is more robust when attending to than ignoring a prepulse. Animal and human Work demonstrates that frontal-striatal-thalamic (FST) circuitry modulates PPI, This study used functional magnetic resonance imaging (fMRI) to investigate FST circuitry during an attention-to-prepulse paradigm in 26 unmedicated schizophrenia-spectrum patients (13 schizotypal personality disorder(SPD), 13 schizophrenia) and 13 healthy controls. During 3T-fMRI acquisition and separately measured psychophysiological assessment of PPI, participants heard an intermixed series of high-and low-pitched tones serving as prepulses to an acoustic-startle stimulus. Event-related BOLD response amplitude curves in FST regions traced on co-registered anatomical MRI were examined. Controls showed greater activation during attended than ignored PPI conditions in all FST regions-dorsolateral prefrontal cortex (Brodmann areas 46, 9), striatum (caudate, putamen), and the thalamic mediodorsal nucleus. In contrast, schizophrenia patients failed to show differential BOLD responses in FST circuitry during attended and ignored prepulses, whereas SPD patients showed greater-than-normal activation during ignored prepulses. Among the three diagnostic groups, lower left caudate BOLD activation during the attended PPI condition was associated with more deficient sensorimotor gating as measured by PPI. Schizophrenia-spectrum patients exhibit inefficient utilization of FST circuitry during attentional modulation of PPI. Schizophrenia patients have reduced recruitment of FST Circuitry during task-relevant stimuli, whereas SPD patients allocate excessive resources during task-irrelevant stimuli. Dysfunctional FST activation, particularly in the caudate may underlie PPI abnormalities in schizophrenia-spectrum patients. (c) 2008 Elsevier Inc. All rights reserved. C1 [Hazlett, Erin A.; Buchsbaum, Monte S.; Zhang, Jing; Newmark, Randall E.; Glanton, Cathryn F.; Zelmanova, Yuliya; Haznedar, M. Mehmet; Chu, King-Wai; Kemether, Eileen M.; New, Antonia S.; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Tang, Cheuk Y.] Mt Sinai Sch Med, Dept Radiol, New York, NY 10029 USA. [New, Antonia S.; Siever, Larry J.] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Nenadic, Igor] Univ Jena, Dept Psychiat & Psychotherapy, D-6900 Jena, Germany. RP Hazlett, EA (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1505, New York, NY 10029 USA. EM erin.hazlett@mssm.edu FU National Alliance for Research on Schizophrenia and Depression (NARSAD) [MH073911] FX This research was supported by an Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD) and MH073911 to E.A.H. NR 64 TC 45 Z9 48 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD SEP PY 2008 VL 42 IS 3 BP 1164 EP 1177 DI 10.1016/j.neuroimage.2008.05.039 PG 14 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 343PA UT WOS:000258864800011 PM 18588988 ER PT J AU Goebel, M Stengel, A Tache, Y AF Goebel, Miriam Stengel, Andreas Tache, Yvette TI Continued controversy on obestatin as a gut hormone influencing food intake and gastrointestinal motility SO OBESITY AND METABOLISM-MILAN LA English DT Editorial Material DE Food intake; gastrointestinal motility; ghrelin; GPR39; obestatin ID PROTEIN-COUPLED RECEPTOR; GHRELIN-ASSOCIATED PEPTIDE; DES-ACYL GHRELIN; PERIPHERAL OBESTATIN; SPLICE VARIANTS; WEIGHT-GAIN; BODY-WEIGHT; RODENTS; RATS; SECRETION AB Obestatin is still trying to keep up with its bigger brother ghrelin and looking for reproducible biological actions on food intake regulation and gastrointestinal motility. Obestatin was initially described to arise from post-translational processing of preproghrelin and to oppose ghrelin-stimulated feeding, gastrointestinal motility and body weight gain and to reduce food intake upon acute or chronic peripheral injection via activation oil the, until then, orphan G-protein-coupled receptor 39 (GPR39). However; all these original findings have been challenged by the inability of the vast majority of subsequent studies to reproduce these new findings. Several groups tried to overcome differences in the experimental settings accounting for varying study outcomes. Unfortunately, the the majority of laboratories failed even after exact application of the original study design to establish reproducible influence of obestatin on food intake, body weight or gut motility while a minority of reports found that obestatin induces a small reduction of food intake in rodents under specific conditions. Controversy also arises regarding the processing of preproghrelin to generate obestatin in the stomach and the circulation along with. its regulation 411 nutrient status. Evidence that obestatin is not the endogenous ligand for GPR39 is compelling. Therefore, existing knowledge curtails the enthusiasm for obestatin as a new player able to control appetite and body weight opposing the well established orexigenic effect of ghrelin. Puzzling questions remain to be solved regarding discrepant results and whether new biological actions wait for the peptide or more likely, other ghrelin gene-derived peptides issued from the recent revised ghrelin genomic structure will prove to be of greater biological significance. Obesity and Metabolism 2008; 4: 143-148. C1 Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, CURE Digest Res Ctr,Dept Med, Los Angeles, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, CURE Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu NR 59 TC 3 Z9 4 U1 0 U2 2 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 1825-3865 J9 OBES METAB-MILAN JI Obes. Metab.-Milan PD SEP PY 2008 VL 4 IS 3 BP 143 EP 148 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 358GW UT WOS:000259906100001 ER PT J AU Goldenbaum, DM Christopher, M Gallagher, RM Fishman, S Payne, R Joranson, D Edmondson, D Mckee, J Thexton, A AF Goldenbaum, Donald M. Christopher, Myra Gallagher, Rollin M. Fishman, Scott Payne, Richard Joranson, David Edmondson, Drew McKee, Judith Thexton, Arthur TI Physicians charged with opioid analgesic-prescribing offenses SO PAIN MEDICINE LA English DT Article DE physicians; opioids; prescribing; prosecution; criminal; charges ID PAIN; PROSECUTION AB Objective. To provide a "big picture" overview of the characteristics and outcomes of recent criminal and administrative cases in which physicians have been criminally prosecuted or charged by medical boards with offenses related to inappropriate prescribing of opioid analgesics. Design. We identified as many criminal and administrative cases of these types as possible that occurred between 1998 and 2006. Cases were identified using a wide variety of sources, including organizational and government agency databases, published news accounts, and Web sites. Factual characteristics of these cases and their outcomes, and of the physicians involved, were then further researched using additional sources and methods. Setting. Study findings are intended to apply to practicing U.S. patient care physicians as a whole. Patients or Other Participants. There were no patients or participants in this study. Outcome Measures. We analyzed the numbers and types of cases and physicians involved, criminal and administrative charges brought, case outcomes and sanctions, specialties, and other characteristics of the physicians involved. Results. The study identified 725 doctors, representing an estimated 0.1% of practicing patient care physicians, who were charged between 1998 and 2006 with criminal and/or administrative offenses related to prescribing opioid analgesics. A plurality of these (39.3%) were General Practice/Family Medicine physicians, compared with 3.5% who were self-identified or board-certified pain specialists. Physicians in this sample were more likely to be male, older, and not board certified (P < 0.001). Drug Enforcement Administration (DEA) criminal and complaint investigations averaged 658 per year (2003-2006) and "for cause" surrenders of DEA registrations averaged 369.7 (2000-2006). Conclusions. Criminal or administrative charges and sanctions for prescribing opioid analgesics are rare. In addition, there appears to be little objective basis for concern that pain specialists have been "singled out" for prosecution or administrative sanctioning for such offenses. C1 [Goldenbaum, Donald M.; Christopher, Myra] Ctr Pract Bioeth, Res Evaluat & Publicat Program, Kansas City, MO 64105 USA. [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Fishman, Scott] Univ Calif Davis, Davis, CA 95616 USA. [Joranson, David] Univ Wisconsin, Madison, WI USA. [Payne, Richard] Duke Univ, Sch Divin, Durham, NC USA. [Edmondson, Drew] Attorney Gen, Oklahoma City, OK USA. [McKee, Judith] Natl Assoc Attorneys Gen, Washington, DC USA. [Thexton, Arthur] Wisconsin Dept Regulat & Licensing, Madison, WI USA. RP Goldenbaum, DM (reprint author), Ctr Pract Bioeth, Res Evaluat & Publicat Program, 1111 Main,Suite 500, Kansas City, MO 64105 USA. EM dgoldenbaum@practicalbioethics.org NR 24 TC 21 Z9 21 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD SEP PY 2008 VL 9 IS 6 BP 737 EP 747 DI 10.1111/j.1526-4637.2008.00482.x PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 339SM UT WOS:000258597600013 PM 18657218 ER PT J AU Visser, A Rehman, S Makoul, G AF Visser, Adriaan Rehman, Shakaib Makoul, Gregory TI Special issue: International Conference on Communication in Healthcare - Charleston 2007 SO PATIENT EDUCATION AND COUNSELING LA English DT Editorial Material C1 [Visser, Adriaan; Rehman, Shakaib] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Makoul, Gregory] St Francis Hosp & Med Ctr, Hartford, CT USA. RP Visser, A (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. EM adriaan.visser@planet.nl NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2008 VL 72 IS 3 SI SI BP 357 EP 358 DI 10.1016/j.pec.2008.06.002 PG 2 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 353QE UT WOS:000259582400001 PM 18684583 ER PT J AU Haidet, P Hatem, DS Fecile, ML Stein, HF Haley, HLA Kimmel, B Mossbarger, DL Inui, TS AF Haidet, Paul Hatem, David S. Fecile, Mary Lynn Stein, Howard F. Haley, Heather-Lyn A. Kimmel, Barbara Mossbarger, David L. Inui, Thomas S. TI The role of relationships in the professional formation of physicians: Case report and illustration of an elicitation technique SO PATIENT EDUCATION AND COUNSELING LA English DT Article; Proceedings Paper CT International Conference on Communication in Healthcare (ICCH) CY OCT 09-12, 2007 CL Charleston, SC SP Amer Acad Commun Healthcare DE physician-patient relations; patient-centered care; organizational culture; education; medical; qualitative research ID RELATIONSHIP-CENTERED CARE; HIDDEN CURRICULUM; MEDICINE AB Objective: Studies of physicians' professional development highlight the important effect that the learning environment has in shaping student attitudes, behaviors, and values. The objective of this study was to better understand the interplay among relationships and experiences in mediating the effects of the learning environment. Methods: We randomly recruited 2nd- and 4th-year students from among volunteers at each of five medical schools. One interviewer at each school conducted a face-to-face, open-ended, semi-structured interview with each student. The interviewers used a method called 'life-circle diagramming' to direct the student to draw a picture of all of the relationships in his/her life that had an influence on the sort of doctor that each student saw him/herself becoming. Interviews lasted between 60 and 120 min. Using a narrative framework that focuses on elements of students' stories (e.g., setting, characters, plot), we analyzed transcripts through an iterative process of individual reading and group discussion to derive themes and relationships among themes. Results: Twenty students completed interviews. These students are embedded in complex webs of relationships with colleagues, friends, family, role models, patients, and others. Most students entered medical school with formed notions of what they wanted to 'be like' as physicians. While students generally gravitated toward relationships with like-minded people, their experiences varied, and some students could sense themselves changing as they moved through school. Such changes were often related to important events or issues. The relationships that students found themselves in during the context of these events had an important effect on students' beliefs about what kinds of behaviors and attitudes were possible and desirable in their future practice. Conclusions: Students proceed through medical school embedded in complex webs of relationships that exert a powerful influence (both positive and negative) on their formation as physicians. Practice Implications: Educational interventions that foster adoption of professional values need to acknowledge the influence of relationships, and assist students to harness and shape relational effects on their growth and development. The life-circle diagramming activity holds potential to promote reflection and self-knowledge, and to provide a foundation for professional growth, Published by Elsevier Ireland Ltd. C1 [Haidet, Paul; Kimmel, Barbara] DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Haidet, Paul; Kimmel, Barbara] Baylor Coll Med, Houston, TX 77030 USA. [Hatem, David S.; Haley, Heather-Lyn A.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Fecile, Mary Lynn] Univ Texas Med Branch, Galveston, TX USA. [Stein, Howard F.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA. [Mossbarger, David L.; Inui, Thomas S.] Regenstrief Inst Inc, Indianapolis, IN USA. [Mossbarger, David L.; Inui, Thomas S.] Indiana Univ, Sch Med, Bloomington, IN 47405 USA. RP Haidet, P (reprint author), DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu OI Haley, Heather-Lyn/0000-0002-4064-9547 NR 23 TC 23 Z9 23 U1 2 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2008 VL 72 IS 3 SI SI BP 382 EP 387 DI 10.1016/j.pec.2008.05.016 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 353QE UT WOS:000259582400005 PM 18619760 ER PT J AU Chang, JC Dado, D Frankel, RM Rodriguez, KL Zickmund, S Ling, BS Arnold, RM AF Chang, Judy C. Dado, Diane Frankel, Richard M. Rodriguez, Keri L. Zickmund, Susan Ling, Bruce S. Arnold, Robert M. TI When pregnant patients disclose substance use: Missed opportunities for behavioral change counseling SO PATIENT EDUCATION AND COUNSELING LA English DT Article; Proceedings Paper CT International Conference on Communication in Healthcare (ICCH) CY OCT 09-12, 2007 CL Charleston, SC SP Amer Acad Commun Healthcare DE prenatal care; obstetrics; substance-use; practitioner-patient interaction; risk communication; qualitative research ID PRENATAL ALCOHOL EXPOSURE; FAMILY-PRACTICE RESIDENTS; SMOKING-CESSATION; OBSTETRICIAN-GYNECOLOGISTS; PHYSICIAN ATTITUDES; MOTIVATIONAL INTERVENTION; MEDICAL-SCHOOLS; LEGAL COERCION; UNITED-STATES; RISK-FACTORS AB Objective: The first obstetric visit is an opportunity to provide counseling to women with substance abuse risks, including smoking, drug use, and alcohol use. Little is known about how obstetric care providers and patients discuss these issues. Our objective was to examine patient-provider communication about substance use behaviors during these visits. Methods: We audio-taped and transcribed verbatim first prenatal visits in an outpatient hospital clinic, then qualitatively analyzed them for content and process of communication using modified grounded theory methods. Results: Twenty-nine providers (21 residents, 5 midwives, 3 nurse practitioners) and 51 patients participated. Twenty-five patients were smokers, 4 used alcohol, and I I used drugs. Provider responses to smoking disclosures included discussions of risks, encouragement to quit-cut down, affirmation of attempts to quit-cut down, and referral to smoking cessation programs. Responses to alcohol or drug disclosures included only a general statement regarding risks and referral to genetics. Conclusion: Providers were less attentive to alcohol and drugs than smoking where they had pre-established patterns of response. Practice implications: Providers should discuss behavioral change strategies and motivations with pregnant patients who use drugs and/or alcohol as well as those who smoke. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Chang, Judy C.; Dado, Diane] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci & Med, UPMC, Pittsburgh, PA 15213 USA. [Frankel, Richard M.] Indiana Univ, Sch Med, Inst Hlth Care, Indianapolis, IN USA. [Rodriguez, Keri L.; Zickmund, Susan; Ling, Bruce S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rodriguez, Keri L.; Zickmund, Susan; Ling, Bruce S.; Arnold, Robert M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Chang, JC (reprint author), Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci & Med, UPMC, 300 Halket St, Pittsburgh, PA 15213 USA. EM jchang@mail.magee.edu FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [L30 RR019716, L30 RR019716-01, L30 RR019716-02]; NICHD NIH HHS [K12 HD043441-01, 5 K12 HD43441-04, K12 HD043441, K12 HD043441-02, K12 HD043441-03] NR 74 TC 16 Z9 16 U1 1 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2008 VL 72 IS 3 SI SI BP 394 EP 401 DI 10.1016/j.pec.2008.06.001 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 353QE UT WOS:000259582400007 PM 18620835 ER PT J AU Verma, S Tavare, CJ Gilles, FH AF Verma, Shalini Tavare, C. Jane Gilles, Floyd H. TI Histologic Features and Prognosis in Pediatric Medulloblastoma SO PEDIATRIC AND DEVELOPMENTAL PATHOLOGY LA English DT Article DE anaplastic medulloblastoma; desmoplastic/nodular medulloblastoma; large cell medulloblastoma; medulloblastoma; medulloblastoma with extensive nodularity ID CHILDRENS CANCER GROUP; ONCOLOGY-GROUP; BRAIN-TUMORS; CHILDHOOD; BEHAVIOR; VARIANT; REPRODUCIBILITY; STRATIFICATION; ANAPLASIA; SYSTEM AB Because individual histologic features in childhood medulloblastoma alter survival likelihood, the recent 4th edition of file World Health Organization (WHO) Classification of Brain Tumors recognizes desmoplastic/nodular medulloblastoma. medulloblastoma with extensive nodularity, large cell medulloblastoma, and anaplastic medulloblastoma, in addition to medulloblastoma with no other distinguishing features. To identify features affecting Survival likelihood, we investigated 33 histologic features in 556 childhood tumors diagnosed as medulloblastoma in the Childhood Brain Turner Consortium (CBTC) database; all features have CBTC verified read-reread reliability and those features important in the classification of medulloblastoma and its WHO variants regardless of their measured reliability. Nineteen features had no effect oil Survival likelihood, and 8 features were too prevalent or too rare to measure their effect oil survival. Nodules, balls, high cell density. and fine fibrillary stroma improved Survival likelihood; necrosis and prominent nucleoli worsened survival likelihood. Of note, the presence of desmoplasia, currently a defining feature (along with nodules) for desmoplastic/nodular medulloblastoma, had no effect oil survival likelihood. We conclude that the presence of nodularity in medulloblastoma is important to improved survival likelihood., particularly when combined with balls and fine fibrillary stroma. Given the "overlap" of desmoplastic/nodular medulloblastoma and nodular medulloblastoma, we Suggest they be combined into a diagnosis of nodular medulloblastoma. with nodules, balls, and fine fibrillary stroma as defining criteria. We also suggest that because of the considerable overlap of anaplastic medulloblastoma and large cell medulloblastoma they be combined into 1 diagnosis of anaplastic/large cell medulloblastoma, with necrosis and prominent nucleoli among file defining criteria. C1 [Tavare, C. Jane; Gilles, Floyd H.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Verma, Shalini] Vet Affairs Greater Los Angeles Med Ctr, LAC USC Med Ctr, Dept Pathol, Los Angeles, CA USA. RP Gilles, FH (reprint author), Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. EM fgilles@chla.usc.edu NR 36 TC 10 Z9 10 U1 0 U2 6 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1093-5266 J9 PEDIATR DEVEL PATHOL JI Pediatr. Dev. Pathol. PD SEP-OCT PY 2008 VL 11 IS 5 BP 337 EP 343 DI 10.2350/07-09-0353.1 PG 7 WC Pathology; Pediatrics SC Pathology; Pediatrics GA 373KD UT WOS:000260969600001 PM 18201118 ER PT J AU Platt, AB Localio, AR Brensinger, CM Cruess, DG Christie, JD Gross, R Parker, CS Price, M Metlay, JP Cohen, A Newcomb, CW Strom, BL Laskin, MS Kimmel, SE AF Platt, Alec B. Localio, A. Russell Brensinger, Colleen M. Cruess, Dean G. Christie, Jason D. Gross, Robert Parker, Catherine S. Price, Maureen Metlay, Joshua P. Cohen, Abigail Newcomb, Craig W. Strom, Brian L. Laskin, Mitchell S. Kimmel, Stephen E. TI Risk factors for nonadherence to warfarin: results from the IN-RANGE study SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE medication adherence; MEMS; warfarin; anticoagulation ID INTERNATIONAL NORMALIZED RATIO; ATRIAL-FIBRILLATION; PATIENT REPORTS; ADHERENCE; THERAPY; ANTICOAGULATION; MEDICATION; OUTCOMES; CARE AB Background Warfarin is widely used to prevent stroke and venous thromboembolism despite its narrow therapeutic window, Warfarin nonadherence is a substantial problem, but risk factors have not been well elucidated. Methods A prospective cohort study of adults initiating warfarin at two anticoagulation clinics (University and VA-affiliated) was performed to determine factors affecting nonadherence to warfarin. Nonadherence, defined by failure to record a correct pill bottle opening each day, was measured daily via electronic medication event monitoring systems (MEMS) caps. A multivariable explanatory model using logistic regression for longitudinal data was used to identify risk factors for nonadherence. Results One hundred eleven subjects were followed for a median of 137 days. Warfarin nonadherence was common (4787 of 22 425 or 21 % of patient-days observed). Factors independently associated with higher odds of nonadherence included education beyond high school (odds ratio (OR) 1.8 (95%CI 1.2-2.7)), lower Short Form (SF)-36 mental component score (OR 1.4 (1.1-1.6) for each 10 point decrease); and impaired cognition (! 19 points) on the Cognitive Capacity Screening Examination (CCSE) (OR 2.9 (1.7-4.8)). Compared to currently employed subjects, unemployed (OR 0.6 (0.3-1.2)) and retired (OR 0.5 (0.3-0.8)) subjects had somewhat improved adherence; disabled subjects over age 55 had worse adherence (OR 1.8 (1.1-3.1)) than younger disabled subjects (OR 0.8 (0.4-1.5)). Conclusions Poor adherence to warfarin is common and risk factors are related to education level, employment status, mental health functioning, and cognitive impairment. Within the carefully controlled anticoagulation clinic setting, such patient-specific factors may be the basis of future interventions to improve nonadherence. Copyright (C) 2008 John Wiley & Sons. Ltd. C1 [Platt, Alec B.; Localio, A. Russell; Brensinger, Colleen M.; Christie, Jason D.; Gross, Robert; Price, Maureen; Metlay, Joshua P.; Cohen, Abigail; Newcomb, Craig W.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Platt, Alec B.; Christie, Jason D.; Gross, Robert; Metlay, Joshua P.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Localio, A. Russell; Gross, Robert; Metlay, Joshua P.; Strom, Brian L.] Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Cruess, Dean G.] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA. [Gross, Robert; Metlay, Joshua P.; Kimmel, Stephen E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Parker, Catherine S.] Beth Israel Deaconess Med Ctr, Dept Internal Med, Boston, MA 02215 USA. [Laskin, Mitchell S.] Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA. RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Clin Epidemiol & Biostat, 717 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM stevek@mail.med.upenn.edu RI Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 FU NIH [R01-HL66176]; AHRQ [P01-HS11530]; [P20RR020741]; [K24HL070936] FX This study was supported by grants from the NIH (R01-HL66176) and AHRQ (P01-HS11530). Dr Kimmel is supported by P20RR020741 and K24HL070936. The funder had no role in tie design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr Kimmel has had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. We thank Mabel Chin, PharmD, for her dedication to our field work. NR 28 TC 57 Z9 61 U1 0 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2008 VL 17 IS 9 BP 853 EP 860 DI 10.1002/pds.1556 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 348NR UT WOS:000259217700001 PM 18271059 ER PT J AU Smith, JP AF Smith, Jason P. TI Treatment options for patients with hepatitis C: Role of pharmacists in optimizing treatment response and managing adverse events SO PHARMACOTHERAPY LA English DT Review DE hepatitis; pegylated interferon alfa-2a; pegylated interferon alfa-2b; ribavirin; epidemiology; mortality; treatment outcome; safety ID ALPHA-2A PLUS RIBAVIRIN; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; EARLY VIROLOGICAL RESPONSE; HIV-INFECTED PATIENTS; INJECTION-DRUG USERS; INTERFERON-ALPHA; PEGINTERFERON ALPHA-2A; VIRUS-INFECTION; COMBINATION THERAPY AB Chronic hepatitis C is associated with substantial morbidity and mortality and poses a considerable socioeconomic burden. Improved treatment regimens, including the standard of care pegylated interferon alfa and ribavirin, have increased sustained virologic response rates, however, treatment has a long duration and is often associated with adverse events that may affect adherence. The goal of therapy is viral eradication and reduced disease-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma. The clinical outcome of hepatitis C virus infection is altered with antiviral treatment, which can be influenced by host (e.g., weight, ethnicity, health) and viral (e.g., genotype, baseline viremia) factors. Overall, sustained virologic response was attained by 54-63% of patients in clinical trials treated with pegylated interferon alfa-2a or -2b and ribavirin. However, this benefit is not without risk. Interferon-induced adverse events include flu-like symptoms, bone marrow suppression, and emotional or cognitive effects, whereas hemolytic anemia accounts for most ribavirin dosage reductions. These adverse events may be ameliorated with dosage adjustments, symptom therapy, and judicious use of preventive strategies (e.g., anti depressants, hematopoietic growth factors). Appropriate management of adverse events can increase treatment adherence, thereby enhancing outcomes and improving quality of life. Pharmacists are in an ideal position to improve the treatment of patients with chronic hepatitis C by providing education about the disease and its treatments and associated adverse events and by emphasizing the importance of treatment adherence for successful outcomes. C1 VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. RP Smith, JP (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM glaliver@yahoo.com NR 68 TC 9 Z9 11 U1 0 U2 1 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD SEP PY 2008 VL 28 IS 9 BP 1151 EP 1161 DI 10.1592/phco.28.9.1151 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 344FI UT WOS:000258911800009 PM 18752386 ER PT J AU Colli, JL Amling, CL AF Colli, J. L. Amling, C. L. TI Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE ecology; prostate cancer; United States; epidemiology ID VITAMIN-D METABOLITES; SUBSEQUENT DEVELOPMENT; GEOGRAPHIC PATTERNS; RISK; COHORT; CARE AB We hypothesized that prostate cancer screening and availability of urologists among states may be associated with reduced prostate cancer mortality in the United States. To test this hypothesis, statespecific prostate cancer mortality rates for white males were compared to urologist population densities and prostate-specific antigen (PSA) screening rates on a state-by-state basis. The urologist population density was calculated by dividing the number of urologists per state by the population. We found that prostate cancer mortality rates correlated inversely with urologist population densities (P<0.01) and PSA screening (P<0.01) suggesting that screening and treatment reduce prostate cancer mortality. C1 [Colli, J. L.; Amling, C. L.] Univ Alabama, Dept Urol, Birmingham, AL 35294 USA. [Colli, J. L.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Colli, JL (reprint author), Univ Alabama, Dept Urol, 1530 3rd Ave S, Birmingham, AL 35294 USA. EM jan.colli@ccc.uab.edu NR 24 TC 9 Z9 9 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD SEP PY 2008 VL 11 IS 3 BP 247 EP 251 DI 10.1038/pcan.2008.7 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 338KB UT WOS:000258505500006 PM 18268527 ER PT J AU New, AS Goodman, M Triebwasser, J Siever, LJ AF New, Antonia S. Goodman, Marianne Triebwasser, Joseph Siever, Larry J. TI Recent advances in the biological study of personality disorders SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Review ID POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN TRANSPORTER GENE; SELF-INJURIOUS-BEHAVIOR; POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; ACTIVATED FDG-PET; OPEN-LABEL TRIAL; IMPULSIVE AGGRESSION; PREFRONTAL CORTEX; FEMALE-PATIENTS AB While it is premature to provide a simple model for the vulnerability to the development of either borderline (BPD) or schizotypal (SPD) personality disorder, it is clear that these heritable disorders lend themselves to fruitful neurobiological exploration. The most promising findings in BPD suggest that a diminished top-down control of affective responses, which is likely to relate to deceased responsiveness of specific midline regions of prefrontal cortex, May Underlie the affective hyperresponsiveness in this disorder. In addition, genetic and neuroendocrine and molecular neuro-imaging finding point to a role for serotonin in this affective disinhibition. Clearly SPD falls within the schizophrenia spectrum, but precisely the nature of what predicts full-blown schizophrenia as opposed to the milder Symptoms of SPD is not yet clear. C1 [New, Antonia S.; Goodman, Marianne; Triebwasser, Joseph; Siever, Larry J.] Mt Sinai Sch Med, New York, NY 10029 USA. [New, Antonia S.; Goodman, Marianne; Triebwasser, Joseph; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP New, AS (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1217, New York, NY 10029 USA. EM antonia.new@mssm.edu NR 161 TC 45 Z9 47 U1 5 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD SEP PY 2008 VL 31 IS 3 BP 441 EP + DI 10.1016/j.psc.2008.03.011 PG 22 WC Psychiatry SC Psychiatry GA 340WZ UT WOS:000258677000007 PM 18638645 ER PT J AU Plotnick, DF Salzer, MS AF Plotnick, Debbie F. Salzer, Mark S. TI Clubhouse Costs and Implications for Policy Analysis in the Context of System Transformation Initiatives SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE clubhouse costs systems; transformation; psychiatric rehabilitation programs; mental health policy ID SUPPORTED EMPLOYMENT; OUTCOMES AB Objective: Documenting service costs is important for psychiatric rehabilitation programs to make persuasive arguments to policymakers/funders about their role in system transformation efforts. The purpose of this study was to report program costs, annual costs per member, and costs per day over three years (2003-2006) for 29 clubhouses that are part of the Pennsylvania Clubhouse Coalition (PCC). Methods: This study utilized data elements that are submitted annually by coalition members to the Pennsylvania Clubhouse Coalition. Results: Our results indicate that clubhouses play a substantial role in the Pennsylvania mental health system, providing almost 180,000 units of contact to more than 2,400 people across the state. Conclusions: Most relevant to Pennsylvania's system transformation is our finding that clubhouse costs are substantially lower than the costs of partial hospital services. Clubhouses are likely serving an important role in lowering costs associated with supporting those who would otherwise utilize partial hospital programs. C1 [Salzer, Mark S.] Univ Penn, CMHPSR, Dept Psychiat, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia VA Med Ctr, VISN 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Salzer, MS (reprint author), Univ Penn, CMHPSR, Dept Psychiat, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM Mark.Salzer@uphs.upenn.edu NR 10 TC 2 Z9 2 U1 1 U2 1 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD FAL PY 2008 VL 32 IS 2 BP 128 EP 131 DI 10.2975/32.2.2008.128.131 PG 4 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 364GH UT WOS:000260323700008 PM 18840568 ER PT J AU Siegle, GJ Ichikawa, N Steinhauer, S AF Siegle, Greg J. Ichikawa, Naho Steinhauer, Stuart TI Blink before and after you think: Blinks occur prior to and following cognitive load indexed by pupillary responses SO PSYCHOPHYSIOLOGY LA English DT Article DE blinks; pupil dilation; cognitive load; attention; Stroop ID LATERAL EYE-MOVEMENTS; EYEBLINK ACTIVITY; MEMORY TASK; PERFORMANCE; ACTIVATION; DEPRESSION; LIGHT; FMRI AB Pupil dilation and blinks provide complementary, mutually exclusive indices of information processing. Though each index is associated with cognitive load, the occurrence of a blink precludes the measurement of pupil diameter. These indices have generally been assessed in independent literatures. We examine the extent to which these measures are related on two cognitive tasks using a novel method that quantifies the proportion of trials on which blinks occur at each sample acquired during the trial. This measure allows cross-correlation of continuous pupil-dilation and blink waveforms. Results indicate that blinks occur during early sensory processing and following sustained information processing. Pupil dilation better reflects sustained information processing. Together these indices provide a rich picture of the time course of information processing, from early reactivity through sustained cognition, and after stimulus-related cognition ends. C1 [Siegle, Greg J.; Ichikawa, Naho; Steinhauer, Stuart] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Ichikawa, Naho] Nagoya Univ, Dept Psychol, Nagoya, Aichi 4648601, Japan. [Steinhauer, Stuart] VA Pittsburgh Healthcare Syst, Dept Psychol, Pittsburgh, PA USA. RP Siegle, GJ (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM gsiegle@pitt.edu FU NIMH NIH HHS [K02 MH082998, MH064159, MH55762] NR 37 TC 54 Z9 56 U1 3 U2 15 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD SEP PY 2008 VL 45 IS 5 BP 679 EP 687 DI 10.1111/j.1469-8986.2008.00681.x PG 9 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 336KD UT WOS:000258361800001 PM 18665867 ER PT J AU Martinez, S Heyneman, LE McAdams, HP Rossi, SE Restrepo, CS Eraso, A AF Martinez, Santiago Heyneman, Laura E. McAdams, H. Page Rossi, Santiago E. Restrepo, Carlos S. Eraso, Andres TI Mucoid impactions: Finger-in-glove sign and other CT and radiographic features SO RADIOGRAPHICS LA English DT Article ID ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CONGENITAL BRONCHIAL ATRESIA; HIGH-RESOLUTION CT; THIN-SECTION CT; ENDOBRONCHIAL LIPOMA; CYSTIC-FIBROSIS; COMPUTED-TOMOGRAPHY; BUD PATTERN; CELLULOSE GRANULOMATOSIS; RADIOLOGIC FINDINGS AB Mucoid impaction is a relatively common finding at chest radiography and computed tomography (CT). Both congenital and acquired abnormalities may cause mucoid impaction of the large airways that often manifests as tubular opacities known as the finger-in-glove sign. The congenital conditions in which this sign most often appears are segmental bronchial atresia and cystic fibrosis. The sign also may be observed in many acquired conditions, include inflammatory and infectious diseases (allergic bronchopulmonary aspergillosis, broncholithiasis, and foreign body aspiration), benign neoplastic processes (bronchial hamartoma, lipoma, and papillomatosis), and malignancies (bronchogenic carcinoma, carcinoid tumor, and metastases). To point to the correct diagnosis, the radiologist must be familiar with the key radiographic and CT features that enable differentiation among the various likely causes. CT is more useful than chest radiography for differentiating between mucoid impaction and other disease processes, such as arteriovenous malformation, and for directing further diagnostic evaluation. In addition, knowledge of the patient's medical history, clinical symptoms and signs, and predisposing factors is important. (C) RSNA, 2008 . radiographics.rsnajnls.org. C1 [Martinez, Santiago; Heyneman, Laura E.; McAdams, H. Page] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. [Rossi, Santiago E.] Ctr Diagnost Dr Enrique Rossi, Dept Radiol, Buenos Aires, DF, Argentina. [Restrepo, Carlos S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Eraso, Andres] US Dept Vet Affairs, Med Ctr, Dept Radiol, Washington, DC USA. RP Martinez, S (reprint author), Duke Univ, Med Ctr, Dept Radiol, Box 3808,Erwin Rd, Durham, NC 27710 USA. EM santiago.martinez@duke.edu RI McAdams, Holman/N-8218-2015 OI McAdams, Holman/0000-0002-7044-3320 NR 45 TC 24 Z9 29 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD SEP-OCT PY 2008 VL 28 IS 5 BP 1369 EP 1382 DI 10.1148/rg.285075212 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 351VS UT WOS:000259454600013 PM 18794313 ER PT J AU Medina-Lezama, J Morey-Vargas, OL Zea-Diaz, H Bolanos-Salazar, JF Corrales-Medina, F Cuba-Bustinza, C Chirinos-Medina, DA Chirinos, JA AF Medina-Lezama, Josefina Morey-Vargas, Oscar L. Zea-Diaz, Humberto Bolanos-Salazar, Juan F. Corrales-Medina, Fernando Cuba-Bustinza, Carolina Chirinos-Medina, Diana A. Chirinos, Julio A. TI Prevalence of lifestyle-related cardiovascular risk factors in Peru: the PREVENCION study SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Alcohol drinking; cardiovascular diseases; diet; physical activity; prevalence; risk factors; smoking; Peru ID PHYSICAL-ACTIVITY QUESTIONNAIRE; ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; ALCOHOL-CONSUMPTION; BINGE DRINKING; LATIN-AMERICA; EPIDEMIOLOGIC TRANSITION; POPULATION; HEALTH; MORTALITY AB Objectives. To estimate the prevalence of lifestyle-related cardiovascular risk factors in the adult population of Arequipa, the second largest city in Peru. Methods. The prevalence and patterns of smoking, alcohol drinking, lack of physical activity, high-fat diet, and low fruit and vegetable intake were evaluated among 1 878 subjects (867 men and 1 011 women) in a population-based study. Results. The age-standardized prevalence of current smoking, former smoking, and never smoking were 21.6%, 14.3%, and 64.1%, respectively. The prevalence of current smoking was significantly higher in men than women (31.1% vs. 12.1%; P < 0.01). The prevalence of current alcohol use was 37.7% and significantly higher in men than women (55.5% vs. 19.7%; P < 0.01). Similarly, the prevalence of binge drinking was 21.2%, and the percentage of men who binge drink (36.1%) was significantly higher than for women (6.4%; P < 0.01). The vast majority of alcohol drinkers reported a pattern of alcohol consumption mainly on weekends and holidays rather than regular drinking with meals during the week. The proportion of insufficiently active people was 57.6% and was significantly higher in women than men (63.3% vs. 51.9%; P < 0.01). Overall, 42.0% of adults reported consuming high-fat diets, 34.5% reported low fruit intake, and 33.3% reported low vegetable intake. Conclusions. The high prevalence of lifestyle-related cardiovascular risk factors found in this Andean population is of concern. Preventive programs are urgently needed to deal with this growing problem. C1 [Medina-Lezama, Josefina; Morey-Vargas, Oscar L.; Zea-Diaz, Humberto; Bolanos-Salazar, Juan F.; Corrales-Medina, Fernando; Cuba-Bustinza, Carolina; Chirinos-Medina, Diana A.] Santa Maria Catholic Univ, Sch Med, Arequipa, Peru. [Medina-Lezama, Josefina; Morey-Vargas, Oscar L.; Zea-Diaz, Humberto; Bolanos-Salazar, Juan F.; Corrales-Medina, Fernando; Cuba-Bustinza, Carolina; Chirinos-Medina, Diana A.] Santa Maria Catholic Univ, Sch Psychol, Arequipa, Peru. [Medina-Lezama, Josefina; Morey-Vargas, Oscar L.; Zea-Diaz, Humberto; Bolanos-Salazar, Juan F.; Corrales-Medina, Fernando; Cuba-Bustinza, Carolina; Chirinos-Medina, Diana A.] Santa Maria Catholic Univ, Santa Maria Res Inst, Arequipa, Peru. [Chirinos, Julio A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Chirinos, JA (reprint author), Philadelphia VA Med Ctr, Div Cardiol, 8B111,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Julio.chirinos@uphs.upenn.edu NR 52 TC 16 Z9 17 U1 0 U2 0 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD SEP PY 2008 VL 24 IS 3 BP 169 EP 179 DI 10.1590/S1020-49892008000900003 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 361ZR UT WOS:000260168500003 PM 19115544 ER PT J AU Horan, WP Blanchard, JJ Clark, LA Green, MF AF Horan, William P. Blanchard, Jack J. Clark, Lee Anna Green, Michael F. TI Affective traits in schizophrenia and schizotypy SO SCHIZOPHRENIA BULLETIN LA English DT Review DE schizophrenia; schizotypy; emotion; affective traits; review ID QUALITY-OF-LIFE; PSYCHOSIS PRONENESS SCALES; RECENT-ONSET SCHIZOPHRENIA; TRIDIMENSIONAL PERSONALITY QUESTIONNAIRE; HIGH-RISK PROJECT; 5-FACTOR MODEL; SOCIAL ANHEDONIA; NEGATIVE SYMPTOMS; SCHIZOAFFECTIVE DISORDER; INDIVIDUAL-DIFFERENCES AB This article reviews empirical studies of affective traits in individuals with schizophrenia spectrum disorders, population-based investigations of vulnerability to psychosis, and genetic and psychometric high-risk samples. The review focuses on studies that use self-report trait questionnaires to assess Negative Affectivity (NA) and Positive Affectivity (PA), which are conceptualized in contemporary models of personality as broad, temperamentally-based dispositions to experience corresponding emotional states. Individuals with schizophrenia report a pattern of stably elevated NA and low PA throughout the illness course. Among affected individuals, these traits are associated with variability in several clinically important features, including functional outcome, quality of life, and stress reactivity. Furthermore, evidence that elevated NA and low PA (particularly the facet of anhedonia) predict the development of psychosis and are detectable in high-risk samples suggests that these traits play a role in vulnerability to schizophrenia, though they are implicated in other forms of psychopathology as well. Results are discussed in terms of their implications for treatment, etiological models, and future research to advance the study of affective traits in schizophrenia and schizotypy. C1 [Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Blanchard, Jack J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Clark, Lee Anna] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. [Green, Michael F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Horan, WP (reprint author), 300 UCLA Med Plaza,Suite 2240, Los Angeles, CA 90095 USA. EM horan@ucla.edu FU National Institute of Mental Health [MH-077141, MH-079231, MH-43292, MH-65707] FX National Institute of Mental Health (MH-077141 to Horan; MH-079231 to Blanchard; MH-43292, MH-65707 to Green). NR 217 TC 130 Z9 130 U1 5 U2 25 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD SEP PY 2008 VL 34 IS 5 BP 856 EP 874 DI 10.1093/schbul/sbn083 PG 19 WC Psychiatry SC Psychiatry GA 349ZQ UT WOS:000259322600009 PM 18667393 ER PT J AU Meda, SA Bhattarai, M Morris, NA Astur, RS Calhoun, VD Mathalon, DH Kiehl, KA Pearlson, GD AF Meda, Shashwath A. Bhattarai, Manish Morris, Nicholas A. Astur, Robert S. Calhoun, Vince D. Mathalon, Daniel H. Kiehl, Kent A. Pearlson, Godfrey D. TI An fMRI study of working memory in first-degree unaffected relatives of schizophrenia patients SO SCHIZOPHRENIA RESEARCH LA English DT Article DE fMRI; prefrontal cortex; Sternberg; working memory; schizophrenia; relatives ID DORSOLATERAL PREFRONTAL CORTEX; CONTEXT-PROCESSING DEFICITS; NONPSYCHOTIC RELATIVES; INDIVIDUAL-DIFFERENCES; CLINICAL SYMPTOMS; BRAIN; SIBLINGS; TASKS; MANIPULATION; MAINTENANCE AB Identifying intermediate phenotypes of genetically complex psychiatric illnesses such as schizophrenia is important. First-degree relatives of persons with schizophrenia have increased genetic risk for the disorder and tend to show deficits on working memory (WM) tasks. An open question is the relationship between such behavioral endophenotypes and the Corresponding brain activation patterns revealed during functional imaging. We measured task performance during a Sternberg WM task and used functional magnetic resonance imaging (fMRI) to assess whether 23 non-affected first-degree relatives showed altered performance and functional activation compared to 43 matched healthy controls. We predicted that a significant proportion of unaffected first-degree relatives would show either aberrant task performance and/or abnormal related fMRI blood oxygen level dependent (BOLD) patterns. While task performance in the relatives was not different than that of controls they were significantly slower in responding to probes., Schizophrenia relatives displayed reduced activation, most markedly in bilateral dorsolateral/ventrolateral (DLPFC/VLPFC) prefrontal and posterior parietal cortex when encoding stimuli and in bilateral DLPFC and parietal areas during response selection. Additionally, fMRI differences in both conditions were modulated by load, with a parametric increase in between-group differences with load in several key regions during encoding and an opposite effect during response selection. (C) 2008 Elsevier B.V. All rights reserved. C1 [Meda, Shashwath A.; Bhattarai, Manish; Morris, Nicholas A.; Astur, Robert S.; Calhoun, Vince D.; Kiehl, Kent A.; Pearlson, Godfrey D.] Hartford Hosp, Inst Living, Olin Neuropsychiat Res Ctr, Hartford, CT 06106 USA. [Astur, Robert S.; Calhoun, Vince D.; Kiehl, Kent A.; Pearlson, Godfrey D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Calhoun, Vince D.; Pearlson, Godfrey D.] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD 21287 USA. [Calhoun, Vince D.; Kiehl, Kent A.] MIND Res Network, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Meda, SA (reprint author), 200 Retreat Ave, Hartford, CT 06106 USA. EM smeda01@harthosp.org RI Calhoun, Vince/H-7146-2013 OI Calhoun, Vince/0000-0001-9058-0747; Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [MH43775, R01 MH060504-08, R01 MH060504-04, R01 MH043775, R01 MH060504-06, R01 MH052886, R01 MH043775-11, R01 MH052886-04A1, R01 MH060504-05, R01 MH043775-13, R01 MH052886-08, R01 MH052886-05, R37 MH043775, R01 MH043775-11S1, MH52886, R01 MH043775-09A1, MH60504, R01 MH060504, R37 MH043775-17, R01 MH043775-10, R01 MH052886-06, R01 MH043326-11, R01 MH043326, MH43326, R01 MH060504-07, R01 MH052886-03, R01 MH043775-12, R01 MH052886-07, R01 MH043326-10, R01 MH085010] NR 45 TC 37 Z9 39 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD SEP PY 2008 VL 104 IS 1-3 BP 85 EP 95 DI 10.1016/j.schres.2008.06.013 PG 11 WC Psychiatry SC Psychiatry GA 357XE UT WOS:000259879700010 PM 18678469 ER PT J AU Alessi, CA Martin, JL Webber, AP Alam, T Littner, MR Harker, JO Josephson, KR AF Alessi, Cathy A. Martin, Jennifer L. Webber, Adam P. Alam, Tarannum Littner, Michael R. Harker, Judith O. Josephson, Karen R. TI More daytime sleeping predicts less functional recovery among older people undergoing inpatient post-acute rehabilitation SO SLEEP LA English DT Article DE sleep; aged; rehabilitation; recovery of function ID ILLNESS RATING-SCALE; HIP FRACTURE; STROKE REHABILITATION; CIRCADIAN-RHYTHMS; NURSING FACILITY; LONG-SLEEP; ADULTS; HEALTH; HOME; HOSPITALIZATION AB Study Objectives: To study the association between sleep/wake patterns among older adults during inpatient post-acute rehabilitation and their immediate and long-term functional recovery Design: Prospective, observational cohort study Setting: Two inpatient post-acute rehabilitation sites (one community and one Veterans Administration) Participants: Older patients (aged : 65 years, N = 245) admitted for inpatient post-acute rehabilitation Interventions: None Measurements and Results: Based on 7-day wrist actigraphy during the rehabilitation stay, mean nighttime percent sleep was only 52.2% and mean daytime percent sleep was 15.8% (16.3% based on structured behavioral observations). Using the Pittsburgh Sleep Quality Index (PSQI), participants reported their sleep was worse during rehabilitation compared to their premorbid sleep. Functional recovery between admission and discharge from rehabilitation (measured by the motor component of the Functional Independence Measure) was not significantly associated with reported sleep quality (PSQI scores) or actigraphically measured nighttime sleep. However, more daytime percent sleep (estimated by actigraphy and observations) during the rehabilitation stay was associated with less functional recovery from admission to discharge, even after adjusting for other significant predictors of functional recovery (mental status, hours of rehabilitation therapy received, rehospitalization, and reason for admission; adjusted R-2 = 0.267, P < 0.0001). More daytime sleeping during rehabilitation remained a significant predictor of less functional recovery in adjusted analyses at 3-month follow-up. Conclusions: Sleep disturbance is common among older people undergoing inpatient post-acute rehabilitation. These data suggest that more daytime sleeping during the rehabilitation stay is associated with less functional recovery for up to three months after admission for rehabilitation. C1 [Alessi, Cathy A.] GRECC, VA Med Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. [Alessi, Cathy A.; Martin, Jennifer L.; Webber, Adam P.; Littner, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Littner, Michael R.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Alessi, CA (reprint author), GRECC, VA Med Ctr, Vet Adm Greater Los Angeles Healthcare Syst, 11E,16111 Plummer St,N Hills, Sepulveda, CA 91343 USA. EM cathy.alessi@va.gov FU Veterans Administration Health Services Research and Development Service [11R 01-053-1, AIA 03047]; Veterans Administration Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center (GRECC); UCLA Claude Pepper Older Americans Independence Center [AG-10415] FX Financial Support: Veterans Administration Health Services Research and Development Service (11R 01-053-1; AIA 03047); Veterans Administration Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center (GRECC); and UCLA Claude Pepper Older Americans Independence Center (AG-10415) NR 43 TC 22 Z9 25 U1 3 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD SEP 1 PY 2008 VL 31 IS 9 BP 1291 EP 1300 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 343YA UT WOS:000258891100012 PM 18788654 ER PT J AU Basile, JN AF Basile, Jan N. TI Rationale for fixed-dose combination therapy to reach lower blood pressure goals SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE angiotensin receptor blockers; calcium channel blockers; cardiovascular disease; combination therapy; hypertension ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; KIDNEY-DISEASE; HYPERTENSIVE PATIENTS; RISK-FACTOR; SYSTOLIC HYPERTENSION; CLINICAL CARDIOLOGY; CALCIUM-ANTAGONIST; METABOLIC SYNDROME AB Expert committees in the United States and Europe formulated their currently recommended target blood pressures of < 140/90 mm Hg or < 130/80 mm Hg in persons with diabetes, chronic kidney disease, or coronary artery disease based on the totality of clinical data available at the time. However, accumulating evidence indicates that increased risk for cardiovascular and renal complications of hypertension may begin at a threshold of 115/75 mm Hg, suggesting that benefit from treatment may occur when blood pressure targets are lower than those currently recommended. Combination therapy with two or more agents having complementary mechanisms of action is the most effective method for achieving strict blood pressure goals in high-risk patients. Several clinical trials are under way to further determine the risks and benefits of lowering blood pressure beyond the currently recommended threshold. C1 [Basile, Jan N.] Med Univ S Carolina, Charleston, SC 29425 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29403 USA. RP Basile, JN (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29403 USA. EM jan.basile@va.gov FU Novartis Pharmaceuticals Corp.; National Heart, Lung , and Blood Institute; Boehringer Ingelheim; Novartis FX Development of this article was supported by Novartis Pharmaceuticals Corp.; Dr Basile receives grant/research support from the National Heart, Lung, and Blood Institute, Boehringer Ingelheim, and Novartis. He has served as a consultant for AstraZeneca, Merck, Novartis, and Daiichi Sankyo and has served on the Speakers' Bureau of Abbott, AstraZeneca, Boehringer Ingelheim, Forest, Merck, Novartis, Pfizer, and Daiichi Sankyo. NR 55 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD SEP PY 2008 VL 101 IS 9 BP 918 EP 924 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 353QL UT WOS:000259583200014 PM 18708973 ER PT J AU Robinson, TM Alexander, SC Hays, M Jeffreys, AS Olsen, MK Rodriguez, KL Pollak, KI Abernethy, AP Arnold, R Tulsky, JA AF Robinson, Tracy M. Alexander, Stewart C. Hays, Margie Jeffreys, Amy S. Olsen, Maren K. Rodriguez, Keri L. Pollak, Kathryn I. Abernethy, Amy P. Arnold, Robert Tulsky, James A. TI Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis SO SUPPORTIVE CARE IN CANCER LA English DT Article DE communication; cancer; medical oncology; prognosis; physician-patient relations ID TREATMENT PREFERENCES; ILL PATIENTS; DISCLOSURE; DOCTORS; HOPE; INFORMATION; PHYSICIANS; CAREGIVERS; COLLUSION; SURVIVAL AB Goals of work Advanced cancer patients' perceptions of prognosis, which are often overly optimistic compared to oncologist estimates, influence treatment preferences. The predictors of patients' perceptions and the effect of oncologist communication on patient understanding are unclear. This study was designed to identify the communication factors that influence patient-oncologist concordance about chance of cure. Materials and methods We analyzed audiorecorded encounters between 51 oncologists and 141 advanced cancer patients with good (n=69) or poor (n=72) concordance about chance of cure. Encounters were coded for communication factors that might influence oncologist-patient concordance, including oncologist statements of optimism and pessimism. Main results Oncologists made more statements of optimism (mean=3.3 per encounter) than statements of pessimism (mean=1.2 per encounter). When oncologists made at least one statement of pessimism, patients were more likely to agree with their oncologist's estimated chance of cure (OR=2.59, 95%CI=1.31-5.12). Statements of optimism and uncertainty were not associated with an increased likelihood that patients would agree or disagree with their oncologists about chance of cure. Conclusions Communication of pessimistic information to patients with advanced cancer increases the likelihood that patients will report concordant prognostic estimates. Communication of optimistic information does not have any direct effect. The best communication strategy to maximize patient knowledge for informed decision making while remaining sensitive to patients' emotional needs may be to emphasize optimistic aspects of prognosis while also consciously and clearly communicating pessimistic aspects of prognosis. C1 [Robinson, Tracy M.] Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37203 USA. [Robinson, Tracy M.] Duke Univ, Sch Med, Durham, NC USA. [Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren K.; Tulsky, James A.] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA. [Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Alexander, Stewart C.; Abernethy, Amy P.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA. [Hays, Margie; Rodriguez, Keri L.; Arnold, Robert] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Olsen, Maren K.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Pollak, Kathryn I.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Pollak, Kathryn I.; Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Duke Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA. [Abernethy, Amy P.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC USA. [Arnold, Robert] Univ Pittsburgh, Sch Med, Inst Doctor Patient Commun, Pittsburgh, PA USA. [Arnold, Robert] Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Pittsburgh, PA USA. [Tulsky, James A.] Duke Univ, Med Ctr, Ctr Aging & Human Dev, Durham, NC USA. RP Robinson, TM (reprint author), Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37203 USA. EM tracy.robinson@vanderbilt.edu OI Abernethy, Amy/0000-0001-6930-8722 FU NCI NIH HHS [R01 CA100387-05, R01 CA 100387, R01 CA100387] NR 32 TC 44 Z9 44 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD SEP PY 2008 VL 16 IS 9 BP 1049 EP 1057 DI 10.1007/s00520-007-0372-2 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 335JI UT WOS:000258286500010 PM 18196288 ER PT J AU Montgomery, B Lavori, P Garzotto, M Lee, K Brophy, M Thaneemit-Chen, S Kelly, W Basler, J Ringer, R Yu, W Whittemore, A Lin, DW AF Montgomery, Bruce Lavori, Philip Garzotto, Mark Lee, Kelvin Brophy, Mary Thaneemit-Chen, Surai Kelly, William Basler, Joseph Ringer, Robert Yu, Wei Whittemore, Alice Lin, Daniel W. TI Veterans affairs cooperative studies program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer SO UROLOGY LA English DT Review ID CELL LUNG-CANCER; ANDROGEN-INDEPENDENT PROGRESSION; EXTERNAL-BEAM RADIOTHERAPY; RADICAL PROSTATECTOMY; RADIATION-THERAPY; HORMONAL-THERAPY; COLON-CANCER; RECURRENCE; TRIAL; FLUOROURACIL C1 [Montgomery, Bruce] Vet Affairs Puget Sound Hlth Care Syst, Div Med Oncol, Seattle, WA 98109 USA. Univ Washington, Seattle, WA 98195 USA. Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. Vet Affairs Portland, Dept Surg, Div Urol, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Vet Affairs Cooperat Studies Coordinating Ctr, Palo Alto, CA USA. Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. Yale Univ, Dept Med, Div Oncol, New Haven, CT 06520 USA. S Texas Vet Adm Hlth Care Syst, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. Cooperat Studies Pharm Coordinating Ctr, Albuquerque, NM USA. RP Montgomery, B (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Med Oncol, S-111-ONC,1660 S Columbian Way, Seattle, WA 98109 USA. EM rbmontgo@u.washington.edu FU Department of Veterans Affairs, Cooperative Studies Program FX This work was supported by the Department of Veterans Affairs, Cooperative Studies Program. NR 42 TC 11 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD SEP PY 2008 VL 72 IS 3 BP 474 EP 480 DI 10.1016/j.urology.2008.02.050 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 357NQ UT WOS:000259853800003 PM 18407333 ER PT J AU Baldwin, SB Solorio, R Washington, DL Yu, HJ Huang, YC Brown, ER AF Baldwin, Susie B. Solorio, Rosa Washington, Donna L. Yu, Hongjian Huang, Yii-Chieh Brown, E. Richard TI Who is using emergency contraception? Awareness and use of emergency contraception among California women and teens SO WOMENS HEALTH ISSUES LA English DT Article ID UNINTENDED PREGNANCY; BEHAVIORAL-MODEL; INCREASED ACCESS; MEDICAL-CARE; KNOWLEDGE; LEVONORGESTREL; REGIMEN; RATES AB Introduction. Emergency contraception (EC) reduces women's risk for pregnancy after unprotected intercourse, and women's awareness of the method is increasingly important for expanding access. However, knowledge of EC alone does not predict use, and few population data exist to describe EC use among those aware of the method. Methods. Using data from the 2003 California Health Interview Survey, we measured EC awareness among 11,392 women ages 15-44, and EC use among 7,178 respondents who were aware of EC and at risk for pregnancy. Using chi(2) analyses and multivariable logistic regression, we examined population characteristics that epidemiologically predict EC awareness and use, including age, race/ethnicity, income, health insurance status, usual source of health care, immigration status, languages spoken at home, and urban versus rural residence. Results. Nearly 76% of respondents had heard of EC, but awareness was lower among teens, women of color, poor women, women with publicly funded health insurance, those without a usual source of care, immigrants, non-English-language speakers, and rural residents. Among women aware of EC, about 4% reported having used the method in the previous year; young age, low income, attending a community/government clinic for care or not having a source of care, and living in an urban area significantly increased the odds for using EC. Conclusions. Among California women in 2003, awareness and use of EC remained low. However, similar rates of use were reported among racial, ethnic, and linguistic subgroups. Those most likely to report use of the method included population groups at high risk for unintended pregnancy. C1 [Baldwin, Susie B.] Los Angeles Cty Dept Pubic Hlth, Off Hlth Assessment & Epidemiol, Los Angeles, CA 90012 USA. [Solorio, Rosa] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Yu, Hongjian; Huang, Yii-Chieh; Brown, E. Richard] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Hlth Policy Res, Los Angeles, CA 90024 USA. RP Baldwin, SB (reprint author), Los Angeles Cty Dept Pubic Hlth, Off Hlth Assessment & Epidemiol, 313 N Figueroa St,Room 127, Los Angeles, CA 90012 USA. EM sbaldwin@ph.lacounty.gov NR 24 TC 19 Z9 22 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD SEP-OCT PY 2008 VL 18 IS 5 BP 360 EP 368 DI 10.1016/j.whi.2008.06.005 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 350DF UT WOS:000259332100004 PM 18774454 ER PT J AU Adibhatla, RM Hatcher, JF AF Adibhatla, Rao Muralikrishna Hatcher, J. F. TI Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies SO BMB REPORTS LA English DT Review DE arachidonic acid; CNS pathologies; neurodegenerative disorders; oxidative stress; phosphatidylcholine; 4-hydroxynonenal ID TRANSIENT CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA PEPTIDE; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; NADPH OXIDASE; BRAIN-INJURY; RAT-BRAIN; GROUP IIA; A(2) AB The importance of lipids in cell signaling and tissue physiology is demonstrated by the many CNS pathologies involving deregulated lipid metabolism. One such critical metabolic event is the activation of phospholipase A(2) (PLA(2)), which results in the hydrolysis of membrane phospholipids and the release of free fatty acids, including arachidonic acid, a precursor for essential cell-signaling eicosanoids. Reactive oxygen species (ROS, a product of arachidonic acid metabolism) react with cellular lipids to generate lipid peroxides, which are degraded to reactive aldehydes (oxidized phospholipid, 4-hydroxynonenal, and acrolein) that bind covalently to proteins, thereby altering their function and inducing cellular damage. Dissecting the contribution of PLA2 to lipid peroxidation in CNS injury and disorders is a challenging proposition due to the multiple forms of PLA2, the diverse sources of ROS, and the lack of specific PLA2 inhibitors. In this review, we summarize the role of PLA(2) in CNS pathologies, including stroke, spinal cord injury, Alzheimer's, Parkinson's, Multiple sclerosis-Experimental autoimmune encephalomyelitis and Wallerian degeneration. C1 [Adibhatla, Rao Muralikrishna; Hatcher, J. F.] Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA. [Adibhatla, Rao Muralikrishna] Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI USA. [Adibhatla, Rao Muralikrishna] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [Adibhatla, Rao Muralikrishna] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Adibhatla, RM (reprint author), Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA. EM adibhatl@neurosurg.wisc.edu FU NIH/NINDS [NS42008]; American Heart Association Greater Midwest [0655757Z]; UW/-School of Medicine and Public Health Research Committee [161-PRJ13MX]; UW-School of Medicine and Public Health; UW-Graduate school; UW-Neurological Surgery Department and laboratory resources FX This work was supported by grants from NIH/NINDS (NS42008), American Heart Association Greater Midwest Affiliate Grant-in-Aid (0655757Z), UW/-School of Medicine and Public Health Research Committee (161-PRJ13MX), UW-School of Medicine and Public Health, UW-Graduate school and UW-Neurological Surgery Department and laboratory resources provided by William S. Middleton VA Hospital (to RMA). The EO6 antibodies were generously provided by Dr Joseph Witztum, Univ. of California-San Diego, La Jolla, CA. NR 54 TC 82 Z9 85 U1 0 U2 12 PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY PI SEOUL PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801, 635-4 , YEOKSAM-DONG, KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA SN 1976-6696 J9 BMB REP JI BMB Rep. PD AUG 31 PY 2008 VL 41 IS 8 BP 560 EP 567 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 343PO UT WOS:000258866200002 PM 18755070 ER PT J AU Zhu, BJ Ascher-Svanum, H Faries, DE Peng, XM Salkever, D Slade, EP AF Zhu, Baojin Ascher-Svanum, Haya Faries, Douglas E. Peng, Xiaomei Salkever, David Slade, Eric P. TI Costs of treating patients with schizophrenia who have illness-related crisis events SO BMC PSYCHIATRY LA English DT Article ID BEHAVIORAL HEALTH-CARE; ANTIPSYCHOTIC MEDICATION; ASSESSMENT PROGRAM; RISK ADJUSTMENT; OUTCOMES; RELAPSE; NONADHERENCE; ADHERENCE; HOSPITALIZATION; DISORDERS AB Background: Relatively little is known about the relationship between psychosocial crises and treatment costs for persons with schizophrenia. This naturalistic prospective study assessed the association of recent crises with mental health treatment costs among persons receiving treatment for schizophrenia. Methods: Data were drawn from a large multi-site, non-interventional study of schizophrenia patients in the United States, conducted between 1997 and 2003. Participants were treated at mental health treatment systems, including the Department of Veterans Affairs (VA) hospitals, community mental health centers, community and state hospitals, and university health care service systems. Total costs over a 1-year period for mental health services and component costs (psychiatric hospitalizations, antipsychotic medications, other psychotropic medications, day treatment, emergency psychiatric services, psychosocial/rehabilitation group therapy, individual therapy, medication management, and case management) were calculated for 1557 patients with complete medical information. Direct mental health treatment costs for patients who had experienced 1 or more of 5 recent crisis events were compared to propensity-matched samples of persons who had not experienced a crisis event. The 5 non-mutually exclusive crisis event subgroups were: suicide attempt in the past 4 weeks (n = 18), psychiatric hospitalization in the past 6 months (n = 240), arrest in the past 6 months (n = 56), violent behaviors in the past 4 weeks (n = 62), and diagnosis of a co-occurring substance use disorder (n = 413). Results: Across all 5 categories of crisis events, patients who had a recent crisis had higher average annual mental health treatment costs than patients in propensity-score matched comparison samples. Average annual mental health treatment costs were significantly higher for persons who attempted suicide ($46,024), followed by persons with psychiatric hospitalization in the past 6 months ($37,329), persons with prior arrests ($31,081), and persons with violent behaviors ($18,778). Total cost was not significantly higher for those with co-occurring substance use disorder ($19,034). Conclusion: Recent crises, particularly suicide attempts, psychiatric hospitalizations, and criminal arrests, are predictive of higher mental health treatment costs in schizophrenia patients. C1 [Zhu, Baojin; Ascher-Svanum, Haya; Faries, Douglas E.; Peng, Xiaomei] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Salkever, David] Univ Maryland Baltimore Cty, Dept Publ Policy, Baltimore, MD 21228 USA. [Slade, Eric P.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Slade, Eric P.] US Dept Vet Affairs, VA VISN5 Mental Illness Res & Educ Clin Ctr, Baltimore, MD USA. RP Ascher-Svanum, H (reprint author), Eli Lilly & Co, Indianapolis, IN 46285 USA. EM ZHU_BAOJIN@LILLY.COM; haya@lilly.com; FARIES_DOUGLAS_E@LILLY.COM; PENG_XIAOMEI@lilly.com; SALKEVER@UMBC.EDU; ESLADE@PSYCH.UMARYLAND.EDU FU Eli Lilly and company FX Financial support for this research was provided by a grant from Eli Lilly and company. The authors also wish to thank the US-SCAP site investigators and others who collaborated in the research. By site, they include Maryland: A. F. Lehman, M. D., M. S. P. H., University of Maryland School of Medicine, and G. Gallucci, M. D., M. H. S., Johns Hopkins Bayview Medical Center ( previously); Colorado: C. Harding, Ph. D., University of Colorado ( previously); Florida: D. Shern, Ph. D., Florida Mental Health Institute, University of South Florida ( previously), and T. Saunders, M. S., Florida Mental Health Institute ( previously); North Carolina: J. Swanson, Ph. D., L. A. Dunn, M. D., and M. Swartz, M. D., Duke University Medical School; California: R. L. Hough, Ph. D., and C. Barrio, Ph. D., Child and Adolescent Services Research Center and San Diego State University; Connecticut: R. A. Rosenheck, M. D., and R. Desai, Ph. D., VA Connecticut Health Care System; Medstat Group: P. Russo, Ph. D., M. S. W., R. N., ( previously), L. Palmer, Ph. D., L. Torres, M. B. A., and B. Cuffel, Ph. D. ( previously); Eli Lilly and Co.: D. Buesching, Ph. D., Bryan M. Johnstone, Ph. D., and T. Croghan, M. D. ( previously); Consultants: D. Salkever, Ph. D., Johns Hopkins University ( previously), E. Slade, Ph. D., Johns Hopkins University ( previously), and W. Hargreaves, Ph. D., and M. Shumway, Ph. D., University of California, San Francisco. The authors wish to thank Paul Crits- Christoph, PhD, who was compensated by Eli Lilly and Company, for his valuable assistance with the preparation of the manuscript. NR 32 TC 9 Z9 10 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-244X J9 BMC PSYCHIATRY JI BMC Psychiatry PD AUG 26 PY 2008 VL 8 AR 72 DI 10.1186/1471-244X-8-72 PG 10 WC Psychiatry SC Psychiatry GA 350EC UT WOS:000259334400001 PM 18727831 ER PT J AU Elder, GA Ragnauth, A Dorr, N Franciosi, S Schmeidler, J Haroutunian, V Buxbaum, JD AF Elder, Gregory A. Ragnauth, Andre Dorr, Nathan Franciosi, Sonia Schmeidler, James Haroutunian, Vahram Buxbaum, Joseph D. TI Increased locomotor activity in mice lacking the low-density lipoprotein receptor SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Alzheimer's disease; acoustic startle; cholesterol; light/dark preference; low-density lipoprotein receptor; Morris water maze; null mutation; open field ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; KNOCKOUT MICE; MESSENGER-RNA; UP-REGULATION; LOW-FAT; CHOLESTEROL; ATHEROSCLEROSIS; EXPRESSION AB While the low-density lipoprotein receptor (LDLR) is best known for its role in regulating serum cholesterol, LDLR is expressed in brain, suggesting that it may play a role in CNS function as well. Here, using mice with a null mutation in LDLR (LDLR-/-), we investigated whether the absence of LDLR affects a series of behavioral functions. We also utilized the fact that plasma cholesterol levels can be regulated in LDLR-/- mice by manipulating dietary cholesterol to investigate whether elevated plasma cholesterol might independently affect behavioral performance. LDLR-/- mice showed no major deficits in general sensory or motor function. However, LDLR-/- mice exhibited increased locomotor activity in an open field test without evidence of altered anxiety in either an open field or a light/dark emergence test. By contrast, modulating dietary cholesterol produced only isolated effects. While both C57BL/6J and LDLR-/- mice fed a high cholesterol diet showed increased anxiety in a light/dark task, and LDLR-/- mice fed a high cholesterol diet exhibited longer target latencies in the probe trial of the Morris water maze, no other findings supported a general effect of cholesterol on anxiety or spatial memory. Collectively these studies suggest that while LDLR-/- mice exhibit no major developmental defects, LDLR nevertheless plays a significant role in modulating locomotor behavior in the adult. (C) 2008 Elsevier B.V. All rights reserved. C1 [Elder, Gregory A.; Ragnauth, Andre; Franciosi, Sonia; Schmeidler, James; Haroutunian, Vahram; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY 10468 USA. [Franciosi, Sonia; Buxbaum, Joseph D.] Mt Sinai Sch Med, Lab Mol Neuropsychiat, New York, NY 10029 USA. [Elder, Gregory A.; Ragnauth, Andre; Dorr, Nathan; Buxbaum, Joseph D.] Mt Sinai Sch Med, Mouse & Rat Rhenotyping Facil, New York, NY 10029 USA. RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1668,1 Gustave Levy Pl, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU NIA NIH HHS [P01 AG010491-06A29001, AG002219, AG010491, P01 AG002219, P01 AG010491, P01 AG010491-10A20006, P01 AG010491-11] NR 32 TC 20 Z9 20 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD AUG 22 PY 2008 VL 191 IS 2 BP 256 EP 265 DI 10.1016/j.bbr.2008.03.036 PG 10 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 317WF UT WOS:000257050400015 PM 18466986 ER PT J AU Lieber, CS Leo, MA Wang, X DeCarli, LM AF Lieber, Charles S. Leo, Maria Anna Wang, Xiaolei DeCarli, Leonore M. TI Alcohol alters hepatic FoxO1, p53, and mitochondrial SIRT5 deacetylation function SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE alcohol; liver; Foxo1; p53; mitochondria; SIRT5 ID TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; GENE-EXPRESSION; LIVER-DISEASE; ETHANOL; ACETYLATION; METABOLISM; SIRTUINS; PHOSPHORYLATION; TOXICITY AB Chronic alcohol consumption affects the gene expression of a NAD-depenclent cleacetylase Sirtuis 1 (SIRT1) and the peroxisome proliferator-activated receptor-gamma coactivator1 alpha (PGC-1 alpha). Our aim was to verify that it also alters the forkhead (FoxO1) and p53 transcription factor proteins, critical in the hepatic response to oxidative stress and regulated by SIRT1 through its deacetylating capacity. Accordingly, rats were pair-fed the Lieber-DeCarli alcohol-containing liquid diets for 28 days. Alcohol increased hepatic mRNA expression of FoxO1 (p = 0.003) and p53 (p = 0.001) while corresponding protein levels remained unchanged. However phospho-FoxO1 and phospho-Akt (protein kinase) were both decreased by alcohol consumption (p = 0.04 and p = 0.02, respectively) while hepatic p53 was found hyperacetylated (p = 0.017). Furthermore, mitochondrial SIRT5 was reduced (p = 0.0025), and PGC-1 alpha hyperacetylated (p = 0.027), establishing their role in protein modification. Thus, alcohol consumption disrupts nuclear-mitochondrial interactions by post-translation protein modifications, which contribute to alteration of mitochondrial biogenesis through the newly discovered reduction of SIRT5. (C) 2008 Elsevier Inc. All rights reserved. C1 [Lieber, Charles S.; Leo, Maria Anna; DeCarli, Leonore M.] James J Peters VA Med Ctr, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. [Lieber, Charles S.; Leo, Maria Anna; Wang, Xiaolei] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Lieber, CS (reprint author), James J Peters VA Med Ctr, Sect Liver Dis & Nutr, 130 W Kingsbridge Rd 151-2, Bronx, NY 10468 USA. EM liebercs@aol.com NR 30 TC 41 Z9 43 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 22 PY 2008 VL 373 IS 2 BP 246 EP 252 DI 10.1016/j.bbrc.2008.06.006 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 327WH UT WOS:000257758700013 PM 18555008 ER PT J AU Jo, OD Martin, J Bernath, A Masri, J Lichtenstein, A Gera, J AF Jo, Oak D. Martin, Jheralyn Bernath, Andrew Masri, Janine Lichtenstein, Alan Gera, Joseph TI Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RNA-BINDING-PROTEINS; FORKHEAD TRANSCRIPTION FACTOR; STRAND ANNEALING ACTIVITY; TRANS-ACTING FACTORS; MESSENGER-RNA; HNRNP A1; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SUBCELLULAR-DISTRIBUTION; TRANSLATIONAL CONTROL; MEDIATED TRANSLATION AB The translation of the cyclin D1 and c-myc mRNAs occurs via internal ribosome entry site (IRES)-mediated initiation under conditions of reduced eIF-4F complex formation and Akt activity. Here we identify hnRNP A1 as an IRES trans-acting factor that regulates cyclin D1 and c-myc IRES activity, depending on the Akt status of the cell. hnRNP A1 binds both IRESs in vitro and in intact cells and enhances in vitro IRES-dependent reporter expression. Akt regulates this IRES activity by inducing phosphorylation of hnRNP A1 on serine 199. Serine 199-phosphorylated hnRNP A1 binds to the IRESs normally but is unable to support IRES activity in vitro. Reducing expression levels of hnRNP A1 or overexpressing a dominant negative version of the protein markedly inhibits rapamycin-stimulated IRES activity in cells and correlated with redistribution of cyclin D1 and c-myc transcripts from heavy polysomes to monosomes. Importantly, knockdown of hnRNP A1 also renders quiescent Akt-containing cells sensitive to rapamycin-induced G(1) arrest. These results support a role for hnRNP A1 in mediating rapamycin-induced alterations of cyclin D1 and c-myc IRES activity in an Akt-dependent manner and provide the first direct link between Akt and the regulation of IRES activity. C1 [Jo, Oak D.; Martin, Jheralyn; Bernath, Andrew; Masri, Janine; Lichtenstein, Alan; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. [Lichtenstein, Alan; Gera, Joseph] David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA. [Lichtenstein, Alan] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90048 USA. RP Gera, J (reprint author), Univ Calif Los Angeles, Dept Res & Dev, Med Ctr, 16111 Plummer St 151,Bldg 1,Rm C111A, Los Angeles, CA 91343 USA. EM gera@ucla.edu FU NCI NIH HHS [R01CA109312, R01CA111448, CA-16042, P30 CA016042]; NIAID NIH HHS [P30 AI028697, AI-28697] NR 55 TC 46 Z9 47 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 22 PY 2008 VL 283 IS 34 BP 23274 EP 23287 DI 10.1074/jbc.M801185200 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 337SI UT WOS:000258455400040 PM 18562319 ER PT J AU Matthews, QL Yang, P Wu, Q Belousova, N Rivera, AA Stoff-Khalili, MA Waehler, R Hsu, HC Li, Z Li, J Mountz, JD Wu, HJ Curiel, DT AF Matthews, Qiana L. Yang, PingAr Wu, Qi Belousova, Natalya Rivera, Angel A. Stoff-Khalili, Mariam A. Waehler, Reinhard Hsu, Hui-Chen Li, Zan Li, Jing Mountz, John D. Wu, Hongju Curiel, David T. TI Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach SO VIROLOGY JOURNAL LA English DT Article ID GENE-TRANSFER; DENDRITIC CELLS; VIRAL VECTORS; RECOMBINANT ADENOVIRUSES; IMMUNE-RESPONSES; VIRUS-INFECTION; FIBER PROTEIN; T-CELLS; IN-VIVO; HEXON AB Despite the many potential advantages of Ad vectors for vaccine application, the full utility of current Ad vaccines may be limited by the host anti-vector immune response. Direct incorporation of antigens into the adenovirus capsid offers a new and exciting approach for vaccination strategies; this strategy exploits the inherent antigenicity of the Ad vector. Critical to exploiting Ad in this new context is the placement of antigenic epitopes within the major Ad capsid protein, hexon. In our current study we illustrate that we have the capability to place a range of antigenic epitopes within Ad5 capsid protein hexon hypervariable regions (HVRs) 2 or 5, thus producing viable Ad virions. Our data define the maximal incorporation size at HVR2 or HVR5 as it relates to identical antigenic epitopes. In addition, this data suggests that Ad5 HVR5 is more permissive to a range of insertions. Most importantly, repeated administration of our hexon-modified viruses resulted in a secondary anti-antigen response, whereas minimal secondary effect was present after administration of Ad5 control. Our study describes antigen placement and optimization within the context of the capsid incorporation approach of Ad vaccine employment, thereby broadening this new methodology. C1 [Matthews, Qiana L.; Rivera, Angel A.; Waehler, Reinhard; Li, Jing; Wu, Hongju; Curiel, David T.] Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA. [Matthews, Qiana L.; Rivera, Angel A.; Waehler, Reinhard; Li, Jing; Wu, Hongju; Curiel, David T.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Matthews, Qiana L.; Rivera, Angel A.; Waehler, Reinhard; Li, Jing; Wu, Hongju; Curiel, David T.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Matthews, Qiana L.; Rivera, Angel A.; Waehler, Reinhard; Li, Jing; Wu, Hongju] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA. [Matthews, Qiana L.; Rivera, Angel A.; Waehler, Reinhard; Li, Jing; Wu, Hongju; Curiel, David T.] Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35294 USA. [Yang, PingAr; Wu, Qi; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Belousova, Natalya] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA. [Stoff-Khalili, Mariam A.] Univ Dusseldorf, Dept Obstet & Gynecol, Med Ctr, Dusseldorf, Germany. [Li, Zan] Alabama Sch Fine Arts, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Curiel, DT (reprint author), Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA. EM qlm@uab.edu; shuang@uab.edu; qiwu@uab.edu; Natalya.Belousova@di.mdacc.tmc.edu; aarivera@uab.edu; mariam.stoff-khalili@uk-koeln.de; waehler@uab.edu; HuiChen.Hsu@ccc.uab.edu; parisintherain@gmail.com; jili@uab.edu; John.Mountz@ccc.uab.edu; hongjuwu@uab.edu; curiel@uab.edu FU National Institutes of Health [5T32AI07493-11, 1R21AI076096-01] FX The authors would also like to acknowledge Dr. Maaike Everts and Erin E. Thacker as well as Yizhe Tang for their critical reading of the manuscript. This work was supported by grants from the National Institutes of Health: 5T32AI07493-11 ( Dr. Casey Morrow), and 1R21AI076096-01 ( Dr. David T. Curiel). NR 44 TC 24 Z9 24 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD AUG 21 PY 2008 VL 5 AR 98 DI 10.1186/1743-422X-5-98 PG 13 WC Virology SC Virology GA 360AM UT WOS:000260029400001 PM 18718011 ER PT J AU Kaplan, RC Kingsley, LA Gange, SJ Benning, L Jacobson, LP Lazar, J Anastos, K Tien, PC Sharrett, R Hodis, HN AF Kaplan, Robert C. Kingsley, Lawrence A. Gange, Stephen J. Benning, Lorie Jacobson, Lisa P. Lazar, Jason Anastos, Kathryn Tien, Phyllis C. Sharrett, Richey Hodis, Howard N. TI Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men SO AIDS LA English DT Article DE AIDS; carotid arteries; epidemiology ID INTIMA-MEDIA THICKNESS; MULTICENTER AIDS COHORT; COMBINATION ANTIRETROVIRAL THERAPY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MYOCARDIAL-INFARCTION; INTERAGENCY HIV; CAROTID ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; FAT DISTRIBUTION AB Objective: To assess the association of HIV infection, HIV disease parameters (including CD4+ T-cell counts, HIV viral load, and AIDS) and antiretroviral medication Use With SLII)Clinical carotid artery atherosclerosis. Design: Cross-sectional study nested within a prospective cohort study. Methods: Among participants in the Women's Interagency HIV Study (1331 HIV-infected woman, 534 HIV-uninfected women) and Multicenter AIDS Cohort Study(600 HIV-infected men, 325 HIV-uninfected men), we measured subclinical carotid artery lesions and common carotid artery intima-media thickness Using B-mode ultrasound. We estimated adjusted mean carotid artery intima-media thickness differences and prevalence rations for carotid lesions associated with HIV-related disease and treatments with multivariate adjustment to control for possible confounding variables. Results: Among HIV-infected individuals, a low CD4+ T-cell count was independently associated with an increased prevalence of carotid lesions. Compared with the reference group of HIV-uninfected individuals, the adjusted prevalence ratio for lesions among HIV-infected individuals with CD4+ T-cell count less than 200 cells/mu l was 2.00 (95% confidence interval, 1.22-3.28) in women and 1.74 (950% confidence interval, 1.04-2.93) in men. No consistent association of antiretroviral medications with carotid atherosclerosis was observed, except for a borderline significant association between protease inhibitor Use and carotid lesions in men (with no association among women). History of clinical AIDS and HIV viral load were not significantly associated with carotid atherosclerosis. Conclusion: Beyond traditional cardiovascular disease risk factors, low CD4+ T-cell count is the most robust risk factor for increased subclinical carotid atherosclerosis in HIV-infected women and men. (C) 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Kaplan, Robert C.; Anastos, Kathryn] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA. [Kingsley, Lawrence A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. [Kingsley, Lawrence A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Gange, Stephen J.; Benning, Lorie; Jacobson, Lisa P.; Sharrett, Richey] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Lazar, Jason] SUNY Hlth Sci Ctr, Dept Med Cardiol, Brooklyn, NY 11203 USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hodis, Howard N.] Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Dept Med, Los Angeles, CA 90033 USA. [Hodis, Howard N.] Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Dept Prevent Med, Los Angeles, CA 90033 USA. RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Belfer 1306C,1300 Morris Pk Ave, Bronx, NY 10461 USA. EM rkaplan@aecom.yu.edu RI Kaplan, Robert/A-2526-2011 OI Gange, Stephen/0000-0001-7842-512X FU NCRR NIH HHS [5-MO1-RR-00722, M01 RR000071, M01 RR000079, M01 RR000083, M01 RR000722, M01 RR023942, M01RR-023942-01, MO1-RR-00071, MO1-RR-00079, MO1-RR-00083]; NHLBI NIH HHS [1R01HL083760-01, R01 HL083760, R01 HL083760-01, R01 HL083760-02, R01 HL083760-03]; NIAID NIH HHS [UO1-AI-35041, K23 AI066943, K23 AI066943-05, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI035039, U01 AI035040, U01 AI035041, U01 AI035042, U01 AI035043, U01 AI037613, U01 AI037984, U01 AI042590, UO1-AI-31834, UO1-AI-34989, UO1-AI-34993, UO1-AI-34994, UO1-AI-35004, UO1-AI-35039, UO1-AI-35040, UO1-AI-35042, UO1-AI-35043, UO1-AI-37613, UO1-AI-37984, UO1-AI-42590]; NICHD NIH HHS [U01 HD032632, UO1-HD-32632] NR 39 TC 149 Z9 152 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD AUG 20 PY 2008 VL 22 IS 13 BP 1615 EP 1624 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 342CG UT WOS:000258761600011 PM 18670221 ER PT J AU Kollef, MH Afessa, B Anzueto, A Veremakis, C Kerr, KM Margolis, BD Craven, DE Roberts, PR Arroliga, AC Hubmayr, RD Restrepo, MI Auger, WR Schinner, R AF Kollef, Marin H. Afessa, Bekele Anzueto, Antonio Veremakis, Christopher Kerr, Kim M. Margolis, Benjamin D. Craven, Donald E. Roberts, Pamela R. Arroliga, Alejandro C. Hubmayr, Rolf D. Restrepo, Marcos I. Auger, William R. Schinner, Regina CA NASCENT Invest Grp TI Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia - The NASCENT Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article; Proceedings Paper CT 20th Annual Congress of the European-Society-of-Intensive-Care-Medicine CY OCT 07-10, 2007 CL Berlin, GERMANY SP European Soc Intens Care Med ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; LARGE US DATABASE; MECHANICAL VENTILATION; DOUBLE-BLIND; IN-VITRO; AIRWAY COLONIZATION; DECONTAMINATION; PREVENTION; CATHETERS AB Context Ventilator-associated pneumonia (VAP) causes substantial morbidity. A silver-coated endotracheal tube has been designed to reduce VAP incidence by preventing bacterial colonization and biofilm formation. Objective To determine whether a silver-coated endotracheal tube would reduce the incidence of microbiologically confirmed VAP. Design, Setting, and Participants Prospective, randomized, single-blind, controlled study conducted in 54 centers in North America. A total of 9417 adult patients (>= 18 years) were screened between 2002 and 2006. A total of 2003 patients expected to require mechanical ventilation for 24 hours or longer were randomized. Intervention Patients were assigned to undergo intubation with 1 of 2 high-volume, low-pressure endotracheal tubes, similar except for a silver coating on the experimental tube. Main Outcome Measures Primary outcome was VAP incidence based on quantitative bronchoalveolar lavage fluid culture with 10(4) colony-forming units/mL or greater in patients intubated for 24 hours or longer. Other outcomes were VAP incidence in all intubated patients, time to VAP onset, length of intubation and duration of intensive care unit and hospital stay, mortality, and adverse events. Results Among patients intubated for 24 hours or longer, rates of microbiologically confirmed VAP were 4.8% (37/766 patients; 95% confidence interval [Cl], 3.4%-6.6%) in the group receiving the silver-coated tube and 7.5% (56/743; 95% Cl, 5.7%-9.7%) (P=.03) in the group receiving the uncoated tube (all intubated patients, 3.8% [37/968; 95% Cl, 2.7%-5.2%] and 5.8% [56/964; 95% Cl, 4.4%-7.5%] [P=.04]), with a relative risk reduction of 35.9% (95% Cl, 3.6%-69.0%; all intubated patients, 34.2% [95% Cl, 1.2%-67.9%]). The silver-coated endotracheal tube was associated with delayed occurrence of VAP (P=.005). No statistically significant between-group differences were observed in durations of intubation, intensive care unit stay, and hospital stay; mortality; and frequency and severity of adverse events. Conclusion Patients receiving a silver-coated endotracheal tube had a statistically significant reduction in the incidence of VAP and delayed time to VAP occurrence compared with those receiving a similar, uncoated tube. Trial Registration clinicaltrials.gov Identifier: NCT00148642. C1 [Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO 63110 USA. [Afessa, Bekele; Hubmayr, Rolf D.] Mayo Clin, Coll Med, Rochester, MN USA. [Anzueto, Antonio; Restrepo, Marcos I.] S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX USA. [Anzueto, Antonio] Univ Hosp, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Veremakis, Christopher] St Johns Mercy Med Ctr, St Louis, MO 63141 USA. [Kerr, Kim M.; Auger, William R.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Margolis, Benjamin D.] W Suburban Hosp, Oak Pk, IL USA. [Craven, Donald E.] Lahey Clin Med Ctr, Burlington, MA 01803 USA. [Craven, Donald E.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Roberts, Pamela R.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Arroliga, Alejandro C.] Cleveland Clin, Cleveland, OH 44106 USA. [Restrepo, Marcos I.] VERDICT, San Antonio, TX USA. [Schinner, Regina] FGK Clin Res GmbH, Munich, Germany. RP Kollef, MH (reprint author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA. EM mkollef@im.wustl.edu RI Restrepo, Marcos/H-4442-2014 NR 47 TC 227 Z9 251 U1 3 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 20 PY 2008 VL 300 IS 7 BP 805 EP 813 DI 10.1001/jama.300.7.805 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 338VM UT WOS:000258537500020 PM 18714060 ER PT J AU Corboy, JR Elkind, MSV AF Corboy, John R. Elkind, Mitchell S. V. TI Maintenance of certification - Ready or not, here it comes SO NEUROLOGY LA English DT Editorial Material ID CLINICAL-EXPERIENCE; HEALTH-CARE; QUALITY C1 [Corboy, John R.] Univ Colorado, Sch Med, Aurora, CO USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Elkind, Mitchell S. V.] Columbia Univ, Sch Med, New York, NY USA. RP Corboy, JR (reprint author), 12631 E 17th Ave,Box B185,POB 6511,Room 5221, Aurora, CO 80045 USA. EM john.corboy@uchsc.edu NR 3 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD AUG 19 PY 2008 VL 71 IS 8 BP 544 EP 545 DI 10.1212/01.wnl.0000323935.26470.c3 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 338RO UT WOS:000258526400002 PM 18711107 ER PT J AU Dagda, RK Zhu, JH Kulich, SM Chu, CT AF Dagda, Ruben K. Zhu, Jianhui Kulich, Scott M. Chu, Charleen T. TI Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress SO AUTOPHAGY LA English DT Article DE autophagy; oxidative stress; mitochondria; mitogen activated protein kinases; 6-hydroxydopamine; Parkinson's disease ID NEUROBLASTOMA SH-SY5Y CELLS; PROTEIN-KINASE; PARKINSONS-DISEASE; CEREBRAL-ISCHEMIA; NEURONAL INJURY; MOUSE MODELS; ACTIVATION; 6-HYDROXYDOPAMINE; ERK1/2; NEURODEGENERATION AB Degenerating neurons of Parkinson's disease (PD) patient brains exhibit granules of phosphorylated extracellular signal-regulated protein kinase 1/2 (ERK1/2) that localize to autophagocytosed mitochondria. Here we show that 6-hydroxydopamine (6-OHDA) elicits activity-related localization of ERK1/2 in mitochondria of SH-SY5Y cells, and these events coincide with induction of autophagy and precede mitochondrial degradation. Transient transfection of wildtype (WT) ERK2 or constitutively active MAPK/ERK Kinase 2 (NIEK2-CA) was sufficient to induce mitophagy to a degree comparable with that elicited by 6-OHDA, while constitutively active ERK2 (ERK2-CA) had a greater effect. We developed green fluorescent protein (GFP) fusion constructs of WT, CA, and kinase-deficient (KD) ERK2 to study the role of ERK2 localization in regulating mitophagy and cell death. Under basal conditions, cells transfected with GFP-ERK2-WT or GFP-ERK2-CA, but not GFP-ERK2-KD, displayed discrete cytoplasmic ERK2 granules of which a significant fraction colocalized with mitochondria and markers of autophagolysosomal maturation. The colocalizing GFP-ERK2/mitochondria granules are further increased by 6-OHDA and undergo autophagic degradation, as bafilomycin-A, an inhibitor of autolysosomal degradation, robustly increased their detection. Interestingly, increasing ERK2-WT or ERK2-CA expression was sufficient to promote comparable levels of macroautophagy as assessed by analysis of the autophagy marker microtubule-associated protein I light chain 3 (LC3). In contrast, the level of mitophagy was more tightly correlated with ERK activity levels, potentially explained by the greater localization of ERK2-CA to mitochondria compared to ERK2-WT. These data indicate that mitochondrial localization of ERK2 activity is sufficient to recapitulate the effects of 6-OHDA on mitophagy and autophagic cell death. C1 [Dagda, Ruben K.; Zhu, Jianhui; Kulich, Scott M.; Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA. [Chu, Charleen T.] Univ Pittsburgh, Ctr Neurosci, Sch Med, Pittsburgh, PA 15261 USA. [Kulich, Scott M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Chu, CT (reprint author), Univ Pittsburgh, Dept Pathol, Sch Med, 200 Lothrop St, Pittsburgh, PA 15261 USA. EM ctc4@pitt.edu RI Chu, Charleen/B-1601-2008 OI Chu, Charleen/0000-0002-5052-8271; Dagda, Ruben/0000-0002-9946-9591 FU National Institutes of Health [AG026389, DC009120]; Veterans Administration Advanced Career Development Award; [T32 NS07495]; [F32 AG030821] FX We thank Simon Watkins and the Center for Biological Imaging (CBI) at the University of Pittsburgh for technical expertise with live confocal and EM imaging, Christopher Fung for constructing stable GFP-LC3 cell lines, Charlotte Diges for technical assistance, and all of the investigators listed in the methods section for providing molecular reagents. This research was supported by funding from the National Institutes of Health (AG026389 and DC009120, CTC) and a Veterans Administration Advanced Career Development Award (SMK). RKD was supported in part by T32 NS07495 and F32 AG030821. NR 72 TC 141 Z9 145 U1 2 U2 16 PU LANDES BIOSCIENCE PI AUSTIN PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD AUG 16 PY 2008 VL 4 IS 6 BP 770 EP 782 PG 13 WC Cell Biology SC Cell Biology GA 339TT UT WOS:000258600900006 PM 18594198 ER PT J AU Sharma, S Lichtenstein, A AF Sharma, Sanjai Lichtenstein, Alan TI Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors SO BLOOD LA English DT Article ID FACTOR-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING DOMAIN; MULTIPLE-MYELOMA; BIM; IDENTIFICATION; INHIBITION; EXPRESSION; REPRESSION; RESISTANCE AB The mechanism by which the glucocorticoid (GC) dexamethasone induces apoptosis in multiple myeloma (MM) cells is unknown, although previous work suggests that either transactivation through the glucocorticoid response element (GRE), transrepression of NF-kappa B, phosphorylation of RAFTK (Pyk2), or induction of Bim is important. We studied this question by ectopically expressing mutant glucocorticoid receptors (GRs) in the dexamethasone-resistant MM1 R cell line, which has lost its GR. Lentiviral-mediated reexpression of wild-type GR restored GRE transactivation, NF-KB transrepression, RAFTK phosphorylation, Bim induction, and dexamethasone-induced apoptosis. We then reexpressed 4 GR mutants, each possessing various molecular effects, into MM1 R cells. A perfect correlation was present between induction of GRE transactivation and induction of apoptosis. In contrast, NF-KB transrepression and RAFTK phosphorylation were not required for apoptosis. Although not required for dexamethasone-mediated apoptosis, NF-KB inhibition achieved by gene transfer suggested that NF-KB trans-repression could contribute to apoptosis in dexamethasone-treated cells. Dexamethasone treatment of MM1R cells expressing a mutant incapable of inducing apoptosis successfully resulted in RAFTK (Pyk2) phosphorylation and Bim induction indicating the latter GR-mediated events were not sufficient to induce apoptosis. MM1R cells expressing mutant GRs will be helpful in defining the molecular mechanisms of dexamethasone-induced apoptosis of myeloma cells. C1 [Sharma, Sanjai; Lichtenstein, Alan] Univ Calif Los Angeles, W Los Angeles & VA Med Ctr, Div Hematol Oncol, Los Angeles, CA 90073 USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, W Los Angeles & VA Med Ctr, Div Hematol Oncol, 11301 Wilshire Blvd,Bldg 304,E1-115, Los Angeles, CA 90073 USA. EM sasharma@mednet.ucla.edu FU NCI NIH HHS [R01 CA111448] NR 31 TC 27 Z9 30 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD AUG 15 PY 2008 VL 112 IS 4 BP 1338 EP 1345 DI 10.1182/blood-2007-11-124156 PG 8 WC Hematology SC Hematology GA 336VH UT WOS:000258392300060 PM 18515658 ER PT J AU Lipsky, BA AF Lipsky, Benjamin A. TI Bone of contention: Diagnosing diabetic foot osteomyelitis SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID PROCALCITONIN; INFECTIONS; PET C1 [Lipsky, Benjamin A.] VA Puget Sound HCS, Seattle, WA 98108 USA. [Lipsky, Benjamin A.] Univ Washington, Seattle, WA 98195 USA. RP Lipsky, BA (reprint author), VA Puget Sound HCS, S-111-PCC,1660 S Columbian Way, Seattle, WA 98108 USA. EM balipsky@u.washington.edu RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 19 TC 21 Z9 21 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2008 VL 47 IS 4 BP 528 EP 530 DI 10.1086/590012 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 327VD UT WOS:000257755700018 PM 18611161 ER PT J AU Effros, RB Fletcher, CV Gebo, K Halter, JB Hazzard, WR Horne, FM Huebner, RE Janoff, EN Justice, AC Kuritzkes, D Nayfield, SG Plaeger, SF Schmader, KE Ashworth, JR Campanelli, C Clayton, CP Rada, B Woolard, NF High, KP AF Effros, Rita B. Fletcher, Courtney V. Gebo, Kelly Halter, Jeffrey B. Hazzard, William R. Horne, Frances McFarland Huebner, Robin E. Janoff, Edward N. Justice, Amy C. Kuritzkes, Daniel Nayfield, Susan G. Plaeger, Susan F. Schmader, Kenneth E. Ashworth, John R. Campanelli, Christine Clayton, Charles P. Rada, Beth Woolard, Nancy F. High, Kevin P. TI Workshop on HIV infection and aging: What is known and future research directions SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MULTICENTER AIDS COHORT; VARICELLA-ZOSTER-VIRUS; CHRONIC KIDNEY-DISEASE; HEPATITIS-C VIRUS; CD4 CELL COUNT; LYMPHATIC TISSUE FIBROSIS; IMMUNE RISK PHENOTYPE; AGE-RELATED-CHANGES AB Highly active antiretroviral treatment has resulted in dramatically increased life expectancy among patients with HIV infection who are now aging while receiving treatment and are at risk of developing chronic diseases associated with advanced age. Similarities between aging and the courses of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome suggest that HIV infection compresses the aging process, perhaps accelerating comorbidities and frailty. In a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the HIV Medical Association, the National Institute on Aging, and the National Institute on Allergy and Infectious Diseases, researchers in infectious diseases, geriatrics, immunology, and gerontology met to review what is known about HIV infection and aging, to identify research gaps, and to suggest high priority topics for future research. Answers to the questions posed are likely to help prioritize and balance strategies to slow the progression of HIV infection, to address comorbidities and drug toxicity, and to enhance understanding about both HIV infection and aging. C1 [High, Kevin P.] Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA. [Effros, Rita B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Fletcher, Courtney V.] Univ Nebraska, Hlth Sci Ctr, Omaha, NE 68182 USA. [Gebo, Kelly] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Huebner, Robin E.; Plaeger, Susan F.] NIAID, Bethesda, MD 20892 USA. [Nayfield, Susan G.] NIA, Bethesda, MD 20892 USA. [Halter, Jeffrey B.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Hazzard, William R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Horne, Frances McFarland; Ashworth, John R.; Clayton, Charles P.] Assoc Specialty Prof, Washington, DC USA. [Janoff, Edward N.] Univ Colorado, Sch Med, Mucolsal & Vaccine Res Program Colorado, Denver, CO 80202 USA. [Justice, Amy C.] Yale Univ, West Haven, CT USA. [Kuritzkes, Daniel] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kuritzkes, Daniel] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rada, Beth] Infect Dis Society Amer, Arlington, VA USA. [Schmader, Kenneth E.] Duke Univ, Sch Med, Durham, NC 27710 USA. [Campanelli, Christine] Amer Geriatr Society, New York, NY USA. RP High, KP (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA. EM khigh@wfubmc.edu RI Gebo, Kelly/B-9223-2009 OI Clayton, Charles/0000-0003-1945-0477 FU NIAAA NIH HHS [U10 AA013566, U10 AA013566-08] NR 174 TC 269 Z9 272 U1 4 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2008 VL 47 IS 4 BP 542 EP 553 DI 10.1086/590150 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 327VD UT WOS:000257755700022 PM 18627268 ER PT J AU Friedland, RP Tedesco, JM Wilson, AC Atwood, CS Smith, MA Perry, G Zagorski, MG AF Friedland, Robert P. Tedesco, Johnathan M. Wilson, Andrea C. Atwood, Craig S. Smith, Mark A. Perry, George Zagorski, Michael G. TI Antibodies to potato virus Y bind the amyloid beta peptide - Immunohistochemical and NMR studies SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ALZHEIMERS-DISEASE PATIENTS; A-BETA; MOUSE MODEL; NEUROFIBRILLARY TANGLES; APOLIPOPROTEIN-E; COAT PROTEIN; AUTOANTIBODIES; IMMUNIZATION; PATHOGENESIS; AGGREGATION AB Studies in transgenic mice bearing mutated human Alzheimer disease (AD) genes show that active vaccination with the amyloid beta(A beta) protein or passive immunization with anti-A beta antibodies has beneficial effects on the development of disease. Although a trial of A beta vaccination in humans was halted because of autoimmune meningoencephalitis, favorable effects on A beta deposition in the brain and on behavior were seen. Conflicting results have been observed concerning the relationship of circulating anti-A beta antibodies and AD. Although these autoantibodies are thought to arise from exposure to A beta, it is also possible that homologous proteins may induce antibody synthesis. We propose that the long-standing presence of anti-A beta antibodies or antibodies to immunogens homologous to the A beta protein may produce protective effects. The amino acid sequence of the potato virus Y (PVY) nuclear inclusion b protein is highly homologous to the immunogenic N-terminal region of A beta. PVY infects potatoes and related crops worldwide. Here, we show through immunocytochemistry, enzyme-linked immunosorbent assay, and NMR studies that mice inoculated with PVY develop antibodies that bind to A beta in both neuritic plaques and neurofibrillary tangles, whereas antibodies to material from uninfected potato leaf show only modest levels of background immunoreactivity. NMR data show that the anti-PVY antibody binds to A beta within the Phe(4) - Ser(8) and His(13)-Leu(17) regions. Immune responses generated from dietary exposure to proteins homologous to A beta may induce antibodies that could influence the normal physiological processing of the protein and the development or progression of AD. C1 [Friedland, Robert P.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA. [Tedesco, Johnathan M.; Zagorski, Michael G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA. [Smith, Mark A.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Wilson, Andrea C.; Atwood, Craig S.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Wilson, Andrea C.; Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Perry, George] Univ Texas San Antonio, Coll Sci, San Antonio, TX 78249 USA. RP Friedland, RP (reprint author), Case Western Reserve Univ, Sch Med, Dept Neurol, 10900 Euclid Ave,T504 SOM, Cleveland, OH 44122 USA. EM robert.friedland@case.edu RI Smith, Mark/A-9053-2009; Perry, George/A-8611-2009; Friedland, Robert/A-2834-2010 OI Perry, George/0000-0002-6547-0172; Friedland, Robert/0000-0001-5721-1843 FU NIA NIH HHS [R01 AG017173-07, R01-AG017173, R01-AG027853] NR 60 TC 12 Z9 15 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 15 PY 2008 VL 283 IS 33 BP 22550 EP 22556 DI 10.1074/jbc.M802088200 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 335VR UT WOS:000258321000023 PM 18505725 ER PT J AU Sugimoto, M Furuta, T Shirai, N Kodaira, C Nishino, M Yamade, M Ikuma, M Sugimura, H Ishizaki, T Hishida, A AF Sugimoto, Mitsushige Furuta, Takahisa Shirai, Naohito Kodaira, Chise Nishino, Masafumi Yamade, Mihoko Ikuma, Mutsuhiro Sugimura, Haruhiko Ishizaki, Takashi Hishida, Akira TI MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese SO LIFE SCIENCES LA English DT Article DE MDR1; Helicobacter pylori; gastric cancer; peptic ulcer; MDR1-C3435T polymorphism ID MULTIDRUG-RESISTANCE GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; P-GLYCOPROTEIN; COLORECTAL-CANCER; INCREASED RISK; EXPRESSION; SUSCEPTIBILITY; CYP2E1; TUMORS; CARCINOGENESIS AB Aims: P-glycoprotein, the gene product of multidrug-resistant transporter-1 (MDR1), confers multidrug resistance against antineoplastic agents but also affects the kinetic disposition of some drugs and carcinogens. MDR1 C3435T polymorphism influences the development of colon cancer and adult acute myeloid leukemia by the association with transporting carcinogen. The aim of this study was to clarify the association of MDR1 C3435T polymorphism with susceptibility to gastric cancer and peptic ulcers in patients with Japanese H. pylori infection. Main methods: We assessed the MDR1 C3435T polymorphism in H. pylori-positive gastritis alone patients (n = 150), gastric cancer (n = 292), gastric ulcer (n = 215), and duodenal ulcer (n = 163) and H. pylori-negative subjects (n = 168) as control by a PCR-based method. Key findings: No significant difference existed in frequencies of MDR1 C3435T polymorphisms between H. pylori-negative controls and H. pylori-positive gastritis alone patients. Moreover, MDR1-3435 T allele carriage didn't affect the risk of gastric cancer or peptic ulcer development. The age- and sex-adjusted odds ratios (ORs) of MDR1 3435 T allele carriers relative to the C/C genotype group for gastric cancer, gastric ulcer and duodenal ulcer risk were 0.96 (95%CI: 0.56-1.66),1.16 (95%CI: 0.72-1.84) and 1.00 (95%CI: 0.61-1.62), respectively. Significance: In this preliminary data, the association with MDR1 C3435T polymorphism and risk for developing H. pylori-related gastric cancer and peptic ulcer in Japanese was low. P-glycoprotein might not be involved in the carcinogenesis of H. pylori-related gastric cancer. (C) 2008 Elsevier Inc. All rights reserved. C1 [Sugimoto, Mitsushige; Kodaira, Chise; Nishino, Masafumi; Yamade, Mihoko; Ikuma, Mutsuhiro; Hishida, Akira] Hamamatsu Univ Sch Med, Dept Med 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. [Furuta, Takahisa] Hamamatsu Univ Sch Med, Clin Res Ctr, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. [Shirai, Naohito] Enshu Gen Hosp, Dept Gastroenterol, Naka Ku, Hamamatsu, Shizuoka 4300929, Japan. [Sugimura, Haruhiko] Hamamatsu Univ Sch Med, Dept Pathol 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. [Ishizaki, Takashi] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan. RP Sugimoto, M (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,Rm 3A-320B, Houston, TX 77030 USA. EM sugimoto@bcm.edu FU YOKOYAMA Foundation for Clinical Pharmacology; 21st century Center of Excellence (COE); Ministry of Education, Culture, Sports, Science and Technology of Japan [19790479] FX This work was supported in part by a Grant-in-Aid from the YOKOYAMA Foundation for Clinical Pharmacology, from the 21st century Center of Excellence (COE) program Medical Photonics (Hamamatsu University School of Medicine), and from the Ministry of Education, Culture, Sports, Science and Technology of Japan (19790479). NR 38 TC 15 Z9 15 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD AUG 15 PY 2008 VL 83 IS 7-8 BP 301 EP 304 DI 10.1016/j.lfs.2008.06.022 PG 4 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 347DI UT WOS:000259120400010 PM 18644389 ER PT J AU Nazem, S Siderowf, AD Duda, JE Brown, GK Ten Have, T Stern, MB Weintraub, D AF Nazem, Sarra Siderowf, Andrew D. Duda, John E. Brown, Gregory K. Ten Have, Torn Stern, Matthew B. Weintraub, Daniel TI Suicidal and death ideation in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; suicide; depression ID PRIMARY-CARE PATIENTS; RISK-FACTORS; GERIATRIC DEPRESSION; RATING-SCALE; LATE-LIFE; POPULATION; SYMPTOMS; AGE; PREVALENCE; FREQUENCY AB Parkinson's disease (PD) is a chronic, disabling illness affecting primarily the elderly and is associated with a high prevalence of depression. Although these are known risk factors for suicidal and death ideation, little is known about the prevalence and correlates of such ideation in PD. A convenience sample of 116 outpatients with idiopathic PI) at two movement disorders centers were administered a modified Paykel Scale for Suicidal and death ideation, as well as an extensive psychiatric, neuropsychological, and neurological battery. Univariate and multivariate logistic regression models were used to determine the correlates Of Suicidal or death ideation. Current death ideation (28%) or suicide ideation (11%) were present in 30% of the sample, and 4% had a lifetime suicide attempt. On univariate logistic regression analysis, increasing severity of depression (odds ratio = 2.92, 95% CI 2.01-4.24, P < 0.001), impulse control disorder (ICD) behaviors sometime during PD (odds ratio = 6.08, 95% CI 1.90-19.49, P = 0.002), and psychosis (odds ratio = 2.45, 95% CI 1.05-5.69, P = 0.04) were associated with either ideation. On multivariate logistic regression analysis, only increasing severity of depressive symptoms (odds ratio = 2.76, 95% CI 1.88-4.07, P < 0.001) predicted Suicidal or death ideation. In conclusion, active suicidal or death ideation occurs in up to one-third of PD patients. Comorbid psychiatric disorders. more than PD-related disease variables, are associated with this ideation, highlighting the need for a comprehensive approach to the clinical care of PD patients. (C) 2008 Movement Disorder Society. C1 [Nazem, Sarra; Brown, Gregory K.; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA. [Ten Have, Torn] Univ Penn, Ctr Clin & Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.nied.upenn.edu FU National Institute of Mental Health [067894] FX Supported by a grant from the National Institute of Mental Health (#067894). NR 62 TC 33 Z9 35 U1 4 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD AUG 15 PY 2008 VL 23 IS 11 BP 1573 EP 1579 DI 10.1002/mds.22130 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 349AD UT WOS:000259250300011 PM 18618660 ER PT J AU Simuni, T Martel, A Zadikoff, C Videnovic, A Vainio, L Weaver, F Miskevics, S Williams, K Surmeier, J AF Simuni, T. Martel, A. Zadikoff, C. Videnovic, A. Vainio, L. Weaver, F. Miskevics, S. Williams, K. Surmeier, J. TI Safety and tolerability of isradipine, a dihydropyridine Ca channel antagonist, in patients with early Parkinson's disease SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 22nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY SEP 21, 2008 CL Salt Lake City, UT C1 [Simuni, T.; Martel, A.; Zadikoff, C.; Videnovic, A.; Vainio, L.; Weaver, F.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Simuni, T.; Martel, A.; Zadikoff, C.; Videnovic, A.; Vainio, L.; Weaver, F.; Miskevics, S.; Williams, K.; Surmeier, J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD AUG 15 PY 2008 VL 23 IS 11 BP 1629 EP 1629 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 349AD UT WOS:000259250300030 ER PT J AU Peterson, A Orwoll, E Fink, H Quinn, J Barrett-Connor, E Shikany, J AF Peterson, A. Orwoll, E. Fink, H. Quinn, J. Barrett-Connor, E. Shikany, J. TI Vitamin D levels in men with Parkinson's disease (PD) SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 22nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY SEP 21, 2008 CL Salt Lake City, UT C1 [Peterson, A.; Quinn, J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Fink, H.] Univ Minnesota, Minneapolis VA Med Ctr, Minneapolis, MN USA. [Barrett-Connor, E.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Shikany, J.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD AUG 15 PY 2008 VL 23 IS 11 BP 1635 EP 1635 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 349AD UT WOS:000259250300052 ER PT J AU Bendlin, BB Ries, ML Lazar, M Alexander, AL Dempsey, RJ Rowley, HA Sherman, JE Johnson, SC AF Bendlin, Barbara B. Ries, Michele L. Lazar, Mariana Alexander, Andrew L. Dempsey, Robert J. Rowley, Howard A. Sherman, Jack E. Johnson, Sterling C. TI Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging SO NEUROIMAGE LA English DT Article ID WHITE-MATTER; AXONAL INJURY; QUANTITATIVE-ANALYSIS; ATROPHY; LESIONS; FORNIX; IMAGES; MEMORY; DEGENERATION; MORPHOLOGY AB Traumatic brain injury (TBI) is associated with brain Volume loss, but there is little information on the regional gray matter (GM) and white matter (WM) changes that contribute to overall loss. Since axonal injury is a common occurrence in TBI, imaging methods that are sensitive to WM damage Such as diffusion-tensor imaging (DTI) may be useful for characterizing microstructural brain injury contributing to regional WM loss in TBI. High-resolution T1-weighted imaging and DTI were used to evaluate regional changes in TBI patients compared to matched controls. Patients received neuropsychological testing and were imaged approximately 2 months and 12.7 months post-injury. Paradoxically, neuropsychological function improved from Visit I to Visit 2, while voxel-based analyses of fractional anisotropy (FA), and mean diffusivity (MD) from the DTI images, and voxel-based analyses of the GM and WM probability maps from the T1-weighted images, mainly revealed significantly greater deleterious GM and WM change over time in patients compared to controls. Cross-sectional comparisons of the DTI measures indicated that patients have decreased FA and increased MID compared to controls over large regions of the brain. TBI affected virtually all of the major fiber bundles in the brain including the corpus callosum, cingulum, the superior and inferior longitudinal fascicules, the uncinate fasciculus, and brain stern fiber tracts. The results indicate that both GM and WM degeneration are significant contributors to brain volume loss in the months following brain injury, and also suggest that DTI measures may be more useful than high-resolution anatomical images in assessment of group differences. Published by Elsevier Inc. C1 [Bendlin, Barbara B.; Ries, Michele L.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Bendlin, Barbara B.; Ries, Michele L.; Johnson, Sterling C.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA. [Lazar, Mariana] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53706 USA. [Dempsey, Robert J.] Univ Wisconsin, Sch Med, Dept Neurosurg, Madison, WI USA. [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med, Madison, WI 53706 USA. [Sherman, Jack E.] Univ Wisconsin, Sch Med, Dept Rehabil Med & Orthoped Surg, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem VA Hosp, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875; Lazar, Mariana/0000-0001-9285-8124; Johnson, Sterling/0000-0002-8501-545X FU Department of Veterans Affairs; NIH [MH65723, MH62015] FX This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), MH62015 (ALA), and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital. The assistance of Britta Jabbar, Shelly Fitzgerald, Gemma Gliori, and Erik Kastman is greatly appreciated. We would also like to acknowledge the kind Support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where MR imaging took place. Finally, we thank all the patients who took part in this Study. NR 41 TC 151 Z9 152 U1 4 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD AUG 15 PY 2008 VL 42 IS 2 BP 503 EP 514 DI 10.1016/j.neuroimage.2008.04.254 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 341DU UT WOS:000258695200007 PM 18556217 ER PT J AU Weintraub, WS Spertus, JA Kolm, P Maron, DJ Zhang, ZF Jurkovitz, C Zhang, W Hartigan, PM Lewis, C Veledar, E Bowen, J Dunbar, SB Deaton, C Kaufman, S O'Rourke, RA Goeree, R Barnett, PG Teo, KK Boden, WE AF Weintraub, William S. Spertus, John A. Kolm, Paul Maron, David J. Zhang, Zefeng Jurkovitz, Claudine Zhang, Wei Hartigan, Pamela M. Lewis, Cheryl Veledar, Emir Bowen, Jim Dunbar, Sandra B. Deaton, Christi Kaufman, Stanley O'Rourke, Robert A. Goeree, Ron Barnett, Paul G. Teo, Koon K. Boden, William E. CA COURAGE Trial Res Grp TI Effect of PCI on quality of life in patients with stable coronary disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID EVALUATION COURAGE TRIAL; ARTERY-DISEASE; MEDICAL THERAPY; HEALTH-STATUS; RITA-2 TRIAL; ANGIOPLASTY; ANGINA; OUTCOMES; REVASCULARIZATION; INTERVENTION AB Background: It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease. Methods: We randomly assigned 2287 patients with stable coronary disease to PCI plus optimal medical therapy or to optimal medical therapy alone. We assessed angina-specific health status (with the use of the Seattle Angina Questionnaire) and overall physical and mental function (with the use of the RAND 36-item health survey [RAND-36]). Results: At baseline, 22% of the patients were free of angina. At 3 months, 53% of the patients in the PCI group and 42% in the medical-therapy group were angina-free (P<0.001). Baseline mean (+/-SD) Seattle Angina Questionnaire scores (which range from 0 to 100, with higher scores indicating better health status) were 66+/-25 for physical limitations, 54+/-32 for angina stability, 69+/-26 for angina frequency, 87+/-16 for treatment satisfaction, and 51+/-25 for quality of life. By 3 months, these scores had increased in the PCI group, as compared with the medical-therapy group, to 76+/-24 versus 72+/-23 for physical limitation (P=0.004), 77+/-28 versus 73+/-27 for angina stability (P=0.002), 85+/-22 versus 80+/-23 for angina frequency (P<0.001), 92+/-12 versus 90+/-14 for treatment satisfaction (P<0.001), and 73+/-22 versus 68+/-23 for quality of life (P<0.001). In general, patients had an incremental benefit from PCI for 6 to 24 months; patients with more severe angina had a greater benefit from PCI. Similar incremental benefits from PCI were seen in some but not all RAND-36 domains. By 36 months, there was no significant difference in health status between the treatment groups. Conclusions: Among patients with stable angina, both those treated with PCI and those treated with optimal medical therapy alone had marked improvements in health status during follow-up. The PCI group had small, but significant, incremental benefits that disappeared by 36 months. (ClinicalTrials.gov number, NCT00007657.). C1 [Weintraub, William S.; Kolm, Paul; Jurkovitz, Claudine; Zhang, Wei; Bowen, Jim] Christiana Care Hlth Syst, Cardiol Sect, Newark, DE 19718 USA. [Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Zhang, Zefeng; Lewis, Cheryl; Veledar, Emir; Dunbar, Sandra B.] Emory Univ, Atlanta, GA 30322 USA. [Hartigan, Pamela M.] Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Deaton, Christi] Univ Manchester, Manchester, Lancs, England. [Kaufman, Stanley] Epimetr Grp, San Francisco, CA USA. [O'Rourke, Robert A.] McMaster Univ, Hamilton, ON, Canada. [Goeree, Ron; Teo, Koon K.] San Antonio Vet Affairs Med Ctr, San Antonio, TX USA. [Barnett, Paul G.] Vet Affairs Hlth Econ Resource Ctr, Palo Alto, CA USA. [Boden, William E.] Western New York Vet Affairs Healthcare Network, Buffalo, NY USA. [Boden, William E.] Kaleida Hlth Syst, Buffalo, NY USA. RP Weintraub, WS (reprint author), Christiana Care Hlth Syst, Cardiol Sect, 4755 Ogletown Stanton Rd, Newark, DE 19718 USA. EM wweintraub@christianacare.org RI Deaton, Christi/F-6485-2010; Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 24 TC 292 Z9 306 U1 4 U2 14 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 14 PY 2008 VL 359 IS 7 BP 677 EP 687 DI 10.1056/NEJMoa072771 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 336XE UT WOS:000258397900004 PM 18703470 ER PT J AU Peterson, ED Rumsfeld, JS AF Peterson, Eric D. Rumsfeld, John S. TI Finding the courage to reconsider medical therapy for stable angina SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DISEASE C1 [Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Peterson, ED (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA. NR 6 TC 13 Z9 13 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 14 PY 2008 VL 359 IS 7 BP 751 EP 753 DI 10.1056/NEJMe0804662 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 336XE UT WOS:000258397900014 PM 18703479 ER PT J AU Salinthone, S Schillace, RV Marracci, GH Bourdette, DN Carr, DW AF Salinthone, Sonemany Schillace, Robynn V. Marracci, Gail H. Bourdette, Dennis N. Carr, Daniel W. TI Lipoic acid stimulates cAMP production via the EP2 and EN prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE multiple sclerosis; thioctic acid; natural killer cells; cAMP; IFN gamma ID NATURAL-KILLER-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; PROSTAGLANDIN E-2; PROTEIN-KINASE; T-CELLS; HUMAN OLIGODENDROCYTES; PERIPHERAL-BLOOD; INTERFERON-GAMMA AB The antioxidant lipoic acid (LA) treats, and prevents the animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). In an effort to understand the therapeutic potential of LA in MS, we sought to define the cellular mechanisms that mediate the effects of LA on human natural killer (NK) cells, which are important in innate immunity as the first line of defense against invading pathogens and tumor cells. We discovered that LA stimulates cAMP production in NK cells in a dose-dependent manner Studies using pharmacological inhibitors and receptor transfection experiments indicate that LA stimulates cAMP production via activation of the EP2 and EN prostanoid receptors and adenylyl cyclase. In addition, LA Suppressed interleukin (IL)-12/IL-18 induced IFN gamma secretion and cytotoxicity in NK cells. These novel findings suggest that LA may inhibit NK cell function via the cAMP signaling pathway Published by Elsevier B.V. C1 [Salinthone, Sonemany; Schillace, Robynn V.; Marracci, Gail H.; Bourdette, Dennis N.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. [Salinthone, Sonemany; Schillace, Robynn V.; Marracci, Gail H.; Bourdette, Dennis N.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Carr, Daniel W.] Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97239 USA. RP Carr, DW (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, RD-8,3710 US Vet Hosp Rd, Portland, OR 97239 USA. EM carrd@ohsu.edu FU Department of Veterans Affairs Biomedical Laboratory Research & Development Service; NIH [P50AT00066-01]; Nancy Davis Center Without Walls FX We would like to thank Sarah Fiedler and Casey Miller ror helpful critique of the manuscript. This research was Supported by the Department of Veterans Affairs Biomedical Laboratory Research & Development Service (D.W.C. and D.N.B.), NIH Grant P50AT00066-01 (D.N.B.), and the Nancy Davis Center Without Walls (D.N.B.). NR 52 TC 24 Z9 25 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 EI 1872-8421 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD AUG 13 PY 2008 VL 199 IS 1-2 BP 46 EP 55 DI 10.1016/j.jneuroim.2008.05.003 PG 10 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 343YL UT WOS:000258892200006 PM 18562016 ER PT J AU Blatt, JA Poole, JE Johnson, GW Callans, DJ Raitt, MH Reddy, RK Marchlinski, FE Yee, R Guarnieri, T Talajic, M Wilber, DJ Anderson, J Chung, K Wong, WS Mark, DB Lee, KL Bardy, GH AF Blatt, Joseph A. Poole, Jeanne E. Johnson, George W. Callans, David J. Raitt, Merritt H. Reddy, Ramakota K. Marchlinski, Francis E. Yee, Raymond Guarnieri, Thomas Talajic, Mario Wilber, David J. Anderson, Jill Chung, Kiyon Wong, Wai Shun Mark, Daniel B. Lee, Kerry L. Bardy, Gust H. CA SCD-HeFT Investigators TI No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE sudden cardiac death; implantable cardioverter-defibrillator; defibrillation threshold testing; DFT testing ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SYSTEM; MULTICENTER; EFFICACY; WAVEFORM; HUMANS; PULSES; TABLES AB Objectives This study investigated whether defibrillation threshold (DFT) testing during implantable cardioverter-defibrillator (ICD) implantation predicts clinical outcomes. Background Defibrillation testing is often performed during insertion of ICDs to confirm shock efficacy. There are no prospective data to suggest that this procedure improves outcomes when modern ICDs are implanted for primary prevention of sudden death. Methods The analysis included the 811 patients who were randomized to the ICD arm of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) and had the device implanted. The DFT testing protocol in SCD-HeFT was designed to limit shock testing in a primary prevention heart failure population. Results Baseline DFT data were available for 717 patients (88.4%). All 717 patients had a DFT of <= 30 J, the maximum output of the device in this study. The DFT was <= 20 J in 97.8% of patients. There was no survival difference between patients with a lower DFT (<= 10 J, n = 547) and a higher DFT (> 10 J, n = 170) (p = 0.41). First shock efficacy was 83.0% for the first clinical ventricular tachyarrhythmia event; there were no differences in shock efficacies when the cohort was subdivided by baseline DFT. Conclusions Low baseline DFTs were obtained in patients with stable, optimally treated heart failure during ICD implantation for primary prevention of sudden death. First shock efficacy for ventricular tachyarrhythmias was high regardless of baseline DFT testing results. Baseline DFT testing did not predict long-term mortality or shock efficacy in this study. C1 [Blatt, Joseph A.] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. [Johnson, George W.; Anderson, Jill; Bardy, Gust H.] Seattle Inst Cardiac Res, Seattle, WA USA. [Callans, David J.; Marchlinski, Francis E.] Univ Penn, Philadelphia, PA 19104 USA. [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA. [Yee, Raymond] Univ Western Ontario, London, ON, Canada. [Guarnieri, Thomas] Johns Hopkins Univ, Baltimore, MD USA. [Talajic, Mario] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Wilber, David J.] Loyola Univ Hlth Syst, Maywood, IL USA. [Chung, Kiyon] Everett Clin, Everett, WA USA. [Mark, Daniel B.; Lee, Kerry L.] Duke Univ, Sch Med, Durham, NC USA. [Wong, Wai Shun] Univ Michigan, Ann Arbor, MI 48109 USA. [Reddy, Ramakota K.] Oregon Cardiol PC, Eugene, OR USA. RP Blatt, JA (reprint author), Univ Washington, Dept Cardiol, Box 356422,1959 NE Pacific St, Seattle, WA 98195 USA. EM jablatt@u.washington.edu OI Mark, Daniel/0000-0001-6340-8087; Raitt, Merritt/0000-0001-5638-7732; Marchlinski, Francis/0000-0001-7962-9423 FU NHLBI NIH HHS [U01 HL055496, U01 HL55297, UO1 HL55496, UO1 HL55766] NR 27 TC 81 Z9 84 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD AUG 12 PY 2008 VL 52 IS 7 BP 551 EP 556 DI 10.1016/j.jacc.2008.04.051 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 336VV UT WOS:000258393800009 PM 18687249 ER PT J AU Finlay, E Shreve, S Casarett, D AF Finlay, Esme Shreve, Scott Casarett, David TI Nationwide veterans affairs quality measure for cancer: The family assessment of treatment at end of life SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID AFTER-DEATH INTERVIEWS; PALLIATIVE CARE; HOSPICE CARE; DATA SET; MEMBERS; PERCEPTIONS; CAREGIVERS; PATIENT; PAIN; SATISFACTION AB The Veterans Affairs (VA) health care system has created a national initiative to measure quality of care at the end of life. This article describes the first phase of this national initiative, the Family Assessment of Treatment at End of Life (FATE), in evaluating the quality of end-of-life care for veterans dying with cancer. In the initial phase, next of kin of patients from five VA Medical Centers were contacted 6 weeks after patients' deaths and invited to participate in a telephone interview, and surrogates for 262 cancer patients completed FATE interviews. Decedents were 98% male with an average age of 72 years. There was substantial variation among sites. Higher FATE scores, consistent with family reports of higher satisfaction with care, were associated with palliative care consultation and hospice referral and having a Do Not Resuscitate order at the time of death, whereas an intensive care unit death was associated with lower scores. Early experience with FATE suggests that it will be a helpful tool to characterize end-of-life cancer care and to identify targets for quality improvement. C1 [Casarett, David] Univ Penn, Ralston Penn Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs VA Med Ctr, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Lebanon VA Med Ctr, Lebanon, NH USA. Off Geriatr & Extended Care, Washington, DC USA. RP Casarett, D (reprint author), Univ Penn, Ralston Penn Ctr, Div Hematol Oncol, 3615 Chestnut St,Rm 304, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 61 TC 38 Z9 38 U1 4 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD AUG 10 PY 2008 VL 26 IS 23 BP 3838 EP 3844 DI 10.1200/JCO.2008.16.8534 PG 7 WC Oncology SC Oncology GA 335ND UT WOS:000258296400004 PM 18688050 ER PT J AU Dy, SM Asch, SM Naeim, A Sanati, H Walling, A Lorenz, KA AF Dy, Sydney M. Asch, Steven M. Naeim, Arash Sanati, Homayoon Walling, Anne Lorenz, Karl A. TI Evidence-based standards for cancer pain management SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID SPINAL-CORD COMPRESSION; BONE METASTASES; RANDOMIZED-TRIAL; PALLIATIVE CARE; SINGLE FRACTION; RADIOTHERAPY; METAANALYSIS; GUIDELINES; DIAGNOSIS; DISEASE AB High-quality management of cancer pain depends on evidence-based standards for screening, assessment, treatment, and follow-up for general cancer pain and specific pain syndromes. We developed a set of standards through an iterative process of structured literature review and development and refinement of topic areas and standards and subjected recommendations to rating by a multidisciplinary expert panel. Providers should routinely screen for the presence or absence and intensity of pain and should perform descriptive pain assessment for patients with a positive screen, including assessment for likely etiology and functional impairment. For treatment, providers should provide pain education, offer breakthrough opioids in patients receiving longacting formulations, offer bowel regimens in patients receiving opioids chronically, and ensure continuity of opioid doses across health care settings. Providers should also follow up on patients after treatment for pain. For metastatic bone pain, providers should offer single-fraction radiotherapy as an option when offering radiation, unless there is a contraindication. When spinal cord compression is suspected, providers should treat with corticosteroids and evaluate with wholespine magnetic resonance imaging scan or myelography as soon as possible but within 24 hours. Providers should initiate definitive treatment ( radiotherapy or surgical decompression) within 24 hours for diagnosed cord compression and should follow up on patients after treatment. These standards provide an initial framework for high-quality evidence-based management of general cancer pain and pain syndromes. C1 [Dy, Sydney M.] Johns Hopkins Univ, Baltimore, MD 21205 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Irvine, Irvine, CA USA. RP Dy, SM (reprint author), Johns Hopkins Univ, Room 609,624 N Broadway, Baltimore, MD 21205 USA. EM sdy@jhsph.edu NR 37 TC 63 Z9 67 U1 0 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD AUG 10 PY 2008 VL 26 IS 23 BP 3879 EP 3885 DI 10.1200/JCO.2007.15.9517 PG 7 WC Oncology SC Oncology GA 335ND UT WOS:000258296400010 PM 18688056 ER PT J AU Dy, SM Lorenz, KA Naeim, A Sanati, H Walling, A Asch, SM AF Dy, Sydney M. Lorenz, Karl A. Naeim, Arash Sanati, Homayoon Walling, Anne Asch, Steven M. TI Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID TERMINALLY-ILL PATIENTS; QUALITY-OF-LIFE; CONTROLLED-TRIAL; PALLIATIVE CARE; CONSENSUS STATEMENT; SUPPORT GROUPS; METHYLPHENIDATE; PREVALENCE; MANAGEMENT; SYMPTOMS AB Purpose The experience of patients with cancer often involves symptoms of fatigue, anorexia, depression, and dyspnea. Methods We developed a set of standards through an iterative process of structured literature review and development and refinement of topic areas and standards and subjected recommendations to rating by a multidisciplinary expert panel. Results For fatigue, providers should screen patients at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for depression and insomnia in newly identified fatigue; and follow up after treatment for fatigue or a secondary cause. For anorexia, providers should screen at the initial visit for cancer affecting the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat underlying causes, provide nutritional counseling for patients undergoing treatment that may affect nutritional intake, and follow up patients given appetite stimulants. For depression, providers should screen newly diagnosed patients, those started on chemotherapy or radiotherapy, those with newly identified advanced disease, and those expressing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up response after treatment. For general dyspnea, providers should evaluate for causes of new or worsening dyspnea, treat or symptomatically manage underlying causes, follow up to evaluate treatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful. For dyspnea and malignant pleural effusions, providers should offer thoracentesis, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with reaccumulation and dyspnea. Conclusion These standards provide a framework for evidence-based screening, assessment, treatment, and follow-up for cancer-associated symptoms. C1 [Dy, Sydney M.] Johns Hopkins Univ, Baltimore, MD 21205 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Irvine, Irvine, CA USA. RP Dy, SM (reprint author), Johns Hopkins Univ, 624 N Broadway,Rm 609, Baltimore, MD 21205 USA. EM sdy@jhsph.edu NR 60 TC 58 Z9 59 U1 2 U2 11 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD AUG 10 PY 2008 VL 26 IS 23 BP 3886 EP 3895 DI 10.1200/JCO.2007.15.9525 PG 10 WC Oncology SC Oncology GA 335ND UT WOS:000258296400011 PM 18688057 ER PT J AU Walling, A Lorenz, KA Dy, SM Naeim, A Sanati, H Asch, SM Wenger, NS AF Walling, Anne Lorenz, Karl A. Dy, Sydney M. Naeim, Arash Sanati, Homayoon Asch, Steven M. Wenger, Neil S. TI Evidence-based recommendations for information and care planning in cancer care SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID LIFE-SUSTAINING TREATMENT; BREAKING BAD-NEWS; TERMINALLY-ILL PATIENTS; PALLIATIVE-CARE; ADVANCE DIRECTIVES; PHYSICIAN ORDERS; DECISION-MAKING; TREATMENT PROGRAM; RANDOMIZED-TRIAL; END AB The practice of oncology is characterized by challenging communication tasks that make it difficult to ensure optimal physician-patient information sharing and care planning. Discussions of diagnosis, prognosis, and patient goals are essential processes that inform decisions. However, data suggest that there are deficiencies in this area. We conducted a systematic review to identify the evidence supporting high-quality clinical practices for information and care planning in the context of cancer care as part of the RAND Cancer Quality-Assessing Symptoms, Side Effects, and Indicators of Supportive Treatment Project. Domains of information and care planning that are important for high-quality cancer care include integration of palliation into cancer care, advance care planning, sentinel events as markers for the need to readdress a patient's goals of care, and continuity of care planning. The standards presented here for information and care planning in cancer care should be incorporated into care pathways and should become the expectation rather than the exception. C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Irvine, Irvine, CA USA. Johns Hopkins Univ, Baltimore, MD USA. RP Walling, A (reprint author), 911 Broxton Ave,3D, Los Angeles, CA 90024 USA. EM awalling@mednet.ucla.edu NR 81 TC 62 Z9 62 U1 3 U2 16 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD AUG 10 PY 2008 VL 26 IS 23 BP 3896 EP 3902 DI 10.1200/JCO.2007.15.9509 PG 7 WC Oncology SC Oncology GA 335ND UT WOS:000258296400012 PM 18688058 ER PT J AU Naeim, A Dy, SM Lorenz, KA Sanati, H Walling, A Asch, SM AF Naeim, Arash Dy, Sydney M. Lorenz, Karl A. Sanati, Homayoon Walling, Anne Asch, Steven M. TI Evidence-based recommendations for cancer nausea and vomiting SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID CHEMOTHERAPY-INDUCED NAUSEA; MODERATELY EMETOGENIC CHEMOTHERAPY; INOPERABLE BOWEL OBSTRUCTION; RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ACUPUNCTURE-POINT STIMULATION; CISPLATIN-BASED CHEMOTHERAPY; RADIOTHERAPY-INDUCED EMESIS; NK1 ANTAGONIST APREPITANT; PLACEBO-CONTROLLED TRIALS AB The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting. To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project. For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms. In addition, patients with cancer and small bowel obstruction were examined as a special subset of patients who present with nausea and vomiting. The standards presented here for preventing and managing nausea and vomiting in cancer care should be incorporated into care pathways and should become the expectation rather than the exception. C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Irvine, Irvine, CA USA. Johns Hopkins Univ, Baltimore, MD USA. RP Naeim, A (reprint author), 10945 LeConte Ave,Ste 2333, Los Angeles, CA 90095 USA. EM anaeim@mednet.ucla.edu NR 54 TC 52 Z9 55 U1 1 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD AUG 10 PY 2008 VL 26 IS 23 BP 3903 EP 3910 DI 10.1200/JCO.2007.15.9533 PG 8 WC Oncology SC Oncology GA 335ND UT WOS:000258296400013 PM 18688059 ER PT J AU Martin, J Masri, J Bernath, A Nishimura, RN Gera, J AF Martin, Jheralyn Masri, Janine Bernath, Andrew Nishimura, Robert N. Gera, Joseph TI Hsp70 associates with Rictor and is required for mTORC2 formation and activity SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Hsp70; Rictor; mTORC2; kinase activity; heat shock ID HEAT-SHOCK-PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; PHOSPHORYLATION; BINDING; GROWTH; RECEPTOR; COMPLEX; STRESS; CANCER AB mTORC2 is a multiprotein kinase composed of mTOR, mLST8, PRR5, mSIN1 and Rictor. The complex is insensitive to rapamycin and has demonstrated functions controlling cell growth, motility, invasion and cytoskeletal assembly. mTORC2 is the major hydrophobic domain kinase which renders Akt fully active via phosphorylation on serine 473. We isolated Hsp70 as a putative Rictor interacting protein in a yeast two-hybrid assay and confirmed this interaction via co-immunoprecipitation and colocalization experiments. In cells expressing an antisense RNA targeting Hsp70, mTORC2 formation and activity were impaired. Moreover, in cells lacking Hsp70 expression, mTORC2 activity was inhibited following heat shock while controls demonstrated increased mTORC2 activity. These differential effects on mTORC2 activity were specific, in that mTORC1 did not demonstrate Hsp70-dependent alterations under these conditions. These data suggest that Hsp70 is a component of mTORC2 and is required for proper assembly and activity of the kinase both constitutively and following heat shock. Published by Elsevier Inc. C1 [Martin, Jheralyn; Masri, Janine; Bernath, Andrew; Nishimura, Robert N.; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90048 USA. [Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA. RP Gera, J (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, 16111 Plummer St 151,Bldg 1,Room C111A, Los Angeles, CA 91343 USA. EM gera@ucia.edu FU NCI NIH HHS [CA109312, R01 CA109312, R01 CA109312-04] NR 36 TC 37 Z9 39 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD AUG 8 PY 2008 VL 372 IS 4 BP 578 EP 583 DI 10.1016/j.bbrc.2008.05.086 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 323BR UT WOS:000257419500013 PM 18505677 ER PT J AU Prasad, R Giri, S Singh, AK Singh, I AF Prasad, Ratna Giri, Shailendra Singh, Avtar K. Singh, Inderjit TI 15-deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases SO JOURNAL OF INFLAMMATION-LONDON LA English DT Article ID ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; CELL ADHESION MOLECULES; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; TRANSCRIPTIONAL REGULATION; MULTIPLE-SCLEROSIS AB Background: The Infiltration of leukocytes across the brain endothelium is a hallmark of various neuroinflammatory disorders. Under inflammatory conditions, there is increased expression of specific cell adhesion molecules (CAMs) on activated vascular endothelial cells which increases the adhesion and infiltration of leukocytes. TNF alpha is one of the major proinflammatory cytokines that causes endothelial dysfunction by various mechanisms including activation of transcription factor NF-kappa B, a key transcription factor that regulates expression of CAMs. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear hormone superfamily of ligand-activated transcriptional factors. 15-deoxy-delta 12, 14-prostaglandin J2 (15d-PGJ2) is a well recognized natural ligand of PPAR gamma and possesses anti-inflammatory properties both in vitro and in vivo. This study aims to elucidate the mechanism of 15-PGJ2 on the adhesion of mononuclear cells to activated endothelial cells. Methods: To delineate the signaling pathway of 15d-PGJ2 mediated effects, we employed an in vitro adhesion assay model of endothelial-monocyte interaction. Expression of CAMs was examined using flow cytometry and real time PCR techniques. To define the mechanism of 15d-PGJ2, we explored the role of NF-kappa B by EMSA (Electrophoretic Mobility Shift Assay) gels, NF-kappa B reporter and p65-transcriptional activities by transient transfection in the brain-derived endothelial cell line (bEND.3). Results: Using an in vitro adhesion assay model, we demonstrate that 15d-PGJ2 inhibits TNF alpha induced monocyte adhesion to endothelial cells, which is mediated by downregulation of endothelial cell adhesion molecules in a PPAR gamma independent manner. 15d-PGJ2 modulated the adhesion process by inhibiting the TNF alpha induced IKK-NF-kappa B pathway as evident from EMSA, NF-kappa B reporter and p65 mediated transcriptional activity results in bEND.3 cells. Conclusion: These findings suggest that 15d-PGJ2 inhibits inflammation at multiple steps and thus is a potential therapeutic target for various inflammatory diseases. C1 [Prasad, Ratna; Giri, Shailendra; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. EM prasadr@musc.edu; giris@musc.edu; avtar.singh@va.gov; singhi@musc.edu FU NIH [NS-40144, NS-22576, NS-34741, NS-37766, NS-40810]; State of South Carolina Spinal Cord Injury Research Fund Board [SCIRF 0406, SCIRF 0506]; National Center for Research Resources [C06 RR018823, C06 RR015455] FX RP and SG are equal contributors for this work. We would like to thank Drs. Anne G. Gilg and Ramandeep Rattan for editing manuscript and Ms Joyce Bryan for procurement of chemicals used in this study. These studies were supported by grants (NS-40144, NS-22576, NS-34741, NS-37766, and NS-40810) from the NIH and (SCIRF 0406 and SCIRF 0506) from State of South Carolina Spinal Cord Injury Research Fund Board. This work was supported by the NIH (NS-22576, NS-34741, NS-37766 and NS-40810) and from the Extramural Research Facilities Program of the National Center for Research Resources (Grants C06 RR018823 and No C06 RR015455). NR 57 TC 11 Z9 13 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-9255 J9 J INFLAMM-LOND JI J. Inflamm.-Lond. PD AUG 8 PY 2008 VL 5 AR 14 DI 10.1186/1476-9255-5-14 PG 10 WC Immunology SC Immunology GA 507FC UT WOS:000270836200001 PM 18691416 ER PT J AU Lee, JK Won, JS Singh, AK Singh, I AF Lee, Jin-Koo Won, Je-Seong Singh, Avtar K. Singh, Inderjit TI Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death SO NEUROSCIENCE LETTERS LA English DT Article DE atorvastatin; excitotoxicity; inflammation; hippocampus; kainic acid; lovastatin and seizure ID NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; INDUCED STATUS-EPILEPTICUS; COA REDUCTASE INHIBITOR; TEMPORAL-LOBE EPILEPSY; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; LEWIS RATS; NEUROLOGIC DISEASES; ALZHEIMERS-DISEASE AB Statins are inhibitors of HMG-CoA reductase that have been recently recognized as anti-inflammatory and neuroprotective drugs. Herein, we investigated anti-excitotoxic and anti-seizure effects of statins by using kainic acid (KA)-rat seizure model, an animal model for temporal lobe epilepsy and excitotoxic neurodegeneration. We observed that pre-treatment with Lipitor (atorvastatin) efficiently reduced KA-induced seizure activities, hippocampal neuron death, monocyte infiltration and proinflammatory gene expression. In addition, we also observed that lovastatin treatment attenuated KA- or glutamate-induced excitotoxicity of cultured hippocampal neurons. These observations suggest a potential for use of statin treatment in modulation of seizures and other neurological diseases associated with excitotoxicity. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Lee, Jin-Koo; Won, Je-Seong; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Lee, Jin-Koo] Hallym Univ, Inst Nat Med, Chunchon, South Korea. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave,505 Childrens Res Bldg, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, R01 NS022576, R01 NS022576-17, R01 NS034741, R01 NS034741-12, R01 NS037766, R01 NS037766-10, R01 NS040144, R37 NS022576] NR 44 TC 55 Z9 58 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD AUG 8 PY 2008 VL 440 IS 3 BP 260 EP 264 DI 10.1016/j.neulet.2008.05.112 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 331MP UT WOS:000258016600014 PM 18583044 ER PT J AU Burgio, KL Kraus, SR Menefee, S Borello-France, D Corton, M Johnson, HW Mallett, V Norton, P FitzGerald, MP Dandreo, KJ Richter, HE Rozanski, T Albo, M Zyczynski, HM Lemack, GE Chai, TC Khandwala, S Baker, J Brubaker, L Stoddard, AM Goode, PS Nielsen-Omeis, B Nager, CW Kenton, K Tennstedt, SL Kusek, JW Chang, TD Nyberg, LM Steers, W AF Burgio, Kathryn L. Kraus, Stephen R. Menefee, Shawn Borello-France, Diane Corton, Marlene Johnson, Harry W. Mallett, Veronica Norton, Peggy FitzGerald, Mary P. Dandreo, Kimberly J. Richter, Holly E. Rozanski, Thomas Albo, Michael Zyczynski, Halina M. Lemack, Gary E. Chai, Toby C. Khandwala, Salil Baker, Jan Brubaker, Linda Stoddard, Anne M. Goode, Patricia S. Nielsen-Omeis, Betsy Nager, Charles W. Kenton, Kimberly Tennstedt, Sharon L. Kusek, John W. Chang, T. Debuene Nyberg, Leroy M. Steers, William CA Urinary Incontinence Treatment Net TI Behavioral therapy to enable women with urge incontinence to discontinue drug treatment SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; URINARY-INCONTINENCE; OLDER WOMEN; OVERACTIVE BLADDER; CLINICAL-TRIALS; TOLTERODINE; IMPACT AB Background: Women with urge urinary incontinence are commonly treated with antimuscarinic medications, but many discontinue therapy. Objective: To determine whether combining antimuscarinic drug therapy with supervised behavioral training, compared with drug therapy alone, improves the ability of women with urge incontinence to achieve clinically important reductions in incontinence episodes and to sustain these improvements after discontinuing drug therapy. Design: 2-stage, multicenter, randomized clinical trial conducted from July 2004 to January 2006. Setting: 9 university-affiliated outpatient clinics. Patients: 307 women with urge-predominant incontinence. Intervention: 10 weeks of open-label, extended-release tolterodine alone (n = 153) or combined with behavioral training (n = 154), followed by discontinuation of therapy and follow-up at 8 months. Measurements: The primary outcome, measured at 8 months, was no receipt of drugs or other therapy for urge incontinence and a 70% or greater reduction in frequency of incontinence episodes. Secondary outcomes were reduction in incontinence, self-reported satisfaction and improvement, and scores on validated questionnaires measuring symptom distress and bother and health-related quality of life. Study staff who performed outcome evaluations, but not participants and interventionists, were blinded to group assignment. Results: 237 participants completed the trial. According to life-table estimates, the rate of successful discontinuation of therapy at 8 months was the same in the combination therapy and drug therapy alone groups (41% in both groups; difference, 0 percentage points [95% CI, -12 to 12 percentage points]). A higher proportion of participants who received combination therapy than drug therapy alone achieved a 70% or greater reduction in incontinence at 10 weeks (69% vs. 58%; difference, 11 percentage points [CI, -0.3 to 22.1 percentage points]). Combination therapy yielded better outcomes over time on the Urogenital Distress Inventory and the Overactive Bladder Questionnaire (both P <0.001) at both time points for patient satisfaction and perceived improvement but not health-related quality of life. Adverse events were uncommon (12 events in 6 participants [3 in each group]). Limitations: Behavioral therapy components (daily bladder diary and recommendations for fluid management) in the group receiving drug therapy alone may have attenuated between-group differences. Assigned treatment was completed by 68% of participants, whereas 8-month outcome status was assessed on 77%. Conclusion: The addition of behavioral training to drug therapy may reduce incontinence frequency during active treatment but does not improve the ability to discontinue drug therapy and maintain improvement in urinary incontinence. Combination therapy has a beneficial effect on patient satisfaction, perceived improvement, and reduction of other bladder symptoms. C1 [Burgio, Kathryn L.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. Dept Vet Affairs, Birmingham, AL USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA. Duquesne Univ, Pittsburgh, PA 15219 USA. SW Texas State Univ, Dallas, TX USA. Univ Maryland, Baltimore, MD 21201 USA. Oakwood Hosp, Dearborn, MI USA. Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. New England Res Inst, Watertown, MA 02172 USA. NIDDKD, NIH, Bethesda, MD 20892 USA. Univ Virginia Hlth Syst, Charlottesville, VA USA. RP Burgio, KL (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, 11G 700 S 19th St, Birmingham, AL 35233 USA. EM kburgio@aging.uab.edu FU NIDDK NIH HHS [U01 DK058229, U01 DK058225, U01 DK058231, U01 DK058234, U01 DK060379, U01 DK060380, U01 DK060393, U01 DK060395, U01 DK060397, U01 DK060401, U01 DK58225, U01 DK58229, U01 DK58231, U01 DK58234, U01 DK60379, U01 DK60380, U01 DK60393, U01 DK60395, U01 DK60397, U01 DK60401] NR 25 TC 62 Z9 63 U1 1 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 5 PY 2008 VL 149 IS 3 BP 161 EP 169 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 336CW UT WOS:000258342900002 PM 18678843 ER PT J AU Allada, R Siegel, JM AF Allada, Ravi Siegel, Jerome M. TI Unearthing the phylogenetic roots of sleep SO CURRENT BIOLOGY LA English DT Review ID IN-VIVO MICRODIALYSIS; SLOW-WAVE SLEEP; LIZARD CTENOSAURA-PECTINATA; BRAIN GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; CIRCADIAN CLOCK; LOCOMOTOR-ACTIVITY; AROUSAL THRESHOLD; MAMMALIAN SLEEP AB Why we sleep remains one of the enduring unanswered questions in biology. At its core, sleep can be defined behaviorally as a homeostatically regulated state of reduced movement and sensory responsiveness. The cornerstone of sleep studies in terrestrial mammals, including humans, has been the measurement of coordinated changes in brain activity during sleep measured using the electroencephalogram (EEG). Yet among a diverse set of animals, these EEG sleep traits can vary widely and, in some cases, are absent, raising questions as to whether they define a universal, or even essential, feature of sleep. Over the past decade, behaviorally defined sleep-like states have been identified in a series of genetic model organisms, including fish, flies and worms. Genetic analyses in these systems are revealing a remarkable conservation in the underlying mechanisms controlling sleep behavior. Taken together, these studies suggest an ancient origin for sleep and raise the possibility that model organism genetics may reveal the molecular mechanisms that guide sleep and wake. C1 [Allada, Ravi] Northwestern Univ, Dept Neurobiol & Physiol, 2205 Tech Dr 2-160, Evanston, IL 60208 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Sch Med, Dept Psychiat, VA GLAHS Sepulveda, North Hills, CA 91343 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA 91343 USA. RP Allada, R (reprint author), Northwestern Univ, Dept Neurobiol & Physiol, 2205 Tech Dr 2-160, Evanston, IL 60208 USA. EM r-allada@northwestern.edu; jsiegel@ucla.edu FU NIMH NIH HHS [R01 MH064109, R01 MH067870, R01 MH067870-05, R01MH067870, R01MH64109]; NINDS NIH HHS [R01 NS052903, 1R01-NS42947, R01 NS042947, R01 NS052903-03, R01 NS059042, R01 NS059042-01A2, R01NS052903] NR 150 TC 85 Z9 85 U1 4 U2 28 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 EI 1879-0445 J9 CURR BIOL JI Curr. Biol. PD AUG 5 PY 2008 VL 18 IS 15 BP R670 EP R679 DI 10.1016/j.cub.2008.06.033 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 335AI UT WOS:000258262800020 PM 18682212 ER PT J AU Douaihy, A Hilsabeck, RC Azzam, P Jain, A Daley, DC AF Douaihy, Antoine Hilsabeck, Robin C. Azzam, Pierre Jain, Abhishek Daley, Dennis C. TI Neuropsychiatric aspects of coinfection with HIV and hepatitis C virus SO AIDS READER LA English DT Review DE HIV/AIDS; hepatitis C; coinfection; neuropsychiatric disorder ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INTERFERON-ALPHA TREATMENT; SUBSTANCE USE DISORDERS; QUALITY-OF-LIFE; COGNITIVE IMPAIRMENT; DRUG-USERS; PSYCHIATRIC-DISORDERS; LIVER-DISEASE; NEUROPSYCHOLOGICAL IMPAIRMENT AB The increasing health care crisis of coinfection with hepatitis C virus (HCV) and HIV has recently attracted the attention of research in the areas of psychiatric and neurocognitive complications related to coinfection. The preliminary data suggest that HIV/HCV coinfection has neurocognitive and psychiatric effects. This review summarizes the findings of what is known about the neurocognitive and psychiatric aspects of HIV/HCV coinfection and discusses the clinical implications and challenges in working with coinfected persons. An integrated, flexible, and interdisciplinary team approach model for treating patients who are coinfected is presented with specific recommendations for clinicians working with this population. C1 [Douaihy, Antoine; Daley, Dennis C.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Hilsabeck, Robin C.] Texas Hlth Sci Ctr, San Antonio, TX USA. [Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Azzam, Pierre; Jain, Abhishek] Univ Pittsburgh, Grad Med Educ Prog, Dept Psychiat, Pittsburgh, PA 15260 USA. [Azzam, Pierre; Jain, Abhishek] Western Psychiat Inst & Clin, Pittsburgh, PA USA. RP Douaihy, A (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. FU National Institute of Neurological Disorders and Stroke (NINDS) [K23NS051244]; National Institute on Drug Abuse [U10 DA020036] FX This project was supported in part by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) (K23NS051244) and in part by a grant from the National Institute on Drug Abuse (U10 DA020036). The content is solely the responsibility of the authors and does not represent the official view of the NINDS or the NTH. NR 115 TC 6 Z9 6 U1 3 U2 4 PU CLIGGOTT PUBLISHING CO PI DARIEN PA 330 BOSTON POST RD, DARIEN, CT 06820 USA SN 1053-0894 J9 AIDS READ JI Aids Read. PD AUG PY 2008 VL 18 IS 8 BP 425 EP + PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 342LY UT WOS:000258786800005 PM 18770900 ER PT J AU Weiss, JJ Bhatti, L Dieterich, DT Edlin, BR Fishbein, DA Goetz, MB Yu, K Wagner, GJ AF Weiss, J. J. Bhatti, L. Dieterich, D. T. Edlin, B. R. Fishbein, D. A. Goetz, M. B. Yu, K. Wagner, G. J. TI Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ALPHA-2A PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; PEGINTERFERON ALPHA-2A; ANTIRETROVIRAL THERAPY; VIRUS-INFECTION; TRIAL; CARE AB Background Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients' dose-taking adherence. Aim To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose-taking adherence in clinic settings. Methods One hundred and eighty patients on treatment for hepatitis C (23% co-infected with HIV) completed a cross-sectional survey at the site of their hepatitis C care. Results Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose-taking adherence was not associated with HCV viral load. Conclusions Self-reported dose non-adherence to hepatitis C treatment occurs frequently. Further studies of dose non-adherence (assessed by method other than self-report) and its relationship to HCV virological outcome are warranted. C1 [Weiss, J. J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Bhatti, L.] AIDS Healthcare Fdn, Los Angeles, CA USA. [Dieterich, D. T.; Fishbein, D. A.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Edlin, B. R.] Cornell Univ, Weill Med Coll, Ctr Study Hepatitis C, New York, NY 10021 USA. [Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA. [Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Yu, K.] W LA Kaiser Permanente, Dept Infect Dis, Los Angeles, CA USA. [Wagner, G. J.] RAND Corp, Hlth Unit, Santa Monica, CA USA. RP Weiss, JJ (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1228, New York, NY 10029 USA. EM Jeffrey.Weiss@msnyuhealth.org OI Goetz, Matthew/0000-0003-4542-992X FU NIMH NIH HHS [K23 MH071177-04, K23 MH071177, K23MH071177] NR 20 TC 24 Z9 24 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD AUG 1 PY 2008 VL 28 IS 3 BP 289 EP 293 DI 10.1111/j.1365-2036.2008.03718.x PG 5 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 327GP UT WOS:000257717900003 PM 19086329 ER PT J AU Jarcho, JM Chang, L Berman, SM Suyenobu, B Naliboff, BD Lieberman, MD Ameen, VZ Mandelkern, MA Mayer, EA AF Jarcho, J. M. Chang, L. Berman, S. M. Suyenobu, B. Naliboff, B. D. Lieberman, M. D. Ameen, V. Z. Mandelkern, M. A. Mayer, E. A. TI Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT(3) receptor antagonist: a pilot study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID FUNCTIONAL G1 DISORDERS; DIARRHEA-PREDOMINANT; CEREBRAL ACTIVATION; BRAIN RESPONSES; VISCERAL PAIN; ALOSETRON; AMYGDALA; STIMULATION; PATHWAYS; PLACEBO AB Background Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT(3)R antagonist alosetron is correlated with reduced amygdala activity. Aim To determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron. Methods Basal psychological distress and neural activity ((15)O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBS patients who then received 3 weeks of alosetron treatment. Results Greater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala. Conclusions Irritable bowel disease symptom improvement with 5-HT(3)R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome. C1 [Jarcho, J. M.; Chang, L.; Berman, S. M.; Suyenobu, B.; Naliboff, B. D.; Lieberman, M. D.; Mandelkern, M. A.; Mayer, E. A.] Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, VAGLAHS, Los Angeles, CA 90073 USA. [Jarcho, J. M.; Lieberman, M. D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90073 USA. [Chang, L.; Berman, S. M.; Suyenobu, B.; Mayer, E. A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. [Berman, S. M.; Naliboff, B. D.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90073 USA. [Naliboff, B. D.; Mandelkern, M. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ameen, V. Z.] GlaxoSmithKline Inc, Res & Dev, Clin Pharmacol & Discovery Med, Res Triangle Pk, NC USA. [Mandelkern, M. A.] UCI, Dept Phys & Radiol Sci, Irvine, CA USA. [Mayer, E. A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90073 USA. [Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90073 USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, VAGLAHS, Bldg 115,Room 22,11310 Wilshire Blvd, Los Angeles, CA 90073 USA. EM emayer@ucla.edu OI Jarcho, Johanna/0000-0001-9075-6968 FU NCCIH NIH HHS [R24 AT002681, R24 AT002681-04]; NIDDK NIH HHS [R01 DK048351, R01 DK 48351, R01 DK048351-08]; NIMH NIH HHS [MH15750, T32 MH015750, T32 MH015750-25] NR 49 TC 20 Z9 20 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD AUG 1 PY 2008 VL 28 IS 3 BP 344 EP 352 DI 10.1111/j.1365-2036.2008.03721.x PG 9 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 327GP UT WOS:000257717900009 PM 19086332 ER PT J AU Daugherty, SL Peterson, PN Magid, DJ Ho, PM Bondy, J Hokanson, JE Ross, CA Rumsfeld, JS Masoudi, FA AF Daugherty, Stacie L. Peterson, Pamela N. Magid, David J. Ho, P. Michael Bondy, Jessica Hokanson, John E. Ross, Colleen A. Rumsfeld, John S. Masoudi, Frederick A. TI The relationship between gender and clinical management after exercise stress testing SO AMERICAN HEART JOURNAL LA English DT Article ID CORONARY-ARTERY-DISEASE; AMERICAN-HEART-ASSOCIATION; SEX-DIFFERENCES; PROGNOSTIC VALUE; TREADMILL; WOMEN; CAPACITY; ANGIOGRAPHY; COMMITTEE; MORTALITY AB Background Controversy remains regarding whether gender differences exist in clinical management after exercise treadmill testing (ETT). Methods We studied 7,506 patients (49.8% women) without documented coronary heart disease referred for ETT from July 2001 to June 2004 in a community-based setting. We assessed the relationship between gender and subsequent diagnostic testing (secondary stress testing or coronary angiography) within 6 months after ETT. Secondary outcomes included subsequent stress testing, coronary angiography, and new cardiology visits in the 6-month interval. Multivariable analyses assessed the relationship between gender and these outcomes adjusting for demographic, clinical, and stress test characteristics. In subsequent analyses, patients were stratified by Duke Treadmill Scores (Duke University, Durham, NC). Results Compared with men, women referred for ETT were older, had a higher prevalence of some cardiac risk factors, achieved lower peak workloads, and, more often, experienced chest pain or ST-segment changes. After accounting for differences in clinical and ETT parameters, gender was not associated with any subsequent diagnostic testing in the 6 months after ETT (OR 1.0, 95% CI 0.85-1.18). In secondary analyses, women were less likely to undergo angiography (OR 0.63, 95% CI 0.47-0.83) with a trend toward more subsequent stress testing. Stratified analyses revealed less subsequent testing in high-to-intermediate Duke Treadmill Score women compared with men (OR 0.61, 95% CI 0.48-0.79). Women and men were equally likely to die (hazards ratio 0.93, 95% CI 0.61-1.44) in the adjusted survival analysis. Conclusions Overall, women and men equally underwent subsequent diagnostic testing after ETT. Although women were less likely to undergo angiography and higher-risk women were less likely to undergo subsequent testing, adverse events were not higher in women. Given these findings, assumptions regarding gender disparities in clinical management after ETT should be reevaluated in other settings. C1 [Daugherty, Stacie L.; Peterson, Pamela N.; Ho, P. Michael; Rumsfeld, John S.; Masoudi, Frederick A.] Univ Colorado Denver, Div Cardiol, Aurora, CO 80045 USA. [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. [Magid, David J.; Bondy, Jessica; Hokanson, John E.] Univ Colorado Denver, Dept Prevent Med & Biometr, Aurora, CO 80045 USA. [Magid, David J.; Ross, Colleen A.; Rumsfeld, John S.; Masoudi, Frederick A.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Div Cardiol, Denver, CO USA. RP Daugherty, SL (reprint author), Univ Colorado Denver, Div Cardiol, 12631 E 17th Ave,B130,POB 6511, Aurora, CO 80045 USA. EM stacie.daugherty@uchsc.edu FU CV Therapeutics, Inc FX This study was funded in part by CV Therapeutics, Inc. The sponsor did not play a role in the design and conduct of the study; in the collection, analysis, or interpretation of the data; or in the preparation, review, and approval of the manuscript. NR 27 TC 7 Z9 7 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD AUG PY 2008 VL 156 IS 2 BP 301 EP 307 DI 10.1016/j.ahj.2008.03.022 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 335ZF UT WOS:000258333400016 PM 18657660 ER PT J AU LoConte, NK Gleason, CE Gunter-Hunt, G Carlsson, CM Siebers, M AF LoConte, Noelle K. Gleason, Carey E. Gunter-Hunt, Gail Carlsson, Cynthia M. Siebers, Michael TI Standardized note template improves screening of firearm access and driving among veterans with dementia SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE firearms; driving; dementia; screening; computerized medical records ID MOTOR-VEHICLE CRASHES; ALZHEIMERS-DISEASE; CARE; AFFAIRS; CLINICIAN; CESSATION; RISK; GUN AB Little is known about screening used in clinical practice to assess driving and firearm safety among patients with dementia. A case-controlled study was performed, including 22 patients with dementia seen in a geriatric evaluation and management clinic and 22 matched patients with dementia seen in a memory assessment clinic. Data about prevalence of firearm use and driving were obtained. In geriatric evaluation and management clinic, 57.9% of patients had dementia, compared with 71.0% in memory assessment clinic, and more patients were diagnosed with Alzheimer dementia in memory assessment clinic (P = .005). In geriatric evaluation and management clinic, 65% of patients had driving screening compared with 100% in memory assessment clinic (P = .07). Four percent in geriatric evaluation and management clinic were screened for firearm access versus 100% in memory assessment clinic (P < .001). In memory assessment clinic, 31.8% had firearms access and 50% were driving. Many patients continued to drive and have access to firearms. The use of templates for the progress note was effective in increasing the screening rate. C1 [LoConte, Noelle K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Hematol Oncol Sect, Madison, WI USA. [Gleason, Carey E.; Carlsson, Cynthia M.; Siebers, Michael] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Geriatr & Gerontol, Madison, WI USA. [Gleason, Carey E.; Gunter-Hunt, Gail; Carlsson, Cynthia M.; Siebers, Michael] Univ Wisconsin, William S Middleton Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Gunter-Hunt, Gail] Univ Wisconsin, Sch Social Work, Madison, WI 53706 USA. RP LoConte, NK (reprint author), 600 Highland Ave,CSC K4-548, Madison, WI 53792 USA. EM ns3@medicine.wisc.edu FU NCI NIH HHS [K12 CA087718] NR 30 TC 5 Z9 6 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD AUG-SEP PY 2008 VL 23 IS 4 BP 313 EP 318 DI 10.1177/1533317508317061 PG 6 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA 346DS UT WOS:000259049200002 PM 18453646 ER PT J AU Barton, C Sklenicka, J Sayegh, P Yaffe, K AF Barton, Cynthia Sklenicka, Julie Sayegh, Philip Yaffe, Kristine TI Contraindicated medication use among patients in a memory disorders clinic SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article; Proceedings Paper CT 58th Annual Meeting of the American-Academy-of-Neurology CY APR 01-08, 2006 CL San Diego, CA SP Amer Acad Neurol DE dementia; medications; Alzheimer's disease ID COGNITIVE IMPAIRMENT; OLDER-ADULTS; CHOLINESTERASE-INHIBITORS; ANTICHOLINERGIC DRUGS; OVERACTIVE BLADDER; CONSENSUS PANEL; ELDERLY-PEOPLE; INAPPROPRIATE; DEMENTIA; CRITERIA AB Background: Inappropriate or contraindicated use of medications in elderly patients is common and associated with poor outcomes. An important risk factor for adverse drug events is the increased sensitivity to drug effects on the central nervous system (CNS). There is a high rate of use of CNS-active drugs in patients with cognitive impairment, despite the fact that these medications may worsen cognition and be a possible "reversible" cause of memory loss. Objectives: The goals of this study were to establish the prevalence of these contraindicated medications in a Population of elderly patients referred to a memory disorders clinic for evaluation and to determine if those individuals receiving contraindicated medications had specific characteristics. This included determining how many patients were concurrently being prescribed a cholinesterase inhibitor. Methods: The review included new patients consecutively evaluated for cognitive complaints in a memory disorders clinic between June 2003 and August 2004. Each patient underwent a comprehensive evaluation by a multi-disciplinary team during a 3-hour clinic appointment. A thorough history of cognitive deficits and associated symptoms was obtained by the physician, who also performed a comprehensive neurologic examination. All patients underwent neuropsychologic testing with an extensive cognitive battery. In addition, patients' electronic medical records were reviewed to determine a list of prescribed and over-the-counter medications at the time of the initial referral. Contraindicated medications were identified using the updated Beers criteria of medications that should be avoided in older patients with cognitive impairment or that have high CNS adverse effects. Results: A total of 100 patients (91 men, 9 women; mean [SD] age, 7-5.8 [9.7] years; 73% white) were included in the study. Eighty-six patients were determined at the time of evaluation to have some kind of cognitive impairment. They were mildly impaired, with a mean (SD) Mini-Mental State Examination score of 22.9 (5.1), based oil a scale of 0 to 30. Twenty-two patients were taking >= 1 contraindicated medication that could potentially affect their cognition; the most frequently prescribed were benzodiazepines, oxybutynin, amitriptyline, fluoxetine, and diphenhydramine. Twenty-eight of the 100 patients were being treated with a cholinesterase inhibitor at the time of their evaluation; of these, 4 (14%) were also taking >= 1 medication with anticholinergic properties. Conclusions: Despite research evidence and recommendations to avoid these CNS-active medications because of their adverse effects, they continue to be prescribed in elderly patients with cognitive impairments. Further research is needed to determine strategies that will help reduce their administration in this population. C1 [Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Sklenicka, Julie] USN, Ctr Med, San Diego, CA 92152 USA. [Sayegh, Philip] Univ So Calif, Dept Psychol, Clin Sci Program, Los Angeles, CA 90089 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Barton, C (reprint author), Univ Calif San Francisco, Dept Neurol, Box 127,4150 Clement St, San Francisco, CA 94121 USA. EM cbarton@memory.ucsf.edu NR 27 TC 21 Z9 21 U1 2 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD AUG PY 2008 VL 6 IS 3 BP 147 EP 152 DI 10.1016/j.amjopharm.2008.08.002 PG 6 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 344US UT WOS:000258953400002 PM 18775389 ER PT J AU Kasckow, J Patterson, T Fellows, I Golshan, S Solorzano, E Mohamed, S AF Kasckow, John Patterson, Thomas Fellows, Ian Golshan, Shahrokh Solorzano, Ellen Mohamed, Somaia TI Functioning in middle aged and older patients with schizophrenia and depressive symptoms: Relationship to psychopathology SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE schizophrenia; functioning; psychopathology; negative symptoms AB Background: Depressive symptoms are common in middle aged and older patients with schizophrenia. The authors hypothesized that worse functioning in these patients would be associated with worse psychopathology. Methods: Outpatients with schizophrenia were >= 40 years old with subsyndromal depression and Hamilton Depression Rating Scale Scores of >= 8. Exclusions were dementia, two months of either mania or major depression or 1 month active substance abuse/dependence. The authors administered performance based functional assessments, the Positive and Negative Syndrome Scale of Schizophrenia [PANSS], and Calgary Depression Rating Scale. Results: PANSS (-) scores were negatively correlated with the UCSD Performance Skills Based Assessment, Social Skills Performance Assessment and Medication Management Ability Assessment total error (MMAA) scores. Digit symbol scores served as a moderator of the relationship between MMAA and PANSS (-) scores. Conclusions: Negative symptoms were associated with functioning. The relationship between negative symptoms and medication errors seem to weaken in subjects with quicker processing speed. C1 VA Pittsburgh Hlth Care System, MIRECC & Behav Hlth Serv, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. San Diego Hlth Care System, San Diego, CA USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care System, MIRECC & Behav Hlth Serv, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM jkasckow@pol.net FU NIMH NIH HHS [R01 MH063798, R01 MH063931, R01 MH063931-05, R01 MH063798-06, MH6398-05] NR 9 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD AUG PY 2008 VL 16 IS 8 BP 660 EP 663 DI 10.1097/JGP.0b013e31816ff746 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 332QD UT WOS:000258097300006 PM 18669944 ER PT J AU Zivin, K McCammon, RJ Davis, MM Halasyamani, LK Kales, HC AF Zivin, Kara McCammon, Ryan J. Davis, Matthew M. Halasyamani, Lakshmi K. Kales, Helen C. TI Increases in Medicare prescription drug plan costs attributable to psychotropic medications SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE prescription medication; medicare prescription drug plan; depression; bipolar disorder' psychosis; dementia ID LATE-LIFE DEPRESSION; BENEFICIARIES; NONADHERENCE; COMORBIDITY; PRESSURES; ADULTS AB Objective: Older patients may regard some medications, particularly psychotropic medications, as discretionary compared with what they perceive as more "essential" nonpsychiatric medications. Patients' concerns about psychotropic medication costs under Medicare Part D may reinforce these impressions. Design: The authors examined which Medicare prescription drug plans (PDPs) would be least expensive for beneficiaries considering the costs of 1) all medications; and 2) only nonpsychiatric medications. Setting: The authors collected data from the PDP online comparison tool provided by the Centers for Medicare and Medicaid Services (CMS). Participants: Hypothetical Medicare beneficiaries. Measurements: The authors examined four clinical scenarios from older outpatients with both chronic medical and psychiatric conditions (including psychosis, bipolar disorder, depression, and dementia with behavioral disturbances). Results: The authors examined data from all 160 plans available in CMS PDP regions in May 2007. There were frequent discrepancies in the least expensive PDPs within region, depending on considering the costs of all medications, or just nonpsychiatric medications. In the clinical scenarios, patients selecting a PDP based on nonpsychiatric medications alone would pick an unnecessarily more expensive plan 74%-100% of the time (when they took any brand name medication), suggesting that excluding psychiatric medications from PDP choices may be excessively costly. However, brand name psychotropic medications significantly increased the costs of the least expensive plans. The latter finding might persuade patients to avoid taking needed psychiatric medication due to cost. Conclusion: This research highlights the complexity that patients with psychiatric and cognitive disorders face when choosing a Medicare PDP. Policymakers and clinicians should be aware of the tradeoffs that beneficiaries with psychiatric disorders face when making PDP plan choices. C1 [Zivin, Kara; Kales, Helen C.] US Dept Vet Affairs, HSR&D, Ctr Excellence, SMITREC, Ann Arbor, MI USA. [Zivin, Kara; McCammon, Ryan J.; Kales, Helen C.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Davis, Matthew M.; Halasyamani, Lakshmi K.] Univ Michigan, Sch Med, Div Gen Internal Med, Ann Arbor, MI 48109 USA. [Davis, Matthew M.] Univ Michigan, Sch Med, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA. [Davis, Matthew M.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA. [Halasyamani, Lakshmi K.] St Joseph Mercy Hosp, Dept Internal Med, Ann Arbor, MI 48104 USA. RP Zivin, K (reprint author), Univ Michigan, Sch Med, Dept Psychiat, 4250 Plymouth Rd,Box 5765, Ann Arbor, MI 48109 USA. EM kzivin@umich.edu NR 17 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD AUG PY 2008 VL 16 IS 8 BP 674 EP 685 DI 10.1097/JGP.0b013e3181794591 PG 12 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 332QD UT WOS:000258097300008 PM 18669946 ER PT J AU Newsome, BB McClellan, WM Allison, JJ Eggers, PW Chen, SC Collins, AJ Kiefe, CI Coffey, CS Warnock, DG AF Newsome, Britt B. McClellan, William M. Allison, Jeroan J. Eggers, Paul W. Chen, Shu-Cheng Collins, Allan J. Kiefe, Catarina I. Coffey, Christopher S. Warnock, David G. TI Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE African American; chronic kidney disease; end-stage renal disease; health disparities; Medicare ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; NUTRITION EXAMINATION SURVEY; GLOMERULAR-FILTRATION-RATE; 3RD NATIONAL-HEALTH; POTENTIAL EXPLANATORY FACTORS; QUALITY-OF-CARE; UNITED-STATES; MEDICARE BENEFICIARIES; SERUM CREATININE AB Background: The prevalence of earlier stage chronic kidney disease is lower for African Americans than whites in the United States. This is counterintuitive given the known 4-fold greater incidence of end-stage renal disease (ESRD) in African Americans. We describe racial differences in the rate of progression to ESRD and address the competing risk of mortality. Study Design: Retrospective analysis of Cooperative Cardiovascular Project data. Setting & Participants: 127,736 Medicare beneficiaries 65 years and older admitted to 4,545 hospitals with acute myocardial infarction between February 1994 and June 1995, with follow-up data for ESRD and mortality through June 2004. Predictors: African American versus white race, estimated glomerular filtration rate (eGFR), and their interaction; other characteristics at hospital admission. Outcomes & Measurements: Time to ESRD using Cox proportional hazards models. Results: Mean age was 77.1 years, with 8,278 African Americans (6.5%) and 49.9% women. Mean baseline eGFRs were 61.4 +/- 31.4 and 57.0 +/- 25.6 mL/min/1.73 m(2) (P < 0.001) for African Americans and whites, respectively. Of 2,161 patients (1.7%) progressing to ESRD (incidence, 3.75/1,000 person-years), 14.9% were African American. The adjusted hazard ratio for ESRD (African Americans versus whites) was 1.90 (95% confidence interval, 1.78 to 2.03); African Americans were at significantly increased risk of incident ESRD at each baseline eGFR stage (P for interaction < 0.001). Racial differences in incident ESRD were not accounted for by differences in mortality. Limitations: Retrospective analysis, residual bias from unmeasured factors, baseline eGFR determined from serum creatinine levels at the time of acute hospitalization. Conclusions: Within a nationally representative sample of Medicare patients with acute myocardial infarction, African Americans had an increased 10-year risk of ESRD regardless of baseline kidney function that was not accounted for by differences in pre-ESRD mortality. C1 [Newsome, Britt B.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Alabama, Ctr Outcomes Effectiveness Res & Educ, Birmingham, AL USA. [Newsome, Britt B.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Newsome, Britt B.; Warnock, David G.] Univ Alabama, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [McClellan, William M.] Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA. [Allison, Jeroan J.] Univ Alabama, Dept Med, Div Gen Internal Med, Birmingham, AL 35294 USA. [Eggers, Paul W.; Chen, Shu-Cheng; Collins, Allan J.] US Renal Data System, Bethesda, MD USA. [Kiefe, Catarina I.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Coffey, Christopher S.] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. RP Newsome, BB (reprint author), 1530 3rd Ave S,MT 40JE2, Birmingham, AL 35294 USA. EM bnewsome@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 FU AHRQ HHS [HS013852]; NHLBI NIH HHS [R01 HL070786, R01 HL70786]; None [HS013852] NR 38 TC 14 Z9 14 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2008 VL 52 IS 2 BP 251 EP 261 DI 10.1053/j.ajkd.2008.03.019 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 330LR UT WOS:000257943400010 PM 18468746 ER PT J AU Jhamb, M Weisbord, SD Steel, JL Unruh, M AF Jhamb, Manisha Weisbord, Steven D. Steel, Jennifer L. Unruh, Mark TI Fatigue in patients receiving maintenance dialysis: A review of definitions, measures, and contributing factors SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE fatigue; end-stage renal disease; quality of life; psychometrics; cytokines; postdialysis fatigue ID QUALITY-OF-LIFE; STAGE RENAL-DISEASE; ECOLOGICAL MOMENTARY ASSESSMENT; CHRONIC KIDNEY-DISEASE; C-REACTIVE PROTEIN; RANDOMIZED CONTROLLED-TRIAL; BLOOD MONONUCLEAR-CELLS; NECROSIS-FACTOR-ALPHA; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS AB Fatigue is a debilitating symptom or side effect experienced by many patients on long-term dialysis therapy. Fatigue has a considerable effect on patient health-related quality of life and is viewed as being more important than survival by some patients. Renal providers face many challenges when attempting to reduce fatigue in dialysis patients. The lack of a reliable, valid, and sensitive fatigue scale complicates the accurate identification of this symptom. Symptoms of daytime sleepiness and depression overlap with fatigue, making it difficult to target specific therapies. Moreover, many chronic health conditions common in the long-term dialysis population may lead to the development of fatigue and contribute to the day-to-day and diurnal variation in fatigue in patients. Key to improving the assessment and treatment of fatigue is improving our understanding of potential mediators, as well as potential therapies. Cytokines have emerged as an important mediator of fatigue and have been studied extensively in patients with cancer-related fatigue. In addition, although erythropoietin-stimulating agents have been shown to mitigate fatigue, the recent controversy regarding erythropoietin-stimulating agent dosing in patients with chronic kidney disease suggests that erythropoietin-stimulating agent therapy may not serve as the sole therapy to improve fatigue in this population. In conclusion, fatigue is an important and often underrecognized symptom in the dialysis population. Possible interventions for minimizing fatigue in patients on long-term dialysis therapy should aim at improving health care provider awareness, developing improved methods of measurement, understanding the pathogenesis better, and managing known contributing factors. C1 [Unruh, Mark] Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. [Jhamb, Manisha] Western Penn Med Ctr, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Weisbord, Steven D.] Univ Pittsburgh, Renal Electrolyte Div, Med Ctr, Pittsburgh, PA USA. [Steel, Jennifer L.] Univ Pittsburgh, Sch Med, Dept Surg, Liver Canc Ctr,Starzl Transplantat Inst, Pittsburgh, PA USA. RP Unruh, M (reprint author), Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, 3550 Terrace St,A915 Scaife Hall, Pittsburgh, PA 15261 USA. EM unruh@pitt.edu RI Jhamb, Manisha/E-4169-2013 FU NIDDK NIH HHS [DK66006, DK77785, K23 DK066006, K23 DK066006-04, R01 DK077785, R01 DK077785-01] NR 131 TC 69 Z9 77 U1 2 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2008 VL 52 IS 2 BP 353 EP 365 DI 10.1053/j.ajkd.2008.05.005 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 330LR UT WOS:000257943400021 PM 18572290 ER PT J AU Figlewicz, DP Bennett, JL Aliakbari, S Zavosh, A Sipols, AJ AF Figlewicz, Dianne P. Bennett, Jennifer L. Aliakbari, Sepideh Zavosh, Aryana Sipols, Alfred J. TI Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE food reward; ventral tegmental area; arcuate nucleus ID FOOD-MOTIVATED BEHAVIOR; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; INTRAVENTRICULAR INSULIN; ADIPOSITY SIGNALS; PARAVENTRICULAR NUCLEUS; REWARD CIRCUITRY; NEUROPEPTIDE-Y; C-FOS AB Findings from our laboratory and others have demonstrated that the hormone insulin has chronic effects within the CNS to regulate energy homeostasis and to decrease brain reward function. In this study, we compared the acute action of insulin to decrease intake of a palatable food in two different behavioral tasks-progressive ratios sucrose self-administration and mu opioid-stimulated sucrose feeding-when administered into several insulin-receptive sites of the CNS. We tested insulin efficacy within the medial hypothalamic arcuate (ARC) and paraventricular (PVN) nuclei, the nucleus accumbens, and the ventral tegmental area. Administration of insulin at a dose that has no chronic effect on body weight (5 mU) into the ARC significantly suppressed sucrose self-administration (75 +/- 5% of paired control). However, although the mu opioid DAMGO, [D-Ala2, N-MePhe4, Gly5-ol]-enkephalin acetate salt, stimulated sucrose intake at all four CNS sites, the ventral tegmental area was the only sensitive site for a direct effect of insulin to antagonize acute (60 min) mu opioid-stimulated sucrose feeding: sucrose intake was 53 +/- 8% of DAMGO-induced feeding, when insulin was coadministered with DAMGO. These findings demonstrate that free feeding of sucrose, and motivated work for sucrose, can be modulated within unique sites of the CNS reward circuitry. Further, they support the interpretation that adiposity signals, such as insulin, can decrease different aspects of ingestion of a palatable food, such as sucrose, in an anatomically specific manner. C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst 151, Seattle, WA USA. [Figlewicz, Dianne P.; Bennett, Jennifer L.; Zavosh, Aryana] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sipols, Alfred J.] Latvian State Univ, Fac Med, LV-1063 Riga, Latvia. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU NIDDK NIH HHS [R01 DK040963] NR 46 TC 61 Z9 61 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD AUG 1 PY 2008 VL 295 IS 2 BP R388 EP R394 DI 10.1152/ajpregu.90334.2008 PG 7 WC Physiology SC Physiology GA 335WB UT WOS:000258322700003 PM 18525010 ER PT J AU Mathalon, DH Ford, JM AF Mathalon, Daniel H. Ford, Judith M. TI Divergent approaches converge on frontal lobe dysfunction in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID ABNORMALITIES C1 [Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv 116d, San Francisco, CA 94121 USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116d, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [R01 MH076989, R01 MH076989-02] NR 12 TC 9 Z9 9 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2008 VL 165 IS 8 BP 944 EP 948 DI 10.1176/appi.ajp.2008.08050735 PG 5 WC Psychiatry SC Psychiatry GA 332WL UT WOS:000258113700004 PM 18676596 ER PT J AU Rottnek, M Riggio, S Byne, W Sano, M Margolis, RL Walker, RH AF Rottnek, Matthew Riggio, Silvana Byne, William Sano, Mary Margolis, Russell L. Walker, Ruth H. TI Schizophrenia in a patient with spinocerebellar ataxia 2: Coincidence of two disorders or a Neurodegenerative disease presenting with psychosis? SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID COGNITIVE-AFFECTIVE SYNDROME; ATAXIA; IMPAIRMENT; DYSMETRIA; CORTEX C1 James J Peters Vet Affairs Med Center, Dept Neurol, New York, NY USA. James J Peters Vet Affairs Med Center, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Dept Neurol, New York, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu NR 21 TC 11 Z9 12 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2008 VL 165 IS 8 BP 964 EP 967 DI 10.1176/appi.ajp.2008.08020285 PG 4 WC Psychiatry SC Psychiatry GA 332WL UT WOS:000258113700009 PM 18676601 ER PT J AU Freedman, R Olincy, A Buchanan, RW Harris, JG Gold, JM Johnson, L Allensworth, D Guzman-Bonilla, A Clement, B Ball, MP Kutnick, J Pender, V Martin, LF Stevens, KE Wagner, BD Zerbe, GO Soti, F Kem, WR AF Freedman, Robert Olincy, Ann Buchanan, Robert W. Harris, Josette G. Gold, James M. Johnson, Lynn Allensworth, Diana Guzman-Bonilla, Alejandrina Clement, Bettye Ball, M. Patricia Kutnick, Jay Pender, Vicki Martin, Laura F. Stevens, Karen E. Wagner, Brandie D. Zerbe, Gary O. Soti, Ferenc Kem, William R. TI Initial phase 2 trial of a nicotinic agonist in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CONSENSUS COGNITIVE BATTERY; ALPHA-BUNGAROTOXIN; NEGATIVE SYMPTOMS; DOUBLE-BLIND; CLOZAPINE; RECEPTORS; RELIABILITY; SMOKING; DEFICIT; GTS-21 AB Objective: Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of alpha(7)-nicotinic receptors. Patients' heavy smoking suggests attempted self-medication through this mechanism. The agent 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A) is a partial alpha(7)-nicotinic agonist and can be taken orally. A phase 1 trial showed evidence for cognitive enhancement in schizophrenia. Method: Thirty-one subjects with schizophrenia received DMXB-A at two different doses and placebo for periods of 4 weeks in a three-arm, two-site, double-blind, crossover phase 2 trial. The MATRICS Consensus Cognitive Battery assessed cognitive effects, and the Scale for the Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Scale (BPRS) assessed clinical effects. Subjects continued their current antipsychotic drug during the trial and were nonsmokers. Results: There were no significant differences in the MATRICS cognitive measures between DMXB-A and placebo over the three treatment arms, but the patients experienced significant improvement at the higher DMXB-A dose on the SANS total score and nearly significant improvement on the BPRS total score. Improvement was most notable on the SANS anhedonia and alogia subscales. Examination of the first treatment arm showed effects of DMXB-A on the attention/vigilance and working memory MATRICS domains, compared to baseline. Five subjects developed mild tremor, and nearly half had mild nausea while taking DMXB-A. Conclusion: DMXB-A, a nicotinic agonist that activates alpha(7)-nicotinic receptors, improved clinical ratings of negative symptoms that are generally resistant to treatment with dopamine antagonist antipsychotic drugs. The clinical utility of this treatment is not yet determined. C1 Denver VA Med Ctr, Dept Psychiat, Denver, CO USA. Denver VA Med Ctr, Dept Prevent Med & Biometr, Denver, CO USA. Univ Maryland, Psychiat Res Ctr, College Pk, MD 20742 USA. Baltimore VA Med Ctr, Dept Psychiat, Baltimore, MD USA. Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA. RP Freedman, R (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat C249 32, Denver, CO 80262 USA. EM Robert.Freedman@UCHSC.edu OI Wagner, brandie/0000-0002-2745-0103 FU NIMH NIH HHS [MH-061412, MH-068582, P50 MH068582, R01 MH061412] NR 39 TC 273 Z9 277 U1 3 U2 10 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD AUG PY 2008 VL 165 IS 8 BP 1040 EP 1047 DI 10.1176/appi.ajp.2008.07071135 PG 8 WC Psychiatry SC Psychiatry GA 332WL UT WOS:000258113700019 PM 18381905 ER PT J AU Esteban, A Frutos-Vivar, F Ferguson, ND Anzueto, A AF Esteban, Andres Frutos-Vivar, Fernando Ferguson, Niall D. Anzueto, Antonio TI Tidal volume in mechanical ventilation: The importance of considering predicted body weight - Reply SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter C1 [Esteban, Andres; Frutos-Vivar, Fernando] Hosp Univ Getafe, Madrid, Spain. [Ferguson, Niall D.] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada. [Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Esteban, A (reprint author), Hosp Univ Getafe, Madrid, Spain. NR 2 TC 1 Z9 1 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD AUG 1 PY 2008 VL 178 IS 3 BP 316 EP 316 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 333OO UT WOS:000258162000021 ER PT J AU Gray, SH Vick, CC Graham, LA Finan, KR Neumayer, LA Hawn, MT AF Gray, Stephen H. Vick, Catherine C. Graham, Laura A. Finan, Kelly R. Neumayer, Leigh A. Hawn, Mary T. TI Variation in mesh placement for ventral hernia repair: an opportunity for process improvement? SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE incisional hernia repair; variation; quality ID ABDOMINAL-WALL HERNIAS; OF-VETERANS-AFFAIRS; INCISIONAL HERNIA; RISK-FACTORS; SURGICAL CARE; RECURRENCE; COMPLICATIONS; OUTCOMES; HERNIORRHAPHY; INFECTION AB BACKGROUND: Incisional hernia repair (IHR) with mesh has been associated with decreased hernia recurrence. We analyzed variation in mesh use for IHR. METHODS: A cohort undergoing IHR from 16 Veterans' Administration (VA) Hospitals was identified. Patient-specific variables were obtained from National Surgical Quality Improvement Program (NSQIP) data. Operative variables were obtained from physician-abstracted operative notes. Univariate and multivariable logistic regression analyses were used to model mesh implantation predictors. RESULTS: A total of 1,123 IHR cases were analyzed; Mesh was implanted in 69.6% (n = 781). Regression models demonstrated repair at a high performing facility was associated with a nearly 4-fold increase in mesh utilization. Other significant predictors include repair of recurrent hernia, chronic steroid use, and multiple fascial defects. CONCLUSIONS: There is variation in the rate of mesh placement for IHR by VA facility, even after accounting for key explanatory variables. Patterns of mesh placement in IHR appear to be based on practice style. (c) 2008 Published by Elsevier Inc. C1 [Gray, Stephen H.; Vick, Catherine C.; Graham, Laura A.; Finan, Kelly R.; Hawn, Mary T.] Birmingham Vet Affairs VA Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. [Gray, Stephen H.; Vick, Catherine C.; Finan, Kelly R.; Hawn, Mary T.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Gray, Stephen H.] Univ Alabama, Dept Med, Hlth Serv & Outcomes Res Training Program, Birmingham, AL 35294 USA. [Neumayer, Leigh A.] Univ Utah, Dept Surg, Salt Lake City, UT USA. [Neumayer, Leigh A.] Univ Utah, VA Med Ctr, Salt Lake City, UT USA. RP Hawn, MT (reprint author), Birmingham Vet Affairs VA Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. EM mhawn@uab.edu OI Gray, Stephen/0000-0002-5702-7226 FU AHRQ HHS [5 T32 HS013852, HS013852]; None [HS013852] NR 36 TC 13 Z9 13 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD AUG PY 2008 VL 196 IS 2 BP 201 EP 206 DI 10.1016/j.amjsurg.2007.09.041 PG 6 WC Surgery SC Surgery GA 334VB UT WOS:000258248200010 PM 18513688 ER PT J AU Mamtani, M Rovin, B Brey, R Camargo, JF Kulkarni, H Herrera, M Correa, P Holliday, S Anaya, JM Ahuja, SK AF Mamtani, M. Rovin, B. Brey, R. Camargo, J. F. Kulkarni, H. Herrera, M. Correa, P. Holliday, S. Anaya, J-M Ahuja, S. K. TI CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID COPY-NUMBER VARIATION; CHEMOKINE RECEPTOR 5; IMMUNODEFICIENCY-VIRUS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; MRL-FAS(LPR) MICE; REVISED CRITERIA; HIV-1 INFECTION; MODIFIER GENES; HUMAN GENOME AB Objectives: There is an enrichment of immune response genes that are subject to copy number variations (CNVs). However, there is limited understanding of their impact on susceptibility to human diseases. CC chemokine ligand 3 like-1 (CCL3L1) is a potent ligand for the HIV coreceptor, CC chemokine receptor 5 (CCR5), and we have demonstrated previously an association between CCL3L1-gene containing segmental duplications and polymorphisms in CCR5 and HIV/AIDS susceptibility. Here, we determined the association between these genetic variations and risk of developing systemic lupus erythaematosus (SLE), differential recruitment of CD3+ and CD68+ leukocytes to the kidney, clinical severity of SLE reflected by autoantibody titres and the risk of renal complications in SLE. Methods: We genotyped 1084 subjects (469 cases of SLE and 615 matched controls with no autoimmune disease) from three geographically distinct cohorts for variations in CCL3L1 and CCR5. Results: Deviation from the average copy number of CCL3L1 found in European populations increased the risk of SLE and modified the SLE-influencing effects of CCR5 haplotypes. The CCR5 human haplogroup (HH)E and CCR5-Delta 32-bearing HHG*2 haplotypes were associated with an increased risk of developing SLE. An individual's CCL3L1-CCR5 genotype strongly predicted the overall risk of SLE, high autoantibody titres, and lupus nephritis as well as the differential recruitment of leukocytes in subjects with lupus nephritis. The CCR5 HHE/HHG*2 genotype was associated with the maximal risk of developing SLE. Conclusion: CCR5 haplotypes HHE and HHG*2 strongly influence the risk of SLE. The copy number of CCL3L1 influences risk of SLE and modifies the SLE-influencing effects associated with CCR5 genotypes. These findings implicate a key role of the CCL3L1-CCR5 axis in the pathogenesis of SLE. C1 [Mamtani, M.; Camargo, J. F.; Kulkarni, H.; Herrera, M.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Ctr AIDS & HIV Infect 1, S Texas Vet Hlth Care System, San Antonio, TX 78229 USA. [Mamtani, M.; Camargo, J. F.; Kulkarni, H.; Herrera, M.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Rovin, B.] Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA. [Rovin, B.] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA. [Brey, R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Correa, P.; Anaya, J-M] Corp Para Invest Biol, Cellular Biol & Immunogenet Unit, Medellin, Colombia. [Holliday, S.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Anaya, J-M] Univ Rosario, Sch Med, Bogota, Colombia. [Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Ctr AIDS & HIV Infect, 7703 Floyd Curl Dr,Room 5 009R, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Correa, Paula/0000-0002-0941-9700 FU NCRR NIH HHS [M01 RR001346]; NIAID NIH HHS [R01 AI043279, AI043279, R37 AI046326]; NIDDK NIH HHS [DK55546, P01 DK055546]; NIMH NIH HHS [MH069270, R01 MH069270]; NINDS NIH HHS [NS35477, R01 NS035477] NR 54 TC 61 Z9 66 U1 1 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD AUG PY 2008 VL 67 IS 8 BP 1076 EP 1083 DI 10.1136/ard.2007.078048 PG 8 WC Rheumatology SC Rheumatology GA 324YK UT WOS:000257555100004 PM 17971457 ER PT J AU Pessler, F Dai, L Diaz-Torne, C Gomez-Vaquero, C Paessler, ME Zheng, DH Einhorn, E Range, U Scanzello, C Schumacher, HR AF Pessler, F. Dai, L. Diaz-Torne, C. Gomez-Vaquero, C. Paessler, M. E. Zheng, D-H Einhorn, E. Range, U. Scanzello, C. Schumacher, H. R. TI The synovitis of "non-inflammatory'' orthopaedic arthropathies: a quantitative histological and immunohistochemical analysis SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID HISTOPATHOLOGICAL GRADING SYSTEM; ANGIOGENESIS; SCORE; KNEE AB Objective: To quantify inflammatory changes in synovial membranes from orthopaedic "non-inflammatory'' arthropathies (Orth. A). Methods: Synovial membranes from patients with femur fracture, avascular necrosis of the femur, plica syndrome, and meniscus and/or ligament injury (n=23); rheumatoid arthritis (n=28); osteoarthritis (OA; n=25); and from normal controls (n=10) were assessed by light microscopy, a histological synovitis score, immunostaining for CD3, CD20, CD38, CD68, Ki-67 and von Willebrand factor, and with an immunohistochemical inflammation score. Results: Orth. A histology varied between normal and markedly inflamed. Predominant abnormalities were mild lining hyperplasia, scattered inflammatory cells and small perivascular infiltrates. The synovitis score classified Orth. A as "mild synovitis''. Inflammatory cells occurred frequently: CD68+ cells in 100% of Orth. A specimens; CD3+, 91%; CD38+, 70%; and CD20+, 39%. Orth. A had 36% greater lining thickness (p=0.04), 40% higher vascular density (p=0.009) and 51.3-fold higher CD38+ cell density (p=0.02) than normal controls; and 60% fewer subintimal Ki-67+ cells (p=0.003), 42% fewer CD68+ lining cells (p<0.01) and 40% fewer subintimal CD68+ cells (p<0.01) than OA. The immunohistochemical inflammation score was 2.2-fold higher in Orth. A than in controls (p=0.048) and similar to OA, with three Orth. A specimens showing marked inflammation. Conclusions: Synovial membranes from "non-inflammatory'' arthropathies featured neovascularisation and inflammation intermediate between normal and OA synovium. These results expand previous findings that mechanical joint injury may lead to a mild-to-moderate synovitis. C1 [Pessler, F.; Range, U.] Tech Univ Dresden, Med Fak Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, D-01307 Dresden, Germany. [Pessler, F.] Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA. [Dai, L.; Zheng, D-H] Sun Yat Sen Univ, Affiliated Hosp 2, Div Rheumatol, Guangzhou 510275, Guangdong, Peoples R China. [Diaz-Torne, C.] Hosp Santa Creu & Sant Pau, Rheumatol Unit, Barcelona, Spain. [Gomez-Vaquero, C.] Hosp Univ Bellvitge, Div Rheumatol, Barcelona, Spain. [Paessler, M. E.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Einhorn, E.] Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA USA. [Dai, L.; Scanzello, C.] Hosp Special Surg, Dept Rheumatol, New York, NY 10021 USA. [Diaz-Torne, C.; Schumacher, H. R.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Schumacher, H. R.] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. RP Pessler, F (reprint author), Tech Univ Dresden, Med Fak Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, Fetscherstr 74, D-01307 Dresden, Germany. EM frank.pessler@uniklinikumdresden.de OI Cesar, Diaz-Torne/0000-0001-6275-7699 FU NCI NIH HHS [T32-CA 09140]; NIAMS NIH HHS [T32-AR 007442] NR 12 TC 44 Z9 45 U1 2 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD AUG PY 2008 VL 67 IS 8 BP 1184 EP 1187 DI 10.1136/ard.2008.087775 PG 4 WC Rheumatology SC Rheumatology GA 324YK UT WOS:000257555100027 PM 18203762 ER PT J AU McEvoy, MD Taylor, AG Zavadzkas, JA Mains, IM Ford, RL Stroud, RE Jeffords, LB Beck, CU Reeves, ST Spinale, FG AF McEvoy, Matthew D. Taylor, Anna-Greta Zavadzkas, Juozas A. Mains, Ira M. Ford, Rachael L. Stroud, Robert E. Jeffords, Laura B. Beck, Christy U. Reeves, Scott T. Spinale, Francis G. TI Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion SO ANNALS OF THORACIC SURGERY LA English DT Article ID BYPASS GRAFT-SURGERY; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; INFARCTION; METAANALYSIS; MICE AB Background. Cardiac surgery can result in left ventricular ischemia and reperfusion (I/R), the release of cytokines such as tumor necrosis factor, and oxidative stress with release of myeloperoxidase. Although aprotinin has been used in cardiac surgery, the likely multiple effects of this serine protease inhibitor limit clinical utility. This study tested the hypothesis that different aprotinin doses cause divergent effects on left ventricular contractility, cytokine release, and oxidative stress in the context of I/R. Methods. Left ventricular I/R (30 minutes I, 60 minutes R) was induced in mice, and left ventricular contractility (maximal end-systolic elastance) determined. Mice were randomly allocated to 2 x 10(4) kallikrein inhibitory units (KIU)/kg aprotinin (n = 11), 4 x 10(4) KIU/kg aprotinin (n = 10), and vehicle (saline, n = 10). Based upon a fluorogenic assay, aprotinin doses of 2 and 4 x 10(4) KIU/kg resulted in plasma concentrations similar to those of the half and full Hammersmith doses, respectively. Results. After I/R, maximal end-systolic elastance fell by more than 40% from baseline (p < 0.05), and this effect was attenuated by 2 x 10(4) KIU/kg but not 4 x 10(4) KIU/kg aprotinin. Tumor necrosis factor increased by more than 60% from control (p < 0.05) with I/R, but was reduced with 4 x 10(4) KIU/kg aprotinin. Myeloperoxidase increased with I/R, and was reduced to the greatest degree by 2 x 10(4) KIU/kg aprotinin. Conclusions. Aprotinin influences left ventricular contractility, cytokine release, and oxidative stress, which are dose dependent. These results provide mechanistic evidence that multiple pathways are differentially affected by aprotinin in a context relevant to cardiac surgery. C1 [Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, 114 Doughty St,Rm 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU NHLBI NIH HHS [R01 HL059165, R01 HL059165-10, P01 HL048788-150006, R01-HL-59165, P01-HL-48788, P01 HL048788] NR 26 TC 4 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD AUG PY 2008 VL 86 IS 2 BP 568 EP 575 DI 10.1016/j.athoracsur.2008.04.025 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 327ZN UT WOS:000257767100032 PM 18640335 ER PT J AU Diwan, A Koesters, AG Capella, D Geiger, H Kalfa, TA Dorn, GW AF Diwan, Abhinav Koesters, Andrew G. Capella, Devan Geiger, Hartmut Kalfa, Theodosia A. Dorn, Gerald W., II TI Targeting erythroblast-specific apoptosis in experimental anemia SO APOPTOSIS LA English DT Article DE apoptosis; anemia; erythropoiesis; erythropoietin ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; RED-BLOOD-CELLS; BCL-X-L; STAT5A(-/-)5B(-/-) MICE; STRESS ERYTHROPOIESIS; STEM-CELLS; SURVIVAL; DEATH; MECHANISM AB Erythrocyte production is regulated by balancing precursor cell apoptosis and survival signaling. Previously, we found that BH3-only proapoptotic factor, Nix, opposed erythroblast-survival signaling by erythropoietin-induced Bcl-xl during normal erythrocyte formation. Since erythropoietin treatment of human anemia has limitations, we explored the therapeutic potential of abrogating Nix-mediated erythroblast apoptosis to enhance erythrocyte production. Nix gene ablation blunted the phenylhydrazine-induced fall in blood count, enhanced hematocrit recovery, and reduced erythroblast apoptosis, despite lower endogenous erythropoietin levels. Similar to erythropoietin, Nix ablation increased early splenic erythroblasts and circulating reticulocytes, while maintaining a pool of mature erythroblasts as erythropoietic reserve. Erythrocytes in Nix-deficient mice showed morphological abnormalities, suggesting that apoptosis during erythropoiesis not only controls red blood cell number, but also serves a "triage" function, preferentially eliminating abnormal erythrocytes. These results support the concept of targeting erythroblast apoptosis to maximize erythrocyte production in acute anemia, which may be of value in erythropoietin resistance. C1 [Diwan, Abhinav; Dorn, Gerald W., II] Washington Univ, Ctr Pharmacogenom, St Louis, MO 63110 USA. [Diwan, Abhinav; Koesters, Andrew G.; Capella, Devan; Dorn, Gerald W., II] Univ Cincinnati, Ctr Mol Cardiovasc Res, Cincinnati, OH USA. [Diwan, Abhinav] US Dept Vet Affairs, St Louis Vet Adm, Med Ctr, St Louis, MO USA. [Geiger, Hartmut; Kalfa, Theodosia A.; Dorn, Gerald W., II] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA. RP Dorn, GW (reprint author), Washington Univ, Ctr Pharmacogenom, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA. EM gdorn@im.wustl.edu FU NHLBI NIH HHS [HL77101, R01 HL059888-09A1, R01 HL059888-08, HL59888, R01 HL080008, R01 HL080008-04, P50 HL077101, R01 HL059888] NR 48 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1360-8185 J9 APOPTOSIS JI Apoptosis PD AUG PY 2008 VL 13 IS 8 BP 1022 EP 1030 DI 10.1007/s10495-008-0236-3 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 325KL UT WOS:000257587700007 PM 18584327 ER PT J AU Faller, LD AF Faller, Larry D. TI Mechanistic studies of sodium pump SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Review DE Na,K-ATPase; sodium pump; active ion transport; phosphoryl group transfer; conformational change; reaction mechanism ID SARCOPLASMIC-RETICULUM CA2+-ATPASE; SITE-DIRECTED MUTAGENESIS; PHOSPHORYL GROUP-TRANSFER; AFFINITY OUABAIN-BINDING; ATPASE ALPHA-SUBUNIT; CALCIUM-PUMP; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; AMINO-ACIDS; NA+/K+-ATPASE AB Sodium pump was the first ion pump discovered. A member of the family of active transporters that catalyze adenosine T-triphosphate hydrolysis by forming a phosphorylated enzyme intermediate, sodium pump couples the energy released to unequal countertransport of sodium and potassium ions. The ion gradient generated by the pump is important for a variety of secondary physiological processes ranging from metabolite transport to electrical excitation of nerve and muscle. Selected experiments relating structure to function are reviewed. (c) 2008 Elsevier Inc. All rights reserved. C1 [Faller, Larry D.] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. [Faller, Larry D.] Vet Adm Greater Los Angeles Hlth Care System, Los Angeles, CA 90073 USA. RP Faller, LD (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90073 USA. EM lfaller@ucla.edu NR 80 TC 20 Z9 20 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD AUG 1 PY 2008 VL 476 IS 1 BP 12 EP 21 DI 10.1016/j.abb.2008.05.017 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 333PX UT WOS:000258165700003 PM 18558080 ER PT J AU Rintala, DH Garber, SL Friedman, JA Holmes, SA AF Rintala, Diana H. Garber, Susan L. Friedman, Jeffrey A. Holmes, Sally Ann TI Preventing recurrent pressure ulcers in veterans with spinal cord injury: Impact of a structured education and follow-up intervention SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE patient education; pressure ulcer; rehabilitation; spinal cord injuries ID SURGICAL-TREATMENT; SORES; MANAGEMENT; RISK; FLAP; EXPERIENCE; CARE AB Objective: To test the hypothesis that enhanced education and structured follow-tip after pressure ulcer surgery will result in fewer recurrences. Design: Randomized controlled trial. Setting: Veterans Affairs medical center. Participants: Forty-nine veteran men with spinal cord injury or dysfunction were approached on admission for pressure ulcer surgery. Five never had surgery, 2 refused to participate, and one withdrew. Forty-one were randomized into 3 groups. Three participants' ulcers did not heal, so follow-up could not begin. Interventions: Group 1 received individualized pressure ulcer education and monthly structured telephone follow-up (n=20); group 2 received monthly mail or telephone follow-up without educational content (n=11); and group 3 received quarterly mail or telephone follow-up without educational content (n=10). Follow-up continued until recurrence, death, or 24 months. Main Outcome Measure: Time to pressure ulcer recurrence. Results: Group 1 had a longer average time to ulcer recurrence or end of study than groups 2 and 3 (19.6mo, 10.1mo, 10.3mo; P=.002) and had a smaller rate of recurrence (33%, 60%, 90%; P=.007). Survival analysis confirmed these findings (P=.009). Conclusions: Individualized education and structured monthly contacts may be effective in reducing the frequency of or delaying pressure ulcer recurrence after surgical repair of an ulcer. C1 [Rintala, Diana H.; Garber, Susan L.; Friedman, Jeffrey A.; Holmes, Sally Ann] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Rintala, Diana H.; Garber, Susan L.; Holmes, Sally Ann] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Friedman, Jeffrey A.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Friedman, Jeffrey A.] Methodist Hosp, Houston, TX 77030 USA. RP Rintala, DH (reprint author), MEDVAMC 153, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM drintala@bcm.tmc.edu NR 49 TC 24 Z9 26 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2008 VL 89 IS 8 BP 1429 EP 1441 DI 10.1016/j.apmr.2007.01.015 PG 13 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 336UP UT WOS:000258390400002 PM 18674978 ER PT J AU Ait-Oufella, H Pouresmail, V Simon, T Blanc-Brude, O Kinugawa, K Merval, R Offenstadt, G Leseche, G Cohen, PL Tedgui, A Mallat, Z AF Ait-Oufella, Hafid Pouresmail, Vahid Simon, Tabassome Blanc-Brude, Olivier Kinugawa, Kiyoka Merval, Regine Offenstadt, Georges Leseche, Guy Cohen, Philip L. Tedgui, Alain Mallat, Ziad TI Defective Mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE apoptosis; atherosclerosis; phagocytosis; inflammation ID OXIDATION-SPECIFIC EPITOPES; PHAGOCYTOSIS; MACROPHAGES; CLEARANCE; ACTIVATION; SITE; MICE AB Objective - To study the role of Mer receptor tyrosine kinase (mertk) in atherosclerosis. Methods and Results - We irradiated and reconstituted atherosclerosis-susceptible C57Bl/6 low-density lipoprotein receptor-deficient female mice (ldlr(-/-)) with either a mertk(+/+) or mertk(-/-) ( tyrosine kinase-defective mertk) bone marrow. The mice were put on high-fat diet for either 8 or 15 weeks. Mertk deficiency led to increased accumulation of apoptotic cells within the lesions, promoted a proinflammatory immune response, and accelerated lesion development. Conclusions - Mertk expression by bone marrow - derived cells is required for the disposal of apoptotic cells and controls lesion development and inflammation. C1 [Ait-Oufella, Hafid; Pouresmail, Vahid; Simon, Tabassome; Blanc-Brude, Olivier; Kinugawa, Kiyoka; Merval, Regine; Tedgui, Alain; Mallat, Ziad] Hop Lariboisiere, Inserm, U689, Ctr Rech Cardiovasc Lariboisiere, F-75010 Paris, France. [Ait-Oufella, Hafid; Offenstadt, Georges] Hop St Antoine, Serv Reanimat Med, F-75571 Paris, France. [Leseche, Guy] Hop Bichat Claude Bernard, Serv Chirurg Thorac & Vasc, F-75877 Paris, France. [Cohen, Philip L.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Mallat, Z (reprint author), Hop Lariboisiere, Inserm, U689, Ctr Rech Cardiovasc Lariboisiere, 41 Bd Chapelle, F-75010 Paris, France. EM mallat@larib.inserm.fr RI Mallat, Ziad/D-4041-2012 OI BLANC-BRUDE, Olivier/0000-0002-4015-0615; Mallat, Ziad/0000-0003-0443-7878; SIMON, Tabassome/0000-0002-4550-0450 NR 21 TC 77 Z9 78 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD AUG 1 PY 2008 VL 28 IS 8 BP 1429 EP 1431 DI 10.1161/ATVBAHA.108.169078 PG 3 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 329PH UT WOS:000257880100005 PM 18467644 ER PT J AU Misra, S Socherman, R Hauser, P Ganzini, L AF Misra, Sahana Socherman, Robert Hauser, Peter Ganzini, Linda TI Appreciation of research information in patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article; Proceedings Paper CT 158th Annual Scientific Meeting of the American-Psychiatric-Association CY MAY 21-26, 2005 CL Atlanta, GA SP Amer Psychiat Assoc DE appreciation; bipolar disorder; decision-making capacity; therapeutic misconception ID DECISION-MAKING CAPACITY; THERAPEUTIC MISCONCEPTION; SCHIZOPHRENIA RESEARCH; INFORMED-CONSENT; ELDERLY-PATIENTS; PARTICIPATION AB Objective: Ethicists have debated whether patients with serious mental illness can appreciate the risks of research participation and make autonomous decisions. We compared the abilities of euthymic and manic bipolar patients to appreciate and make voluntary decisions regarding research participation. Methods: Twenty-six subjects with mania and 25 euthymic subjects reviewed hypothetical consent forms for three research studies of varying risk. We assessed subjects' appreciation of: their diagnosis and need for treatment; the researcher's role; the risks of participation; and the degree of influence of family, the treating clinician, and payment on decisions to participate. Results: Most subjects (92%) agreed they had bipolar disorder requiring medication treatment. Subjects were less likely to participate in riskier studies. About half of subjects erroneously believed that researchers would make decisions based solely on what would be the best care for them (therapeutic misconception); and in randomized medication trials, they mistakenly believed they had improved chances of receiving one treatment over another. There were no differences between mood groups on these measures. Over half of subjects (59%) indicated that their mental health provider might influence them to participate in a study even when they did not want to, but most rejected a role for family in decision making. Payment was rated as having little impact on decisions to participate in research. Conclusion: Mania does not substantially influence appreciation of research participation. Subjects with bipolar disorder, regardless of mood state, are at risk for therapeutic misconception and optimistic bias. Special protections may be needed when mental health professionals approach their own patients to participate in research. C1 [Misra, Sahana; Socherman, Robert; Hauser, Peter; Ganzini, Linda] Portland VA Med Ctr, Portland, OR 97239 USA. [Misra, Sahana; Socherman, Robert; Hauser, Peter; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hauser, Peter] Portland VA Mood Disorders Res & Treatment Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Ganzini, Linda] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Misra, S (reprint author), Portland VA Med Ctr, R&D 66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM misras@ohsu.edu NR 23 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD AUG PY 2008 VL 10 IS 5 BP 635 EP 646 DI 10.1111/j.1399-5618.2008.00609.x PG 12 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 327GN UT WOS:000257717700009 PM 18657248 ER PT J AU Mazarati, A Siddarth, P Baldwin, RA Shin, D Caplan, R Sankar, R AF Mazarati, Andrey Siddarth, Prabha Baldwin, Roger A. Shin, Don Caplan, Rochelle Sankar, Raman TI Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine SO BRAIN LA English DT Article DE comorbidity; depression; epilepsy; hippocampus; serotonin ID TEMPORAL-LOBE EPILEPSY; CHRONIC ANTIDEPRESSANT TREATMENT; SEROTONIN REUPTAKE TRANSPORTER; SPONTANEOUS RECURRENT SEIZURES; STRESS-INDUCED ANHEDONIA; CHRONIC MILD STRESS; ANIMAL-MODEL; RAT MODEL; 5-HYDROXYINDOLEACETIC ACID; DECREASED EXPRESSION AB Depression represents one of the most common comorbidities in patients with epilepsy. However, the mechanisms of depression in epilepsy patients are poorly understood. Establishment of animal models of this comorbidity is critical for both understanding the mechanisms of the condition, and for preclinical development of effective therapies. The current study examined whether a commonly used animal model of temporal lobe epilepsy (TLE) is characterized by behavioural and biochemical alterations involved in depression. Male Wistar rats were subjected to LiCl and pilocarpine status epilepticus (SE). The development of chronic epileptic state was confirmed by the presence of spontaneous seizures and by enhanced brain excitability. Post-SE animals exhibited increase in immobility time under conditions of forced swim test (FST) which was indicative of despair-like state, and loss of taste preference in saccharin solution consumption test which pointed to the symptomatic equivalence of anhedonia. Biochemical studies revealed compromised serotonergic transmission in the raphe-hippocampal serotonergic pathway: decrease of serotonin (5-HT) concentration and turnover in the hippocampus, measured by high performance liquid chromatography, and decrease of 5-HT release from the hippocampus in response to raphe stimulation, measured by fast cyclic voltammetry. Administration of fluoxetine (FLX, 20 mg/kg/day for 10 days) to naive animals significantly shortened immobility time under conditions of FST, and inhibited 5-HT turnover in the hippocampus. In post-SE rats FLX treatment led to a further decrease of hippocampal 5-HT turnover; however, performance in FST was not improved. At the same time, FLX reversed SE-induced increase in brain excitability. In summary, our studies provide initial evidence that post-SE model of TLE might serve as a model of the comorbidity of epilepsy and depression. The finding that behavioural equivalents of depression were resistant to an antidepressant medication suggested that depression in epilepsy might have distinct underlying mechanisms beyond alterations in serotonergic pathways. C1 [Mazarati, Andrey; Shin, Don; Caplan, Rochelle; Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Siddarth, Prabha; Caplan, Rochelle] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Baldwin, Roger A.] Univ Calif Los Angeles, David Geffen Sch Med, W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90095 USA. [Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RP Mazarati, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Room 22-474 MDCC 175217, Los Angeles, CA 90095 USA. EM mazarati@ucla.edu FU NINDS NIH HHS [NS043409, NS046516, NS059505, R01 NS043409, R01 NS046516, R21 NS059505] NR 73 TC 81 Z9 81 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD AUG PY 2008 VL 131 BP 2071 EP 2083 DI 10.1093/brain/awn117 PN 8 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 335XW UT WOS:000258329900015 PM 18559371 ER PT J AU Matioc, AA AF Matioc, Adrian A. TI Use of the Airtraq (R) with a fibreoptic bronchoscope in a difficult intubation outside the operating room SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Letter ID MORBIDLY OBESE-PATIENTS; TRACHEAL INTUBATION; LARYNGOSCOPES; MACINTOSH C1 Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. RP Matioc, AA (reprint author), Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. EM adrian.matioc@va.gov NR 5 TC 10 Z9 11 U1 0 U2 0 PU CANADIAN ANESTHESIOLOGISTS SOC PI TORONTO PA 1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA SN 0832-610X J9 CAN J ANAESTH JI Can. J. Anaesth.-J. Can. Anesth. PD AUG PY 2008 VL 55 IS 8 BP 561 EP 562 PG 2 WC Anesthesiology SC Anesthesiology GA 338FK UT WOS:000258491400014 PM 18676394 ER PT J AU Chen, C Mendez, E Houck, J Fan, WH Lohavanichbutr, P Doody, D Yueh, B Futran, ND Upton, M Farwell, DG Schwartz, SM Zhao, LP AF Chen, Chu Mendez, Eduardo Houck, John Fan, Wenhong Lohavanichbutr, Pawadee Doody, Dave Yueh, Bevan Futran, Neal D. Upton, Melissa Farwell, D. Gregory Schwartz, Stephen M. Zhao, Lue Ping TI Gene expression profiling identifies genes predictive of oral squamous cell carcinoma SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID NECK-CANCER; LAMININ GAMMA-2-CHAIN; SURGICAL MARGINS; IV GENES; HEAD; RECEPTOR; COLLAGEN; CHAIN; OVEREXPRESSION; LEUKOPLAKIA AB Oral squamous cell carcinoma (OSCC) is associated with substantial mortality and morbidity. To identify potential biomarkers for the early detection of invasive OSCC, we compared the gene expressions of incident primary OSCC, oral dysplasia, and clinically normal oral tissue from surgical patients without head and neck cancer or preneoplastic oral lesions (controls), using Affymetrix U133 2.0 Plus arrays. We identified 131 differentially expressed probe sets using a training set of 119 OSCC patients and 35 controls. Forward and stepwise logistic regression analyses identified 10 successive combinations of genes which expression differentiated OSCC from controls. The best model included LAMC2, encoding laminin-gamma 2 chain, and COL4A1, encoding collagen, type IV alpha 1 chain. Subsequent modeling without these two markers showed that COL1A1, encoding collagen, type I alpha 1 chain, and PADI1, encoding peptidyl arginine deiminase, type 1, could also distinguish OSCC from controls. We validated these two models using an internal independent testing set of 48 invasive OSCC and 10 controls and an external testing set of 42 head and neck squamous cell carcinoma cases and 14 controls (GEO GSE6791), with sensitivity and specificity above 95%. These two models were also able to distinguish dysplasia (n = 17) from control (n = 35) tissue. Differential expression of these four genes was confirmed by quantitative reverse transcription-PCR. If confirmed in larger studies, the proposed models may hold promise for monitoring local recurrence at surgical margins and the development of second primary oral cancer in patients with OSCC. C1 [Chen, Chu; Mendez, Eduardo; Houck, John; Lohavanichbutr, Pawadee; Doody, Dave; Yueh, Bevan; Schwartz, Stephen M.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA. [Chen, Chu; Schwartz, Stephen M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Chen, Chu; Mendez, Eduardo; Yueh, Bevan; Futran, Neal D.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Upton, Melissa] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Zhao, Lue Ping] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Mendez, Eduardo; Yueh, Bevan] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Farwell, D. Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M5-C800 POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053 FU National Cancer Institute [R01CA095419]; National Institute on Deafness and Other Communication Disorders [T32DC00018]; NIH [K12RR023265]; Fred Hutchinson Cancer Research Center FX U.S. NIH (R01CA095419 from the National Cancer Institute, National Research Service Award T32DC00018 from the National Institute on Deafness and Other Communication Disorders, and trans-NIH K12RR023265 Career Development Programs for Clinical Researchers) and by institutional funds from the Fred Hutchinson Cancer Research Center. NR 49 TC 87 Z9 90 U1 0 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD AUG PY 2008 VL 17 IS 8 BP 2152 EP 2162 DI 10.1158/1055-9965.EPI-07-2893 PG 11 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 342RI UT WOS:000258800800045 PM 18669583 ER PT J AU Singh, M Peterson, ED Milford-Beland, S Rumsfeld, JS Spertus, JA AF Singh, Mandeep Peterson, Eric D. Milford-Beland, Sarah Rumsfeld, John S. Spertus, John A. TI Validation of the Mayo Clinic Risk Score for In-Hospital Mortality After Percutaneous Coronary Interventions Using the National Cardiovascular Data Registry SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE angiography; angioplasty; complications; risk factors AB Background-We sought to validate the recently developed Mayo Clinic Risk Score model for in-hospital mortality after percutaneous coronary intervention using an independent data set. The Mayo Clinic Risk Score has 7 simple clinical and noninvasive variables, available before coronary angiography, for prediction of in-hospital mortality. External validation using an independent data set would support broader applicability of the model. Methods and Results-In-hospital mortality after percutaneous coronary intervention on 309 351 patients from the National Cardiovascular Data Registry admitted from January 1, 2004, to March, 30, 2006, was studied. Using the Mayo Clinic Risk Score equation, we assigned predicted probabilities of death to each patient. The area under the receiver-operating characteristics curve was 0.884, indicating excellent discrimination overall as well as among subgroups, including gender, diabetes mellitus, renal failure, low ejection fraction, different age groups, and multivessel disease. Ninety-seven percent of patients undergoing percutaneous coronary intervention had a Mayo Clinic Risk Score <10, indicating low to intermediate risk. The Mayo Clinic Risk Score model initially slightly underpredicted event rates when applied in National Cardiovascular Data Registry data (observed 1.23% versus predicted 1.10%), but this underprediction was corrected after recalibration. The recalibrated risk score discriminated (c index = 0.885) and calibrated well in an National Cardiovascular Data Registry validation data set consisting of procedures performed between April 1, 2006, and March 30, 2007. Conclusions-Seven variables can be combined into a convenient risk scoring system before coronary angiography is performed to predict in-hospital mortality after percutaneous coronary intervention. This model may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process before percutaneous coronary intervention. (Circ Cardiovasc Intervent. 2008;1:36-44.) C1 [Singh, Mandeep] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Peterson, Eric D.; Milford-Beland, Sarah] Duke Clin Res Inst, Durham, NC USA. [Spertus, John A.] Mid Amer Heart Inst UMKC, Kansas City, MO USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Singh, M (reprint author), Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA. EM singh.mandeep@mayo.edu FU American College of Cardiology FX Drs Spertus and Peterson have a research contract with the American College of Cardiology. NR 23 TC 16 Z9 16 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD AUG PY 2008 VL 1 IS 1 BP 36 EP 44 DI 10.1161/CIRCINTERVENTIONS.107.755991 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V11AH UT WOS:000207504000007 PM 20031653 ER PT J AU Charles, PGP Wolfe, R Whitby, M Fine, MJ Fuller, AJ Stirling, R Wright, AA Ramirez, JA Christiansen, KJ Waterer, GW Pierce, RJ Armstrong, JG Korman, TM Holmes, P Obrosky, DS Peyrani, P Johnson, B Hooy, M Grayson, ML AF Charles, Patrick G. P. Wolfe, Rory Whitby, Michael Fine, Michael J. Fuller, Andrew J. Stirling, Robert Wright, Alistair A. Ramirez, Julio A. Christiansen, Keryn J. Waterer, Grant W. Pierce, Robert J. Armstrong, John G. Korman, Tony M. Holmes, Peter Obrosky, D. Scott Peyrani, Paula Johnson, Barbara Hooy, Michelle Grayson, M. Lindsay CA Australian Community Acquired Pneu TI SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 47th Interscience Conference on Antimicrobial Agents and Chemotherapy CY SEP 17-20, 2007 CL Chicago, IL ID RESEARCH TEAM COHORT; CONTROLLED-TRIAL; SEVERITY INDEX; VALIDATION; RULE; PERSPECTIVE; GUIDELINES; MANAGEMENT; ADMISSION; AMERICAN AB Background. Existing severity assessment tools, such as the pneumonia severity index (PSI) and CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >= 65 years), predict 30-day mortality in community-acquired pneumonia (CAP) and have limited ability to predict which patients will require intensive respiratory or vasopressor support (IRVS). Methods. The Australian CAP Study (ACAPS) was a prospective study of 882 episodes in which each patient had a detailed assessment of severity features, etiology, and treatment outcomes. Multivariate logistic regression was performed to identify features at initial assessment that were associated with receipt of IRVS. These results were converted into a simple points-based severity tool that was validated in 5 external databases, totaling 7464 patients. Results. In ACAPS, 10.3% of patients received IRVS, and the 30-day mortality rate was 5.7%. The features statistically significantly associated with receipt of IRVS were low systolic blood pressure (2 points), multilobar chest radiography involvement (1 point), low albumin level (1 point), high respiratory rate (1 point), tachycardia (1 point), confusion (1 point), poor oxygenation (2 points), and low arterial pH (2 points): SMART-COP. A SMART-COP score of >= 3 points identified 92% of patients who received IRVS, including 84% of patients who did not need immediate admission to the intensive care unit. Accuracy was also high in the 5 validation databases. Sensitivities of PSI and CURB-65 for identifying the need for IRVS were 74% and 39%, respectively. Conclusions. SMART-COP is a simple, practical clinical tool for accurately predicting the need for IRVS that is likely to assist clinicians in determining CAP severity. C1 [Charles, Patrick G. P.; Grayson, M. Lindsay] Austin Hlth, Dept Infect Dis, Heidelberg, Vic 3084, Australia. [Pierce, Robert J.] Austin Hlth, Dept Resp & Sleep Med, Heidelberg, Vic 3084, Australia. [Charles, Patrick G. P.; Grayson, M. Lindsay] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia. [Wolfe, Rory; Grayson, M. Lindsay] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia. [Korman, Tony M.] Monash Med Ctr, Dept Infect Dis, Clayton, Vic 3168, Australia. [Holmes, Peter] Monash Med Ctr, Dept Resp Med, Clayton, Vic 3168, Australia. [Whitby, Michael; Johnson, Barbara] Princess Alexandra Hosp, Dept Infect Dis, Woolloongabba, Qld 4102, Australia. [Armstrong, John G.] Princess Alexandra Hosp, Dept Resp Med, Woolloongabba, Qld 4102, Australia. [Fuller, Andrew J.] Alfred Hosp, Dept Infect Dis, Prahran, Vic 3181, Australia. [Stirling, Robert; Hooy, Michelle] Alfred Hosp, Dept Resp Med, Prahran, Vic 3181, Australia. [Wright, Alistair A.] W Gippsland Hosp, Warragul, Australia. [Christiansen, Keryn J.] Royal Perth Hosp, Dept Microbiol & Infect Dis, PathWest Lab Med, Perth, WA, Australia. [Waterer, Grant W.] Royal Perth Hosp, Dept Resp Med, Perth, WA, Australia. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.; Obrosky, D. Scott] VA Pittsburgh Healthcare Syst, Ctr Healthcare Equ Res & Promot, Pittsburgh, PA USA. [Ramirez, Julio A.; Peyrani, Paula] Univ Louisville, Div Infect Dis, Louisville, KY 40292 USA. RP Charles, PGP (reprint author), Austin Hlth, Dept Infect Dis, POB 5555, Heidelberg, Vic 3084, Australia. EM patrick.charles@austin.org.au RI Whitby, Michael/B-7231-2011; Korman, Tony/I-3099-2013 OI Korman, Tony/0000-0002-6155-8353 NR 29 TC 187 Z9 208 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2008 VL 47 IS 3 BP 375 EP 384 DI 10.1086/589754 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 322UH UT WOS:000257400300010 PM 18558884 ER PT J AU Teng, MS Yuen, AS Kim, HT AF Teng, Margie S. Yuen, Audrey S. Kim, Hubert T. TI Enhancing osteochondral allograft viability: Effects of storage media composition SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article; Proceedings Paper CT 5th Musculoskeletal Transplant Foundation Symposium CY OCT 07, 2007 CL Vancouver, CANADA ID CHONDROCYTE APOPTOSIS; ARTICULAR-CARTILAGE; COLD-STORAGE; TRANSPLANTATION; SURVIVAL; INHIBITION AB Osteochondral allograft transplantation is a well-accepted treatment for articular cartilage damage. However, chondrocyte viability declines during graft storage, which may compromise graft performance. We first tested the hypothesis that the composition of commonly used storage media affects the viability of articular chondrocytes over time; we then tested the hypothesis that the addition of insulin growth factor-1 or the apoptosis inhibitor ZVAD-fmk could enhance the storage properties of serum-free media. Bovine osteochondral grafts were stored at 4 degrees C in lactated Ringer's, Dulbecco's modified eagle's media (DMEM), DMEM supplemented with either insulin growth factor-1 or ZVAD-fmk, and a commercial storage media. Chondrocyte viability in lactated Ringer's declined rapidly to 20.4% at 2 weeks. Viability in DMEM declined more slowly to 54.8% at 2 weeks and 31.2% at 3 weeks. Viability in commercial storage media was 83.6% at 3 weeks and 44.8% at 4 weeks. Viability was increased in DMEM + insulin growth factor-1 (56.4%) and DMEM + ZVAD (52.4%) at 3 weeks compared with DMEM alone. These results confirm the hypotheses that media composition greatly influences chondrocyte viability during cold storage and that insulin growth factor-1 and ZVAD improve the storage properties of DMEM. C1 [Kim, Hubert T.] San Francisco VA Med Ctr, Orthoped Surg Sect, San Francisco, CA 94121 USA. [Teng, Margie S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, Orthoped Surg Sect, 4150 Clement St 112, San Francisco, CA 94121 USA. EM kimh@orthosurg.ucsf.edu NR 19 TC 17 Z9 23 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD AUG PY 2008 VL 466 IS 8 BP 1804 EP 1809 DI 10.1007/s11999-008-0302-8 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 323IS UT WOS:000257440400006 PM 18506560 ER PT J AU Kim, HT Teng, MS Dang, AC AF Kim, Hubert T. Teng, Margie S. Dang, Alexis C. TI Chondrocyte apoptosis: Implications for osteochondral allograft transplantation SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article; Proceedings Paper CT 5th Musculoskeletal Transplant Foundation Symposium CY OCT 07, 2007 CL Vancouver, CANADA ID HUMAN OSTEOARTHRITIC CARTILAGE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; IN-VITRO; CELL-DEATH; INTRAARTICULAR FRACTURE; ARTICULAR-CARTILAGE; CASPASE INHIBITORS; UP-REGULATION; FOLLOW-UP AB Osteochondral allograft transplantation is a useful technique to manage larger articular cartilage injuries. One factor that may compromise the effectiveness of this procedure is chondrocyte cell death that occurs during the storage, preparation, and implantation of the osteochondral grafts. Loss of viable chondrocytes may negatively affect osteochondral edge integration and long-term function. A better understanding of the mechanisms responsible for chondrocyte loss could lead to interventions designed to decrease cell death and improve results. Recent studies indicate that apoptosis, or programmed cell death, is responsible for much of the chondrocyte death associated with osteochondral allograft transplantation. Theoretically, some of these cells can be rescued by blocking important apoptotic mediators. We review the role of apoptosis in cartilage degeneration, focusing on apoptosis associated with osteochondral transplantation. We also review the pathways thought to be responsible for regulating chondrocyte apoptosis, as well as experiments testing inhibitors of the apoptotic pathway. These data suggest that key contributors to the apoptotic process can be manipulated to enhance chondrocyte survival. This knowledge may lead to better surgical outcomes for osteochondral transplantation. C1 [Kim, Hubert T.] San Francisco VA Med Ctr, Orthoped Surg Sect, San Francisco, CA 94121 USA. [Teng, Margie S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Dang, Alexis C.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, Orthoped Surg Sect, 4150 Clement St 112, San Francisco, CA 94121 USA. EM kimh@orthosurg.ucsf.edu NR 50 TC 12 Z9 17 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD AUG PY 2008 VL 466 IS 8 BP 1819 EP 1825 DI 10.1007/s11999-008-0304-6 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 323IS UT WOS:000257440400008 PM 18506558 ER PT J AU Mauldin, PD Guimaraes, P Albin, RL Dorsey, ER Bainbridge, JL Siderowf, A AF Mauldin, Patrick D. Guimaraes, Paulo Albin, Roger L. Dorsey, E. Ray Bainbridge, Jacquelyn L. Siderowf, Andrew CA NINDS NET-PD Investigators TI Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: The FS-TOO resource utilization substudy SO CLINICAL THERAPEUTICS LA English DT Article DE health care resources; Parkinson's disease; clinical trials ID RANDOMIZED CLINICAL-TRIAL AB Objective: The aim of this substudy was to determine the agreement between 2 approaches for measuring health care resource utilization (eg, number of hospital visits, number of primary care physician visits) in trial participants with Parkinson's disease (PD). Methods: A substudy of the 1-year multicenter futility trial of GPI-1485 and coenzyme Q(10) (FS-TOO) was performed to assess health care resource utilization agreement by measuring participant utilization recall after 12 months versus measuring participant utilization recall at regular 3-month intervals. Trial participants were selected from patients in the National Institutes of Health-sponsored FS-TOO multicenter study. Persons aged >= 30 years with confirmed PD diagnosis within the previous 5 years were eligible for inclusion in the substudy. Participants were also required to have at least 2 of 3 cardinal manifestations of PD (tremor, rigidity, and bradykinesia). Participants were excluded from the study if they had presence of atypical Parkinson's syndromes due to drugs, metabolic identified neurogenetic disorders, encephalitis, or other degenerative diseases. Agreement was determined using Lin's concordance and Cohen's kappa statistics. Results: Between March and July of 2004, a total of 424 potential subjects were identified and evaluated for trial eligibility. Of these, 213 subjects (139 men, 74 women; mean [SD] age, 61.5 [10.3] years) met entry criteria and were included in the study. Trial participants were randomized equally to I of 3 groups. The 3 groups had similar baseline characteristics in terms of demographic data (age, race, sex, employment status, and annual income), total Unified Parkinson Disease Rating Scale (UPDRS) score, and UPDRS subscores. In this substudy, 141 participants had a true baseline visit, indicating a clinical baseline date, and 182 participants completed the Baseline Resource Utilization Form within 3 months of the true baseline visit. The comparison of concordance between the summed information over 3-month recalls and the 12-month recall from baseline was derived from these 182 participants. The level of agreement between the 2 approaches was high, ranging from 64.4% to 95.1%. Where disagreement was identified, the more frequent measurement approach (every 3 months) led to higher estimates, ranging from 20.4% to 77.4%. Conclusion: The results of this trial indicate internal consistency with the self-reported measures of health care resource utilization, suggesting that these simple measures might provide reliable information about units of health care resource utilization in the context of clinical trials for PD. C1 [Mauldin, Patrick D.] Med Univ S Carolina, Dept Clin Pharm & Outcomes Sci, Coll Pharm, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Guimaraes, Paulo] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Albin, Roger L.] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI USA. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [Bainbridge, Jacquelyn L.] Univ Colorado Denver & Hlth Sci Ctr, Dept Clin Pharm, Denver, CO USA. [Siderowf, Andrew] Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA. RP Mauldin, PD (reprint author), Med Univ S Carolina, Dept Clin Pharm & Outcomes Sci, Coll Pharm, POB 250144,QF213B, Charleston, SC 29425 USA. EM mauldinp@musc.edu RI Guimaraes, Paulo/A-7085-2008 OI Guimaraes, Paulo/0000-0002-2992-1028 FU National Institute of Neurological Disorders and Stroke [U01NS043127, U01NS043128, U10NS44415] FX This study was sponsored by the National Institute of Neurological Disorders and Stroke (U01NS043127, U01NS043128, and U10NS44415 through 4455). NR 10 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD AUG PY 2008 VL 30 IS 8 BP 1553 EP 1557 DI 10.1016/j.clinthera.2008.08.001 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 350KN UT WOS:000259351400014 PM 18803996 ER PT J AU Lo Re, V Kostman, JR Amorosa, VK AF Lo Re, Vincent, III Kostman, Jay R. Amorosa, Valerianna K. TI Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century SO CLINICS IN LIVER DISEASE LA English DT Review ID CHRONIC HEPATITIS-C; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; STAGE LIVER-DISEASE; ALPHA-2A PLUS RIBAVIRIN; RANDOMIZED CONTROLLED-TRIAL; EARLY VIROLOGICAL RESPONSE; INTERFERON-BASED THERAPY; WEIGHT-BASED RIBAVIRIN AB Because of shared routes of transmission, hepatitis C virus (HCV) coinfection is common among HIV-infected persons. Because of the effectiveness of antiretroviral therapy, chronic HCV has now emerged as a major cause of morbidity and mortality in this population. Because chronic HCV is highly prevalent among HIV-infected patients and has a rapid disease progression, antiviral therapy with pegylated interferon plus ribavirin is critical for the long-term survival of HIV/HCV-coinfected patients. In this article, the authors review the (1) epidemiology of HCV among HIV-infected individuals, (2) effect of HIV on the natural history of chronic HCV, (3) impact of antiretroviral therapy on HCV coinfection, and (4) management of chronic HCV in the HIV-infected person. C1 [Lo Re, Vincent, III; Kostman, Jay R.; Amorosa, Valerianna K.] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Amorosa, Valerianna K.] Philadelphia Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA 19104 USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Div Infect Dis, Dept Med, 502 Robert Wood Johnson Pavil, Philadelphia, PA 19104 USA. EM vincent.lore@uphs.upenn.edu RI Lo Re, Vincent/N-7817-2015 FU NIAID NIH HHS [K01 AI070001, K01 AI 070001-01A1, K01 AI070001-01A1] NR 146 TC 19 Z9 19 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD AUG PY 2008 VL 12 IS 3 BP 587 EP + DI 10.1016/j.cld.2008.03.009 PG 24 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 437LE UT WOS:000265488200007 PM 18625430 ER PT J AU Jones, NP Siegle, GJ Thase, ME AF Jones, Neil P. Siegle, Greg J. Thase, Michael E. TI Effects of rumination and initial severity on remission to Cognitive Therapy for depression SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE Cognitive Therapy; rumination; response styles theory; depression ID MAJOR DEPRESSION; RESPONSE STYLES; BEHAVIOR THERAPY; EMOTIONAL INFORMATION; PROBING INTERACTIONS; SLEEP PROFILES; MOOD; SYMPTOMS; RECOVERY; SCALE AB Trait rumination, a tendency to focus on depressive symptoms and negative information, is associated with longer and more severe episodes of depression. This study examined whether trait rumination was also associated with initial remission from unipolar depression in Cognitive Therapy, which we hypothesized would target this coping style. Eighty one patients completed measures of depressive severity and rumination before and after 16-20 sessions of procedurally determined Cognitive Therapy. Pre-treatment rumination and severity were generally associated with later initial remission and lower odds of achieving remission. Limited evidence also suggested that for the most severe patients, rumination was associated with earlier initial remission and greater odds of achieving initial remission. Cognitive Therapy was associated with significant reductions in both rumination and severity. Results suggest that (1) pre-treatment assessment of rumination and severity could help to plan treatment course and (2) Cognitive Therapy is associated with changes in cognitive coping styles. C1 [Jones, Neil P.; Siegle, Greg J.; Thase, Michael E.] Univ Pittsburgh, Ctr Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Thase, Michael E.] Univ Penn, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Jones, NP (reprint author), Univ Pittsburgh, Ctr Med, Western Psychiat Inst & Clin, 3811 OHara Street, Pittsburgh, PA 15213 USA. EM jonesnp@upmc.edu NR 59 TC 24 Z9 24 U1 0 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD AUG PY 2008 VL 32 IS 4 BP 591 EP 604 DI 10.1007/s10608-008-9191-0 PG 14 WC Psychology, Clinical SC Psychology GA 339LG UT WOS:000258578500010 ER PT J AU Zier, LS Burack, JH Micco, G Chipman, AK Frank, JA Luce, JM White, DB AF Zier, Lucas S. Burack, Jeffrey H. Micco, Guy Chipman, Anne K. Frank, James A. Luce, John M. White, Douglas B. TI Doubt and belief in physicians' ability to prognosticate during critical illness: The perspective of surrogate decision makers SO CRITICAL CARE MEDICINE LA English DT Article DE prognosis; proxy; decision-making; intensive care unit; critical care ID OF-LIFE CARE; INTENSIVE-CARE; PROACTIVE APPROACH; CONTROLLED-TRIAL; FAMILY-MEMBERS; UNITED-STATES; ILL PATIENTS; END; SUPPORT; DEATH AB Objectives: Although discussing a prognosis is a duty of physicians caring for critically ill patients, little is known about surrogate decision-makers' beliefs about physicians' ability to prognosticate. We sought to determine: 1) surrogates' beliefs about whether physicians can accurately prognosticate for critically ill patients; and 2) how individuals use prognostic information in their role as surrogate decision-makers. Design, Setting, and Patients. Multicenter study in intensive care units of a public hospital, a tertiary care hospital, and a veterans' hospital. We conducted semistructured interviews with 50 surrogate decision-makers of critically ill patients. We analyzed the interview transcripts using grounded theory methods to inductively develop a framework to describe surrogates' beliefs about physicians' ability to prognosticate. Validation methods included triangulation by multidisciplinary analysis and member checking. Measurements and Main Results. Overall, 88% (44 of 50) of surrogates expressed doubt about physicians' ability to prognosticate for critically ill patients. Four distinct themes emerged that explained surrogates' doubts about prognostic accuracy: a belief that God could alter the course of the illness, a belief that predicting the future is inherently uncertain, prior experiences where physicians' prognostications were inaccurate, and experiences with prognostication during the patient's intensive care unit stay. Participants also identified several factors that led to belief in physicians' prognostications, such as receiving similar prognostic estimates from multiple physicians and prior experiences with accurate prognostication. Surrogates' doubts about prognostic accuracy did not prevent them from wanting prognostic information. Instead, most surrogate decision-makers view physicians' prognostications as rough estimates that are valuable in informing decisions, but are not determinative. Surrogates identified the act of prognostic disclosure as a key step in preparing emotionally and practically for the possibility that a patient may not survive. Conclusions. Although many surrogate decision-makers harbor some doubt about the accuracy of physicians' prognostications, they highly value discussions about prognosis and use the information for multiple purposes. C1 [Zier, Lucas S.; Burack, Jeffrey H.; Micco, Guy; Chipman, Anne K.] Univ Calif Berkeley, Sch Publ Hlth, UC Berkeley UC San Francisco Joint Med Program, Berkeley, CA 94720 USA. [Burack, Jeffrey H.] Alta Bates Summit Med Ctr, E Bay AIDS Res Inst, Oakland, CA USA. [Burack, Jeffrey H.; Micco, Guy] Univ Calif Berkeley, Sch Publ Hlth, Div Community Hlth & Human Dev, Berkeley, CA 94720 USA. [Luce, John M.] San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA. [Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Frank, James A.; Luce, John M.; White, Douglas B.] Univ Calif San Francisco, San Francisco Sch Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [White, Douglas B.] Univ Calif San Francisco, Dept Med, Program Med Eth, San Francisco, CA 94143 USA. RP Zier, LS (reprint author), Univ Calif Berkeley, Sch Publ Hlth, UC Berkeley UC San Francisco Joint Med Program, Berkeley, CA 94720 USA. EM dwhite@medicine.ucsf.edu FU NCRR NIH HHS [KL2 RR024130]; NHLBI NIH HHS [R56 HL088440]; NIA NIH HHS [K23 AG032875, K23 AG032875-01] NR 34 TC 47 Z9 47 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD AUG PY 2008 VL 36 IS 8 BP 2341 EP 2347 DI 10.1097/CCM.0b013e318180ddf9 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 335DN UT WOS:000258271100018 PM 18596630 ER PT J AU Ho, PM Maddox, TM Ross, C Rumsfeld, JS Magid, DJ AF Ho, P. Michael Maddox, Thomas M. Ross, Colleen Rumsfeld, John S. Magid, David J. TI Impaired chronotropic response to exercise stress testing in patients with diabetes predicts future cardiovascular events SO DIABETES CARE LA English DT Article ID PROGNOSTIC VALUE; MORTALITY; TREADMILL AB OBJECTIVES - To assess the association between impaired chronotropic response (CR) and adverse events among patients With diabetes referred for exercise treadmill testing (ETT). RESEARCH DESIGN AND METHODS - impaired CR was defined as achievement of <80% of a patient's heart rate reserve. We used multivariable Cox proportional hazards regression to assess the independent association between impaired CR and adverse outcomes adjusting for demographics, comorbidities, and treadmill variables including the Duke Treadmill score. RESULTS - Of 1,341 patients with diabetes, 35.7% (n = 479) demonstrated impaired CR during ETT. Patients with impaired CR were at increased risk of all-cause mortality, myocardial infarction, or coronary revascularization procedures. In multivariable analyses, impaired CR remained significantly associated with adverse outcomes (hazard ratio 1.53 [95% CI 1.10-2.14]). CONCLUSIONS - Among Patients with diabetes, impaired CR is common during ETT and is associated with adverse outcomes. Impaired CR can be used as another noninvasive tool to risk-stratify patients with diabetes following ETT. C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.; Magid, David J.] Univ Colorado, Denver, CO 80202 USA. [Ho, P. Michael; Maddox, Thomas M.; Ross, Colleen; Rumsfeld, John S.; Magid, David J.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. RP Ho, PM (reprint author), Denver VA Med Ctr, Denver, CO USA. EM michael.ho@uchsc.edu FU CV Therapeutics, Inc; VA Research & Development Career Development FX This study was Funded in part by CV Therapeutics, Inc. The sponsors were not directly involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation of the manuscript. P.M.H. is supported by a VA Research & Development Career Development Award. NR 7 TC 8 Z9 8 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD AUG PY 2008 VL 31 IS 8 BP 1531 EP 1533 DI 10.2337/dc08-0616 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 338CH UT WOS:000258482000012 PM 18477812 ER PT J AU Chou, HS Palmer, JP Jones, AR Waterhouse, B Ferreira-Cornwell, C Krebs, J Goldstein, BJ AF Chou, H. S. Palmer, J. P. Jones, A. R. Waterhouse, B. Ferreira-Cornwell, C. Krebs, J. Goldstein, B. J. TI Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes SO DIABETES OBESITY & METABOLISM LA English DT Article DE combination drug therapy; glimepiride; glycaemic control; rosiglitazone; sulphonylurea; type 2 diabetes mellitus ID DOUBLE-BLIND; GLYCEMIC CONTROL; CARDIOVASCULAR-DISEASE; ANTIDIABETIC THERAPY; CONSENSUS STATEMENT; METABOLIC SYNDROME; MELLITUS; PIOGLITAZONE; GLIMEPIRIDE; MANAGEMENT AB Aim: This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM). Methods: Drug-naive subjects (n = 901) were enrolled into this 28-week, double-blind, parallel-group study if their glycosylated haemoglobin A(1c) (HbA(1c)) was > 7.5% but <= 12%. Subjects were randomized to receive either GLIM [4 mg once daily (OD) maximal], RSG (8 mg OD maximal) or RSG/GLIM FDC regimen A (4 mg/4 mg OD maximal) or RSG/GLIM FDC regimen B (8 mg/4 mg OD maximal). Patients were assessed for efficacy and safety every 4 weeks for the first 12 weeks of the study, and at weeks 20 and 28. The primary efficacy endpoint was change in HbA(1c) from baseline. Key secondary endpoints included the proportion of patients achieving recommended HbA(1c) and fasting plasma glucose (FPG) targets; change from baseline in FPG, insulin, C-reactive protein (CRP), adiponectin, free fatty acids and lipids; and percentage change in homeostasis model assessment-estimated insulin sensitivity and beta-cell function. Safety evaluations included adverse-event (AE) monitoring and clinical laboratory evaluations. Results: At week 28, both RSG/GLIM FDC regimens significantly reduced HbA(1c) (mean +/- s.d.: -2.4 +/- 1.4% FDC regimen A; -2.5 +/- 1.4% FDC regimen B) to a greater extent than RSG (-1.8 +/- 1.5%) or GLIM (-1.7 +/- 1.4%) monotherapy (model-adjusted mean treatment difference, p < 0.0001 vs. both RSG and GLIM). Significantly more subjects achieved HbA(1c) target levels of <= 6.5 and < 7% with either RSG/GLIM FDC regimen compared with RSG or GLIM alone (model-adjusted odds ratio, p < 0.0001 for both comparisons). Similarly, a significantly greater reduction in FPG levels was observed in subjects treated with the RSG/GLIM FDC [mean +/- s.d. (mg/dl): -69.5 +/- 57.5 FDC regimen A; -79.9 +/- 56.8 FDC regimen B) compared with RSG (-56.6 +/- 58.1) or GLIM (-42.2 +/- 66.1) monotherapy (model-adjusted mean treatment difference, p < 0.0001 for both comparisons). Improvement in CRP was also observed in subjects who were treated with a RSG/GLIM FDC or RSG monotherapy compared with GLIM monotherapy. RSG/GLIM FDC was generally well tolerated, with no new safety or tolerability issues identified from its monotherapy components, and a similar AE profile was observed across FDC regimens. The most commonly reported AE was hypoglycaemia, and the incidence of confirmed symptomatic hypoglycaemia (3.6-5.5%) was comparable among subjects treated with an RSG/GLIM FDC and GLIM monotherapy. Conclusions: Compared with RSG or GLIM monotherapy, the RSG/GLIM FDC improved glycaemic control with no significant increased risk of hypoglycaemia. RSG/GLIM FDC provides an effective and well-tolerated treatment option for drug-naive individuals with T2DM. C1 [Goldstein, B. J.] Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA. [Chou, H. S.; Jones, A. R.; Waterhouse, B.; Ferreira-Cornwell, C.; Krebs, J.] GlaxoSmithKline Inc, Cardiovasc & Metab Med Dev Ctr, King Of Prussia, PA USA. [Palmer, J. P.] VA Puget Sound Health Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Palmer, J. P.] Univ Washington, Seattle, WA 98195 USA. RP Goldstein, BJ (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, 1020 Locust St,Suite 349, Philadelphia, PA 19107 USA. EM barry.goldstein@jefferson.edu NR 43 TC 12 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1462-8902 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD AUG PY 2008 VL 10 IS 8 BP 626 EP 637 DI 10.1111/j.1463-1326.2007.00753.x PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 324JE UT WOS:000257514100003 PM 17645558 ER PT J AU Perez, M Hildreth, K Herbert, DC McMahan, CA Izumi, T Mitra, S Walter, CA AF Perez, M. Hildreth, K. Herbert, D. C. McMahan, C. A. Izumi, T. Mitra, S. Walter, C. A. TI Spontaneous mutagenesis frequencies correlate with APE1 abundance in murine spermatogenic cells SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract CT 39th Annual Meeting of the Environment-Mutagen-Society CY OCT 18-22, 2008 CL PR SP Environm Mutagen Soc C1 [Perez, M.; Hildreth, K.; Herbert, D. C.; McMahan, C. A.; Walter, C. A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Walter, C. A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Izumi, T.; Mitra, S.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD AUG PY 2008 VL 49 IS 7 BP 553 EP 553 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA 341PG UT WOS:000258725800144 ER PT J AU Tapp, A Wood, A Kilzieh, N Martin, L Kennedy, A Raskind, M AF Tapp, A. Wood, A. Kilzieh, N. Martin, L. Kennedy, A. Raskind, M. TI Incidence of tardive dyskinesia in patients receiving first or second generation antipsychotic therapy SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 21st Congress of the European-College-of-Neuropsychopharmacology CY AUG 30-SEP 03, 2008 CL Barcelona, SPAIN SP European Coll Neuropsychopharmacol C1 [Tapp, A.; Wood, A.; Kilzieh, N.; Martin, L.; Kennedy, A.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Raskind, M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 2 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD AUG PY 2008 VL 18 SU 4 BP S420 EP S420 DI 10.1016/S0924-977X(08)70613-8 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 353UK UT WOS:000259593801171 ER PT J AU Fan, Y Deng, P Wang, YC Lu, HC Xu, ZC Schulz, PE AF Fan, Yuan Deng, Ping Wang, Yu-Chi Lu, Hui-Chen Xu, Zao C. Schulz, Paul E. TI Transient cerebral ischemia increases CA1 pyramidal neuron excitability SO EXPERIMENTAL NEUROLOGY LA English DT Article ID IN-VIVO; HIPPOCAMPAL-NEURONS; FOREBRAIN ISCHEMIA; GLOBAL-ISCHEMIA; H-CHANNELS; GERBIL HIPPOCAMPUS; RAT HIPPOCAMPUS; INTRACEREBRAL MICRODIALYSIS; MEMBRANE-PROPERTIES; PROTEIN-KINASE AB In human and experimental animals, the hippocampal CA1 region is one of the most vulnerable areas of the brain to ischemia. Pyramidal neurons in this region die 2-3 days after transient cerebral ischemia whereas other neurons in the same region remain intact. The mechanisms underlying the selective and delayed neuronal death are unclear. We tested the hypothesis that there is an increase in post-synaptic intrinsic excitability of CA1 pyramidal neurons after ischemia that exacerbates glutamatergic excitotoxicity. We performed whole-cell patch-clamp recordings in brain slices obtained 24 h after in vivo transient cerebral ischemia. We found that the input resistance and membrane time constant of the CA1 pyramidal neurons were significantly increased after ischemia, indicating an increase in neuronal excitability. This increase was associated with a decrease in voltage sag, suggesting a reduction of the hyperpolarization-activated nonselective cationic current (I-h). Moreover, after blocking I-h with ZD7288, the input resistance of the control neurons increased to that of the post-ischemia neurons, suggesting that a decrease in I-h contributes to increased excitability after ischemia. Finally, when lamotrigine, an enhancer of dendritic I-h, was applied immediately after ischemia, there was a significant attenuation of CA1 cell loss. These data suggest that an increase in CA1 pyramidal neuron excitability after ischemia may exacerbate cell loss. Moreover, this dendritic channelopathy may be amenable to treatment. (C) 2008 Elsevier Inc. All rights reserved. C1 [Fan, Yuan; Schulz, Paul E.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Deng, Ping; Xu, Zao C.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Wang, Yu-Chi; Lu, Hui-Chen] Baylor Coll Med, Cain Fdn Labs, Dept Pediat, Houston, TX 77030 USA. [Schulz, Paul E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Fan, Y (reprint author), Baylor Coll Med, Dept Neurol, 6501 Fannin St,NB204, Houston, TX 77030 USA. EM yf139876@gmail.com FU NINDS NIH HHS [F32 NS011034] NR 52 TC 19 Z9 19 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD AUG PY 2008 VL 212 IS 2 BP 415 EP 421 DI 10.1016/j.expneurol.2008.04.032 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 334WL UT WOS:000258252000024 PM 18559277 ER PT J AU Borrero, SB Reeves, MF Schwarz, EB Bost, JE Creinin, MD Ibrahim, SA AF Borrero, Sonya B. Reeves, Matthew F. Schwarz, Eleanor B. Bost, James E. Creinin, Mitchell D. Ibrahim, Said A. TI Race insurance status, and desire for tubal sterilization reversal SO FERTILITY AND STERILITY LA English DT Article DE tubal sterilization; poststerilization regret; desire for reversal; race/ethnicity; insurance status ID FEMALE STERILIZATION; UNITED-STATES; REGRET AB Objective: To examine the independent effects of race/ethnicity and insurance status on desire for tubal sterilization reversal. Design: Secondary analysis of cross-sectional data collected by the 2002 National Survey of Family Growth (NSFG). Setting: Interviews were conducted in person by a trained female interviewer in the participant's home. Patient(s): The NSFG is designed to represent women and men 15-44 years of age in the U.S. household population. The sample consisted of 934 women who had undergone tubal sterilization at any time before being interviewed. Intervention(s): None. Main Outcome Measure(s): Desire for sterilization reversal. Result(s): Among women older than 30 years at time of surgery, black women were significantly more likely to desire sterilization reversal compared with white women (adjusted odds ratio, 2.6; 95% confidence interval, 1.2, 5.8). In the total cohort and in the subset of women 30 years or younger, there were no significant raciallethnic variations in desire for sterilization reversal. Conclusion(S): Among women over age 30 at the time of tubal sterilization, black women were much more likely to express desire for reversal than white women. C1 [Ibrahim, Said A.] VA Pittsburgh HealthCare Syst, Ctr Hlth Equ and Promot, Pittsburgh, PA 15240 USA. [Borrero, Sonya B.] VA Pittsburgh HealthCare Syst, Div Gen Internal Med, Pittsburgh, PA 15240 USA. [Reeves, Matthew F.; Schwarz, Eleanor B.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA. [Reeves, Matthew F.; Schwarz, Eleanor B.; Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA. [Schwarz, Eleanor B.] Ctr Res Hlth Care, Div Gen Internal Med, Providence, RI 02912 USA. [Bost, James E.] Univ Pittsburgh, Sch Med, Inst Clin Res Educ, Pittsburgh, PA 15260 USA. [Creinin, Mitchell D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Ibrahim, SA (reprint author), VA Pittsburgh HealthCare Syst, Ctr Hlth Equ Res and Promot 151C, Pittsburgh, PA 15240 USA. EM said.ibrahim2@med.va.gov RI Potter, Joseph/A-3122-2008 OI Reeves, Matthew/0000-0001-7749-7447; Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU NCATS NIH HHS [KL2 TR000146]; NCRR NIH HHS [KL2 RR024154, KL2 RR024154-02] NR 12 TC 11 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD AUG PY 2008 VL 90 IS 2 BP 272 EP 277 DI 10.1016/j.fertnstert.2007.06.041 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 338CW UT WOS:000258483800004 PM 17880952 ER PT J AU Lieberman, D Levin, B Mcfarland, B Brooks, D Smith, R AF Lieberman, David Levin, Bernard Mcfarland, Beth Brooks, Durado Smith, Robert TI Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps - Reply SO GASTROENTEROLOGY LA English DT Letter C1 [Lieberman, David; Levin, Bernard; Mcfarland, Beth; Brooks, Durado; Smith, Robert] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD AUG PY 2008 VL 135 IS 2 BP 710 EP 711 DI 10.1053/j.gastro.2008.07.001 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 337MJ UT WOS:000258439900046 ER PT J AU Mulligan, MK Ponomarev, I Boehm, SL Owen, JA Levin, PS Berman, AE Blednov, YA Crabbe, JC Williams, RW Miles, MF Bergeson, SE AF Mulligan, M. K. Ponomarev, I. Boehm, S. L., II Owen, J. A. Levin, P. S. Berman, A. E. Blednov, Y. A. Crabbe, J. C. Williams, R. W. Miles, M. F. Bergeson, S. E. TI Alcohol trait and transcriptional genomic analysis of C57BL/6 substrains SO GENES BRAIN AND BEHAVIOR LA English DT Article DE alcohol; B6; brain; C57BL/6J; C57BL/6NCrl; consumption; expression; microarray; preference; substrain ID ACUTE FUNCTIONAL TOLERANCE; SEROTONIN TRANSPORTER; GENE-EXPRESSION; MICROARRAY DATA; INBRED STRAINS; MOUSE STRAINS; MICE; ETHANOL; DRINKING; PREFERENCE AB C57BL/6 inbred mice have been widely used as research models; however, widespread demand has led to the creation of several B6 substrains with markedly different phenotypes. In this study, we report that two substrains of C57BL/6 mice, C57BL/6J (B6J) and C57BL/6NCrl (B6C), separated over 50 years ago at two different breeding facilities differ significantly in alcohol consumption and alcohol preference. The genomes of these two substrains are estimated to differ by only 1-2% of all gene loci, providing a unique opportunity to extract particular expression signatures between these substrains that are associated with quantifiable behavioral differences. Expression profiling of the cortex and striatum, hippocampus, cerebellum and the ventral brain region from alcohol-naive B6C and B6J mice showed intervals on three chromosomes that are enriched in clusters of coregulated transcripts significantly divergent between the substrains. Additional analysis identified two genomic regions containing putative copy number differences between the substrains. One such region on chromosome 14 contained an estimated 3n copy number in the B6J genome compared with B6C. Within this interval, a gene of unknown function, D14Ertd449e, was found to be both associated with alcohol preference and vary in copy number across several inbred strain lineages. H2afz, Psen1, Wdfy1 and Clu were also identified as candidate genes that may be involved in influencing alcohol consumption. C1 [Bergeson, S. E.] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, S Plains Alcohol & Addict Res Ctr, Lubbock, TX 79430 USA. [Mulligan, M. K.; Ponomarev, I.; Levin, P. S.; Blednov, Y. A.] Univ Texas Austin, Waggoner Ctr Alcohol & Addict Res, Austin, TX USA. [Boehm, S. L., II] SUNY Binghamton, Dept Psychol, Behav Neurosci Program, Binghamton, NY USA. [Berman, A. E.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Berman, A. E.] Vet Affairs Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Crabbe, J. C.] Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA. [Crabbe, J. C.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Williams, R. W.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA. [Miles, M. F.] Virginia Commonwealth Univ, Dept Pharmacol, Ctr Study Biol Complex, Richmond, VA USA. [Miles, M. F.] Virginia Commonwealth Univ, Dept Toxicol, Ctr Study Biol Complex, Richmond, VA USA. [Miles, M. F.] Virginia Commonwealth Univ, Dept Neurol, Ctr Study Biol Complex, Richmond, VA USA. RP Bergeson, SE (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, S Plains Alcohol & Addict Res Ctr, 3601 4th St,STOP 6592, Lubbock, TX 79430 USA. EM susan.bergeson@ttuhsc.edu OI Williams, Robert/0000-0001-8924-4447 FU NCI NIH HHS [U01CA105417]; NCRR NIH HHS [U24RR021760]; NIAAA NIH HHS [K01 AA013403, K01AA013403, P60AA10760, R01AA0014717, U01 AA013475, U01AA013475, U01AA013520, U01AA01662, U01AA13499, U01AA13519, U24AA13513]; NIDA NIH HHS [P20-DA21131] NR 42 TC 33 Z9 33 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1601-1848 EI 1601-183X J9 GENES BRAIN BEHAV JI Genes Brain Behav. PD AUG PY 2008 VL 7 IS 6 BP 677 EP 689 DI 10.1111/j.1601-183X.2008.00405.x PG 13 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 334GF UT WOS:000258209600008 PM 18397380 ER PT J AU Sung, JJY Lau, JYW Young, GP Sano, Y Chiu, HM Byeon, JS Yeoh, KG Goh, KL Sollano, J Rerknimitr, R Matsuda, T Wu, KC Ng, S Leung, SY Makharia, G Chong, VH Ho, KY Brooks, D Lieberman, DA Chan, FKL AF Sung, J. J. Y. Lau, J. Y. W. Young, G. P. Sano, Y. Chiu, H. M. Byeon, J. S. Yeoh, K. G. Goh, K. L. Sollano, J. Rerknimitr, R. Matsuda, T. Wu, K. C. Ng, S. Leung, S. Y. Makharia, G. Chong, V. H. Ho, K. Y. Brooks, D. Lieberman, D. A. Chan, F. K. L. CA Asia Pacific Working Grp Colorecta TI Asia Pacific consensus recommendations for colorectal cancer screening SO GUT LA English DT Review ID FECAL OCCULT-BLOOD; COMPUTED TOMOGRAPHIC COLONOGRAPHY; MULTICENTER COLONOSCOPY SURVEY; CONTRAST BARIUM ENEMA; FLEXIBLE SIGMOIDOSCOPY; COLON-CANCER; VIRTUAL COLONOSCOPY; ASYMPTOMATIC ADULTS; CHINESE POPULATION; CT COLONOGRAPHY AB Colorectal cancer (CRC) is rapidly increasing in Asia, but screening guidelines are lacking. Through reviewing the literature and regional data, and using the modified Delphi process, the Asia Pacific Working Group on Colorectal Cancer and international experts launch consensus recommendations aiming to improve the awareness of healthcare providers of the changing epidemiology and screening tests available. The incidence, anatomical distribution and mortality of CRC among Asian populations are not different compared with Western countries. There is a trend of proximal migration of colonic polyps. Flat or depressed lesions are not uncommon. Screening for CRC should be started at the age of 50 years. Male gender, smoking, obesity and family history are risk factors for colorectal neoplasia. Faecal occult blood test (FOBT, guaiac-based and immunochemical tests), flexible sigmoidoscopy and colonoscopy are recommended for CRC screening. Double-contrast barium enema and CT colonography are not preferred. In resource-limited countries, FOBT is the first choice for CRC screening. Polyps 5-9 mm in diameter should be removed endoscopically and, following a negative colonoscopy, a repeat examination should be performed in 10 years. Screening for CRC should be a national health priority in most Asian countries. Studies on barriers to CRC screening, education for the public and engagement of primary care physicians should be undertaken. There is no consensus on whether nurses should be trained to perform endoscopic procedures for screening of colorectal neoplasia. C1 [Sung, J. J. Y.; Lau, J. Y. W.; Ng, S.; Chan, F. K. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China. [Young, G. P.] Flinders Univ S Australia, Sch Med, Dept Med, Adelaide, SA, Australia. [Sano, Y.] Sano Hosp, Tarumi Ku, Kobe, Hyogo, Japan. [Chiu, H. M.] Natl Taiwan Univ Hosp, Hlth Management Ctr, Dept Internal Med, Taipei, Taiwan. [Byeon, J. S.] Asan Med Ctr, Dept Internal Med, Div Gastroenterol, Seoul, South Korea. [Yeoh, K. G.] Natl Univ Singapore, Clin Res Ctr, Singapore 117548, Singapore. [Goh, K. L.] Univ Malaya, Dept Med, Div Gastroenterol, Kuala Lumpur, Malaysia. [Sollano, J.] Univ Santo Tomas, Dept Med, Manila, Philippines. [Rerknimitr, R.] Chulalongkorn Univ, Fac Med, Dept Internal Med, Gastroenterol Unit, Bangkok 10330, Thailand. [Matsuda, T.] Natl Canc Ctr, Div Endoscopy, Chuo Ku, Tokyo, Japan. [Wu, K. C.] Xijing Hosp, Dept Gastroenterol, Xian, Shaanxi, Peoples R China. [Leung, S. Y.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China. [Makharia, G.] All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, India. [Chong, V. H.] Raja Isteri Pengiran Anak Saleha Hosp, Dept Med, Gastroenterol Unit, Bandar Seri Begawan, Brunei. [Ho, K. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore. [Brooks, D.] Amer Canc Soc, Dallas, TX USA. [Chan, F. K. L.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. RP Sung, JJY (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China. EM joesung@cuhk.edu.hk RI Goh, Khean-Lee/B-6404-2009; Hossain, Sarah /C-7332-2009; Chan, Francis K. L./F-4851-2010; Leung, Suet Yi/C-4340-2009 OI Hossain, Sarah /0000-0003-1355-0979; Chan, Francis K. L./0000-0001-7388-2436; CHIU, HAN-MO/0000-0003-2786-8056 NR 125 TC 199 Z9 219 U1 2 U2 30 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD AUG PY 2008 VL 57 IS 8 BP 1166 EP 1176 DI 10.1136/gut.2007.146316 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 326GI UT WOS:000257646200026 PM 18628378 ER PT J AU Muder, RR Cunningham, C McCray, E Squier, C Perreiah, P Jain, R Sinkowitz-Cochran, RL Jernigan, JA AF Muder, Robert R. Cunningham, Candace McCray, Ellesha Squier, Cheryl Perreiah, Peter Jain, Rajiv Sinkowitz-Cochran, Ronda L. Jernigan, John A. TI Implementation of an industrial systems-engineering approach to reduce the incidence of methicillin-resistant Staphylococcus aureus infection SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID SURGICAL SITE INFECTION; BACTEREMIA; EPIDEMIOLOGY; GUIDELINE; MORTALITY; PRECAUTIONS; PREVENTION; HOSPITALS; OUTCOMES AB OBJECTIVE. To measure the effectiveness of an industrial systems-engineering approach to a methicillin-resistant Staphylococcus aureus (MRSA) prevention program. DESIGN. Before-after intervention study SETTING. An intensive care unit (ICU) and a surgical unit that was not an ICU in the Pittsburgh Veterans Administration hospital PATIENTS. All patients admitted to the study units INTERVENTION. We implemented an MRSA infection control program that consisted of the following 4 elements: ( 1) the use of standard precautions for all patient contact, with emphasis on hand hygiene; ( 2) the use of contact precautions for interactions with patients known to be infected or colonized with MRSA; ( 3) the use of active surveillance cultures to identify patients who were asymptomatically colonized with MRSA; and ( 4) use of an industrial systems-engineering approach, the Toyota Production System, to facilitate consistent and reliable adherence to the infection control program. RESULTS. The rate of healthcare-associated MRSA infection in the surgical unit decreased from 1.56 infections per 1,000 patient-days in the 2 years before the intervention to 0.63 infections per 1,000 patient-days in the 4 years after the intervention (a 60% reduction; P = . 003). The rate of healthcare-associated MRSA infection in the ICU decreased from 5.45 infections per 1,000 patient-days in the 2 years before to the intervention to 1.35 infections per 1,000 patient-days in the 3 years after the intervention (a 75% reduction; P = .001). The combined estimate for reduction in the incidence of infection after the intervention in the 2 units was 68% (95% confidence interval, 50%-79%; P < .001). CONCLUSIONS. Sustained reduction in the incidence of MRSA infection is possible in a setting where this pathogen is endemic. An industrial systems-engineering approach can be adapted to facilitate consistent and reliable adherence to MRSA infection prevention practices in healthcare facilities. C1 [Muder, Robert R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Muder, Robert R.; Jain, Rajiv] Univ Pittsburgh, Sch Med, Pittsburgh Reg Healthcare Initiat, Pittsburgh, PA USA. [Perreiah, Peter] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Sinkowitz-Cochran, Ronda L.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM Robert.Muder@va.gov NR 31 TC 39 Z9 39 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2008 VL 29 IS 8 BP 702 EP U38 DI 10.1086/589981 PG 14 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 335XH UT WOS:000258326800004 PM 18624651 ER PT J AU Gowen, BB Judge, JW Wong, MH Jung, KH Aylsworth, CF Melby, PC Rosenberg, B Morrey, JD AF Gowen, Brian B. Judge, John W. Wong, Min-Hui Jung, Kie-Hoon Aylsworth, Charles F. Melby, Peter C. Rosenberg, Barnett Morrey, John D. TI Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen SO INTERNATIONAL IMMUNOPHARMACOLOGY LA English DT Article DE Punta Toro virus; Phlebovirus; antiviral; immune modulator; profilin ID GAMMA PRODUCTION; DENDRITIC CELLS; T-CELLS; IN-VIVO; PROTEIN; MICE; INVOLVEMENT; DISEASE; IL-2 AB Recombinant Eimeria antigen (rEA) has been shown to have potent anticancer and antiviral activity in respective mouse disease models, presumably through robust immune stimulation that occurs via TLR11, a pattern recognition receptor that recognizes profilin-like proteins expressed on apicomplexan protozoans. Comparable immunostimulatory activity in other species has yet to be demonstrated. Since rEA is known to be highly effective in treating Punta Toro virus (PTV) infection in mice, its ability to elicit protective immunity in the hamster PTV infection model was investigated. rEA was given atone, or in combination with IL-18 or IL-2, and virally challenged hamsters were observed for mortality. Cytokine transcript profiles for IL-12p40, IL-21, IFN-gamma and TNF-alpha were assessed to evaluate the induction of these inflammatory mediators known to be induced in mice following exposure to rEA. A dose of 100 mu g of rEA, given once 4 h prior to viral challenge, and a second time on day 3 of the infection, was found to be the most effective prophylactic therapy protecting 60% of treated hamsters from mortality, compared to only 5-10% observed in animals receiving placebo. Increased expression of IFN-gamma and IL-12p40 was evident following treatment with rEA. The data suggest that rEA does induce host antiviral responses in hamsters that result in significant protection from death, although determining the most appropriate dose for intervention in other species, including humans, will likely be challenging. (C) 2008 Elsevier B.V. All rights reserved. C1 [Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA. [Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA. [Judge, John W.; Aylsworth, Charles F.] Barros Res Inst, Holt, MI USA. [Aylsworth, Charles F.] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA. [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Gowen, BB (reprint author), Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA. EM bgowen@cc.usu.edu FU NIAID NIH HHS [N01 AI015435, N01AI15435, N01-AI-15435] NR 18 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-5769 J9 INT IMMUNOPHARMACOL JI Int. Immunopharmacol. PD AUG PY 2008 VL 8 IS 8 BP 1089 EP 1094 DI 10.1016/j.intimp.2008.03.019 PG 6 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA 325GM UT WOS:000257577000004 PM 18550012 ER PT J AU Royall, DR Palmer, RF Chiodo, LK Polk, MJ Markides, KS Hazuda, H AF Royall, Donald R. Palmer, Raymond F. Chiodo, Laura K. Polk, Marsha J. Markides, Kyriakos S. Hazuda, Helen TI Clock-drawing potentially mediates the effect of depression on mortality: replication in three cohorts SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 20th Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 01-04, 2007 CL New Orleans, LA SP Amer Assoc Geriat Psychiat DE cognition; old age; longitudinal; survival analysis ID COGNITIVE IMPAIRMENT; EXECUTIVE CONTROL; ELDERLY RETIREES; FREEDOM HOUSE; SYMPTOMS; ASSOCIATION; ARRHYTHMIAS; PREDICTOR; COMMUNITY; DISEASE AB Objective Previously studies have associated visuospatial tasks, particularly 'clock-drawing', with mortality. We sought to determine whether clock-drawing also mediates the association between depressive symptoms and mortality. Participants Non-institutionalized Hispanic and non-Hispanic White elderly volunteers. Measurements Survival curves were generated as a function of baseline depressive symptom ratings. Significant models were adjusted for CLOX performance. CLOX is divided into CLOX 1, a measure of executive control, and CLOX2, a measure of visuospatial skills. Design Retrospective analysis of three longitudinal cohorts. Results CLOX2 and depressive symptoms were both associated with mortality in unadjusted models. CLOX2 predicted survival independently of CLOX1 in all three cohorts. CLOX2 also attenuated, and/or mediated the association between depressive symptoms and mortality. These results withstood adjustment for age and education in all three cohorts. Conclusion Regardless of the sample examined, or the measure of depressive symptoms applied, the association between depressive symptoms and mortality appears to be at least partially mediated by visuospatial skills. This finding supports our hypothesis that right hemisphere structural brain disease, particularly that involving the insula, may mediate depression's effects on mortality. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Royall, Donald R.; Polk, Marsha J.] S Texas Vet Hlth Syst Audie L Murphy Div GRECC, Dept Psychiat, San Antonio, TX USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Royall, Donald R.; Chiodo, Laura K.; Hazuda, Helen] S Texas Vet Hlth Syst Audie L Murphy Div GRECC, Dept Med, San Antonio, TX USA. [Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Markides, Kyriakos S.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77550 USA. RP Royall, DR (reprint author), S Texas Vet Hlth Syst Audie L Murphy Div GRECC, Dept Psychiat, San Antonio, TX USA. EM royall@uthscsa.edu FU NIA NIH HHS [5 R01 AG 010939-12, 5 R01 AG 16518, R01 AG010939, R01 AG016518]; NINDS NIH HHS [NS 45121-01A1, R21 NS045121] NR 35 TC 5 Z9 6 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD AUG PY 2008 VL 23 IS 8 BP 821 EP 829 DI 10.1002/gps.1990 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 337IC UT WOS:000258427800008 PM 18302318 ER PT J AU Rao, SV Ou, FS Wang, TY Roe, MT Brindis, R Rumsfeld, JS Peterson, ED AF Rao, Sunil V. Ou, Fang-Shu Wang, Tracy Y. Roe, Matthew T. Brindis, Ralph Rumsfeld, John S. Peterson, Eric D. TI Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention A Report From the National Cardiovascular Data Registry SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE percutaneous coronary intervention; radial artery; outcomes AB Objectives Our goal was to compare trends in the prevalence and outcomes of the radial and femoral approaches to percutaneous coronary intervention (PCI) in contemporary clinical practice. Background There are few current data on the use and outcomes of the radial approach to PCI (r-PCI) in clinical practice. Methods Data from 593,094 procedures in the National Cardiovascular Data Registry (606 sites; 2004 to 2007) were analyzed to evaluate trends in use and outcomes of r-PCI. Logistic regression was used to evaluate the adjusted association between r-PCI and procedural success, bleeding complications, and vascular complications. Outcomes in elderly patients, women, and patients with acute coronary syndrome were specifically examined. Results Although the proportion of r-PCI procedures has recently increased, it only accounts for 1.32% of total procedures (n = 7,804). Compared with the femoral approach, the use of r-PCI was associated with a similar rate of procedural success (adjusted odds ratio: 1.02 [95% confidence interval: 0.93 to 1.12]) but a significantly lower risk for bleeding complications (odds ratio: 0.42 [95% confidence interval: 0.31 to 0.56]) after multivariable adjustment. The reduction in bleeding complications was more pronounced among patients <75 years old, women, and patients undergoing PCI for acute coronary syndrome. Conclusions The use of r-PCI is rare in contemporary clinical practice, but it is associated with a rate of procedural success similar to the femoral approach and with lower rates of bleeding and vascular complications, even among high-risk groups. These results suggest that wider adoption of r-PCI in clinical practice may improve the safety of PCI. (J Am Coll Cardiol Intv 2008;1:379-86) 2008 by the American College of Cardiology Foundation C1 [Rao, Sunil V.; Ou, Fang-Shu; Wang, Tracy Y.; Roe, Matthew T.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. [Brindis, Ralph] Oakland Kaiser Hosp, Div Cardiol, Oakland, CA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Rao, SV (reprint author), Durham VA Med Ctr, 508 Fulton St 111A,Durham, Durham, NC 27705 USA. EM sunil.rao@duke.edu FU National Cardiovascular Data Registry FX This analysis was funded by the National Cardiovascular Data Registry. NR 19 TC 298 Z9 313 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD AUG PY 2008 VL 1 IS 4 BP 379 EP 386 DI 10.1016/j.jcin.2008.05.007 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V12FX UT WOS:000207586200006 PM 19463333 ER PT J AU Janckila, AJ Neustadt, DH Yam, LT AF Janckila, Anthony J. Neustadt, David H. Yam, Lung T. TI Significance of serum TRACP in rheumatoid arthritis SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE rheumatoid arthritis; TRACP; inflammation; macrophage; bone resorption; osteoclast ID RESISTANT ACID-PHOSPHATASE; MONOCLONAL-ANTIBODIES; BONE METABOLISM; CANCER-PATIENTS; ISOFORM 5A; I COLLAGEN; 5B; MARKERS; EXPRESSION; CARTILAGE AB Human serum contains two related isoforms of TRACP: TRACP 5a and TRACP 5b. Serum TRACP 5a protein is increased in about one third of rheumatoid arthritis (RA) sera. This study was undertaken to examine the significance of serum TRACP isoforms 5a and 5b as disease markers of inflammation and bone destruction in RA. One hundred eighteen patients were recruited including 50 with RA (25 with nodules), 26 with osteoarthritis (OA), and 42 with other rheumatic diseases. Twenty-six healthy adults served as controls. Serum TRACP 5a activity, TRACP 5a protein, and TRACP 5b activity were determined by in-house immunoassays. Greactive protein (CRP) was determined by in-house immunoassay using commercial antibodies and CRP. Other commercial markers included bone-specific alkaline phosphatase (BALP), C-telopeptides of type-1 collagen (ICTP), cartilage glycoprotein-39 (YKL-40), and IgM rheumatoid factors (IgM-RF). Mean TRACP 5a protein was significantly elevated only in RA compared with healthy controls and other disease groups. TRACP 5a protein correlated significantly only with lgM-RF in RA. Among RA patients, mean TRACP 5a protein and IgM RF were significantly higher in nodule formers. In contrast, TRACP 5b activity was slightly elevated in RA and correlated with BALP, ICTP, and YKL-40 but not with lgM-RF or CRP. Mean TRACP 5b activity was no different in RA patients with or without nodules. TRACP isoforms could be useful disease markers in RA; TRACP 5a protein may be a measure of systemic inflammatory macrophage burden and disease severity. TRACP 5b activity is a marker for osteoclast number and perhaps local or systemic bone destruction. C1 [Janckila, Anthony J.; Yam, Lung T.] US Dept Vet Affairs, Med Ctr, Louisville, KY 40206 USA. [Janckila, Anthony J.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA. [Neustadt, David H.; Yam, Lung T.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. RP Janckila, AJ (reprint author), US Dept Vet Affairs, Med Ctr, 800 Zorn Ave, Louisville, KY 40206 USA. EM Anthony.Janckila@va.gov NR 39 TC 25 Z9 26 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD AUG PY 2008 VL 23 IS 8 BP 1287 EP 1295 DI 10.1359/JBMR.080329 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 330GH UT WOS:000257928200014 PM 18410226 ER PT J AU Ahmed, A Aboshady, I Munir, SM Gondi, S Brewer, A Gertz, SD Lai, DJ Shaik, NA Shankar, KJ Deswal, A Casscells, SW AF Ahmed, Amany Aboshady, Ibrahim Munir, Shahzeb M. Gondi, Sreedevi Brewer, Alan Gertz, S. David Lai, Dejian Shaik, Naushad A. Shankar, K. J. Deswal, Anita Casscells, S. Ward TI Decreasing body temperature predicts early rehospitalization in congestive heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE hypothermia; mortality; prognostic indicators; rehospitalization ID COLD PRESSOR TEST; EXERCISE PERFORMANCE; SEASONAL-VARIATION; ANGIOTENSIN-II; HYPOTHERMIA; MORTALITY; NOREPINEPHRINE; EXPRESSION; PROGNOSIS; STRESS AB Background: In congestive heart failure (CHF). a low body temperature at hospital admission predicts in-hospital mortality. We hypothesized that a postdischarge reduction in body temperature predicts early CHF rehospitalization and death. Methods: We reviewed the records of 198 patients discharged after CHF hospitalization. We categorized the patients as hypothermic or normothermic (cutoff point, 36.3 degrees C/97.4 degrees F) according to body temperature at discharge. We classified the 2 groups according to the direction of temperature change between discharge e and the first follow-up visit: normothermic/non-decreasing temperature (N+), normothermic/ decreasing temperature (N-), hypothermic/non-decreasing temperature (H+), and hypothermic/decreasing temperature (H-). Results: Ninety-three patients (47%) had decreasing temperatures, and 105 patients (53%) had non-decreasing temperatures. Kaplan-Meier analysis revealed a significant intergroup difference in survival (P=.01) and rehospitalization time (P =.005). On logistic regression, a decreasing temperature was significantly associated with rehospitalization within 180 days (odds ratio, 4.01; 95% confidence interval, 1.63-10.02; P =.003). On Cox regression, the hazard ratios for death were 3.19 (P =.07) 6.49 (P =.004), and 5.17 (P =.07), for the N-, H+, and H- groups, respectively, versus the N+ group. For rehospitalization time, the hazard ratios were 7.02 (P = .01), 4.24 (P = .08), and 13.43 (P = .005) for the N-, H+, and H- groups, respectively, versus the N+ group. Conclusion: Decreasing body temperatures can predict readmission. decreased time to rehospitalization, and (in combination with hypothermia) decreased survival. C1 [Ahmed, Amany; Aboshady, Ibrahim; Munir, Shahzeb M.; Gondi, Sreedevi; Brewer, Alan; Shankar, K. J.; Casscells, S. Ward] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA. [Ahmed, Amany; Aboshady, Ibrahim; Munir, Shahzeb M.; Gondi, Sreedevi; Shankar, K. J.; Casscells, S. Ward] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [Gertz, S. David] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel. [Lai, Dejian] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Shaik, Naushad A.] Emory Univ, Atlanta, GA 30322 USA. [Deswal, Anita] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Deswal, Anita] Baylor Coll Med, Houston, TX 77030 USA. RP Ahmed, A (reprint author), St Lukes Episcopal Hosp, Texas Heart Inst, 6770 Bertner Ave,MC 2-255, Houston, TX 77030 USA. RI Ahmed, Ali/A-2934-2008 OI Ahmed, Ali/0000-0002-6832-6424 NR 43 TC 9 Z9 9 U1 1 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2008 VL 14 IS 6 BP 489 EP 496 DI 10.1016/j.cardfail.2008.02.008 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 339FY UT WOS:000258564700008 PM 18672197 ER PT J AU Shalaby', A Atwood, C Selzer, F Marwan, R Goiesan, J Strollo, P AF Shalaby', Alaa Atwood, Charles Selzer, Faith Marwan, Refaat Goiesan, John Strollo, Patrick TI Periodic breathing during wakefulness in cardiae resynchronization therapy: Can it predict outcome? SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 12th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 21-24, 2008 CL Toronto, CANADA SP Heart Failure Soc Amer C1 [Shalaby', Alaa; Atwood, Charles; Marwan, Refaat] VA Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. [Selzer, Faith] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Shalaby', Alaa; Atwood, Charles; Marwan, Refaat; Goiesan, John; Strollo, Patrick] Univ Pittsburgh, Div Cardiol, Pittsburgh, PA USA. [Shalaby', Alaa; Atwood, Charles; Marwan, Refaat; Goiesan, John; Strollo, Patrick] Univ Pittsburgh, Div Pulmonol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2008 VL 14 IS 6 SU 1 MA 043 BP S15 EP S16 DI 10.1016/j.cardfail.2008.06.055 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 339GC UT WOS:000258565100044 ER PT J AU Cheung, RC Currie, S Shen, H Bini, EJ Ho, SB Anand, BS Hu, KQ Wright, TL Morgan, TR AF Cheung, Ramsey C. Currie, Sue Shen, Hui Bini, Edmund J. Ho, Samuel B. Anand, Bhupinderjit S. Hu, Ke-Qin Wright, Teresa L. Morgan, Timothy R. CA VA HCV-001 Study Grp TI Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE noninvasive tests; liver biopsy; performance characteristics; veterans; fibrosis indexes; hepatitis C ID CHRONIC VIRAL-HEPATITIS; STANDARD LABORATORY TESTS; SIMPLE NONINVASIVE INDEX; LIVER-BIOPSY; VIRUS-INFECTION; CIRRHOSIS; INTRAOBSERVER; AMINOTRANSFERASE; VARIABILITY; MARKERS AB Goals: To determine the validity of fibrosis indexes based on simple laboratory tests in daily practice. Background: Fibrosis indexes were developed in referral centers using high-quality data. Methods: We compared the performance characteristics of several such indexes with liver biopsies in a cohort of 490 diverse veterans with chronic hepatitis C from 24 centers. All laboratory tests including interpretation of the liver biopsy were done locally. The following indexes were calculated and correlated with a 5-point fibrosis stage (F0-F4) on liver biopsies: platelet counts (< 100 or < 150 x 10(9)/L), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), Pohl score, AST-to-platelet ratio index (APRI) and "Lok's model." Results: Our cohort was predominantly male with 24% blacks, and fibrosis stages of 0, 1, 2, 3, and 4 in 11%, 24%, 28%, 24%, and 13%, respectively. All indexes performed better in predicting advanced (F3-4) than significant (F2-4) fibrosis. When patients with F3-4 were compared to those with F0-2, the area under the receiver operating characteristics curve were 0.534 and 0.641 for platelet count < 100 and < 150 x 10(9)/L, respectively, 0.524 for AAR, 0.534 for Pohl score, 0.693 for Lok's model, and 0.765 for APRI. The sensitivity, specificity, and predictive values of APRI and Lok's model were only slightly lower than those reported by the authors using the recommended cutoffs in clinical trial settings. Alcohol use within 12 months, normalization of AST, ALT, and race (blacks/non-blacks) had minimal impact on the performance. Conclusions: AAR, Pohl, and platelet counts < 100 x 10(9)/L have limited ability to predict significant/advanced fibrosis with area under the receiver operating characteristics curve similar to 0.5. However, platelet counts < 150 x 10(9)/L, Lok's model and APRI performed well for advanced fibrosis in our daily practice setting. C1 [Cheung, Ramsey C.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Cheung, Ramsey C.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Currie, Sue; Shen, Hui; Wright, Teresa L.] VA Med Ctr, San Francisco, CA USA. [Bini, Edmund J.] VA Med Ctr, New York, NY USA. [Ho, Samuel B.] VA Med Ctr, Minneapolis, MN USA. [Anand, Bhupinderjit S.] VA Med Ctr, Houston, TX USA. [Hu, Ke-Qin] VA Med Ctr, Loma Linda, CA USA. [Morgan, Timothy R.] VA Med Ctr, Long Beach, CA USA. RP Cheung, RC (reprint author), VA Palo Alto HCS, Div Gastroenterol & Hepatol, 154C,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM rcheung@stanford.edu NR 31 TC 24 Z9 24 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD AUG PY 2008 VL 42 IS 7 BP 827 EP 834 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 336UJ UT WOS:000258389800012 PM 18285716 ER PT J AU Mastali, M Babbitt, JT Li, Y Landaw, EM Gau, V Churchill, BM Haake, DA AF Mastali, Mitra Babbitt, Jane T. Li, Yang Landaw, Elliot M. Gau, Vincent Churchill, Bernard M. Haake, David A. TI Optimal probe length and target location for electrochemical detection of selected uropathogens at ambient temperature SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID 16S RIBOSOMAL-RNA; ESCHERICHIA-COLI; BIOSENSORS; DNA; HYBRIDIZATION; AMPLIFICATION; BACTERIA; FISH AB We have previously demonstrated the clinical validity of the rapid detection of uropathogens by use of a DNA biosensor. This assay involves the hybridization of capture and detector probe pairs with bacterial 16S rRNA target molecules to form a DNA-RNA sandwich on the sensor surface. Horseradish peroxidase-conjugated antibody binds to the detector probe to enzymatically amplify the hybridization signal. These previous studies involved the hybridization of bacterial 16S rRNA target sequences with 35-mer oligonucleotide probe pairs at 65 degrees C. Achievement of point-of-care technology will be greatly facilitated by ambient-temperature detection. The purpose of this study was to examine the effects of probe length and target location on signal intensity using hybridization temperatures of 20 to 25 degrees C. Signal intensity was found to vary dramatically with hybridization location in the species-specific bulge region of 16S rRNA helix 18. Probe pairs of as short as 10 nucleotides in length were able to produce a significant electrochemical signal, and signal intensity was correlated with probe length for probes of 10 to 20 nucleotides in length. The sensitivity of the Escherichia coli-specific 15-mer probe pairs was approximately 330 cells. These shorter probes allowed differentiation of Klebsiella pneumoniae from Proteus mirabilis 16S rRNA target sequences differing by a single nucleotide. A panel of oligonucleotide probe pairs ranging from 11 to 23 nucleotides in length was able to distinguish among seven groups of urinary tract pathogens. In conclusion, we have developed short oligonucleotide probe pairs for the species-specific identification of uropathogens at ambient temperature by use of an electrochemical sensor. C1 [Mastali, Mitra; Babbitt, Jane T.; Haake, David A.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Li, Yang; Churchill, Bernard M.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Landaw, Elliot M.] Univ Calif Los Angeles, Dept Biomath, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gau, Vincent] GeneFluidics, Monterey Pk, CA 91754 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU National Institute of Biomedical Imaging and Bioengineering [EB00127]; National Institute of Allergy and Infectious Diseases [AI075565]; Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research FX This study was supported by Bioengineering Research Partnership Grant EB00127 (to B. M. C.) from the National Institute of Biomedical Imaging and Bioengineering, by Cooperative Agreement Award AI075565 (to D. A. H.) from the National Institute of Allergy and Infectious Diseases, and by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research. B. M. C. is the Judith and Robert Winston Chair in Pediatric Urology. NR 20 TC 11 Z9 11 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD AUG PY 2008 VL 46 IS 8 BP 2707 EP 2716 DI 10.1128/JCM.00423-08 PG 10 WC Microbiology SC Microbiology GA 344EI UT WOS:000258908700032 PM 18562584 ER PT J AU Schaefer, JT Nuovo, GJ Yen, BTS Werner, B AF Schaefer, Jochen T. Nuovo, Gerard J. Yen, Benedict T. S. Werner, Betina TI Prominent eosinophilic intranuclear inclusions in melanocytes of a melanocytic nevus: the aftermath of an infection with molluscum contagiosum? A case report SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article ID PARAMYXOVIRUS-LIKE INCLUSIONS; POLYMERASE-CHAIN-REACTION; MARINESCO BODIES; CORPUSCLES; ATAXIAS; PROTEIN; VIRUS; GENE AB A 65-year-old Latino man presented to his dermatologist for the removal of two melanocytic nevi from the back. The first nevus was removed from the right scapula and contained melanocytes with prominent eosinophilic nuclear inclusion bodies. The second nevus was removed from the paravertebral region, without evidence of inclusion bodies. Ultrastructurally, the inclusions in the first nevus contained dispersed finely granular, homogenous bodies without a limiting membrane. Immunohistochemistry characterized them as ubiquitin-positive material. Reverse transcriptase in situ polymerase chain reaction analysis was positive for molluscum-specific primers, suggesting that the inclusions encountered in the first nevus were secondary to a remote, local molluscum viral infection of melanocytes. C1 [Schaefer, Jochen T.] Cornell Univ, Weill Med Coll, Div Dermatopathol, Dept Pathol & Lab Med, New York, NY 10044 USA. [Nuovo, Gerard J.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA. [Yen, Benedict T. S.] Univ Calif San Francisco, San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94143 USA. [Yen, Benedict T. S.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Werner, Betina] Univ Curitiba, Dept Pathol, Curitiba, Parana, Brazil. RP Schaefer, JT (reprint author), Cornell Univ, Weill Med Coll, Div Dermatopathol, Dept Pathol & Lab Med, 1300 York Ave,F-309, New York, NY 10044 USA. EM jos9117@nyp.org NR 22 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD AUG PY 2008 VL 35 IS 8 BP 782 EP 788 DI 10.1111/j.1600-0560.2007.00902.x PG 7 WC Dermatology; Pathology SC Dermatology; Pathology GA 327GD UT WOS:000257716700014 PM 18430043 ER PT J AU Jaeger, JR Spielman, D Cronholm, PF Applebaum, S Holmes, WC AF Jaeger, Jeffrey R. Spielman, Darren Cronholm, Peter F. Applebaum, Sam Holmes, William C. TI Screening male primary care patients for intimate partner violence perpetration SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE male patients; intimate partner violence; primary care provider AB BACKGROUND: Primary prevention of intimate partner violence (IPV) at the level of the primary care provider is unexplored. OBJECTIVE: We sought to identify whether men disclose current IPV perpetration when asked by a primary care provider. DESIGN: Cross-sectional study. PARTICIPANTS: Consecutive male patients of 6 providers in public health, university, and VA hospital clinics. MEASUREMENTS: Men were screened for IPV perpetration during routine visits, then given a Conflict Tactics Scale questionnaire (CTS2) to complete and mail back anonymously. RESULTS: One hundred twenty-eight men were screened; 46 (36%) returned CTS2 questionnaires. Twenty-three and 2 men disclosed past and current perpetration to providers, respectively. Providers assessed lethality/safety issues in 58% of those reporting a perpetration history (including both with current perpetration), responded with direct counseling to 63% (including both with current perpetration), and referred 17% for services related to the screening (including 1 with current perpetration). Nine and 26 men reported current, CTS2-assessed physical and psychological aggression of a partner, respectively. CONCLUSIONS: Men appear to underreport current IPV perpetration in face-to-face primary care encounters when compared to other methods of reporting. Men may more readily report past IPV perpetration in face-to-face encounters. C1 [Jaeger, Jeffrey R.; Holmes, William C.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Jaeger, Jeffrey R.; Spielman, Darren; Cronholm, Peter F.] Inst Safe Families, Philadelphia, PA USA. [Cronholm, Peter F.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Cronholm, Peter F.] Univ Penn, Sch Med, Firearm & Injury Ctr Penn, Philadelphia, PA 19104 USA. [Cronholm, Peter F.; Holmes, William C.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Holmes, William C.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Cronholm, Peter F.; Holmes, William C.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Jaeger, JR (reprint author), 3701 Marker St,Suite 760, Philadelphia, PA 19104 USA. EM JaegerJ@uphs.upenn.edu NR 24 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2008 VL 23 IS 8 BP 1152 EP 1156 DI 10.1007/s11606-008-0634-9 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 337RX UT WOS:000258454300005 PM 18459009 ER PT J AU Nicolaidis, C Gregg, J Galian, H McFarland, B Curry, M Gerrity, M AF Nicolaidis, Christina Gregg, Jessica Galian, Hilary McFarland, Bentson Curry, MaryAnn Gerrity, Martha TI "You Always End up Feeling Like You're Some Hypochondriac": Intimate partner violence survivors' experiences addressing depression and pain SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE intimate partner violence; depression; pain; physical symptoms; qualitative research; physician-patient relationship ID PHYSICAL HEALTH CONSEQUENCES; SYMPTOM CHECKLIST HSCL; DOMESTIC VIOLENCE; SOMATIC SYMPTOMS; PRIMARY-CARE; WOMEN; FAMILY; DISORDERS; SEVERITY; VICTIMS AB OBJECTIVE: Little is known regarding how providers should use information about intimate partner violence (IPV) to care for depressed patients. Our objective was to explore what depressed IPV survivors believe about the relationship between abuse, mental health, and physical symptoms and to elicit their recommendations for addressing depression. DESIGN: Focus group study. PATIENTS/PARTICIPANTS: Adult, English-speaking, female, Internal Medicine clinic patients with depressive symptoms and a history of IPV. INTERVENTIONS: Thematic analysis using an inductive approach (consistent with grounded theory), at a semantic level, with an essentialist paradigm. MEASUREMENTS AND MAIN RESULTS: Twenty three women participated in 5 focus groups. Although selected because of their depression, participants often felt their greatest concerns were physical. They acknowledged that their abuse history, depression, and physical complaints compound each other. They appreciated the need for health care workers to know about their depression and IPV history to get a "full picture" of their health, but they were often hesitant to discuss such issues with providers because of their fear that such information would make providers think their symptoms were "all in their head" or would encourage providers to discount their pain. Participants discussed difficulties related to trust and control in relationships with providers and gave recommendations as to how providers can earn their trust. CONCLUSIONS: Understanding a patient's IPV history may allow providers to develop a better therapeutic relationship. To treat depression adequately, it is important for providers to reassure patients that they believe their physical symptoms; to communicate respect for patients' intelligence, experience, and complexity; and to share control. C1 [Nicolaidis, Christina; Gregg, Jessica; Galian, Hilary; Gerrity, Martha] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med, Portland, OR 97201 USA. [Nicolaidis, Christina; McFarland, Bentson] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [McFarland, Bentson] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Curry, MaryAnn] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Gerrity, Martha] Portland VA Med Ctr, Portland, OR USA. RP Nicolaidis, C (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med, Portland, OR 97201 USA. EM nicolaid@ohsu.edu OI McFarland, Bentson/0000-0001-9149-5616 FU NIMH NIH HHS [K23 MH073008-03, K23 MH073008] NR 34 TC 11 Z9 11 U1 2 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2008 VL 23 IS 8 BP 1157 EP 1163 DI 10.1007/s11606-008-0606-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 337RX UT WOS:000258454300006 PM 18443884 ER PT J AU Goetz, MB Hoang, T Bowman, C Knapp, H Rossman, B Smith, R Anaya, H Osborn, T Gifford, AL Asch, SM AF Goetz, Matthew Bidwell Hoang, Tuyen Bowman, Candice Knapp, Herschel Rossman, Barbara Smith, Robert Anaya, Henry Osborn, Teresa Gifford, Allen L. Asch, Steven M. CA QUERI HIV Hepatitis Program TI A system-wide intervention to improve HIV testing in the Veterans Health Administration SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE diagnosis; HIV testing; quality improvement ID HUMAN-IMMUNODEFICIENCY-VIRUS; QUALITY-OF-CARE; CLINICAL REMINDERS; UNITED-STATES; COST-EFFECTIVENESS; CHRONIC ILLNESS; PERSONS AWARE; INFECTION; RECOMMENDATIONS; TRANSMISSION AB BACKGROUND: Although the benefits of identifying and treating asymptomatic HIV-infected individuals are firmly established, health care providers often miss opportunities to offer HIV-testing. OBJECTIVE: To evaluate whether a multi-component intervention increases the rate of HIV diagnostic testing. DESIGN: Pre- to post-quasi-experiment in 5 Veterans Health Administration facilities. Two facilities received the intervention; the other three facilities were controls. The intervention included a real-time electronic clinical reminder that encourages HIV testing, and feedback reports and a provider activation program. PATIENTS: Persons receiving health care between August 2004 and September 2006 who were at risk but had not been previously tested for HIV infection MEASUREMENTS: Pre- to post-changes in the rates of HIV testing at the intervention and control facilities RESULTS: At the two intervention sites, the adjusted rate of testing increased from 4.8% to 10.8% and from 5.5% to 12.8% (both comparisons, p <.001). In addition, there were 15 new diagnoses of HIV in the pre-intervention year (0.46% of all tests) versus 30 new diagnoses in the post-intervention year (0.45% of all tests). No changes were observed at the control facilities. CONCLUSIONS: Use of clinical reminders and provider feedback, activation, and social marketing increased the frequency of HIV testing and the number of new HIV diagnoses. These findings support a multimodal approach toward achieving the Centers for Disease Control and Prevention's goal of having every American know their HIV status as a matter of routine clinical practice. C1 [Goetz, Matthew Bidwell; Rossman, Barbara] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111 F, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bowman, Candice; Smith, Robert] VA San Diego Healthcare Syst, San Diego, CA USA. [Osborn, Teresa] VISN 22, Long Beach, CA USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Adm Hosp, VA Bedford Ctr Hlth Qual Qoutcomes & Econ Res, Bedford, MA 01730 USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111 F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 53 TC 38 Z9 38 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2008 VL 23 IS 8 BP 1200 EP 1207 DI 10.1007/s11606-008-0637-6 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 337RX UT WOS:000258454300013 PM 18452045 ER PT J AU McDermott, KA Helfrich, CD Sales, AE Rumsfeld, JS Ho, PM Fihn, SD AF McDermott, Kelly A. Helfrich, Christian D. Sales, Anne E. Rumsfeld, John S. Ho, P. Michael Fihn, Stephan D. TI A review of interventions and system changes to improve time to reperfusion for ST-segment elevation myocardial infarction SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE cardiac reperfusion; myocardial infarction; systematic review; quality improvement ID NURSE INITIATED THROMBOLYSIS; TO-BALLOON TIME; PERCUTANEOUS CORONARY INTERVENTION; EMERGENCY-DEPARTMENT; PRIMARY ANGIOPLASTY; NEEDLE TIMES; CARE-UNIT; NATIONAL-REGISTRY; CRITICAL PATHWAY; REDUCES DOOR AB OBJECTIVE: Identify and describe interventions to reduce time to reperfusion for patients with ST-segment elevation myocardial infarction (STEMI). DATA SOURCE: Key word searches of five research databases: MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, Web of Science, and Cochrane Clinical Trials Registry. INTERVENTIONS: We included controlled and uncontrolled studies of interventions to reduce time to reperfusion. One researcher reviewed abstracts and 2 reviewed full text articles. Articles were subsequently abstracted into structured data tables, which included study design, setting, intervention, and outcome variables. We inductively developed intervention categories from the articles. A second researcher reviewed data abstraction for accuracy. MEASUREMENTS AND MAIN RESULTS: We identified 666 articles, 42 of which met inclusion criteria. We identified 11 intervention categories and classified them as either process specific (e.g., emergency department administration of thrombolytic therapy, activation of the catheterization laboratory by emergency department personnel) or system level (e.g., continuous quality improvement, critical pathways). A majority of studies (59%) were single-site pre/post design, and nearly half (47%) had sample sizes less than 100 patients. Thirty-two studies (76%) reported significantly lower door to reperfusion times associated with an intervention, 12 (29%) of which met or exceeded guideline recommended times. Relative decreases in times to reperfusion ranged from 15 to 82% for door to needle and 13-64% for door to balloon. CONCLUSIONS: We identified an array of process and system-based quality improvement interventions associated with significant improvements in door to reperfusion time. However, weak study designs and inadequate information about implementation limit the usefulness of this literature. C1 [McDermott, Kelly A.; Helfrich, Christian D.; Sales, Anne E.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Sales, Anne E.] Univ Alberta, Edmonton, AB, Canada. [Rumsfeld, John S.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. RP Sales, AE (reprint author), 3-114 Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada. EM anne.sales@ualberta.ca RI Sales, Anne/D-9678-2012; Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768; Sales, Anne/0000-0001-9360-3334 NR 64 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2008 VL 23 IS 8 BP 1246 EP 1256 DI 10.1007/s11606-008-0563-7 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 337RX UT WOS:000258454300021 PM 18459014 ER PT J AU May, FJ Li, L Zhang, SL Guzman, H Beasley, DWC Tesh, RB Higgs, S Raj, P Bueno, R Randle, Y Chandler, L Barrett, ADT AF May, Fiona J. Li, Li Zhang, Shuliu Guzman, Hilda Beasley, David W. C. Tesh, Robert B. Higgs, Stephen Raj, Pushker Bueno, Rudy, Jr. Randle, Yvonne Chandler, Laura Barrett, Alan D. T. TI Genetic variation of St. Louis encephalitis virus SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID WEST-NILE-VIRUS; TRANS-OVARIAL TRANSMISSION; MURRAY VALLEY ENCEPHALITIS; PARTIAL NUCLEOTIDE-SEQUENCE; STRONG PURIFYING SELECTION; YELLOW-FEVER VIRUS; PAPUA-NEW-GUINEA; JAPANESE ENCEPHALITIS; PHYLOGENETIC ANALYSIS; ENVELOPE PROTEIN AB St. Louis encephalitis virus (SLEV) has been regularly isolated throughout the Americas since 1933. Previous phylogenetic studies involving 62 isolates have defined seven major lineages (IVII), further divided into 14 clades. In this study, 28 strains isolated in Texas in 1991 and 2001 2003, and three older, previously unsequenced strains from Jamaica and California were sequenced over the envelope protein gene. The inclusion of these new sequences, and others published since 2001, has allowed better delineation of the previously published SLEV lineages, in particular the clades of lineage 11. Phylogenetic analysis of 106 isolates identified 13 clades. All 1991 and 2001 -2003 isolates from NUeces, Jefferson and Harris Counties (Texas Gulf Coast) group in clacle 1113 with other isolates from these counties isolated during the 1 980s and 1 990s. This lack of evidence for introduction of novel strains into the Texas Gulf Coast over a long period of time is consistent with overwintering of SLEV in this region. Two El Paso isolates, both from 2002, group in clade VA with recent Californian isolates from 1998-2001 and some South American strains with a broad temporal range. Overall, these data are consistent with multiple introductions of SLEV from South America into North America, and provide support for the hypothesis that in most situations, SLEV circulates within a locality, with occasional incursions from other areas. Finally, SLEV has much lower nucleotice (10.1 %) and amino acid variation (2.8 %) than other members of the Japanese encephalitis virus complex (maximum variation 24.6% nucleotide and 11.8% amino acid). C1 [May, Fiona J.; Li, Li; Zhang, Shuliu; Guzman, Hilda; Beasley, David W. C.; Tesh, Robert B.; Higgs, Stephen; Barrett, Alan D. T.] Univ Texas Galveston, Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. [May, Fiona J.; Li, Li; Zhang, Shuliu; Guzman, Hilda; Beasley, David W. C.; Tesh, Robert B.; Higgs, Stephen; Barrett, Alan D. T.] Univ Texas Galveston, Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA. [May, Fiona J.; Li, Li; Zhang, Shuliu; Guzman, Hilda; Beasley, David W. C.; Tesh, Robert B.; Higgs, Stephen; Barrett, Alan D. T.] Univ Texas Galveston, Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA. [May, Fiona J.; Li, Li; Guzman, Hilda; Tesh, Robert B.; Higgs, Stephen; Barrett, Alan D. T.] Univ Texas Galveston, Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Zhang, Shuliu; Beasley, David W. C.] Univ Texas Galveston, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA. [Raj, Pushker] Texas Dept State Hlth Serv, Austin, TX USA. [Bueno, Rudy, Jr.; Randle, Yvonne] Harris Cty Publ Hlth & Environm Serv, Mosquito Control Div, Houston, TX 77021 USA. [Chandler, Laura] Philadelphia VA Med Ctr, Lab Med, Philadelphia, PA 19104 USA. RP Barrett, ADT (reprint author), Univ Texas Galveston, Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. EM abarrett@UTMB.EDU FU NIAID NIH HHS [R01 AI067847, N01AI25489, N01AI30027, R01 AI 45559, N01-AI 25489, R01 AI067847-03, R01 AI 67847] NR 58 TC 17 Z9 17 U1 0 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD AUG PY 2008 VL 89 BP 1901 EP 1910 DI 10.1099/vir.0.2008/000190-0 PN 8 PG 10 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 335PF UT WOS:000258301800013 PM 18632961 ER PT J AU Zhang, XK Moussa, O Larue, A Bradshaw, S Molano, I Spyropoulos, DD Gilkeson, GS Watson, DK AF Zhang, Xian K. Moussa, Omar LaRue, Amanda Bradshaw, Sarah Molano, Ivan Spyropoulos, Demetri D. Gilkeson, Gary S. Watson, Dennis K. TI The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID DNA-BINDING SPECIFICITIES; ETS FAMILY; IMMUNE-RESPONSE; RENAL-DISEASE; HUMAN CANCER; PRE-B; GENE; EXPRESSION; DIFFERENTIATION; PROTEINS AB Fli-1 belongs to the Ets transcription factor family and is expressed primarily in hematopoietic cells, including most cells active in immunity. To assess the role of Fli-1 in lymphocyte development in vivo, we generated mice that express a truncated Fli-1 protein, lacking the C-terminal transcriptional activation domain (Fli-1(Delta CTA)). Fli-1(Delta CTA)/Fli-1(Delta CTA) mice had significantly fewer splenic follicular B cells, and an increased number of transitional and marginal zone B cells, compared with wild-type controls. Bone marrow reconstitution studies demonstrated that this phenotype is the result of lymphocyte intrinsic effects. Expression of Ig alpha and other genes implicated in B cell development, including Pax-5, E2A, and Egr-1, are reduced, while Id1 and Id2 are increased in Fli-1(Delta CTA)/Fli-1(Delta CTA) mice. Proliferation of B cells from Fli-1(Delta CTA)/Fli-1(Delta CTA) mice was diminished, although intracellular Ca2+ flux in B cells from Fli-1(Delta CTA)/Fli-1(Delta CTA) mice was similar to that of wild-type controls after anti-IgM stimulation. Immune responses and in vitro class switch recombination were also altered in Fli-1(Delta CTA)/Fli-1(Delta CTA) mice. Thus, Fli-1 modulates B cell development both centrally and peripherally, resulting in a significant impact on the in vivo immune response. C1 [Zhang, Xian K.; Bradshaw, Sarah; Molano, Ivan; Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Zhang, Xian K.; LaRue, Amanda; Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. [Moussa, Omar; LaRue, Amanda; Spyropoulos, Demetri D.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Zhang, XK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,MSC637,Suite 912, Charleston, SC 29425 USA. EM zhangjo@muse.edu FU NCI NIH HHS [P01 CA078582, P01-CA78582]; NIAMS NIH HHS [R03 AR054546, AR051385, AR054546, K01 AR051385, K01 AR051385-01A1, R03 AR054546-01] NR 64 TC 34 Z9 34 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD AUG 1 PY 2008 VL 181 IS 3 BP 1644 EP 1654 PG 11 WC Immunology SC Immunology GA 329VG UT WOS:000257898100009 PM 18641300 ER PT J AU Livorsi, DJ Daver, NG Atmar, RL Shelburne, SA White, AC Musher, DM AF Livorsi, Daniel J. Daver, Naval G. Atmar, Robert L. Shelburne, Samuel A. White, A. Clinton Musher, Daniel M. TI Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA SO JOURNAL OF INFECTION LA English DT Article DE vertebral osteomyelitis; abscess; Stophylococcus aureus ID SURGICAL-MANAGEMENT; US HOSPITALS; EPIDEMIOLOGY; INFECTIONS; BACTEREMIA; SURVEILLANCE; DENMARK AB Objectives: Hematogenous vertebral osteomyelitis is caused predominantly by Staphylococcus aureus. The rise in incidence of methicillin-resistant S. aureus (MRSA) has complicated the treatment of this infection. Our objective was to evaluate therapeutic outcomes for S. aureus vertebral. osteomyelitis in a setting of high MRSA prevalence. Methods: We conducted a retrospective chart review of all patients who presented with S. aureus vertebral osteomyelitis over a 7-year period at 2 tertiary care hospitals in Houston, TX, USA. Results: Thirty-five patients were identified who received >= 2-week course of parenteral antibiotics and had a follow-up period of at least 12 months post-therapy. MRSA was responsible for 20 (57%) cases. Mean duration of total antibiotic therapy was 61.4 days. The overall relapse rate was 14%. At 12 months post-therapy, 86% patients were cured. The one factor significantly associated with relapse was presence of undrained abscesses (p = 0.04). Conclusions: When the mean duration of effective antibiotic therapy was 60 days, cure rates for S. aureus vertebral, osteomyelitis exceeded 80%. Drainage of all associated abscesses correlated with a significantly higher rate of cure. (c) 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved. C1 [Livorsi, Daniel J.; Daver, Naval G.; Atmar, Robert L.; Shelburne, Samuel A.; Musher, Daniel M.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. [White, A. Clinton] Univ Texas Galveston, Med Branch, Div Infect Dis, Galveston, TX 77555 USA. [Atmar, Robert L.; Shelburne, Samuel A.; White, A. Clinton] Ben Taub Gen Hosp, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. RP Livorsi, DJ (reprint author), 108 Ponce Leon Court, Decatur, GA 30030 USA. EM dlivorsi@alumni.rice.edu OI White, A Clinton/0000-0002-9668-4632 FU NCI NIH HHS [P30 CA016672] NR 15 TC 27 Z9 28 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD AUG PY 2008 VL 57 IS 2 BP 128 EP 131 DI 10.1016/j.jinf.2008.04.012 PG 4 WC Infectious Diseases SC Infectious Diseases GA 345VQ UT WOS:000259026000007 PM 18562009 ER PT J AU Cheng, CF Fan, JH Bandyopahdhay, B Mock, D Guan, SX Chen, M Woodley, DT Li, W AF Cheng, Chleh-Fang Fan, Jianhua Bandyopahdhay, Balaji Mock, Dennis Guan, Shengxi Chen, Mei Woodley, David T. Li, Wei TI Profiling motility signal-specific genes in primary human keratinocytes SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID DERMAL FIBROBLAST MIGRATION; EPIDERMAL-GROWTH-FACTOR; CELL MOTILITY; HUMAN SKIN; IN-VITRO; REEPITHILIALIZATION; LOCOMOTION; BETA; INHIBITION; MECHANISMS AB Regulation of human keratinocyte (HK) migration is critical for skin wound healing. Profiling HK migration-specific genes could help us gain a comprehensive understanding of the process. The main challenge is to separate genes that are unrelated to migration, but simultaneously induced by the same growth factor. In this study, we took advantage of a unique response of HKs to transforming growth factor-beta (TGF-beta), which inhibits proliferation but not migration of HKs, to suppress selectively the proliferation-related genes. Furthermore we stimulated HKs independently with TGF-alpha or insulin and identified the common genes and eliminated TGF-alpha- or insulin-specific genes. Under these conditions, we obtained profiles of the immediate-early genes (IEGs, at 30 minutes), early genes (EGs, at 60 minutes), and delayed-early genes (DEGs, at 120 minutes) by microarray analyses, followed by quantitative real-time reverse transcription-PCR (QRT-PCR) validation and functional characterization by RNA interference (RNAi). Our results revealed the following: (1) 25 upregulated and 1 downregulated IEGs; (2) 58 upregulated and 15 downregulated EGs, and (3) 13 upregulated and 3 downregulated DEGs in both TGF-alpha- and insulin-stimulated HKs. Three genes, all encoding secreted molecules, were investigated in HK migration. These cell motility-specific gene profiles may prove useful to skin wound healing. C1 [Cheng, Chleh-Fang; Fan, Jianhua; Bandyopahdhay, Balaji; Guan, Shengxi; Chen, Mei; Woodley, David T.; Li, Wei] Univ So Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90089 USA. [Cheng, Chleh-Fang; Fan, Jianhua; Bandyopahdhay, Balaji; Guan, Shengxi; Chen, Mei; Woodley, David T.; Li, Wei] Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA. [Mock, Dennis] Univ So Calif, CHLA, Genome Core Lab, Los Angeles, CA 90089 USA. [Woodley, David T.; Li, Wei] VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. RP Li, W (reprint author), Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90089 USA. EM wli@usc.edu FU NIAMS NIH HHS [GM/AR67100-01, AR46538] NR 41 TC 7 Z9 7 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD AUG PY 2008 VL 128 IS 8 BP 1981 EP 1990 DI 10.1038/jid.2008.34 PG 10 WC Dermatology SC Dermatology GA 331SA UT WOS:000258031700018 PM 18323786 ER PT J AU Lugo, JN Barnwell, LF Ren, Y Lee, WL Johnston, LD Kim, R Hrachovy, RA Sweatt, JD Anderson, AE AF Lugo, Joaquin N. Barnwell, Lyndon Forbes Ren, Yajun Lee, Wai Ling Johnston, Lisa Danielle Kim, Rebecca Hrachovy, Richard A. Sweatt, John David Anderson, Anne E. TI Altered phosphorylation and localization of the A-type channel, Kv4.2 in status epilepticus SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE epilepsy; extracellular signal-regulated kinase; ion channels; mitogen-activated protein kinase; protein phosphorylation; seizures ID ACTIVATED PROTEIN-KINASE; HIPPOCAMPAL PYRAMIDAL NEURONS; TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; DENDRITIC K+ CHANNELS; MAP KINASE; SYNAPTIC PLASTICITY; POTASSIUM CHANNELS; RAT HIPPOCAMPUS; RECEPTOR TRAFFICKING AB Extracelluar signal-regulated kinase (ERK) pathway activation has been demonstrated following convulsant stimulation; however, little is known about the molecular targets of ERK in seizure models. Recently, it has been shown that ERK phosphorylates Kv4.2 channels leading to down-regulation of channel function, and substantially alters dendritic excitability. In the kainate model of status epilepticus (SE), we investigated whether ERK phosphorylates Kv4.2 and whether the changes in Kv4.2 were evident at a synaptosomal level during SE. Western blotting was performed on rat hippocampal whole cell, membrane, synaptosomal, and surface biotinylated extracts following systemic kainate using an antibody generated against the Kv4.2 ERK sites and for Kv4.2, ERK, and phospho-ERK. ERK activation was associated with an increase in Kv4.2 phosphorylation during behavioral SE. During SE, ERK activation and Kv4.2 phosphorylation were evident at the whole cell and synaptosomal levels. In addition, while whole-cell preparations revealed no alterations in total Kv4.2 levels, a decrease in synaptosomal and surface expression of Kv4.2 was evident after prolonged SE. These results demonstrate ERK pathway coupling to Kv4.2 phosphorylation. The finding of decreased Kv4.2 levels in hippocampal synaptosomes and surface membranes suggest additional mechanisms for decreasing the dendritic A-current, which could lead to altered intrinsic membrane excitability during SE. C1 [Anderson, Anne E.] Cain Fdn Labs, Feigin Ctr, Dept Pediat, Houston, TX 77030 USA. [Barnwell, Lyndon Forbes; Hrachovy, Richard A.; Anderson, Anne E.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Hrachovy, Richard A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Sweatt, John David] Univ Alabama, Dept Neurobiol, Birmingham, AL USA. [Anderson, Anne E.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. RP Anderson, AE (reprint author), Cain Fdn Labs, Feigin Ctr, Dept Pediat, MC 3-6365, Houston, TX 77030 USA. EM annea@bcm.edu OI Sweatt, J. David/0000-0003-3567-485X FU NINDS NIH HHS [F32 NS056664-01A2, R01 NS049427, F32 NS056664, R01 NS049427-03] NR 50 TC 42 Z9 42 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2008 VL 106 IS 4 BP 1929 EP 1940 DI 10.1111/j.1471-4159.2008.05508.x PG 12 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 333RQ UT WOS:000258170400040 PM 18513371 ER PT J AU Miller, LA Collins, RL Kent, TA AF Miller, Lisa A. Collins, Robert L. Kent, Thomas A. TI Language and the modulation of impulsive aggression SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; BORDERLINE PERSONALITY-DISORDER; TEMPORAL-LOBE EPILEPSY; ORBITAL FRONTAL-CORTEX; PREFRONTAL CORTEX; WORKING-MEMORY; EMOTION REGULATION; LIMBIC SYSTEM; BEHAVIOR; BRAIN AB The current conceptualization of the functional anatomy of impulsive aggression relies on data largely derived from studies of animal models of defensive rage. However, animal models cannot account for the replicable findings of verbal pairments and abnormalities ties in the language processing regions of the brain, described in more recent studies of impulsive aggression in humans. The authors present an updated model of impulsive aggression that preserves the core defensive rage functional anatomy while implicating the brain regions associated directly and indirectly with language processing and their relationship to executive function as integral to the etiology, modulation, and treatment of impulsive aggression. C1 [Miller, Lisa A.; Collins, Robert L.; Kent, Thomas A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Miller, Lisa A.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Collins, Robert L.; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Kent, TA (reprint author), 2B223 Neurol,2002 Holcombe Blvd, Houston, TX 77030 USA. EM tkent@bcm.tmc.edu OI Kent, Thomas/0000-0002-9877-7584 FU VA (South Central MI-RECC) FX This work was supported by the VA (South Central MI-RECC). The authors thank Lynn Maher, Ph.D., and Andrew Papanicoloau, Ph.D., for their critical review of the manuscript This work is dedicated to the memory of Ernest Barratt, Ph.D. NR 79 TC 11 Z9 11 U1 4 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD AUG PY 2008 VL 20 IS 3 BP 261 EP 273 DI 10.1176/appi.neuropsych.20.3.261 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 353WK UT WOS:000259599500002 PM 18806230 ER PT J AU Gilger, MA El-Serag, HB Gold, BD Dietrich, CL Tsou, VM McDuffie, A Shub, MD AF Gilger, Mark A. El-Serag, Hashem B. Gold, Benjamin D. Dietrich, Craig L. Tsou, V. M. McDuffie, Addie Shub, Mitchell D. TI Prevalence of endoscopic findings of erosive esophagitis in children: A population-based study SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE erosive esophagitis; outcomes research; pediatric endoscopy ID GASTROESOPHAGEAL-REFLUX DISEASE; ATRESIA AB Purpose: Symptoms of gastroesophageal reflux. disease (GERD) occur in 2% to 7% of children. The manifestations of GERD can be limited to symptoms (eg, heartburn, regurgitation) or can be more complicated, such as erosive esophagitis, esophageal strictures, or Barrett esophagus. The prevalence of such GERD complications in children is unknown. The purpose of this study was to determine the prevalence of endoscopic findings of erosive esophagitis in children. Patients and Methods: All children ages 0 to 17 years, 11 months who underwent upper endoscopy that was recorded in the Pediatric Endoscopic Database System-Clinical Outcomes Research Initiative between 1999 and 2002 were included. Endoscopic reports that were incomplete or that did not include demographic features, indications for endoscopy, or endoscopic findings were excluded. Erosive esophagitis was defined either descriptively or by the Los Angeles classification. Esophageal biopsy was not evaluated. Results: A total of 7188 children who underwent upper endoscopy fulfilled the inclusion and exclusion criteria. Of those, 888 (12.4%) had erosive esophagitis. The median age of children with erosive esophagitis was 12.7 +/- 4.9 years versus 10.0 +/- 5.1 years in those without erosive esophagitis (P <= 0.0001). Of those with erosive esophagitis, 55.2% (490/888) were male, compared with 48.2% (3040/6300) in those without erosive esophagitis (P <= 0.0001). Erosive esophagitis was found in 29 of 531 (5.5%) children ages 0 to 1 years and progressively increased to 106 in 542 individuals (19.6%) by age 17. Hiatal hernia was found in 68 (7.7%) of children with erosive esophagitis, compared with 157 (2.5%) without erosive esophagitis (P <= 0.0001. The prevalence of Barrett esophagus, esophageal stricture, ulcer, previous surgery, nodules, foreign body or retained food, and anatomic abnormalities was not significantly different between children with erosive esophagitis and those without. Conclusions: The frequency of erosive esophagitis is slightly higher in male children and increases with age. In contrast to erosive esophagitis in adults, there were no significant variations according to race or ethnicity. Hiatal hernia is the only endoscopic observation that predicts erosive esophagitis. C1 [Gilger, Mark A.; Dietrich, Craig L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Vet Adm Hosp, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Gold, Benjamin D.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Tsou, V. M.; McDuffie, Addie] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Shub, Mitchell D.] Phoenix Childrens Hosp, Phoenix, AZ USA. RP Gilger, MA (reprint author), Texas Childrens Hosp, CCC 1010, Houston, TX 77030 USA. EM mgilger@bcm.edu FU NIDDK NIH HHS [R01-DK30144-21/23] NR 18 TC 28 Z9 33 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD AUG PY 2008 VL 47 IS 2 BP 141 EP 146 PG 6 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 331JY UT WOS:000258009700005 PM 18664864 ER PT J AU Elhai, JD Grubaugh, AL Richardson, JD Egede, LE Creamer, M AF Elhai, Jon D. Grubaugh, Anouk L. Richardson, J. Don Egede, Leonard E. Creamer, Mark TI Outpatient medical and mental healthcare utilization models among military veterans: Results from the 2001 National Survey of Veterans SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE mental health services; military veterans; United States Department of Veterans Affairs; health services ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; SERVICE USE; HELP-SEEKING; PREDICTORS; AFFAIRS; ERA AB Using Andersen's (1995) [Andersen R.M. Revisiting the behavioral model and access to medical care: does it matter? Journal of Health and Social Behavior 1995;36: 1-10] behavioral model of healthcare use as our theoretical framework, we examined predisposing (i.e., sociodemographic), enabling (i.e., access resources), and need (i.e., illness) models of outpatient medical and mental healthcare utilization among a national sample of US veterans. Participants were 20,048 nationally representative participants completing the 2001 National Survey of Veterans. Outcomes were healthcare use variables for the past year, including the number of Veterans Affairs (VA) and non-VA outpatient healthcare visits, and whether VA and non-VA mental health treatment was used. Univariate results demonstrated that numerous predisposing, enabling and need variables predicted both VA and non-VA healthcare use intensity and mental healthcare use. In multivariate analyses, predisposing, enabling and need variables demonstrated significant associations with both types of healthcare use, but accounted for more variance in mental healthcare use. Need variables provided an additive effect over predisposing and enabling variables in accounting for medical and mental healthcare use, and accounted for some of the strongest effects. The results demonstrate that need remains an important factor that drives healthcare use among veterans and does not seem to be overshadowed by socioeconomic factors that may create unfair disparities in treatment access. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. [Grubaugh, Anouk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Richardson, J. Don] Vet Affairs Canada, Med Serv, Hamilton, ON L8N 3J9, Canada. [Richardson, J. Don] St Josephs Hlth Care London Parkwood Hosp, Operat Stress Injury Clin, London, ON, Canada. [Egede, Leonard E.] Med Univ S Carolina, Dept Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Creamer, Mark] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Heidelberg West, Vic 3081, Australia. RP Elhai, JD (reprint author), Univ S Dakota, Disaster Mental Hlth Inst, 414 E Clark St, Vermillion, SD 57069 USA. EM jonelhai@fastmail.fm; grubaugh@musc.edu; jdrichardson@sympatico.ca; egedel@musc.edu; markcc@unimelb.edu.au NR 25 TC 27 Z9 27 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD AUG PY 2008 VL 42 IS 10 BP 858 EP 867 DI 10.1016/j.jpsychires.2007.09.006 PG 10 WC Psychiatry SC Psychiatry GA 325QQ UT WOS:000257603800010 PM 18005993 ER PT J AU Kren, K Michael, P Johnson, EQ Thiessen, C Busey, JC AF Kren, Kari Michael, Pam Johnson, Eluira Q. Thiessen, Charlotte Busey, J. Craig TI Referral systems in ambulatory care - Providing access to the nutrition care process SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID MANAGEMENT C1 [Michael, Pam] Amer Dietet Assoc, Nutr Serv Coverage Team, Chicago, IL USA. [Johnson, Eluira Q.] Med Nutr Therapy Diabet & Dis Management Serv, EQJ Associates, Omaha, NE USA. [Thiessen, Charlotte] US Dept Vet Affairs, Nebraska Western Iowa Healthcare Syst, Omaha, NE USA. RP Kren, K (reprint author), 120 S Riverside Plaza,Suite 2000, Chicago, IL 60606 USA. EM kkren@eatright.org NR 15 TC 3 Z9 4 U1 0 U2 1 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD AUG PY 2008 VL 108 IS 8 BP 1375 EP 1379 DI 10.1016/j.jada.2008.05.001 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 335KZ UT WOS:000258290800020 PM 18656580 ER PT J AU Vivrette, R Martin, JL Kramer, BJ AF Vivrette, Rebecca Martin, Jennifer L. Kramer, B. Josea TI An attempt to characterize factors that affect participation in minimal-risk research of older adults: What can we learn from published research findings? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Vivrette, Rebecca] Vet Affairs Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Sepulveda, CA USA. [Martin, Jennifer L.; Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Educ & Clin Ctr, Los Angeles, CA 90095 USA. RP Vivrette, R (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Sepulveda, CA USA. FU NIA NIH HHS [K23 AG028452, P60 AG010415, K23 AG028452-02, K23 AG028452-01A1] NR 4 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2008 VL 56 IS 8 BP 1584 EP 1586 DI 10.1111/j.1532-5415.2008.01791.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 340AD UT WOS:000258617500040 PM 18808614 ER PT J AU Ratcliffe, MB Howard, C Mann, M del Nido, P AF Ratcliffe, Mark B. Howard, Cheryl Mann, Michael del Nido, Pedro TI National Institutes of Health funding for cardiothoracic surgical research SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID SURGERY AB Objective: Our objective was determine the status of National Institutes of Health (NIH) funding for cardiothoracic surgery research. Summary Background Data: (1) Funding from the NIH is critical if new procedures and devices are to be developed. (2) The success rate for NIH applications coming from cardiothoracic surgery faculty is thought to be inferior. (3) Per capita numbers of surgical NIH application and awards and application success fate have recently been found to be below the average for the NIH. Methods: Application and award data for full-time academic cardiothoracic surgeons were obtained by matching records in the NIH IMPAC 11 database with membership rosters of The Society of Thoracic Surgeons and The American Association for Thoracic Surgery. Manpower data were obtained from 1999, 2003, and 2005 reports of the STS/AATS Workforce committee. Society membership was used as a surrogate for investigator experience. Results: The number of NIH applications has increased steeply in the past 7 years; however, the number of awards has remained constant. This pattern was observed for surgery and cardiothoracic surgery as well. Until 2003, the cardiothoracic surgery application success rate was actually higher than that of surgery and the NIH as a whole (between 25% and 40%). Since then, however, the cardiothoracic surgery application success rate has declined steeply and is now only 14%. NIH applications and awards per 100 cardiothoracic surgeons, although similar to those of surgery, are very much less than the NIH as a whole. Conclusion: Per capita NIH funding of cardiothoracic surgeons is very much less than that of the NIH as a whole. The primary cause is the low per capita number of applications submitted by cardiothoracic surgeons. Junior cardiothoracic faculty should be encouraged to apply for career development awards. However, since the ability to shift cost from clinical to academic faculty is declining, affirmative action from the NIH may be necessary. C1 [Ratcliffe, Mark B.] San Francisco VA Med Ctr, Surg Serv 112, San Francisco, CA 94121 USA. [Ratcliffe, Mark B.; Mann, Michael] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Howard, Cheryl] NHLBI, Div Sci Program Operat, Bethesda, MD 20892 USA. [del Nido, Pedro] Childrens Hosp, Boston, MA 02115 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@rned.va.gov NR 14 TC 16 Z9 16 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD AUG PY 2008 VL 136 IS 2 BP 392 EP 397 DI 10.1016/j.jtcvs.2008.04.009 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 338UQ UT WOS:000258535300021 PM 18692647 ER PT J AU Chen, HJJ Brown, K Barack, BM AF Chen, Hui Jenny Jie Brown, Kathleen Barack, Bruce M. TI Absence of the left brachiocephalic vein with venous return through the left superior intercostal vein - CT findings SO JOURNAL OF THORACIC IMAGING LA English DT Editorial Material DE asymptomatic congenital thoracic venous anomalies; congenital absence of the left brachiocephalic vein; left superior intercostal vein; embryogenesis ID LEFT INNOMINATE VEIN; EMBRYOLOGY AB Asymptomatic congenital thoracic venous anomalies are becoming clinically more relevant with the increasing utilization of minimally invasive surgical vascular procedures, such as left-sided implantable cardioverter defibrillator implantation. The purpose of this report is to describe the computed tomography findings of the congenital absence of the left. brachiocephalic vein in a patient with no evidence of congenital cardiovascular disease and no prior history of central venous instrumentation. In this patient, the left internal jugular and the left subclavian veins drain via the left superior intercostal vein, the accessory hemiazygous, the hemiazygous, and the azygous vein into the right brachiocephalic vein to form the superior vena cava. The clinical significance and possible embryogenesis of this anomaly are discussed. C1 [Chen, Hui Jenny Jie; Brown, Kathleen] Univ Calif Los Angeles, Med Ctr, Dept Radiol Sci, Los Angeles, CA 90024 USA. [Barack, Bruce M.] VA Greater Los Angeles Healthcare Syst, Dept Imaging, Los Angeles, CA USA. RP Chen, HJJ (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Radiol Sci, Los Angeles, CA 90024 USA. EM jenzhao@ucla.edu NR 14 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0883-5993 J9 J THORAC IMAG JI J. Thorac. Imaging PD AUG PY 2008 VL 23 IS 3 BP 202 EP 205 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 344DF UT WOS:000258905300010 PM 18728550 ER PT J AU Meffert, SM Metzler, TJ Henn-Haase, C McCaslin, S Inslicht, S Chemtob, C Neylan, T Marmar, CR AF Meffert, Susan M. Metzler, Thomas J. Henn-Haase, Clare McCaslin, Shannon Inslicht, Sabra Chemtob, Claude Neylan, Thomas Marmar, Charles R. TI A prospective study of trait anger and PTSD symptoms in police SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; EMERGENCY SERVICES PERSONNEL; VIETNAM VETERANS; TRAUMATIC EVENTS; PREDICTORS; DISTRESS; EXPOSURE; VICTIMS; PREVALENCE; HOSTILITY AB It is unknown whether anger is a risk factor for the development of posttraumatic stress disorder (PTSD) symptoms, arises as a consequence of PTSD, or both. Two hypotheses were tested in 180 police recruits: Greater trait anger during training will predict greater PTSD symptoms at one year; greater PTSD symptoms at one year will predict greater state anger at one year. Both hypotheses were confirmed, suggesting that trait anger is a risk factor for PTSD symptoms, but that PTSD symptoms are also associated with an increase of state anger. Increased anger is important not only because of the impact it has on individual distress and physical health, but also because of its potential public health impact. C1 [Meffert, Susan M.; McCaslin, Shannon] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Meffert, Susan M.; Metzler, Thomas J.; Henn-Haase, Clare; McCaslin, Shannon; Inslicht, Sabra] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Chemtob, Claude] Mt Sinai Sch Med, New York, NY USA. RP Meffert, SM (reprint author), Univ Calif San Francisco, Dept Psychiat, VAMC Bldg 8,Box 116P, San Francisco, CA 94143 USA. EM smeffert@lppi.ucsf.edu FU NIMH NIH HHS [R01 MH056350, R25 MH060482] NR 33 TC 31 Z9 32 U1 2 U2 8 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2008 VL 21 IS 4 BP 410 EP 416 DI 10.1002/jts.20350 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 344BI UT WOS:000258899800007 PM 18720397 ER PT J AU Thompson, CE Taylor, FB McFall, ME Barnes, RF Raskind, MA AF Thompson, Charles E. Taylor, Fletcher B. McFall, Miles E. Barnes, Robert F. Raskind, Murray A. TI Nonnightmare distressed awakenings in veterans with posttraumatic stress disorder: Response to prazosin SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID SLEEP DISTURBANCES; TRAUMA NIGHTMARES; COMBAT VETERANS; PTSD; SYMPTOMS AB Twenty-two veterans with posttraumatic stress disorder (PTSD) were assessed for trauma-related nightmares and nonnightmare distressed awakenings (NNDA) before and after treatment with the alpha-1 adrenoreceptor antagonist prazosin at an average bedtime dose of 9.6 mg/day. Ratings combining frequency and intensity dimensions of trauma-related nightmares decreased from 3.6 to 2.2, NNDA from 5.2 to 2. 1, and sleep difficulty from 7.2 to 4. 1 per week. These results suggest that increased brain adrenergic activity may contribute to the pathophysiology of both trauma-related nightmares and NNDA in PTSD. C1 [Thompson, Charles E.; McFall, Miles E.; Barnes, Robert F.; Raskind, Murray A.] VA Northwest Network, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Taylor, Fletcher B.] Rainier Associates, Tacoma, WA USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, 1600 S Columbian Way,S116, Seattle, WA 98108 USA. EM murray.raskind@va.gov FU NIMH NIH HHS [R01 MH069867, R01 MH069867-04] NR 19 TC 36 Z9 38 U1 0 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2008 VL 21 IS 4 BP 417 EP 420 DI 10.1002/jts.20351 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 344BI UT WOS:000258899800008 PM 18720392 ER PT J AU Penrod, JD Litke, A Hawkes, WG Magaziner, J Doucette, JT Koval, KJ Silberzweig, SB Egol, KA Siu, AL AF Penrod, Joan D. Litke, Ann Hawkes, William G. Magaziner, Jay Doucette, John T. Koval, Kenneth J. Silberzweig, Stacey B. Egol, Kenneth A. Siu, Albert L. TI The association of race, gender, and comorbidity with mortality and function after hip fracture SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE hip fracture; mobility; activities of daily living; mortality ID RECOVERY SCORE; FOLLOW-UP; REHABILITATION; PREDICTORS; OUTCOMES; PERFORMANCE; SURVIVAL; SURGERY; ILLNESS; COHORT AB Background. Few studies of hip fracture have large enough samples of men, minorities, and persons with specific comorbidities to examine differences in their mortality and functional outcomes. To address this problem, we combined three cohorts of hip fracture patients to produce a sample of 2692 patients followed for 6 months. Method. Data on mortality, mobility, and other activities of daily living (ADLs) were available from all three cohorts. We used multiple regression to examine the association of race, gender, and comorbidity with 6-month survival and function, controlling for prefracture mobility and ADLs, age, fracture type, cohort, and admission year. Results. The mortality rate at 6 months was 12%: 9% for women and 19% for men. Whites and women were more likely than were nonwhites and men to survive to 6 months, after adjusting for age, comorbidities, and prefracture mobility and function. Whites were more likely than were nonwhites to walk independently or with help at 6 months compared to not walking, after adjusting for age, comorbidities, and prefracture mobility and function. Dementia had a negative impact on survival, mobility, and ADLs at 6 months. The odds of survival to 6 months were significantly lower for people with chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and/or cancer. Parkinson's disease and stroke had negative impacts on mobility and ADLs, respectively, among survivors at 6 months. Conclusions. The finding of higher mortality and worse mobility for nonwhite patients with hip fractures highlights the need for more research on race/ethnicity disparities in hip fracture care. C1 [Egol, Kenneth A.] NYU, Hosp Joint Dis, Trauma Serv, New York, NY USA. [Koval, Kenneth J.] Dartmouth Hitchcock Med Ctr, Dept Orthopaed, Lebanon, NH 03766 USA. [Doucette, John T.] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA. [Hawkes, William G.; Magaziner, Jay] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Penrod, Joan D.; Litke, Ann; Silberzweig, Stacey B.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Penrod, Joan D.; Siu, Albert L.] James J Peters VA Med Ctr, Program Res Serious Phys & Mental Illness & Geria, Bronx, NY 10468 USA. [Penrod, Joan D.; Siu, Albert L.] James J Peters VA Med Ctr, Ctr Clin, Bronx, NY 10468 USA. RP Penrod, JD (reprint author), James J Peters VA Med Ctr, Ctr Clin, 130 Kingsbridge Rd, Bronx, NY 10468 USA. EM joan.penrod@mssm.edu FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [TRP 02-149]; National Institute on Aging (NIA) [RO1AG21992, R01 AG06322, R01 HD0073, R37 AG09901, P30 AG028747]; Mid-career Investigator Award [K24 AG00918] FX Drs. Penrod and Sin were Supported by the Department of Veterans Affairs. Veterans Health Administration, Health Services Research and Development Service (project no. TRP 02-149). Additional support was provided the National Institute on Aging (NIA; Research Grant RO1AG21992 and Mid-career Investigator Award K24 AG00918 to Dr. Sin). Drs. Hawkes and Magaziner were also supported by NIA grants R01 AG06322, R01 HD0073, R37 AG09901, and P30 AG028747. NR 33 TC 70 Z9 73 U1 0 U2 2 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD AUG PY 2008 VL 63 IS 8 BP 867 EP 872 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 352RT UT WOS:000259515800013 PM 18772476 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI Women in nephrology: one mother's strategies for success in academic medicine SO KIDNEY INTERNATIONAL LA English DT Editorial Material C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu NR 5 TC 2 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD AUG PY 2008 VL 74 IS 4 BP 401 EP 402 DI 10.1038/ki.2008.338 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 332ED UT WOS:000258064100001 PM 18670400 ER PT J AU Zald, PB Hamilton, BE Larsen, ML Cohen, JI AF Zald, Philip B. Hamilton, Bronwyn E. Larsen, Michael L. Cohen, James I. TI The Role of Computed Tomography for Localization of Parathyroid Adenomas SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT Annual Meeting of the Western Section of the Triological-Society CY JAN 31-FEB 02, 2008 CL Rancho Mirage, CA SP Triol Soc Western Sect DE Hyperparathyroidism; parathyroid adenoma; computed tomography; endocrine surgery; otolaryngology; hypercalcemia; sestamibi; ultrasound ID PRIMARY HYPERPARATHYROIDISM; DIRECTED PARATHYROIDECTOMY; PREOPERATIVE LOCALIZATION; SURGERY; ULTRASOUND; CT; SESTAMIBI AB Objective/Hypothesis: The purpose of this study was to evaluate the use of computed tomography (CT) for localization of parathyroid adenomas (PA) when first-line imaging is indeterminate. Study Design: Retrospective case series. Methods: A search of operating room and radiology records identified 223 surgical explorations for primary hyperparathyroidism. Adenoma locations on CT, ultrasound, and nuclear scintigraphy were correlated with an independent review of operative records. Results: The presence of adenoma in the correct side and quadrant of the neck was predicted by CT in 89% and 77% of studies, respectively. When first-line studies were indeterminate, the positive predictive value of CT for localization of PA to the correct side and quadrant of the neck was 87% and 69%, respectively. Conclusions: When first-line localization studies are indeterminate in patients with primary hyperparathyroidism, CT is a valuable, rapid, and widely available imaging modality that can be used to localize PA. C1 [Zald, Philip B.; Cohen, James I.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA. [Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Div Neuroradiol, Portland, OR 97239 USA. [Larsen, Michael L.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Cohen, James I.] Portland VA Med Ctr, Dept Otolaryngol, Portland, OR USA. RP Cohen, JI (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland VAMC P3-OC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohenj@ohsu.edu NR 16 TC 21 Z9 23 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD AUG PY 2008 VL 118 IS 8 BP 1405 EP 1410 DI 10.1097/MLG.0b013e318177098c PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 368ZP UT WOS:000260662600013 PM 18528308 ER PT J AU Ranji, SR Steinman, MA Shojania, KG Gonzales, R AF Ranji, Sumant R. Steinman, Michael A. Shojania, Kaveh G. Gonzales, Ralph TI Interventions to reduce unnecessary antibiotic prescribing - A systematic review and quantitative analysis SO MEDICAL CARE LA English DT Review DE quality improvement; systematic review; antibiotic; prescribing ID RANDOMIZED CONTROLLED-TRIAL; ACUTE OTITIS-MEDIA; RESPIRATORY-TRACT INFECTIONS; RESISTANT STREPTOCOCCUS-PNEUMONIAE; QUALITY IMPROVEMENT STRATEGIES; DELAYED PRESCRIPTIONS REDUCE; GENERAL-PRACTICE; PRIMARY-CARE; ANTIMICROBIAL RESISTANCE; ACUTE BRONCHITIS AB Background: Overuse of antibiotics in ambulatory care persists despite many efforts to address this problem. We performed a systematic review and quantitative analysis to assess the effectiveness of quality improvement (QI) strategies to reduce antibiotic prescribing for acute outpatient illnesses for which antibiotics are often inappropriately prescribed. Research Design and Methods: We searched the Cochrane Collaboration's Effective Practice and Organisation of Care database, supplemented by MEDLINE and manual review of article bibliographies. We included randomized trials, controlled before-after studies, and interrupted time series. Two independent reviewers abstracted all data, and disagreements were resolved by consensus and discussion with a third reviewer. The primary outcome was the absolute reduction in the proportion of patients receiving antibiotics. Results: Forty-three studies reporting 55 separate trials met inclusion criteria. Most studies (N = 38) addressed prescribing for acute respiratory infections (ARIs). Among the 30 trials eligible for quantitative analysis, the median reduction in the proportion of subjects receiving antibiotics was 9.7% [interquartile range (IQR), 6.6-13.7%] over 6 months median follow-up. No single QI strategy or combination of strategies was clearly superior. However, active clinician education strategies trended toward greater effectiveness than passive strategies (P = 0.096). Compared with studies targeting specific conditions or patient populations, broad-based interventions extrapolated to larger community-level impacts on total antibiotic use, with savings of 17-117 prescriptions per 1000 person-years. Study methodologic quality was fair. Conclusions: QI efforts are effective at reducing antibiotic use in ambulatory settings, although much room for improvement remains. Strategies using active clinician education and targeting management of all ARIs (rather than single conditions in single age groups) may yield larger reductions in community-level antibiotic use. C1 [Ranji, Sumant R.; Steinman, Michael A.; Gonzales, Ralph] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Shojania, Kaveh G.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Gonzales, Ralph] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Ranji, SR (reprint author), Univ Calif San Francisco, Dept Med, 533 Parnassus Ave,Box 0131 San Francisco, San Francisco, CA 94143 USA. EM sumantr@medicine.ucsf.edu NR 94 TC 93 Z9 94 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD AUG PY 2008 VL 46 IS 8 BP 847 EP 862 PG 16 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 331LT UT WOS:000258014400012 PM 18665065 ER PT J AU Holschneider, DP Maarek, JMI AF Holschneider, D. P. Maarek, J. -M. I. TI Brain maps on the go: Functional imaging during motor challenge in animals SO METHODS LA English DT Article DE brain mapping; neuroplasticity; neurorehabilitation; motor activity; sport sciences ID CEREBRAL BLOOD-FLOW; EXTERNALLY TRIGGERED MOVEMENTS; PARKINSONS-DISEASE; BASAL GANGLIA; INDICATOR FRACTIONATION; STATISTICAL-ANALYSIS; ENERGY-METABOLISM; PHYSICAL-EXERCISE; TREADMILL WALKING; NONTETHERED RATS AB Brain mapping in the freely moving animal is useful for studying motor circuits, not only because it avoids the potential confound of sedation or restraints, but because activated brain states may serve to accentuate differences that only manifest partially while a subject is in the resting state. Perfusion or metabolic mapping using autoradiography allows one to examine changes in brain function at the circuit level across the entire brain with a spatial resolution (similar to 100 mu) appropriate for the rat or mouse brain, and a temporal resolution (seconds-miinutes) sufficient for capturing acute brain changes. Here we summarize the application of these methods to the functional brain mapping of behaviors involving locomotion of small animals, methods for the three-dimensional reconstruction of the brain from autoradiographic sections, voxel based analysis of the whole brain, and generation of maps of the flattened rat cortex. Application of these methods in animal models promises utility in improving our understanding of motor function in the normal brain, and of the effects of neuropathology and treatment interventions such as exercise have on the reorganization of motor circuits. (C) 2008 Elsevier Inc. All rights reserved. C1 [Holschneider, D. P.] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA. [Holschneider, D. P.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. [Holschneider, D. P.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Holschneider, D. P.; Maarek, J. -M. I.] Univ So Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90033 USA. [Holschneider, D. P.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Holschneider, DP (reprint author), Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, 1333 San Pablo St,BMT 403,MC 9112, Los Angeles, CA 90033 USA. EM holschne@usc.edu FU NIBIB [1R01 NS050171] FX Supported by the NIBIB 1R01 NS050171. NR 75 TC 18 Z9 18 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 J9 METHODS JI Methods PD AUG PY 2008 VL 45 IS 4 BP 255 EP 261 DI 10.1016/j.ymeth.2008.04.006 PG 7 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 348MO UT WOS:000259214800002 PM 18554522 ER PT J AU Liu, Y Buck, DC Neve, KA AF Liu, Yong Buck, David C. Neve, Kim A. TI Novel interaction of the dopamine D-2 receptor and the Ca2+ binding protein S100B: Role in D-2 receptor function SO MOLECULAR PHARMACOLOGY LA English DT Article ID MEDIATED ERK ACTIVATION; TARGET PROTEINS; S-100 PROTEIN; CALMODULIN; IDENTIFICATION; SYSTEM; KINASE; FAMILY; TRANSACTIVATION; MODULATION AB S100B is a calcium-binding protein with both extracellular and intracellular regulatory activities in the mammalian brain. We have identified a novel interaction between S100B and the dopamine D-2 receptor. Our results also suggest that the binding of S100B to the dopamine D-2 receptor enhances receptor signaling. This conclusion is based on the following observations: 1) S100B and the third cytoplasmic loop of the dopamine D-2 receptor interact in a bacterial two-hybrid system and in a poly-histidine pull-down assay; 2) immunoprecipitation of the D-2 receptor also precipitates FLAG-S100B from human embryonic kidney 293 cell homogenates and endogenous S100B from rat neostriatal homogenates; 3) S100B immunoreactivity was detected in cultured neostriatal neurons expressing the D-2 receptor; 4) a putative S100B binding motif is located at residues 233 to 240 of the D-2 receptor, toward the amino terminus of the third cytoplasmic loop. D-3-IC3, which does not bind S100B, does not contain this motif; and 5) coexpression of S100B in D-2 receptor-expressing 293 cells selectively increased D-2 receptor stimulation of extracellular signal-regulated kinases and inhibition of adenylate cyclase. C1 [Liu, Yong; Buck, David C.; Neve, Kim A.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Buck, David C.; Neve, Kim A.] Portland VA Med Ctr, Portland, OR USA. RP Neve, KA (reprint author), 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM nevek@ohsu.edu FU NIMH NIH HHS [R01 MH045372-17, R01 MH045372, MH045372] NR 39 TC 25 Z9 28 U1 0 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD AUG PY 2008 VL 74 IS 2 BP 371 EP 378 DI 10.1124/mol.108.044925 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 329GH UT WOS:000257854400009 PM 18445708 ER PT J AU Samaha, FF McKenney, J Bloedon, LT Sasiela, WJ Rader, DJ AF Samaha, Frederick F. McKenney, James Bloedon, LeAnne T. Sasiela, William J. Rader, Daniel J. TI Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia SO NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE LA English DT Article DE ezetimibe; hypercholesterolemia; microsomal triglyceride transfer protein inhibitor ID TREATMENT PANEL-III; APO-B-SECRETION; MTP-INHIBITOR; RATING-SCALE; VITAMIN-E; CHOLESTEROL; DISEASE; ABETALIPOPROTEINEMIA; ATHEROSCLEROSIS; IMPLITAPIDE AB Background Many patients with coronary heart disease do not achieve recommended LDL-cholesterol levels, due to either intolerance or inadequate response to available lipid- lowering therapy. Microsomal triglyceride transfer protein (MTP) inhibitors might provide an alternative way to lower LDL- cholesterol levels. We tested the safety and LDL- cholesterol- lowering efficacy of an MTP inhibitor, AEGR- 733 ( Aegerion Pharmaceuticals Inc., Bridgewater, NJ), alone and in combination with ezetimibe. Methods We performed a multicenter, double- blind, 12- week trial, which included 84 patients with hypercholesterolemia. Patients were randomly assigned ezetimibe 10 mg daily ( n = 29); AEGR- 733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks and 10 mg daily for the last 4 weeks ( n = 28); or ezetimibe 10 mg daily and AEGR- 733 administered with the dose titration described above ( n = 28). Results Ezetimibe monotherapy led to a 20 - 22% decrease in LDLcholesterol concentrations. AEGR- 733 monotherapy led to a dosedependent decrease in LDL- cholesterol concentration: 19% at 5.0 mg, 26% at 7.5 mg and 30% at 10 mg. Combined therapy produced similar but larger dose- dependent decreases ( 35%, 38% and 46%, respectively). The number of patients who discontinued study drugs owing to adverse events was five with ezetimibe alone, nine with AEGR- 733 alone, and four with combined ezetimibe and AEGR- 733. Discontinuations from AEGR- 733 were due primarily to mild transaminase elevations. Conclusions Inhibition of LDL production with low- dose AEGR- 733, either alone or in combination with ezetimibe, could be an effective therapeutic option for patients unable to reach target LDL- cholesterol levels. C1 [Samaha, Frederick F.] Univ Penn, Med Ctr, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Samaha, Frederick F.] Univ Penn, Div Cardiovasc Med, Dept Med, Sch Med, Philadelphia, PA 19104 USA. [McKenney, James] Virginia Commonwealth Univ, Sch Pharm, Richmond, VA USA. [Bloedon, LeAnne T.; Rader, Daniel J.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Sasiela, William J.] Aeger Pharmaceut, Bridgewater, NJ USA. RP Samaha, FF (reprint author), Univ Penn, Med Ctr, Philadelphia VA Med Ctr, 8th Floor Cardiol,MC 111C,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM rick.samaha@va.gov NR 28 TC 128 Z9 133 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1743-4297 J9 NAT CLIN PRACT CARD JI Nat. Clin. Pract. Cardiovasc. Med. PD AUG PY 2008 VL 5 IS 8 BP 497 EP 505 DI 10.1038/ncpcardio1250 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 329KZ UT WOS:000257867800016 PM 18506154 ER PT J AU Davis, LE Beckham, JD Tyler, KL AF Davis, Larry E. Beckham, J. David Tyler, Kenneth L. TI North American encephalitic arboviruses SO NEUROLOGIC CLINICS LA English DT Review ID WEST-NILE-VIRUS; ST-LOUIS ENCEPHALITIS; EASTERN EQUINE ENCEPHALITIS; COLORADO TICK FEVER; CD8(+) T-CELLS; CULEX-PIPIENS-QUINQUEFASCIATUS; LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGLOBULIN-M ANTIBODY; MR-IMAGING FINDINGS; NEW-YORK-CITY AB Arboviruses continue to be a major cause of encephalitis in North America, and West Nile virus neuroinvasive disease is now the dominant cause of encephalitis. Transmission to humans of North American arboviruses occurs by infected mosquitoes or ticks. Most infections are asymptomatic or produce a flulike illness. Rapid serum or cerebrospinal fluid IgM antibody capture ELISA assays are available to diagnosis the acute infection for all North American arboviruses. Unfortunately, no antiviral drugs are approved for the treatment of arbovirus infection and current therapy is supportive. C1 [Davis, Larry E.] New Mexico Vet Affairs Hlth Care Syst, Albuquerque, NM 87108 USA. [Davis, Larry E.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA. [Beckham, J. David] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. [Beckham, J. David; Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. RP Davis, LE (reprint author), New Mexico Vet Affairs Hlth Care Syst, 1500 San Pedro Dr SE, Albuquerque, NM 87108 USA. EM ledavis@unm.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIAID NIH HHS [T32AI07537, T32 AI007537]; NINDS NIH HHS [R01 NS050138-04, R01 NS051403, R01 NS050138, R01 NS051403-04, R01 NS050138-05S1, R01 NS050138-05] NR 115 TC 14 Z9 14 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD AUG PY 2008 VL 26 IS 3 BP 727 EP + DI 10.1016/j.ncl.2008.03.012 PG 32 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 344EX UT WOS:000258910500008 PM 18657724 ER PT J AU Zhang, XY Zhou, DF Wu, GY Cao, LY Tan, YL Haile, CN Li, J Lu, L Kosten, TA Kosten, TR AF Zhang, Xiang Yang Zhou, Dong Feng Wu, Gui Ying Cao, Lian Yuan Tan, Yun Long Haile, Colin N. Li, Jun Lu, Lin Kosten, Therese A. Kosten, Thomas R. TI BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE schizophrenia; antipsychotic; weight gain; BDNF; genotype; association ID NEUROTROPHIC FACTOR; ATYPICAL ANTIPSYCHOTICS; MELANOCORTIN-4 RECEPTOR; GENE POLYMORPHISM; ENERGY-BALANCE; DIABETIC MICE; RAT-BRAIN; OBESITY; PHARMACOGENETICS; MANAGEMENT AB Recent evidence suggests that centrally released brain-derived neurotrophic factor ( BDNF) modulates eating behavior and metabolism that is responsible for body weight fluctuation. BDNF also may play an important role in the therapeutic action of antipsychotic medications. We investigated whether the Val66Met polymorphism of the BDNF gene affected weight gain after long-term antipsychotic treatment in schizophrenia. The polymorphism was genotyped in 196 Chinese patients with schizophrenia on long-term antipsychotic medication. Serum BDNF was measured in all patients and 50 normal controls. Mean body mass index (BMI) change was evaluated retrospectively by means of clinical records. The results showed that there was a significant relationship between the three BDNF Val/Met genotypes and mean BMI gain, with genotype having a strong effect on BMI gain in male but not female patients. BDNF levels were significantly lower in patients than normal controls, and negatively correlated with BMI gain in female but not male patients. Our results suggest that variation in the BDNF gene may be a risk factor for weight gain in male patients with schizophrenia on long-term antipsychotic treatment, and decreased BDNF levels may be associated with weight gain in females. C1 [Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Zhou, Dong Feng] Peking Univ, Inst Mental Hlth, Beijing 100083, Peoples R China. [Zhang, Xiang Yang; Wu, Gui Ying; Cao, Lian Yuan; Tan, Yun Long] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. [Li, Jun] Anhui Med Univ, Coll Pharmacol, Hefei, Anhui, Peoples R China. [Lu, Lin] Natl Inst Drug Dependence, Beijing, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; zhoudf@bjmu.edu.cn OI Haile, Colin/0000-0001-8293-7291 FU NIDA NIH HHS [P50-DA18827, K05-DA0454] NR 33 TC 49 Z9 53 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD AUG PY 2008 VL 33 IS 9 BP 2200 EP 2205 DI 10.1038/sj.npp.1301619 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 325XN UT WOS:000257622200015 PM 17987059 ER PT J AU Meropol, SB Chen, Z Metlay, JP AF Meropol, Sharon B. Chen, Zhen Metlay, Joshua P. TI Adverse events associated with pediatric antibiotic use SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Meropol, Sharon B.; Chen, Zhen; Metlay, Joshua P.] Univ PA, Cntr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Meropol, Sharon B.; Metlay, Joshua P.] Univ PA, Penn Cntr Educ & Res Therapeut, Philadelphia, PA USA. [Metlay, Joshua P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2008 VL 17 SU 1 MA 623 BP S273 EP S273 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 337FE UT WOS:000258420100623 ER PT J AU Meropol, SB Chen, Z Metlay, JP AF Meropol, Sharon B. Chen, Zhen Metlay, Joshua P. TI Antibiotics for upper respiratory infections SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Meropol, Sharon B.; Chen, Zhen; Metlay, Joshua P.] UPenn, Cntr Clin Epidem & Biostat, Philadelphia, PA USA. [Meropol, Sharon B.; Metlay, Joshua P.] UPenn, Penn Cntr Educ & Res Therapeut, Philadelphia, PA USA. [Metlay, Joshua P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Metlay, Joshua P.] Univ PA, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2008 VL 17 SU 1 MA 477 BP S209 EP S210 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 337FE UT WOS:000258420100477 ER PT J AU Pugh, MJV Zeber, JE Copeland, LA Tabares, JV Cramer, JA AF Pugh, Mary Jo V. Zeber, John E. Copeland, Laurel A. Tabares, Jeff V. Cramer, Joyce A. TI Psychiatric disease burden profiles among veterans with epilepsy: The association with health services utilization SO PSYCHIATRIC SERVICES LA English DT Article ID QUALITY-OF-LIFE; COMORBID DEPRESSION; MENTAL-ILLNESS; IMPACT; CARE; PEOPLE AB Objective: This brief report describes patterns of psychiatric comorbidities among patients with epilepsy and their relationship with health care utilization. Methods: The study identified psychiatric comorbid conditions in a cohort of veterans identified as having epilepsy in fiscal year 1999. From these diagnoses, nine psychiatric disease burden profiles were created. Logistic regression examined variation in emergency, neurology, and primary care for groups having different profiles and compared them with those with only epilepsy. Results: Of the 23,752 individuals identified, 48% had comorbid psychiatric conditions; most had multiple psychiatric diagnoses. Compared with patients with epilepsy only, those with comorbid psychiatric conditions were more likely to have emergency care and high primary care utilization; those with serious mental illness (psychotic disorders) were less likely to receive neurology care. Conclusions: Multiple co-occurring psychiatric diseases are common among patients with epilepsy. Addressing the mental health and medical needs of these patients, particularly those with serious mental illness, represents a challenge for health organizations. C1 [Pugh, Mary Jo V.; Zeber, John E.; Copeland, Laurel A.; Tabares, Jeff V.] Vet Evidence Based Res Disseminat Implementat Ctr, Hlth Serv Res & Dev Serv, Dept Vet Affairs, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Zeber, John E.; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Cramer, Joyce A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Pugh, MJV (reprint author), Vet Evidence Based Res Disseminat Implementat Ctr, Hlth Serv Res & Dev Serv, Dept Vet Affairs, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 FU HSRD VA [I01 HX000329] NR 15 TC 9 Z9 9 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD AUG PY 2008 VL 59 IS 8 BP 925 EP 928 DI 10.1176/appi.ps.59.8.925 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 333YZ UT WOS:000258190800017 PM 18678692 ER PT J AU Li, YQ Wang, XY Zhai, HF Zheng, YQ Zhang, XY Kosten, T Lu, L AF Li, Yan-Qin Wang, Xiao-Yi Zhai, Hai-feng Zheng, Yong-Qiu Zhang, Xiang Yang Kosten, Therese Lu, Lin TI Effects of early postnatal sibling deprivation on anxiety and vulnerability to cocaine in offspring rats SO PSYCHOPHARMACOLOGY LA English DT Article DE early postnatal sibling deprivation; anxiety behavior; natural reward; conditioned place preference; cocaine ID NEONATAL MATERNAL SEPARATION; CONDITIONED PLACE PREFERENCE; ADULT MALE RATS; FEMALE RATS; NEUROENDOCRINE RESPONSES; BEHAVIORAL SENSITIZATION; COGNITIVE-DEVELOPMENT; STRESS EXPERIENCE; MENTAL-HEALTH; CARE AB Rationale Early-life experience has long-term consequences on affective behavior and drug abuse in adults. While many manipulations used to study these consequences alter mother-infant interactions, the effects of sibling interactions are less well characterized. Objectives To examine the long-term effects of early postnatal sibling deprivation (EPSD) on anxiety-like behavior, sucrose preference and behavioral responses to cocaine in adult rats. Materials and methods After EPSD manipulation, in which litters were culled to one pup on postnatal day 1 (PN1) or 7 (PN7), the dams' maternal behavior was observed. After the pups reached adulthood, we tested their behavioral responses in the elevated plus maze and sucrose consumption, and to cocaine conditioned place preference and cocaine sensitization. Results The pups with EPSD on PN1 received more maternal licking/grooming during the first postnatal week. EPSD on PN1 but not PN7 enhanced locomotor activity in the open field test and exploration of open arms in the elevated plus maze in both female and male offspring. While EPSD had no effect on sucrose intake in adult rats, it decreased vulnerability to cocaine sensitization and cocaine conditioned place preference in male but not female rats. Conclusion Our findings that early postnatal sibling deprivation influences maternal licking/grooming behavior, as well as anxiety-like behavior and vulnerability to drugs in pups that have grown to adulthood, suggests that both sibling interaction and maternal behavior, play critical roles in individual development. C1 [Li, Yan-Qin; Wang, Xiao-Yi; Zhai, Hai-feng; Zheng, Yong-Qiu; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China. [Zhang, Xiang Yang; Kosten, Therese] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Lu, L (reprint author), Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd,Haidian Dist, Beijing 100083, Peoples R China. EM linlu@bjmu.edu.cn NR 53 TC 6 Z9 6 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD AUG PY 2008 VL 199 IS 2 BP 245 EP 253 DI 10.1007/s00213-008-1169-9 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 322NR UT WOS:000257383100011 PM 18452033 ER PT J AU Siegel, RE AF Siegel, Robert E. TI More Environmental Prevention of Gram-Negative Infections Needed Response SO RESPIRATORY CARE LA English DT Letter C1 James J Peters Vet Affairs, Med Ctr, Intens Care Unit, Bronx, NY USA. RP Siegel, RE (reprint author), James J Peters Vet Affairs, Med Ctr, Intens Care Unit, Bronx, NY USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD AUG PY 2008 VL 53 IS 8 BP 1092 EP 1092 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 335YU UT WOS:000258332300016 ER PT J AU Horan, WP Braff, DL Nuechterlein, KH Sugar, CA Cadenhead, KS Calkins, ME Dobie, DJ Freedman, R Greenwood, TA Gur, RE Gur, RC Light, GA Mintz, J Olincy, A Radant, AD Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Stone, WS Swerdlow, NR Tsuang, DW Tsuang, MT Turetsky, BI Green, MF AF Horan, William P. Braff, David L. Nuechterlein, Keith H. Sugar, Catherine A. Cadenhead, Kristin S. Calkins, Monica E. Dobie, Dorcas J. Freedman, Robert Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Mintz, James Olincy, Ann Radant, Allan D. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Swerdlow, Neal R. Tsuang, Debbie W. Tsuang, Ming T. Turetsky, Bruce I. Green, Michael F. TI Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; endophenotype; working memory; genetics ID NAIVE PATIENTS; NEUROPSYCHOLOGICAL DEFICITS; ENDOPHENOTYPE CONCEPT; COGNITIVE DEFICITS; FOLLOW-UP; METAANALYSIS; GENES; HERITABILITY; SYMPTOMS; SPAN AB Working memory (WM) impairment is a promising candidate endophenotype for schizophrenia that could facilitate the identification of susceptibility genes for this disorder. The validity of this putative endophenotype was assessed by determining whether 149 probands with schizophrenia and 337 of their first-degree relatives demonstrated WM impairment as compared to 190 unaffected community comparison subjects. Subjects were participants in the Consortium on the Genetics of Schizophrenia (COGS) project, a seven-site research network that was established to investigate the genetic architecture of endophenotypes for schizophrenia. Participants received comprehensive clinical assessments and completed two verbal WM tasks, one requiring transient on-line storage and another requiring maintenance plus complex manipulation of information by reordering the stimuli. Schizophrenia probands performed worse than the other groups on both tasks, with larger deficits found for the more challenging reordering WM task. The probands' relatives performed more poorly than community comparison subjects Oil both tasks, but the difference was significant only for the more challenging maintenance plus complex manipulation WM task. This WM impairment was not attributable to diagnoses of schizophrenia spectrum disorder, mood disorders, or substance use disorders in the relatives. In conjunction with evidence that WM abilities are substantially heritable, the Current results support the validity and usefulness of verbal WM impairments in manipulation of information as endophenotypes for schizophrenia in large-scale genetic linkage and association studies. (C) 2008 Elsevier B.V. All rights reserved. C1 [Horan, William P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Aftercare Res Program, Los Angeles, CA 90095 USA. [Braff, David L.; Cadenhead, Kristin S.; Greenwood, Tiffany A.; Light, Gregory A.; Schork, Nicholas J.; Swerdlow, Neal R.; Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Dobie, Dorcas J.; Radant, Allan D.; Tsuang, Debbie W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dobie, Dorcas J.; Radant, Allan D.; Tsuang, Debbie W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Seidman, Larry J.; Stone, William S.; Tsuang, Ming T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Publ Psychiat Div, Massachusetts Mental Hlth Ctr,Dept Psychiat, Boston, MA 02215 USA. [Seidman, Larry J.; Stone, William S.; Tsuang, Ming T.] Harvard Univ, Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Aftercare Res Program, 300 UCLA Med Plaza,Suite 2255, Los Angeles, CA 90095 USA. EM horan@ucla.edu; DBraff@ucsd.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894 FU NIMH NIH HHS [R01 MH065554-05, R01 MH065554, R01 MH065558, R01 MH065558-05, R01 MH065562, R01 MH065562-05, R01 MH065571, R01 MH065571-05, R01 MH065578, R01 MH065578-05, R01 MH065588-05, R01 MH065707, R01 MH065707-05, R01 MH084071] NR 55 TC 61 Z9 62 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD AUG PY 2008 VL 103 IS 1-3 BP 218 EP 228 DI 10.1016/j.schres.2008.02.014 PG 11 WC Psychiatry SC Psychiatry GA 338CC UT WOS:000258481500027 PM 18406578 ER PT J AU Bowie, CR Harvey, PD AF Bowie, Christopher R. Harvey, Philip D. TI Communication abnormalities predict functional outcomes in chronic schizophrenia: Differential associations with social and adaptive functions SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; thought disorder; communication; social; functional; cognition; outcome ID FORMAL THOUGHT-DISORDER; COGNITIVE DEFICITS; NEUROCOGNITIVE DEFICITS; EMPIRICAL-ASSESSMENT; FACTORIAL STRUCTURE; CLINICAL SYMPTOMS; OLDER PATIENTS; FOLLOW-UP; CAPACITY; IMPAIRMENTS AB Communication abnormalities are hallmark features of schizophrenia. Despite the prevalence and persistence of these symptoms, little is known about their functional implications. In this study, we examined, in a sample of chronically institutionalized schizophrenia patients (N=317), whether two types of communication abnormalities (i.e., verbal under-productivity and disconnected speech) had differential relationships with social and adaptive outcomes. Baseline ratings of verbal underproductivity, disconnected speech, global cognitive performance, and clinical symptoms, were entered into stepwise regression analyses to examine their relationship with 2.5 year social and adaptive outcomes. At baseline, disconnected speech was significantly associated with socially impolite behavior, while verbal underproductivity was associated with social disengagement and impaired friendships. Both types of communication abnormalities were significantly associated with other types of social skills. Verbal underproductivity predicted follow-up social skills, social engagement, and friendships, accounting for more variance than. cognition or symptoms. In contrast to social outcomes, adaptive outcomes were predicted by baseline neurocognition and clinical symptoms, but not communication abnormalities. These findings provide evidence for specific relationships of communication disorder subtypes with diverse impairments in social functions. In this chronically institutionalized sample, communication disorder was a stronger predictor of social, but not adaptive, outcomes than neurocognition or clinical symptoms. Published by Elsevier B.V. C1 [Bowie, Christopher R.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Bowie, Christopher R.] James J Peters Bronx VA Med Ctr, Bronx, NY 10468 USA. [Harvey, Philip D.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30032 USA. RP Bowie, CR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,4th Floor,Box 1230, New York, NY 10029 USA. EM christopher.bowie@mssm.edu FU NIMH [MH 63116]; Mount. Sinai Silvio Conte Neuroscience Center [NIMH MH 36692, KL Davis PI]; VAVISN 3 MIRECC FX This research was supported by NIMH Grant Number MH 63116 to Dr. Harvey, the Mount. Sinai Silvio Conte Neuroscience Center (NIMH MH 36692; KL Davis PI) and the VAVISN 3 MIRECC. These sponsors had no role in study design, collection of data, data analysis., interpretation of results, or writing of the manuscript. NR 48 TC 43 Z9 46 U1 4 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD AUG PY 2008 VL 103 IS 1-3 BP 240 EP 247 DI 10.1016/j.schres.2008.05.006 PG 8 WC Psychiatry SC Psychiatry GA 338CC UT WOS:000258481500029 PM 18571378 ER PT J AU Lee, J Nuechterlein, KH Subotnik, KL Sugar, CA Ventura, J Gretchen-Doorly, D Kelly, K Green, MF AF Lee, Junghee Nuechterlein, Keith H. Subotnik, Kenneth L. Sugar, Catherine A. Ventura, Joseph Gretchen-Doorly, Denise Kelly, Kimberly Green, Michael F. TI Stability of visual masking performance in recent-onset schizophrenia: An 18-month longitudinal study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE visual masking; stability; vulnerability; recent-onset schizophrenia; longitudinal study ID INFORMATION-PROCESSING DEFICITS; AFFECTIVELY DISTURBED PATIENTS; BACKWARD-MASKING; UNAFFECTED SIBLINGS; VULNERABILITY; CHANNELS; TRANSIENT; DISORDER; STRESS; SYSTEM AB Visual masking deficit in schizophrenia has been suggested to be a potential vulnerability marker for schizophrenia. An important characteristic of a vulnerability marker is stability over time, but relatively little is known about the longitudinal course of masking performance of schizophrenia patients. In this study, we examined the stability of visual masking performance in recent onset schizophrenia patients over an 18-month period. We administered both forward and backward masking trials with multiple stimulus onset asynchronies for four masking conditions at three time points (baseline, 6-month, and 18-month). Recent-onset schizophrenia patients showed stable masking performance for both forward and backward conditions over a period of 18 months. Furthermore, the stable performance was observed across all four masking conditions. The findings of this study provide further support for the view that visual masking deficits reflect a possible Vulnerability marker for schizophrenia. (C) 2008 Published by Elsevier B.V. C1 [Lee, Junghee] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. [Lee, Junghee; Nuechterlein, Keith H.; Subotnik, Kenneth L.; Sugar, Catherine A.; Ventura, Joseph; Gretchen-Doorly, Denise; Kelly, Kimberly; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90073 USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90073 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90073 USA. RP Lee, J (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, MIRECC, 11301 Wilshire Blvd,Bldg 210,MC 210A, Los Angeles, CA 90073 USA. EM JungheeLee@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU [MH43292]; [MH66286]; [MH37705] FX This work is supported by grants MH43292 to Dr. Green arid MH66286 and MH37705 to Dr. Nuechterlein. NR 39 TC 7 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD AUG PY 2008 VL 103 IS 1-3 BP 266 EP 274 DI 10.1016/j.schres.2008.03.005 PG 9 WC Psychiatry SC Psychiatry GA 338CC UT WOS:000258481500032 PM 18450427 ER PT J AU Weintraub, HS Basile, J AF Weintraub, Howard S. Basile, Jan TI The pleiotropic effects of antihypertensive agents: Do they account for additional cardiovascular benefit beyond BP reduction? SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; calcium antagonists; cardiovascular disease; hypertension; pleiotropic effects ID ANGIOTENSIN-CONVERTING-ENZYME; CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE REDUCTION; SMOOTH-MUSCLE-CELLS; END-POINT REDUCTION; LOSARTAN INTERVENTION; HYPERTENSIVE PATIENTS; ATRIAL-FIBRILLATION; ALDOSTERONE SYSTEM AB Hypertension commonly Clusters with other cardiovascular risk factors, giving rise to the concept that hypertension is a multifaceted disease that potentially shares common pathogenic pathways with other risk factors. The renin-angiotensin-aldosterone system has a central role in the shared mechanisms of hypertension and cardiovascular disease, primarily through angiotensin II. Increased levels of angiotensin II disrupt the balance of vasoactive substances and growth factors that regulate endothelial structure and function, and inhibition of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor or angiotensin II type I receptor blocker helps restore this equilibrium. Some pathogenic mechanisms may also be favorably affected by calcium channel blockade. While the relative contribution of pleiotropic effects to clinical benefit is difficult to quantity, based on recent data it is reasonable to consider using newer antihypertensive agents in selected high-risk patients to realize the benefits that may derive front interfering with pathogenic mechanisms of disease. C1 [Weintraub, Howard S.] NYU Med Ctr, Ctr Prevent Cardiovasc Dis, New York, NY 10016 USA. [Weintraub, Howard S.; Basile, Jan] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29425 USA. RP Weintraub, HS (reprint author), NYU Med Ctr, Ctr Prevent Cardiovasc Dis, 530 1st Ave, New York, NY 10016 USA. EM howard.weintraub@nyumc.org OI Weintraub, Howard/0000-0002-8159-0465 NR 48 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD AUG PY 2008 VL 101 IS 8 BP 818 EP 823 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 339NV UT WOS:000258585200012 PM 18622353 ER PT J AU Brinton, EA Hodis, HN Merriam, GR Harman, SM Naftolin, F AF Brinton, Eliot A. Hodis, Howard N. Merriam, George R. Harman, S. Mitchell Naftolin, Frederick TI Can menopausal hormone therapy prevent coronary heart disease? SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID CONJUGATED EQUINE ESTROGENS; HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; PLUS PROGESTIN; MEDROXYPROGESTERONE ACETATE; VENOUS THROMBOEMBOLISM; VASCULAR FUNCTION; BREAST-CANCER AB observational studies show that women who take menopausal hormone therapy (MHT) have a greatly reduced risk of coronary heart disease (CHD). But in some large randomized controlled trials, MHT failed to decrease CHD and so has been deemed inappropriate for long-term prophylaxis against atherosclerosis or other chronic diseases associated with the menopause. Despite the apparent strength of this conclusion, several recent reports suggest that MHT could be atheroprotective when started close to the menopause, and effects of early discontinuation of MHT have never been studied in randomized trials. Here, we examine these reports and highlight existing uncertainty regarding the effects of long-term continuation versus early discontinuation of early-start MHT on atherosclerosis and CHD risk. We call for new research on this question, and an evidence-based review of existing recommendations for MHT. C1 [Brinton, Eliot A.] Univ Utah, Sch Med, Salt Lake City, UT 84108 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Dept Med, Los Angeles, CA 90089 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Dept Prevent Med, Los Angeles, CA 90089 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Seattle, WA 98493 USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ 85016 USA. [Harman, S. Mitchell] Univ Arizona, Coll Med, Phoenix, AZ 85016 USA. [Naftolin, Frederick] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10016 USA. RP Brinton, EA (reprint author), Univ Utah, Sch Med, Salt Lake City, UT 84108 USA. EM eliot.brinton@utah.edu FU Aurora Foundation FX The authors acknowledge a grant from the Aurora Foundation in support of this work, and are grateful to Dr. JoArnn Manson for valuable discussions. NR 60 TC 8 Z9 10 U1 0 U2 3 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD AUG PY 2008 VL 19 IS 6 BP 206 EP 212 DI 10.1016/j.tem.2008.03.002 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 338BS UT WOS:000258480500003 PM 18450469 ER PT J AU Bernstein, J Esterhai, JL Staska, M Reinhardt, S Mitchell, ME AF Bernstein, Joseph Esterhai, John L. Staska, Mitchell Reinhardt, Sally Mitchell, Marc E. TI The prevalence of occult peripheral arterial disease among patients referred for orthopedic evaluation of leg pain SO VASCULAR MEDICINE LA English DT Article DE claudication; degenerative joint disease; peripheral artery disease ID TOTAL KNEE REPLACEMENT; PRIMARY-CARE/; MORTALITY AB Lower extremity peripheral arterial disease (PAD) and musculoskeletal conditions both produce symptoms of leg pain, and may coexist. This study assesses the prevalence of PAD among patients referred to orthopedic surgery for evaluation of lower extremity pain. Fifty consecutive patients aged 50 years or more who had a chief complaint of leg pain, no history of trauma, and no previous history of PAD were studied prospectively. The presence of known risk factors for PAD and classic claudication symptoms was assessed by telephone interview and medical record review. Individuals were then evaluated by measurement of the ankle-brachial index (ABI) using Doppler and pulse volume recordings (PVR). A patient was deemed to have PAD if the ABI was below 0.9 or if the PVR demonstrated significant abnormalities. Occult PAD was detected in 10 of the 50 patients (20%) on the basis of the non-invasive vascular studies. There were no differences between patients with PAD and those without PAD regarding the presence of risk factors for PAD. None of the patients without PAD had claudication, while only one of the 10 patients with PAD had symptoms of classic claudication. In conclusion, 20% of patients referred by primary care providers to the orthopedic surgery clinic for lower extremity pain were discovered to have occult PAD. The majority of these patients did not have claudication. Orthopedic surgeons and primary care providers must maintain an appropriately high index of suspicion for PAD when evaluating patients with non-traumatic lower extremity pain. C1 [Mitchell, Marc E.] Univ Mississippi, Dept Surg, Jackson, MS 39216 USA. [Bernstein, Joseph; Esterhai, John L.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Bernstein, Joseph; Esterhai, John L.; Staska, Mitchell; Reinhardt, Sally] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Mitchell, ME (reprint author), Univ Mississippi, Dept Surg, 2500 N State St, Jackson, MS 39216 USA. EM memitchell@surgery.umsmed.edu NR 14 TC 4 Z9 4 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X J9 VASC MED JI Vasc. Med. PD AUG PY 2008 VL 13 IS 3 BP 235 EP 238 DI 10.1177/1358863X08091970 PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 346PS UT WOS:000259081900004 PM 18687760 ER PT J AU Xu, GG Intano, GW McCarrey, JR Walter, RB McMahan, CA Walter, CA AF Xu, Guogang Intano, Gabriel W. McCarrey, John R. Walter, Ronald B. McMahan, C. Alex Walter, Christi A. TI Recovery of a low mutant frequency after ionizing radiation-induced mutagenesis during spermatogenesis SO MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS LA English DT Article DE ionizing radiation; mutagenesis; spermatogenic cells; Lac I mouse ID SEMINIFEROUS EPITHELIAL FUNCTION; SPERMATOGONIAL STEM-CELLS; ATOMIC-BOMB SURVIVORS; LACI TRANSGENIC MICE; MALE GERM-CELLS; TESTICULAR CELLS; INDUCED MUTATION; DOSE-RESPONSE; GENETIC RISKS; X-RAYS AB Humans are exposed to ionizing radiation (IR) under various circumstances, e.g. cosmic radiation, diagnostic X-rays and radiotherapy for cancer. It has been shown that IR can impair spermatogenesis and can cause mutations in germ cells. However, the mutagenic responses of germ cells exposed to IR at different stages of testicular maturation have not been examined by directly assessing the mutant frequency in defined spermatogenic cell types. This study was performed to address whether preadult exposure to IR can increase mutations in adult germ cells that could in turn have a major impact on adult reproductive function and the health of ensuing offspring. Male Lac I transgenic mice were irradiated with a single dose of 2.5 Gy of gamma-ray at different ages before adulthood, reflecting different stages of testicular maturation, and then mutant frequency (MF) was determined directly in spermatogenic cell types emanating from the irradiated precursor cells. The results showed that (I) preadult exposure to IR did not significantly increase MF in adult epididymal spermatozoa; (2) spermatogenic stages immediately following the irradiated stage(s) displayed an elevated mutant frequency; but (3) the mutant frequency was restored to unirradiated levels in later stages of spermatogenesis. These findings provide evidence that there is a mechanism(s) to prevent spermatogenic cells with elevated mutant frequencies from progressing through spermatogenesis. Published by Elsevier B.V. C1 [Xu, Guogang; Intano, Gabriel W.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [McCarrey, John R.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. [Walter, Ronald B.] SW Texas State Univ, Dept Chem & Biochem, San Marcos, TX 78666 USA. [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] Audie Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NIH [AG24364, AG21163] FX This work was supported by NIH grants AG24364 and AG21163 to Dr. C.A. Walter. The contents are solely the responsibility of the authors, and do not necessarily represent the official views of the NIH. NR 53 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1383-5718 J9 MUTAT RES-GEN TOX EN JI Mutat. Res. Genet. Toxicol. Environ. Mutagen. PD JUL 31 PY 2008 VL 654 IS 2 BP 150 EP 157 DI 10.1016/j.mrgentox.2008.05.012 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology GA 342UN UT WOS:000258809200007 PM 18582597 ER PT J AU Sun, SL Wang, F Wei, J Cao, LY Wu, GY Lu, L Kosten, TA Kosten, TR Zhang, XY AF Sun, Shilong Wang, Fan Wei, Jun Cao, Lian Yuan Wu, Gui Ying Lu, Lin Kosten, Therese A. Kosten, Thomas R. Zhang, Xiang Yang TI Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population SO NEUROSCIENCE LETTERS LA English DT Article DE schizophrenia; interleukin-3 receptor; polymorphism; association; cytokine ID INTERLEUKIN-3 AB Schizophrenia has been observed to be associated with various abnormalities in cytokines and cytokine receptors. Three very recent reports showed the evidence that the IL3 gene, colony stimulating factor 2 receptor alpha (CSF2RA), beta (CSF2RB) and IL-3 receptor alpha (IL3RA), the IL-specific receptor sub-units for CSF2 and IL3, respectively, are associated with schizophrenia. To examine the association of the IBRA polymorphism (rs6603272) with schizophrenia in a Chinese population, 310 physically healthy patients with schizophrenia were compared with 330 age-, sex-matched normal controls. Statistically significant differences were observed in both allelic and genotypic frequencies of the rs6603272 polymorphism (Allele, chi(2) = 6.24, d.f. = 1, p =0.013, odds ratio (OR)= 1.35, 95% Cl 1.07-1.71; Genotype, chi(2) = 6.85, d.f. = 2, p = 0.033). Our results indicate a small but significant contribution of the IBRA polymorphism to susceptibility to schizophrenia, suggesting that the IL3 pathway may be involved in schizophrenia. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Wu, Gui Ying; Kosten, Therese A.; Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, VA Med Ctr, Houston, TX 77030 USA. Jilin Univ, Neurosci Res Ctr, Changchun 130023, Peoples R China. Jilin Univ, MH Radiobiol Res Unit, Changchun 130023, Peoples R China. [Wang, Fan; Cao, Lian Yuan; Zhang, Xiang Yang] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. [Wei, Jun] Univ Highlands and Islands, Ness Fdn, Inverness IV3 8GY, Scotland. [Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China. RP Zhang, XY (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM jun.wei@ness.uhi.ac.uk; kosten@bcm.edu; xyzhang@bcm.edu FU NIDA NIH HHS [P50-DA18827, K05-DA0454] NR 12 TC 16 Z9 17 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUL 25 PY 2008 VL 440 IS 1 BP 35 EP 37 DI 10.1016/j.neulet.2008.05.029 PG 3 WC Neurosciences SC Neurosciences & Neurology GA 326EE UT WOS:000257640200009 PM 18547720 ER PT J AU Baratelli, F Takedatsu, H Hazra, S Peebles, K Luo, J Kurimoto, PS Zeng, G Batra, RK Sharma, S Dubinett, SM Lee, JM AF Baratelli, Felicita Takedatsu, Hiroko Hazra, Saswati Peebles, Katherine Luo, Jie Kurimoto, Pam S. Zeng, Gang Batra, Raj K. Sharma, Sherven Dubinett, Steven M. Lee, Jay M. TI Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer SO JOURNAL OF TRANSLATIONAL MEDICINE LA English DT Article ID CD4(+) T-CELLS; ADENOVIRAL VECTOR; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; TUMOR-IMMUNITY; VACCINATION; ANTIGEN; CHEMOKINE; VACCINES; IMMUNOTHERAPY AB Background: Our previous studies have demonstrated that transduction of human dendritic cells (DC) with adenovirus encoding secondary lymphoid chemokine, CCL21, led to secretion of biologically active CCL21 without altering DC phenotype or viability. In addition, intratumoral injections of CCL21-transduced DC into established murine lung tumors resulted in complete regression and protective anti-tumor immunity. These results have provided the rationale to generate a clinical grade adenoviral vector encoding CCL-21 for ex vivo transduction of human DC in order to assess intratumoral administration in late stage human lung cancer. Methods: In the current study, human monocyte-derived DC were differentiated by exposure to GM-CSF and IL-4 from cryopreserved mononuclear cells obtained from healthy volunteers. Transduction with clinical grade adenoviral vector encoding CCL21 (1167 viral particles per cell) resulted in secretion of CCL21 protein. Results: CCL21 protein production from transduced DC was detected in supernatants (24-72 hours, 3.5-6.7 ng/4-5 x 10(6) cells). DC transduced with the clinical grade adenoviral vector were > 88% viable (n = 16), conserved their phenotype and maintained integral biological activities including dextran uptake, production of immunostimulatory cytokines/chemokines and antigen presentation. Furthermore, supernatant from CCL21-DC induced the chemotaxis of T2 cells in vitro. Conclusion: Viable and biologically active clinical grade CCL21 gene-modified DC can be generated from cryopreserved PBMC. C1 [Baratelli, Felicita; Takedatsu, Hiroko; Hazra, Saswati; Peebles, Katherine; Luo, Jie; Kurimoto, Pam S.; Batra, Raj K.; Sharma, Sherven; Dubinett, Steven M.; Lee, Jay M.] Univ Calif Los Angeles, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med,Dept Med, Los Angeles, CA 90095 USA. [Dubinett, Steven M.] Univ Calif Los Angeles, Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Batra, Raj K.; Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA 90073 USA. [Zeng, Gang] Univ Calif Los Angeles, Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Lee, Jay M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiothorac Surg, Los Angeles, CA 90095 USA. RP Lee, JM (reprint author), Univ Calif Los Angeles, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med,Dept Med, Los Angeles, CA 90095 USA. EM fbaratelli@mednet.ucla.edu; htakedatsu@mednet.ucla.edu; shazra@mednet.ucla.edu; katherine.peebles@gmail.com; jluo@mednet.ucla.edu; pkurimoto@mednet.ucla.edu; gzeng@mednet.ucla.edu; rbatra@ucla.edu; ssharma@mednet.ucla.edu; sdubinett@mednet.ucla.edu; jaymoonlee@mednet.ucla.edu OI Batra, Raj K./0000-0002-1126-543X FU UCLA Lung Cancer [SPORE NCI P50 CA90388]; UC Tobacco Related Research Program; Department of Veteran Affairs; UCLA Cancer Gene Medicine Training Program [NCI 5 K12 CA076095]; Ronald Binder Memorial Fund for Lung Cancer Research; NCI Rapid Access to Intervention Development ( RAID) Program [476]; National Institutes of Health [CA-16042, AI-28697]; Jonsson Comprehensive Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA FX Supported by the UCLA Lung Cancer SPORE NCI P50 CA90388, Grants from the UC Tobacco Related Research Program, Merit Review research funds from the Department of Veteran Affairs, UCLA Cancer Gene Medicine Training Program NCI 5 K12 CA076095, and the Ronald Binder Memorial Fund for Lung Cancer Research. Resources for the manufacture and testing of clinical-grade AdCCL21 were provided by the NCI Rapid Access to Intervention Development ( RAID) Program, Project # 476.; Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer for AIDS Research Flow Cytometry Core Facility supported by National Institutes of Health awards CA-16042 and AI-28697, by the Jonsson Comprehensive Cancer Center, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA. NR 47 TC 27 Z9 28 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1479-5876 J9 J TRANSL MED JI J. Transl. Med. PD JUL 22 PY 2008 VL 6 AR 38 DI 10.1186/1479-5876-6-38 PG 17 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 337JZ UT WOS:000258433700002 PM 18644162 ER PT J AU Yamaoka, Y AF Yamaoka, Yoshio TI Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Helicobacter pylori; BabA; pathogenesis; Lewis antigens ID ANTIGEN-BINDING ADHESIN; HUMAN GASTRIC EPITHELIUM; BLOOD-GROUP ANTIGENS; COMPLETE GENOME SEQUENCE; OUTER-MEMBRANE PROTEINS; DUODENAL-ULCER; CLINICAL-RELEVANCE; VIRULENCE FACTORS; HUMAN STOMACH; MUCOUS LAYER AB Interactions between BabA and Lewis b (Le(b)) related antigens are the best characterized adhesin-receptor interactions in Helicobacter pylori (H pylori). Several mechanisms for the regulation of BabA expression are predicted, including at both transcriptional and translational levels. The formation of chimeric proteins (babA/B or babB/A chimeras) seems to play an especially important role in translational regulation. Chimeric BabB/A protein had the potential to bind Le(b); however, protein production was subject to phase variation through slipped strand mispairing. The babA gene was cloned initially from strain CCUG17875, which contains a silent babA1 gene and an expressed babA2 gene. The sequence of these two genes differs only by the presence of a 10 bp deletion in the signal peptide sequence of babA1 that eliminates its translational initiation codon. However, the babA1 type deletion was found only in strain CCUG17875. A few studies evaluated BabA status by immunoblot and confirmed that BabA-positive status in Western strains was closely associated with severe clinical outcomes. BabA-positive status also was associated with the presence of other virulence factors (e.g. cagA-positive status and vacA s1 genotype). A small class of strains produced low levels of the BabA protein and lacked Le(b) binding activity. These were more likely to be associated with increased mucosal inflammation and severe clinical outcomes than BabA-positive strains that exhibited Le(b) binding activity. The underlying mechanism is unclear, and further studies will be necessary to investigate how the complex BabA-receptor network is functionally coordinated during the interaction of H pylori with the gastric mucosa. (c) 2008 The WJG Press. All rights reserved. C1 [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, 2002 Holcombe Blvd,111D,Rm 3A-320, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [R01 DK062813, R01 DK62813, R01 DK062813-04] NR 55 TC 42 Z9 47 U1 0 U2 2 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JUL 21 PY 2008 VL 14 IS 27 BP 4265 EP 4272 DI 10.3748/wjg.14.4265 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 333JG UT WOS:000258148200001 PM 18666312 ER PT J AU Vacharaksa, A Asrani, AC Gebhard, KH Fasching, CE Giacaman, RA Janoff, EN Ross, KF Herzberg, MC AF Vacharaksa, Anjalee Asrani, Anil C. Gebhard, Kristin H. Fasching, Claudine E. Giacaman, Rodrigo A. Janoff, Edward N. Ross, Karen F. Herzberg, Mark C. TI Oral keratinocytes support non-replicative infection and transfer of harbored HIV-1 to permissive cells SO RETROVIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; UTERINE EPITHELIAL-CELLS; SURFACE HEPARAN-SULFATE; SERUM-FREE MEDIUM; TYPE-1 INFECTION; LANGERHANS CELLS; GENE-EXPRESSION; HUMAN SALIVA; TRANSMISSION; ENTRY AB Background: Oral keratinocytes on the mucosal surface are frequently exposed to HIV-1 through contact with infected sexual partners or nursing mothers. To determine the plausibility that oral keratinocytes are primary targets of HIV-1, we tested the hypothesis that HIV-1 infects oral keratinocytes in a restricted manner. Results: To study the fate of HIV-1, immortalized oral keratinocytes (OKF6/TERT-2; TERT-2 cells) were characterized for the fate of HIV-specific RNA and DNA. At 6 h post inoculation with X4 or R5-tropic HIV-1, HIV-1gag RNA was detected maximally within TERT-2 cells. Reverse transcriptase activity in TERT-2 cells was confirmed by VSV-G-mediated infection with HIV-NL43.env-EGFP. AZT inhibited EGFP expression in a dose-dependent manner, suggesting that viral replication can be supported if receptors are bypassed. Within 3 h post inoculation, integrated HIV-1 DNA was detected in TERT-2 cell nuclei and persisted after subculture. Multiply spliced and unspliced HIV-1 mRNAs were not detectable up to 72 h post inoculation, suggesting that HIV replication may abort and that infection is non-productive. Within 48 h post inoculation, however, virus harbored by CD4 negative TERT-2 cells trans infected co-cultured peripheral blood mononuclear cells (PBMCs) or MOLT4 cells (CD4+ CCR5+) by direct cell-to-cell transfer or by releasing low levels of infectious virions. Primary tonsil epithelial cells also trans infected HIV-1 to permissive cells in a donor-specific manner. Conclusion: Oral keratinocytes appear, therefore, to support stable non-replicative integration, while harboring and transmitting infectious X4- or R5-tropic HIV-1 to permissive cells for up to 48 h. C1 [Vacharaksa, Anjalee; Asrani, Anil C.; Gebhard, Kristin H.; Giacaman, Rodrigo A.; Ross, Karen F.; Herzberg, Mark C.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA. [Vacharaksa, Anjalee; Asrani, Anil C.; Gebhard, Kristin H.; Fasching, Claudine E.; Giacaman, Rodrigo A.; Janoff, Edward N.; Ross, Karen F.; Herzberg, Mark C.] Minneapolis VA Med Ctr, Mucosal & Vaccine Res Ctr, Minneapolis, MN 55417 USA. [Janoff, Edward N.] Univ Colorado, Div Infect Dis, Colorado Ctr AIDS Res, Denver, CO 80220 USA. [Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado, Denver, CO 80220 USA. [Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Herzberg, MC (reprint author), Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA. EM tang0160@umn.edu; asran003@umn.edu; kristingebhard@mac.com; Claudine.Fasching@va.gov; giac0015@umn.edu; Edward.Janoff@ucdenver.edu; rossx007@umn.edu; mcherzb@umn.edu RI Giacaman, Rodrigo/A-9811-2010 OI Giacaman, Rodrigo/0000-0003-3362-5173 FU NIH [DE015503, DE15506, HD4136, DE72621] FX These studies were supported by NIH grants-in-aid DE015503 (to MCH), DE15506 (KFR), HD41361 (ENJ), DE72621 (ENJ), the Veterans Affairs Research Service, and the Mucosal and Vaccine Research Center. This manuscript has been submitted in partial fulfillment of the requirements for the PhD degree in oral biology by AV. NR 74 TC 19 Z9 19 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD JUL 17 PY 2008 VL 5 AR 66 DI 10.1186/1742-4690-5-66 PG 14 WC Virology SC Virology GA 337XV UT WOS:000258469700002 PM 18637194 ER PT J AU Wang, SB Yang, Q Fung, KM Lin, HK AF Wang, Shaobin Yang, Qing Fung, Kar-Ming Lin, Hsueh-Kung TI AKR1C2 and AKR1C3 mediated prostaglandin D-2 metabolism augments the P13K/Akt proliferative signaling pathway in human prostate cancer cells SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article DE aldo-keto reductase; prostaglandin; prostate cancer ID ACTIVATED PROTEIN-KINASE; KETO REDUCTASE AKR1C3; ANDROGEN RECEPTOR; DEHYDROGENASE ISOFORMS; INCREASED EXPRESSION; F SYNTHASE; ADENOCARCINOMA; PROGRESSION; APOPTOSIS; TARGET AB Members of the aldo-keto reductase (AKR) superfamily have been implicated in prostaglandin (PG) metabolism and prostate cancer. AKR1C3 possesses 11-ketoprostaglandin reductase activity and is capable of converting PGD(2) to 9 alpha. 11 beta-PGF(2 alpha)., whereas AKR1C2-mediated PG metabolism remains unclear. The accumulation of PGF(2 alpha). may generate proliferative signals to promote prostate cell growth. Levels of AKR1C2 and AKR1C3 expression are elevated in localized and advanced prostate cancer. To study the significance of AKR1C2-and AKR1C3-mediated PGD(2) conversion in human prostatecell proliferation, we stably transfected androgen insensitive human prostate cancer PC-3 cells with AKR1C2 or AKR1C3 cDNA. PC-3 cells overexpressing AKR1C2 and AKR1C3 had elevated cell proliferation in response to PGD2 Stimulation as compared to mock transfectants. Overexpression of AKR1C2 or AKR1C3 did not alter levels of PGF receptor (FP) expression. Inclusion of an FP antagonist (AL8810) significantly suppressed PGD(2)-stimulated PC-3 cell proliferation in these stable transfectants. In addition, PGD2 significantly elevated levels of total Akt protein expression and Akt Ser(473) phosphorylation in AKR1C2 and AKR1C3 stable transfectants; and inclusion of a phosphatidylinositol 3-kinase (PI3K) chemical inhibitor (LY294002) attenuated PGD(2)-stimulated cell proliferation in these transfectants. Our results suggested that both AKR1C2 and AKR1C3 mediate similar PGD2 conversion toward the accumulation of proliferative signals through FP and PI3K/Akt signaling pathways to promote prostate cell proliferation. Published by Elsevier Ireland Ltd. C1 [Wang, Shaobin; Yang, Qing; Lin, Hsueh-Kung] Univ Oklahoma, Hlth Sci Ctr, Dept Urol, Oklahoma City, OK 73104 USA. [Wang, Shaobin; Lin, Hsueh-Kung] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA. [Fung, Kar-Ming] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA. [Fung, Kar-Ming; Lin, Hsueh-Kung] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. RP Lin, HK (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Urol, 920 Stanton L Young Blvd,WP 3150, Oklahoma City, OK 73104 USA. EM hk-in@ouhsc.edu RI wang, shaobin/D-7168-2011; wang, shaobin/A-2415-2015; wang, shaobin/L-8539-2015 OI wang, shaobin/0000-0002-0931-7210; NR 46 TC 27 Z9 29 U1 1 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD JUL 16 PY 2008 VL 289 IS 1-2 BP 60 EP 66 DI 10.1016/j.mce.2008.04.004 PG 7 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 329BK UT WOS:000257841700008 PM 18508192 ER PT J AU Farr, MJ Lang, CC LaManca, JJ Zile, MR Francis, G Tavazzi, L Gaasch, WH Sutton, MSJ Itoh, H Mancini, D AF Farr, Mary Jane Lang, Chim C. LaManca, John J. Zile, Michael R. Francis, Gary Tavazzi, Luigi Gaasch, William H. Sutton, Martin St. John Itoh, Haruki Mancini, Donna CA MCC-135 GO1 Invest TI Cardiopulmonary exercise variables in diastolic versus systolic heart failure SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID TRANSPLANTATION; DYSFUNCTION AB The response to cardiopulmonary exercise (CPX) in patients with heart failure (HF) with normal left ventricular (LV) ejection fractions (EFs) is not well characterized. To determine if CPX testing could distinguish between patients with HF with normal EFs (> 50%; i.e., diastolic HF) and those with decreased EFs ( >= 50%; i.e., systolic HF), CPX responses were compared between 185 patients with systolic HF (79% men, mean age 62.6 +/- 10.9 years) and 43 with diastolic HF (54% men, mean age 67.4 +/- 9.8 years) enrolled in a phase 11 multicenter clinical trial. All patients were evaluated with echocardiography and a standardized CPX test as part of the trial. CPX variables, including oxygen uptake at peak exercise (peak VO2) and the slope of the ventilation/carbon dioxide production ratio (VE/VCO2), were determined and analyzed by core laboratory personnel. Echocardiographic measurements included the LV EF, the E/A ratio, filling time, cavity volumes, right ventricular function, and mitral regurgitation. Patients in the diastolic HF group tended to be older (p < 0.08), with more women (p < 0.006) and with greater body mass indexes (p < 0.02), than those in the systolic HF group. There was no significant difference in the use of P blockers or the incidence of coronary artery disease. Patients with diastolic HF had decreased E/A ratios (0.9 +/- 0.4 vs 1.4 +/- 1.1, p < 0.02, diastolic HF vs systolic HF) and increased filling times (30.4 +/- 3.2 vs 26.5 +/- 4.7 ms, p < 0.01, diastolic HF vs systolic HF). No significant differences in peak VO2 (14.4 +/- 1.9 vs 15.6 3.2 ml/kg/min, p = 0.06, diastolic HF vs systolic HF) were observed. The VE/VCO2 ratios for the 2 groups were abnormal and comparable (32 2 +/- 7.5 vs 34.0 +/- 8.3, p = 0.3, diastolic HF vs systolic HF). In conclusion, the CPX response in patients with diastolic HF and systolic HF is markedly abnormal and indistinguishable with regard to peak VO2 and ventilation despite marked differences in the LV EF. (C) 2008 Elsevier Inc. All rights reserved. C1 [Farr, Mary Jane; LaManca, John J.; Mancini, Donna] Columbia Univ, Div Cardiol, New York, NY 10027 USA. [Lang, Chim C.] Univ Dundee, Ninewells Hosp & Med Sch, Div Med & Therapeut, Dundee DD1 9SY, Scotland. [Zile, Michael R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Francis, Gary] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Tavazzi, Luigi] Osped Gen, Div Cardiol, Pavia, Italy. [Gaasch, William H.] Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA. [Sutton, Martin St. John] Univ Penn, Philadelphia, PA 19104 USA. [Itoh, Haruki] Sakakibara Heart Inst, Tokyo, Japan. RP Lang, CC (reprint author), Columbia Univ, Div Cardiol, New York, NY 10027 USA. EM c.c.lang@dundee.ac.uk NR 9 TC 20 Z9 20 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 15 PY 2008 VL 102 IS 2 BP 203 EP 206 DI 10.1016/j.amjcard.2008.03.041 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 327MZ UT WOS:000257734500018 PM 18602522 ER PT J AU Schuster, MG Edwards, JE Sobel, JD Darouiche, RO Karchmer, AW Hadley, S Slotman, G Panzer, H Biswas, P Rex, JH AF Schuster, Mindy G. Edwards, John E., Jr. Sobel, Jack D. Darouiche, Rabih O. Karchmer, Adolf W. Hadley, Susan Slotman, Gus Panzer, Helene Biswas, Pinaki Rex, John H. TI Empirical fluconazole versus placebo for intensive care unit patients - A randomized trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CRITICALLY-ILL PATIENTS; SURGICAL-PATIENTS; DOUBLE-BLIND; PROSPECTIVE MULTICENTER; NEUTROPENIC PATIENTS; CANDIDAL INFECTIONS; AMPHOTERICIN-B; RISK-FACTORS; EPIDEMIOLOGY; PROPHYLAXIS AB Background: Invasive infection with Candida species is an important cause of morbidity and mortality in intensive care unit (ICU) patients. Optimal preventive strategies have not been clearly defined. Objective: To see whether empirical fluconazole improves clinical outcomes more than placebo in adult ICU patients at high risk for invasive candidiasis. Design: Double-blind, placebo-controlled, randomized trial conducted from 1995 to 2000. Setting: 26 ICUs in the United States. Patients: 270 adult ICU patients with fever despite administration of broad-spectrum antibiotics. All had central venous catheters and an Acute Physiology and Chronic Health Evaluation II score greater than 16. Intervention: Patients were randomly assigned to either intravenous fluconazole, 800 mg daily, or placebo for 2 weeks and were followed for 4 weeks thereafter. Two hundred forty-nine participants were available for outcome assessment. Measurements: A composite primary outcome that defined success as all 4 of the following: resolution of fever; absence of invasive fungal infection; no discontinuation because of toxicity; and no need for a nonstudy, systemic antifungal medication (as assessed by a blinded oversight committee). Results: Only 44 of 122 (36%) fluconazole recipients and 48 of 127 (38%) placebo recipients had a successful outcome (relative risk, 0.95 [95% CI, 0.69 to 1.32; P = 0.781). The main reason for failure was lack of resolution of fever (51 % for fluconazole and 57% for placebo). Documented invasive candidiasis occurred in 5% of fluconazole recipients and 9% of placebo recipients (relative risk, 0.57 [CI, 0.22 to 1.491). Seven (5%) fluconazole recipients and 10 (7%) placebo recipients had adverse events resulting in discontinuation of the study drug. Discontinuation because of abnormal liver test results occurred in 3 (2%) fluconazole recipients and 5 (4%) placebo recipients. Limitations: Twenty-one randomly assigned patients were not included in the analysis because they either did not meet entry criteria or did not have postbaseline assessments. Fewer fungal infections than anticipated occurred in the control group. Confidence bounds were wide and did not exclude potentially important differences in outcomes between groups. Conclusion: In critically ill adults with risk factors for invasive candidiasis, empirical fluconazole did not clearly improve a composite outcome more than placebo. C1 [Schuster, Mindy G.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA. Wayne State Univ, Sch Med, Detroit Med Ctr, Detroit, MI USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Texas Houston, Sch Med, Houston, TX USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Tufts Univ New England Med Ctr, Boston, MA USA. Univ Med & Dent New Jersey, Newark, NJ 07103 USA. Pfizer, New York, NY USA. RP Schuster, MG (reprint author), Univ Penn, Sch Med, 3 Silverstein,Suite E,3400 Spruce St, Philadelphia, PA 19104 USA. EM schustem@mail.med.upenn.edu NR 27 TC 102 Z9 110 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 15 PY 2008 VL 149 IS 2 BP 83 EP 90 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 329GA UT WOS:000257853700002 PM 18626047 ER PT J AU Safdar, A Rodriguez, GH Rueda, AM Wierda, WG Ferrajoli, A Musher, DM O'Brien, S Koller, CA Bodey, GR Keating, MJ AF Safdar, Amar Rodriguez, Gilhen H. Rueda, Adriana M. Wierda, William G. Ferrajoli, Alessandra Musher, Daniel M. O'Brien, Susan Koller, Charles A. Bodey, Gerald R. Keating, Michael J. TI Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia - A prospective, randomized trial of safety and immunogenicity SO CANCER LA English DT Article DE Streptococcus pneumonia; pneumococcal vaccine; chronic lymphocytic leukemia; granulocyte-macrophage-colony-stimulating factor; immunogenicity; reactogenicity ID ANTIBODY-RESPONSES; INFLUENZA VACCINE; DENDRITIC CELLS; RECEPTOR; DISEASE; CANCER AB BACKGROUND. For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). METHODS. Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 mu g) given before or after vaccination. Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV They were randomized to receive 3 doses of GM-CSF either before or after vaccination or to receive no GM-CSE. RESULTS. A 4-fold rise in immunoglobulin G (IgG) to capsular polysaccharides from Streptococcus pneumoniae types 4, 613, 9V, 14, 19F, and 23F occurred in <10% of patients in each of the 3 groups. There were no differences in geometric mean IgG levels in any of the 3 groups 4 weeks or 12 weeks after vaccination. CONCLUSIONS. In patients with CLL, the response to pure polysaccharide pneumococcal vaccine was low despite immune enhancement with multiple doses of GM-CSF In all patients, reactogenicity was minor. C1 [Safdar, Amar; Rodriguez, Gilhen H.; Bodey, Gerald R.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Unit 402, Houston, TX 77030 USA. [Rueda, Adriana M.; Musher, Daniel M.] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Houston, TX USA. [Rueda, Adriana M.; Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Wierda, William G.; Ferrajoli, Alessandra; O'Brien, Susan; Koller, Charles A.; Keating, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Safdar, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Unit 402, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM asafdar@mdanderson.org FU NCI NIH HHS [CA16672, P30 CA016672] NR 15 TC 16 Z9 18 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD JUL 15 PY 2008 VL 113 IS 2 BP 383 EP 387 DI 10.1002/cncr.23561 PG 5 WC Oncology SC Oncology GA 322WM UT WOS:000257406000018 PM 18470901 ER PT J AU Chaiswing, L Zhong, WX Cullen, JJ Oberley, LW Oberley, TD AF Chaiswing, Luksana Zhong, Weixiong Cullen, Joseph J. Oberley, Larry W. Oberley, Terry D. TI Extracellular redox state regulates features associated with prostate cancer cell invasion SO CANCER RESEARCH LA English DT Article ID SUPEROXIDE-DISMUTASE; THIOL/DISULFIDE REDOX; OXIDATIVE STRESS; TUMOR-CELLS; THIOREDOXIN; CARCINOMA; METASTASIS; EXPRESSION; LINES AB We have examined the possible role of extracellular reduction-oxidation (redox) state in regulation of biological/biochemical features associated with prostate cancer cell invasion. DU145, PC-3, and RWPE1-derived human prostate cancer (WPE1-NB26) cell lines were used for the present in vitro analysis. Increasing levels of nitric oxide using S-nitroso-N-acetylpenicillamine resulted in a decrease in cell invasion ability, whereas increasing levels of extracellular superoxide radical (O-2(center dot-)) using xanthine/xanthine oxidase resulted in an increase in cell invasion ability in these three cell lines. WPE1-NB26 cells exhibited an increased glutathione/glutathione disulfide ratio in the medium in comparison with RWPE1 cells (immortalized but nonmalignant prostate epithelial cells), suggesting an alteration of extracellular redox state of WPE1-NB26 cells. We hypothesized that O-2(center dot-) production at or near the plasma membrane or in the adjacent extracellular matrix at least partially regulated prostate cancer cell invasion. Using adenovirus-mediated extracellular superoxide dismutase (EC- SOD) gene transduction to enzymatically decrease O-2(center dot-) levels, we showed that in the presence of heparin, adenovirus EC- SOD gene transduction resulted in an increase in the expression of EC-SOD outside the cells with resultant inhibition of cell invasion ability. This inhibition correlated with reduced metalloproteinase [matrix metalloproteinase (MMP) 2/membrane type 1-MMP] activities and increased levels of extracellular nitrite. Our results suggest a prominent role of extracellular redox status in regulation of cell invasion, which may provide opportunities for therapeutic interventions. C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Cullen, Joseph J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA. [Cullen, Joseph J.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA. [Oberley, Larry W.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, A-35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu NR 27 TC 35 Z9 36 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JUL 15 PY 2008 VL 68 IS 14 BP 5820 EP 5826 DI 10.1158/0008-5472.CAN-08-0162 PG 7 WC Oncology SC Oncology GA 327ZZ UT WOS:000257768300040 PM 18632636 ER PT J AU Alanay, A Chen, CH Lee, S Murray, SS Brochmann, EJ Miyazaki, M Napoli, A Wang, JC AF Alanay, Ahmet Chen, ChiHui Lee, Sang Murray, Samuel S. Brochmann, Elsa J. Miyazaki, Masashi Napoli, Antonia Wang, Jeffrey C. TI The adjunctive effect of a binding peptide on bone morphogenetic protein enhanced bone healing in a rodent model of spinal fusion SO SPINE LA English DT Article DE rhBMP-2; bone morphogenetic binding peptide; spinal fusion; adjuvant ID ANTERIOR CERVICAL DISKECTOMY; LUMBAR FUSION; LIGAMENTUM-FLAVUM; INTERBODY FUSION; MARROW-CELLS; RHBMP-2; GRAFT; COMPLICATIONS; COMPRESSION; EFFICACY AB Study Design. A prospective 8-week interventional trial employing a rat model of spinal fusion to test the effect on bone morphogenetic protein binding peptide (BBP) on rhBMP-2 induced bone healing. Objectives. To determine if the addition of BBP to the collagen sponges used as a carrier for rhBMP-2 reduces the amount of rhBMP-2 required to achieve a satisfactory clinical outcome. Summary of Background Data. Bone morphogenetic proteins (BMPs) although effective in promoting osseous growth and spinal fusion have limitations in their extensive use because of higher costs and possible adverse effects including ectopic bone formation and local inflammatory reaction, particularly in the cervical spine. Methods. Posterolateral intertransverse process spinal fusion at L4-L5 was performed in Lewis rats. Two doses of BBP (500 mu g, and 1000 mu g) were tested with or without "low dose" (1 mu g) rhBMP-2 and the results were compared with the low dose (1 mu g) rhBMP-2. Fusion was evaluated by radiology, histology, and manual palpation tests. Results. Radiology revealed significant earlier fusion with 1000 mu g BBP + 1 mu g BMP-2 combination when compared with low dose BMP-2 (1 mu g) only (P < 0.05). Manual palpation and histology at eighth week revealed higher rate of fusion with the same combination with a nearly significant difference (P = 0.057). Conclusion. Specific growth factor binding agents, such as BBP, can be compounded into carriers used in fusion procedures to decrease the dosage of BMP and possibly decrease the side effects which are most likely dose-related. This may also decrease costs and improve clinical outcomes. C1 [Alanay, Ahmet] Hacettepe Univ, Fac Med, Dept Orthopaed & Traumatol, TR-06100 Ankara, Turkey. [Chen, ChiHui; Lee, Sang; Miyazaki, Masashi; Napoli, Antonia; Wang, Jeffrey C.] Univ Calif Los Angeles, Sch Med, Dept Orthopaed & Traumatol, Los Angeles, CA 90095 USA. [Murray, Samuel S.; Brochmann, Elsa J.] Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Murray, Samuel S.; Brochmann, Elsa J.] VA Greater Los Angeles Hlth Care System, Sepulveda, CA USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. RP Wang, JC (reprint author), Univ Calif Los Angeles, Comprehens Spine Ctr, 1250 16th St,7th floor Tower 745, Los Angeles, CA 90095 USA. EM jwang@mednet.ucla.edu RI Alanay, Ahmet/D-7634-2015 FU NIAMS NIH HHS [5R21AR53259] NR 26 TC 29 Z9 30 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JUL 15 PY 2008 VL 33 IS 16 BP 1709 EP 1713 DI 10.1097/BRS.0b013e31817e9dfd PG 5 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 327PF UT WOS:000257740300001 PM 18580546 ER PT J AU Ross, JS Mulvey, GK Stauffer, B Patlolla, V Bernheim, SM Keenan, PS Krumholz, HM AF Ross, Joseph S. Mulvey, Gregory K. Stauffer, Brett Patlolla, Vishnu Bernheim, Susannah M. Keenan, Patricia S. Krumholz, Harlan M. TI Statistical models and patient predictors of readmission for heart failure - A systematic review SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 8th Scientific Forum of the American-Heart-Association on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 11, 2007 CL Washinton, DC SP Amer Heart Assoc ID BRAIN NATRIURETIC PEPTIDE; CARDIAC TROPONIN-T; VENTRICULAR EJECTION FRACTION; PRESERVED SYSTOLIC FUNCTION; QUALITY-OF-CARE; DISEASE MANAGEMENT PROGRAMS; OPTIMIZE-HF REGISTRY; ACID-BINDING PROTEIN; SHORT-TERM OUTCOMES; HOSPITAL READMISSION AB Background: Readmission after heart failure (HF) hospitalization is an increasing focus for physicians and policy makers, but statistical models are needed to assess patient risk and to compare hospital performance. We performed a systematic review to describe models designed to compare hospital rates of readmission or to predict patients' risk of readmission, as well as to identify studies evaluating patient characteristics associated with hospital readmission, all among patients admitted for HF. Methods: We identified relevant studies published between January 1, 1950, and November 19, 2007, by searching MEDLINE, Scopus, PsycINFO, and all 4 Ovid Evidence-Based Medicine Reviews. Eligible English-language publications reported on readmission after HF hospitalization among adult patients. We excluded experimental studies and publications without original data or quantitative outcomes. Results: From 941 potentially relevant articles, 117 met inclusion criteria: none contained models to compare readmission rates among hospitals, 5 (4.3%) presented models to predict patients' risk of readmission, and 112 (95.7%) examined patient characteristics associated with readmission. Studies varied in case identification, used multiple types of data sources, found few patient characteristics consistently associated with readmission, and examined differing outcomes, often either readmission alone or a combined outcome of readmission or death, measured across varying periods (from 14 days to 4 years). Two articles reported model discriminations of patient readmission risk, both of which were modest (C statistic, 0.60 for both). Conclusions: Our systematic review identified no model designed to compare hospital rates of readmission, while models designed to predict patients' readmission risk used heterogeneous approaches and found substantial inconsistencies regarding which patient characteristics were predictive. Clinically, patient risk stratification is challenging. From a policy perspective, a validated risk-standardized statistical model to accurately profile hospitals using readmission rates is unavailable in the published English-language literature to date. C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10027 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY 10027 USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Hlth Serv Res & Dev Targeted Res Enhancement Prog, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Mulvey, Gregory K.; Stauffer, Brett; Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. [Mulvey, Gregory K.; Stauffer, Brett; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA. [Patlolla, Vishnu; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT 06520 USA. [Bernheim, Susannah M.] Yale Univ, Sch Med, Sect Geriatr, Dept Med, New Haven, CT 06520 USA. [Keenan, Patricia S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10027 USA. EM joseph.ross@mssm.edu FU NIA NIH HHS [T32AG1934] NR 141 TC 162 Z9 164 U1 2 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 14 PY 2008 VL 168 IS 13 BP 1371 EP 1386 DI 10.1001/archinte.168.13.1371 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 325NH UT WOS:000257595100003 PM 18625917 ER PT J AU Zhou, XH Li, CM Yang, Z AF Zhou, X. H. Li, C. M. Yang, Z. TI Improving interval estimation of binomial proportions SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES LA English DT Article DE binomial; diagnostic accuracy; skewness; confidence interval; Edgeworth expansion ID CONFIDENCE-INTERVALS AB In this paper, we propose one new confidence interval for the binomial proportion; our interval is based on the Edgeworth expansion of a logit transformation of the sample proportion. We provide theoretical justification for the proposed interval and also compare the finite-sample performance of the proposed interval with the three best existing intervals the Wilson interval, the Agresti Coull interval and the Jeffreys interval in terms of their coverage probabilities and expected lengths. We illustrate the proposed method in two real clinical studies. C1 [Zhou, X. H.] VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Zhou, X. H.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Li, C. M.] Pfizer Inc, New York, NY 10017 USA. [Yang, Z.] Shandong Univ, Jinan 250100, Shandong, Peoples R China. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, Met Pk W,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM azhou@u.washington.edu NR 21 TC 13 Z9 14 U1 0 U2 2 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1364-503X J9 PHILOS T R SOC A JI Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci. PD JUL 13 PY 2008 VL 366 IS 1874 BP 2405 EP 2418 DI 10.1098/rsta.2008.0037 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 303US UT WOS:000256067000013 PM 18407898 ER PT J AU Kumar, M Reeve, JR Hu, W Miller, LJ Keire, DA AF Kumar, Mohanraja Reeve, Joseph R., Jr. Hu, Weidong Miller, Laurence J. Keire, David A. TI The micelle-associated 3D structures of Boc-Y(SO(3))-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK(1) receptor-bound model SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTOR; NUCLEAR-MAGNETIC-RESONANCE; AFFINITY CHOLECYSTOKININ RECEPTORS; FLUORESCENCE-TRANSFER MEASUREMENTS; HORMONE MEMBRANE INTERACTIONS; 3RD EXTRACELLULAR LOOP; COMMON AMINO-ACIDS; NMR-SPECTROSCOPY; INTERMOLECULAR INTERACTIONS; SEROTONIN(1A) RECEPTOR AB JMV-180 (1) and CCK-8(s) are high affinity ligands at the CCK(1) receptor that have similar and different actions via this receptor. Here we calculate the tertiary structure of 1 or CCK-8(s) in the presence of dodecylphosphocholine micelles at pH 5.0 and 35 degrees C from 2D (1)H NMR data recorded at 600 MHz. The NMR derived 3D structures of 1 and CCK-8(s) share a common type I beta-turn around residues Nle3/M3 and G4 and diverge from each other structurally at the N- and C-termini. The fluorescence and circular dichroism spectral properties of these peptides are consistent with their NMR derived structures. The structures determined in the presence of DPC micelles are compared to available models of 1 or CCK-8(s) bound to the CCK(1) receptor. For CCK and 1, these comparisons show that DPC micelle associated structures duplicate some important aspects of the models calculated from cross-linking derived constraints at the CCK(1) receptor. C1 [Kumar, Mohanraja; Reeve, Joseph R., Jr.; Keire, David A.] VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. [Kumar, Mohanraja; Reeve, Joseph R., Jr.; Keire, David A.] Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Hu, Weidong] Beckman Res Inst, City Hope, Duarte, CA 90010 USA. [Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA. RP Reeve, JR (reprint author), VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. EM jreeve@ucla.edu FU NIDDK NIH HHS [P30 DK041301, R01 DK032878, R37 DK032878, DK32878, DK 41301, DK33850, R01 DK033850] NR 81 TC 4 Z9 4 U1 0 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD JUL 10 PY 2008 VL 51 IS 13 BP 3742 EP 3754 DI 10.1021/jm701401j PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 322QS UT WOS:000257391000011 PM 18540665 ER PT J AU Silbert, LC Nelson, C Howieson, DB Moore, MM Kaye, JA AF Silbert, L. C. Nelson, C. Howieson, D. B. Moore, M. M. Kaye, J. A. TI Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline SO NEUROLOGY LA English DT Article ID AUSTRIAN STROKE PREVENTION; HEALTHY OLDEST-OLD; CARDIOVASCULAR HEALTH; ELDERLY-PATIENTS; RATING-SCALE; MRI; LESIONS; BRAIN; PEOPLE; PERFORMANCE AB Background: White matter hyperintensity (WMH) change on brain MRI is observed with increased frequency in the elderly and has been independently associated with neurologic decline. The degree to which the location and rate of volume increase in WMH affects other structural brain changes along with cognitive and motor performance over time may determine subsequent degrees of risk for dementia and other syndromes of aging. Methods: One hundred four cognitively intact men and women followed longitudinally for up to 13 years underwent at least three MRIs with corresponding annual cognitive and neurologic assessments. Brain volume, ventricular CSF (vCSF), and total periventricular (PV) and subcortical WMH volumes were measured. Progression of MRI volumes was examined in relation to rates of cognitive, motor, and cerebral volume change based on slopes of outcomes. Results: Higher initial total and PV WMH volume was associated with total WMH, PV WMH, and vCSF progression, and with increased time and number of steps to walk 30 feet. Progression of PV WMH volume was associated with increased time to walk 30 feet. Progression of subcortical WMH volume was associated with decreased performance on logical memory testing and increased rate of vCSF volume change. Conclusion: Increased total and periventricular (PV) white matter hyperintensity (WMH) burden and progression of PV WMH burden are associated with decreased gait performance over time, while progression of subcortical WMH volume is associated with memory decline in cognitively intact elderly. Greater progression of WMH burden is associated with an increased risk of memory and gait dysfunction, and thus should not be considered a benign process. C1 [Silbert, L. C.; Nelson, C.; Howieson, D. B.; Moore, M. M.; Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. [Silbert, L. C.; Kaye, J. A.] Portland VA Med Ctr, Portland, OR USA. RP Silbert, LC (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Dis Ctr, CR 131,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM silbertl@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 NR 34 TC 96 Z9 98 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JUL 8 PY 2008 VL 71 IS 2 BP 108 EP 113 DI 10.1212/01.wnl.0000316799.86917.37 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 322WV UT WOS:000257406900007 PM 18606964 ER PT J AU Kim, MH Choi, BH Jung, SR Sernka, TJ Kim, S Kim, KT Hille, B Nguyen, TD Koh, DS AF Kim, Mean-Hwan Choi, Bo-Hwa Jung, Seung-Ryoung Sernka, Thomas J. Kim, Seunghwan Kim, Kyong-Tai Hille, Bertil Nguyen, Toan D. Koh, Duk-Su TI Protease-activated receptor-2 increases exocytosis via multiple signal transduction pathways in pancreatic duct epithelial cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MOLECULAR-CLONING; SECRETION; AMPEROMETRY; CA2+; MECHANISMS; PROTECTION AB Protease-activated receptor-2 (PAR-2) is activated when trypsin cleaves its NH2 terminus to expose a tethered ligand. We previously demonstrated that PAR-2 activates ion channels in pancreatic duct epithelial cells (PDEC). Using real-time optical fluorescent probes, cyan fluorescence protein-Epac1-yellow fluorescence protein for cAMP, PHPLC-delta 1-enhanced green fluorescent protein for phosphatidylinositol 4,5-bisphosphate, and protein kinase C gamma (PKC gamma)-C1-yellow fluorescence protein for diacylglycerol, we now define the signaling pathways mediating PAR-2 effect in dog PDEC. Although PAR-2 activation does not stimulate acAMPincrease, it induces phospholipase C to hydrolyze phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol. Intracellular Ca2+ mobilization from inositol 1,4,5-trisphosphate- sensitive Ca2+ stores and a subsequent Ca2+ influx through store-operated Ca2+ channels cause a biphasic increase in intracellular Ca2+ concentration ([Ca2+](i)), measured with Indo-1 dye. Single-cell amperometry demonstrated that this increase in [Ca2+] i in turn causes a biphasic increase in exocytosis. A protein kinase assay revealed that trypsin also activates PKC isozymes to stimulate additional exocytosis. Paralleling the increased exocytosis, mucin secretion from PDEC was also induced by trypsin or the PAR-2 activating peptide. Consistent with the serosal localization of PAR-2, 1 mu M luminal trypsin did not induce exocytosis in polarized PDEC monolayers; on the other hand, 10 mu M trypsin at 37 degrees C damaged the epithelial barrier sufficiently so that it could reach and activate the serosal PAR-2 to stimulate exocytosis. Thus, in PDEC, PAR-2 activation increases [Ca2+](i) and activates PKC to stimulate exocytosis and mucin secretion. These functions may mediate the reported protective role of PAR-2 in different models of pancreatitis. C1 [Koh, Duk-Su] Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Kim, Mean-Hwan; Jung, Seung-Ryoung; Kim, Seunghwan; Koh, Duk-Su] POSTECH, Dept Phys, Pohang 790784, South Korea. [Choi, Bo-Hwa; Kim, Kyong-Tai] POSTECH, Dept Life Sci, Pohang 790784, South Korea. [Sernka, Thomas J.; Nguyen, Toan D.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Nguyen, Toan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Koh, DS (reprint author), Univ Washington, Sch Med, Dept Physiol & Biophys, Hlth Sci Bldg, Seattle, WA 98195 USA. EM koh@u.washington.edu FU NIDDK NIH HHS [DK55885]; NIGMS NIH HHS [GM083913] NR 29 TC 17 Z9 18 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 4 PY 2008 VL 283 IS 27 BP 18711 EP 18720 DI 10.1074/jbc.M801655200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 319LR UT WOS:000257165600028 PM 18448425 ER PT J AU Waxman, EA Duda, JE Giasson, BI AF Waxman, Elisa A. Duda, John E. Giasson, Benoit I. TI Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions SO ACTA NEUROPATHOLOGICA LA English DT Article DE alpha-synuclein; antibodies; fibrillization; Lewy bodies; Parkinson's disease ID MULTIPLE SYSTEM ATROPHY; FAMILIAL PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; FIBRIL FORMATION; PROTEIN DOMAINS; TRANSGENIC MICE; DEMENTIA; MUTATION; AGGREGATION AB Sensitive detection of alpha-synuclein (alpha-syn) pathology is important in the diagnosis of disorders like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy and in providing better insights into the etiology of these diseases. Several monoclonal antibodies that selectively react with aggregated alpha-syn in pathological inclusions and reveal extensive and underappreciated alpha-syn pathology in the brains of diseased patients were previously reported by Duda et al. (Ann Neurol 52:205-210, 2002). We sought to characterize the specificity of some of these antibodies (Syn 505, Syn 506 and Syn 514); using C-terminal and N-terminal truncations of alpha-syn, all three antibodies were determined to require N-terminal epitopes that minimally comprise amino acids 2-4, but possibly extend to amino acid 12 of alpha-syn. The selectivity of these antibodies was further assessed using biochemical analysis of human brains and reactivity to altered recombinant alpha-syn proteins with duplication variants of amino acids 1-12. In addition, by expressing wild-type or a double mutant (E46K/A53T) of alpha-syn in cultured cells and by comparing their immunoreactivities to another antibody (SNL-4), which has a similar primary epitope, it was determined that Syn 505, Syn 506 and Syn 514 recognize conformational variants of alpha-syn that is enhanced by the presence of the double mutations. These studies indicate that antibodies Syn 505, Syn 506 and Syn 514 preferentially recognize N-terminal epitopes in complex conformations, consistent with the dramatic conformational change associated with the polymerization of alpha-synuclein into amyloid fibrils that form pathological inclusions. C1 [Waxman, Elisa A.; Giasson, Benoit I.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. [Duda, John E.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. RP Giasson, BI (reprint author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk,123 John Morgan Bldg, Philadelphia, PA 19104 USA. EM giassonb@mail.med.upenn.edu FU NIA NIH HHS [AG09215, P01 AG009215, T32 AG000255, T32 AG000255-11A1, T32 AG00255]; NINDS NIH HHS [NS053488, P50 NS053488] NR 52 TC 34 Z9 34 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD JUL PY 2008 VL 116 IS 1 BP 37 EP 46 DI 10.1007/s00401-008-0375-1 PG 10 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 324UF UT WOS:000257544200004 PM 18414880 ER PT J AU Yarlagadda, SG Klein, CL Jani, A AF Yarlagadda, Sri G. Klein, Christina L. Jani, Alkesh TI Long-term renal outcomes after delayed graft function SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE delayed graft function; graft survival; outcomes; kidney function ID ACUTE TUBULAR-NECROSIS; HEART-BEATING DONORS; KIDNEY-TRANSPLANTATION; RISK-FACTORS; ACUTE REJECTION; CARDIAC DEATH; ALLOGRAFT SURVIVAL; COLD ISCHEMIA; PULSATILE PRESERVATION; PREDICTIVE FACTORS AB Delayed graft function (DGF) describes dysfunction of the kidney allograft immediately after transplantation and is the most common complication in the immediate posttransplantation period. Although a standardized definition for DGF is lacking, it is most commonly defined as the need for dialysis within the first week after transplant. DGF is caused by a variety of factors related to the donor and recipient as well as organ procurement techniques. The occurrence of DGF affects both allograft and patient outcomes. In addition to prolonging hospital stay and increasing the costs associated with transplantation, DGF is associated with an increased incidence of acute rejection after transplantation and is associated with poorer long-term graft outcomes. Both immunologic and nonimmunologic mechanisms contribute to DGF. The risk factors for DGF that have been identified are reviewed as well as the impact of DGF on long-term outcomes. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved. C1 Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Nephrol Sect, Denver, CO 80262 USA. RP Jani, A (reprint author), Denver Vet Affairs Med Ctr, Mail Code 111C,1055 Clermont, Denver, CO 80220 USA. EM Alkesh.jani@uchsc.edu FU NIDDK NIH HHS [1 K08 DK069512-01] NR 77 TC 30 Z9 34 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD JUL PY 2008 VL 15 IS 3 BP 248 EP 256 DI 10.1053/j.ackd.2008.04.005 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 322YH UT WOS:000257410700006 PM 18565476 ER PT J AU Walley, AY Krupitsky, EM Cheng, DM Raj, A Edwards, EM Bridden, C Egorova, VY Zvartau, EE Woody, GE Samet, JH AF Walley, Alexander Y. Krupitsky, Evgeny M. Cheng, Debbie M. Raj, Anita Edwards, Erika M. Bridden, Carly Egorova, Valentina Y. Zvartau, Edwin E. Woody, George E. Samet, Jeffrey H. TI Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users SO AIDS AND BEHAVIOR LA English DT Article DE cannabis; alcohol; Russia; HIV; risk behaviors ID ST-PETERSBURG; INJECTION RISK; SUBSTANCE USE; DEPENDENCE; WOMEN; MEN; METHAMPHETAMINE; ASSOCIATION; NALTREXONE; ADDICTION AB Cannabis and heavy alcohol use potentially increase HIV transmission by increasing risky drug behaviors. We studied 404 subjects entering treatment for heroin dependence, in St. Petersburg, Russia. We used the HIV Risk Assessment Battery (RAB) drug subscale to measure risky drug behavior. Although all heavy alcohol users had risky drug behaviors, their drug RAB scores did not differ from non-heavy alcohol users in unadjusted or adjusted analyses. Cannabis use was significantly associated with drug RAB scores in unadjusted analyses (mean difference 1.7 points) and analyses adjusted for age, sex, and employment (mean difference 1.3 points). When also adjusting for stimulant use, the impact of cannabis use was attenuated and no longer statistically significant (mean difference 1.1 points). Because of the central role of risky drug behaviors in the Russian HIV epidemic, it is important to understand how the use of multiple substances, including cannabis and alcohol, impacts risky drug behaviors. C1 [Walley, Alexander Y.; Cheng, Debbie M.; Bridden, Carly; Samet, Jeffrey H.] Boston Univ, Med Ctr, Clin Addict Res & Educ Unit, Sect Gen Internal Med,Dept Med, Boston, MA 02118 USA. [Walley, Alexander Y.; Cheng, Debbie M.; Bridden, Carly; Samet, Jeffrey H.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Krupitsky, Evgeny M.; Egorova, Valentina Y.; Zvartau, Edwin E.] Pavlov State Med Univ St Petersburg, St Petersburg Sci Res Ctr Addict & Psychopharmaco, St Petersburg, Russia. [Cheng, Debbie M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Raj, Anita; Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Edwards, Erika M.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA. [Woody, George E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Woody, George E.] Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Walley, AY (reprint author), Boston Univ, Med Ctr, Clin Addict Res & Educ Unit, Sect Gen Internal Med,Dept Med, 91 E Concord St,Suite 200, Boston, MA 02118 USA. EM awalley@bu.edu OI Samet, Jeffrey/0000-0002-0897-3400; Bridden, Carly/0000-0002-7208-7235; Walley, Alexander/0000-0002-8158-4882 FU NIAAA NIH HHS [K24-AA015674, K24 AA015674, R21 AA014821, R21-AA014821]; NIAID NIH HHS [T32 AI052074, T32 AI052074-05, T32-AI52074 04]; NIDA NIH HHS [K05 DA017009, K05 DA017009-06, K05-DA 17009, R25 DA013582, R25-DA13582, U10 DA013043, U10 DA013043-05, U10-DA13043] NR 43 TC 9 Z9 9 U1 3 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD JUL PY 2008 VL 12 IS 4 BP 662 EP 669 DI 10.1007/s10461-007-9243-6 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 315VJ UT WOS:000256908000016 PM 17487577 ER PT J AU Abraham, NS Castillo, DL Hartman, C AF Abraham, N. S. Castillo, D. L. Hartman, C. TI National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; PEPTIC-ULCER DISEASE; PRIMARY PREVENTION; ELDERLY PERSONS; RISK; INHIBITORS; OUTCOMES; ASPIRIN; DEATH; PRESCRIPTION AB Background Upper gastrointestinal events (UGIE), myocardial infarction (MI) and cerebrovascular accident (CVA) are known morbities among recent NSAID users. Aim To assess all-cause mortality following UGIE, MI or CVA among recent NSAID users. Methods Veterans > 65 prescribed an NSAID at any Veterans Affairs (VA) facility were identified using prescription fill data and their records linked to a merged VA-Medicare database. Each person-day was assessed for NSAID, coxib or proton pump inhibitor (PPI) exposure. Incidence density ratios and hazard rates of death were calculated following UGIE, MI and CVA adjusting for demographics, co-morbidity, prescription channeling, geographic location and pharmacological covariates. Results Among 474 495 patients [97.8% male; 85.3% white; 73.9 years (s.d. 5.6)], death followed at a rate of 5.5 per 1000 person-years (95% CI: 5.4-5.6) post-UGIE, 17.7 per 1000 person-years (95% CI: 17.5-17.9) post-MI and 21.8 per 1000 person-years (95% CI: 21.6-22.0) post-CVA. CVA was associated with greatest risk of death [hazard ratio (HR) 12.4; 95% CI: 10.9-14.3] followed by MI (HR 10.7; 95% CI: 9.2-11.6) and UGIE (HR 3.3; 95% CI: 2.8-3.9). Predictors of mortality were advancing age and co-morbidity, increased use of coxibs and failure to ensure adequate gastroprotection. Conclusion Among elderly veterans with recent NSAID use, an UGIE, MI or CVA is a clinically relevant premorbid event. C1 [Abraham, N. S.; Castillo, D. L.; Hartman, C.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Abraham, N. S.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Abraham, N. S.] Baylor Coll Med, Houston, TX 77030 USA. RP Abraham, NS (reprint author), DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM nabraham@bcm.edu NR 32 TC 17 Z9 17 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JUL 1 PY 2008 VL 28 IS 1 BP 97 EP 106 DI 10.1111/j.1365-2036.2008.03706.x PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 308MT UT WOS:000256395400009 PM 18397385 ER PT J AU Hirschman, KB Kapo, JM Karlawish, JHT AF Hirschman, Karen B. Kapo, Jennifer M. Karlawish, Jason H. T. TI Identifying the factors that facilitate or hinder advance planning by persons with dementia SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE advance care planning; Alzheimer disease; decision making; advance directives ID ALZHEIMERS-DISEASE; DECISION; CARE; DIRECTIVES; DIAGNOSIS; SURVIVAL; ILLNESS; PATIENT; ADULTS AB members of patients with advanced dementia to identify the factors that facilitate or hinder advance planning by persons with dementia. All interviews were analyzed using qualitative data analysis techniques. The majority (77%) of family members reported that their relative had some form of written advance directive, and at least half reported previous discussions about health care preferences (57%), living situation or placement issues (50%), and finances or estate planning (60%) with the patient. Family members reported some themes that prompted planning and others that were barriers to planning. Events that most often triggered planning were medical, living situation, or financial issues associated with a friend or family member of the patient (57%). Barriers to planning included both passive and active avoidance. The most common form of passive avoidance was not realizing the importance of planning until it was too late to have the discussion (63%). The most common form of active avoidance was avoiding the discussion (53%). These data suggest potentially remediable strategies to address barriers to advance planning discussions. C1 [Hirschman, Karen B.] Univ Penn, Sch Nursing, Div Behav & Hlth Sci, Philadelphia, PA 19104 USA. [Hirschman, Karen B.] Univ Penn, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Kapo, Jennifer M.; Karlawish, Jason H. T.] Univ Penn, Dept Med, Div Geriatr, Philadelphia, PA 19104 USA. [Hirschman, Karen B.; Kapo, Jennifer M.; Karlawish, Jason H. T.] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. [Karlawish, Jason H. T.] Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. [Karlawish, Jason H. T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Kapo, Jennifer M.; Karlawish, Jason H. T.] Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. [Kapo, Jennifer M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Hirschman, KB (reprint author), Univ Penn, Sch Nursing, Div Behav & Hlth Sci, 3615 Chestnut St,Ralston House, Philadelphia, PA 19104 USA. EM hirschk@nursing.upenn.edu FU Age-Related Neurodegenerative Diseases [NIH/NIA T32 AG-00255]; Alzheimer's Association [NIRG-05-13570]; the NIA [1R01AG025524-01A2, R01-AG020627, P30-AG10124]; HRSA Geriatric Academic Career Award [1 K01 HP 00099-01]; Greenwall Faculty Scholars Award in Bioethics FX Supported through a training grant in Age-Related Neurodegenerative Diseases (NIH/NIA T32 AG-00255; K.B.H.). Dr Karen B. Hirschman is supported by grants from the Alzheimer's Association (NIRG-05-13570), the NIA (1R01AG025524-01A2), and the Marian S. Ware Alzheimer Program. Dr Jennifer M. Kapo is supported by a HRSA Geriatric Academic Career Award (1 K01 HP 00099-01). Dr Jason H. T. Karlawish is supported by a Greenwall Faculty Scholars Award in Bioethics and NIA grants R01-AG020627 and P30-AG10124 and the Marian S. Ware Alzheimer Program. NR 25 TC 21 Z9 21 U1 1 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD JUL-SEP PY 2008 VL 22 IS 3 BP 293 EP 298 DI 10.1097/WAD.0b013e318169d669 PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 352UA UT WOS:000259521700015 PM 18580595 ER PT J AU La Rue, A Hermann, B Jones, JE Johnson, S Asthana, S Sager, MA AF La Rue, Asenath Hermann, Bruce Jones, Jana E. Johnson, Sterling Asthana, Sanjay Sager, Mark A. TI Effect of parental family history of Alzheimer's disease on serial position profiles SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; memory; serial position effect; prospective study; family history of dementia ID APOLIPOPROTEIN-E; COGNITIVE IMPAIRMENT; GENETIC RISK; LATE-LIFE; MEMORY; DEMENTIA; METAANALYSIS; PERFORMANCE; DIAGNOSIS; RELATIVES AB Background: An exaggerated recency effect (ie, disproportionate recall of last-presented items) has been consistently observed in the word list learning of patients with Alzheimer's disease (AD). Our study sought to determine whether there were similar alterations in serial position learning among asymptomatic persons at risk for AD as a result of parental family history. Methods: Subjects included 623 asymptomatic middle-aged children of patients with AD (median, 53 years) and 157 control participants whose parents survived to at least age 70 without AD or other memory disorders. All participants were administered the Rey Auditory Verbal Learning Test, which requires learning and recall of 15 unrelated nouns. Results: There was no significant difference in total words recalled between the AD children and control groups. However, compared with controls, AD children exhibited a significantly greater tendency to recall words from the end (recency) versus beginning (primacy) of the list. Serial position effects were unrelated to apolipoprotein allele epsilon 4 or depressive symptoms. Conclusions: Asymptomatic persons at risk for AD by virtue of family history do not show a difference in total words recalled compared with controls, but they exhibit a distinctly different serial position curve, suggesting greater reliance on immediate as opposed to episodic memory. This is the same serial position pattern observed in mild AD, seen here in reduced severity. Longitudinal follow-up is planned to determine whether changes in serial position patterns are a meaningful marker for preclinical detection of AD. (C) 2008 The Alzheimer's Association. All rights reserved. C1 [La Rue, Asenath; Hermann, Bruce; Jones, Jana E.; Johnson, Sterling; Asthana, Sanjay; Sager, Mark A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Wisconsin Alzheimers Inst, Madison, WI 53706 USA. [Hermann, Bruce; Jones, Jana E.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Johnson, Sterling; Asthana, Sanjay; Sager, Mark A.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Sect Geriatr & Gerontol, Madison, WI USA. [Johnson, Sterling; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP La Rue, A (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Wisconsin Alzheimers Inst, Madison, WI 53706 USA. EM larue@wisc.edu OI Johnson, Sterling/0000-0002-8501-545X FU NCRR NIH HHS [M01RR03186, M01 RR003186]; NIA NIH HHS [K07 AG021582, K07 AG021582-03, R01 AG027161, R01 AG027161-02] NR 38 TC 45 Z9 45 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUL PY 2008 VL 4 IS 4 BP 285 EP 290 DI 10.1016/j.jalz.2008.03.009 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 326NC UT WOS:000257665200009 PM 18631980 ER PT J AU Streim, JE Porsteinsson, AP Breder, CD Swanink, R Marcus, R McQuade, R Carson, WH AF Streim, Joel E. Porsteinsson, Anton P. Breder, Christopher D. Swanink, Rene Marcus, Ronald McQuade, Robert Carson, William H. TI A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE aripiprazole; Alzheimer disease; dementia; behavioral symptoms; psychotic symptoms ID MANSFIELD AGITATION INVENTORY; BEHAVIORAL DISTURBANCES; CEREBROVASCULAR EVENTS; PSYCHIATRIC-SYMPTOMS; ATYPICAL ANTIPSYCHOTICS; LONGITUDINAL EVALUATION; EXTRAPYRAMIDAL SIGNS; CONTROLLED TRIALS; CAREGIVER BURDEN; ELDERLY-PATIENTS AB Objective: To evaluate the efficacy and safety of aripiprazole treatment for psychotic symptoms associated with Alzheimer disease (AD). Methods: In this parallel group, randomized, double-blind, placebo-controlled, flexible-dose trial, institutionalized subjects with AD and psychotic symptoms were randomized to aripiprazole (n = 131) or placebo (n = 125) for 10 weeks. The aripiprazole starting dose was 2 mg/day, and could be titrated to higher doses ( 5, 10, and 15 mg/day) based on efficacy and tolerability. Results: No significant differences in mean change [2 X SD] from baseline between aripiprazole ( mean dose similar to 9 mg/day at endpoint; range = 0.7-15.0 mg) and placebo were detected in the coprimary efficacy endpoints of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) Psychosis score ( aripiprazole, -4.53 [9.23]; placebo, -4.62 [9.56]; F = 0.02, df = 1, 222, p = 0.883 [ANCOVA]) and Clinical Global Impression (CGI)-Severity score ( aripiprazole, -0.57 [1.63]; placebo, -0.43 [1.65]; F = 1.67, df = 1, 220, p = 0.198 [ANCOVA]) at endpoint. However, improvements in several secondary efficacy measures (NPI-NH Total, Brief Psychiatric Rating Scale Total, CGI - improvement, Cohen-Mansfield Agitation Inventory and Cornell Depression Scale scores) indicated that aripiprazole may confer clinical benefits beyond the primary outcome measures. Treatment-emergent adverse events (AEs) were similar in both groups, except for somnolence ( aripiprazole, 14%; placebo, 4%). Somnolence with aripiprazole was of mild or moderate intensity, and not associated with accidental injury. Incidence of AEs related to extrapyramidal symptoms was low with aripiprazole (5%) and placebo (4%). Conclusions: In nursing home residents with AD and psychosis, aripiprazole did not confer specific benefits for the treatment of psychotic symptoms; but psychological and behavioral symptoms, including agitation, anxiety, and depression, were improved with aripiprazole, with a low risk of AEs. C1 [Streim, Joel E.] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Porsteinsson, Anton P.] Res & Educ Program AD CARE, Program Neurobehav Therapeut Alzheimers Dis Care, Rochester, NY USA. [Breder, Christopher D.; Marcus, Ronald] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [Swanink, Rene] Bristol Myers Squibb Co, Braine lAlleud, Belgium. [McQuade, Robert; Carson, William H.] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA. RP Streim, JE (reprint author), Univ Penn, Sect Geriatr Psychiat, 3535 Market St,Room 3053, Philadelphia, PA 19104 USA. EM jstreim@mail.med.upenn.edu NR 56 TC 38 Z9 39 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUL PY 2008 VL 16 IS 7 BP 537 EP 550 DI 10.1097/JGP.0b013e318165db77 PG 14 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 321FJ UT WOS:000257289800003 PM 18591574 ER PT J AU Jarvik, L AF Jarvik, Lissy TI Concept of disease in geriatric psychiatry SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Letter C1 [Jarvik, Lissy] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Jarvik, Lissy] US Dept Vet Affairs, Little Rock, AR USA. RP Jarvik, L (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUL PY 2008 VL 16 IS 7 BP 614 EP 615 DI 10.1097/JGP.0b013e3181753a7d PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 321FJ UT WOS:000257289800014 PM 18591583 ER PT J AU Cooper, CB Dransfield, M AF Cooper, Christopher B. Dransfield, Mark TI Primary care of the patient with chronic obstructive pulmonary disease - Part 4: Understanding the clinical manifestations of a progressive disease SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; comorbidity; hyperinflation; exacerbation; lung volume reduction; pharmacotherapy ID LUNG-VOLUME-REDUCTION; EMPHYSEMA TREATMENT TRIAL; EXERCISE CAPACITY; MYOCARDIAL-INFARCTION; ACUTE EXACERBATIONS; COPD EXACERBATIONS; FLUTICASONE PROPIONATE; SYSTEMIC INFLAMMATION; LONGITUDINAL CHANGES; ELDERLY PERSONS AB This article reviews the main factors influencing the pathophysiology, symptoms, and progression of chronic obstructive pulmonary disease (COPD), including dynamic hyperinflation, exacerbations, and comorbid illness. Key clinical trials and reviews were identified. After formal presentations to a panel of pulmonary specialists and primary care physicians, a series of concepts, studies, and practical clinical implications related to COPD progression were integrated into this article, the last in a 4-part mini-symposium. The main points of roundtable consensus were as follows: (1) COPD is characterized by declining pulmonary function as classically measured by forced expiratory volume in 1 second (FEV1), but the complex pathophysiology and the rationale for bronchodilator therapy are actually better understood in terms of progressive hyperinflation, both at rest (static) and worsening during exercise (dynamic) and exacerbations; (2) although COPD progression is often thought of as inevitable and continuous, the clinical course is actually quite variable and probably influenced by the frequency of exacerbations; (3) preventing exacerbations with pharmacologic and nonpharmacologic care can influence overall morbidity; (4) comorbidities such as lung cancer, cardiovascular disease, and skeletal muscle dysfunction also contribute to declining patient health; and (5) surgical lung volume reduction and lung transplantation should be considered for selected patients with very severe COPD. We conclude that the concept of COPD as a gradual but relentlessly progressive illness that is best monitored via FEV1 is outdated and likely compromises patient care. Many patients now being managed in primary care settings will benefit from an earlier, broad-based, and aggressive approach to management. (C) 2008 Elsevier Inc. All rights reserved. C1 [Cooper, Christopher B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dransfield, Mark] Univ Alabama, Birmingham, AL USA. [Dransfield, Mark] Birmingham VA Med Ctr, Birmingham, AL USA. RP Cooper, CB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Conte Ave,37-131 CHS, Los Angeles, CA 90095 USA. EM ccooper@mednet.ucla.edu NR 75 TC 19 Z9 19 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUL PY 2008 VL 121 IS 7 SU 1 BP S33 EP S45 DI 10.1016/j.amjmed.2008.04.005 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 312YL UT WOS:000256708200005 PM 18558106 ER PT J AU Kellogg, DL Zhao, JL Wu, Y AF Kellogg, Dean L., Jr. Zhao, Joan L. Wu, Yubo TI Endothelial nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE skin blood flow; microdialysis; nitric oxide; NOSIII; laser-Doppler flowmetry ID SKIN BLOOD-FLOW; ACTIVE VASODILATATION; LOCAL TEMPERATURE; HEAT-STRESS; INACTIVATION; INHIBITION; PATHWAYS; EXERCISE; ISOFORMS; NERVES AB Nitric oxide (NO) participates in locally mediated vasodilation induced by increased local skin temperature (Tloc) and in sympathetically mediated vasodilation during whole body heat stress. We hypothesized that endothelial NOS (eNOS) participates in the former, but not the latter, response. We tested this hypothesis by examining the effects of the eNOS antagonist N-G-amino-L-arginine (L-NAA) on skin blood flow (SkBF) responses to increased Tloc and whole body heat stress. Microdialysis probes were inserted into forearm skin for drug delivery. One microdialysis site was perfused with L-NAA in Ringer solution and a second site with Ringer solution alone. SkBF [laser-Doppler flowmetry (LDF)] and blood pressure [mean arterial pressure (MAP)] were monitored, and cutaneous vascular conductance (CVC) was calculated (CVC = LDF divided by MAP). In protocol 1, Tloc was controlled with LDF/local heating units. Tloc initially was held at 34 degrees C and then increased to 41.5 degrees C. In protocol 2, after a normothermic period, whole body heat stress was induced (water-perfused suits). At the end of both protocols, 58 mM sodium nitroprusside was perfused at both microdialysis sites to cause maximal vasodilation for data normalization. In protocol 1, CVC at 34 degrees C Tloc did not differ between L-NAA-treated and untreated sites (P > 0.05). Local skin warming to 41.5 degrees C Tloc increased CVC at both sites. This response was attenuated at L-NAA-treated sites (P < 0.05). In protocol 2, during normothermia, CVC did not differ between L-NAA-treated and untreated sites (P > 0.05). During heat stress, CVC rose to similar levels at L-NAA-treated and untreated sites (P > 0.05). We conclude that eNOS is predominantly responsible for NO generation in skin during responses to increased Tloc, but not during reflex responses to whole body heat stress. C1 [Kellogg, Dean L., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Hosp Div, Educ & Clin Ctr, Dept Vet Affairs, S Texas Vet Hlth Care System, San Antonio, TX USA. RP Kellogg, DL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr & Gerontol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu FU NHLBI NIH HHS [HL-065599] NR 45 TC 64 Z9 65 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUL PY 2008 VL 295 IS 1 BP H123 EP H129 DI 10.1152/ajpheart.00082.2008 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 325MU UT WOS:000257593800016 PM 18469149 ER PT J AU Mani, SK Shiraishi, H Balasubramanian, S Yamane, K Chellaiah, M Cooper, G Banik, N Zile, MR Kuppuswamy, D AF Mani, Santhosh K. Shiraishi, Hirokazu Balasubramanian, Sundaravadivel Yamane, Kentaro Chellaiah, Meenakshi Cooper, George Banik, Naren Zile, Michael R. Kuppuswamy, Dhandapani TI In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE caspases; cardiomyopathy; heart failure; cytoskeleton ID ENDOPLASMIC-RETICULUM STRESS; CARDIAC MYOCYTE APOPTOSIS; HEART-FAILURE; CONTRACTILE DYSFUNCTION; CELL-DEATH; GELSOLIN; HYPERTROPHY; CALPASTATIN; RAT; DEGRADATION AB Calpain activation is linked to the cleavage of several cytoskeletal proteins and could be an important contributor to the loss of cardiomyocytes and contractile dysfunction during cardiac pressure overload (PO). Using a feline right ventricular (RV) PO model, we analyzed calpain activation during the early compensatory period of cardiac hypertrophy. Calpain enrichment and its increased activity with a reduced calpastatin level were observed in 24- to 48-h-PO myocardium, and these changes returned to basal level by 1 wk of PO. Histochemical studies in 24-h-PO myocardium revealed the presence of TdT-mediated dUTP nick-end label (TUNEL)-positive cardiomyocytes, which exhibited enrichment of calpain and gelsolin. Biochemical studies showed an increase in histone H2B phosphorylation and cytoskeletal binding and cleavage of gelsolin, which indicate programmed cardiomyocyte cell death. To test whether calpain inhibition could prevent these changes, we administered calpeptin (0.6 mg/kg iv) by bolus injections twice, 15 min before and 6 h after induction of 24- h PO. Calpeptin blocked the following PO-induced changes: calpain enrichment and activation, decreased calpastatin level, caspase-3 activation, enrichment and cleavage of gelsolin, TUNEL staining, and histone H2B phosphorylation. Although similar administration of a caspase inhibitor, N-benzoylcarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VD-fmk), blocked caspase-3 activation, it did not alleviate other aforementioned changes. These results indicate that biochemical markers of cardiomyocyte cell death, such as sarcomeric disarray, gelsolin cleavage, and TUNEL-positive nuclei, are mediated, at least in part, by calpain and that calpeptin may serve as a potential therapeutic agent to prevent cardiomyocyte loss and preserve myocardial structure and function during cardiac hypertrophy. C1 [Mani, Santhosh K.; Shiraishi, Hirokazu; Balasubramanian, Sundaravadivel; Yamane, Kentaro; Cooper, George; Zile, Michael R.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Banik, Naren] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA. [Cooper, George; Zile, Michael R.; Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Chellaiah, Meenakshi] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA. RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, 114 Doughty St, Charleston, SC 29425 USA. EM kuppusd@musc.edu FU NHLBI NIH HHS [HL-48788] NR 68 TC 29 Z9 31 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUL PY 2008 VL 295 IS 1 BP H314 EP H326 DI 10.1152/ajpheart.00085.2008 PG 13 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 325MU UT WOS:000257593800038 PM 18487434 ER PT J AU Sultzer, DL Davis, SM Tariot, PN Dagerman, KS Lebowitz, BD Lyketsos, CG Rosenheck, RA Hsiao, JK Lieberman, JA Schneider, LS AF Sultzer, David L. Davis, Sonia M. Tariot, Pierre N. Dagerman, Karen S. Lebowitz, Barry D. Lyketsos, Constantine G. Rosenheck, Robert A. Hsiao, John K. Lieberman, Jeffrey A. Schneider, Lon S. CA CATIE-AD Study Grp TI Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID INTERVENTION EFFECTIVENESS CATIE; RATING-SCALE BPRS; NEUROPSYCHIATRIC SYMPTOMS; DEMENTIA; MANAGEMENT; INVENTORY; PSYCHOSIS; DONEPEZIL; RISK AB Objective: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior. Method: The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) Alzheimer's disease effectiveness study included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician's discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals. Results: In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo. Conclusion: In this descriptive analysis of outpatients with Alzheimer's disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Gero Neuropsychiat Div, Los Angeles, CA USA. Quintiles, Res Triangle Pk, NC USA. Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. Banner Alzheimers Inst, Phoenix, AZ USA. Univ Calif San Diego, Sch Med, Div Geriatr Psychiat, La Jolla, CA 92093 USA. Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD USA. Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. VA Connecticut Hlth Care Syst, New Haven, CT USA. NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Sultzer, DL (reprint author), 3 South,116AE,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dsultzer@ucla.edu OI Adler, Lawrence/0000-0002-6619-2493 FU NIMH NIH HHS [N01 MH-9001, N01 MH90001] NR 34 TC 121 Z9 126 U1 2 U2 14 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JUL PY 2008 VL 165 IS 7 BP 844 EP 854 DI 10.1176/appi.ajp.2008.07111779 PG 11 WC Psychiatry SC Psychiatry GA 321PX UT WOS:000257320100013 PM 18519523 ER PT J AU Lee, SJ Go, AS Lindquist, K Bertenthal, D Covinsky, KE AF Lee, Sei J. Go, Alan S. Lindquist, Karla Bertenthal, Daniel Covinsky, Kenneth E. TI Chronic conditions and mortality among the oldest old SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MYOCARDIAL-INFARCTION; FUNCTIONAL STATUS; PROGNOSTIC INDEX; ELDERLY PERSONS; RISK-FACTORS; COMORBIDITY; ADULTS; VALIDATION; DISABILITY; SURVIVAL AB Objectives. We sought to determine whether chronic conditions and functional limitations are equally predictive of mortality among older adults. Methods. Participants in the 1998 wave of the Health and Retirement Study (N = 19 430) were divided into groups by decades of age, and their vital status in 2004 was determined. We used multivariate Cox regression to determine the ability of chronic conditions and functional limitations to predict morta,lity. Results. As age increased, the ability of chronic conditions to predict mortality declined rapidly, whereas the ability of functional limitations to predict mortality declined more slowly. In younger participants (aged 50-59 years), chronic conditions were stronger predictors of death than were functional limitations (Harrell C statistic 0.78 vs. 0.73; P=.001). In older participants (aged 90-99 years), functional limitations were stronger predictors of death than were chronic conditions (Harrell C statistic 0.67 vs. 0.61; P=.004). Conclusions. The importance of chronic conditions as a predictor of death declined rapidly with increasing age. Therefore, risk-adjustment models that only consider comorbidities when comparing mortality rates across providers may be inadequate for adults older than 80 years. C1 [Lee, Sei J.; Bertenthal, Daniel; Covinsky, Kenneth E.] San Francisco VA Med Ctr, HSR&D Res Enhancement Award Program, San Francisco, CA 94121 USA. [Lee, Sei J.; Lindquist, Karla; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Go, Alan S.] No Calif Kaiser Permanente, Div Res, Oakland, CA USA. RP Lee, SJ (reprint author), San Francisco VA Med Ctr, HSR&D Res Enhancement Award Program, 4150 Clement St,Bldg 1,Room 211A, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu FU NHLBI NIH HHS [HL091179, U19 HL091179]; NIA NIH HHS [T32 AG000212-16, K24 AG029812, R01 AG023626, T32 AG000212, T32 AG000212-15]; NIDDK NIH HHS [DK060902, U01 DK060902] NR 46 TC 45 Z9 46 U1 3 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2008 VL 98 IS 7 BP 1209 EP 1214 DI 10.2105/AJPH.2007.130955 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 319ZE UT WOS:000257202700017 PM 18511714 ER PT J AU Copeland, LA Zeber, JE Pugh, MJ Mortensen, EM Restrepo, MI Lawrence, VA AF Copeland, Laurel A. Zeber, John E. Pugh, Marv Jo Mortensen, Eric M. Restrepo, Marcos I. Lawrence, Valerie A. TI Postoperative complications in the seriously mentally ill - A systematic review of the literature SO ANNALS OF SURGERY LA English DT Review ID MECHANICALLY VENTILATED PATIENTS; QUALITY IMPROVEMENT PROGRAM; SCHIZOPHRENIC-PATIENTS; SURGICAL QUALITY; DEPRESSED-PATIENTS; CORTISOL RESPONSE; PRIMARY-CARE; MORTALITY; ANESTHESIA; CONFUSION AB Objective: To determine the knowledge base on clinical outcomes of surgery among persons diagnosed with serious mental illness. Background: Despite a burgeoning literature during the last 20 years regarding perioperative risk management, little is known about intraoperative and postoperative complications among patients with schizophrenia and other serious mental illnesses. Methods: A systematic literature search of Medline (1966-August 2007) and review of studies was conducted. Eligible studies were of any design with at least 10 patients diagnosed with serious mental illness, reporting perioperative medical, surgical, or psychiatric complications. Results: The search identified 1367 potentially relevant publications; only 12 met eligibility criteria. Of 10 studies of patients with schizophrenia, 9 had fewer than 100 patients, whereas one large retrospective study reported higher rates of postoperative complications among 466 schizophrenia patients compared with 338,257 controls. These studies suggest that patients with schizophrenia, compared with those without mental illness, may have higher pain thresholds, higher rates of death and postoperative complications, and differential outcomes (eg, confusion, ileus) by anesthetic technique. Two studies evaluated outcomes in patients with major depressive disorder and found higher rates of postoperative delirium and postoperative confusion. Both schizophrenia and depression patients experienced more postoperative confusion or delirium when psychiatric medications were discontinued preoperatively. We identified no studies of perioperative outcomes in patients with bipolar or posttraumatic stress disorder. Conclusions: There are few studies of perioperative outcomes in patients with serious mental illness. Future research should assess surgical risks among patients with serious psychiatric conditions using rigorous methods and well-defined clinical outcomes. C1 [Copeland, Laurel A.; Zeber, John E.; Pugh, Marv Jo; Mortensen, Eric M.; Restrepo, Marcos I.; Lawrence, Valerie A.] S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSRD, San Antonio, TX USA. [Copeland, Laurel A.; Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Pugh, Marv Jo; Mortensen, Eric M.; Restrepo, Marcos I.; Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Copeland, LA (reprint author), S Texas Vet Hlth Care Syst VERDICT Res, 7400 Merton Minter,11C6, San Antonio, TX 78229 USA. EM copelandl@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 NR 45 TC 34 Z9 35 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD JUL PY 2008 VL 248 IS 1 BP 31 EP 38 DI 10.1097/SLA.0b013e3181724f25 PG 8 WC Surgery SC Surgery GA 320CS UT WOS:000257211900006 PM 18580204 ER PT J AU Bilimoria, KY Bentrem, DJ Ko, CY Stewart, AK Winchester, DP Talamonti, MS Halverson, AL AF Bilimoria, Karl Y. Bentrem, David J. Ko, Clifford Y. Stewart, Andrew K. Winchester, David P. Talamonti, Mark S. Halverson, Amy L. TI Squamous cell carcinoma of the anal canal: Utilization and outcomes of recommended treatment in the United States SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 61st Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 13-16, 2008 CL Chicago, IL SP Soc Surg Oncol DE squamous cell carcinoma of the anal canal; anal neoplasm; National Cancer Data Base; surgery; chemotherapy; radiation; survival; treatment ID CANCER DATA-BASE; ACTIVE ANTIRETROVIRAL THERAPY; POPULATION-BASED REAPPRAISAL; GASTRIC ADENOCARCINOMA; EPIDERMOID CARCINOMA; RACIAL DISPARITIES; PANCREATIC-CANCER; RADIATION-THERAPY; RANDOMIZED-TRIAL; HOSPITAL TYPES AB Background: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation. Resection is now reserved for persistent or recurrent disease. Our objectives were (1) to evaluate treatment trends over the past 20 years, (2) to assess contemporary treatment utilization, and (3) to examine the impact of recommended vs nonguideline treatment on survival. Methods: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified. Regression models were used to assess factors associated with use of nonguideline treatment (vs chemoradiation +/- surgery). Univariate and multivariate methods were used to assess the impact of treatment on survival. Results: From 1985 to 2005, the use of chemoradiation increased significantly with a concomitant decrease in treatment with surgery alone (P < .0001). However, only 74.9% (5014 of 6696) of patients underwent primary chemoradiation therapy in 2003-2005. Overall, 22.7% (1523 of 6696) of patients received treatment that was not concordant with established guidelines: primary surgery (13.0%) and primary chemotherapy or radiation (9.7%). Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III). Patients undergoing chemoradiation ( +/- surgery) had higher 5-year survival rates than patients who received nonguideline treatment (64% vs 58%; hazard ratio 0.82, 95% confidence interval [95% CI] 0.77-0.87; P < .0001). Conclusion: Primary chemoradiation therapy has supplanted surgical treatment and is associated with better outcomes; however, nearly a quarter of patients are still receiving treatment that is not concordant with established guidelines. C1 [Bilimoria, Karl Y.; Bentrem, David J.; Winchester, David P.; Talamonti, Mark S.; Halverson, Amy L.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bilimoria, Karl Y.; Ko, Clifford Y.; Stewart, Andrew K.; Winchester, David P.] Amer Coll Surg, Canc Programs, Chicago, IL USA. [Winchester, David P.; Talamonti, Mark S.] Evanston NW Healthcare, Dept Surg, Evanston, IL USA. RP Bilimoria, KY (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu NR 52 TC 10 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD JUL PY 2008 VL 15 IS 7 BP 1948 EP 1958 DI 10.1245/s10434-008-9905-2 PG 11 WC Oncology; Surgery SC Oncology; Surgery GA 320GY UT WOS:000257222900019 PM 18414951 ER PT J AU Esnaola, NF Gebregziabher, M Knott, K Finney, C Silvestri, GA Reed, CE Ford, ME AF Esnaola, Nestor F. Gebregziabher, Mulugeta Knott, Kelly Finney, Chris Silvestri, Gerard A. Reed, Carolyn E. Ford, Marvella E. TI Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 54th Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 07-10, 2007 CL Bonita Springs, FL SP SE Thorac Surg Assoc ID RACIAL-DIFFERENCES; SURGERY; DISPARITIES; SURVIVAL; OUTCOMES AB Background. Early studies using Medicare data reported racial disparities in surgical treatment of localized, non-small cell lung cancer. We analyzed the independent effect of race on use of surgical resection in a recent, population-based sample of patients with localized non-small cell lung cancer, controlling for comorbidity and socioeconomic status. Methods. All cases of localized non-small cell lung cancer reported to our state Cancer Registry between 1996 and 2002 were identified and linked to the Inpatient/Outpatient Surgery Files and 2000 Census. Comorbidity (Romano-Charlson index) was calculated using administrative data codes. Educational level and income were estimated using census data. Characteristics of white and African American patients were compared using chi(2) tests. Odds ratios of resection and 95% confidence intervals were calculated using logistic regression. Results. We identified 2,506 white and 550 African American patients. African Americans were more likely to be younger, male, not married, less educated, poor, and uninsured or covered by Medicaid (all p < 0.0001), and to reside in rural communities (p = 0.0005). Use of surgical resection across races was lower than previously reported, and African Americans were significantly less likely to undergo surgery compared with whites (44.7% versus 63.4%; p < 0.0001). Even after controlling for sociodemographics, comorbidity, and tumor factors, the adjusted odds ratio for resection for African Americans was 0.43 (95% confidence interval, 0.34 to 0.55). Conclusions. Underuse of surgical resection for localized, non-small cell lung cancer is a persistent problem, particularly among African Americans. Further studies are urgently needed to identify the patient-, physician-, and health system-related factors underlying these observations and optimize resection rates for non-small cell lung cancer. C1 [Esnaola, Nestor F.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. S Carolina Off Res & Stat, Columbia, SC USA. RP Esnaola, NF (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr,Suite 7018,MSC 295, Charleston, SC 29425 USA. EM esnaolan@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU NCI NIH HHS [P30 CA138313] NR 25 TC 37 Z9 37 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUL PY 2008 VL 86 IS 1 BP 220 EP 227 DI 10.1016/j.athoracsur.2008.02.072 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 316FK UT WOS:000256934400031 PM 18573427 ER PT J AU Vallor, AC Kirkpatrick, WR Najvar, LK Bocanegra, R Kinney, MC Fothergill, AW Herrera, ML Wickes, BL Graybill, JR Patterson, TF AF Vallor, Ana C. Kirkpatrick, William R. Najvar, Laura K. Bocanegra, Rosie Kinney, Marsha C. Fothergill, Annette W. Herrera, Monica L. Wickes, Brian L. Graybill, John R. Patterson, Thomas F. TI Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID EXPERIMENTAL MURINE ASPERGILLOSIS; BRONCHOALVEOLAR LAVAGE FLUID; INVASIVE ASPERGILLOSIS; AMPHOTERICIN-B; ANIMAL-MODELS; VORICONAZOLE; EFFICACY; DNA; THERAPY; PHARMACOKINETICS AB Early diagnosis of invasive pulmonary aspergillosis is problematic in some patient groups due to the lack of rapid, sensitive, specific, and reliable diagnostic tests. Fungal burden and therapeutic efficacy were assessed by survival, quantitative culture (CFU counts), galactomannan enzyme immunoassay (GM-EIA), and quantitative PCR (qPCR) in a new guinea pig model of invasive pulmonary aspergillosis using an aerosol challenge. At 1 day postinfection, qPCR determined that the pulmonary fungal burden was 2 log(10) higher than that determined by CFU counting and increased significantly (P < 0.03) over time. In contrast, the tissue burden assessed by CFU counting did not rise over the course of the study. Therapy with the antifungal drug voriconazole produced statistically significant decreases in pulmonary fungal burden, as detected by CFU counting (P < 0.02), qPCR, and GM-EIA (both P < 0.0002). Daily assessment of the progression of fungal infection in serum was performed by qPCR and GM-EIA. GM-EIA demonstrated a statistically significant reduction in the fungal load on days 6 and 7 in voriconazole-treated animals compared to time-matched controls (P < 0.02). Confirmation of fungal tissue burden by two or more methods should provide a more precise account of the burden, allowing improved assessment of diagnostic and therapeutic strategies in invasive pulmonary aspergillosis. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Kinney, Marsha C.; Fothergill, Annette W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Herrera, Monica L.; Wickes, Brian L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. RP Vallor, AC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,Mail Code 7881, San Antonio, TX 78229 USA. EM vallora@uthscsa.edu FU NIAID NIH HHS [N01AI30041] NR 32 TC 49 Z9 49 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUL PY 2008 VL 52 IS 7 BP 2593 EP 2598 DI 10.1128/AAC.00276-08 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 319SE UT WOS:000257183400041 PM 18474582 ER PT J AU Wikman, H Vessella, R Pantel, K AF Wikman, Harriet Vessella, Robert Pantel, Klaus TI Cancer micrometastasis and tumour dormancy SO APMIS LA English DT Review DE tumour dormancy; cancer micrometastasis; dissemintaed tumour cells; microenvironment; oncogenes and tumour suppressor genes; angiogenesis; immune surveillance ID MINIMAL RESIDUAL DISEASE; BONE-MARROW MICROMETASTASIS; POLYMERASE-CHAIN-REACTION; PRIMARY BREAST-CANCER; UROKINASE-RECEPTOR; RT-PCR; PERIPHERAL-BLOOD; PROSTATE-CANCER; EPITHELIAL-CELLS; CARCINOMA-CELLS AB Many epithelial cancers carry a poor prognosis even after curative resection of early stage tumours. Tumour progression in these cancer patients has been attributed to the existence and persistence of disseminated tumour cells (DTC) in various body compartments as a sign of minimal residual disease. Bone marrow (BM) has been shown to be a common homing organ and reservoir for DTC. A significant correlation between the presence of DTC in BBM and metastatic relapse has been reported in various tumour types. However, only a portion of patients with DTC in BM at primary surgery relapse. Thus far, little is known about the conditions required for the persisitence of dormancy of the escape from the dormant phase into the active phase of metastasis formation. Thereby, this peculiar stage of conveivably balanced tumour cell division and death may last for decades in cancer patients. Most likely, the ability of a dormant DTC to "be activated" is a complex process involving (i) somatic aberrations in the tumor cells, (ii) the interaction of the DTC with the new microenvironment at the secondary site, and (iii) hereditary components of the host (i.e., cancer patients). In this review, we will summarize the key findings of research on micrometastatic cancer cells and discuss these findings in the context of the concept of tumour dormancy. C1 [Wikman, Harriet; Pantel, Klaus] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, D-20246 Hamburg, Germany. [Vessella, Robert] Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA. [Vessella, Robert] VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. RP Pantel, K (reprint author), Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany. EM pantel@uke.uni-hamburg.de NR 146 TC 82 Z9 84 U1 1 U2 13 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0903-4641 J9 APMIS JI APMIS PD JUL-AUG PY 2008 VL 116 IS 7-8 BP 754 EP 770 DI 10.1111/j.1600-0463.2008.01033.x PG 17 WC Immunology; Microbiology; Pathology SC Immunology; Microbiology; Pathology GA 345ZG UT WOS:000259037600019 PM 18834417 ER PT J AU Shah, SS DiCristina, CM Bell, LM Have, TT Metlay, JP AF Shah, Samir S. DiCristina, Cara M. Bell, Louis M. Have, Tom Ten Metlay, Joshua P. TI Primary early thoracoscopy and reduction in length of hospital stay and additional procedures among children with complicated pneumonia SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; PEDIATRIC PARAPNEUMONIC EMPYEMA; NONOPERATIVE THERAPY; EFFUSIONS; MANAGEMENT; OUTCOMES; CARE; DRAINAGE; SURGERY; RISK AB Objective: To determine the effect of initial procedure type on the length of hospital stay (LOS) and on the requirement for additional pleural fluid drainage procedures in a large multicenter cohort of children with pneumonia complicated by pleural effusion. Design: Retrospective cohort study. Setting: Administrative database containing inpatient resource use data from 27 tertiary care children's hospitals. Participants: Patients between 12 months and 18 years of age diagnosed as having complicated pneumonia were eligible for the study if they were discharged from the hospital between January 1, 2001, and December 31, 2005, and underwent early (within 2 days of the index hospitalization) pleural fluid drainage. Intervention: Pleural fluid drainage, categorized as chest tube placement, video-assisted thoracoscopic surgery (VATS), or thoracotomy. Main Outcome Measures: The LOS and the requirement for additional pleural fluid drainage. Results: Nine hundred sixty-one of 2862 patients (33.6%) with complicated pneumonia underwent early pleural fluid drainage. Initial procedures included chest tube placement (n = 714), VATS (n = 50), and thoracotomy (n = 197). The median patient age was 4.0 years (interquartile range, 2.0-8.0 years). The median LOS was 10 days (interquartile range, 7-14 days). Two hundred ninety-eight patients (31.0%) required at least 1 additional pleural fluid drainage procedure, and 44 patients (4.6%) required more than 2 pleural fluid drainage procedures. In linear regression analysis, children undergoing primary VATS had a 24% (adjusted beta coefficient, -0.24; 95% confidence interval, -0.41 to -0.07) shorter LOS than patients undergoing primary chest tube placement; this translated into a 2.8-day reduction in the LOS for those undergoing early primary VATS. In logistic regression analysis, patients undergoing primary VATS had an 84% (adjusted odds ratio, 0.16; 95% confidence interval, 0.06-0.42) reduction in the requirement for additional pleural fluid drainage procedures compared with patients undergoing primary chest tube placement. Conclusion: Our large retrospective multicenter study demonstrates that, compared with primary chest tube placement, primary VATS is associated with shorter LOS and fewer additional procedural interventions. C1 [Shah, Samir S.; DiCristina, Cara M.; Bell, Louis M.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Shah, Samir S.; Bell, Louis M.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA. [Shah, Samir S.; Have, Tom Ten; Metlay, Joshua P.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Shah, Samir S.; Bell, Louis M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Shah, Samir S.; Have, Tom Ten; Metlay, Joshua P.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biosta, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Shah, SS (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, Room 1526,N Campus,34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA. EM shahs@email.chop.edu OI Shah, Samir/0000-0001-7902-7000 FU NCRR NIH HHS [KL1RR024132] NR 40 TC 35 Z9 35 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD JUL PY 2008 VL 162 IS 7 BP 675 EP 681 DI 10.1001/archpedi.162.7.675 PG 7 WC Pediatrics SC Pediatrics GA 323HQ UT WOS:000257437600010 PM 18606939 ER PT J AU Gallagher, RM Rosenthal, L AF Gallagher, Rollin M. Rosenthal, Lisa TI Hypogonadism in men treated with chronic opioids - The authors respond SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Letter C1 [Gallagher, Rollin M.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Rosenthal, Lisa] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2008 VL 89 IS 7 BP 1414 EP 1414 DI 10.1016/j.apmr.2008.05.009 PG 1 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 323LK UT WOS:000257447400030 ER PT J AU Carter, CS Barch, DM Buchanan, RW Bullmore, ET Krystal, JH Cohen, J Geyer, M Green, M Nuechterlein, KH Robbins, T Silverstein, S Smith, EE Strauss, M Wykes, T Heinssen, R AF Carter, Cameron S. Barch, Deanna M. Buchanan, Robert W. Bullmore, Edward T. Krystal, John H. Cohen, Jonathan Geyer, Mark Green, Michael Nuechterlein, Keith H. Robbins, Trevor Silverstein, Steven Smith, Edward E. Strauss, Milton Wykes, Til Heinssen, Robert TI Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia initiative SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material DE cognitive neuroscience; schizophrenia; translational research; treatment development ID BATTERY AB This overview describes the generation and development of the ideas that led to the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. It also describes the organization, process, and products of the first meeting. The CNTRICS initiative involves a series of three conferences that will systematically address barriers to translating paradigms developed in the basic animal and human cognitive neuroscience fields for use in translational research aimed at developing novel treatments for cognitive impairments in schizophrenia. The articles in this special section report on the results of the first conference, which used a criterion-based consensus-building process to develop a set of cognitive constructs to be targeted for translation efforts. C1 [Carter, Cameron S.] Univ Calif Davis, UC Davis Imaging Res Ctr, Dept Psychiat, Sacramento, CA 95817 USA. [Barch, Deanna M.] Washington Univ, Dept Psychiat, St Louis, MO USA. [Buchanan, Robert W.] Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. [Bullmore, Edward T.] Univ Cambridge, Dept Psychiat, Cambridge, England. [Krystal, John H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Cohen, Jonathan] Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA. [Geyer, Mark] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Green, Michael] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90024 USA. [Robbins, Trevor] Univ Cambridge, Dept Psychol, Cambridge, England. [Silverstein, Steven] Univ Med & Dent New Jersey, New Brunswick, NJ USA. [Smith, Edward E.] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Strauss, Milton] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. [Wykes, Til] Inst Psychiat, Dept Psychiat, London SE5 8AF, England. [Heinssen, Robert] NIMH, Bethesda, MD 20892 USA. RP Carter, CS (reprint author), Univ Calif Davis, UC Davis Imaging Res Ctr, Dept Psychiat, 4701 X St, Sacramento, CA 95817 USA. EM cameron.carter@ucdmc.ucdavis.edu RI Wykes, Til/B-7894-2008; Wykes, Til/B-3812-2011; Barch, Deanna/G-8638-2013; Bullmore, Edward/C-1706-2012 OI Wykes, Til/0000-0002-5881-8003; Bullmore, Edward/0000-0002-8955-8283 FU Medical Research Council [G0001354]; NIMH NIH HHS [R13 MH078710-01, R13 MH078710] NR 6 TC 106 Z9 111 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JUL 1 PY 2008 VL 64 IS 1 BP 4 EP 10 DI 10.1016/j.biopsych.2008.03.020 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 314CE UT WOS:000256785500002 PM 18466880 ER PT J AU Scott, BL Park, JY Deeg, HJ Marr, KA Boeckh, M Chauncey, TR Appelbaum, FR Storb, R Storer, BE AF Scott, Bart L. Park, J. Y. Deeg, H. Joachim Marr, Kieren A. Boeckh, Michael Chauncey, Thomas R. Appelbaum, Frederick R. Storb, Rainer Storer, Barry E. TI Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE neutropenia; MDS; stem cell transplant ID STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; INVASIVE ASPERGILLOSIS; TARGETED BUSULFAN; FUNGAL-INFECTIONS; CYCLOPHOSPHAMIDE; GRAFT AB A retrospective cohort analysis was performed to determine the impact of neutropenia on the outcome of hematopoietic cell transplantation (HSCT) in patients with myelodysplasia (MDS). Among 291 consecutive patients, 178 (61%) had absolute neutrophil counts (ANCs) <1500/mu L and 113 (39%) had ANCs >= 1500/mu L within 2 weeks before HSCT. Neutropenic patients more often had poor-risk karyotypes (34% versus 12%, P < .0001) and high-risk International Prognostic Scoring System scores (37% veresus 18%, P = .0006). After HSCT, the rate of infections caused by Gram-positive bacteria and invasive fungal infections was significantly increased among neutropenic patients (rate ratio [RR] 1.77, P = .02 and RR = 2.56, P = .03, respectively), whereas infections caused by Gram-negative bacteria were not affected (RR 1.33, P = .53). The hazards of non-relapse mortality (NRM) (hazard ratio [HR] = 1.62 [1.1-2.4], P = .01), overall mortality (HR = 1.55 [1.1-2.1], P = 0.007), and infection-related mortality (HR = 2.22 [1.2-4.2], P = .01) were increased in neutropenic patients, whereas relapse, engraftment, and graft-versus-host-disease were not affected. After adjusting for cytogenetic risk and marrow myeloblast percentages, neutropenic patients remained at significant hazard for infection-related mortality (HR = 1.94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT. (C) 2008 American Society for Blood and Marrow Transplantation. C1 [Scott, Bart L.; Deeg, H. Joachim; Marr, Kieren A.; Boeckh, Michael; Chauncey, Thomas R.; Appelbaum, Frederick R.; Storb, Rainer; Storer, Barry E.] Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. [Scott, Bart L.; Deeg, H. Joachim; Boeckh, Michael; Chauncey, Thomas R.; Appelbaum, Frederick R.; Storb, Rainer; Storer, Barry E.] Univ Washington, Sch Med, Seattle, WA USA. [Park, J. Y.] Kangdong Sacred Heart Hosp Seoul, Seoul, South Korea. [Marr, Kieren A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chauncey, Thomas R.] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Scott, BL (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM bscott@fhcrc.org FU NCI NIH HHS [CA18029, P01 CA018029, P01 CA018029-33, P30 CA015704, P30 CA015704-34]; NHLBI NIH HHS [R01 HL082941-03, HL084054, HL36444, HL82941, K23 HL084054, K23 HL084054-02, P01 HL036444, P01 HL036444-27, R01 HL082941] NR 27 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD JUL PY 2008 VL 14 IS 7 BP 799 EP 806 DI 10.1016/j.bbmt.2008.04.011 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 316SW UT WOS:000256971000010 PM 18541200 ER PT J AU Campbell, KL Campbell, PT Ulrich, CM Wener, M Alfano, CM Foster-Schubert, K Rudolph, RE Potter, JD McTiernan, A AF Campbell, Kristin L. Campbell, Peter T. Ulrich, Cornelia M. Wener, Mark Alfano, Catherine M. Foster-Schubert, Karen Rudolph, Rebecca E. Potter, John D. McTiernan, Anne TI No reduction in C-reactive protein following a 12-month randomized controlled trial of exercise in men and women SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID OBESE POSTMENOPAUSAL WOMEN; TIME PHYSICAL-ACTIVITY; BODY-MASS INDEX; CARDIORESPIRATORY FITNESS; WEIGHT-LOSS; INFLAMMATORY MARKERS; COLORECTAL-CANCER; IMMUNE-SYSTEM; RISK-FACTORS; ADULTS AB Low-grade systemic inflammation is suggested to play a role in the development of several chronic diseases including cancer. Higher levels of physical activity and lower adiposity have been associated with reduced levels of markers of systemic inflammation, such as C-reactive protein (CRP); however, reductions in CRP have not been consistently observed in randomized controlled trials of exercise. Purpose: To examine the effect of a 12-month aerobic exercise intervention on CRP levels in men and women. Methods: One hundred two men and 100 women, sedentary and of ages 40 to 75 years, with mean body mass index (BMI) of 29.9 and 28.7 kg/m(2), respectively, were randomly assigned to a 12-month moderate-tovigorous aerobic exercise intervention (6 d/wk, 60 min/d, 60-85% maximum heart rate) or control group. Fasting blood samples were collected at baseline and at 12 months. CRP levels were measured by high-sensitivity latex-enhanced nephelometry. Results: At baseline, CRP was 1.16 and 2.11 mg/L for men and women, respectively, and CRP was correlated with percent body fat (r = 0.48, P <= 0.001), BMI (r= 0.37, P :! 0.001), and aerobic fitness (r = - 0.49, P <= 0.001). No intervention effects were observed for CRP in men or women, or when stratified by baseline BMI (<30 versus >= 30 kg/m(2)), baseline CRP (<3 versus >= 3 mg/L), or change in body weight, body composition, or aerobic fitness. Conclusion: A 12-month moderate-to-vigorous aerobic exercise intervention did not affect CRP levels in previously sedentary men or women with average-risk CRP values at baseline. C1 [Campbell, Kristin L.; Campbell, Peter T.; Ulrich, Cornelia M.; Foster-Schubert, Karen; Rudolph, Rebecca E.; Potter, John D.; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA. [Wener, Mark; Foster-Schubert, Karen] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Rudolph, Rebecca E.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Program, Seattle, WA USA. [Alfano, Catherine M.] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA. [Alfano, Catherine M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. RP McTiernan, A (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, 1100 Fairview Ave N,M4-B402, Seattle, WA 98109 USA. EM amctiern@fhcrc.org OI Potter, John/0000-0001-5439-1500 FU NCI NIH HHS [R01 CA077572, U54 CA116847-03, U54 CA116847, U54 CA 116847, R01 CA 77572-01] NR 36 TC 32 Z9 33 U1 1 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUL PY 2008 VL 17 IS 7 BP 1714 EP 1718 DI 10.1158/1055-9965.EPI-08-0088 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 327NJ UT WOS:000257735500020 PM 18628422 ER PT J AU Mulligan, JK Lathers, DMR Young, MRI AF Mulligan, Jennifer K. Lathers, Deanne M. R. Young, M. Rita I. TI Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE endothelial cell; suppressor; tumor; immune suppression; Lewis lung carcinoma ID BREAST-CANCER; NITRIC-OXIDE; ACTIVATION; DIFFERENTIATION; SUPPRESSION; PROGRESSION; MECHANISMS; EXPRESSION; SECRETION; MONOCYTES AB Introduction Patients and mice with solid tumors, such as Lewis lung carcinoma (LLC), have defects in functions of immune effector cells. Endothelial cells, a component of the tumor vasculature, are potential regulators of immune cell functions. Therefore, these studies examined the impact of exposure to LLC tumor on the ability of endothelial cells to modulate immune cell functions. Materials and methods Endothelial cells were pre-treated with LLC tumor-conditioned medium (Endo(T-sup)) for 24 h. Control endothelial cells that were exposed to medium (Endo(Media)) or epithelial cell-conditioned medium (Endo(Epi-sup)). After the initial 24 h incubation, endothelial cells were washed and fresh media was added. Cells were allowed to incubate for an additional 24 h. Supernatants from Endo(Media), Endo(Epi-sup) or Endo(T-sup) were collected and assayed for immune modulatory products and for immune modulatory activity. Results Supernatant from Endo(T-sup) contained increased levels of PGE(2), IL-6 and VEGF as compared to Endo(Media) and Endo(Epi-sup) controls. NK cell activity, as measured by TNF-alpha and IFN-gamma secretion, was increased following exposure to media conditioned by Endo(Media) and Endo(Epi-sup). Exposure of NK cells to supernatants of Endo(T-sup), also increases TNF-alpha and IFN-gamma secretion, but to a lesser extent than by Endo(Media) and Endo(T-sup). Examination of macrophage functions demonstrated that supernatant from Endo(T-sup) decreased microbead phagocytosis and increased production of the immune suppressive mediators, IL-10 and PGE(2). Lastly, T-cell responses to stimulation with anti-CD3 in the presence of supernatants from Endo(T-sup) were examined. IFN-gamma production by CD8(+) T-cells was reduced after exposure to Endo(T-sup)-conditioned medium, as compared to cells treatments with medium or control conditioned medium. Production of IFN-gamma by CD4(+) T-cells exposed to Endo(T-sup) was not altered. Conclusions Taken together, these studies demonstrate that tumors skew endothelial cells to disrupt NK cell, T-cell and macrophages functions, and represents a novel mechanism of tumor-induced immune suppression. C1 [Mulligan, Jennifer K.; Lathers, Deanne M. R.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. [Lathers, Deanne M. R.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Lathers, DMR (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM konopa@musc.edu; rita.young@va.gov FU NCI NIH HHS [R01 CA085266, R01 CA085266-06, R01 CA097813, R01 CA 85266, R01 CA128837-05, R01 CA 97813, R01 CA128837] NR 30 TC 13 Z9 13 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD JUL PY 2008 VL 57 IS 7 BP 951 EP 961 DI 10.1007/s00262-007-0425-x PG 11 WC Oncology; Immunology SC Oncology; Immunology GA 294HR UT WOS:000255397600002 PM 18058097 ER PT J AU Mukheriee, R Criddle, DN Gukvoskaya, A Pandol, S Petersen, OH Sutton, R AF Mukheriee, R. Criddle, D. N. Gukvoskaya, A. Pandol, S. Petersen, O. H. Sutton, R. TI Mitochondrial injury in pancreatitis SO CELL CALCIUM LA English DT Review DE pancreatitis; mitochondria; calcium signaling; apoptosis; necrosis ID INOSITOL TRISPHOSPHATE RECEPTORS; PERMEABILITY TRANSITION PORE; ACID ETHYL-ESTERS; CELL-DEATH; ACINAR-CELLS; BILE-ACIDS; NECROTIZING PANCREATITIS; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; CA2+ SIGNALS AB Pancreatitis is an increasingly common disease that carries a significant mortality and which lacks specific therapy. Pathological calcium signalling is an important contributor to the initiating cell injury, caused by or acting through mitochondrial inhibition. A principal effect of disordered cell signalling and impaired mitochondrial function is cell death, either by apoptosis that is primarily protective, or by necrosis that is deleterious, both locally and systemically. Mitochondrial calcium overload is particularly important in necrotic injury, which may include damage mediated by the mitochondrial permeability transition pore. The role of reactive oxygen species remains controversial. Present understanding of the part played by disordered pancreatic acinar calcium signalling and mitochondrial inhibition offers several new potential therapeutic targets. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Mukheriee, R.; Sutton, R.] Univ Liverpool, Royal Liverpool Univ Hosp, Div Surg & Oncol, Liverpool L69 3BX, Merseyside, England. [Mukheriee, R.; Criddle, D. N.; Petersen, O. H.; Sutton, R.] Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England. [Gukvoskaya, A.; Pandol, S.] Univ Calif Los Angeles, USC, Res Ctr Alcohol Liver & Pancreat Dis, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Sutton, R (reprint author), Univ Liverpool, Royal Liverpool Univ Hosp, Div Surg & Oncol, Daulby St, Liverpool L69 3BX, Merseyside, England. EM r.sutton@liv.ac.uk RI Petersen, Ole/E-8708-2010; Sutton, Robert/I-3587-2016 OI Sutton, Robert/0000-0001-6600-562X FU Medical Research Council; NIDDK NIH HHS [DK 59508, DK 59936] NR 64 TC 42 Z9 42 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0143-4160 J9 CELL CALCIUM JI Cell Calcium PD JUL PY 2008 VL 44 IS 1 BP 14 EP 23 DI 10.1016/j.ceca.2007.11.013 PG 10 WC Cell Biology SC Cell Biology GA 326KB UT WOS:000257656400003 PM 18207570 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Setting the agenda SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID ACUTE KIDNEY INJURY; RENAL REPLACEMENT THERAPY; QUESTIONS; FAILURE; AKI C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123,111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 12 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2008 VL 3 IS 4 BP 933 EP 934 DI 10.2215/CJN.02340508 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 320UO UT WOS:000257260700002 PM 18579670 ER PT J AU Hsu, J Johansen, KL Hsu, CY Kaysen, GA Chertow, GM AF Hsu, Joy Johansen, Kirsten L. Hsu, Chi-yuan Kaysen, George A. Chertow, Glenn M. TI Higher serum creatinine concentrations in black patients with chronic kidney disease: Beyond nutritional status and body composition SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID BIOELECTRICAL-IMPEDANCE ANALYSIS; HEMODIALYSIS VASCULAR ACCESS; CHRONIC RENAL-INSUFFICIENCY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RACIAL-DIFFERENCES; SKELETAL-MUSCLE; UNITED-STATES; RISK-FACTORS; RACE AB Background and objectives: Serum creatinine concentrations tend to be higher in black than white individuals and people of other races or ethnicities. These differences have been assumed to be largely related to race-related differences in body composition, especially muscle mass. Design, setting, participants, & measurements: In a diverse population of hemodialysis patients, we compared mean serum creatinine concentrations in black versus nonblack patients, adjusting for case mix (age, gender, diabetes, and dialysis vintage), body size (height, weight), laboratory parameters of nutritional status (albumin, predialysis blood urea nitrogen, transferrin, phosphorus, glucose), dialysis dosage (urea reduction ratio), and parameters of bioelectrical impedance (resistance and reactance), proxies for body composition. Results: Adjusted mean serum creatinine concentrations were significantly higher in black versus nonblack patients (11.7 versus 10.0 mg/dl; P < 0.0001). Black patients were roughly four-fold more likely to have a serum creatinine concentration > 10 mg/dl and six-fold more likely to have a serum creatinine concentration > 15 mg/dl. Higher serum creatinine concentrations were associated with a lower relative risk for death (0.93; 95% confidence interval 0.88 to 0.98 per mg/dl); the association was slightly more pronounced among nonblack patients. Conclusions: Serum creatinine concentrations are significantly higher in black compared with nonblack hemodialysis patients; these differences are not readily explained by differences in nutritional status or body composition. C1 [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Stanford, CA 94305 USA. [Hsu, Joy; Johansen, Kirsten L.; Hsu, Chi-yuan; Chertow, Glenn M.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Johansen, Kirsten L.] Univ Calif Davis, Nephrol Sect, San Francisco VA Med Ctr, Davis, CA 95616 USA. [Kaysen, George A.] Univ Calif Davis, Div Nephrol, Dept Med, Davis, CA 95616 USA. [Kaysen, George A.] Univ Calif Davis, Dept Biochem, Davis, CA 95616 USA. RP Chertow, GM (reprint author), Stanford Univ, Sch Med, Div Nephrol, Dept Med, Grant Bldg,S-161, Stanford, CA 94305 USA. EM gchertow@stanford.edu NR 50 TC 12 Z9 12 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2008 VL 3 IS 4 BP 992 EP 997 DI 10.2215/CJN.00090108 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 320UO UT WOS:000257260700011 PM 18417750 ER PT J AU Desai, AA Bolus, R Nissenson, A Bolus, S Solomon, MD Khawar, O Gitlin, M Talley, J Spiegel, BMR AF Desai, Amar A. Bolus, Roger Nissenson, Allen Bolus, Sally Solomon, Matthew D. Khawar, Osman Gitlin, Matthew Talley, Jennifer Spiegel, Brennan M. R. TI Identifying best practices in dialysis care: Results of cognitive interviews and a national survey of dialysis providers SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PRACTICE PATTERNS; VASCULAR ACCESS; QUALITY INDICATORS; ANEMIA MANAGEMENT; PATIENT OUTCOMES; UNITED-STATES; HEMODIALYSIS; MORTALITY; DISEASE; DOPPS AB Background and objectives: Because there is wide variation in case-mix adjusted outcomes across dialysis facilities, it is possible that top-performing facilities use practices not shared by others. We sought to catalogue "best practices" that may account for interfacility variations in outcomes. Design, setting, participants, & measurements: This multidisciplinary study identified candidate best practices in dialysis through a staged process, including systematic review, cognitive interviews, and a national "virtual focus group" of dialysis providers. The resulting candidate practices were rank-ordered by perceived importance as determined by mean RAND Appropriateness Scores from a national survey of nephrologists, nurses, and opinion leaders. Results: A total of 135 candidate best practices were identified. Among these, respondents believed dialysis outcomes are most strongly related to 1) characteristics of multidisciplinary care conferences, 2) technician proficiency in protecting vascular access, 3) training of nurses to provide education in fluid management, vascular access, and nutrition, 4) use of random and blinded audits of staff performance, and 5) communication and teamwork among staff. In contrast, there was wide disagreement about the importance of facility-based health maintenance practices, optimal staffing ratios, frequency of dialysis-based physician visits, and optimal frequency of multidisciplinary care. Conclusions: This study provides a "conceptual map" of candidate dialysis best practices and highlights areas of general agreement and disagreement. These findings can help the dialysis community think critically about what may define "best practice" and provide targets for future research in quality improvement. C1 [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, VA Ctr Outcomes Res & Educ,Dept Med, Los Angeles, CA 90073 USA. [Desai, Amar A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Solomon, Matthew D.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA. [Desai, Amar A.] Stanford Univ, Ctr Hlth Policy & Primary Care Outcomes Res, Palo Alto, CA 94304 USA. [Gitlin, Matthew] Amgen Inc, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, VA Ctr Outcomes Res & Educ,Dept Med, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU NIDDK NIH HHS [P30 DK041301, 2P30 DK 041301-17] NR 30 TC 16 Z9 16 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUL PY 2008 VL 3 IS 4 BP 1066 EP 1076 DI 10.2215/CJN.04421007 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 320UO UT WOS:000257260700021 PM 18417745 ER PT J AU Lieberman-Blum, SS Fung, HB Bandres, JC AF Lieberman-Blum, Sharon S. Fung, Horatio B. Bandres, Juan C. TI Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection SO CLINICAL THERAPEUTICS LA English DT Review DE maraviroc; CCR5-receptor antagonist; entry inhibitor; HIV-1 infection ID HEALTHY-VOLUNTEERS; CCR5 ANTAGONIST; ENTRY INHIBITORS; CYP3A4 INHIBITORS; PHARMACOKINETICS; FUSION; RESISTANCE; ANTIRETROVIRALS; INDIVIDUALS; ASSOCIATION AB Background: The emergence of viral resistance is one of the greatest challenges in the treatment of HIV infection. Maraviroc is the first member of a new class of antiretroviral medications, the CCR5-receptor antagonists. It is approved by the US Food and Drug Administration (FDA) for use in combination with other antiretroviral agents in treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1. Objective: This article provides an overview of the pharmacology, efficacy, and tolerability of maraviroc in the treatment of HIV-1 infection. Methods: Relevant information was identified through a search of MEDLINE (January 2000-May 2008) using the terms maraviroc, UK-427,8S7, and CCRS-receptor antagonist. Also consulted were abstracts from the International AIDS Society Conference, the Conference on Retroviruses and Opportunistic Infections, and other relevant scientific meetings. Additional publications were found by searching the reference lists of the identified articles and the FDA Web site. Results: Maraviroc is a selective, reversible, small-molecule CCR5-receptor antagonist. In vitro, it has potent anti-HIV-1 activity, with a mean 90% inhibitory concentration of 2.0 nmol/L. It is widely distributed, with a V(d) of similar to 194 L. Maraviroc is moderately metabolized in the liver (65.3%), primarily via the cytochrome P450 3A4 isozyme. It has an elimination t(1/2) of 15.9 to 22.9 hours. Until more data are available, maraviroc should be avoided in patients with severe hepatic insufficiency; dose adjustment does not appear to be necessary on the basis of age, sex, or renal function. In 2 Phase IIb/III studies, maraviroc 300 mg PO QD or BID was found to be more efficacious than placebo in reducing the viral load at 48 weeks in treatment-experienced, CCR5-tropic HIV-1-infected patients receiving an optimized background regimen (difference vs placebo-QD arm: -0.89 log(10) copies/mL [97.5% CI, -1.17 to -0.62]; BID arm: -1.05 log(10) copies/mL [97.5% CI, -1.33 to -0.78]). The proportion of patients with a viral load < 50 copies/mL was 43.2% in the QD arm and 45.5% in the BID arm, compared with 16.7% in the placebo arm (P < 0.001, both treatment arms vs placebo). In treatment-naive patients infected with CCR5-tropic virus only, maraviroc 300 mg PO BID was not noninferior to oral efavirenz 600 mg QD (difference = -4.2%; lower bound of the 1-sided 97.5% CI, -10.9 [predefined statistical cutoff for noninferiority, -10]). Maraviroc was generally well tolerated in clinical trials. The most frequently reported (>= 5%) adverse events were upper respiratory tract infection (20.0%), cough (12.7%), pyrexia (12.0%), rash (9.6%), musculoskeletal complaints (8.7%,), gastrointestinal and abdominal pain (8.2%), dizziness (8.2%), appetite disorders (7.3%), insomnia (7.0%c), herpes infection (6.8%), sinusitis (6.3%), joint complaints (6.1%), bronchitis (5.9%), and constipation (5.4%). The recommended dose of maraviroc differs based on concomitant medications, ranging from 150 to 600 mg BID. Conclusion: When used in combination with other antiretroviral agents, maraviroc appears to be a promising agent for treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1. C1 [Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Med Surg Patient Care Ctr, Bronx, NY 10468 USA. [Lieberman-Blum, Sharon S.] James J Peters Vet Affairs Med Ctr, Serv Pharm, Bronx, NY 10468 USA. [Bandres, Juan C.] James J Peters Vet Affairs Med Ctr, Infect Dis Sect, Bronx, NY 10468 USA. RP Fung, HB (reprint author), James J Peters Vet Affairs Med Ctr, Med Surg Patient Care Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Horatio.fung@va.gov NR 58 TC 74 Z9 80 U1 6 U2 23 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD JUL PY 2008 VL 30 IS 7 BP 1228 EP 1250 DI 10.1016/j.clinthera.2008.07.008 PG 23 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 337GD UT WOS:000258422600004 PM 18691983 ER PT J AU Rakonczay, Z Hegyi, P Dosa, S Ivanyi, B Jarmay, K Biczo, G Hracsko, Z Varga, IS Karg, E Kaszaki, J Varro, A Lonovics, J Boros, I Gukovsky, I Gukovskaya, AS Pandol, SJ Takacs, T AF Rakonczay, Zoltan, Jr. Hegyi, Peter Dosa, Sandor Ivanyi, Bela Jarmay, Katalin Biczo, Gyoergy Hracsko, Zsuzsanna Varga, Ilona S. Karg, Eszter Kaszaki, Josef Varro, Andras Lonovics, Janos Boros, Imre Gukovsky, Ilya Gukovskaya, Anna S. Pandol, Stephen J. Takacs, Tamas TI A new severe acute necrotizing pancreatitis model induced by L-ornithine in rats SO CRITICAL CARE MEDICINE LA English DT Article DE L-ornithine; L-arginine; acute pancreatitis ID ACUTE HEMORRHAGIC-PANCREATITIS; KAPPA-B ACTIVATION; NITRIC-OXIDE; OXIDATIVE STRESS; L-ARGININE; CERULEIN; TRYPSINOGEN; INVOLVEMENT; PREVENT AB Objective: Intraperitoneal administration of large doses of L-arginine is known to induce severe acute pancreatitis in rats. We therefore set out to determine whether metabolites of L-arginine (L-ornithine, L-citrulline, and nitric oxide) cause pancreatitis. Design: The authors conducted an in vivo animal study. Setting: This study was conducted at a university research laboratory. Subjects: Study subjects were male Wistar rats. Interventions: Dose-response and time course changes of laboratory and histologic parameters of pancreatitis were determined after L-arginine, L-ornithine, L-citrulline, or sodium nitroprusside (nitric oxide donor) injection. Measurements and Main Results: Intraperitoneal injection of 3 g/kg L-ornithine but not L-citrulline or nitroprusside caused severe acute pancreatitis; 4 to 6 g/kg L-ornithine killed the animals within hours. Serum and ascitic amylase activities were significantly increased, whereas pancreatic amylase activity was decreased after intraperitoneal injection of 3 g/kg L-ornithine. The increase in pancreatic trypsin activity (9-48 hrs) correlated with the degradation of I kappa B proteins and elevated interleukin-1 beta levels. Oxidative stress in the pancreas was evident from 6 hrs; HSP72 synthesis was increased from 4 hrs after L-ornithine administration. Morphologic examination of the pancreas showed massive interstitial edema, apoptosis, and necrosis of acinar cells and infiltration of neutrophil granulocytes and monocytes 18 to 36 hrs after 3 g/kg L-ornithine injection. One month after L-ornithine injection, the pancreas appeared almost normal; the destructed parenchyma was partly replaced by fat. Equimolar administration of L-arginine resulted in lower pancreatic weight/body weight ratio, pancreatic myeloperoxidase activity, and histologic damage compared with the L-ornithine-treated group. L-ornithine levels in the blood were increased 54-fold after intraperitoneal administration Of L-arginine. Conclusions: We have developed a simple, noninvasive model of acute necrotizing pancreatitis in rats by intraperitoneal injection of 3 g/kg L-ornithine. Interestingly, we found that, compared with L-arginine, L-ornithine was even more effective at inducing pancreatitis. Large doses Of L-arginine produce a toxic effect on the pancreas, at least in part, through L-ornithine. C1 [Rakonczay, Zoltan, Jr.; Hegyi, Peter; Jarmay, Katalin; Lonovics, Janos; Takacs, Tamas] Univ Szeged, Dept Med 1, Szeged, Hungary. [Dosa, Sandor; Ivanyi, Bela] Univ Szeged, Dept Pathol, Szeged, Hungary. [Hracsko, Zsuzsanna; Varga, Ilona S.; Boros, Imre] Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary. [Karg, Eszter] Univ Szeged, Dept Pediat, Szeged, Hungary. [Varro, Andras] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary. [Gukovsky, Ilya; Gukovskaya, Anna S.; Pandol, Stephen J.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Rakonczay, Z (reprint author), Univ Szeged, Dept Med 1, Szeged, Hungary. EM raz@in1st.szote.u-szeged.hu RI Karg, Eszter/G-9158-2011; Varro, Andras/M-2647-2016 OI Varro, Andras/0000-0003-0745-3603 NR 33 TC 26 Z9 27 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JUL PY 2008 VL 36 IS 7 BP 2117 EP 2127 DI 10.1097/CCM.0b013e31817d7f5c PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 322XL UT WOS:000257408500017 PM 18594222 ER PT J AU Grathwohl, KW Venticinque, SG AF Grathwohl, Kurt W. Venticinque, Steven G. TI Organizational characteristics of the austere intensive care unit: The evolution of military trauma and critical care medicine, applications for civilian medical care systems SO CRITICAL CARE MEDICINE LA English DT Article DE critical care; intensive care; emergency mass critical care; US military; multidisciplinary critical care teams; intensive care unit organizations ID ILL PATIENTS; OUTCOMES; MORTALITY; EARTHQUAKE; INJURY AB Critical care in the U.S. military has significantly evolved in the last decade. More recently, the U.S. military has implemented organizational changes, including the use of multidisciplinary teams in austere environments to improve outcomes in severely injured polytrauma combat patients. Specifically, organizational changes in combat support hospitals located in combat zones during Operation Iraqi Freedom have led to decreased intensive care unit mortality and length of stay as well as resource use. These changes were implemented without increases in logistic support or the addition of highly technologic equipment. The mechanism for improvement in mortality is likely attributable to the adherence of basic critical care medicine fundamentals. This intensivist-directed team model provides sophisticated critical care even in the most austere environments. To optimize critically injured patients' outcomes, intensive care organizational models similar to the U.S. military, described in this article, can possibly be adapted to those of civilian care during disaster management to meet the challenges of emergency mass critical care. C1 [Grathwohl, Kurt W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesia & Operat Serv, Div Anesthesiol & Crit Care Med,Trauma Div, Brooke Army Med Ctr,Dept Surg, San Antonio, TX 78229 USA. [Venticinque, Steven G.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Adm Hosp, San Antonio, TX 78229 USA. [Venticinque, Steven G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Trauma Div, San Antonio, TX 78229 USA. RP Grathwohl, KW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesia & Operat Serv, Div Anesthesiol & Crit Care Med,Trauma Div, Brooke Army Med Ctr,Dept Surg, San Antonio, TX 78229 USA. EM kurt.grathwohl@amedd.army.mil NR 34 TC 18 Z9 19 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JUL PY 2008 VL 36 IS 7 SU S BP S275 EP S283 DI 10.1097/CCM.0b013e31817da825 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 324AU UT WOS:000257490700005 PM 18594253 ER PT J AU Grathwohl, KW Venticinque, SG Blackbourne, LH Jenkins, DH AF Grathwohl, Kurt W. Venticinque, Steven G. Blackbourne, Lorne H. Jenkins, Donald H. TI The evolution of military trauma and critical care medicine: Applications for civilian medical care systems SO CRITICAL CARE MEDICINE LA English DT Editorial Material C1 [Grathwohl, Kurt W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesia & Operat Serv, Div Anesthesiol & Crit Care Med, San Antonio, TX 78229 USA. [Venticinque, Steven G.] Univ Texas Hlth Sci Ctr San Antonio, Brooke Army Med Ctr, Dept Surg, Trauma Div, San Antonio, TX 78229 USA. [Blackbourne, Lorne H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol & Crit Care Med, San Antonio, TX 78229 USA. [Jenkins, Donald H.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Adm Hosp, Dept Surg, Trauma Div, San Antonio, TX 78229 USA. [Jenkins, Donald H.] USA, Inst Surg Res, Brooke Army Med Ctr, Trauma Serv, Ft Sam Houston, TX 78234 USA. [Jenkins, Donald H.] Wilford Hall USAF Med Ctr, Dept Surg, Lackland AFB, TX 78236 USA. RP Grathwohl, KW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesia & Operat Serv, Div Anesthesiol & Crit Care Med, San Antonio, TX 78229 USA. EM kurtgrathwohl@amedd.army.mil NR 2 TC 6 Z9 6 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JUL PY 2008 VL 36 IS 7 SU S BP S253 EP S254 DI 10.1097/CCM.0b013e31817e325a PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 324AU UT WOS:000257490700001 PM 18594249 ER PT J AU Haney, EM Bliziotes, MM AF Haney, Elizabeth M. Bliziotes, M. Michael TI Male osteoporosis: new insights in an understudied disease SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE bone mineral density; fracture; men; osteoporosis ID BONE-MINERAL DENSITY; ABSOLUTE FRACTURE RISK; ESTABLISHED PRIMARY OSTEOPOROSIS; VITAMIN-D SUPPLEMENTATION; NON-SPINE FRACTURE; OLDER MEN; HIP FRACTURE; ALENDRONATE TREATMENT; TESTOSTERONE THERAPY; CONTROLLED-TRIALS AB Purpose of review Osteoporosis in men is increasingly recognized as an important health problem. New research contributes to our knowledge of gender differences in osteoporosis risk, diagnosis and management. We undertook this review to summarize recent developments in the field of male osteoporosis. Recent findings The paper reviews recently published studies that reveal new insights into male osteoporosis. It addresses epidemiology, risk factors, use of clinical risk assessment tools, diagnosis and treatment. New data continue to suggest that men have higher mortality rates than women after hip fracture, and that men may experience fractures at higher bone mineral density values than women. Treatments for osteoporosis have been studied mostly in women, but trials including both men and women are now being conducted. Likewise, there are several newer cohorts with bone and fracture outcomes that include men and women. The Osteoporotic Fractures in Men (MrOS) study is the first United States-based cohort to include only men; this study is contributing importantly to our understanding of epidemiology and risk factors for osteoporosis in men. Summary Men and their physicians should be aware of the risk for osteoporosis and the gender differences that exist within this disease. Further research is needed to continue to understand differences in pathophysiology, epidemiology and risk factors, and to promote appropriate therapies among men. C1 [Haney, Elizabeth M.] Oregon Hlth & Sci Univ, Div Gen Internal Med, Dept Med, Portland, OR 97239 USA. [Haney, Elizabeth M.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Bliziotes, M. Michael] Portland VA Med Ctr, Portland, OR USA. RP Haney, EM (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med, Dept Med, 3181 SW Sam Jackson Ark Rd,L-475, Portland, OR 97239 USA. EM haneye@ohsu.edu FU NIAMS NIH HHS [K23 AR 051926, K23 AR051926, R01 AR 052018] NR 48 TC 23 Z9 25 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD JUL PY 2008 VL 20 IS 4 BP 423 EP 428 DI 10.1097/BOR.0b013e3283025eb0 PG 6 WC Rheumatology SC Rheumatology GA 322ML UT WOS:000257379200008 PM 18525355 ER PT J AU Graham, DY Kato, M Asaka, A AF Graham, D. Y. Kato, M. Asaka, A. TI Gastric endoscopy in the 21st century: Appropriate use of an invasive procedure in the era of non-invasive testing SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE gastrin; gastroscopy; histology; intestinal metaplasia; pepsinogen ID HELICOBACTER-PYLORI INFECTION; INTESTINAL METAPLASIA; CLINICAL-PRACTICE; MUCOSAL ATROPHY; ACID-SECRETION; CANCER; ERADICATION; CARCINOMA; BIOPSY; SYSTEM AB Background. The acceptance of the premise that Helicobacter pylori infection is aetiologically related to gastric cancer and peptic ulcer and that the risk of gastric cancer among Helicobacter pylori infected individuals is related to the extent, severity and duration of atrophic gastritis has led to major changes in medical and endoscopic practices. The development of non-invasive methods to detect Helicobacter pylori and to estimate the extent and severity of gastritis has reduced the need for diagnostic endoscopy in asymptomatic individuals. Methods and Results. Here we provide recommendations regarding deciding whether non-invasive and endoscopic assessment of the gastric mucosa is preferred. We also include specific recommendations and caveats regarding the preferred biopsy number and sites as well as the identification of specimens, to allow the pathologist to reliable stage the severity and extent of gastritis, and thus provide prognostic information needed for patient managements (e.g., whether endoscopic surveillance is recommended). Conclusion. In summary, while there is clearly a role for gastric endoscopy and endoscopic biopsy in the Helicobacter pylori era, obtaining useful diagnostic and prognostic information is critically dependent upon attention to detail with regard to biopsy site and identification as to the location from where the specimen was taken. (c) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. C1 [Graham, D. Y.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Graham, D. Y.] Baylor Coll Med, Houston, TX 77030 USA. [Kato, M.; Asaka, A.] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu RI Kato, Mototsugu/A-6736-2012 FU NIDDK NIH HHS [DK56338, P30 DK056338, P30 DK056338-06A2] NR 26 TC 11 Z9 11 U1 0 U2 0 PU PACINI EDITORE PI PISA PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY SN 1590-8658 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD JUL PY 2008 VL 40 IS 7 BP 497 EP 503 DI 10.1016/j.dld.2008.02.032 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 327AW UT WOS:000257702100003 PM 18403275 ER PT J AU El-Serag, HB Pilgrim, P Tatevian, N Medrano, M Kitagawa, S Gilger, M AF El-Serag, Hashem B. Pilgrim, Petra Tatevian, Nina Medrano, Miles Kitagawa, Seiji Gilger, Mark TI Prevalence and histological features of the gastric cardia-type mucosa in children SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE gastric; cardia; H. pylori; metaplasia; intestinal; Barrett's esophagus ID GASTROESOPHAGEAL REFLUX QUESTIONNAIRE; HELICOBACTER-PYLORI INFECTION; INTESTINAL METAPLASIA; INFLAMMATION; JUNCTION; ESOPHAGITIS; SYMPTOMS; VALIDITY; INFANTS AB Background It has been suggested that the presence of gastric cardia in adults (with or without inflammation or intestinal cells) is a metaplastic condition. The presence of gastric cardia in children would argue against this contention. We examined the presence and determinants of gastric cardia-type mucosa at a normally located z-line in children without underlying gastroesophageal reflux disease (GERD)-predisposing disorders. Methods We conducted a prospective study of consecutive pediatric patients undergoing routine upper endoscopy. We excluded patients with coagulopathy or bleeding disorder, prior gastric or esophageal surgery, major congenital disorders, or neurodevelopmental disorders. Biopsies were obtained with the endoscope in the anterograde position within 5 mm below the endoscopic z-line, and were examined for the presence of gastric cardia-type mucosa, defined as both mucous and oxynto-mucous glands. Results Eighteen (47%) of 38 subjects has gastric cardia mucosa. There were no significant differences in age, gender, or race between patients with and without gastric cardia-type mucosa. There were no differences between the groups in weight and height either at birth or at the time of endoscopy, in the mother's age at childbirth or history of peripartum problems. There were no differences in symptoms suggestive of reflux such as spitting up or difficulty of gaining weight. Neither history of gastroesophageal testing nor histological esophagitis (38% versus 40%) was different between the groups with and without gastric cardia-type mucosa. Conclusions Gastric cardia-type mucosa is unlikely to be a metaplastic condition since it is present in a large proportion of children undergoing endoscopy. Neither histological esophagitis nor GERD symptoms are significantly associated with the presence of gastric cardia-type mucosa. C1 [Tatevian, Nina] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Kitagawa, Seiji; Gilger, Mark] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [El-Serag, Hashem B.; Pilgrim, Petra; Medrano, Miles] Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Gastroenterol Sect, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 18 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUL PY 2008 VL 53 IS 7 BP 1792 EP 1796 DI 10.1007/s10620-008-0247-5 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 307JF UT WOS:000256314500006 PM 18373198 ER PT J AU Currie, SL Ryan, JC Tracy, D Wright, TL George, S McQuaid, R Kim, M Shen, H Monto, A AF Currie, Sue L. Ryan, James C. Tracy, Daniel Wright, Teresa L. George, Sally McQuaid, Rosemary Kim, Michael Shen, Hui Monto, Alexander TI A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus (vol 93, pg 148, 2008) SO DRUG AND ALCOHOL DEPENDENCE LA English DT Correction C1 [Currie, Sue L.; Ryan, James C.; Tracy, Daniel; Kim, Michael; Shen, Hui; Monto, Alexander] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Ryan, James C.; Wright, Teresa L.; George, Sally; McQuaid, Rosemary; Kim, Michael; Monto, Alexander] San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA. RP Currie, SL (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM sue.currie@va.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JUL 1 PY 2008 VL 96 IS 1-2 BP 192 EP 192 DI 10.1016/j.drugalcdep.2008.02.001 PG 1 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 317JY UT WOS:000257017300022 ER PT J AU Bui, PH Quesada, A Handforth, A Hankinson, O AF Bui, Peter H. Quesada, Arnulfo Handforth, Adrian Hankinson, Oliver TI The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil SO DRUG METABOLISM AND DISPOSITION LA English DT Article ID IN-VITRO; RO 40-5967; CYTOCHROME-P450 ENZYMES; CYNOMOLGUS MONKEY; DRUG-INTERACTIONS; RISK-ASSESSMENT; METABOLISM; RO-40-5967; RAT; NNC-55-0396 AB A novel mibefradil derivative, NNC55-0396, designed to be hydrolysis-resistant, was shown to be a selective T-type Ca(2+) channel inhibitor without L-type Ca(2+) channel efficacy. However, its effects on cytochromes P450 (P450s) have not previously been examined. We investigated the inhibitory effects of NNC55-0396 toward seven major recombinant human P450s-CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2C8, CYPC19, and CYP2E1 - and compared its effects with those of mibefradil and its hydrolyzed metabolite, Ro40-5966. Our results show that CYP3A4 and CYP2D6 are the two P450s most affected by mibefradil, Ro40-5966, and NNC55-0396. Mibefradil (IC(50) = 33 +/- 3 nM, K(i) = 23 +/- 0.5 nM) and Ro40-5966 (IC(50) = 30 +/- 7.8 nM, K(i) = 21 +/- 2.8 nM) have a 9- to 10-fold greater inhibitory activity toward recombinant CYP3A4 benzyloxy-4-trifluoromethylcoumarin-O- debenzylation activity than NNC55-0396 (IC(50) = 300 +/- 30 nM, K(i) = 210 +/- 6 nM). More dramatically, mibefradil (IC(50) = 566 +/- 71 nM, K(i) = 202 +/- 39 nM) shows 19-fold higher inhibition of CYP3A-associated testosterone 6 beta-hydroxylase activity in human liver microsomes compared with NNC55-0396 (IC(50) = 11 +/- 1.1 mu M, K(i) = 3.9 +/- 0.4 mu M). Loss of testosterone 6 beta-hydroxylase activity by recombinant CYP3A4 was shown to be time-and concentration-dependent with both compounds. However, NNC55-0396 (K(I) = 3.87 mu M, K(inact) = 0.061/min) is a much less potent mechanism-based inhibitor than mibefradil (K(I) = 83 nM, K(inact) = 0.048/min). In contrast, NNC55-0396 (IC(50) = 29 +/- 1.2 nM, K(i) = 2.8 +/- 0.3 nM) and Ro40-5966 (IC(50) = 46 +/- 11 nM, K(i) = 4.5 +/- 0.02 nM) have a 3- to 4-fold greater inhibitory activity toward recombinant CYP2D6 than mibefradil (IC(50) = 129 +/- 21 nM, K(i) = 12.7 +/- 0.9 nM). Our results suggest that NNC55-0396 could be a more favorable T-type Ca(2+) antagonist than its parent compound, mibefradil, which was withdrawn from the market because of strong inhibition of CYP3A4. C1 [Hankinson, Oliver] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Bui, Peter H.; Hankinson, Oliver] Univ Calif Los Angeles, Mol Toxicol Interdepartmental Program, Los Angeles, CA 90095 USA. [Bui, Peter H.; Hankinson, Oliver] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Quesada, Arnulfo] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA. [Quesada, Arnulfo; Handforth, Adrian] Vet Affairs Greater Los Angeles, Neurol & Res Serv, Los Angeles, CA USA. RP Hankinson, O (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 650 Charles Young Dr, Los Angeles, CA 90095 USA. EM ohank@mednet.ucla.edu FU NIEHS NIH HHS [R01 ES015384-03, R01 ES015384, R01ES015384] NR 39 TC 16 Z9 17 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0090-9556 J9 DRUG METAB DISPOS JI Drug Metab. Dispos. PD JUL PY 2008 VL 36 IS 7 BP 1291 EP 1299 DI 10.1124/dmd.107.020115 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 315UG UT WOS:000256905100017 PM 18411403 ER PT J AU Ramsay, RE Uthman, B Pryor, FM Rowan, AJ Bainbridge, J Spitz, M Sirven, JI Frederick, TE AF Ramsay, R. Eugene Uthman, Basim Pryor, Flavia M. Rowan, A. James Bainbridge, Jacquelyn Spitz, Mark Sirven, Joseph I. Frederick, Tim E. TI Topiramate in older patients with partial-onset seizures: A pilot double-blind, dose-comparison study SO EPILEPSIA LA English DT Article DE epilepsy; elderly patients; topiramate; monotherapy ID NEWLY-DIAGNOSED EPILEPSY; ANTIEPILEPTIC DRUGS; ELDERLY-PATIENTS; CARBAMAZEPINE; MONOTHERAPY; LAMOTRIGINE AB Purpose: Pharmacokinetics of antiepileptic drugs (AEDs) can be altered by age-related changes in physiology, thereby altering clinical effects, especially tolerability, in older adults. We compared two dosages of topiramate (TPM) in a pilot study of patients >= 60 years of age with partial-onset seizures. Methods: In this 24-week, double-blind, randomized, parallel-group study, patients with one or more seizures in previous 6 months were randomized to treatment with 50 or 200 mg/day TPM. TPM was initiated as monotherapy or added to one AED and titrated by 25 mg/day per week to target or maximum tolerated dose as the concomitant AED, if any, was withdrawn. Results: Thirty-eight patients were randomized to the 50 mg/day TPM (mean age, 68 years) and 39-200 mg/day TPM (69 years). Seizure control was similar with the two dosages when TPM could be used as monotherapy, whereas 200 mg TPM was more effective than 50 mg in patients requiring adjunctive therapy. The overall incidence of adverse events was similar for the two dosages-66% with 50 mg and 62% with 200 mg TPM. Most common adverse events were somnolence (TPM 50, 13%; TPM 200, 8%), dizziness (13% vs. 8%), and headache (13% vs. 5%). Of 10 (13%) patients reporting a cognitive-related adverse event, six patients were assigned to the 50-mg group. A total of 14 patients (18%; seven in each group) discontinued TPM due to adverse events. Conclusions: This pilot study supports the practice of using low-to-moderate dosages of AEDs in older adults. C1 [Ramsay, R. Eugene; Pryor, Flavia M.] Miami VA Med Ctr, Miami, FL USA. [Uthman, Basim] N Florida S Georgia Vet Hlth System, Neurol Serv, Gainesville, FL USA. [Rowan, A. James] James J Peters VA Med Ctr, Bronx, NY USA. [Bainbridge, Jacquelyn; Spitz, Mark] Univ Colorado, Denver, CO 80202 USA. [Sirven, Joseph I.] Mayo Clin Scottsdale, Scottsdale, AZ USA. [Frederick, Tim E.] New Orleans VA Med Ctr, New Orleans, LA USA. RP Ramsay, RE (reprint author), Univ Miami, Int Ctr Epilepsy, 1150 NW 14th St,Suite 410, Miami, FL 33136 USA. EM eramsay@epiworld.com RI Ramsay, R. Eugene/D-4491-2011 NR 15 TC 28 Z9 29 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD JUL PY 2008 VL 49 IS 7 BP 1180 EP 1185 DI 10.1111/j.1528-1167.2008.01584.x PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 326KV UT WOS:000257658600008 PM 18494791 ER PT J AU Bohnen, NI Studenski, SA Constantine, GM Moore, RY AF Bohnen, N. I. Studenski, S. A. Constantine, G. M. Moore, R. Y. TI Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE biomarker; diagnostic accuracy; motor; non-motor; olfaction; Parkinson disease; tremor ID OLFACTORY FUNCTION; MORTALITY; ACCURACY; SCALE; SIGNS AB Background and purpose: The diagnosis of Parkinson disease (PD) is made typically on the basis of motor abnormalities. PD is now recognized to have both motor and non-motor manifestations, indicating a need for the development of reliable non-motor diagnostic tests for PD. The aim of the present study was to compare the accuracy of various clinical motor and non-motor tests for the diagnosis of PD. Methods: Forty-five PD patients (Hoehn and Yahr stages 1-3; mean age 59.5 +/- 10.0 years) and 45 healthy controls matched for gender and age completed a clinimetric motor test battery to assess limb bradykinesia, tremor and balance. Non-motor tests consisted of depression, anxiety and smell identification ratings. Area under the receiver operator characteristic curve (AUC) analysis was used. Results: We found that smell identification was the most accurate predictor of the presence of PD within the overall group of patients and matched control subjects (AUC = 0.886) and also in the subgroups of mild severity (Hoehn and Yahr stages 1-1.5; AUC = 0.923), young-onset (AUC = 0.888) and female PD patients ( AUC = 0.797). The second best diagnostic test was the grooved pegboard test for the clinically most affected body side. Conclusions: We conclude that olfactory function is the most accurate diagnostic predictor within a heterogeneous sample of patients with PD. C1 [Bohnen, N. I.; Moore, R. Y.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Bohnen, N. I.; Studenski, S. A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Studenski, S. A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Constantine, G. M.] Univ Pittsburgh, Dept Math & Stat, Pittsburgh, PA 15260 USA. RP Bohnen, NI (reprint author), Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48106 USA. EM nbohnen@umich.edu FU NINDS NIH HHS [NS-019608] NR 34 TC 25 Z9 27 U1 1 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-5101 J9 EUR J NEUROL JI Eur. J. Neurol. PD JUL PY 2008 VL 15 IS 7 BP 685 EP 691 DI 10.1111/j.1468-1331.2008.02148.x PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 311XV UT WOS:000256634600010 PM 18435767 ER PT J AU Du, W Zhou, Y Adam, Z Koretsky, T Bagby, GC Pang, QS AF Du, Wei Zhou, Yun Adam, Zsuzsanna Koretsky, Tara Bagby, Grover C. Pang, Qishen TI TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic stem cells and suppresses inflammation-associated leukemogenesis in mice SO EXPERIMENTAL HEMATOLOGY LA English DT Meeting Abstract CT ISEH 37th Annual Scientific Meeting/6th International Neonatal Hematology and Immunology Meeting CY JUL 09-12, 2008 CL Boston, MA C1 [Du, Wei; Zhou, Yun; Adam, Zsuzsanna; Pang, Qishen] Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA. [Koretsky, Tara; Bagby, Grover C.] Portland VA Med Ctr, Portland, OR USA. [Pang, Qishen] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA. RI Du, Wei/A-8739-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD JUL PY 2008 VL 36 IS 7 SU 1 BP S34 EP S35 PG 2 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 322BF UT WOS:000257349500079 ER PT J AU Miravitlles, M Anzueto, A AF Miravitlles, Marc Anzueto, Antonio TI Moxifloxacin: a respiratory fluoroquinolone SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE chronic bronchitis; community-acquired pneumonia; moxifloxacin; rhinosinusitis; quinolones ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; ACUTE BACTERIAL EXACERBATIONS; RESISTANT STREPTOCOCCUS-PNEUMONIAE; ASSOCIATION ALAT RECOMMENDATIONS; COURSE 5-DAY MOXIFLOXACIN; LONG-TERM OUTCOMES; IN-VITRO ACTIVITY; QUALITY-OF-LIFE; CHRONIC-BRONCHITIS AB Background: Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae. Objective: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections. Method: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections. Results: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates. Conclusions: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines. C1 [Miravitlles, Marc] Hosp Clin Barcelona, Serv Pneumol, Inst Clin Torax IDIBAPS, Ciber Enfermedades Resp CIBERES, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. RP Miravitlles, M (reprint author), Hosp Clin Barcelona, Serv Pneumol, Inst Clin Torax IDIBAPS, Ciber Enfermedades Resp CIBERES, Barcelona, Spain. EM marcm@clinic.ub.es OI Miravitlles, Marc/0000-0002-9850-9520 NR 107 TC 12 Z9 18 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-6566 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD JUL PY 2008 VL 9 IS 10 BP 1755 EP 1772 DI 10.1517/14656560802193773 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 325WT UT WOS:000257620100013 PM 18570608 ER PT J AU Kozell, L Belknap, JK Hofstetter, JR Mayeda, A Buck, KJ AF Kozell, L. Belknap, J. K. Hofstetter, J. R. Mayeda, A. Buck, K. J. TI Mapping a locus for alcohol physical dependence and associated withdrawal to a 1.1 Mb interval of mouse chromosome 1 syntenic with human chromosome 1q23.2-23.3 SO GENES BRAIN AND BEHAVIOR LA English DT Article DE C57BL/6J (B6); convulsion; DBA/2J (D2); ethanol; interval-specific congenic strain; quantitative trait locus ID QUANTITATIVE TRAIT LOCI; RECOMBINANT INBRED MICE; GENETIC DISSECTION; CONGENIC STRAINS; SEIZURE SUSCEPTIBILITY; ETHANOL WITHDRAWAL; COMPLEX TRAITS; MURINE LOCI; LINKAGE; IDENTIFICATION AB Physiological dependence and associated withdrawal episodes are thought to constitute a motivational force perpetuating continued alcohol use/abuse. Although no animal model duplicates alcoholism, models for specific factors, like the withdrawal syndrome, are useful to identify potential determinants of liability in humans. We previously detected quantitative trait loci (QTLs) with large effects on predisposition to physical dependence and associated withdrawal following chronic or acute alcohol exposure to a large region of chromosome 1 in mice (Alcdp1 and Alcw1, respectively). Here, we provide the first confirmation of Alcw1 in a congenic strain, and, using interval-specific congenic strains, narrow its position to a minimal 1.1 Mb (maximal 1.7 Mb) interval syntenic with human chromosome 1q23.2-23.3. We also report the development of a small donor segment congenic that confirms capture of a gene(s) affecting physical dependence after chronic alcohol exposure within this small interval. This congenic will be invaluable for determining whether this interval harbors a gene(s) involved in additional alcohol responses for which QTLs have been detected on distal chromosome 1, including alcohol consumption, alcohol-conditioned aversion and -induced ataxia. The possibility that this QTL plays an important role in such diverse responses to alcohol makes it an important target. Moreover, human studies have identified markers on chromosome 1q associated with alcoholism, although this association is still suggestive and mapped to a large region. Thus, the fine mapping of this QTL and analyses of the genes within the QTL interval can inform developing models for genetic determinants of alcohol dependence in humans. C1 [Kozell, L.; Belknap, J. K.; Buck, K. J.] Oregon Hlth & Sci Univ, Dept Vet Affairs Med Ctr, Portland, OR 97201 USA. [Kozell, L.; Belknap, J. K.; Buck, K. J.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA. [Hofstetter, J. R.; Mayeda, A.] Indiana Univ, Sch Med, Roudebush VA Med Ctr, Indianapolis, IN USA. [Hofstetter, J. R.; Mayeda, A.] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN USA. RP Buck, KJ (reprint author), Portland VA Med Ctr, Mailcode R&D40,3710 Vet Hosp Rd, Portland, OR 97239 USA. EM buckk@ohsu.edu OI Kozell, Laura/0000-0003-3059-2046 FU NIAAA NIH HHS [AA06243, AA011114, AA10760]; NIDA NIH HHS [DA05228] NR 45 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1601-1848 J9 GENES BRAIN BEHAV JI Genes Brain Behav. PD JUL PY 2008 VL 7 IS 5 BP 560 EP 567 DI 10.1111/j.1601-183X.2008.00391.x PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 326QA UT WOS:000257672800007 PM 18363856 ER PT J AU Heusner, CL Beutler, LR Houser, CR Palmiter, RD AF Heusner, Carrie L. Beutler, Lisa R. Houser, Carolyn R. Palmiter, Richard D. TI Deletion of GAD67 in dopamine receptor-1 expressing cells causes specific motor deficits SO GENESIS LA English DT Article DE dopamine; GABA; striatum; behavior; Cre-Iox; recombination ID GLUTAMIC-ACID DECARBOXYLASE; GAMMA-AMINOBUTYRIC-ACID; TEMPORAL-LOBE EPILEPSY; MEDIUM SPINY NEURONS; HUNTINGTONS-DISEASE; MICE LACKING; GABAERGIC NEURONS; NUCLEUS-ACCUMBENS; GENE-EXPRESSION; TRANSGENIC MICE AB The medium spiny neurons (MSNs), which comprise the direct and indirect output pathways from the striatum, use gamma-aminobutyric acid (GABA) as their major fact-acting neurotransmitter. We generated mice carrying a conditional allele of the Gad1 gene, which encodes GAD67, one of the two enzymes responsible for GABA biosynthesis, and bred them to mice expressing Cre recombinase at the dopamine D1 receptor locus (Drd1a) to selectively reduce GABA synthesis in the direct output pathway from the striatum. We show that these mice are deficient in some types of motor skills, but normal for others, suggesting a differential role for GABA release from D1 receptor-containing neurons. C1 [Heusner, Carrie L.; Palmiter, Richard D.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA. [Beutler, Lisa R.; Palmiter, Richard D.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Palmiter, Richard D.] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, Carolyn R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. RP Palmiter, RD (reprint author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA. EM palmiter@u.washington.edu FU BLRD VA [I01 BX000404]; Howard Hughes Medical Institute NR 47 TC 22 Z9 22 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-954X J9 GENESIS JI Genesis PD JUL PY 2008 VL 46 IS 7 BP 357 EP 367 DI 10.1002/dvg.20405 PG 11 WC Developmental Biology; Genetics & Heredity SC Developmental Biology; Genetics & Heredity GA 334EL UT WOS:000258205000003 PM 18615733 ER PT J AU Rodriguez, KL Appelt, CJ Switzer, GE Sonel, AF Arnold, RM AF Rodriguez, Keri L. Appelt, Cathleen J. Switzer, Galen E. Sonel, Ali F. Arnold, Robert M. TI "They diagnosed bad heart": A qualitative exploration of patients' knowledge about and experiences with heart failure SO HEART & LUNG LA English DT Article ID ELDERLY-PATIENTS; HEALTH OUTCOMES; CHRONIC ILLNESS; CHRONIC DISEASE; OF-LIFE; COMMUNICATION; CARE; SATISFACTION; EDUCATION; CANCER AB BACKGROUND: Patient education is central to the management of individuals with heart failure; therefore, it is important to know what these patients understand and experience both clinically and personally. OBJECTIVES: This study qualitatively explored patients' knowledge regarding a heart failure diagnosis, their understanding of their cardiac care providers' treatment recommendations, and their views concerning the impact of heart failure on their daily lives and prognosis. METHODS: A qualitative study was conducted whereby data were collected through 25 telephone interviews with adults being followed for heart failure at a Veterans Affairs medical center. Subjects were interviewed using semistructured open-ended questions. Audiotaped responses were analyzed using grounded theory methods. RESULTS: The majority of participants were elderly, male, and white, and had New York Heart Association class II disease. Participants without angina typically experienced a lengthy and difficult diagnostic delay, with symptoms misattributed to comorbid diseases. Most understood the importance of self-monitoring and adhering to physician recommendations, and their discussions of life-changing effects typically focused on loss of physical functioning and decreased quality of life. Although participants wanted to know their prognosis, most had not received information about it or about advance care planning. CONCLUSION: Patients require opportunities for enhanced communication with physicians and health care team members during the challenging diagnostic period and subsequently need more information about their medical condition and prognosis. C1 [Rodriguez, Keri L.; Switzer, Galen E.; Sonel, Ali F.] Univ Pittsburgh, Sch Med, Ctr Hlth Equity Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Rodriguez, Keri L.; Switzer, Galen E.; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15260 USA. [Appelt, Cathleen J.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA. [Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Sonel, Ali F.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA 15260 USA. [Sonel, Ali F.] Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA 15260 USA. [Arnold, Robert M.] Univ Pittsburgh, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. [Arnold, Robert M.] Univ Pittsburgh, Inst Enhance Palliat Care, Pittsburgh, PA 15260 USA. RP Rodriguez, KL (reprint author), Univ Pittsburgh, Sch Med, Ctr Hlth Equity Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. FU NCI NIH HHS [3R01 CA100387-03S1] NR 40 TC 38 Z9 38 U1 2 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 J9 HEART LUNG JI Heart Lung PD JUL-AUG PY 2008 VL 37 IS 4 BP 257 EP 265 DI 10.1016/i.hrtlng.2007.09.001 PG 9 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 333DA UT WOS:000258131200002 PM 18620101 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI Exercise and dialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Review DE exercise; physical activity; end-stage renal disease; hemodialysis ID STAGE RENAL-DISEASE; QUALITY-OF-LIFE; MAINTENANCE HEMODIALYSIS-PATIENTS; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; PERITONEAL-DIALYSIS; BLOOD-PRESSURE; CARDIOVASCULAR COMPLICATIONS; REHABILITATION PROGRAMS; PROGRESSIVE EXERCISE AB Fortunately, the literature on exercise among patients on hemodialysis has grown too broad to be included in a single review. The focus of this review is on interventional studies, with an emphasis on those studies that included a control group. The good news is that there is ample evidence that exercise can improve fitness (VO2 peak), physical functioning, and some cardiovascular risk factors in the dialysis population. However, there have been few comparative studies, and there is no consensus regarding the most beneficial regimen or the one most acceptable to large numbers of patients. A new set of recommendations from the American College of Sports Medicine and the American Heart Association for older individuals and individuals with chronic diseases is relevant for our patient population and can be used to guide exercise prescription until disease-specific data are available to fill the gap. C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.johansen@ucsf.edu NR 85 TC 31 Z9 34 U1 2 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD JUL PY 2008 VL 12 IS 3 BP 290 EP 300 DI 10.1111/j.1542-4758.2008.00269.x PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 327DU UT WOS:000257710600002 PM 18638081 ER PT J AU Harris, RA Sugimoto, K Kaplan, DE Ikeda, F Kmoun, M Chang, KM AF Harris, Rebecca A. Sugimoto, Kazushi Kaplan, David E. Ikeda, Fusao Kmoun, Malek Chang, Kyong-Mi TI Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans SO HEPATOLOGY LA English DT Article ID VIRAL CLEARANCE; RACIAL-DIFFERENCES; IMMUNE-RESPONSE; HCV INFECTION; EX-VIVO; HLA; MHC; ALLELES; GENES; POPULATION AB The outcome of hepatitis C virus (HCV) infection has been associated with antiviral CD4 T cell response, human leukocyte antigens (HLA) class II genotypes, and ethnicity. However, HLA class II molecules restrict the nature of CD4 T cell response, and HLA distributions differ between ethnic groups. In this study, we asked whether HLA class II genotypes associated with HCV clearance are shared between Caucasian and African Americans and whether they contribute to enhanced antiviral CD4 T cell response. In a cohort of 93 HCV-seropositive subjects from Northeast America with defined ethnicity, virological outcome, and HCV-specific CD4 T cell proliferation, we confirm the previously reported associations between HCV clearance and two HILA types (DQB1*03, DRB1*11) while identifying a new association with DRB3*02. Strikingly, these associations were identified only among Caucasian [DQB1*03: odds ratio (OR), 10.4; P = 0.031, DRB1*11: OR, 7.0, P = 0.019; DRB3*02: OR, 8.3, P = 0.005; DQB1*03-DRB3*02: OR, 13.5, P = 0.001) but not among African American patients. Furthermore, although HLA DQB1*03, DRB1*11, and DRB3*02 genotypes were associated with increased HCV-specific CD4 T cell response in univariate analyses, these associations were lost when controlling for virological outcomes. Conclusion: We conclude that the immunogenetic basis for HCV clearance differs between ethnic groups and that the association between HLA class II and HCV clearance is not directly explained by antiviral CD4 T cell response. C1 [Harris, Rebecca A.; Sugimoto, Kazushi; Kaplan, David E.; Ikeda, Fusao; Chang, Kyong-Mi] Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19014 USA. [Harris, Rebecca A.; Sugimoto, Kazushi; Kaplan, David E.; Ikeda, Fusao; Chang, Kyong-Mi] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Harris, Rebecca A.] Haverford Coll, Haverford, PA 19041 USA. [Kmoun, Malek] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19014 USA. [Kmoun, Malek] Univ Penn, Sch Med, Lab Med, Philadelphia, PA 19014 USA. RP Chang, KM (reprint author), Univ Penn, Sch Med, Div Gastroenterol, Dept Med, 600 CRB,415 Curie Blvd, Philadelphia, PA 19014 USA. EM kmchang@mail.med.upenn.edu OI Kaplan, David E./0000-0002-3839-336X FU Howard Hughes Medical Institute; NCRR NIH HHS [M01 RR000040]; NIAAA NIH HHS [AA12849, R01 AA012849, R01 AA012849-03, R01 AA012849-04, R01 AA012849-05]; NIAID NIH HHS [AI47519, R01 AI047519, R01 AI047519-06, R01 AI047519-07, R01 AI047519-08, R01 AI047519-09]; NIDDK NIH HHS [P30 DK050306, P30 DK050306-09, P30 DK050306-10, P30 DK050306-11, P30 DK050306-12, P30 DK050306-13, P30DK50306] NR 56 TC 37 Z9 37 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JUL PY 2008 VL 48 IS 1 BP 70 EP 79 DI 10.1002/hep.22287 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 321JP UT WOS:000257301100011 PM 18537178 ER PT J AU Hsu, CC Lin, YE Chen, YS Liu, YC Muder, RR AF Hsu, Cheng-Chuan Lin, Yusen E. Chen, Yao-Shen Liu, Yung-Ching Muder, Robert R. TI Validation study of artificial neural network models for prediction of methicillin-resistant Staphylococcus aureus carriage SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INTENSIVE-CARE-UNIT; ACTIVE SURVEILLANCE CULTURES; MRSA BACTEREMIA; COST; EPIDEMIOLOGY; COLONIZATION; ENTEROCOCCI; INFECTIONS; ADMISSION; PREVENT AB objective. Use of active surveillance cultures for methicillin-resistant Staphylococcus aureus (MRSA) for all patients admitted to the intensive care unit has been shown to reduce nosocomial transmission. However, the cost-effectiveness and the utility of implementing use of active surveillance cultures nationwide remain controversial. We sought to develop an artificial neural network (ANN) model that would predict the likelihood of MRSA colonization. setting. Two acute care hospitals, one in Pittsburgh (hospital A) and one in Kaohsiung, Taiwan (hospital B). methods. Nasal cultures were performed for all patients admitted to the hospitals. A total of 46 potential risk factors in hospital A and 86 potential risk factors in hospital B associated with MRSA colonization were assessed. Culture results were obtained; 75% of the data were used for training our ANN model, and the remaining 25% were used for validating our ANN model. The culture results were the "gold standard" for determining the accuracy of the model predictions. results. The ANN model predictions were accurate 95.2% of the time for hospital A(sensitivity, 94.3%; specificity, 96.0%) and 94.2% of the time for hospital B (sensitivity, 96.6%; specificity, 91.8%), integrating all potential risk factors into the model. Only 17 potential risk factors were needed for the hospital A ANN model (accuracy, 90.9%; sensitivity, 98.5%; specificity, 83.4%), and only 20 potential risk factors were needed for the hospital B ANN model (accuracy, 90.5%; sensitivity, 96.6%; specificity, 84.3%), if the minimal risk factor method was used. Cross-validation analysis showed an average accuracy of 85.6% (sensitivity, 91.3%; specificity, 80.0%). conclusion. Our ANN model can be used to predict with an accuracy of more than 90% which patients carry MRSA. The false-negative rates were significantly lower than the false-positive rates in the ANN predictions, which can serve as a safety buffer in case of patient misclassification. C1 [Hsu, Cheng-Chuan; Lin, Yusen E.; Chen, Yao-Shen] Natl Kaohsiung Normal Univ, Grad Inst Environm Educ, Kaohsiung 824, Taiwan. [Chen, Yao-Shen; Liu, Yung-Ching] Kaohsiung Vet Gen Hosp, Infect Dis Sect, Kaohsiung, Taiwan. [Muder, Robert R.] Vet Affairs Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. RP Lin, YE (reprint author), Natl Kaohsiung Normal Univ, Grad Inst Environm Educ, 62 Shenchong Rd, Kaohsiung 824, Taiwan. EM easonlin@nknucc.nknu.edu.tw NR 26 TC 3 Z9 3 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUL PY 2008 VL 29 IS 7 BP 607 EP 614 DI 10.1086/588588 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 323NF UT WOS:000257452100005 PM 18549315 ER PT J AU Rojas, A Meherem, S Kim, YH Washington, MK Willis, JE Markowitz, SD Grady, WM AF Rojas, Andres Meherem, Shereen Kim, Young-Ho Washington, Mary Kay Willis, Joseph E. Markowitz, Sanford D. Grady, William M. TI The aberrant methylation of TSF1 suppresses TGF-beta 1 activation in colorectal cancer SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE thrombospondin; transforming growth factor beta; methylation; colorectal cancer; epigenetics ID GROWTH-FACTOR-BETA; RECEPTOR-TYPE-II; CPG ISLAND METHYLATION; TGF-BETA; COLON-CANCER; EPIGENETIC INACTIVATION; INSTRUCTIVE MECHANISM; GASTRIC-CANCER; GENE; THROMBOSPONDIN-1 AB Colorectal cancer arises from the progressive accumulation of mutations and epigenetic alterations in colon epithelial cells. Such alterations often deregulate signaling pathways that affect the formation of colon cancer, such as the Wnt, RAS-MAPK and TGF-beta pathways. The tumor promoting effects of mutations in genes, such as APC, have been demonstrated in cancer cell lines and in mouse models of intestinal cancer; however, the biological effects of most epigenetic events identified in colorectal cancer remain unknown. Consequently, we assessed whether the aberrant methylation of TSPI, the gene for thrombospondin 1, a regulator of TGF-beta ligand activation, is an epigenetic mechanism for inhibiting the TGF-beta signaling pathway. We found methylated TSPI occurs in colon cancer cell lines (33%), colon adenomas (14%) and colon adenocarcinomas (21%). In primary colorectal cancers, loss of TSPI expression correlated with impaired TGF-beta signaling as indicated by decreased Smad2 phosphorylation and nuclear localization. Furthermore, methylation-induced silencing of TSPI expression reduced the concentration of secreted active TGF-beta 1 and attenuated TGF-beta signaling. Reversal of TSPI methylation resulted in increased TSPI mediated activation of the latent LAP:TGF-beta complex and subsequent TGF-P receptor activation. Our results demonstrate that the aberrant methylation of TSP1 has biological consequences and provide evidence that the aberrant methylation of TSPI is a novel epigenetic mechanism for suppressing TGF-P signaling in colorectal cancer. (C) 2008 Wiley-Liss, Inc. C1 [Rojas, Andres; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Willis, Joseph E.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Meherem, Shereen] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Kim, Young-Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea. [Washington, Mary Kay] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. [Markowitz, Sanford D.] Howard Hughes Med Inst, Cleveland, OH USA. [Rojas, Andres; Grady, William M.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA. [Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Grady, William M.] VA Puget Sound Hlth Care Syst, R&D Serv, Seattle, WA USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N D4-100, Seattle, WA 98109 USA. EM wgrady@fhcrc.org FU NCI NIH HHS [R01 CA115513, R01 CA115513-01A2] NR 46 TC 29 Z9 35 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD JUL 1 PY 2008 VL 123 IS 1 BP 14 EP 21 DI 10.1002/ijc.23608 PG 8 WC Oncology SC Oncology GA 302MU UT WOS:000255973200004 PM 18425817 ER PT J AU Roseman, AS Kasckow, J Fellows, I Osatuke, K Patterson, TL Mohamed, S Zisook, S AF Roseman, Ashley S. Kasckow, John Fellows, Ian Osatuke, Katerine Patterson, Thomas L. Mohamed, Somaia Zisook, Sidney TI Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE schizophrenia; insight; quality of life ID SCHIZOAFFECTIVE DISORDER; SUBJECTIVE RESPONSE; RATING-SCALE; PSYCHOSIS; OUTPATIENTS; MEDICATION; DEPRESSION; ILLNESS; ANTIPSYCHOTICS; SYMPTOMATOLOGY AB Objective The quality of life (QOL) for individuals with schizophrenia is determined by a number of factors, not limited to symptomatology. The current study examined lack of insight as one such factor that may influence subjective QOL or functional capacity. It was hypothesized that insight would significantly interact with symptom severity to influence subjective QOL. Insight was not expected to influence the relation between symptom severity and functional capacity. Methods Participants were middle-aged and older outpatients who met diagnostic criteria for schizophrenia or schizoaffective disorder, and subsyndromal depression. Insight, psychopathology, and subjective QOL were assessed via semi-structured interviews and functional capacity was assessed via performance-based measures. Results Insight interacts with negative symptom severity to predict subjective QOL. Severity of negative symptoms and insight contribute directly to functional capacity. Conclusions Individuals with intact insight may be better able to manage their symptoms, resulting in improved QOL. Treatment implications for improving the QOL of middle age and older adults with schizophrenia are discussed. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Roseman, Ashley S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77230 USA. [Kasckow, John] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Fellows, Ian; Patterson, Thomas L.; Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Patterson, Thomas L.; Zisook, Sidney] San Diego Vet Affairs Hlth Serv Ctr, San Diego, CA USA. [Mohamed, Somaia] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. RP Roseman, AS (reprint author), Univ Texas MD Anderson Canc Ctr, Unit 1330,POB 301439, Houston, TX 77230 USA. EM acsenior@hotmail.com FU NIMH NIH HHS [MH66248, MH19934, P30 MH066248, R0-1 MH 063931-04, R01 MH063931, R01 MH063931-01, R01 MH6398, T32 MH019934] NR 44 TC 15 Z9 18 U1 2 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JUL PY 2008 VL 23 IS 7 BP 760 EP 765 DI 10.1002/gps.1978 PG 6 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 327KZ UT WOS:000257729300015 PM 18205246 ER PT J AU Stwald, SK Swank, PR Khan, MM AF Stwald, Sharon K. Swank, Paul R. Khan, Myrna M. TI Predictors of functional independence and stress level of stroke survivors at discharge from inpatient rehabilitation SO JOURNAL OF CARDIOVASCULAR NURSING LA English DT Article DE depression; recovery of function; rehabilitation; stress; stroke ID SELF-RATED HEALTH; IMPACT SCALE; DEPRESSION; COMORBIDITY; RELIABILITY; MORTALITY; COMMUNITY; VETERANS; SYSTEM AB Background and Research Objective: Stroke is the primary cause of long-term disability among older adults. This study identifies predictors of functional independence and perceived stress for stroke survivors discharged home from inpatient rehabilitation with a spousal caregiver. Subjects and Methods: Stroke survivors (N = 97) were interviewed immediately after discharge to obtain scores on the National Institutes of Health Stroke Scale, Functional Independence Measure (FIM), Stroke Impact Scale, Geriatric Depression Scale-15, Perceived Stress Scale, and Perceived Health Status. Demographic and stroke-related data were abstracted from their inpatient rehabilitation charts. Descriptive and regression analyses determined the relationships among variables and the models that best predicted functional independence and perceived stress. Results: Stroke survivors perceived a 50% recovery in their function upon discharge from inpatient rehabilitation. National Institutes of Health Stroke Scale, age, socioeconomic status, and number of complications predicted 63% of the variance of the total FIM score (F(6,88)= 24.64; P <.0001). Total FIM, depression, and Stroke Impact Scale Emotion subscale predicted 45% of the Perceived Stress Scale score (F(6,88) = 12.04; P <.0001). Conclusions: Variables that predict the stroke survivors' recovery are complex as the severity of the stroke combines with demographic and economic variables and depression to predict functional independence and perceived stress. These factors need to be considered when preparing a discharge plan for stroke survivors who are discharged home from rehabilitation. C1 [Stwald, Sharon K.] Univ Texas Houston, Sch Nursing, Ctr Aging, Isla Carroll Turner Chair Gerontol Nursing, Houston, TX 77030 USA. [Swank, Paul R.] Univ Texas Houston, Sch Med, Houston, TX USA. [Khan, Myrna M.] Baylor Coll Med, Michael E De Bakey VA Med Ctr, Houston, TX 77030 USA. RP Stwald, SK (reprint author), Univ Texas Houston, Sch Nursing, Ctr Aging, Isla Carroll Turner Chair Gerontol Nursing, SONSCC Room 644,6901 Bertner St, Houston, TX 77030 USA. EM Sharon.K.Ostwald@uth.tmc.edu NR 32 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0889-4655 J9 J CARDIOVASC NURS JI J. Cardiovasc. Nurs. PD JUL-AUG PY 2008 VL 23 IS 4 BP 371 EP 377 PG 7 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 322YG UT WOS:000257410600011 ER PT J AU Bischoff, DS Zhu, JH Makhijani, NS Yamaguchi, DT AF Bischoff, David S. Zhu, Jian-Hua Makhijani, Nalini S. Yamaguchi, Dean T. TI Acidic pH stimulates the production of the angiogenic CXC chemokine, CXCL8 (interieukin-8), in human adult mesenchymal stem cells via the extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and NF-kappa B pathwavs SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE ELR+ CXC chemokines; human mesenchymal stem cells; acidic extracellular pH; osteoblastic differentiation ID ENDOTHELIAL GROWTH-FACTOR; INTERLEUKIN-1-BETA-INDUCED IL-8 EXPRESSION; INTERLEUKIN-8 GENE-EXPRESSION; G-BETA-GAMMA; STROMAL CELLS; CARCINOMA CELLS; GRANULE CELLS; IN-VIVO; RECEPTORS; ACIDOSIS AB Bloodvessel injury results in limited oxygen tension and diffusion leading to hypoxia, increased anaerobic metabolism, and elevated production of acidic metabolites that cannot be easily removed due to the reduced blood flow. Therefore, an acidic extracellular pH occurs in the local microenvironment of disrupted bone. The potential role of acidic pH and glu-leu-arg (ELR+) CXC chemokines in early events in bone repair was studied in human mesenchymal stem cells (hMSCs) treated with medium of decreasing pH (7.4, 7.0, 6.7, and 6.4). The cells showed a reciprocal increase in CXCL8(interleukin-8, IL-8) mRNA levels as extracellular pH decreased. At pH 6.4, CXCL8 mRNA was induced >60x in comparison to levels at pH 7.4. hMSCs treated with osteogenic medium (OGM) also showed an increase in CXCL8 mRNA with decreasing pH; although, at a lower level than that seen in cells grown in non-OGM. CXCL8 protein was secreted into the medium at all pHs with maximal induction at pH 6.7. Inhibition of the G-protein-coupled receptor alpha, G(alpha i), suppressed CXCL8 levels in response to acidic pH; whereas phospholipase C inhibition had no effect on CXCL8. The use of specific mitogen-activated protein kinase (MAPK) signal transduction inhibitors indicated that the pH-dependent increase in CXCL8 mRNA is due to activation of ERK and p38 pathways. The JNK pathway was not involved. NF-kappa B inhibition resulted in a decrease in CXCL8 levels in hMSCs grown in non-OGM. However, OGM-differentiated hMSCs showed an increase in CXCL8 levels when treated with the NF-kappa B inhibitor PDTC, a pyrrolidine derivative of dithiocarbamate. C1 [Bischoff, David S.; Zhu, Jian-Hua; Makhijani, Nalini S.; Yamaguchi, Dean T.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Bischoff, David S.; Yamaguchi, Dean T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Yamaguchi, DT (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dean.yamaguchi@med.va.gov NR 58 TC 12 Z9 15 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD JUL 1 PY 2008 VL 104 IS 4 BP 1378 EP 1392 DI 10.1002/jcb.21714 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 325DA UT WOS:000257567300021 PM 18275043 ER PT J AU Basile, J Thiers, B Maize, J Lathers, DMR AF Basile, Jeff Thiers, Bruce Maize, John, Sr. Lathers, Deanne M. R. TI Chemokine receptor expression in non-melanoma skin cancer SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article ID LANGERHANS CELL HISTIOCYTOSIS; CXCR4 EXPRESSION; BASAL-CELL; METASTASIS; CARCINOMA; MELANOMA; CCR6; INVOLVEMENT; PATTERN; NECK AB Background: Previous studies suggest that chemokines and chemokine receptors have a role in the metastatic process. A correlation exists between the specific expression of these chemoattractive, pro-inflammatory cytokines and the ability of cancer to disseminate. Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6. However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated. Methods: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues. Results: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin. Conclusions: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer. The exact mechanism by which this occurs requires further study. C1 [Lathers, Deanne M. R.] Res Serv, Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Basile, Jeff] Med Univ S Carolina, Dept Grad Studies, Coll Med, Charleston, SC USA. [Thiers, Bruce; Maize, John, Sr.] Dept Dermatol, Charleston, SC USA. [Thiers, Bruce; Maize, John, Sr.] Dept Otolaryngol, Charleston, SC USA. RP Lathers, DMR (reprint author), Res Serv, Ralph H Johnson VA Med Ctr, 109 Bee St MS 151, Charleston, SC 29401 USA. EM lathers@musc.edu NR 20 TC 9 Z9 10 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JUL PY 2008 VL 35 IS 7 BP 623 EP 629 DI 10.1111/j.1600-0560.2007.00879.x PG 7 WC Dermatology; Pathology SC Dermatology; Pathology GA 311PY UT WOS:000256613300002 PM 18312436 ER PT J AU Bair-Merritt, MH Holmes, WC Holmes, JH Feinstein, J Feudtner, C AF Bair-Merritt, Megan H. Holmes, William C. Holmes, John H. Feinstein, Jamie Feudtner, Chris TI Does intimate partner violence epidemiology differ between homes with and without children? A population-based study of annual prevalence and associated risk factors SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE intimate partner violence; risk factors; children; prevalence ID DOMESTIC VIOLENCE; BEHAVIORS; WOMEN AB We sought to determine whether intimate partner violence (IPV) risk factors differed depending upon the presence of children in the home, and to estimate the annual prevalence of IPV first in the general population and then in homes with and without children. We analyzed data from a cross-sectional random sample of 6,836 women in southeastern Pennsylvania interviewed by telephone in 2004. The magnitude of association between IPV and risk factors varied between homes with and without children for women's alcohol problems (with children, odds ratio (OR) 7.7; 95% confidence interval (CI) 2.9, 20.9; without children, OR 2.4; 95% CI 0.9, 6.0), and mental health problems (with children, OR 4.0; 95% CI 1.8, 8.9; without children, OR 3.0; 95% CI 1.6, 5.7). Poverty was significantly associated with IPV only in homes without children (OR 3.6; 95% CI 1.9, 7.2). Annual IPV prevalence was 1.2% overall, 1.4% in homes with children, and 1.1% in homes without children. One in 63 children lived in a home with IPV. Differences in IPV risk factors in homes with and without children suggest distinct underlying IPV mechanisms or consequences in these contexts. C1 [Bair-Merritt, Megan H.] Johns Hopkins Univ, Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD 21218 USA. [Holmes, William C.] Philadelphia Vet Adm Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Holmes, William C.; Holmes, John H.; Feudtner, Chris] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Holmes, William C.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Bair-Merritt, Megan H.; Feinstein, Jamie; Feudtner, Chris] Childrens Hosp Philadelphia, Div Gen Pediat, Pediat Generalist Res Grp, Philadelphia, PA 19104 USA. RP Bair-Merritt, MH (reprint author), Johns Hopkins Univ, Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD 21218 USA. EM mbairme1@jhmi.edu OI Bair-Merritt, Megan/0000-0002-1876-9817 NR 25 TC 14 Z9 14 U1 2 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD JUL PY 2008 VL 23 IS 5 BP 325 EP 332 DI 10.1007/s10896-008-9154-y PG 8 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 296UM UT WOS:000255571300004 ER PT J AU Bowen, JL Cook, DA Gerrity, M Kalet, AL Kogan, JR Spickard, A Wayne, DB AF Bowen, Judith L. Cook, David A. Gerrity, Martha Kalet, Adina L. Kogan, Jennifer R. Spickard, Anderson Wayne, Diane B. TI Navigating the JGIM special issue on medical education SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Bowen, Judith L.; Gerrity, Martha] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland VA Med Ctr, Portland, OR 97201 USA. [Cook, David A.] Mayo Clin, Coll Med, Off Educ Res, Div Gen Internal Med, Rochester, MN USA. [Wayne, Diane B.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Spickard, Anderson] Vanderbilt Univ Sch Med, Dept Med & Biomed Informat, Nashville, TN USA. [Kogan, Jennifer R.] Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia, PA USA. [Kalet, Adina L.] NYU, Sch Med, Dept Med, Div Gen Internal Med,Div Educ Informat, New York, NY 10003 USA. RP Bowen, JL (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland VA Med Ctr, Portland, OR 97201 USA. EM bowenj@ohsu.edu NR 44 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 899 EP 902 DI 10.1007/s11606-008-0675-0 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400001 PM 18612714 ER PT J AU Cook, DA Bowen, JL Gerrity, MS Kalet, AL Kogan, JR Spickard, A Wayne, DB AF Cook, David A. Bowen, Judith L. Gerrity, Martha S. Kalet, Adina L. Kogan, Jennifer R. Spickard, Anderson Wayne, Diane B. TI Proposed standards for medical education submissions to the journal of general internal medicine SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical education; scholarship; research design; research methods; writing ID HEALTH-SERVICES RESEARCH; QUALITATIVE RESEARCH; SYSTEMATIC REVIEWS; RANDOMIZED-TRIALS; OUTCOMES RESEARCH; USERS GUIDES; VALIDITY; STATEMENT; GUIDELINES; EPIDEMIOLOGY AB To help authors design rigorous studies and prepare clear and informative manuscripts, improve the transparency of editorial decisions, and raise the bar on educational scholarship, the Deputy Editors of the Journal of General Internal Medicine articulate standards for medical education submissions to the Journal. General standards include: (1) quality questions, (2) quality methods to match the questions, (3) insightful interpretation of findings, (4) transparent, unbiased reporting, and (5) attention to human subjects' protection and ethical research conduct. Additional standards for specific study types are described. We hope these proposed standards will generate discussion that will foster their continued evolution. C1 [Cook, David A.] Mayo Clin Coll Med, Div Gen Internal Med, Rochester, MN 55905 USA. [Cook, David A.] Mayo Clin Coll Med, Off Educ Res, Rochester, MN 55905 USA. [Bowen, Judith L.] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Portland, OR 97201 USA. [Kalet, Adina L.] NYU, Sch Med, Dept Med, Div Educ Informat, New York, NY USA. [Kalet, Adina L.] NYU, Sch Med, Dept Med, Div Gen Internal Med, New York, NY USA. [Kogan, Jennifer R.] Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia, PA USA. [Spickard, Anderson] Vanderbilt Univ Sch Med, Dept Med & Biomed Informat, Nashville, TN USA. [Wayne, Diane B.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Cook, DA (reprint author), Mayo Clin Coll Med, Off Educ Res, Baldwin 4-A,200 1st St SW, Rochester, MN 55905 USA. EM cook.david33@mayo.edu NR 79 TC 14 Z9 15 U1 4 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 908 EP 913 DI 10.1007/s11606-008-0676-z PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400003 PM 18612716 ER PT J AU Eckstrom, E Desai, SS Hunter, AJ Allen, E Tanner, CE Lucas, LM Joseph, CL Ririe, MR Doak, MN Humphrey, LL Bowen, JL AF Eckstrom, Elizabeth Desai, Sima S. Hunter, Alan J. Allen, Elizabeth Tanner, Craig E. Lucas, Linda M. Joseph, Carol L. Ririe, Marnie R. Doak, Melanie N. Humphrey, Linda L. Bowen, Judith L. TI Aiming to improve care of older adults: An innovative faculty development workshop SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Continuing Medical Education workshop; geriatrics; standardized learners; Graduate Medical Education AB INTRODUCTION/AIMS: Internists care for older adults and teach geriatrics to trainees, but they often feel ill-prepared for these tasks. The aims of our 1-day Continuing Medical Education workshop were to improve the knowledge and self-perceived competence of general internists in their care of older adults and to increase their geriatrics teaching for learners. SETTING:Two internal medicine training programs encompassing University, Veterans Affairs, and a community-based hospital in Portland, OR, USA. PROGRAM DESCRIPTION:Course faculty identified gaps in assessment of cognition, function, and decisional capacity; managing care transitions; and treatment of behavioral symptoms. To address these gaps, our workshop provided geriatric content discussions followed by small group role plays to apply newly learned content. Forty teaching faculty participated. PROGRAM EVALUATION:Participants completed 13-item multiple-choice pre- and post-workshop geriatric knowledge tests, pre- and post-workshop surveys of self-perceived competence to care for older adults, and completed an open-ended 'commitment to change' prompt after the intervention. Knowledge scores improved following the intervention (61% to 72%, p < .0001), as did self-perceived competence (11 of 14 items significant). Seventy-one percent of participants reported success in meeting their commitment to change goals. DISCUSSION:A 1-day intervention improved teaching faculty knowledge and self-perceived competence to care for older patients and led to self-perceived changes in teaching behaviors. C1 [Eckstrom, Elizabeth; Desai, Sima S.; Hunter, Alan J.; Bowen, Judith L.] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland, OR 97239 USA. [Allen, Elizabeth; Lucas, Linda M.; Joseph, Carol L.; Doak, Melanie N.; Humphrey, Linda L.] Portland VA Med Ctr, Portland, OR USA. [Tanner, Craig E.] Univ Arizona, Coll Med, Tucson, AZ USA. [Ririe, Marnie R.] St Lukes Hlth Syst, Boise, ID USA. RP Eckstrom, E (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, L475,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM eckstrom@ohsu.edu NR 11 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 1053 EP 1056 DI 10.1007/s11606-008-0593-1 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400031 PM 18612743 ER PT J AU Castiglioni, A Shewchuk, RM Willett, LL Heudebert, GR Centor, RM AF Castiglioni, Analia Shewchuk, Richard M. Willett, Lisa L. Heudebert, Gustavo R. Centor, Robert M. TI A pilot study using nominal group technique to assess residents' perceptions of successful attending rounds SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc Gen Internal Med DE attending physicians; interns; nominal group technique; residents; ward rounds ID WARD ROUNDS AB BACKGROUND: Ward attending rounds are fundamental for internal medicine residency training. An improved understanding of interns' and residents' perceptions of attending rounds should inform training programs and attending physicians. OBJECTIVES:The aim of this study was to assess residents' perceptions of successful attending rounds. DESIGN:We convened two groups of interns and two groups of residents, to elicit their perceptions on attending rounds. SUBJECTS: Participants were recruited by e-mail and conference announcements from the 49 interns and 80 residents in the internal medicine and medicine-pediatrics residency programs. MEASUREMENTS:The nominal group technique (NGT) uses a structured group process to elicit and prioritize answers to a carefully articulated question. MAIN RESULTS:Seven interns (14%) identified 27 success factors and ranked attending approachability and enthusiasm and high quality teaching as most important. A second group of six (12%) interns identified 40 detractors and ranked having "mean attendings," receiving disrespectful comments, and too long or too short rounds as the most significant detractors. Nine (11%) residents identified 32 success factors and ranked attention to length of rounds, house staff autonomy, and establishing goals/expectations as the most important success factors. A second group of six (8%) residents identified 34 detractors and ranked very long rounds, interruptions and time constraints, and poor rapport between team members as the most significant detractors). CONCLUSIONS:Although there was some overlap in interns' and residents' perceptions of attending rounds, interns identified interpersonal factors as the most important factors; whereas residents viewed structural factors as most important. These findings should assist attending physicians improve the way they conduct rounds targeting both interns and residents needs. C1 [Castiglioni, Analia; Willett, Lisa L.; Heudebert, Gustavo R.; Centor, Robert M.] Univ Alabama, Div Gen Internal Med, Birmingham, AL USA. [Shewchuk, Richard M.] Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL USA. [Castiglioni, Analia; Heudebert, Gustavo R.; Centor, Robert M.] Birmingham VAMC, Birmingham, AL USA. RP Castiglioni, A (reprint author), Univ Alabama, Div Gen Internal Med, FOT 720,1530 3rd Ave, Birmingham, AL 35294 USA. EM acastigl@uab.edu NR 19 TC 28 Z9 28 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 1060 EP 1065 DI 10.1007/s11606-008-0668-z PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400033 PM 18612745 ER PT J AU Glasheen, JJ Siegal, EM Epstein, K Kutner, J Prochazka, AV AF Glasheen, Jeffrey J. Siegal, Eric M. Epstein, Kenneth Kutner, Jean Prochazka, Allan V. TI Fulfilling the promise of hospital medicine: Tailoring internal medicine training to address hospitalists' needs SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medical education; hospitalist training; hospitalist; hospital medicine; residency redesign ID LENGTH-OF-STAY; CONTROLLED-TRIAL; HIP FRACTURE; CARE; PATIENT; SERVICE; COSTS; EXPERIENCE; OUTCOMES; SYSTEM AB Categorical internal medicine (IM) residency training has historically effectively prepared graduates to manage the medical needs of acutely ill adults. The development of the field of hospital medicine, however, has resulted in hospitalists filling clinical niches that have been traditionally ignored or underemphasized in categorical IM training. Furthermore, hospitalists are increasingly leading inpatient safety, quality and efficiency initiatives that require understanding of hospital systems, multidisciplinary care and inpatient quality assessment and performance improvement. Taken in this context, many graduating IM residents are under-prepared to practice as effective hospitalists. In this paper, we outline the rationale for targeted training in hospital medicine and discuss the content and methods for delivering this training. C1 [Glasheen, Jeffrey J.] Univ Colorado, Denver Sch Med, Internal Med Residency Training Program, Aurora, CO 80045 USA. [Glasheen, Jeffrey J.; Kutner, Jean] Univ Colorado, Denver Sch Med, Div Gen Internal Med, Dept Med, Aurora, CO 80045 USA. [Glasheen, Jeffrey J.] Univ Colorado, Denver Sch Med, Hosp Med Serv, Aurora, CO 80045 USA. [Siegal, Eric M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Epstein, Kenneth] Univ Colorado, Denver Sch Med, IPC Hospitalist Co, Med Affairs & Clin Res, Aurora, CO 80045 USA. [Prochazka, Allan V.] Univ Colorado, Denver Sch Med, Denver VA Med Ctr, Aurora, CO 80045 USA. RP Glasheen, JJ (reprint author), Univ Colorado, Denver Sch Med, Hosp Med Serv, Mailstop F-782,12401 E 17th Ave,POB 6510, Aurora, CO 80045 USA. EM jeffrey.glasheen@uchsc.edu NR 37 TC 15 Z9 15 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 1110 EP 1115 DI 10.1007/s11606-008-0646-5 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400042 PM 18612754 ER PT J AU Haidet, P AF Haidet, Paul TI Where we're headed: A new wave of scholarship on educating medical professionalism SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE education, medical, physician's role; education, medical, undergraduate; education, medical, graduate; social environment, organizational culture; schools, medical; internship and residency; professional practice; ethics, professional; professional-patient relations; learning; teaching; psychology, educational C1 [Haidet, Paul] DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Haidet, Paul] Baylor Coll Med, Houston, TX 77030 USA. RP Haidet, P (reprint author), 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu NR 11 TC 9 Z9 9 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2008 VL 23 IS 7 BP 1118 EP 1119 DI 10.1007/s11606-008-0670-5 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 324AH UT WOS:000257489400044 PM 18612756 ER PT J AU Anderson, ML Glasheen, JJ AF Anderson, Mel L. Glasheen, Jeffrey J. TI Critical literature 2007: Clinical topics SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID CONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED-TRIAL; SODIUM-BICARBONATE; HEART-FAILURE; N-ACETYLCYSTEINE; PREVENTION; METRONIDAZOLE; THERAPY; DISEASE C1 [Anderson, Mel L.] Denver VA Med Ctr, Dept Med, Med Serv, Denver, CO 80220 USA. [Glasheen, Jeffrey J.] Univ Colorado, Hosp Med Sect, Denver, CO 80202 USA. RP Anderson, ML (reprint author), Denver VA Med Ctr, Dept Med, Med Serv, 1055 Clermont St, Denver, CO 80220 USA. EM melver.anderson@va.gov NR 15 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JUL-AUG PY 2008 VL 3 IS 4 BP 333 EP 341 DI 10.1002/jhm.345 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 339GW UT WOS:000258567100009 PM 18698593 ER PT J AU Bosque, PJ Tyler, KL AF Bosque, P. J. Tyler, K. L. TI Prions' travels - Feces and transmission of prion diseases SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID INFECTION; SCRAPIE; BLOOD; EXCRETION; HAMSTERS; DEER C1 [Bosque, P. J.; Tyler, K. L.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. [Tyler, K. L.] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Tyler, K. L.] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. [Bosque, P. J.] Denver Hlth Med Ctr, Dept Med Neurol, Denver, CO USA. [Tyler, K. L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 13 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 1 PY 2008 VL 198 IS 1 BP 8 EP 9 DI 10.1086/588194 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 311XD UT WOS:000256632800004 PM 18505382 ER PT J AU Catano, G Agan, BK Kulkarni, H Telles, V Marconi, VC Dolan, MJ Ahuja, SK AF Catano, Gabriel Agan, Brian K. Kulkarni, Hemant Telles, Vanessa Marconi, Vincent C. Dolan, Matthew J. Ahuja, Sunil K. TI Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: The advantage of heterozygosity for coding mutations SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC ID HUMAN-IMMUNODEFICIENCY-VIRUS; DELAYED-TYPE HYPERSENSITIVITY; COMPLEMENT ACTIVATION; TYPE-1 INFECTION; PROTEIN GENE; ANTITUMOR-ACTIVITY; AIDS PROGRESSION; MODIFIER GENES; VIRAL-LOAD; IN-VITRO AB Background. The in vivo impact of mannose-binding lectin (MBL), a molecule involved in innate immunity, on the pathogenesis of human immunodeficiency virus (HIV)-1 infection and AIDS is unknown. Methods. A total of 1102 HIV-positive and 2213 HIV-negative adult subjects were screened for polymorphisms in the coding and promoter regions of MBL2, the gene that encodes MBL. Results. Variations in MBL2 did not influence the risk of acquiring HIV-1. Heterozygosity for coding mutations (O allele) and homozygosity for the-221 promoter polymorphism (X allele) in MBL2 were associated with a delay in and an accelerated rate of disease progression, respectively. MBL2 variations influenced the rate of progression to AIDS-defining illnesses. In a multivariate model, the effects of MBL2 variations were independent of several parameters known to influence disease progression, including steady-state viral load, baseline CD4(+) T cell counts, and delayed-type hypersensitivity skin test responses, an in vivo marker of cell-mediated immunity. The effects of MBL2 variations were most evident in those who possessed protective genotypes of CCR5 and a high copy number of CCL3L1, the most potent HIV-suppressive CCR5 ligand. Conclusions. MBL2 genotypes are independent determinants of HIV disease progression and heterozygosity for MBL2 coding mutations confer disease-retarding effects. MBL-dependent immune responses may play a role in the pathogenesis of HIV infection. C1 [Catano, Gabriel; Kulkarni, Hemant; Telles, Vanessa; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Vet Administrat Res Ctr AIDS & HIV 1 Infect, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Catano, Gabriel; Kulkarni, Hemant; Telles, Vanessa; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Immunol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Agan, Brian K.; Marconi, Vincent C.; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA. [Agan, Brian K.; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA. [Agan, Brian K.; Marconi, Vincent C.; Dolan, Matthew J.] San Antonio Mil Med Ctr, San Antonio, TX USA. [Catano, Gabriel; Marconi, Vincent C.; Dolan, Matthew J.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, VA HIV AIDS Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM mdolan@idcrp.org; ahujas@uthscsa.edu RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669 FU NIAID NIH HHS [HU0001-05-2-0011, R01 AI043279, R37 AI046326]; NIMH NIH HHS [R01 MH069270] NR 48 TC 28 Z9 31 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 1 PY 2008 VL 198 IS 1 BP 72 EP 80 DI 10.1086/588712 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 311XD UT WOS:000256632800014 PM 18498240 ER PT J AU Tehranian, R Rose, ME Vagni, V Pickrell, AM Griffith, RP Liu, H Clark, RSB Dixon, CE Kochanek, PM Graham, SH AF Tehranian, Roya Rose, Marie E. Vagni, Vincent Pickrell, Alicia M. Griffith, Raymond P. Liu, Hao Clark, Robert S. B. Dixon, C. Edward Kochanek, Patrick M. Graham, Steven H. TI Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE apoptosis; Bax; TBI; transgenic mice ID CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; TRANSGENIC MICE; BCL-2 PROTEIN; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; APOPTOSIS; RATS; MITOCHONDRIA; EXPRESSION AB Apoptosis contributes to delayed neuronal cell death in traumatic brain injury (TBI). To investigate if Bax plays a role in neuronal cell death and functional outcome after TBI, Bax gene disrupted (null) mice and wild-type (WT) controls were subjected to the controlled cortical impact (CCI) model of TBI. Motor function in WT and Bax null mice was evaluated using the round beam balance and the wire grip test on days 0-5. Spatial memory was assessed using a Morris Water Maze adopted for mice on days 14-18 post-injury. For histopathological analysis, animals were sacrificed 24 h and 21 days post-injury. In all three behavioral tests, the sham and TBI-injured Bax null mice performed significantly worse than their WT sham and TBI-injured counterparts. However, Bax null mice exhibited a higher percentage of surviving neurons in the CA1 and CA3 regions of hippocampus measured at 21 days post-injury. At 24 h after trauma, Bax null mice had fewer TUNEL positive cells in the CA1 and dentate regions of hippocampus as compared to WT mice, suggesting that deletion of the Bax gene ameliorates hippocampal cell death after TBI. Sham-operated Bax null mice had significantly greater brain volume as compared to WT mice. Thus, it is possible that Bax deficiency in the transgenic mice produces developmental behavioral effects, perhaps due to Bax's role in regulating cell death during development. C1 [Tehranian, Roya; Rose, Marie E.; Pickrell, Alicia M.; Liu, Hao; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Tehranian, Roya; Rose, Marie E.; Liu, Hao; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA. [Vagni, Vincent; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, 7108 Highland Dr, Pittsburgh, PA 15206 USA. EM sgra@pitt.edu RI Kochanek, Patrick/D-2371-2015 OI Kochanek, Patrick/0000-0002-2627-913X FU NINDS NIH HHS [NS30318, P50 NS030318-10] NR 50 TC 29 Z9 36 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL PY 2008 VL 25 IS 7 BP 755 EP 767 DI 10.1089/neu.2007.0441 PG 13 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 326BX UT WOS:000257634000004 PM 18627254 ER PT J AU Giri, S Prasad, R Khan, M Singh, A Singh, I AF Giri, Shailendra Prasad, Rama Khan, Mushfiquddin Singh, Avtar Singh, Inderjit TI 15-deoxy-delta 12, 14-prostaglandin J2 attenuates endothelial-monocyte interaction: Implication for inflammatory diseases SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 26th Annual National-Neurotrauma-Society Symposium CY JUL 27-30, 2008 CL Orlando, FL SP Natl Neurotrauma Soc C1 [Giri, Shailendra; Prasad, Rama; Khan, Mushfiquddin; Singh, Inderjit] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL PY 2008 VL 25 IS 7 MA P9 BP 856 EP 856 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 326BX UT WOS:000257634000020 ER PT J AU Khan, M Hoda, N Giri, S Singh, I Singh, A AF Khan, Mushfiquddin Hoda, Nasrul Giri, Shailendra Singh, Inderjit Singh, Avtar TI Protection of endothelial function by S-nitrosoglutathione following acute injury in a rat model of experimental stroke SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 26th Annual National-Neurotrauma-Society Symposium CY JUL 27-30, 2008 CL Orlando, FL SP Natl Neurotrauma Soc C1 [Khan, Mushfiquddin; Hoda, Nasrul; Giri, Shailendra; Singh, Inderjit] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL PY 2008 VL 25 IS 7 MA P50 BP 866 EP 866 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 326BX UT WOS:000257634000062 ER PT J AU Wallis, RA Panizzon, K AF Wallis, Roi Ann Panizzon, Kimberly TI Treatment with mono-ADP-ribosylation inhibitors protect against the increased susceptibility seen in CA1 hippocampal neurons in aged rats SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 26th Annual National-Neurotrauma-Society Symposium CY JUL 27-30, 2008 CL Orlando, FL SP Natl Neurotrauma Soc C1 [Panizzon, Kimberly] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Wallis, Roi Ann] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL PY 2008 VL 25 IS 7 MA P67 BP 870 EP 870 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 326BX UT WOS:000257634000076 ER PT J AU Whitehead, AJ Dobscha, SK Morasco, BJ Ruimy, S Blissell, C Hauser, P AF Whitehead, Ashlee J. Dobscha, Steven K. Morasco, Benjamin J. Ruimy, Samantha Blissell, Cara Hauser, Peter TI Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE opioids; hepatitis C; pain management; medication misuse; veterans ID MEDICALLY ILL PATIENTS; PSYCHIATRIC-DISORDERS; MUSCULOSKELETAL PAIN; UNITED-STATES; MANAGEMENT; PREVALENCE; INFECTION; ADDICTION; ISSUES; CARE AB To examine the prevalence of pain, substance use disorder (SUD) diagnoses, and opioid analgesic prescription patterns among veterans infected with the hepatitis C virus (HCV), a retrospective review of the medical records of 8,224 HCV-positive (HCV+) veterans was performed. Twenty-nine percent and 46% of HCV+ patients were prescribed opioids in the prior one and three years, respectively. Sixty-seven percent of HCV+ patients had documented pain diagnoses and 56% had SUD diagnoses. Patients with co-occurring pain and SUD were less likely to be prescribed opioids than patients with pain only (prior year: 36% vs. 43%, P < 0.001; three years: 56% vs. 60%, P < 0.01). There, were no differences in numbers of early opioid prescription fills or numbers of opioid prescribers when comparing patients with co-occurring pain and SUD to patients with pain only. Veterans with co-occurring pain and opioid use disorder had fewer early opioid fills than veterans with pain only (prior year: 2.6 vs. 5.3 days, P < 0.01; three years: 6.1 vs. 13.4 days, P < 0.001). These data demonstrate that pain and SUD diagnoses were common among HCV+ patients, and that opioids were frequently prescribed. Co-occurring SUD was not associated with indicators of prescription opioid misuse. C1 [Whitehead, Ashlee J.; Morasco, Benjamin J.; Ruimy, Samantha; Blissell, Cara; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97207 USA. [Whitehead, Ashlee J.; Dobscha, Steven K.; Morasco, Benjamin J.; Ruimy, Samantha; Blissell, Cara; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97207 USA. [Dobscha, Steven K.] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97207 USA. [Hauser, Peter] Portland VA Med Ctr, JENS Lab, Portland, OR 97207 USA. [Dobscha, Steven K.; Morasco, Benjamin J.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. RP Whitehead, AJ (reprint author), Portland VA Med Ctr, NW Hepatitis C Resource Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM ashlee.whitehead@va.gov NR 34 TC 23 Z9 23 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUL PY 2008 VL 36 IS 1 BP 39 EP 45 DI 10.1016/j.jpainsymman.2007.08.013 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 326VY UT WOS:000257688400005 PM 18358690 ER PT J AU Williams, BR Sawyer, P Roseman, JM Allman, RM AF Williams, Beverly R. Sawyer, Patricia Roseman, Jeffrey M. Allman, Richard M. TI Marital status and health: Exploring pre-widowhood SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OLDER-ADULTS; PHYSICAL HEALTH; ANTICIPATORY GRIEF; MARRIED-WOMEN; DEPRESSIVE SYMPTOMATOLOGY; PSYCHOLOGICAL ADJUSTMENT; HEART-FAILURE; MENTAL-HEALTH; SPOUSAL LOSS; MORTALITY AB Background: Health and function vary by marital status across the life-course, but little is known about older adults approaching spousal loss (pre-widowed). Objective: To explore health and function by marital status focusing on the pre-widowed and to examine factors associated with shorter time to spousal loss. Participants, design, and measurements: We used 3 years of data from African American and white community-dwelling older adults in the UAB Study of Aging (N = 1000). Participants were categorized as "continuously married" (married at baseline and 3 years), "widowed" (widowed at baseline), "single" (never married/divorced); and " pre-widowed" (married at baseline and widowed within 3 years). Assessments included sociodemographic characteristics, and measures of depression, anxiety, life-space mobility, and self-reported health. chi(2) and analysis of variance (ANOVA) were used to examine baseline differences. Using Cox regression, we explored factors having independent and significant associations with shorter time to spousal loss among married older adults. Results: There were significant differences by marital status category for sociodemographic factors, health, and function. Pre-widows differed from other categories by sociodemographic characteristics as well as levels of depression, anxiety and self-reported health. Among married older adults, being female and having lower self-reported health at baseline were independent significant hazards for shorter time to widowhood; while rural residence and providing spousal care were independent significant hazards for a longer progression to widowhood. Conclusions: Health deficits associated with spousal bereavement may be evident earlier in the marital transition than previously thought, warranting attention to the health of elderly persons whose spouses have chronic/life-limiting conditions. C1 [Williams, Beverly R.; Allman, Richard M.] Birmingham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35233 USA. [Sawyer, Patricia] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Sawyer, Patricia] Univ Alabama, Dept Gerontol, Birmingham, AL USA. [Sawyer, Patricia] Univ Alabama, Dept Geriatr, Birmingham, AL USA. [Sawyer, Patricia] Univ Alabama, Dept Palliat Care, Birmingham, AL USA. [Roseman, Jeffrey M.] Univ Alabama, Dept Epidemiol, Birmingham, AL USA. RP Williams, BR (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, 700 19th St S, Birmingham, AL 35233 USA. EM beverly.williams3@va.gov FU NIA NIH HHS [R01 AG015062] NR 74 TC 11 Z9 11 U1 2 U2 15 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JUL-AUG PY 2008 VL 11 IS 6 BP 848 EP 856 DI 10.1089/jpm.2007.0190 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 343ZX UT WOS:000258896100013 PM 18715177 ER PT J AU Krasnoff, JB Kohn, MA Choy, FKK Doyle, J Johansen, K Painter, PL AF Krasnoff, Joanne B. Kohn, Michael A. Choy, Frankie K. K. Doyle, Julie Johansen, Kirsten Painter, Patricia L. TI Interunit and Intraunit Reliability of the RT3 Triaxial Accelerometer SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE physical activity measurement; reproducibility; accelerometry ID INTENSITY PHYSICAL-ACTIVITY; ACTIVITY MONITORS; ENERGY-EXPENDITURE; VALIDITY; CALIBRATION; VALIDATION; FIELD; VARIABILITY; WOMEN AB Background: Interest in the quantification of physical activity is on the rise. Triaxial accelerometry has frequently been used; however, research on the reliability of these devices is limited. We examine the interunit and intraunit reliability of 22 RT3 triaxial accelerometers using a performance-documented laboratory agitator. Methods: The RT3 units were tested while moving in 2 directions (antero-posterior, medio-lateral) and speeds (150 and 275 RPM) on a shaker with simultaneous documented performance output for three 24-hour periods. Results: Minimal shaker variance was recorded for all trials (coefficients of variation [CVs] < 0.52%). Our data demonstrate good reliability within RT3s (CVs < 1.81%) but poor reliability among the 22 units (CVs range = 9.5% to 34.7%). Conclusions: In longitudinal studies, each subject should use the same RT3 unit at each assessment. The use of multiple RT3 units in cross-sectional studies is not recommended because data interpretation would be compromised by the high between-unit variability. C1 [Krasnoff, Joanne B.] Univ Calif San Francisco, Dept Med, Exercise Physiol & Body Composit Lab, San Francisco, CA 94143 USA. [Kohn, Michael A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Choy, Frankie K. K.] San Francisco Vet Adm Med Ctr, NCIRE Biomed Engn, San Francisco, CA 94121 USA. [Doyle, Julie; Johansen, Kirsten] San Francisco Vet Adm Med Ctr, Div Nephrol, San Francisco, CA 94121 USA. [Painter, Patricia L.] Univ Minnesota, Dept Med, Div Renal Dis, Minneapolis, MN 55455 USA. RP Krasnoff, JB (reprint author), Univ Calif San Francisco, Dept Med, Exercise Physiol & Body Composit Lab, San Francisco, CA 94143 USA. FU NCRR NIH HHS [M01 RR-0079]; NINR NIH HHS [R01NR008286] NR 30 TC 23 Z9 24 U1 0 U2 0 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD JUL PY 2008 VL 5 IS 4 BP 527 EP 538 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V18OZ UT WOS:000208015400005 PM 18648118 ER PT J AU Kaysen, GA Johansen, KL Cheng, SC Jin, CS Chertow, GM AF Kaysen, George A. Johansen, Kirsten L. Cheng, Su-Chen Jin, Chengshi Chertow, Glenn M. TI Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States SO JOURNAL OF RENAL NUTRITION LA English DT Article ID C-REACTIVE PROTEIN; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; ENERGY-EXPENDITURE; MORTALITY; INFLAMMATION; CREATININE; RISK; INTERLEUKIN-6; DETERMINANTS AB Objective and Methods: Serum albumin concentrations are associated with mortality, and respond to nutritional and inflammatory states. To explore whether changing demographics and practice patterns in dialysis have influenced serum albumin concentrations, we analyzed trends in serum albumin among incident patients on dialysis from 1995 through 2004. Results: Mean serum albumin concentrations declined significantly over time, even after accounting for changes in age, diabetes, body size, and other factors. Although laboratory assays were not uniform within or across years, serum albumin declined over time, regardless of the reported laboratory lower limit of normal. Moreover, serum albumin retained its potent association with mortality over time. Lower serum albumin was especially hazardous among younger patients and blacks, and was less hazardous among persons with diabetes as a primary cause of kidney disease. Conclusions: Despite higher body weights and the initiation of dialysis earlier in the course of progressive chronic kidney disease, hypoalbuminemia remains common and hazardous to persons starting dialysis. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved. C1 [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Stanford, CA 94305 USA. [Kaysen, George A.] Univ Calif Davis, Div Nephrol, Dept Med, Davis, CA 95616 USA. [Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA. [Kaysen, George A.] VA No Calif, Sacramento, CA USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Div Nephrol, San Francisco, CA USA. [Johansen, Kirsten L.; Cheng, Su-Chen; Jin, Chengshi] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Chertow, GM (reprint author), Stanford Univ, Sch Med, Div Nephrol, Dept Med, Grant Bldg,S-161, Stanford, CA 94305 USA. EM gchertow@stanford.edu FU NIDDK NIH HHS [K24 DK085446, N01 DK022498-002, N01-DK-7-5007, N01 DK022498, T32 DK007357] NR 30 TC 20 Z9 20 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 J9 J RENAL NUTR JI J. Renal Nutr. PD JUL PY 2008 VL 18 IS 4 BP 323 EP 331 DI 10.1053/j.jrn.2008.04.002 PG 9 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA 326DI UT WOS:000257637800001 PM 18558296 ER PT J AU Gallun, FJ Durlach, NI Colburn, HS Shinn-Cunningham, BG Best, V Mason, CR Kidd, G AF Gallun, Frederick J. Durlach, Nathaniel I. Colburn, H. Steven Shinn-Cunningham, Barbara G. Best, Virginia Mason, Christine R. Kidd, Gerald, Jr. TI The extent to which a position-based explanation accounts for binaural release from informational masking SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article; Proceedings Paper CT 30th Midwinter Meeting of the Association-for-Reseach-in-Otolaryngology CY FEB 10-15, 2007 CL Denver, CO SP Assoc Res Otolaryngol ID LEVEL DIFFERENCES; INTERAURAL FLUCTUATIONS; CANCELLATION THEORY; SPATIAL SEPARATION; GATED-NOISE; SPEECH; MASKERS; FREQUENCY; UNMASKING; TIME AB Detection was measured for a 500 Hz tone masked by noise (an "energetic" masker) or sets of ten randomly drawn tones (an "informational" masker). Presenting the maskers diotically and the target tone with a variety of interaural differences (interaural amplitude ratios and/or interaural time delays) resulted in reduced detection thresholds relative to when the target was presented diotically ("binaural release from masking"). Thresholds observed when time and amplitude differences applied to the target were "reinforcing" (favored the same ear, resulting in a lateralized position for the target) were not significantly different from thresholds obtained when differences were "opposing" (favored opposite ears, resulting in a centered position for the target). This irrelevance of differences in the perceived location of the target is a classic result for energetic maskers but had not previously been shown for informational maskers. However, this parallellism between the patterns of binaural release for energetic and informational maskers was not accompanied by high correlations between the patterns for individual listeners, supporting the idea that the mechanisms for binaural release from energetic and informational masking are fundamentally different. (c) 2008 Acoustical Society of America. C1 [Gallun, Frederick J.; Durlach, Nathaniel I.; Colburn, H. Steven; Shinn-Cunningham, Barbara G.; Best, Virginia; Mason, Christine R.; Kidd, Gerald, Jr.] Boston Univ, Hearing Res Ctr, Boston, MA 02215 USA. RP Gallun, FJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM frederick.gallun@va.gov RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU NIDCD NIH HHS [F32 DC006526-03, DC00100, DC04545, DC04663, F32 DC006526, P30 DC004663, P30 DC004663-03, R01 DC000100, R01 DC000100-33, R01 DC004545, R01 DC004545-08, R03 DC008395, R03 DC008395-02] NR 44 TC 7 Z9 7 U1 1 U2 4 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD JUL PY 2008 VL 124 IS 1 BP 439 EP 449 DI 10.1121/1.2924127 PG 11 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 327ZW UT WOS:000257768000040 PM 18646988 ER PT J AU Vaughan, N Storzbach, D Furukawa, I AF Vaughan, Nancy Storzbach, Daniel Furukawa, Izumi TI Investigation of Potential Cognitive Tests for Use with Older Adults in Audiology Clinics SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article; Proceedings Paper CT Annual Convention of the American-Speech-Language-Hearing-Association CY NOV 16-18, 2006 CL Miami, FL SP Amer Speech Language Hearing Assoc DE Neurocognitive tests; principal components analysis; speech recognition ID WORKING-MEMORY; ELDERLY LISTENERS; SPEECH RECOGNITION; HEARING-LOSS; AGE; COMPREHENSION; ATTENTION; CAPACITY; DEFICITS; TASKS AB Background: Cognitive declines in working memory and processing speed are hallmarks of aging. Deficits in speech understanding also are seen in aging individuals. A clinical test to determine whether the cognitive aging changes contribute to aging speech understanding difficulties would be helpful for determining rehabilitation strategies in audiology clinics. Purpose: To identify a clinical neurocognitive test or battery of tests that could be used in audiology clinics to help explain deficits in speech recognition in some older listeners. Research Design: A correlational study examining the association between certain cognitive test scores and speech recognition performance. Speeded (time-compressed) speech was used to increase the cognitive processing load. Study Sample: Two hundred twenty-five adults aged 50 through 75 years were participants in this study. Both batteries of tests were administered to all participants in two separate sessions. Data Collection and Analysis: A selected battery of neurocognitive tests and a time-compressed speech recognition test battery using various rates of speech were administered. Principal component analysis was used to extract the important component factors from each set of tests, and regression models were constructed to examine the association between tests and to identify the neurocognitive test most strongly associated with speech recognition performance. Results: A sequencing working memory test (Letter-Number Sequencing [LNS]) was most strongly associated with rapid speech understanding. The association between the LNS test results and the compressed sentence recognition scores (CSRS) was strong even when age and hearing loss were controlled. Conclusions: The LNS is a sequencing test that provides information about temporal processing at the cognitive level and may prove useful in diagnosis of speech understanding problems, and in the development of aural rehabilitation and training strategies. C1 [Vaughan, Nancy; Storzbach, Daniel; Furukawa, Izumi] Portland VA Med Ctr, Vet Affairs Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. RP Storzbach, D (reprint author), Portland VA Med Ctr, Vet Affairs Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Daniel.Storzbach@med.va.gov NR 31 TC 6 Z9 8 U1 1 U2 9 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JUL-AUG PY 2008 VL 19 IS 7 BP 533 EP 541 DI 10.3766/jaaa.19.7.2 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 386IG UT WOS:000261876300002 PM 19248729 ER PT J AU Lott, JP Werth, VP Kovarik, CL AF Lott, Jason P. Werth, Victoria P. Kovarik, Carrie L. TI Cutaneous Mycobacterium haemopbhilum infection in iatrogenically immunocompromised patients without transplantation SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID HAEMOPHILUM INFECTION; SP-NOV; SKIN; HUMANS AB Cutaneous Mycobacterium haemophilum infections are most often the result of HIV or transplantation-associated immunosuppression. Rarely, M haemophilum, may infect healthy patients or iatrogenically immunosuppressed patients without transplantation. We herein report two cases of cutaneous M haemophilum infection in HIV-negative patients without transplantation undergoing iatrogenic immunosuppression. Our cases and a literature review highlight the various clinical contexts in which M haemophilum may arise in this patient population. Accordingly, we emphasize that a high index of suspicion is needed for diagnosis, which ultimately relies on skin biopsy, histopathologic examination, and culture. C1 [Lott, Jason P.; Werth, Victoria P.; Kovarik, Carrie L.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19130 USA. [Kovarik, Carrie L.] Univ Penn, Sch Med, Dept Internal Med, Div Infect Dis, Philadelphia, PA 19130 USA. [Werth, Victoria P.; Kovarik, Carrie L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kovarik, CL (reprint author), Univ Penn, Sch Med, Dept Dermatol, 3600 Spruce St,2 Maloney Bldg, Philadelphia, PA 19130 USA. EM carrie.kovarik@uphs.upenn.edu NR 22 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUL PY 2008 VL 59 IS 1 BP 139 EP 142 DI 10.1016/j.jaad.2008.01.023 PG 4 WC Dermatology SC Dermatology GA 318UM UT WOS:000257118300018 PM 18328595 ER PT J AU White, JV Ayoob, KT Benedict, MA Chynoweth, MD Gregoire, M Howard, RL McCool, A Parrott, S Ramsey, SH Thiessen, C Thomsen, KN Bender, T Myers, E Michael, P AF White, Jane V. Ayoob, Keith T. Benedict, Melinda A. Chynoweth, Michele D. Gregoire, Mary Howard, Robert L. McCool, Audrey Parrott, Scott Ramsey, Susan H. Thiessen, Charlotte Thomsen, Kim N. Bender, Tori Myers, Esther Michael, Pam TI Registered dietitians' coding practices and patterns of code use SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article AB Coding, coverage, and reimbursement are vital to the clinical segment of our profession. The objective of this study was to assess understanding and use of the medical nutrition therapy (MNT) procedure codes. Its design was a targeted, cross-sectional, Internet survey. Participants were registered dietitians (RDs) preselected based on Medicare Part B provider status, randomly selected RDs from the American Dietetic Association database based on clinical practice designation, and self-selected RDs. Parameters assessed were knowledge and use of existing MNT and/or alternative procedure codes, barriers to code use/compensation, need for additional codes for existing/emerging services, and practice demographics. Results suggest that MNT is being reimbursed for a variety of diseases and conditions. Many RDs working in clinic settings are undereducated about code use of any kind, reporting that code selection frequently is determined not by the RD providing the service, but by "someone else." Self-employed RDs are less likely to rely on others to administrate paperwork required for reimbursement, including selection of procedure codes for billable nutrition. services. Self-employed RDs are more likely to be reimbursed by private or commercial payers and RDs working in clinic settings are more likely to be reimbursed by Medicare; however, the proportion of Medicare providers in both groups is high. RDs must be knowledgeable and accountable for both the business and clinical side of their nutrition practices; using correct codes and following payers' claims processing policies and procedures. This survey and analysis is a first step in understanding the complex web of relationships between clinical practice, MNT code use, and reimbursement. C1 [White, Jane V.] Univ Tennessee, Dept Family Med, Knoxville, TN 37920 USA. [Ayoob, Keith T.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. [Gregoire, Mary] Rush Univ, Med Ctr, Food & Nutr Serv, Chicago, IL 60612 USA. [Howard, Robert L.] Midtown Nutr, New York, NY USA. [McCool, Audrey] Univ Nevada, William F Harrah Coll Hotel Adm, Las Vegas, NV 89154 USA. [Ramsey, Susan H.] Sodexho Hlth Care Serv, Washington Crossing, PA USA. [Thiessen, Charlotte] US Dept Vet Affairs, Nebraska Western Iowa Healthcare Syst, Omaha, NE USA. [Thomsen, Kim N.] USA, Med Command Headquarters, Ft Sam Houston, TX USA. [Bender, Tori; Michael, Pam] Amer Dietet Assoc, Nutr Serv Coverage Team, Chicago, IL USA. [Myers, Esther] Amer Dietet Assoc, Sci Affairs & Res Team, Chicago, IL USA. RP White, JV (reprint author), Univ Tennessee, Dept Family Med, 1924 Alcoa Hwy, Knoxville, TN 37920 USA. EM jwhite13@utk.edu NR 2 TC 1 Z9 1 U1 0 U2 0 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD JUL PY 2008 VL 108 IS 7 BP 1242 EP 1248 DI 10.1016/j.jada.2008.04.015 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 321KG UT WOS:000257303000030 PM 18589037 ER PT J AU Boockvar, KS Gruber-Baldini, AL Stuart, B Zimmerman, S Magaziner, J AF Boockvar, Kenneth S. Gruber-Baldini, Ann L. Stuart, Bruce Zimmerman, Sheryl Magaziner, Jay TI Medicare expenditures for nursing home residents triaged to nursing home or hospital for acute infection SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE infection; nursing homes; health expenditures; Medicare ID RANDOMIZED CONTROLLED-TRIAL; LONG-TERM-CARE; FACILITY RESIDENTS; PROPENSITY SCORES; RISK ADJUSTMENT; PNEUMONIA; DEMENTIA; EVERCARE; OUTCOMES; PAYMENT AB OBJECTIVES: To compare Medicare payments of nursing home residents triaged to nursing home with those of nursing home residents triaged to the hospital for acute infection care. DESIGN: Observational study with propensity score matching. SETTING: Fifty-nine nursing homes in Maryland. PARTICIPANTS: Two thousand two hundred eighty-five individuals admitted to the 59 nursing homes and followed between 1992 and 1997. MEASUREMENTS: Demographic and clinical data were obtained from interviews and medical record review and linked to Medicare payment records. Incident infection was ascertained according to medical record review for new infectious diagnoses or prescription of antibiotics. Hospital triage was defined as hospital transfer within 3 days of infection onset. Hospital triage patients were paired with similar nursing home triage patients using propensity score matching. Medicare expenditures for triage groups were compared in 1997 dollars. RESULTS: Of 3,618 infection cases, 28% were genitourinary infections, 20% skin, 14% upper respiratory, 12% lower respiratory, 4% gastrointestinal, and 2% bloodstream. Two hundred fifty-six pairs of hospital and nursing home triage cases fulfilled matching criteria. Mean Medicare payments +/- standard deviation were $5,202 +/- 7,310 and $996 +/- 2,475 per case in the hospital and nursing home triage groups, respectively, for a mean difference of $4,206 (95% confidence interval=$3,260-5,151). Mean payments per case in the hospital triage group were $3,628 higher in inpatient expenditures, $482 higher in physician visit expenditures, $161 higher in emergency department expenditures, and $147 higher in skilled nursing day expenditures. CONCLUSION: Per-case Medicare expenditures are higher with hospital triage than for nursing home triage for nursing home residents with acute infection. This result may be used to estimate cost savings to Medicare of interventions designed to reduce hospital use by nursing home residents. C1 [Stuart, Bruce] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA. [Gruber-Baldini, Ann L.; Magaziner, Jay] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Zimmerman, Sheryl] Univ N Carolina, Sch Social Work, Chapel Hill, NC USA. [Zimmerman, Sheryl] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. [Boockvar, Kenneth S.] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. RP Boockvar, KS (reprint author), James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU NIA NIH HHS [R29 AG11407, R01 AG008211, R0L AG8211] NR 35 TC 9 Z9 9 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2008 VL 56 IS 7 BP 1206 EP 1212 DI 10.1111/j.1532-5415.2008.01748.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 332HJ UT WOS:000258073800006 PM 18482299 ER PT J AU Guy, TS Tseng, E AF Guy, T. Sloane Tseng, Elaine TI Robotic cardiac surgery: Give it more time! SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Letter C1 [Guy, T. Sloane; Tseng, Elaine] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Guy, T. Sloane; Tseng, Elaine] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Guy, TS (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. NR 5 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JUL PY 2008 VL 136 IS 1 BP 237 EP 238 DI 10.1016/j.jtcvs.2008.02.056 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 322OT UT WOS:000257385900053 PM 18603100 ER PT J AU Kamat, A Ghosh, PM Glover, RL Zhu, B Yeh, CK Choudhury, GG Katz, MS AF Kamat, Amrita Ghosh, Paramita M. Glover, Renee L. Zhu, Bing Yeh, Chih-Ko Choudhury, Goutam Ghosh Katz, Michael S. TI Reduced expression of epidermal growth factor receptors in rat liver during aging SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE extracellular signal-regulated kinase; hepatocytes; receptor dimerization; receptor tyrosine kinase ID AGE-RELATED DECLINE; EGF RECEPTOR; DNA-SYNTHESIS; TYROSINE KINASE; THYROID-HORMONE; LIGAND-BINDING; HEPATOCYTES; ACTIVATION; TRANSCRIPTION; REGENERATION AB Proliferative responsiveness of hepatocytes to epidermal growth factor (EGF) declines during aging. The role of EGF receptors in mediating age-dependent changes of EGF-induced mitogenic signaling in liver remains incompletely understood. We assessed EGF receptor expression levels in whole liver specimens as well as in freshly isolated and cultured hepatocytes from young adult and senescent Fischer 344 male rats. Hepatic EGF receptor messenger RNA and protein levels, and the number of high- and low-affinity receptor binding sites, decreased with aging. Ligand-induced EGF receptor activation, determined by receptor dimerization and tyrosine phosphorylation, was reduced in old animals in parallel with the age-related decline in receptor expression. Stimulation of the extracellular signal-regulated kinase pathway by EGF was also attenuated in hepatocytes from old animals. Our results implicate decreased expression of EGF receptors as a key determinant of reduced mitogenic signaling responsive to EGF stimulation of liver during aging. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Kamat, Amrita; Glover, Renee L.; Choudhury, Goutam Ghosh; Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh, Paramita M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Zhu, Bing; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. RP Kamat, A (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, San Antonio, TX 78229 USA. EM kamat@uthscsa.edu FU NCI NIH HHS [R21 CA109057]; NIDDK NIH HHS [R01 DK050190, R01 DK 50190] NR 43 TC 5 Z9 6 U1 0 U2 0 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JUL PY 2008 VL 63 IS 7 BP 683 EP 692 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 336UE UT WOS:000258389300005 PM 18693222 ER PT J AU Jonker, SS Anderson, DF Davis, LE Yang, Q Faber, JJ Giraud, GD AF Jonker, S. S. Anderson, D. F. Davis, L. E. Yang, Q. Faber, J. J. Giraud, G. D. TI Persistent changes in arterial blood gases in fetal sheep SO LABORATORY ANIMALS LA English DT Article DE fetal surgery; anaesthesia; pregnancy; sheep ID AMNIOTIC-FLUID; ANESTHESIA AB Two anaesthetic protocols were compared using pregnant sheep. In both groups of animals, anaesthesia was induced using an intravenous (i.v.) injection of diazepam and ketamine. The ewes were then intubated for positive pressure ventilation using 0.8 L/min of nitrous oxide and 2 L/min oxygen with 1.1-1.8% halothane. If the ewe showed any signs of awakening, one of two protocols was followed. First, the halothane concentration was increased to 2-3 until the ewe was completely anaesthetized. Second, the halothane concentration was not altered, but the ewe was given doses of i.v. diazepam (0.1 mg/kg) and ketamine (1 mg/kg) until again completely anaesthetized. At the completion of surgery, maternal recovery was rapid and similar between the two groups. However, five days after surgery, the fetal arterial Po-2 and oxygen content of the fetuses receiving additional halothane (1.9 +/- 0.2 kPa and 4.4 +/- 1.0 mL/100 mL) were statistically significantly depressed when compared with the fetuses receiving additional diazepam and ketamine (2.9 +/- 0.1 kPa and 7.0 +/- 0.5 mL/100 mL). These results led us to conclude that certain anaesthetic protocols, in spite of good maternal recovery, can lead to deleterious effects upon the fetus that persist for at least five days after surgery. C1 [Jonker, S. S.; Anderson, D. F.; Faber, J. J.; Giraud, G. D.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [Davis, L. E.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. [Yang, Q.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Giraud, G. D.] Portland VA Med Ctr, Portland, OR USA. RP Jonker, SS (reprint author), Univ Iowa, 1270 CBRB,285 Newton Rd, Iowa City, IA 52242 USA. EM sonnet-jonker@uiowa.edu RI Yang, Qin/O-8508-2015 OI Jonker, Sonnet/0000-0002-1097-2562 FU NHLBI NIH HHS [R01 HL045043, R01 HL045043-15, HL 45043]; NICHD NIH HHS [R01 HD037376-05, P01 HD034430, R01 HD037376, P01 HD034430-12, HD 37376, 5P01 HD 34430] NR 8 TC 3 Z9 3 U1 0 U2 4 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0023-6772 J9 LAB ANIM-UK JI Lab. Anim. PD JUL PY 2008 VL 42 IS 3 BP 326 EP 330 DI 10.1258/la.2007.06005e PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 333VH UT WOS:000258180400009 PM 18625587 ER PT J AU Becker, DJ Gordon, RY Morris, PB Yorko, J Gordon, YJ Li, MY Iqbal, N AF Becker, David J. Gordon, Ram Y. Morris, Patti B. Yorko, Jacqueline Gordon, Y. Jerold Li, Mingyao Iqbal, Nayyar TI Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial SO MAYO CLINIC PROCEEDINGS LA English DT Article ID CORONARY-ARTERY-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; MYOCARDIAL-INFARCTION; DIETARY-SUPPLEMENTS; MEDITERRANEAN DIET; WEIGHT-REDUCTION; HEART-DISEASE; RISK-FACTORS; CHOLESTEROL; OMEGA-3-FATTY-ACIDS AB OBJECTIVE: To compare the lipid-lowering effects of an alternative regimen (lifestyle changes, red yeast rice, and fish oil) with a standard dose of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin). PATIENTS AND METHODS: This randomized trial enrolled 74 patients with hypercholesterolemia who met Adult Treatment Panel III criteria for primary prevention using statin therapy. All participants were randomized to an alternative treatment group (AG) or to receive simvastatin (40 mg/d) in this open-label trial conducted between April 1, 2006, and June 30, 2006. The alternative treatment included therapeutic lifestyle changes, Ingestion of red yeast rice, and fish oil supplements for 12 weeks. The simvastatin group received medication and traditional counseling. The primary outcome measure was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary measures were changes in other lipoproteins and weight loss. RESULTS: There was a statistically significant reduction in LDL-C levels in both the AG (-42.4%+/- 15%) (P <.001) and the simvastatin group (-39.6%+/- 20%) (P <.001). No significant differences were noted between groups. The AG also demonstrated significant reductions in triglycerides (-29% vs -9.3%; 95% confidence interval, -61 to -11.7; P=.003) and weight (-5.5% vs -0.4%; 95% confidence interval, -5.5 to -3.4; P <.001) compared with the simvastatin group. CONCLUSION: Lifestyle changes combined with ingestion of red yeast rice and fish oil reduced LDL-C in proportions similar to standard therapy with shrivastatin. Pending confirmation in larger trials, this multifactorial, alternative approach to lipid lowering has promise for a subset of patients unwilling or unable to take statins. C1 [Becker, David J.; Gordon, Ram Y.; Morris, Patti B.; Yorko, Jacqueline] Univ Penn Hlth Syst, Chestnut Hill Hosp, Div Cardiol, Philadelphia, PA USA. [Gordon, Y. Jerold] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Li, Mingyao] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Iqbal, Nayyar] Univ Penn, Philadelphia VA Med Ctr, Div Endocrinol, Philadelphia, PA 19104 USA. RP Becker, DJ (reprint author), Mayo Clin & Mayo Fdn, 1722 Bethlehem Pike, Flourtown, PA 19095 USA. EM dbeckerchcardiology@hotmail.com NR 44 TC 47 Z9 48 U1 1 U2 8 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JUL PY 2008 VL 83 IS 7 BP 758 EP 764 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 319XJ UT WOS:000257198000004 PM 18613992 ER PT J AU Xu, G Herzig, M Rotrekl, V Walter, CA AF Xu, Guogang Herzig, Maryanne Rotrekl, Vladimir Walter, Christi A. TI Base excision repair, aging and health span SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Review DE base excision repair; aging; DNA damage; mutagenesis; health span ID DNA-POLYMERASE-BETA; STRAND BREAK REPAIR; AMYOTROPHIC-LATERAL-SCLEROSIS; OXIDATIVELY DAMAGED DNA; LACI TRANSGENIC MICE; HOGG1 SER326CYS POLYMORPHISM; MULTIPLE COLORECTAL ADENOMA; GAMMA-RADIATION SENSITIVITY; INDUCED CYTIDINE DEAMINASE; ALZHEIMERS-DISEASE BRAIN AB DNA damage and mutagenesis are suggested to contribute to aging through their ability to mediate cellular dysfunction. The base excision repair (BER) pathway ameliorates a large number of DNA lesions that arise spontaneously. Many of these lesions are reported to increase with age. Oxidized guanine, repaired largely via base excision repair, is particularly well studied and shown to increase with age. Spontaneous mutant frequencies also increase with age which suggests that mutagenesis may contribute to aging. It is widely accepted that genetic instability contributes to age-related occurrences of cancer and potentially other age-related pathologies. BER activity decreases with age in multiple tissues. The specific BER protein that appears to limit activity varies among tissues. DNA polymerase-p is reduced in brain from aged mice and rats while AP endonuclease is reduced in spermatogenic cells obtained from old mice. The differences in proteins that appear to limit BER activity among tissues may represent true tissue-specific differences in activity or may be due to differences in techniques, environmental conditions or other unidentified differences among the experimental approaches. Much remains to be addressed concerning the potential role of BER in aging and age-related health span. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Xu, Guogang; Herzig, Maryanne; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Rotrekl, Vladimir] Masaryk Univ, Inst Expt Med, Dept Mol Embryol, Fac Med,Dept Biol, Brno 62500, Czech Republic. [Walter, Christi A.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NIA NIH HHS [AG 24364, R01 AG021163, AG 21163, R01 AG021163-05, R01 AG024364, R01 AG024364-04] NR 271 TC 54 Z9 56 U1 0 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD JUL-AUG PY 2008 VL 129 IS 7-8 BP 366 EP 382 DI 10.1016/j.mad.2008.03.001 PG 17 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 328RS UT WOS:000257816100003 PM 18423806 ER PT J AU Hunt, SC Orsborn, M Checkoway, H Biggs, ML McFall, M Takaro, TK AF Hunt, Stephen C. Orsborn, Mack Checkoway, Harvey Biggs, Mary L. McFall, Miles Takaro, Tim K. TI Later life disability status following incarceration as a prisoner of war SO MILITARY MEDICINE LA English DT Article ID FORMER PRISONERS; KOREAN CONFLICT; MORTALITY; TRAUMA; PREVALENCE; RESILIENCE; CAPTIVITY; SURVIVORS; VETERANS; PACIFIC AB Objective: Incarceration-related predictors of later life disability in former prisoners of war (POWs) have not been previously described. The objective of this project was to identify aspects of POW incarceration which are associated with later life disability status. Methods: Cross-sectional retrospective study of 328 former U.S. military personnel held as POWs (World War II and Korean and Vietnam Wars) who presented for evaluations at a Veterans Affairs medical center between January 1, 1997 and December 31, 2004 outcome measures were: (1) total number of later life disability conditions attributable to incarceration and (2) cumulative percentage later life disability attributable to these conditions. Results: We found significant associations between later life disability and POW experiences, including experiencing or witnessing torture, solitary confinement, forced marches, dysentry, pellagra, vitamin deficiencies, scabies, depression, and suicidal thoughts. Conclusions: Conditions of captivity and health concerns or emotional distress during captivity may contribute to long-term adverse health outcomes as measured by later life disabilities in individuals incarcerated as POWs. C1 [Hunt, Stephen C.; Orsborn, Mack; McFall, Miles] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Checkoway, Harvey; Biggs, Mary L.] Univ Washington, Dept Epidemiol Biostat, Seattle, WA 98195 USA. [Takaro, Tim K.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. RP Hunt, SC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 22 TC 10 Z9 10 U1 0 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD JUL PY 2008 VL 173 IS 7 BP 613 EP 618 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 328CH UT WOS:000257774600001 PM 18700592 ER PT J AU Luttrell, LM AF Luttrell, Louis M. TI Reviews in molecular biology and biotechnology: Transmembrane signaling by G protein-coupled receptors SO MOLECULAR BIOTECHNOLOGY LA English DT Review DE G protein-coupled receptors; heterotrimeric GTP-binding proteins; signal transduction; second messenger systems; G protein-coupled receptor kinases; arrestins ID GROWTH-FACTOR RECEPTOR; HETEROTRIMERIC G-PROTEINS; BETA-ADRENERGIC-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; GTPASE-ACTIVATING PROTEINS; NUCLEAR EXPORT SIGNAL; MAP KINASE ACTIVATION; TERNARY COMPLEX MODEL; PHOSPHOLIPASE-C-BETA; BETA(2)-ADRENERGIC RECEPTOR AB As the most diverse type of cell surface receptor, the importance heptahelical G protein-coupled receptors (GPCRs) to clinical medicine cannot be overestimated. Visual, olfactory and gustatory sensation, intermediary metabolism, cell growth and differentiation are all influenced by GPCR signals. The basic receptor-G protein-effector mechanism of GPCR signaling is tuned by a complex interplay of positive and negative regulatory events that amplify the effect of a hormone binding the receptor or that dampen cellular responsiveness. The association of heptahelical receptors with a variety of intracellular partners other than G proteins has led to the discovery of potential mechanisms of GPCR signaling that extend beyond the classical paradigms. While the physiologic relevance of many of these novel mechanisms of GPCR signaling remains to be established, their existence suggests that the mechanisms of GPCR signaling are even more diverse than previously imagined. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu RI Marion-Poll, Frederic/D-8882-2011 OI Marion-Poll, Frederic/0000-0001-6824-0180 NR 227 TC 61 Z9 62 U1 2 U2 19 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1073-6085 J9 MOL BIOTECHNOL JI Mol. Biotechnol. PD JUL PY 2008 VL 39 IS 3 BP 239 EP 264 DI 10.1007/s12033-008-9031-1 PG 26 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA 311TD UT WOS:000256622400008 PM 18240029 ER PT J AU Page, ST Amory, JK Matsumoto, AM AF Page, Stephanie T. Amory, John K. Matsumoto, Alvin M. TI Des testosterone supplementation improve health and function in elderly men? SO NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material DE aging; androgen; supplementation; testosterone ID OLDER MEN; MORTALITY C1 [Page, Stephanie T.; Amory, John K.; Matsumoto, Alvin M.] Univ Washington, Sch Med, Seattle, WA USA. RP Matsumoto, AM (reprint author), VA Puget Sound Hlth Care Syst, Clin Res Unit, Educ & Clin Ctr, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM alvin.matsumoto@med.va.gov FU NIA NIH HHS [K23 AG027238, K23 AG027238-03]; NICHD NIH HHS [K23 HD045386] NR 6 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1745-8366 J9 NAT CLIN PRACT ENDOC JI Nat. Clin. Pract. Endocrinol. Metab. PD JUL PY 2008 VL 4 IS 7 BP 374 EP 375 DI 10.1038/ncpendmet0840 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 315YX UT WOS:000256917200006 PM 18493229 ER PT J AU Borghesani, PR Johnson, LC Shelton, AL Peskind, ER Aylward, EH Schellenberg, GD Cherrier, MM AF Borghesani, Paul R. Johnson, L. Clark Shelton, Amy L. Peskind, Elaine R. Aylward, Elizabeth H. Schellenberg, Gerard D. Cherrier, Monique M. TI Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer; apolipoprotein; hippocampus; APOE*4; perspective; visuospatial learning; encoding; recognition; fMRI; route; survey ID APOLIPOPROTEIN-E GENOTYPE; E TYPE-4 ALLELE; CEREBRAL GLUCOSE-METABOLISM; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; BRAIN ACTIVATION; EPISODIC MEMORY; GENETIC RISK; EPSILON-4 ALLELE; WORKING-MEMORY AB The apolipoprotein epsilon 4 allele (APOE*4) is a major genetic risk factor for Alzheimer's disease (AD) and has been associated with altered cortical activation as assessed by functional neuroimaging in cognitively normal younger and older carriers. We chose to evaluate medial temporal lobe (MTL) activation during encoding and recognition using a perspective-dependent (route or survey) visuospatial memory task by monitoring the blood-oxygen-level -dependent (BOLD) fMRI response in older, non-demented APOE*4 carriers (APOE*4+) and non-carriers (APOE*4-). During encoding, the APOE*4- group had greater average task-associated BOLD responses in ventral visual pathways, including the MTLs, as compared to the APOE*4+ group. Furthermore, MTL activation was greater during route encoding than survey encoding on average in APOE*4-, but not APOE*4+, subjects. During recognition, both groups performed similarly and no BOLD signal differences were found. Finally, within-group analysis revealed MTL activation during encoding was correlated with recognition performance in APOE*4-, but not APOE*4+ subjects. Reduced task-associated MTL activation that does not correlate with either visuospatial perspective or task performance suggests that MTL dysregulation occurs prior to clinical symptoms of dementia in APOE*4 carriers. (C) 2007 Elsevier Inc. All rights reserved. C1 [Borghesani, Paul R.; Peskind, Elaine R.] VAPSHCS, MIRECC, Seattle, WA 98108 USA. [Borghesani, Paul R.; Peskind, Elaine R.; Cherrier, Monique M.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Johnson, L. Clark] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth Nursing, Seattle, WA 98195 USA. [Shelton, Amy L.] Johns Hopkins Univ, Dept Psychol & Brain Sci, Baltimore, MD 21218 USA. [Aylward, Elizabeth H.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Peskind, Elaine R.; Schellenberg, Gerard D.; Cherrier, Monique M.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. RP Borghesani, PR (reprint author), VAPSHCS, MIRECC, S-116 6East,1660 Columbian Way, Seattle, WA 98108 USA. EM paulrb@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG005136-16, P50 AG005136-17, P50 AG05136, T32 AG000258, T32 AG000258-01A1, T32 AG00258]; PHS HHS [AGO0258, AGO5136] NR 72 TC 28 Z9 28 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2008 VL 29 IS 7 BP 981 EP 991 DI 10.1016/j.neurobiolaging.2007.01.012 PG 11 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 309JR UT WOS:000256457000003 PM 17350142 ER PT J AU Labus, JS Naliboff, BN Fallon, J Berman, SM Suyenobu, B Bueller, JA Mandelkern, M Mayer, EA AF Labus, J. S. Naliboff, B. N. Fallon, J. Berman, S. M. Suyenobu, B. Bueller, J. A. Mandelkern, M. Mayer, E. A. TI Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: A network analysis SO NEUROIMAGE LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; PARTIAL LEAST-SQUARES; EVENT-RELATED FMRI; PHYSIOLOGICAL CONDITION; ORBITOFRONTAL CORTEX; CEREBRAL ACTIVATION; GENDER-DIFFERENCES; RECTAL DISTENSION; CINGULATE GYRUS; IBS PATIENTS AB Differences in brain responses to aversive visceral stimuli may underlie previously reported sex differences in symptoms as well as perceptual and emotional responses to such stimuli in patients with irritable bowel syndrome (IBS). The goal of the current study was to identify brain networks activated by expected and delivered aversive visceral stimuli in male and female patients with chronic abdominal pain, and to test for sex differences in the effective connectivity of the circuitry comprising these networks. Network analysis was applied to assess the brain response of 46 IBS patients (22 men and 24 women) recorded using [O-15] water positron emission tomography during rest/ baseline and expected and delivered aversive rectal distension. Functional connectivity results from partial least squares analyses provided support for the hypothesized involvement of 3 networks corresponding to: 1) visceral afferent information processing (thalamus, insula and dorsal anterior cingulate cortex, orbital frontal cortex), 2) emotionalarousal (amygdala, rostral and subgenual cingulate regions, and locus coeruleus complex) and 3) cortical modulation (frontal and parietal cortices). Effective connectivity results obtained via structural equation modeling indicated that sex-related differences in brain response are largely due to alterations in the effective connectivity of emotionalarousal circuitry rather than visceral afferent processing circuits. Sex differences in the cortico-limbic circuitry involved in emotionalarousal, pain facilitation and autonomic responses may underlie the observed differences in symptoms, and in perceptual and emotional responses to aversive visceral stimuli. (C) 2008 Elsevier Inc. All rights reserved. C1 [Labus, J. S.; Naliboff, B. N.; Berman, S. M.; Suyenobu, B.; Bueller, J. A.; Mandelkern, M.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Med, Los Angeles, CA 90095 USA. [Labus, J. S.; Naliboff, B. N.; Berman, S. M.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Labus, J. S.; Berman, S. M.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Naliboff, B. N.] VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073 USA. Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA. [Fallon, J.; Mandelkern, M.] Univ Calif Irvine, Dept Phys, Irvine, CA 92697 USA. RP Labus, JS (reprint author), Ctr Neurovisceral Sci & Womens Hlth, Peter V Ueberroth Bldg,Rm 2338C2,10945 Leconte Av, Los Angeles, CA 90095 USA. EM jlabus@ucla.edu FU NCCIH NIH HHS [R24 AT002681]; NIDDK NIH HHS [K08 DK071626, K08 DK071626-02, P50 DK064539, R01 DK 48351, R01 DK048351] NR 73 TC 75 Z9 77 U1 6 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JUL PY 2008 VL 41 IS 3 BP 1032 EP 1043 DI 10.1016/j.neuroimage.2008.03.009 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 306TW UT WOS:000256271700030 PM 18450481 ER PT J AU Jenkinson, CP Coletta, DK Flechtner-Mors, M Hu, SL Fourcaudot, MJ Rodriguez, LM Schneider, J Arya, R Stern, MP Blangero, J Duggirala, R DeFronzo, RA AF Jenkinson, Christopher P. Coletta, Dawn K. Flechtner-Mors, Marion Hu, Shirley L. Fourcaudot, Marcel J. Rodriguez, Lenore M. Schneider, Jennifer Arya, Rector Stern, Michael P. Blangero, John Duggirala, Ravindranath DeFronzo, Ralph A. TI Association of genetic variation in ENPP1 with obesity-related phenotypes SO OBESITY LA English DT Article ID K121Q POLYMORPHISM; INSULIN-RESISTANCE; MEXICAN-AMERICANS; LINKAGE ANALYSIS; PLASMA-GLUCOSE; VARIANTS; PC-1; PREDISPOSE; CHILDHOOD; GENOTYPE AB Ectonucleotide pyrophosphatase phosphodiesterase (ENPP1) is a positional candidate gene at chromosome 6q23 where we previously detected strong linkage with fasting-specific plasma insulin and obesity in Mexican Americans from the San Antonio Family Diabetes Study (SAFDS). We genotyped 106 single-nucleotide polymorphisms (SNPs) within ENPP1 in all 439 subjects from the linkage study, and measured association with obesity and metabolic syndrome (MS)-related traits. Of 72 polymorphic SNPs, 24 were associated, using an additive model, with at least one of eight key metabolic traits. Three traits were associated with at least four SNPs. They were high-density lipoprotein cholesterol (HDL-C), leptin, and fasting plasma glucose (FPG). HDL-C was associated with seven SNPs, of which the two most significant P values were 0.0068 and 0.0096. All SNPs and SNP combinations were analyzed for functional contribution to the traits using the Bayesian quantitative-trait nucleotide (BQTN) approach. With this SNP-prioritization analysis, HDL-C was the most strongly associated trait in a four-SNP model (P = 0.00008). After accounting for multiple testing, we conclude that ENPP1 is not a major contributor to our previous linkage peak with MS-related traits in Mexican Americans. However, these results indicate that ENPP1 is a genetic determinant of these traits in this population, and are consistent with multiple positive association findings in independent studies in diverse human populations. C1 [Jenkinson, Christopher P.; Coletta, Dawn K.; Fourcaudot, Marcel J.; Rodriguez, Lenore M.; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabetes, San Antonio, TX 78229 USA. [Jenkinson, Christopher P.; Schneider, Jennifer; Blangero, John] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Jenkinson, Christopher P.; Hu, Shirley L.; DeFronzo, Ralph A.] S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. [Flechtner-Mors, Marion] Univ Ulm, Dept Med, Ulm, Baden Wurttembe, Germany. [Arya, Rector; Stern, Michael P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. RP Jenkinson, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabetes, San Antonio, TX 78229 USA. EM jenkinsonc@uthscsa.edu RI Coletta, Dawn/G-6382-2016 OI Coletta, Dawn/0000-0001-5819-5152 FU NCRR NIH HHS [M01 RR001346, M01-RR-01346]; NIDDK NIH HHS [DK024092, DK047482, DK053889-06, DK067690, R01 DK024092, R01 DK047482, R01 DK053889, R01 DK067690, R01 DK079195, R56 DK024092] NR 24 TC 10 Z9 10 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD JUL PY 2008 VL 16 IS 7 BP 1708 EP 1713 DI 10.1038/oby.2008.262 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 321RX UT WOS:000257325300035 PM 18464750 ER PT J AU Dobscha, SK Corson, K Flores, JA Tansill, EC Gerrity, MS AF Dobscha, Steven K. Corson, Kathryn Flores, Jennifer A. Tansill, Erin C. Gerrity, Martha S. TI Veterans affairs primary care clinicians' attitudes toward chronic pain and correlates of opioid prescribing rates SO PAIN MEDICINE LA English DT Editorial Material DE addiction; chronic pain; narcotics; pain management; primary care; satisfaction ID PHYSICIAN JOB-SATISFACTION; CHRONIC NONMALIGNANT PAIN; DISORDERS; HEALTH; ANALGESICS; MANAGEMENT; KNOWLEDGE; THERAPY; ABUSE AB Objectives. The primary objective of this study was to identify veterans affairs (VA) primary care clinicians' attitudes regarding chronic pain treatment. A secondary objective was to explore relationships between clinician and practice characteristics and an objective measure of opioid prescribing rates. Design. Cross-sectional study of clinician survey and pharmacy data. Participants. Forty-five VA clinicians from five primary care clinics of one VA medical center. Measures. Survey of pain-related attitudes and behaviors, satisfaction with treatment resources, and job satisfaction; percentage of patients in clinicians' panels prescribed opioids (PCPO). Results. Seventy-one percent of clinicians felt moderately or strongly confident in their ability to treat chronic pain, and 77% moderately or strongly agreed that skilled pain management is a high priority. However, 73% moderately or strongly agreed that patients with chronic pain are a major source of frustration and 38% reported moderate or greater dissatisfaction with their ability to provide optimal pain treatment. Fifty-two percent moderately or strongly agreed that their management is influenced by previous experiences with patients addicted to drugs. The mean PCPO was 16.5% (SD = 6.7). In bivariate comparisons, clinician panel size, job and resource satisfaction, and professional training were associated with opioid prescribing rates. Conclusion. High clinician confidence and interest in treating chronic pain concurrent with low satisfaction with ability to provide optimal treatment suggests a need for more system support. VA primary care clinicians are frequently influenced by fears of contributing to dependence or addiction. The relationships among panel size, job satisfaction, and opioid prescribing rates merit additional investigation. C1 [Dobscha, Steven K.; Corson, Kathryn; Flores, Jennifer A.; Tansill, Erin C.; Gerrity, Martha S.] Portland VA Med Ctr, Columbia Ctr Study Chron, Portland, OR 97207 USA. [Dobscha, Steven K.; Corson, Kathryn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97207 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Columbia Ctr Study Chron, POB 1034 R&D 66, Portland, OR 97207 USA. EM steven.dobscha@va.gov NR 31 TC 63 Z9 63 U1 0 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUL-AUG PY 2008 VL 9 IS 5 BP 564 EP 571 DI 10.1111/j.1526-4637.2007.00330.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 334MD UT WOS:000258225000009 PM 18777608 ER PT J AU Meghani, SH Gallagher, RM AF Meghani, Salimah H. Gallagher, Rollin M. TI Disparity vs inequity: Toward reconceptualization of pain treatment disparities SO PAIN MEDICINE LA English DT Article DE disparities; inequities; pain; pain treatment; race; ethnicity; minorities ID LOW-BACK-PAIN; COOPERATIVE-ONCOLOGY-GROUP; HEALTH-CARE; CANCER PAIN; EMERGENCY-DEPARTMENT; POSTOPERATIVE PAIN; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; OPIOID ANALGESICS AB Context. "Disparity" and "inequity" are two interdependent, yet distinct concepts that inform our discourse on ethics and morals in pain medicine practice and in health policy. Disparity implies a difference of some kind, whereas inequity implies unfairness and injustice. An overwhelming body of literature documents racial/ethnic disparities in health. The debate on health disparities is generally formulated using the principle of "horizontal equity," which requires that individuals having the same needs be treated equally. While some types of health treatments are amenable to the principle of horizontal equity, others may not be appropriately studied in this way. The existing research surrounding racial/ethnic disparities in pain treatment presents a conceptual predicament when placed within the framework of horizontal equity. Objective. Using pain treatment as a prototype, we advance the conceptual debate about racial/ ethnic disparities in health. More specifically, we ask three questions: (1) When may disparities be considered inequities? (2) When may disparities not be considered inequities? (3) What are the uncertainties in the disparity-inequity discourse? Discussion. Significant policy implications may result from the manner in which health disparities are conceptualized. Increasingly, researchers and policy makers use the term disparity interchangeably with inequity. This usage confuses the meaning and application of these distinct concepts. In a given health care setting, different types of disparities may operate simultaneously, each requiring serious scrutiny to avoid categorical interpretation leading to misguided practice and policy. While the science of pain treatment disparities is still emerging, the authors present one perspective toward the conceptualization of racial/ethnic disparities in pain treatment. C1 [Meghani, Salimah H.] Univ Penn, Ctr Hlth Dispar Res, Sch Nursing, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Gallagher, Rollin M.] Univ Penn, Ctr Pain Med Res & Policy, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Philadelphia Vet Affairs Med Ctr, Pain Med Serv, Philadelphia, PA USA. RP Meghani, SH (reprint author), Univ Penn, Ctr Hlth Dispar Res, Sch Nursing, Claire M Fagin Hall 418 Curie Blvd, Philadelphia, PA 19104 USA. EM meghanis@nursing.upenn.edu NR 73 TC 6 Z9 6 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUL-AUG PY 2008 VL 9 IS 5 BP 613 EP 623 DI 10.1111/j.1526-4637.2007.00344.x PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 334MD UT WOS:000258225000014 PM 18777609 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Opioid analgesia: Managing risks and obtaining benefits SO PAIN MEDICINE LA English DT Editorial Material ID CHRONIC NONCANCER PAIN; PRIMARY-CARE; MANAGEMENT C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUL-AUG PY 2008 VL 9 SU 2 BP S143 EP S144 DI 10.1111/j.1526-4637.2008.00485.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 335JP UT WOS:000258287200001 ER PT J AU Pastor, R McKinnon, CS Scibelli, AC Burkhart-Kasch, S Reed, C Ryabinin, AE Coste, SC Stenzel-Poore, MP Phillips, TJ AF Pastor, Raul McKinnon, Carrie S. Scibelli, Angela C. Burkhart-Kasch, Sue Reed, Cheryl Ryabinin, Andrey E. Coste, Sarah C. Stenzel-Poore, Mary P. Phillips, Tamara J. TI Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: A urocortin(1)-independent mechanism SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE addiction; CP-154,526; HPA axis; knockout mice; psychomotor sensitization ID PITUITARY-ADRENAL AXIS; ANXIETY-LIKE BEHAVIOR; PSYCHOMOTOR-STIMULANT SENSITIZATION; STRESS-INDUCED SENSITIZATION; MESSENGER-RNA EXPRESSION; LONG-TERM EXPRESSION; FACTOR CRF; UNITARY PHENOMENON; MOTOR-ACTIVITY; ANIMAL-MODELS AB A common expression of neuroadaptations induced by repeated exposure to addictive drugs is a persistent sensitized behavioral response to their stimulant properties. Neuroplasticity underlying drug-induced sensitization has been proposed to explain compulsive drug pursuit and consumption characteristic of addiction. The hypothalamic-pituitary-adrenal (HPA) axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keystone in drug-induced neuroadaptation. Corticosterone-activated glucocorticoid receptors (GRs) mediate the development of sensitization to ethanol (EtOH), implicating the HPA axis in this process. EtOH-induced increases in corticosterone require CRF activation of CRF, receptors. We posited that CRF, signaling pathways are crucial for EtOH-induced sensitization. We demonstrate that mice lacking CRF, receptors do not show psychomotor sensitization to ROH, a phenomenon that was also absent in CRF1 + 2 receptor double-knockout mice. Deletion of CRF2 receptors alone did not prevent sensitization. A blunted endocrine response to EtOH was found only in the genotypes showing no sensitization. The CRF, receptor antagonist CP-154,526 attenuated the acquisition and prevented the expression of EtOH-induced psychomotor sensitization. Because CRF, receptors are also activated by urocortin-1 (Ucn(1)), we tested Ucn(1) knockout mice for EtOH sensitization and found normal sensitization in this genotype. Finally, we show that the GR antagonist mifepristone does not block the expression of EtOH sensitization. CRF and CRF, receptors, therefore, are involved in the neurobiological adaptations that underlie the development and expression of psychomotor sensitization to EtOH. A CRF/CRF,mediated mechanism involving the HPA axis is proposed for acquisition, whereas an extrahypothalamic CRF/CRF, participation is suggested for expression of sensitization to EtOH. C1 [Pastor, Raul; McKinnon, Carrie S.; Scibelli, Angela C.; Burkhart-Kasch, Sue; Reed, Cheryl; Ryabinin, Andrey E.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Coste, Sarah C.; Stenzel-Poore, Mary P.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Pastor, Raul; McKinnon, Carrie S.; Scibelli, Angela C.; Burkhart-Kasch, Sue; Reed, Cheryl; Ryabinin, Andrey E.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Phillips, Tamara J.] Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. [Pastor, Raul] Univ Jaume 1, Area Psicobiol, Castellon de La Plana 12071, Spain. RP Phillips, TJ (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM phillipt@ohsu.edu FU NIAAA NIH HHS [R01AA13331, P60 AA010760, P60AA010760, R01 AA013331, R01 AA013738, R01AA013738]; NIMH NIH HHS [R01 MH065689, R01MH65689]; PHS HHS [UO1016647] NR 74 TC 43 Z9 43 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUL 1 PY 2008 VL 105 IS 26 BP 9070 EP 9075 DI 10.1073/pnas.0710181105 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 322DC UT WOS:000257354400049 PM 18591672 ER PT J AU Zanjani, F Miller, B Turiano, N Ross, J Oslin, D AF Zanjani, Faika Miller, Bree Turiano, Nicholas Ross, Jennifer Oslin, David TI Effectiveness of telephone-based referral care management, a brief intervention to improve psychiatric treatment engagement SO PSYCHIATRIC SERVICES LA English DT Article ID BRIEF PHYSICIAN ADVICE; ALCOHOL-PROBLEMS; UNITED-STATES; USE DISORDERS; AT-RISK; DSM-IV; DEPRESSION; DRINKERS; COMORBIDITY; POPULATION AB Objective: This study examined the effectiveness of a telephone-based referral care management (TBR-CM) intervention for improving engagement in psychiatric treatment. Methods: From September 2005 to May 2006, 169 primary care patients at the Philadelphia Veterans Affairs Medical Center completed a psychiatric diagnostic interview and were identified as needing psychiatric care. From this total of eligible patients, 113 ( 67%) gave informed consent and were randomly assigned to receive either usual care or the intervention. Usual care consisted of participants' being schedule for a behavioral health care appointment, followed by a letter and reminder by telephone. The intervention group received the same, plus one or two brief motivational telephone sessions. Participant interviews and medical records provided study data. Results: Research participants were primarily African American and 22-83 years old. In the sample, 40 patients (39%) had severe depression, 40 ( 39%) had substance use problems, and 33 ( 22%) had co-occurring severe depression and substance abuse. Overall, 40 participants (70%) in the intervention group compared with 18 ( 32%) in the usual care group engaged in at least one psychiatric treatment appointment ( p <. 001). Analyses also indicated that on average the intervention group attended more appointments ( more than three) compared with the usual care group ( less than two) ( p=. 008). Conclusions: The TBR-CM intervention program was effective at improving psychiatric treatment engagement. Future research is necessary to examine effectiveness of TBR-CM in more heterogeneous and larger samples and to evaluate economic benefits versus costs of intervention delivery. C1 [Zanjani, Faika] Univ Kentucky, Dept Gerontol, Lexington, KY 40536 USA. [Miller, Bree; Ross, Jennifer; Oslin, David] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Turiano, Nicholas] Purdue Univ, Dept Child Dev & Family Studies, W Lafayette, IN 47907 USA. RP Zanjani, F (reprint author), Univ Kentucky, Dept Gerontol, 900 S Limestone,306B Wethington Bldg, Lexington, KY 40536 USA. EM f.zanjani@uky.edu FU NIMH NIH HHS [5 T32 MH 19931] NR 30 TC 31 Z9 31 U1 2 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL PY 2008 VL 59 IS 7 BP 776 EP 781 DI 10.1176/appi.ps.59.7.776 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 319YV UT WOS:000257201800013 PM 18586995 ER PT J AU Bogart, LM Howerton, D Lange, J Becker, K Setodji, CM Asch, SM AF Bogart, Laura M. Howerton, Devery Lange, James Becker, Kirsten Setodji, Claude Mfssan Asch, Steven M. TI Scope of in rapid HIV testing in urban US hospitals SO PUBLIC HEALTH REPORTS LA English DT Article ID NATIONAL PROBABILITY SAMPLES; HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-PREVALENCE DISEASES; HEALTH-CARE SETTINGS; EMERGENCY-DEPARTMENT; REVISED RECOMMENDATIONS; SERVICES UTILIZATION; RANDOMIZED-TRIAL; EXPERIENCE; ROUTINE AB Objective. The present study examined the scope of rapid human immunodeficiency virus (HIV) testing in urban U.S. hospitals. Methods. In a multistage national probability sample, 12 primary metropolitan statistical areas (three per region) were sampled randomly, with weights proportionate to acquired immunodeficiency syndrome (AIDS) populations. All 671 eligible hospitals within areas were selected. Laboratory staff from 584 hospitals (87%) were interviewed by telephone in 2005. Results. About 52% reported rapid HIV test availability (50% in occupational health, 29% in labor and delivery, and 13% in emergency department/urgent care), and 86% of hospitals offering rapid tests processed them in the laboratory. In multivariate models, rapid test availability was more likely in hospitals serving more patients, and located in high-poverty, high-AIDS prevalence areas, and in the South or Midwest vs. West. It was less likely in hospitals serving areas with large percentages of people who were black/African American or Hispanic/Latino (p<0.05). Conclusions. Rapid HIV testing is increasing across urban U.S. hospitals, primarily for occupational exposure and in hospitals with greater resources and need. To achieve routine HIV screening, policies should encourage greater breadth of diffusion of rapid testing at the point of care, especially in smaller facilities, the West, and communities with racial/ethnic diversity. C1 [Bogart, Laura M.; Becker, Kirsten; Setodji, Claude Mfssan; Asch, Steven M.] RAND Corp, Santa Monica, CA 90407 USA. [Howerton, Devery; Lange, James] Ctr Dis Control & Prevent, Lab Practice Evaluat & Genom Branch, Atlanta, GA USA. [Asch, Steven M.] Vet Affairs Greater Los Angeles Healthcare, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bogart, LM (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM lbogart@rand.org FU NCCDPHP CDC HHS [U48 DP000056, U48/DP000056]; ODCDC CDC HHS [U65/CCU924523-01] NR 52 TC 11 Z9 11 U1 3 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2008 VL 123 IS 4 BP 494 EP 503 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 310ZX UT WOS:000256570700013 PM 18763412 ER PT J AU Ellis, C Egede, LE AF Ellis, Charles Egede, Leonard E. TI Ethnic disparities in stroke recognition in individuals with prior stroke SO PUBLIC HEALTH REPORTS LA English DT Article ID AMERICAN-HEART-ASSOCIATION; RISK-FACTOR SURVEY; WARNING SIGNS; HEALTH-CARE; EMERGENCY-DEPARTMENT; KNOWLEDGE; AWARENESS; DELAY; SYMPTOMS; TIME AB Objective. Studies of stroke awareness suggest that knowledge of early warning signs of stroke is low in high-risk groups. However, little is known about stroke knowledge among individuals with a history of prior stroke who are at significant risk for recurrent stroke. Methods. Data from 2,970 adults with a history of prior stroke from the 2003 Behavioral Risk Factor Surveillance System were examined. Recognition of the five warning signs of stroke and appropriate action to call 911 was compared across three racial/ethnic groups: non-Hispanic white, non-Hispanic black, and Hispanic/other. Multiple logistic regression analyses were used to: (1) determine the association between race/ethnicity and recognition of multiple stroke signs and appropriate first action and (2) identify independent correlates of recognition of multiple stroke signs and taking appropriate action to seek treatment among individuals with prior stroke. Results. Recognition of all five signs of stroke and taking appropriate action to call 911 was lowest among the non-Hispanic black group (22.3%) and Hispanic/other group (16.7%). In multivariate models, Hispanic/other (odds ratio [OR) 0.42 [0.25, 0.71]), age 50-64 (OR 0.64 [0.43, 0.971), age >= 65 (OR 0.36 [0.23, 0.551), and >high school education (OR 1.79 [1.22, 2.63]) emerged as independent correlates of recognition of all five signs of stroke and first action to call 911. Conclusions. Less than 35% of people with prior stroke can distinguish the complex symptom profile of a stroke and take appropriate action to call 911. Targeted educational activities that are sensitive to differences in race/ethnicity, age, and education levels are needed for individuals with prior stroke. C1 [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. [Ellis, Charles] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Disparities Res, 135 Rutledge Ave,Rm 280H, Charleston, SC 29425 USA. EM egedel@musc.edu NR 33 TC 11 Z9 12 U1 1 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2008 VL 123 IS 4 BP 514 EP 522 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 310ZX UT WOS:000256570700015 PM 18763414 ER PT J AU Wynn, JK Lee, J Horan, WP Green, MF AF Wynn, Jonathan K. Lee, Junghee Horan, William P. Green, Michael F. TI Using event related potentials to explore stages of facial affect recognition deficits in schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article DE face processing; emotion identification; ERP ID VISUAL-EVOKED-POTENTIALS; SOCIAL COGNITION INFLUENCE; NEUROCOGNITIVE DEFICITS; EMOTION RECOGNITION; BIPOLAR DISORDER; FACE PERCEPTION; N170; BRAIN; LOCALIZATION; IMPAIRMENTS AB Schizophrenia patients show impairments in identifying facial affect; however, it is not known at what stage facial affect processing is impaired. We evaluated 3 event-related potentials (ERPs) to explore stages of facial affect processing in schizophrenia patients. Twenty-six schizophrenia patients and 27 normal controls participated. In separate blocks, subjects identified the gender of a face, the emotion of a face, or if a building had 1 or 2 stories. Three ERPs were examined: (1) P100 to examine basic visual processing, (2) N170 to examine facial feature encoding, and (3) N250 to examine affect decoding. Behavioral performance on each task was also measured. Results showed that schizophrenia patients' P100 was comparable to the controls during all 3 identification tasks. Both patients and controls exhibited a comparable N170 that was largest during processing of faces and smallest during processing of buildings. For both groups, the N250 was largest during the emotion identification task and smallest for the building identification task. However, the patients produced a smaller N250 compared with the controls across the 3 tasks. The groups did not differ in behavioral performance in any of the 3 identification tasks. The pattern of intact P100 and N170 suggest that patients maintain basic visual processing and facial feature encoding abilities. The abnormal N250 suggests that schizophrenia patients are less efficient at decoding facial affect features. Our results imply that abnormalities in the later stage of feature decoding could potentially underlie emotion identification deficits in schizophrenia. C1 [Wynn, Jonathan K.; Lee, Junghee; Horan, William P.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. [Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. RP Wynn, JK (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC, Bldg 210, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014 OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH-43292, MH-65707] NR 49 TC 48 Z9 53 U1 7 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JUL PY 2008 VL 34 IS 4 BP 679 EP 687 DI 10.1093/schbul/sbn047 PG 9 WC Psychiatry SC Psychiatry GA 323AV UT WOS:000257417300014 PM 18499704 ER PT J AU Jetter, GM Cavazos, JE AF Jetter, Gina Mapes Cavazos, Jose E. TI Epilepsy in the elderly SO SEMINARS IN NEUROLOGY LA English DT Article DE epilepsy; geriatrics; antiepileptic drugs ID NONCONVULSIVE STATUS EPILEPTICUS; NURSING-HOME RESIDENTS; ANTIEPILEPTIC DRUG-USE; TONIC CLONIC SEIZURES; VITAMIN-D LEVELS; SERUM CONCENTRATIONS; BONE TURNOVER; CARBAMAZEPINE; PHENYTOIN; AGE AB There are many unique characteristics in elderly patients with epilepsy. The incidence of seizures in this age group is the highest of any age group and continues to increase as people live longer. Etiology of seizures is different than for adults and includes cerebrovascular disease, dementia, closed head injury, and metabolic encephalopathies. The elderly patient with epilepsy most often presents with complex partial seizures that have a higher recurrence rate than the younger population. The seizures are often difficult to diagnose since they present with atypical symptoms, particularly prolonged postictal symptoms, including memory lapses, confusion, altered mental status, and inattention. There are also therapeutic challenges due to age-related changes in pharmacokinetics, including variations in absorption, distribution, metabolism, and excretion. These must be considered when selecting antiepileptic drug (AED) therapy to avoid harmful side effects. In addition, several of the AEDs have drug-drug interactions, a problem potentially exacerbated in this population of patients due to the use of medications for comorbid conditions. C1 [Jetter, Gina Mapes; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Comprehens Epilepsy Ctr, San Antonio, TX 78229 USA. [Cavazos, Jose E.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Cavazos, JE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 7703 Floyd Curl Dr,MC7883, San Antonio, TX 78229 USA. EM cavazosj@uthscsa.edu RI Cavazos, Jose/J-4122-2016 OI Cavazos, Jose/0000-0001-5777-2608 NR 41 TC 17 Z9 18 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 J9 SEMIN NEUROL JI Semin. Neurol. PD JUL PY 2008 VL 28 IS 3 BP 336 EP 341 DI 10.1055/s-2008-1079338 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 336OL UT WOS:000258374400008 PM 18777480 ER PT J AU Morgenthaler, TI Lee-Chiong, T Alessi, C Friedman, L Aurora, RN Boehlecke, B Brown, T Chesson, AL Kapur, V Maganti, R Owens, J Pancer, J Swick, TJ Zak, R AF Morgenthaler, Timothy I. Lee-Chiong, Teofilo Alessi, Cathy Friedman, Leah Aurora, R. Nisha Boehlecke, Brian Brown, Terry Chesson, Andrew L., Jr. Kapur, Vishesh Maganti, Rama Owens, Judith Pancer, Jeffrey Swick, Todd J. Zak, Rochelle CA Stand Practice Committee AASM TI Response to Zee,P., Melantonin for the treatment of advanced sleep phase disorder. SLEEP 2008;31 : 923 SO SLEEP LA English DT Letter ID RECOMMENDATIONS; STRENGTH; QUALITY C1 [Lee-Chiong, Teofilo] Natl Jewish Med & Res Ctr, Denver, CO USA. [Alessi, Cathy] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Sepulveda, CA USA. [Friedman, Leah] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA. [Aurora, R. Nisha; Zak, Rochelle] Mt Sinai Med Ctr, Ctr Sleep Med, New York, NY 10029 USA. [Boehlecke, Brian] Univ N Carolina, Chapel Hill, NC USA. [Brown, Terry] St Joseph Mem Hosp, Sleep Disorders Ctr, Murphysboro, IL USA. [Chesson, Andrew L., Jr.] Louisiana State Univ, Med Ctr, Dept Neurol, Shreveport, LA USA. [Kapur, Vishesh] Univ Washington, Sleep Disorders Ctr Harborview, Seattle, WA 98195 USA. [Maganti, Rama] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Owens, Judith] Rhode Isl Hosp, Dept Pediat Ambulatory Pediat, Providence, RI USA. [Swick, Todd J.] Methodist Hosp, Methodist Neurol Inst, Houston, TX 77030 USA. [Morgenthaler, Timothy I.] Mayo Clin, Mayo Sleep Disordcrs Cciner, Rochester, MN 55905 USA. RP Morgenthaler, TI (reprint author), Mayo Clin, Mayo Sleep Disordcrs Cciner, Rochester, MN 55905 USA. RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097 NR 6 TC 1 Z9 1 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD JUL 1 PY 2008 VL 31 IS 7 BP 925 EP 925 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 321GX UT WOS:000257293800002 ER PT J AU Song, X Zhou, XH AF Song, Xiao Zhou, Xiao-Hua TI A semiparametric approach for the covariate specific ROC curve with survival outcome SO STATISTICA SINICA LA English DT Article DE location model; proportional hazards model; receiver operating characteristic curve; survival analysis ID MODEL AB The receiver operating characteristic (ROC) curve has been extended to survival data recently, including the nonparametric approach by Heagerty, Lumley and Pepe (2000) and the semiparametric approach by Heagerty and Zheng (2005) using standard survival analysis techniques based on two different time-dependent ROC curve definitions. However, both approaches do not involve covariates other than the biomarker and cannot be used to estimate the ROC curve adjusted for covariates. To account for the covariate effect, we propose a joint model approach which assumes that the hazard of failure depends on the biomarker and the covariates through a proportional hazards model and that the biomarker depends the covariates through a semiparametric location model. We propose semiparametric estimators for covariate-specific ROC curves corresponding to the two time-dependent ROC curve definitions, respectively. We show that the estimators are consistent and converge to Gaussian processes. In the case of no covariates., the estimators are demonstrated to be more efficient than the Heagerty-Lumley-Pepe estimator and the Heagerty-Zheng estimator via simulation studies. In addition. the estimators can be easily extended to other survival models. We apply these estimators to an HIV dataset. C1 [Song, Xiao] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Song, X (reprint author), Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA. EM xsong@uga.edu; azhou@u.washington.edu NR 11 TC 22 Z9 22 U1 0 U2 3 PU STATISTICA SINICA PI TAIPEI PA C/O DR H C HO, INST STATISTICAL SCIENCE, ACADEMIA SINICA, TAIPEI 115, TAIWAN SN 1017-0405 J9 STAT SINICA JI Stat. Sin. PD JUL PY 2008 VL 18 IS 3 BP 947 EP 965 PG 19 WC Statistics & Probability SC Mathematics GA 337UA UT WOS:000258459800010 ER PT J AU Kelley, L Chou, CL Dibble, SL Robertson, PA AF Kelley, Leah Chou, Calvin L. Dibble, Suzanne L. Robertson, Patricia A. TI A critical intervention in lesbian, gay, bisexual, and transgender health: Knowledge and attitude outcomes among second-year medical students SO TEACHING AND LEARNING IN MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-of-Professors-of-Gynecology-and-Obstetrics/Council-on-Reside nt-Education-in-Obstetrics-and-Gynecology CY MAR 02-06, 2005 CL Salt Lake City, UT SP Assoc Professors Gynecol & Obstet, Council Resident Educ Obstet & Gynecol ID HOMOSEXUALITY; CARE; SCHOOLS; ISSUES; PANEL; MEN AB Background: Lesbian, gay, bisexual, and transgender (LGBT) persons represent an underserved population susceptible to health care disparities. Description: In February 2004, we implemented an LGBT health curriculum for students at the University of California at San Francisco. Confidential matched questionnaires elicited students' knowledge, attitudes, and beliefs about LGBT health issues before and after the intervention. Evaluation: The surveyed population (52% response rate) was demographically similar to the entire class. There was statistically significant change in the responses to 4 of 16 questionnaire items (p <= .001; largest absolute change was 0.57 on a 5-point scale). Students demonstrate increased knowledge about access to health care and LGBT relationships, increased willingness to treat patients with gender identity issues, and enhanced awareness that sexual identity and practices are clinically relevant. Conclusions: Our simple curricular intervention led to significant short-term changes in a small number of survey items assessing students' knowledge and beliefs about LGBT persons. C1 [Kelley, Leah; Robertson, Patricia A.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Chou, Calvin L.] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA. [Dibble, Suzanne L.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. RP Chou, CL (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM calvin.chou@ucsf.edu NR 19 TC 40 Z9 41 U1 4 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PD JUL-SEP PY 2008 VL 20 IS 3 BP 248 EP 253 DI 10.1080/10401330802199567 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 340AE UT WOS:000258617600008 PM 18615300 ER PT J AU Peden-Adams, MM Keller, JM EuDaly, JG Berger, J Gilkeson, GS Keil, DE AF Peden-Adams, Margie M. Keller, Jennifer M. EuDaly, Jackie G. Berger, Jennifer Gilkeson, Gary S. Keil, Deborah E. TI Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate SO TOXICOLOGICAL SCIENCES LA English DT Article DE PFOS; immunotoxicity; immune; humoral immunity; PFC assay; TNP-LPS; serum levels ID PROLIFERATOR-ACTIVATED RECEPTOR; NF-KAPPA-B; PEROXISOME PROLIFERATOR; AMMONIUM PERFLUOROOCTANOATE; PERFLUORINATED COMPOUNDS; PPAR-ALPHA; IN-VIVO; IMMUNOGLOBULIN PRODUCTION; DEVELOPMENTAL TOXICITY; PERFLUORODECANOIC ACID AB Adult male and female B6C3F1 mice were exposed to perfluorooctane sulfonate (PFOS) daily via gavage for 28 days (0, 0.005, 0.05, 0.1, 0.5, 1, or 5 mg/kg total administered dose [TAD]). Following exposure, various immune parameters were assessed and serum PFOS concentrations were determined. Lymphocyte proliferation was not altered in either gender. Natural killer cell activity was increased compared with control at 0.5, 1, and 5 mg/kg TAD in male mice but was not altered in female mice. At these treatment levels, splenic T-cell immunophenotypes were minimally altered in females, but all T-cell subpopulations were significantly modulated in males beginning at 0.1 mg/kg TAD. The sheep red blood cell (SRBC) plaque-forming cell (PFC) response was suppressed in male mice beginning at 0.05 mg/kg TAD and in females at 0.5 mg/kg TAD. Serum trinitrophenyl (TNP)-specific IgM titers were also decreased by PFOS after TNP-LPS (TNP conjugated to lipopolysacharide) challenge suggesting that the humoral immune effects may be attributed to the B-cell rather than T-cell because both T-dependent (SRBC) and T-independent (TI) (TNP-LPS) antigens result in suppressed IgM production. Based on the PFC response, the low observed effect level (LOEL) for males was 0.05 mg/kg TAD (ED50 = 0.021 mg/kg TAD) and for females was 0.5 mg/kg TAD (ED50 = 0.59 mg/kg TAD). Measured PFOS serum concentrations at these dose levels were 91.5 +/- 22.2 ng/g and 666 +/-+/- 108 ng/g (mean +/- SD), respectively. The male LOEL serum level was approximately 14-fold lower than reported mean blood levels from occupationally exposed humans and fell in the upper range of concentrations reported for the general population. Overall, this study provides a profile of PFOS immunotoxicity showing effects at levels reported in humans and identifies the B-cells as a potential target. C1 [Peden-Adams, Margie M.] MUSC, Dept Pediat, Charleston, SC 29412 USA. [Peden-Adams, Margie M.; EuDaly, Jackie G.; Gilkeson, Gary S.] MUSC, Dept Med Rheumatol & Immunol, Charleston, SC 29412 USA. [Peden-Adams, Margie M.; EuDaly, Jackie G.] MUSC, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA. [Keller, Jennifer M.] Natl Inst Stand & Technol, Hollings Marine Lab, Charleston, SC 29412 USA. [Berger, Jennifer; Keil, Deborah E.] Univ Nevada, Clin Sci Lab, Las Vegas, NV 89154 USA. [Gilkeson, Gary S.] Ralph Johnson VAMC, Med Res Serv, Charleston, SC 29403 USA. RP Peden-Adams, MM (reprint author), MUSC, Dept Pediat, 221 Ft Johnson Rd, Charleston, SC 29412 USA. EM pedenada@musc.edu NR 62 TC 99 Z9 101 U1 4 U2 23 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD JUL PY 2008 VL 104 IS 1 BP 144 EP 154 DI 10.1093/toxsci/kfn059 PG 11 WC Toxicology SC Toxicology GA 313UY UT WOS:000256766700014 PM 18359764 ER PT J AU Ernst, JD Lewinsohn, DM Behar, S Blythe, M Schlesinger, LS Kornfeld, H Sette, A AF Ernst, Joel D. Lewinsohn, David M. Behar, Samuel Blythe, Martin Schlesinger, Larry S. Kornfeld, Hardy Sette, Alessandro TI Meeting report: NIH workshop on the tuberculosis immune epitope database SO TUBERCULOSIS LA English DT Article DE tuberculosis; immunity; epitope; lymphocyte; HLA; antibody ID CD8(+) T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; INFECTION; MOUSE; RECOGNITION; PERSISTENCE; DIVERSITY; INSIGHTS; STRAINS; PEPTIDE AB The Immune Epitope Database (IEDB), an online resource available at http://immuneepitope.org/, contains data on T cell and B cells epitopes of multiple pathogens, including M. tuberculosis. A workshop held in June, 2007 reviewed the existing database, discussed the utility of reference sets of epitopes, and identified knowledge gaps pertaining to epitopes and immune responses in tuberculosis. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Ernst, Joel D.] NYU, Sch Med, Div Infect Dis, New York, NY 10016 USA. [Lewinsohn, David M.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. [Behar, Samuel] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Blythe, Martin; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Dept Vaccine Discovery, La Jolla, CA 92037 USA. [Schlesinger, Larry S.] Ohio State Univ, Med Ctr, Div Infect Dis, Columbus, OH 43210 USA. [Schlesinger, Larry S.] Ohio State Univ, Med Ctr, Ctr Microbial Interface Biol, Columbus, OH 43210 USA. [Kornfeld, Hardy] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA. RP Ernst, JD (reprint author), NYU, Sch Med, Div Infect Dis, 522 1st Ave,Smilow 901, New York, NY 10016 USA. EM joel.ernst@med.nyu.edu; lewinsod@ohsu.edu; sbehar@rics.bwh.harvard.edu; mblythe@liai.org; larry.schlesinger@osumc.edu; hardy.kornfetd@umassmed.edu; alex@liai.org RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494; Ernst, Joel/0000-0001-9951-6207; Behar, Samuel/0000-0002-3374-6699 FU NIAID NIH HHS [R01 AI046097, R01 AI046097-09, R01 AI051242, R01 AI051242-06, R01 AI059667, R01 AI059667-04, R01 AI067731] NR 22 TC 18 Z9 19 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JUL PY 2008 VL 88 IS 4 BP 366 EP 370 DI 10.1016/j.tube.2007.11.002 PG 5 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 331JG UT WOS:000258007900010 PM 18068490 ER PT J AU Anger, JT Saigal, CS Wang, MM Yano, EM AF Anger, Jennifer T. Saigal, Christopher S. Wang, MingMing Yano, Elizabeth M. CA Urologic Dis Amer Project TI Urologic disease burden in the United States: Veteran users of Department of Veterans Affairs healthcare SO UROLOGY LA English DT Article ID NUTRITION EXAMINATION SURVEY; URINARY-INCONTINENCE; NATIONAL-HEALTH; PREVALENCE; MEN AB OBJECTIVES To determine the disease burden, measured by resource utilization, of four Urologic conditions among veteran users of U.S. Department of Veterans Affairs (VA) healthcare services and to assess variations by selected sociodemographic characteristics. METHODS We applied expert-derived diagnosis clusters to establish four patient cohorts from a population of U.S. veterans aged 18 years and older with at least one Outpatient visit in a VA healthcare facility in fiscal year 2001 (n = 3,691,519): (1) benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), (2) kidney stones (KS), (3) urinary tract infections (UTI), and (4) urinary incontinence (UI). We identified patients with qualifying diagnosis codes associated with Outpatient visits in the national VA Outpatient Clinic file, thereby generating case Counts for each diagnostic category. RESULTS Among veteran users of VA healthcare services, when defined as the primary reason for the visit, the prevalence of BPH/LUTS was 4811 per 100,000 veterans (4.8%); the prevalence of KS was 597 per 100,000 (0.6%); the prevalence of UTI was 4265 and 1719 per 100,000 female and male veterans, respectively (4.3%) and 1.7%); and the prevalence of UI was 2161 and 515 per 100,000 female and male veterans, respectively (2.2% and 0.5%). Prevalence of these conditions when ascertained by capturing diagnoses appearing as secondary reasons for a physician visit was much higher. CONCLUSIONS Although we expected the prevalence of urologic conditions to be high among veterans who use the VA system for care, We found the burden Of Urologic disease among veterans to be comparable to other national data sets. Prevalence estimates based on primary diagnosis, rather than secondary or "any" diagnosis, significantly underestimated the disease burden among veterans. C1 [Anger, Jennifer T.] Univ Calif Los Angeles, Dept Urol, Sch Med, Santa Monica, CA 90404 USA. Univ Calif Los Angeles, RAND Hlth, Santa Monica, CA 90404 USA. Univ Calif Los Angeles, VA Greater Los Angeles HSR&D Ctr Excellence, Study Healthcare Provider Behav, Sepulveda, CA USA. Calif State Univ Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90032 USA. RP Anger, JT (reprint author), Univ Calif Los Angeles, Dept Urol, Sch Med, 1260 15th St,Suite 1200, Santa Monica, CA 90404 USA. EM janger@mednet.ucla.edu FU NIDDK NIH HHS [N01 DK012460] NR 18 TC 7 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JUL PY 2008 VL 72 IS 1 BP 37 EP 41 DI 10.1016/j.urology.2007.11.163 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 329QZ UT WOS:000257887000011 PM 18342928 ER PT J AU Hermsen, JL Ibele, AR Faucher, LD Nale, JK Schurr, MJ Kudsk, KA AF Hermsen, Joshua L. Ibele, Anna R. Faucher, Lee D. Nale, Jennifer K. Schurr, Michael J. Kudsk, Kenneth A. TI Retrievable inferior vena cava filters in high-risk trauma and surgical patients: Factors influencing successful removal SO WORLD JOURNAL OF SURGERY LA English DT Article ID INTRAVASCULAR ULTRASOUND; VENOUS THROMBOEMBOLISM; SAFETY AB Background An Inferior vena cava filter (IVCF) provides prophylaxis against pulmonary embolism in patients that cannot be anticoagulated. A removable IVCF (R-IVCF) provides prophylaxis during a high-risk period while potentially eliminating long-term complications associated with a permanent IVCF. Factors influencing success of R-IVCF removal are ill-defined. Methods The study was a retrospective review of a prospectively maintained patient registry comprising patients who received an R-IVCF (Bard Recovery (TM) and G2 (TM)) at an academic level 1 trauma center. The influence of time in vivo, filter design, and filter head position on computed abdominal tomographic (CAT) scan (touching caval wall vs. free) on removal success was examined. Results Ninety-two patients each received an R-IVCF. Thirty-nine patients underwent removal attempt and 30 R-IVCFs were removed. Time in vivo did not affect removal success (success: 228 +/- 104 days versus unsuccessful: 289 +/- 158 days, p = 0.18). Filter design impacted filter head position (Recovery: 43% touching versus G2: 6% touching, p = 0.023). Position of the filter head influenced removal success (touching: 50% success versus free: 88% success, p = 0.021). Conclusions Position of the filter head is the key determinant of removal success. Specific device designs may impact filter head position as was the case with the two designs in this analysis. Time in vivo does not affect removal success. C1 [Hermsen, Joshua L.; Ibele, Anna R.; Faucher, Lee D.; Nale, Jennifer K.; Schurr, Michael J.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI 53705 USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM KUDSK@surgery.wisc.edu FU NIGMS NIH HHS [R01 GM53439] NR 13 TC 14 Z9 16 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD JUL PY 2008 VL 32 IS 7 BP 1444 EP 1449 DI 10.1007/s00268-007-9462-z PG 6 WC Surgery SC Surgery GA 314RN UT WOS:000256826600029 PM 18264826 ER PT J AU Wang, Q Zengin, A Ying, W Newell, KA Wang, P Yeo, W Wong, PTH Yenari, MA Huang, XF AF Wang, Q. Zengin, A. Ying, W. Newell, K. A. Wang, P. Yeo, W. Wong, P. T. -H. Yenari, M. A. Huang, X. -F. TI Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain SO NEUROSCIENCE LA English DT Article DE statins; muscarinic receptors; hydroxymethylglutaryl-coenzyme; reductase inhibitors; upregulation; Alzheimer's disease ID STRIATAL DOPAMINE RELEASE; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; IN-VIVO MICRODIALYSIS; ALZHEIMERS-DISEASE; M2-MUSCARINIC DRUGS; PREFRONTAL CORTEX; TRANSGENIC MICE; ALPHA-FORM; STATINS AB Statins are increasingly being used for the treatment of a variety of conditions beyond their original indication for cholesterol lowering. We previously reported that simvastatin affected the dopaminergic system in the rat brain. This study aims to investigate regional changes of muscarinic M1/4 receptors in the rat brain after 4-week administration of simvastatin (1 or 10 mg/kg/day). M1/4 receptor distribution and alterations in the post-mortem rat brain were detected by [H-3]pirenzepine binding autoradiography. Simvastatin (1 mg/kg/day) increased [H-3]pirenzepine binding, predominantly in the prefrontal cortex (171%, P<0.001), primary motor cortex (153%, P=0.001), cingulate cortex (109%, P<0.001), hippocampus (138%, P<0.001), caudate putamen (122%, P=0.002) and nucleus accumbens (170%, P<0.001) compared with controls; while lower but still significant increases of [H-3]pirenzepine binding were observed in the examined regions following simvastatin (10 mg/kg/day) treatment. Our results also provide strong evidence that chronic simvastatin administration, especially at a low dosage, up-regulates M1/4 receptor binding, which is likely to be independent of its muscarinic agonist-like effect. Alterations in [H-3]pirenzepine binding in the examined brain areas may represent the specific regions that mediate the clinical effects of simvastatin treatment on cognition and memory via the muscarinic cholinergic system. These findings contribute to a better understanding of the critical roles of simvastatin in treating neurodegenerative disorders, via muscarinic receptors. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Wang, Q.; Zengin, A.; Newell, K. A.; Yeo, W.; Huang, X. -F.] Univ Wollongong, Neurobiol Res Ctr, Sch Hlth Sci, Wollongong, NSW 2522, Australia. [Wang, Q.; Zengin, A.; Newell, K. A.; Yeo, W.; Huang, X. -F.] Univ Wollongong, Grad Sch Med, Wollongong, NSW 2522, Australia. [Ying, W.; Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Ying, W.; Yenari, M. A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Wong, P. T. -H.] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore 117597, Singapore. [Wang, P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Wang, Q (reprint author), Univ Wollongong, Neurobiol Res Ctr, Sch Hlth Sci, Wollongong, NSW 2522, Australia. EM denniswq@yahoo.com RI Huang, Xu-Feng/D-6053-2013; Newell, Kelly/K-5550-2014; Huang, Xu-Feng/H-7408-2015 OI Newell, Kelly/0000-0002-1245-5585; Huang, Xu-Feng/0000-0002-5895-2253; Zengin, Ayse/0000-0001-6428-6165 NR 53 TC 12 Z9 13 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD JUN 26 PY 2008 VL 154 IS 3 BP 1100 EP 1106 DI 10.1016/j.neuroscience.2008.04.026 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 319OE UT WOS:000257172500024 PM 18501522 ER PT J AU Winton, MJ Van Deerlin, VM Kwong, LK Yuan, W Wood, EM Yu, CE Schellenberg, GD Rademakers, R Caselli, R Karydas, A Trojanowski, JQ Miller, BL Lee, VMY AF Winton, Matthew J. Van Deerlin, Vivianna M. Kwong, Linda K. Yuan, Wuxing Wood, Elisabeth McCarty Yu, Chang-En Schellenberg, Gerard D. Rademakers, Rosa Caselli, Richard Karydas, Anna Trojanowski, John Q. Miller, Bruce L. Lee, Virginia M. -Y. TI A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro SO FEBS LETTERS LA English DT Article DE TDP-43; FTLD-U; ALS; TARDBP mutations; A90V ID FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; DNA-BINDING PROTEIN; DEMENTIA; INCLUSIONS; MUTATIONS AB TAR DNA-binding protein-43 (TDP-43) is a highly conserved, ubiquitously expressed nuclear protein that was recently identified as the disease protein in frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS). Pathogenic TDP-43 gene (TARDBP) mutations have been identified in familial ALS kindreds, and here we report a TARDBP variant (A90V) in a FTLD/ALS patient with a family history of dementia. Significantly, A90V is located between the bipartite nuclear localization signal sequence of TDP-43 and the in vitro expression of TDP-43-A90V led to its sequestration with endogenous TDP-43 as insoluble cytoplasmic aggregates. Thus, A90V may be a genetic risk factor for FTLD/ALS because it predisposes nuclear TDP-43 to redistribute to the cytoplasm and form pathological aggregates. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. C1 [Winton, Matthew J.; Van Deerlin, Vivianna M.; Kwong, Linda K.; Yuan, Wuxing; Wood, Elisabeth McCarty; Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Van Deerlin, Vivianna M.; Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Sch Med, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA. [Van Deerlin, Vivianna M.; Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. [Yu, Chang-En; Schellenberg, Gerard D.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. [Yu, Chang-En; Schellenberg, Gerard D.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98108 USA. [Rademakers, Rosa] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA. [Caselli, Richard] Mayo Clin, Dept Neurosci, Scottsdale, AZ 85259 USA. [Caselli, Richard] Arizona Alzheimers Dis Ctr, Scottsdale, AZ 85259 USA. [Karydas, Anna; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94117 USA. RP Lee, VMY (reprint author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. EM vmylee@mail.med.upenn.edu FU NIA NIH HHS [P01 AG017586-09, AG 05142, AG 10124, AG 10129, AG 16574, AG 17586, P01 AG017586, P01 AG019724, P30 AG010124, P30 AG010124-09, P30 AG010129, P50 AG005136, P50 AG005136-25, P50 AG005142, P50 AG016574, P01 AG017586-089002]; NIMH NIH HHS [MH 57899, R01 MH057899] NR 19 TC 47 Z9 49 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD JUN 25 PY 2008 VL 582 IS 15 BP 2252 EP 2256 DI 10.1016/j.febslet.2008.05.024 PG 5 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 326PI UT WOS:000257671000018 PM 18505686 ER PT J AU Maddox, TM Reid, KJ Spertus, JA Mittleman, M Krumholz, HM Parashar, S Ho, PM Rumsfeld, JS AF Maddox, Thomas M. Reid, Kimberly J. Spertus, John A. Mittleman, Murray Krumholz, Harlan M. Parashar, Susmita Ho, P. Michael Rumsfeld, John S. TI Angina at 1 year after myocardial infarction - Prevalence and associated findings SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 80th Annual Scientific Session of the American-Heart-Association CY NOV 04-07, 2007 CL Orlando, FL SP Amer Heart Assoc ID QUALITY-OF-LIFE; CORONARY-ARTERY-DISEASE; 3-YEAR FOLLOW-UP; SMOKING-CESSATION; BYPASS-SURGERY; HEALTH-STATUS; HEART-DISEASE; MAJOR DEPRESSION; RANDOMIZED-TRIAL; UNSTABLE ANGINA AB Background: Eradication of angina is a primary goal of care after myocardial infarction (MI). However, the prevalence of angina 1 year after MI and factors associated with it are unknown. Methods: From January 1, 2003, through June 28, 2004, 2498 patients with acute MI were recruited from 9 hospitals in the United States. Among this multicenter cohort of patients, angina was measured by the Seattle Angina Questionnaire 1 year after hospitalization for MI. Multivariate regression modeling identified the sociodemographic factors, clinical history, MI presentation, inpatient treatments, and outpatient treatments associated with 1-year angina, adjusted for site. Results: Of 1957 patients in the cohort, 389 (19.9%) reported angina 1 year after MI. After multivariate analysis, patients with 1-year angina were more likely to be younger (relative risk [RR] per 10-year decrease, 1.19; 95% confidence interval [ CI],1.09-1.30), to be nonwhite males (RR, 1.50; 95% CI, 1.16-1.96), to have had prior angina (RR, 1.78; 95% CI, 1.54-2.06), to have undergone prior coronary artery bypass graft surgery (RR, 1.92; 95% CI, 1.512.44), and to experience recurrent rest angina during their hospitalization (RR, 1.54; 95% CI, 1.22-1.93). Among the outpatient variables, patients with 1-year angina were more likely to continue smoking (RR, 1.23; 95% CI, 1.02-1.48), to undergo revascularization after index hospitalization (percutaneous coronary intervention or coronary artery bypass graft) (RR, 1.37; 95% CI, 1.09-1.73), and to have significant new (RR, 1.96; 95% CI, 1.34-2.87), persistent (RR, 1.88; 95% CI, 1.29-2.75), or transient (RR, 1.77; 95% CI, 1.49-2.11) depressive symptoms. Conclusions: Angina occurs in nearly 1 of 5 patients 1 year after MI. It is associated with several modifiable factors, including persistent smoking and depressive symptoms. C1 [Maddox, Thomas M.; Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Cardiol Sect, Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80209 USA. [Reid, Kimberly J.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Mittleman, Murray] Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, Boston, MA 02215 USA. [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Sect Cardiovasc Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Robert Wood Johnson Clin Scholars Program, Dept Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Parashar, Susmita] Emory Univ, Sch Med, Dept Med, Div Gen Internal Med, Atlanta, GA USA. RP Maddox, TM (reprint author), Univ Colorado, Cardiol Sect, Denver Vet Affairs Med Ctr, Dept Med, 111B,1055 Clermont St, Denver, CO 80209 USA. EM thomas.maddox@va.gov FU NHLBI NIH HHS [P50 HL077113] NR 44 TC 42 Z9 43 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 23 PY 2008 VL 168 IS 12 BP 1310 EP 1316 DI 10.1001/archinte.168.12.1310 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 315YR UT WOS:000256916600015 PM 18574088 ER PT J AU Weisbord, SD Mor, MK Resnick, AL Hartwig, KC Sonel, AF Fine, MJ Palevsky, PM AF Weisbord, Steven D. Mor, Maria K. Resnick, Abby L. Hartwig, Kathryn C. Sonel, Ali F. Fine, Michael J. Palevsky, Paul M. TI Prevention, incidence, and outcomes of contrast-induced acute kidney injury SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK PATIENTS; INDUCED NEPHROPATHY; RENAL-FUNCTION; CORONARY-ANGIOGRAPHY; N-ACETYLCYSTEINE; INSUFFICIENCY; INTERVENTION; STRATEGIES; HYDRATION AB Background: Little is known about whether health care providers (physicians) implement preventive care for contrast-induced acute kidney injury (CIAKI). The objectives of our prospective cohort study were (1) to assess provider use of preventive strategies for CIAKI, (2) to determine the incidence of CIAKI, and (3) to examine the association of CIAKI with adverse outcomes at 30 days, including death, need for dialysis, and hospital admission. Methods: We prospectively identified patients with estimated glomerular filtration rates less than 60 mL/min/ 1.73 m(2) undergoing procedures with intravascular radiocontrast agents and recorded the use of intravenous fluids and N-acetylcysteine and the discontinuation of nonsteroidal anti-inflammatory medications. We measured postprocedure serum creatinine levels to quantify the incidence of CIAKI and tracked 30-day mortality and need for dialysis or hospitalization to evaluate the association of CIAKI with these outcomes. Results: Preprocedure and postprocedure intravenous fluids were administered to 264 of 660 study patients (40.0%), more commonly with coronary angiography than with computed tomography (91.2% vs 16.6%, P <.001). N-acetylcysteine was administered to 39.2% of patients, while only 6.8% of patients using nonsteroidal anti-inflammatory drugs were instructed to discontinue the medication. In a propensity analysis, the use of intravenous fluids was associated with a reduced rate of CIAKI. The incidence of CIAKI was lowest following computed tomography (range, 0.0%-10.9%) and was highest following noncoronary angiography (range, 1.9%-34.0%). Eleven patients (1.7%) died, l patient (0.2%) required dialysis, and 83 patients (12.6%) were hospitalized; however, CIAKI was not independently associated with hospital admission or death. Conclusions: Strategies to prevent CIAKI are implemented nonuniformly. Although biochemical evidence of CIAKI is relatively common, clinically significant CIAKI is rare. These findings should help health care providers focus the use of preventive care on the highest-risk patients and have important implications for future clinical trials. C1 [Weisbord, Steven D.; Mor, Maria K.; Resnick, Abby L.; Hartwig, Kathryn C.; Sonel, Ali F.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Hartwig, Kathryn C.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Mail Stop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU NIAID NIH HHS [K24 AI001769] NR 26 TC 57 Z9 59 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUN 23 PY 2008 VL 168 IS 12 BP 1325 EP 1332 DI 10.1001/archinte.168.12.1325 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 315YR UT WOS:000256916600017 PM 18574090 ER PT J AU Lai, YY Hsieh, KC Nguyen, D Peever, J Siegel, JM AF Lai, Y. -Y. Hsieh, K. -C. Nguyen, D. Peever, J. Siegel, J. M. TI Neurotoxic lesions at the ventral mesopontine junction change sleep time and muscle activity during sleep: An animal model of motor disorders in sleep SO NEUROSCIENCE LA English DT Article DE periodic leg movements; REM sleep behavior disorder; Parkinsonism; pons; retrorubral nucleus; substantia nigra ID RESTLESS-LEGS-SYNDROME; IN-VIVO MICRODIALYSIS; MEDULLARY RETICULAR-FORMATION; STEM-MEDIATED LOCOMOTION; PARADOXICAL REM SLEEP; CHOLINERGIC CELL AREA; LEWY BODY DISEASE; BEHAVIOR DISORDER; LOCUS-COERULEUS; PARKINSONS-DISEASE AB There is no adequate animal model of restless legs syndrome (RLS) and periodic leg movements disorder (PLMD), disorders affecting 10% of the population. Similarly, there is no model of rapid eye movement (REM) sleep behavior disorder (RBD) that explains its symptoms and its link to Parkinsonism. We previously reported that the motor inhibitory system in the brainstem extends from the medulla to the ventral mesopontine junction (VMPJ). We now examine the effects of damage to the VMPJ in the cat. Based on the lesion sites and the changes in sleep pattern and behavior, we saw three distinct syndromes resulting from such lesions; the rostrolateral, rostromedial and caudal VMPJ syndromes. The change in sleep pattern was dependent on the lesion site, but was not significantly correlated with the number of dopaminergic neurons lost. An increase in wakefulness and a decrease in slow wave sleep (SWS) and REM sleep were seen in the rostrolateral VMPJ-Iesioned animals. In contrast, the sleep pattern was not significantly changed in the rostromedial and caudal VMPJ-Iesioned animals. All three groups of animals showed a significant increase in periodic and isolated leg movements in SWS and increased tonic muscle activity in REM sleep. Beyond these common symptoms, an increase in phasic motor activity in REM sleep, resembling that seen in human RBD, was found in the caudal VMPJ-lesioned animals. In contrast, the increase in motor activity in SWS in rostral VMPJ-Iesioned animals is similar to that seen in human RLS/PLMD patients. The proximity of the VMPJ region to the substantia nigra suggests that the link between RLS/PLMD and Parkinsonism, as well as the progression from RBD to Parkinsonism may be mediated by the spread of damage from the regions identified here into the substantia nigra. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Lai, Y. -Y.; Hsieh, K. -C.; Nguyen, D.; Siegel, J. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Neurobiol Res 151A3, North Hills, CA 91343 USA. [Lai, Y. -Y.; Hsieh, K. -C.; Nguyen, D.; Siegel, J. M.] Vet Adm Greater Los Angeles Healthcare Syst Sepul, North Hills, CA 91343 USA. [Peever, J.] Univ Toronto, Dept Physiol, Syst Neurobiol Lab, Toronto, ON M5S 3G5, Canada. [Peever, J.] Univ Toronto, Dept Cell & Syst Biol, Syst Neurobiol Lab, Toronto, ON M5S 3G5, Canada. RP Lai, YY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Neurobiol Res 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM yylai@ucia.edu FU BLRD VA [I01 BX001753]; NHLBI NIH HHS [HL041370, R01 HL041370, R01 HL041370-16A2, R37 HL041370]; NIDA NIH HHS [R01 DA034748]; NIMH NIH HHS [R01 MH064109]; NINDS NIH HHS [R01 NS042566-01A2, NS042566, R01 NS014610, R01 NS042566, R01 NS042566-02, R01 NS042566-03, R01 NS042566-04, R01 NS069640] NR 87 TC 33 Z9 33 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD JUN 23 PY 2008 VL 154 IS 2 BP 431 EP 443 DI 10.1016/j.neuroscience.2008.03.085 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 319OB UT WOS:000257172200004 PM 18487021 ER PT J AU Tang, XN Cairns, B Cairns, N Yenari, MA AF Tang, X. N. Cairns, B. Cairns, N. Yenari, M. A. TI Apocynin improves outcome in experimental stroke with a narrow dose range SO NEUROSCIENCE LA English DT Article DE apocynin; superoxide; NADPH oxidase; stroke; brain hemorrhage ID FUNCTIONAL NADPH OXIDASE; MILD HYPOTHERMIA; CEREBRAL-ISCHEMIA; REACTIVE OXYGEN; HEMORRHAGIC TRANSFORMATION; EMBOLIC STROKE; BRAIN; EXPRESSION; MECHANISMS; PROTEIN AB Inflammation following ischemic stroke is known to contribute to injury. NADPH oxidase (NOX) is a major enzyme system originally studied in immune cells that leads to superoxide (O center dot(-)) generation. Apocynin is a NOX inhibitor that has been studied as a potential treatment in experimental stroke. Here we explored the effect of different doses of apocynin in a mouse model of 2 h transient middle cerebral artery occlusion (tMCAO) followed by 22 h reperfusion. Apocynin, given i.v. at a dose of 2.5 mg/kg 30 min before reperfusion, improved neurological function (P<0.01), reduced infarct volume (P<0.05), and reduced the incidence of cerebral hemorrhage (P<0.05), but not at higher doses of 3.75 and 5 mg/kg, where it actually increased brain hemorrhage. Apocynin also tended to reduce mortality at the lower dose, but not at higher doses. Using hydroethine fluorescence to delineate O center dot(-) in the brain, neurons and some microglia/macrophages, but not vascular endothelial cells were found to contain O center dot(-). Apocynin at protective doses markedly prevented ischemia-induced increases in O center dot(-). Our data suggested that apocynin can protect against experimental stroke, but with a narrow therapeutic window. Published by Elsevier Ltd on behalf of IBRO. C1 [Tang, X. N.; Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Tang, X. N.; Yenari, M. A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Tang, X. N.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. [Cairns, B.; Cairns, N.] Combinix Inc, Mountain View, CA USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS NIH HHS [P50 NS014543, P01 NS014543, P01 NS014543-300002, P01 NS037520, P01 NS037520-060004, P01 NS037520-100004, P01NS37520, P50 NS014543-290002, R01 NS040516, R01 NS040516-09, R01 NS40516] NR 33 TC 91 Z9 93 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD JUN 23 PY 2008 VL 154 IS 2 BP 556 EP 562 DI 10.1016/j.neuroscience.2008.03.090 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 319OB UT WOS:000257172200016 PM 18511205 ER PT J AU Edderkaoui, M Odinokova, I Ohno, I Gukovsky, I Go, VLW Pandol, SJ Gukovskaya, AS AF Edderkaoui, Mouad Odinokova, Irina Ohno, Izumi Gukovsky, Ilya Go, Vay Liang W. Pandol, Stephen J. Gukovskaya, Anna S. TI Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE ellagic acid; nuclear factor-kappa B; apoptosis; pancreatic cancer ID IN-VITRO; DEATH; MITOCHONDRIAL; PROLIFERATION; QUERCETIN; PATHWAYS; SURVIVAL; OXIDASE; PROTECT; GROWTH AB AIM: To determine the effect of ellagic acid on apoptosis and proliferation in pancreatic cancer cells and to determine the mechanism of the pro-survival effects of ellagic acid. METHODS: The effect of ellagic acid on apoptosis was assessed by measuring Phosphatidylserine externalization, caspase activity, mitochondrial membrane potential and DNA fragmentation; and proliferation by measuring DNA thymidine incorporation. Mitochondrial membrane potential was measured in permeabilized cells, and in isolated mitochondria. Nuclear factor kappa B (NF-kappa B) activity was measured by electromobility shift assay (EMSA). RESULTS: We show that ellagic acid, a polyphenolic compound in fruits and berries, at concentrations 10 to 50 mmol/L stimulates apoptosis in human pancreatic adenocarcinoma cells. Further, ellagic acid decreases proliferation by up to 20-fold at 50 mmol/L. Ellagic acid stimulates the mitochondrial pathway of apoptosis associated with mitochondrial depolarization, cytochrome C release, and the downstream caspase activation. Ellagic acid does not directly affect mitochondria. Ellagic acid dose-dependently decreased NF-kappa B binding activity. Furthermore, inhibition of NF-kappa B activity using IkB wild type plasmid prevented the effect of ellagic acid on apoptosis. CONCLUSION: Our data indicate that ellagic acid stimulates apoptosis through inhibition of the prosurvival transcription factor NF-kappa B. (C) 2008 The WJG Press. All rights reserved. C1 [Gukovskaya, Anna S.] W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Edderkaoui, Mouad; Odinokova, Irina; Ohno, Izumi; Gukovsky, Ilya; Go, Vay Liang W.; Pandol, Stephen J.; Gukovskaya, Anna S.] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. [Odinokova, Irina] Russian Acad Sci, Inst Theoret & Expt Biophys, Moscow 142290, Russia. RP Gukovskaya, AS (reprint author), W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NCCIH NIH HHS [1P01AT003960-01, P01 AT003960] NR 29 TC 63 Z9 72 U1 0 U2 10 PU W J G PRESS PI BEIJING PA APT 1066, YISHOU GARDEN, NO 58, NORTH LANGXINZHUANG RD, PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JUN 21 PY 2008 VL 14 IS 23 BP 3672 EP 3680 DI 10.3748/wjg.14.3672 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 325HS UT WOS:000257580600009 PM 18595134 ER PT J AU Chi, LY Yu, J Zhu, H Li, XG Zhu, SG Kindy, MS AF Chi, Ling-Yi Yu, Jin Zhu, Hong Li, Xin-Gang Zhu, Shu-Gan Kindy, Mark S. TI The dual role of tumor necrosis factor-alpha in the pathophysiology of spinal cord injury SO NEUROSCIENCE LETTERS LA English DT Article DE spinal cord injury; tumor necrosis factor-alpha; apoptosis; astrocytes ID TRANSGENIC MICE; FUNCTIONAL RECOVERY; ASTROCYTES; EXPRESSION; RATS; ACTIVATION; APOPTOSIS; NGF AB Recent studies have demonstrated that tumor necrosis factor-alpha (TNF-alpha) is one of the most important mediators in spinal cord injury (SCI). However, the role of TNF-alpha in this process is still under debate due to conflicting evidence. Here, we utilized TNF-alpha transgenic (tg) rats and wild-type (wt) littermates to further investigate the role of TNF-alpha in SCI. We observed that, in the acute phase post-SCI (<= 3 days), TNF-alpha tg rats showed higher expression of TNF-alpha protein and more apoptotic cells in the spinal cord than wt rats, while in the chronic period (>= 7 days), TNF-alpha tg rats exhibited persistent baseline level of TNF-alpha protein, better tissue healing, and more activated astrocytes in the border of the lesion than wt rats. These data further demonstrate that TNF-alpha plays a dual role in SCI and its role probably depends on when it is released after SCI and on which cellular population it acts on. Published by Elsevier Ireland Ltd. C1 [Chi, Ling-Yi; Li, Xin-Gang; Zhu, Shu-Gan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China. [Chi, Ling-Yi; Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.] Shandong Univ, Sch Med, Dept Anat, Jinan 250012, Shandong, Peoples R China. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Li, XG (reprint author), Shandong Univ, Qilu Hosp, Dept Neurosurg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China. EM drlixingangneurosurgery@yahoo.com.cn; drkms2000@yahoo.com.cn NR 21 TC 11 Z9 13 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN 20 PY 2008 VL 438 IS 2 BP 174 EP 179 DI 10.1016/j.neulet.2008.04.043 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 321AQ UT WOS:000257276900010 PM 18468795 ER PT J AU Roy, D Talajic, M Nattel, S Wyse, DG Dorian, P Lee, KL Bourassa, MG Arnold, JMO Buxton, AE Camm, AJ Connolly, SJ Dubuc, M Ducharme, A Guerra, PG Hohnloser, SH Lambert, J Le Heuzey, JY O'Hara, G Pedersen, OD Rouleau, JL Singh, BN Stevenson, LW Stevenson, WG Thibault, B Waldo, AL AF Roy, Denis Talajic, Mario Nattel, Stanley Wyse, D. George Dorian, Paul Lee, Kerry L. Bourassa, Martial G. Arnold, J. Malcolm O. Buxton, Alfred E. Camm, A. John Connolly, Stuart J. Dubuc, Marc Ducharme, Anique Guerra, Peter G. Hohnloser, Stefan H. Lambert, Jean Le Heuzey, Jean-Yves O'Hara, Gilles Pedersen, Ole Dyg Rouleau, Jean-Lucien Singh, Bramah N. Stevenson, Lynne Warner Stevenson, William G. Thibault, Bernard Waldo, Albert L. CA Atrial Fibrillation & Congestive H TI Rhythm control versus rate control for atrial fibrillation and heart failure SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; VENTRICULAR SYSTOLIC DYSFUNCTION; ANTIARRHYTHMIC DRUG-THERAPY; SINUS RHYTHM; PROGNOSTIC-SIGNIFICANCE; RANDOMIZED-TRIAL; MORTALITY; RISK; MAINTENANCE; AMIODARONE AB Background It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied. Methods We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation. The primary outcome was the time to death from cardiovascular causes. Results A total of 1376 patients were enrolled (682 in the rhythm-control group and 694 in the rate-control group) and were followed for a mean of 37 months. Of these patients, 182 (27%) in the rhythm-control group died from cardiovascular causes, as compared with 175 (25%) in the rate-control group (hazard ratio in the rhythm-control group, 1.06; 95% confidence interval, 0.86 to 1.30; P=0.59 by the log-rank test). Secondary outcomes were similar in the two groups, including death from any cause (32% in the rhythm-control group and 33% in the rate-control group), stroke (3% and 4%, respectively), worsening heart failure (28% and 31%), and the composite of death from cardiovascular causes, stroke, or worsening heart failure (43% and 46%). There were also no significant differences favoring either strategy in any predefined subgroup. Conclusions In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy. C1 [Roy, Denis; Talajic, Mario; Nattel, Stanley; Bourassa, Martial G.; Dubuc, Marc; Ducharme, Anique; Guerra, Peter G.; Lambert, Jean; Rouleau, Jean-Lucien; Thibault, Bernard] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Roy, Denis; Talajic, Mario; Nattel, Stanley; Bourassa, Martial G.; Dubuc, Marc; Ducharme, Anique; Guerra, Peter G.; Lambert, Jean; Rouleau, Jean-Lucien; Thibault, Bernard] Univ Montreal, Montreal, PQ, Canada. [Wyse, D. George] Libin Cardiovasc Inst, Calgary, AB, Canada. [Dorian, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Lee, Kerry L.] Duke Univ, Med Ctr, Durham, NC USA. [Arnold, J. Malcolm O.] London Hlth Sci Ctr, London, ON, Canada. [Buxton, Alfred E.] Rhode Isl Hosp, Lifespan Acad Ctr, Providence, RI USA. [Camm, A. John] Univ London St Georges Hosp, Med Ctr, London, England. [Connolly, Stuart J.] Populat Hlth Res Inst, Hamilton, ON, Canada. [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany. [Le Heuzey, Jean-Yves] Hop Europeen Georges Pompidou, Paris, France. [O'Hara, Gilles] Inst Cardiol Quebec, Quebec City, PQ, Canada. [Pedersen, Ole Dyg] Bispebjerg Hosp, Copenhagen, Denmark. [Singh, Bramah N.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Stevenson, Lynne Warner; Stevenson, William G.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Waldo, Albert L.] Case Western Reserve Univ Hosp, Med Ctr, Cleveland, OH 44106 USA. RP Roy, D (reprint author), Montreal Heart Inst, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada. EM d_roy@icm-mhi.com OI Bourassa, Martial G./0000-0002-4439-8650 NR 44 TC 615 Z9 649 U1 4 U2 28 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 19 PY 2008 VL 358 IS 25 BP 2667 EP 2677 DI 10.1056/NEJMoa0708789 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 314NC UT WOS:000256815100003 PM 18565859 ER PT J AU Grady, WM Parkin, RK Mitchell, PS Lee, JH Kim, YH Tsuchiya, KD Washington, MK Paraskeva, C Willson, JKV Kaz, AM Kroh, EM Allen, A Fritz, BR Markowitz, SD Tewari, M AF Grady, W. M. Parkin, R. K. Mitchell, P. S. Lee, J. H. Kim, Y-H Tsuchiya, K. D. Washington, M. K. Paraskeva, C. Willson, J. K. V. Kaz, A. M. Kroh, E. M. Allen, A. Fritz, B. R. Markowitz, S. D. Tewari, M. TI Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer SO ONCOGENE LA English DT Article DE microRNA; epigenetic; colorectal cancer; colon cancer; methylation; apoptosis ID OLIGONUCLEOTIDE ARRAYS; EXPRESSION PROFILES; COLON-CANCER; IDENTIFICATION; TARGETS; TUMOR; HYPERMETHYLATION; SIGNATURE; NEOPLASIA; MECHANISM AB MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR- 342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation ( 56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer ( 12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR- 342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes. C1 [Grady, W. M.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Kaz, A. M.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Grady, W. M.; Kaz, A. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA. [Grady, W. M.; Kaz, A. M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Parkin, R. K.; Mitchell, P. S.; Kroh, E. M.; Fritz, B. R.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA. [Lee, J. H.; Kim, Y-H] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul, South Korea. [Tsuchiya, K. D.] Seattle Childrens Hosp & Reg Med Ctr, Seattle, WA USA. [Washington, M. K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Paraskeva, C.] Univ Bristol, Bristol, Avon, England. [Willson, J. K. V.] Univ Texas SW, Sch Med, Dallas, TX USA. [Allen, A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Markowitz, S. D.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Markowitz, S. D.] Univ Hosp Cleveland, Cleveland, OH 44106 USA. [Markowitz, S. D.] Howard Hughes Med Inst, Cleveland, OH USA. RP Tewari, M (reprint author), Fred Hutchinson Canc Res Ctr, Human Biol & Clin Res Div, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA. EM mtewari@fhcrc.org NR 29 TC 168 Z9 181 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD JUN 19 PY 2008 VL 27 IS 27 BP 3880 EP 3888 DI 10.1038/onc.2008.10 PG 9 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 315UC UT WOS:000256904700013 PM 18264139 ER PT J AU Wang, J Ho, L Zhao, W Ono, K Rosensweig, C Chen, LH Humala, N Teplow, DB Pasinetti, GM AF Wang, Jun Ho, Lap Zhao, Wei Ono, Kenjiro Rosensweig, Clark Chen, Linghong Humala, Nelson Teplow, David B. Pasinetti, Giulio M. TI Grape-derived polyphenolics prevent A beta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease SO JOURNAL OF NEUROSCIENCE LA English DT Article DE Alzheimer's disease; A beta peptide; amyloid beta; cognitive; dementia; Morris water maze; spatial memory ID TRANSGENIC MICE; PROTEIN; DEMENTIA; WINE; NEUROPATHOLOGY; A-BETA(1-42); AGGREGATION; CONSUMPTION; AMYLOIDOSIS; TOXICITY AB Alzheimer's disease ( AD) is a neurodegenerative disorder characterized by progressive impairments in memory and cognition. Extracellular accumulation of soluble high-molecular-weight (HMW) A beta oligomers has been proposed to be largely responsible for AD dementia and memory deficits in the Tg2576 mice, a model of AD. In this study, we found that a naturally derived grape seed polyphenolic extract can significantly inhibit amyloid beta-protein aggregation into high-molecular-weight oligomers in vitro. When orally administered to Tg2576 mice, this polyphenolic preparation significantly attenuates AD-type cognitive deterioration coincidentally with reduced HMW soluble oligomeric A beta in the brain. Our study suggests that grape seed-derived polyphenolics may be useful agents to prevent or treat AD. C1 [Pasinetti, Giulio M.] Mt Sinai Sch Med, Icahn Res Inst, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Ono, Kenjiro; Rosensweig, Clark; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Rosensweig, Clark; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Icahn Res Inst, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010 OI Rosensweig, Clark/0000-0001-6364-2025 FU NCCIH NIH HHS [P01 AT004511, P01 AT004511-01, P01 AT004511-020001, P01 AT004511-020003]; NIA NIH HHS [AG027818, P01 AG027818] NR 33 TC 177 Z9 184 U1 0 U2 13 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 18 PY 2008 VL 28 IS 25 BP 6388 EP 6392 DI 10.1523/JNEUROSCI.0364-08.2008 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 315OT UT WOS:000256890000012 PM 18562609 ER PT J AU Grady, D Cauley, JA Geiger, MJ Kornitzer, M Mosca, L Collins, P Wenger, NK Song, J Mershon, J Barrett-Connor, E AF Grady, Deborah Cauley, Jane A. Geiger, Mary Jane Kornitzer, Marcel Mosca, Lori Collins, Peter Wenger, Nanette K. Song, Jingli Mershon, John Barrett-Connor, Elizabeth CA Raloxifene Use Heart Trial Investi TI Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID ESTROGEN-RECEPTOR-BETA; SURGICAL ADJUVANT BREAST; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; ER-ALPHA; TAMOXIFEN; REDUCTION; NUTRITION; OUTCOMES; DISEASE AB Background In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, was found to reduce the risk of invasive breast cancer and vertebral fractures but not the risk of cardiovascular events. Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup. Methods Reported breast cancer was adjudicated by an independent committee based on medical records and pathology reports. The primary analyses used Cox proportional hazards models with time to first breast cancer as the outcome. Subgroup effects were analyzed using similar models with terms for treatment by subgroup. All statistical tests were two-sided. Results As previously reported, raloxifene reduced the incidence of invasive breast cancer by 44% (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.38 to 0.83; absolute risk reduction = 1.2 invasive breast cancers per 1000 women treated for 1 year). The lower incidence of invasive breast cancer reflected a 55% lower incidence of invasive estrogen receptor (ER)-positive tumors (HR = 0.45; 95% CI = 0.28 to 0.72). However, raloxifene treatment did not reduce the incidence of noninvasive breast cancer or of invasive ER-negative breast cancer. The reduced incidence of invasive breast cancer was similar across subgroups, including those defined by age, body mass index, family history of breast cancer, prior use of postmenopausal hormones, and 5-year estimated risk of invasive breast cancer. Conclusion Raloxifene reduces risk of invasive ER-positive breast cancer regardless of a woman's baseline breast cancer risk but does not reduce risk of noninvasive or ER-negative breast cancers. These results confirm those of the Multiple Outcomes of Raloxifene Evaluation, a previous randomized trial among women with osteoporosis. C1 [Grady, Deborah] Univ Calif San Francisco, San Francisco, CA 94115 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Geiger, Mary Jane; Song, Jingli; Mershon, John] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Kornitzer, Marcel] Free Univ Brussels, Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Brussels, Belgium. [Mosca, Lori] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton Hosp, Dept Cardiac Med, London, England. [Wenger, Nanette K.] Emory Univ, Sch Med, Atlanta, GA USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family & Prevent Med & Med, La Jolla, CA 92093 USA. RP Grady, D (reprint author), Univ Calif San Francisco, 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA. EM deborah.grady@ucsf.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NHLBI NIH HHS [K24 HL076346] NR 27 TC 27 Z9 27 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD JUN 18 PY 2008 VL 100 IS 12 BP 854 EP 861 DI 10.1093/jnci/djn153 PG 8 WC Oncology SC Oncology GA 316VY UT WOS:000256979000009 PM 18544744 ER PT J AU El-Serag, HB Wieman, M Richardson, P AF El-Serag, H. B. Wieman, M. Richardson, P. TI The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PROTON-PUMP INHIBITOR; THERAPY; RISK; ADENOCARCINOMA; DYSPLASIA AB Aim To examine use of acid-decreasing medications, especially proton pump inhibitors (PPIs), in patients with gastro-oesophageal reflux disorder (GERD) with and without Barrett's oesophagus (BO) in a large-scale study. Methods We conducted a retrospective cohort study of patients with newly diagnosed BO (ICD-9 code 5302) and patients with GERD and no BO (ICD-9 53081, 5301) in Department of Veterans Affairs (VA) databases. Filled prescriptions for oral PPI and histamine2-receptor antagonists (H2RA) were identified in the VA Pharmacy Benefit Management database during 365 days following diagnosis. Groups with or without PPI or H2RA were compared in unadjusted and adjusted regression analyses. Chart review was used to validate diagnoses in a subset of patients with and without BO. Results We evaluated 7732 patients with BO and 13 457 with GERD and no BO diagnosed between 1/2000 and 12/2002. At least one PPI prescription was filled during the first year following diagnosis in 91.5% of BO and 61.4% of non-BO patients (P < 0.0001), and one H2RA in 31.7% of BO and 59.4% of non-BO patients (P < 0.0001), respectively. However, 6.1% of BO patients were prescribed neither. Median duration for PPI filled prescriptions was twice as long for BO (221.7 vs. 106.9 days) compared with non-BO patients. The ratio of PPI or H2RA filled prescription days to available follow-up days among BO subjects was 0.66 (122.8 days were not covered with prescription for either), and 0.55 in GERD patients with no BO (165.0 days on neither). Conclusions Veterans Affairs patients with BO are 50% more likely to be prescribed a PPI than patients with GERD and no BO. However, on average, PPI prescriptions cover only 60% of follow-up time for BO patients. C1 [El-Serag, H. B.; Wieman, M.; Richardson, P.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Sect Gastroenterol & Hlth Serv Res, Houston, TX USA. [El-Serag, H. B.; Wieman, M.; Richardson, P.] Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 13 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JUN 15 PY 2008 VL 27 IS 12 BP 1293 EP 1299 DI 10.1111/j.1365-2036.2008.03690.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 301XZ UT WOS:000255931100014 PM 18363892 ER PT J AU Saag, KG Teng, GG Patkar, NM Anuntiyo, J Finney, C Curtis, JR Paulus, HE Mudano, A Pisu, M Elkins-Melton, M Outman, R Allison, JJ Almazor, MS Bridges, SL Chatham, WW Hochberg, M Maclean, C Mikuls, T Moreland, LW O'Dell, J Turkiewicz, AM Furst, DE AF Saag, Kenneth G. Teng, Gim Gee Patkar, Nivedita M. Anuntiyo, Jeremy Finney, Catherine Curtis, Jeffrey R. Paulus, Harold E. Mudano, Amy Pisu, Maria Elkins-Melton, Mary Outman, Ryan Allison, Jeroan J. Almazor, Maria Suarez Bridges, S. Louis, Jr. Chatham, W. Winn Hochberg, Marc Maclean, Catherine Mikuls, Ted Moreland, Larry W. O'Dell, James Turkiewicz, Anthony M. Furst, Daniel E. TI American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Review ID ANTITUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; LOW-DOSE METHOTREXATE; GOLD SODIUM THIOMALATE; ALPHA MONOCLONAL-ANTIBODY; RECEIVING CONCOMITANT METHOTREXATE; ELECTIVE ORTHOPEDIC-SURGERY; RANDOMIZED CONTROLLED-TRIAL; HEPATITIS-C-VIRUS; ADALIMUMAB PLUS METHOTREXATE AB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. C1 [Anuntiyo, Jeremy; Finney, Catherine; Paulus, Harold E.; Maclean, Catherine; O'Dell, James; Furst, Daniel E.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Saag, Kenneth G.; Teng, Gim Gee; Patkar, Nivedita M.; Curtis, Jeffrey R.; Mudano, Amy; Pisu, Maria; Elkins-Melton, Mary; Outman, Ryan; Allison, Jeroan J.; Bridges, S. Louis, Jr.; Chatham, W. Winn; Turkiewicz, Anthony M.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Almazor, Maria Suarez] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hochberg, Marc] Univ Maryland, Baltimore, MD 21201 USA. [Maclean, Catherine; O'Dell, James] RAND Corp, Santa Monica, CA USA. [Finney, Catherine; O'Dell, James] W Los Angeles VAMC, Los Angeles, CA USA. [Mikuls, Ted] Univ Nebraska, Omaha, NE 68182 USA. [Moreland, Larry W.] Univ Pittsburgh, Pittsburgh, PA USA. RP Furst, DE (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA. EM furst@mednet.ucla.edu OI Allison, Jeroan/0000-0003-4472-2112 FU NIAMS NIH HHS [K23 AR053351, K24 AR052361]; PHS HHS [U18-H510389] NR 258 TC 747 Z9 810 U1 4 U2 33 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2008 VL 59 IS 6 BP 762 EP 784 DI 10.1002/art.23721 PG 23 WC Rheumatology SC Rheumatology GA 312TA UT WOS:000256692500003 PM 18512708 ER PT J AU Sakai, K Kita, M Sawai, N Shiomi, S Sumida, Y Kanemasa, K Mitsufuji, S Imanishi, J Yamaoka, Y AF Sakai, Kyoko Kita, Masakazu Sawai, Naoki Shiomi, Satoshi Sumida, Yoshio Kanemasa, Kazuyuki Mitsufuji, Shoji Imanishi, Jiro Yamaoka, Yoshio TI Levels of interleukin-18 are markedly increased in Helicobacter pylori-Infected gastric mucosa among patients with specific IL18 genotypes SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 20th International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation CY SEP 20-22, 2007 CL Istanbul, TURKEY SP European Helicobacter Study Grp ID IFN-GAMMA PRODUCTION; MESSENGER-RNA; INTERFERON-GAMMA; T-CELLS; SERUM INTERLEUKIN-18; EXPRESSION; CYTOKINE; POLYMORPHISMS; IL-18; PROMOTER AB Background. The cellular immune response in gastric mucosa infected with Helicobacter pylori is proposed to be predominantly of the T helper cell type 1 type. Methods. Interleukin (IL)-18, IL-12, and interferon (IFN)-gamma levels were measured in gastric mucosal biopsy specimens by reverse-transcription polymerase chain reaction (PCR) and by enzyme-linked immunosorbent assay; IL18 polymorphisms were determined by PCR. Results. Biopsy specimens from 128 patients (56 with nonulcer dyspepsia, 28 with gastric ulcers, 28 with duodenal ulcers, and 16 with gastric cancer) were examined; 96 patients had H. pylori infection. IL-18 levels were markedly up-regulated in mucosa infected with H. pylori (P < .001), whereas IL-12 and IFN-gamma levels were independent of H. pylori status. IL-18 levels correlated with IFN-gamma levels only in infected patients (R = 0.31 to R = 0.51). IL-18 levels were the determining factor for monocyte infiltration in H. pylori-infected mucosa (P = .001). H. pylori-infected patients displaying IL18-607C/C and-137G/G had higher IL-18 levels than did those with other genotypes and were more likely to experience treatment failure. Conclusion. H. pylori infection induces IL-18 in the gastric mucosa. H. pylori-infected patients with IL18-607C/C and -137G/G have higher IL-18 levels, which causes severe gastric inflammation. IL18 genotype might be a marker for predicting the effects of eradication therapy. C1 [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Gastroenterol Sect, Houston, TX USA. [Sakai, Kyoko; Sumida, Yoshio; Kanemasa, Kazuyuki] Nara City Hosp, Dept Gastroenterol & Hepatol, Nara, Japan. [Sakai, Kyoko; Sawai, Naoki; Shiomi, Satoshi; Mitsufuji, Shoji] Kyoto Prefectural Univ Med, Dept Gastroenterol, Kyoto, Japan. [Kita, Masakazu; Imanishi, Jiro] Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto, Japan. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Gastroenterol Sect, 2002 Holcombe Blvd 111D,Rm 3A-320, Houston, TX USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK 62813, R01 DK062813, R01 DK062813-04] NR 38 TC 16 Z9 18 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 15 PY 2008 VL 197 IS 12 BP 1752 EP 1761 DI 10.1086/588196 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 307JN UT WOS:000256315300017 PM 18442334 ER PT J AU Brent, GA AF Brent, Gregory A. TI Graves' disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ANTITHYROID DRUGS; RADIOIODINE TREATMENT; THYROID-HORMONE; PAINLESS THYROIDITIS; CONSENSUS STATEMENT; I-131 THERAPY; BLOOD-FLOW; HYPERTHYROIDISM; MANAGEMENT; OPHTHALMOPATHY AB A 23- year- old woman presents with palpitations. Over the past 6 months, she has reported loose stools, a 10- lb ( 4.5- kg) weight loss despite a good appetite and food intake, and increased irritability. She appears to be anxious and has a pulse of 119 beats per minute and a blood pressure of 137/ 80 mm Hg. Her thyroid gland is diffusely and symmetrically enlarged to twice the normal size, and it is firm and non-tender; a thyroid bruit is audible. She has an eyelid lag, but no proptosis or periorbital edema. The serum thyrotropin level is 0.02 mu U per milliliter ( normal range, 0.35 to 4.50) and the level of free thyroxine is 4.10 ng per deciliter ( normal range, 0.89 to 1.76). How should she be further evaluated and treated? C1 Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU NIDDK NIH HHS [R01 DK 67233] NR 56 TC 184 Z9 211 U1 2 U2 29 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 12 PY 2008 VL 358 IS 24 BP 2594 EP 2605 DI 10.1056/NEJMcp0801880 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 311IJ UT WOS:000256593600007 PM 18550875 ER PT J AU Han, ES Muller, FL Perez, VI Qi, WB Liang, HY Xi, L Fu, CX Doyle, E Hickey, M Cornell, J Epstein, CJ Roberts, LJ Van Remmen, H Richardson, A AF Han, Eun-Soo Muller, Florian L. Perez, Viviana I. Qi, Wenbo Liang, Huiyun Xi, Liang Fu, Chunxiao Doyle, Erin Hickey, Morgen Cornell, John Epstein, Charles J. Roberts, L. Jackson Van Remmen, Holly Richardson, Arlan TI The in vivo gene expression signature of oxidative stress SO PHYSIOLOGICAL GENOMICS LA English DT Article DE oxidative stress; gene expression; p53 target genes; Sod1; Gpx1 ID MITOCHONDRIAL SUPEROXIDE DISMUTASE; LIFE-SPAN; CU,ZN-SUPEROXIDE DISMUTASE; P53-DEPENDENT APOPTOSIS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; CELLULAR-RESPONSE; MOUSE DEVELOPMENT; MOLECULAR-WEIGHT; SELENOPROTEIN-W AB How higher organisms respond to elevated oxidative stress in vivo is poorly understood. Therefore, we measured oxidative stress parameters and gene expression alterations (Affymetrix arrays) in the liver caused by elevated reactive oxygen species induced in vivo by diquat or by genetic ablation of the major antioxidant enzymes CuZn-superoxide dismutase (Sod1) and glutathione peroxidase-1 (Gpx1). Diquat (50 mg/kg) treatment resulted in a significant increase in oxidative damage within 3-6 h in wild-type mice without any lethality. In contrast, treatment of Sod1(-/-) or Gpx1(-/-) mice with a similar concentration of diquat resulted in a significant increase in oxidative damage within an hour of treatment and was lethal, i.e., these mice are extremely sensitive to the oxidative stress generated by diquat. The expression response to elevated oxidative stress in vivo does not involve an upregulation of classic antioxidant genes, although long-term oxidative stress in Sod1(-/-) mice leads to a significant upregulation of thiol antioxidants (e.g., Mt1, Srxn1, Gclc, Txnrd1), which appears to be mediated by the redox-sensitive transcription factor Nrf2. The main finding of our study is that the common response to elevated oxidative stress with diquat treatment in wild-type, Gpx1(-/-), and Sod1(-/-) mice and in untreated Sod1(-/-) mice is an upregulation of p53 target genes (p21, Gdf15, Plk3, Atf3, Trp53inp1, Ddit4, Gadd45a, Btg2, Ndrg1). A retrospective comparison with previous studies shows that induction of these p53 target genes is a conserved expression response to oxidative stress, in vivo and in vitro, in different species and different cells/organs. C1 [Cornell, John; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Han, Eun-Soo; Xi, Liang; Fu, Chunxiao; Doyle, Erin; Hickey, Morgen] Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA. [Muller, Florian L.; Perez, Viviana I.; Qi, Wenbo; Liang, Huiyun; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biostat & Epidemiol, San Antonio, TX 78245 USA. [Cornell, John; Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Epstein, Charles J.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Roberts, L. Jackson] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA. [Roberts, L. Jackson] Vanderbilt Univ, Dept Med, Nashville, TN USA. RP Richardson, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM richardsona@uthscsa.edu FU NIA NIH HHS [R01 AG023843, 1P30-AG-13319, 5T3-AG021890-02, AG-14674-04S1, P01 AG019316, P01 AG019316-010003, P01 AG020591, P01 AG020591-019002, P01-AG-020591, P01-AG-19316, P30 AG013319, P30 AG013319-10, P30 AG013319-119009, R01 AG023843-01, R01-AG-23843, R37 AG026557, R37 AG026557-01, R37-AG026557, T32 AG021890]; NIGMS NIH HHS [R37 GM042056, R37 GM042056-19, R37-GM-42056] NR 94 TC 115 Z9 117 U1 1 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD JUN 12 PY 2008 VL 34 IS 1 BP 112 EP 126 DI 10.1152/physiolgenomics.00239.2007 PG 15 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 314OT UT WOS:000256819400013 PM 18445702 ER PT J AU Crump, B Landefeld, CS Shojania, KG Auerbach, AD AF Crump, Bernard Landefeld, C. Seth Shojania, Kaveh G. Auerbach, Andrew D. TI Should we use large scale healthcare interventions without clear evidence that benefits outweigh costs and harms? SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material C1 [Crump, Bernard] NHS Inst Innovat & Improvement, Coventry CV4 7AL, W Midlands, England. [Landefeld, C. Seth; Auerbach, Andrew D.] Univ Calif San Francisco, San Francisco, CA 94118 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. [Shojania, Kaveh G.] Ottawa Hlth Res Inst, Ottawa, ON, Canada. RP Crump, B (reprint author), NHS Inst Innovat & Improvement, Coventry CV4 7AL, W Midlands, England. EM bernard.crump@institute.nhs.uk; sethl@medicine.ucsf.edu NR 0 TC 5 Z9 5 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD JUN 7 PY 2008 VL 336 IS 7656 BP 1276 EP 1277 DI 10.1136/bmj.a145 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 312XO UT WOS:000256705900028 PM 18535068 ER PT J AU Cao, XH Antonyuk, SV Seetharaman, SV Whitson, LJ Taylor, AB Holloway, SP Strange, RW Doucette, PA Valentine, JS Tiwari, A Hayward, LJ Padua, S Cohlberg, JA Hasnain, SS Hart, PJ AF Cao, Xiaohang Antonyuk, Svetlana V. Seetharaman, Sai V. Whitson, Lisa J. Taylor, Alexander B. Holloway, Stephen P. Strange, Richard W. Doucette, Peter A. Valentine, Joan Selverstone Tiwari, Ashutosh Hayward, Lawrence J. Padua, Shelby Cohlberg, Jeffrey A. Hasnain, S. Samar Hart, P. John TI Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ZINC SUPEROXIDE-DISMUTASE; COPPER CHAPERONE CCS; ALS-LINKED SOD1; CU,ZN-SUPEROXIDE DISMUTASE; DIMER STABILITY; MOTOR-NEURONS; MOUSE MODEL; HUMAN CU; AGGREGATION; MUTATIONS AB Mutations in the gene encoding human copper-zinc superoxide dismutase (SOD1) cause a dominant form of the progressive neurodegenerative disease amyotrophic lateral sclerosis. Transgenic mice expressing the human G85R SOD1 variant develop paralytic symptoms concomitant with the appearance of SOD1-enriched proteinaceous inclusions in their neural tissues. The process(es) through which misfolding or aggregation of G85R SOD1 induces motor neuron toxicity is not understood. Here we present structures of the human G85R SOD1 variant determined by single crystal x-ray diffraction. Alterations in structure of the metal-binding loop elements relative to the wild type enzyme suggest a molecular basis for the metal ion deficiency of the G85R SOD1 protein observed in the central nervous system of transgenic mice and in purified recombinant G85R SOD1. These findings support the notion that metal-deficient and/or disulfide-reduced mutant SOD1 species contribute to toxicity in SOD1-linked amyotrophic lateral sclerosis. C1 [Cao, Xiaohang; Seetharaman, Sai V.; Whitson, Lisa J.; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Cao, Xiaohang; Seetharaman, Sai V.; Whitson, Lisa J.; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Ctr Geriatr Res Educ & Clin, Dept Vet Affairs, San Antonio, TX 78229 USA. [Antonyuk, Svetlana V.; Strange, Richard W.; Hasnain, S. Samar] SERC, Daresbury Lab, Mol Biophys Grp, Sci & Technol Facil Council, Warrington WA4 4AD, Cheshire, England. [Doucette, Peter A.; Valentine, Joan Selverstone] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA. [Tiwari, Ashutosh; Hayward, Lawrence J.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA. [Padua, Shelby; Cohlberg, Jeffrey A.] Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu RI Tiwari, Ashutosh/A-7458-2008; Antonyuk, Svetlana/B-6002-2013 OI Tiwari, Ashutosh/0000-0001-7373-349X; Antonyuk, Svetlana/0000-0002-2779-9946 FU NIGMS NIH HHS [GM28222]; NINDS NIH HHS [NS049134, NS39112, NS44170, R01 NS039112, R01 NS039112-08, R01 NS044170] NR 59 TC 42 Z9 44 U1 3 U2 12 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 6 PY 2008 VL 283 IS 23 BP 16169 EP 16177 DI 10.1074/jbc.M801522200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 307QD UT WOS:000256332500075 PM 18378676 ER PT J AU Smith, B Chu, LK Smith, TC Amoroso, PJ Boyko, EJ Hooper, TI Gackstetter, GD Ryan, MAK AF Smith, Besa Chu, Laura K. Smith, Tyler C. Amoroso, Paul J. Boyko, Edward J. Hooper, Tomoko I. Gackstetter, Gary D. Ryan, Margaret A. K. CA Millennium Cohort Study Team TI Challenges of self-reported medical conditions and electronic medical records among members of a large military cohort SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article ID MILLENNIUM COHORT; HEART-ATTACK; RISK-FACTORS; US MILITARY; HEALTH; VALIDATION; AGREEMENT; QUESTIONNAIRE; VALIDITY; STROKE AB Background: Self- reported medical history data are frequently used in epidemiological studies. Self- reported diagnoses may differ from medical record diagnoses due to poor patient- clinician communication, self- diagnosis in the absence of a satisfactory explanation for symptoms, or the " health literacy" of the patient. Methods: The US Department of Defense military health system offers a unique opportunity to evaluate electronic medical records with near complete ascertainment while on active duty. This study compared 38 self- reported medical conditions to electronic medical record data in a large population- based US military cohort. The objective of this study was to better understand challenges and strengths in self- reporting of medical conditions. Results: Using positive and negative agreement statistics for less- prevalent conditions, nearperfect negative agreement and moderate positive agreement were found for the 38 diagnoses. Conclusion: This report highlights the challenges of using self- reported medical data and electronic medical records data, but illustrates that agreement between the two data sources increases with increased surveillance period of medical records. Self- reported medical data may be sufficient for ruling out history of a particular condition whereas prevalence studies may be best served by using an objective measure of medical conditions found in electronic healthcare records. Defining medical conditions from multiple sources in large, long- term prospective cohorts will reinforce the value of the study, particularly during the initial years when prevalence for many conditions may still be low. C1 [Smith, Besa; Chu, Laura K.; Smith, Tyler C.; Ryan, Margaret A. K.] USN, Hlth Res Ctr, Dept Def Ctr Deployment Hlth Res, Washington, DC 20375 USA. [Amoroso, Paul J.] Madigan Army Med Ctr, Tacoma, WA 98431 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Gackstetter, Gary D.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Hooper, Tomoko I.; Gackstetter, Gary D.] Analyt Serv Inc ANSER, Arlington, VA USA. RP Smith, B (reprint author), USN, Hlth Res Ctr, Dept Def Ctr Deployment Hlth Res, Washington, DC 20375 USA. EM besa.smith@med.navy.mil; laurakaychu@yahoo.com; tyler.smith2@med.navy.mil; paul.amoroso@us.army.mil; eboyko@u.washington.edu; thooper@usuhs.mil; gary.gackstetter@anser.org; margaret.ryan@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X NR 28 TC 37 Z9 38 U1 2 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD JUN 5 PY 2008 VL 8 AR 37 DI 10.1186/1471-2288-8-37 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 335PE UT WOS:000258301700001 PM 18644098 ER PT J AU Sullivan, G Blevins, D Kauth, MR AF Sullivan, Greer Blevins, Dean Kauth, Michael R. TI Translating clinical training into practice in complex mental health systems: Toward opening the 'Black Box' of implementation SO IMPLEMENTATION SCIENCE LA English DT Article ID FACILITATION AB Background: Implementing clinical training in a complex health care system is challenging. This report describes two successive trainings programs in one Veterans Affairs healthcare network and the lessons we drew from their success and failures. The first training experience led us to appreciate the value of careful implementation planning while the second suggested that use of an external facilitator might be an especially effective implementation component. We also describe a third training intervention in which we expect to more rigorously test our hypothesis regarding the value of external facilitation. Results: Our experiences appear to be consonant with the implementation model proposed by Fixsen. In this paper we offer a modified version of the Fixsen model with separate components related to training and implementation. Conclusion: This report further reinforces what others have noted, namely that educational interventions intended to change clinical practice should employ a multilevel approach if patients are to truly benefit from new skills gained by clinicians. We utilize an implementation research model to illustrate how the aims of the second intervention were realized and sustained over the 12-month follow-up period, and to suggest directions for future implementation research. The present report attests to the validity of, and contributes to, the emerging literature on implementation research. C1 [Sullivan, Greer; Blevins, Dean; Kauth, Michael R.] Cent Arkansas Vet Healthcare Syst, SC MIRECC, N Little Rock, AR USA. [Sullivan, Greer; Blevins, Dean] Cent Arkansas Vet Healthcare Syst, HSR&D, CeMHOR, N Little Rock, AR USA. [Sullivan, Greer; Blevins, Dean] Univ Arkansas Med Sci, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA. [Kauth, Michael R.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kauth, Michael R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Sullivan, G (reprint author), Cent Arkansas Vet Healthcare Syst, SC MIRECC, N Little Rock, AR USA. EM gsullivan@uams.edu; blevinsdean@uams.edu; michael.kauth@va.gov FU VA South Central MIRECC FX This work was supported by the VA South Central MIRECC. The VA played no direct role in decisions related to the study design, data analysis or interpretation, manuscript preparation or decision to submit this paper. The authors thank Snigdha Mukherjee, Kathy Henderson, Joann Kirchner, Marisue Cody, Debra Hollis, Becky Lancaster, Donna Lipin, and Butch Fort for their assistance in the design of the programs and the evaluation and in securing the data reported in this manuscript. The authors thank Lisa Martone for her assistance in coordinating the trainers in one intervention. We also thank the University of Arkansas for Medical Sciences Office of Grants and Scientific Publications and Susan Moore and Carrie Edlund for their editorial assistance. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U. S. Department of Veterans Affairs. NR 18 TC 17 Z9 17 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD JUN 3 PY 2008 VL 3 AR 33 DI 10.1186/1748-5908-3-33 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432RJ UT WOS:000265151500001 PM 18522742 ER PT J AU Denmark, DL Buck, KJ AF Denmark, D. L. Buck, K. J. TI Identification of potential candidate genes and testing for a role in susceptibility to ethanol dependence and associated withdrawal SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism/International-Society-for-Biomedical-Rese arch-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 11A EP 11A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200004 ER PT J AU Kozell, LB Milner, LC Wickman, K Buck, KJ AF Kozell, L. B. Milner, L. C. Wickman, K. Buck, K. J. TI Delineation of a role for KIR3.3 (GIRK3) in sedative-hypnotic drug physiological dependence using a novel KCNJ9 null mutant mouse SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Cntr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 12A EP 12A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200008 ER PT J AU Buck, KJ AF Buck, K. J. TI QTG identification for alcohol physiological dependence and associated withdrawal in mice SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Buck, K. J.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Buck, K. J.] Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 13A EP 13A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200010 ER PT J AU Lieber, CS Leo, MA Wang, X DeCarli, LM AF Lieber, C. S. Leo, M. A. Wang, X. DeCarli, L. M. TI Chronic alcohol consumption interferes with gene regulators of mitochondrial biogenesis in rats SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 James J Peters VA Med Ctr, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Bronx, NY 10468 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 41A EP 41A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200124 ER PT J AU Meyerhoff, DJ Gazdzinski, S Yeh, PH Durazzo, TC AF Meyerhoff, D. J. Gazdzinski, S. Yeh, P. -H. Durazzo, T. C. TI Microstructural abnormalities in alcoholics are related to cognitive test performance and recover in non-smoking alcoholics during abstinence SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Meyerhoff, D. J.; Gazdzinski, S.; Yeh, P. -H.; Durazzo, T. C.] Univ Calif San Francisco, San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 101A EP 101A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200363 ER PT J AU Durazzo, TC Gazdzinski, S Meyerhoff, DJ AF Durazzo, T. C. Gazdzinski, S. Meyerhoff, D. J. TI Magnetic resonance derived and neuropsychological predictors of relapse in treatment seeking alcoholics SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Durazzo, T. C.; Gazdzinski, S.; Meyerhoff, D. J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Neuroimaging Neurodegenerat Dis, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 103A EP 103A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200370 ER PT J AU Chen, G Kozell, LB Hitzemann, R Buck, KJ AF Chen, Gang Kozell, Laura B. Hitzemann, Robert Buck, Kari J. TI Involvement of the limbic basal ganglia in ethanol withdrawaly SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 146A EP 146A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200544 ER PT J AU Durazzo, TC Rothlind, JC Gazdzinski, S Mon, A Meyerhoff, DJ AF Durazzo, T. C. Rothlind, J. C. Gazdzinski, S. Mon, A. Meyerhoff, D. J. TI Neurocognition in short-term abstinent treatment-seeking alcoholics: The influence of common comorbidities and sociodemograhic factors SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Durazzo, T. C.; Rothlind, J. C.; Gazdzinski, S.; Mon, A.; Meyerhoff, D. J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Neuroimaging Neurodegenerat Dis, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 175A EP 175A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200658 ER PT J AU Leontieva, L Dimmock, JA Carey, KB Ploutz-Snyder, RJ Cavallerano, M DeRycke, SB Meszaros, Z Batki, SL AF Leontieva, L. Dimmock, J. A. Carey, K. B. Ploutz-Snyder, R. J. Cavallerano, M. DeRycke, S. B. Meszaros, Z. Batki, S. L. TI Monitored naltrexone treatment of alcohol dependence in schizophrenia: Patient and provider attitudes SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. UCSF, Dept Psychiat, San Francisco, CA USA. VA Ctr Integrated Healthcare, Syracuse, NY USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 248A EP 248A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200950 ER PT J AU Mckay, JR Lynch, KG Van Horn, D Ward, K Oslin, D AF McKay, J. R. Lynch, K. G. Van Horn, D. Ward, K. Oslin, D. TI Effectiveness of extended telephone continuing care SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 249A EP 249A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497200956 ER PT J AU Williams, EC Bryson, CL Sun, H Frey, MS Bradley, KA AF Williams, E. C. Bryson, C. L. Sun, H. Frey, M. S. Bradley, K. A. TI Association between anginal symptoms and alcohol screening scores in va outpatients SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 VA Puget Sound, NW Ctr Excellence Hlth Serv, Res & Dev, Seattle, WA 98101 USA. Univ Washington, Seattle, WA 98101 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 265A EP 265A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497201017 ER PT J AU Pandol, SJ Gukovskaya, A Go, VLW AF Pandol, S. J. Gukovskaya, A. Go, V. L. W. TI Alcohol abuse, pancreatitis and pancreatic cancer SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Pandol, S. J.; Gukovskaya, A.; Go, V. L. W.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Hlth Care Syst, Dept Med, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 297A EP 297A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497201137 ER PT J AU Myrick, H AF Myrick, Hugh TI FMRI studies of craving SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT Joint Scientific Meeting of the Research-Society-on-Alcoholism and the International-Society-for-Biomedical-Research-on-Alcoholism CY JUN 27-JUL 02, 2008 CL Washington, DC SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Myrick, Hugh] Med Univ S Carolina, Charleston Alcohol Res Ctr, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2008 VL 32 IS 6 SU 1 BP 331A EP 331A PG 1 WC Substance Abuse SC Substance Abuse GA 309YX UT WOS:000256497201276 ER EF